{"generated":"2026-10-03T15:50:28-07:00","rows":[{"id":"study-NCT01246765","cat":"studies","name":"National Pregnancy Registry for Psychiatric Medications","status":"RECRUITING","sponsor":"Massachusetts General Hospital","drugs":["esketamine","ketamine"],"nct":"NCT01246765","nsites":1,"countries":"United States","ccs":["US"],"start":"2008-11","official":"Lee S Cohen, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT01246765","sites":["Massachusetts General Hospital — Boston, United States"],"conds":["Pregnant Women","Psychotropic Drugs"],"condg":["Other"],"contact":{"n":"Bryn Rediger","p":"(617) 724-8020","e":"brediger@partners.org"},"enroll":5000,"eid":"NCT01246765"},{"id":"study-NCT02122562","cat":"studies","name":"Ketamine Alcohol (in Treatment-Resistant Depression)","status":"RECRUITING","phase":"Phase 2","sponsor":"Mark Niciu","drugs":["ketamine"],"nct":"NCT02122562","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-04-23","official":"Mark J Niciu, M.D. Ph.D. (University of Iowa Health Care (UIHC))","src":"https://clinicaltrials.gov/study/NCT02122562","sites":["University of Iowa Health Care — Iowa City, United States"],"conds":["Magnetic Resonance Imaging","Major Depression","Alcoholism"],"condg":["Depression","Addiction & substance use"],"contact":{"n":"Osura R Amarajeewa, M.B.B.S.","p":"(319)-353-8536","e":"osura-amarajeewa@uiowa.edu"},"enroll":60,"eid":"NCT02122562"},{"id":"study-NCT02543983","cat":"studies","name":"Neurobiology of Suicide","status":"RECRUITING","phase":"Phase 2","sponsor":"National Institute of Mental Health (NIMH)","drugs":["ketamine"],"nct":"NCT02543983","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-12-01","official":"Carlos A Zarate, M.D. (National Institute of Mental Health (NIMH))","src":"https://clinicaltrials.gov/study/NCT02543983","sites":["National Institutes of Health Clinical Center — Bethesda, United States"],"conds":["Healthy Volunteers","Depression"],"condg":["Depression","Healthy volunteers"],"contact":{"n":"Laura R Waldman, L.C.S.W.","p":"(301) 768-2833","e":"laura.waldman@nih.gov"},"enroll":325,"eid":"NCT02543983"},{"id":"study-NCT03289949","cat":"studies","name":"The Neurobiological Effect of 5-HT2AR Modulation","status":"RECRUITING","phase":"Phase 1","sponsor":"Gitte Moos Knudsen","drugs":["psilocybin"],"nct":"NCT03289949","nsites":1,"countries":"Denmark","ccs":["DK"],"start":"2017-03-03","official":"Gitte M Knudsen, Professor (Neurobiology Research Unit, Rigshospitalet)","src":"https://clinicaltrials.gov/study/NCT03289949","sites":["Neurobiology Research Unit, Rigshospitalet — Copenhagen, Denmark"],"conds":["Basic Science"],"condg":["Other"],"contact":{"n":"Gitte M Knudsen, Professor","p":"+45 35456720","e":"gmk@nru.dk"},"enroll":200,"eid":"NCT03289949"},{"id":"study-NCT03065335","cat":"studies","name":"Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder","status":"RECRUITING","phase":"Phase 1","sponsor":"National Institute of Mental Health (NIMH)","drugs":["ketamine"],"nct":"NCT03065335","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-05-25","official":"Carlos A Zarate, M.D. (National Institute of Mental Health (NIMH))","src":"https://clinicaltrials.gov/study/NCT03065335","sites":["National Institutes of Health Clinical Center — Bethesda, United States"],"conds":["Healthy Volunteer","Major Depressive Disorder","Depression"],"condg":["Depression","Healthy volunteers"],"contact":{"n":"Adilah M Kirton","p":"(301) 549-0315","e":"adilah.meredith-kirton@nih.gov"},"enroll":150,"eid":"NCT03065335"},{"id":"study-NCT03272698","cat":"studies","name":"ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression","status":"RECRUITING","phase":"Phase 4","sponsor":"University of Saskatchewan","drugs":["ketamine"],"nct":"NCT03272698","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2017-09-01","official":"Jonathan Gamble, MD (University of Saskatchewan)","src":"https://clinicaltrials.gov/study/NCT03272698","sites":["Royal University Hospital — Saskatoon, Canada"],"conds":["Treatment Resistant Depression","Ketamine"],"condg":["Depression"],"contact":{"n":"Una Goncin","p":"3066551183","e":"ung039@usask.ca"},"enroll":62,"eid":"NCT03272698"},{"id":"study-NCT05985811","cat":"studies","name":"Ketamine Enhances Analgesia and Mood in Chronic Pain Patients","status":"RECRUITING","sponsor":"Salem Anaesthesia Pain Clinic","drugs":["ketamine"],"nct":"NCT05985811","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2018-02-02","official":"Olumuyiwa Bamgbade, MD,FRCPC (Salem Anaesthesia Pain Clinic)","src":"https://clinicaltrials.gov/study/NCT05985811","sites":["Salem Anaesthesia Pain Clinic — Surrey, Canada"],"conds":["Mood Disorder; Opioid","Mood Insomnia"],"condg":["Addiction & substance use"],"contact":{"n":"Olumuyiwa Bamgbade, MD,FRCPC","p":"17786286600","e":"salem.painclinic@gmail.com"},"enroll":500,"eid":"NCT05985811"},{"id":"study-NCT03781128","cat":"studies","name":"Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache","status":"RECRUITING","phase":"Phase 2","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD"],"nct":"NCT03781128","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2019-01-02","official":"Matthias Liechti (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT03781128","sites":["Clinical Pharmacology & Toxicology, University Hospital Basel — Basel, Switzerland"],"conds":["Cluster Headache"],"condg":["Chronic pain & headache"],"contact":{"n":"Matthias Liechti, Prof.","p":"0041 61 328 68 68","e":"matthias.liechti@usb.ch"},"enroll":30,"eid":"NCT03781128"},{"id":"study-NCT03735563","cat":"studies","name":"Premedication for Less Invasive Surfactant Administration","status":"RECRUITING","phase":"Phase 4","sponsor":"University of Oulu","drugs":["ketamine"],"nct":"NCT03735563","nsites":1,"countries":"Finland","ccs":["FI"],"start":"2019-02-11","official":"Riitta Marttila, MD, docent (Oulu University and Oulu University Hospital)","src":"https://clinicaltrials.gov/study/NCT03735563","sites":["Oulu University Hospital — Oulu, Finland"],"conds":["Surfactant Deficiency Syndrome Neonatal"],"condg":["Other"],"contact":{"n":"Eveliina Ronkainen, MD, PhD","p":"+358 8 3152011","e":"eveliina.ronkainen@oulu.fi"},"enroll":40,"eid":"NCT03735563"},{"id":"study-NCT03973268","cat":"studies","name":"Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression","status":"RECRUITING","phase":"Phase 1","sponsor":"National Institute of Mental Health (NIMH)","drugs":["ketamine"],"nct":"NCT03973268","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-01-21","official":"Carlos A Zarate, M.D. (National Institute of Mental Health (NIMH))","src":"https://clinicaltrials.gov/study/NCT03973268","sites":["National Institutes of Health Clinical Center — Bethesda, United States"],"conds":["Depression","Major Depressive Disorder","Major Depression"],"condg":["Depression"],"contact":{"n":"Yamila I Carmona","p":"(301) 256-8971","e":"yamila.carmona@nih.gov"},"enroll":70,"eid":"NCT03973268"},{"id":"study-NCT04480918","cat":"studies","name":"University of Iowa Interventional Psychiatry Service Patient Registry","status":"RECRUITING","sponsor":"Mark Niciu","drugs":["esketamine","ketamine"],"nct":"NCT04480918","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-11-02","official":"Mark J Niciu, M.D., Ph. D. (University of Iowa Hospitals & Clinics); Nicholas T Trapp, M.D., M.S. (University of Iowa Hospitals & Clinics)","src":"https://clinicaltrials.gov/study/NCT04480918","sites":["University of Iowa Health Care — Iowa City, United States"],"conds":["Treatment Resistant Depression","Major Depressive Episode","Major Depression","Major Depressive Disorder","Bipolar Disorder","Bipolar Depression"],"condg":["Depression","OCD","Bipolar"],"contact":{"n":"Karin Nielsen, MS","p":"319-384-6521","e":"karin-nielsen@uiowa.edu"},"enroll":1000,"eid":"NCT04480918"},{"id":"study-NCT04161066","cat":"studies","name":"Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine","status":"RECRUITING","phase":"Phase 1","sponsor":"University of Wisconsin, Madison","drugs":["psilocybin"],"nct":"NCT04161066","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-01-13","official":"Randall Brown, MD PhD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT04161066","sites":["University of Wisconsin — Madison, United States"],"conds":["Opioid Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"PROTEA Research","p":"608-444-2397","e":"protea.research@mailplus.wisc.edu"},"enroll":10,"eid":"NCT04161066"},{"id":"study-NCT04123314","cat":"studies","name":"Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT04123314","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-03-24","official":"Albert Garcia-Romeu, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT04123314","sites":["Johns Hopkins Center for Psychedelic and Consciousness Research — Baltimore, United States"],"conds":["Depressive Symptoms","Depression","Alzheimer Disease","Mild Cognitive Impairment"],"condg":["Depression","Neurology & cognition"],"contact":{"n":"Ian Geithner, MPS","p":"4105505466","e":"igeithn1@jhmi.edu"},"enroll":20,"eid":"NCT04123314"},{"id":"study-NCT04892251","cat":"studies","name":"Ketamine Assisted Psychotherapy for Opioid Use Disorder","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"University of Utah","drugs":["ketamine"],"nct":"NCT04892251","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-05-20","official":"Eric L Garland (University of Utah)","src":"https://clinicaltrials.gov/study/NCT04892251","sites":["Center on Mindfulness and Integrative Health Intervention Development — Salt Lake City, United States"],"conds":["Opioid-use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Research Coordinator","p":"801-581-3826","e":"eric.garland@socwk.utah.edu"},"enroll":60,"eid":"NCT04892251"},{"id":"study-NCT04861051","cat":"studies","name":"Understanding Ketamine's Dissociative Effects (KD Study)","status":"RECRUITING","phase":"Phase 1","sponsor":"Stanford University","drugs":["ketamine"],"nct":"NCT04861051","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-07-26","official":"Karl Deisseroth, MD, PhD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT04861051","sites":["Stanford University School of Medicine — Palo Alto, United States"],"conds":["Epilepsy"],"condg":["Neurology & cognition"],"contact":{"n":"Arjay Cordero","p":"650-580-9000","e":"arjayc@stanford.edu"},"enroll":20,"eid":"NCT04861051"},{"id":"study-NCT04877977","cat":"studies","name":"Long-term Observation of Participants With Mood Disorders","status":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","drugs":["ketamine"],"nct":"NCT04877977","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-08-17","official":"Elizabeth D Ballard, Ph.D. (National Institute of Mental Health (NIMH))","src":"https://clinicaltrials.gov/study/NCT04877977","sites":["National Institutes of Health Clinical Center — Bethesda, United States"],"conds":["Depression","Suicide Risk"],"condg":["Depression"],"contact":{"n":"Elizabeth D Ballard, Ph.D.","p":"(301) 435-9399","e":"elizabeth.ballard@nih.gov"},"enroll":1000,"eid":"NCT04877977"},{"id":"study-NCT05156060","cat":"studies","name":"Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Natalie Lockney","drugs":["ketamine"],"nct":"NCT05156060","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-01-24","official":"Natalie Lockney, MD (Vanderbilt-Ingram Cancer Center)","src":"https://clinicaltrials.gov/study/NCT05156060","sites":["Vanderbilt-Ingram Cancer Center — Nashville, United States"],"conds":["Head and Neck Cancer","Locally Advanced Head and Neck Carcinoma"],"condg":["Cancer-related distress"],"contact":{"n":"Vanderbilt-Ingram Service for Timely Access","p":"800-811-8480","e":"cip@vumc.org"},"enroll":64,"eid":"NCT05156060"},{"id":"study-NCT05301608","cat":"studies","name":"Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT05301608","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-03-03","official":"Frederick S Barrett, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT05301608","sites":["Johns Hopkins Center for Psychedelic and Consciousness Research — Baltimore, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"contact":{"n":"Gabi Lofland","p":"(410) 550-2253","e":"gloflan1@jhmi.edu"},"enroll":30,"eid":"NCT05301608"},{"id":"study-NCT05306899","cat":"studies","name":"Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches","status":"RECRUITING","phase":"Phase 3","sponsor":"University Health Network, Toronto","drugs":["ketamine"],"nct":"NCT05306899","nsites":2,"countries":"Canada","ccs":["CA"],"start":"2022-06-01","official":"Anuj Bhatia, MD, PhD (University Health Network, Toronto)","src":"https://clinicaltrials.gov/study/NCT05306899","sites":["Women's College Hospital — Toronto, Canada","Toronto Western Hospital — Toronto, Canada"],"conds":["Chronic Daily Headache"],"condg":["Chronic pain & headache"],"contact":{"n":"Emad Al Azazi","p":"+1 (416) 603 5800","e":"KetHead@uhn.ca"},"enroll":56,"eid":"NCT05306899"},{"id":"study-NCT04763343","cat":"studies","name":"Ketamine Treatment of Youth Suicide Attempters","status":"RECRUITING","phase":"Phase 3","sponsor":"Tatiana Falcone, MD","drugs":["ketamine"],"nct":"NCT04763343","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-06-27","official":"Tatiana Falcone, M.D. (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT04763343","sites":["The Cleveland Clinic — Cleveland, United States"],"conds":["Suicide, Attempted"],"condg":["Other"],"contact":{"n":"Christina Deisz, LISW-S","p":"(440) 225-6193","e":"deiszc@ccf.org"},"enroll":60,"eid":"NCT04763343"},{"id":"study-NCT05577585","cat":"studies","name":"Ketamine in OCD: Efficacy and Effects on Stress and Cognition","status":"RECRUITING","phase":"N/A","sponsor":"Medical University of Vienna","drugs":["esketamine","ketamine"],"nct":"NCT05577585","nsites":1,"countries":"Austria","ccs":["AT"],"start":"2022-10-01","official":"Christoph Kraus, MD PhD (Medical University of Vienna, Department of Psychiatry and Psychotherapy)","src":"https://clinicaltrials.gov/study/NCT05577585","sites":["Medical University of Vienna, Department of Psychiatry and Psychotherapy — Vienna, Austria"],"conds":["Obsessive-Compulsive Disorder","Psychiatric Disorder"],"condg":["OCD"],"contact":{"n":"Christoph Kraus, MD PhD","p":"+4314040035680","e":"christoph.kraus@muv.ac.at"},"enroll":60,"eid":"NCT05577585"},{"id":"study-NCT05584826","cat":"studies","name":"MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other","status":"RECRUITING","phase":"Phase 2","sponsor":"Sunstone Medical","drugs":["MDMA"],"nct":"NCT05584826","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-10-06","official":"Manish Agrawal, MD (Sunstone Medical, PC)","src":"https://clinicaltrials.gov/study/NCT05584826","sites":["Sunstone Medical, PC — Rockville, United States"],"conds":["Cancer","Adjustment Disorders"],"condg":["Cancer-related distress"],"contact":{"n":"Study Contact","p":"301-750-3401","e":"clinical.specialists@sunstonetherapies.com"},"enroll":20,"eid":"NCT05584826"},{"id":"study-NCT05450432","cat":"studies","name":"Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression","status":"RECRUITING","phase":"Phase 4","sponsor":"Massachusetts General Hospital","drugs":["esketamine","ketamine"],"nct":"NCT05450432","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-10-13","src":"https://clinicaltrials.gov/study/NCT05450432","sites":["Massachusetts General Hospital — Boston, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Cristina Cusin, MD","p":"617-724-5510","e":"mghketamindstudy@partners.org"},"enroll":100,"eid":"NCT05450432"},{"id":"study-NCT05401227","cat":"studies","name":"Glutamatergic Mechanisms: Aim2","status":"RECRUITING","phase":"Phase 1","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT05401227","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-10-15","official":"Joshua Kantrowitz, MD (NYSPI)","src":"https://clinicaltrials.gov/study/NCT05401227","sites":["NYSPI — New York, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"contact":{"n":"Joshua Kantrowitz","p":"6467748477","e":"joshua.kantrowitz@nyspi.columbia.edu"},"enroll":120,"eid":"NCT05401227"},{"id":"study-NCT07146503","cat":"studies","name":"Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression","status":"RECRUITING","sponsor":"Riccardo Guglielmo","drugs":["esketamine"],"nct":"NCT07146503","nsites":5,"countries":"Italy","ccs":["IT"],"start":"2022-11-01","official":"Elisa Briasco, MD (Unige); Elisa Cavanna, MD (Unige)","src":"https://clinicaltrials.gov/study/NCT07146503","sites":["Ospedale Policlinico San Martino — Genova, Italy","Csm Dds 8 — Genova, Italy","Università di Chieti — Chieti, Italy","ASST Fatebenefratelli Sacco — Milan, Italy","ASST Pavia — Pavia, Italy"],"conds":["Depression and Quality of Life","Treatment Resistant Depression (TRD)","Anhedonia","Apathy","Anxiety","Cognition"],"condg":["Depression","Anxiety"],"contact":{"n":"Riccardo Guglielmo, MD","p":"+390105552202","e":"riccardo.guglielmo@unige.it"},"enroll":100,"eid":"NCT07146503"},{"id":"study-NCT05327699","cat":"studies","name":"Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"Emory University","drugs":["ketamine"],"nct":"NCT05327699","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-11-08","official":"Michael Treadway, PhD (Emory University)","src":"https://clinicaltrials.gov/study/NCT05327699","sites":["Emory University — Atlanta, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Michael Treadway, PhD","p":"(404) 727-7541","e":"ketaminestudy@emory.edu"},"enroll":140,"eid":"NCT05327699"},{"id":"study-NCT05337618","cat":"studies","name":"Improving Neurotrauma by Depolarization Inhibition With Combination Therapy (INDICT)","status":"RECRUITING","phase":"Phase 2","sponsor":"University of Cincinnati","drugs":["ketamine"],"nct":"NCT05337618","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-12-16","src":"https://clinicaltrials.gov/study/NCT05337618","sites":["University of Cincinnati — Cincinnati, United States"],"conds":["Traumatic Brain Injury"],"condg":["PTSD & trauma","Neurology & cognition"],"contact":{"n":"Jed A Hartings, PhD","p":"513-295-2370","e":"jed.hartings@uc.edu"},"enroll":72,"eid":"NCT05337618"},{"id":"study-NCT06038409","cat":"studies","name":"Ketamine Treatment Plans for Chronic Conditions","status":"RECRUITING","sponsor":"RIVER Foundation","drugs":["ketamine"],"nct":"NCT06038409","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-01-01","official":"Edward Lesofski, MS (RIVER Foundation)","src":"https://clinicaltrials.gov/study/NCT06038409","sites":["RIVER Telehealth — Helena, United States"],"conds":["Chronic Pain","Depressive Disorder","Anxiety Disorders","Chronic Disease"],"condg":["Depression","Anxiety","Chronic pain & headache"],"contact":{"n":"Ed Lesofski","p":"406-465-9504","e":"ed@riverofchange.org"},"enroll":500,"eid":"NCT06038409"},{"id":"study-NCT05696691","cat":"studies","name":"Ketamine & Crisis Response Plan for Suicidal Ideation in the ED","status":"RECRUITING","phase":"Phase 2/Phase 3","sponsor":"The University of Texas Health Science Center at San Antonio","drugs":["ketamine"],"nct":"NCT05696691","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-01-06","official":"Robert De Lorenzo, MD, MSM (The University of Texas Health Science Center at San Antonio); Romeo Fairley, MD, MPH (The University of Texas Health Science…","src":"https://clinicaltrials.gov/study/NCT05696691","sites":["University Hospital — San Antonio, United States"],"conds":["Suicide"],"condg":["Other"],"contact":{"n":"Stehanie Perez, MHA","p":"2104508973","e":"perezs11@uthscsa.edu"},"enroll":24,"eid":"NCT05696691"},{"id":"study-NCT06630065","cat":"studies","name":"Study of the Neural Circuits Underlying the Negative Emotional Bias of Depressive Disorders and Their Response to Ketamine","status":"RECRUITING","phase":"N/A","sponsor":"Centre Hospitalier St Anne","drugs":["ketamine"],"nct":"NCT06630065","nsites":1,"countries":"France","ccs":["FR"],"start":"2023-03-13","official":"Chantal Henry, Pr (GHU Paris Psychiatry & Neurosciences)","src":"https://clinicaltrials.gov/study/NCT06630065","sites":["- Groupe hospitalo-universitaire Paris Psychiatrie et Neurosciences — Paris, France"],"conds":["Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Chantal Henry, Pr","p":"0145658452","e":"ch.henry@ghu-paris.fr"},"enroll":96,"eid":"NCT06630065"},{"id":"study-NCT06488586","cat":"studies","name":"IV Ketamine vs. IN Esketamine for MDD TRD","status":"RECRUITING","sponsor":"Gustavo Vazquez","drugs":["esketamine","ketamine"],"nct":"NCT06488586","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2023-03-20","official":"Gustavo H Vazquez, MD,PhD,FRCPC (Queen&#39;s University)","src":"https://clinicaltrials.gov/study/NCT06488586","sites":["Providence Care Hospital — Kingston, Canada"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"contact":{"n":"Gustavo H Vazquez, MD,PhD,FRCPC","p":"+1 (613)-544-4900","e":"g.vazquez@queensu.ca"},"enroll":80,"eid":"NCT06488586"},{"id":"study-NCT07002684","cat":"studies","name":"Metabolic Profiling of Esketamine Treatment in Depressive Disorder","status":"RECRUITING","sponsor":"University of Zagreb","drugs":["esketamine"],"nct":"NCT07002684","nsites":1,"countries":"Croatia","ccs":["HR"],"start":"2023-04-01","official":"Tea Fabijanić, MD (University of Zagreb)","src":"https://clinicaltrials.gov/study/NCT07002684","sites":["Tea Fabijanić — Zagreb, Croatia"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Tea Fabijanić, MD","p":"+385915698801","e":"tea.fabijan@gmail.com"},"enroll":100,"eid":"NCT07002684"},{"id":"study-NCT05786066","cat":"studies","name":"The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects","status":"RECRUITING","phase":"Phase 2","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT05786066","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-04-03","official":"Naomi Driesen, PhD (Yale University / VACHS West Haven)","src":"https://clinicaltrials.gov/study/NCT05786066","sites":["VA Connecticut Healthcare System — West Haven, United States"],"conds":["Depressive Disorder","Major Depressive Disorder","Bipolar Disorder","Post Traumatic Stress Disorder","Suicidal Ideation"],"condg":["Depression","PTSD & trauma","Bipolar"],"contact":{"n":"Naomi Driesen, PhD","p":"203-508-7765","e":"naomi.driesen@yale.edu"},"enroll":30,"eid":"NCT05786066"},{"id":"study-NCT05768477","cat":"studies","name":"Different Treatments in Chronic Pain Patients.","status":"RECRUITING","sponsor":"University Ghent","drugs":["ketamine"],"nct":"NCT05768477","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2023-04-06","official":"Jessica Van Oosterwijck (Department of Rehabilitation Sciences, Faculty of Health Sciences, Ghent University, Belgium)","src":"https://clinicaltrials.gov/study/NCT05768477","sites":["AZ St Lucas — Ghent, Belgium"],"conds":["Chronic Pain","Nociplastic Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Jessica Van Oosterwijck, Professor","p":"+32 9 332 69 19","e":"jessica.vanoosterwijck@ugent.be"},"enroll":1000,"eid":"NCT05768477"},{"id":"study-NCT05398484","cat":"studies","name":"Psilocybin Therapy in Advanced Cancer","status":"RECRUITING","phase":"Phase 2/Phase 3","sponsor":"NYU Langone Health","drugs":["psilocybin"],"nct":"NCT05398484","nsites":2,"countries":"United States","ccs":["US"],"start":"2023-05-24","official":"Stephen Ross, MD (NYU Langone Medical Center)","src":"https://clinicaltrials.gov/study/NCT05398484","sites":["University of Colorado Anschutz Medical campus (CU AMC) — Aurora, United States","NYU Langone Health — New York, United States"],"conds":["Advanced Cancer"],"condg":["Cancer-related distress"],"contact":{"n":"Sydney Weiner, MA","p":"212-263-6283","e":"sydney.weiner@nyulangone.org"},"enroll":200,"eid":"NCT05398484"},{"id":"study-NCT05732155","cat":"studies","name":"Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury.","status":"RECRUITING","phase":"Phase 2","sponsor":"HaEmek Medical Center, Israel","drugs":["MDMA"],"nct":"NCT05732155","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2023-06-01","src":"https://clinicaltrials.gov/study/NCT05732155","sites":["Emek medical center — Afula, Israel"],"conds":["Post Traumatic Stress Disorder","Moral Injury","MDMA ('Ecstasy')"],"condg":["PTSD & trauma"],"contact":{"n":"Guy Schusheim, Dr","p":"972-4-6494138","e":"guy_sc@clalit.org.il"},"enroll":60,"eid":"NCT05732155"},{"id":"study-NCT05915013","cat":"studies","name":"Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response","status":"RECRUITING","phase":"Phase 1","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT05915013","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-09-07","official":"John Krystal, MD (Yale University Medical School); Naomi R Driesen, Ph.D. (Yale University Medical School)","src":"https://clinicaltrials.gov/study/NCT05915013","sites":["Yale University — New Haven, United States"],"conds":["Depressive Disorder, Major","Post Traumatic Stress Disorder"],"condg":["Depression","PTSD & trauma"],"contact":{"n":"Naomi Driesen, Ph.D.","p":"203-508-7765","e":"naomi.driesen@yale.edu"},"enroll":50,"eid":"NCT05915013"},{"id":"study-NCT05095857","cat":"studies","name":"The Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury","status":"RECRUITING","phase":"Phase 4","sponsor":"Copenhagen University Hospital, Rigshospitalet","drugs":["esketamine","ketamine"],"nct":"NCT05095857","nsites":1,"countries":"Denmark","ccs":["DK"],"start":"2023-09-15","official":"Trine H Andreasen, MD (Copenhagen University Hospital, Rigshospitalet)","src":"https://clinicaltrials.gov/study/NCT05095857","sites":["Rigshospitalet — Copenhagen, Denmark"],"conds":["Subarachnoid Hemorrhage, Aneurysmal","Intracerebral Hemorrhage","Traumatic Brain Injury"],"condg":["PTSD & trauma","Neurology & cognition"],"contact":{"n":"Trine H Andreasen, MD","p":"+4535455982","e":"trine.hjorslev.andreasen@regionh.dk"},"enroll":400,"eid":"NCT05095857"},{"id":"study-NCT06070766","cat":"studies","name":"RIVER At Home Ketamine Protocols","status":"RECRUITING","sponsor":"RIVER Foundation","drugs":["ketamine"],"nct":"NCT06070766","nsites":2,"countries":"United States","ccs":["US"],"start":"2023-10-01","official":"Dharma Rose, D.O. M.S. (RIVER Foundation); Frank Yurseak, Ph.D. (RIVER Foundation)","src":"https://clinicaltrials.gov/study/NCT06070766","sites":["RIVER Foundation — Bigfork, United States","RIVER Telehealth — Helena, United States"],"conds":["Chronic Condition","Chronic Pain","Chronic Disease","Major Depressive Disorder","Post Traumatic Stress Disorder","Anxiety Disorders"],"condg":["Depression","Anxiety","PTSD & trauma","Chronic pain & headache"],"contact":{"n":"Ed Lesofski, M.S.","p":"406-431-4890","e":"ed@riverofchange.org"},"enroll":50000,"eid":"NCT06070766"},{"id":"study-NCT05962424","cat":"studies","name":"HNC: Human Neural Circuits Electrophysiology During Cognition","status":"RECRUITING","phase":"Phase 1","sponsor":"Stanford University","drugs":["ketamine"],"nct":"NCT05962424","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-10-05","official":"Karl Deisseroth, MD, PhD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT05962424","sites":["Stanford University — Palo Alto, United States"],"conds":["Psychiatric Disorder"],"condg":["Other"],"contact":{"n":"Arjay Cordero","p":"650-580-9000","e":"arjayc@stanford.edu"},"enroll":120,"eid":"NCT05962424"},{"id":"study-NCT06103760","cat":"studies","name":"Positioning of Esketamine Treatment in the Real-world Management of Depression","status":"RECRUITING","phase":"Phase 4","sponsor":"Royal North Shore Hospital","drugs":["esketamine"],"nct":"NCT06103760","nsites":1,"countries":"Australia","ccs":["AU"],"start":"2023-10-31","official":"Gin Malhi (Royal North Shore Hospital, University of Sydney)","src":"https://clinicaltrials.gov/study/NCT06103760","sites":["Royal North Shore Hospital — St Leonards, Australia"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Erica Bell","p":"02 9462 9905","e":"NSLHD-researchpoet@health.nsw.gov.au"},"enroll":162,"eid":"NCT06103760"},{"id":"study-NCT05452772","cat":"studies","name":"5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder","status":"RECRUITING","phase":"Phase 2","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT05452772","nsites":3,"countries":"United States","ccs":["US"],"start":"2023-11-01","official":"Matthew Johnson, Ph.D (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT05452772","sites":["University of Alabama at Birmingham — Birmingham, United States","Johns Hopkins University School of Medicine — Baltimore, United States","New York University — New York, United States"],"conds":["Tobacco Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Matthew Johnson, Ph.D","p":"410-550-0056","e":"mwj@jhu.edu"},"enroll":66,"eid":"NCT05452772"},{"id":"study-NCT05068791","cat":"studies","name":"Psilocybin-facilitated Treatment for Chronic Pain","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"University of Alabama at Birmingham","drugs":["psilocybin"],"nct":"NCT05068791","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-11-01","src":"https://clinicaltrials.gov/study/NCT05068791","sites":["UAB Beacon Tower — Birmingham, United States"],"conds":["Fibromyalgia, Primary"],"condg":["Chronic pain & headache"],"contact":{"n":"Peter Hendricks, Ph.D.","p":"205-202-1387","e":"phendricks@uab.edu"},"enroll":30,"eid":"NCT05068791"},{"id":"study-NCT06525584","cat":"studies","name":"Ketamine Infusion as a Method of Cerebral Protection in Children","status":"RECRUITING","phase":"N/A","sponsor":"Kemerovo State Medical University","drugs":["ketamine"],"nct":"NCT06525584","nsites":1,"countries":"Russia","ccs":["RU"],"start":"2023-11-05","src":"https://clinicaltrials.gov/study/NCT06525584","sites":["Artem Ivkin — Kemerovo, Russia"],"conds":["Brain Injuries"],"condg":["Neurology & cognition"],"enroll":196,"eid":"NCT06525584"},{"id":"study-NCT05934669","cat":"studies","name":"IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED","status":"RECRUITING","phase":"Phase 4","sponsor":"University of Oklahoma","drugs":["ketamine"],"nct":"NCT05934669","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-11-14","official":"Ryan Mckee, MD (University of Oklahoma)","src":"https://clinicaltrials.gov/study/NCT05934669","sites":["University of Oklahoma Health Sciences Center — Oklahoma City, United States"],"conds":["Laceration of Skin","Anxiety","Discharge Time"],"condg":["Anxiety"],"contact":{"n":"Gavely Toor, DO","p":"405-271-2429","e":"gavely-toor@ouhsc.edu"},"enroll":90,"eid":"NCT05934669"},{"id":"study-NCT06140927","cat":"studies","name":"Effect of Ketamine on Intraoperative Motor Evoked Potentials","status":"RECRUITING","phase":"Phase 3","sponsor":"University of California, San Francisco","drugs":["ketamine"],"nct":"NCT06140927","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-12-01","official":"Marc Buren, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06140927","sites":["University of California, San Francisco — San Francisco, United States"],"conds":["Spine Fusion","Spine Tumor","Spinal Stenosis"],"condg":["Other"],"contact":{"n":"Marc Buren, MD","p":"4154768369","e":"marc.buren@ucsf.edu"},"enroll":20,"eid":"NCT06140927"},{"id":"study-NCT06480201","cat":"studies","name":"Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression","status":"RECRUITING","phase":"Phase 1","sponsor":"Texas A&M University","drugs":["ketamine"],"nct":"NCT06480201","nsites":2,"countries":"United States","ccs":["US"],"start":"2024-01-01","src":"https://clinicaltrials.gov/study/NCT06480201","sites":["Wells Medicine — Houston, United States","Texas A&M (Houston Methodist Hospital Location) — Houston, United States"],"conds":["Healthy","Major Depressive Disorder","Treatment Resistant Depression"],"condg":["Depression","Healthy volunteers"],"contact":{"n":"Julia Engelhardt","p":"7136777595","e":"epmadlab@tamu.edu"},"enroll":100,"eid":"NCT06480201"},{"id":"study-NCT06480500","cat":"studies","name":"i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial","status":"RECRUITING","phase":"Phase 2","sponsor":"University Health Network, Toronto","drugs":["ketamine"],"nct":"NCT06480500","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2024-01-02","official":"Rodrigo Mansur (University Health Network, Toronto)","src":"https://clinicaltrials.gov/study/NCT06480500","sites":["Toronto General Hospital — Toronto, Canada"],"conds":["Major Depressive Disorder","Suicide","Treatment Resistant Depression"],"condg":["Depression"],"contact":{"n":"Simryn Selby, MSc","p":"416-603-5800","e":"simryn.selby@uhn.ca"},"enroll":110,"eid":"NCT06480500"},{"id":"study-NCT06725277","cat":"studies","name":"The OBSERVE Protocol","status":"RECRUITING","sponsor":"Yale University","drugs":["esketamine","ketamine"],"nct":"NCT06725277","nsites":8,"countries":"United States","ccs":["US"],"start":"2024-01-21","official":"Samuel Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06725277","sites":["Mood Institute — Milford, United States","Yale School of Medicine — New Haven, United States","Emory University — Atlanta, United States","University of Michigan — Ann Arbor, United States","LifeStance Health — Moore, United States","Athena Care — Nashville, United States","Houston Center for Advanced Psychiatric Treatment — Bellaire, United States","Seattle NTC — Seattle, United States"],"conds":["Major Depression Disorder"],"condg":["Depression"],"contact":{"n":"Cindy Voghell","p":"203-737-4784","e":"cynthia.voghell@yale.edu"},"enroll":450,"eid":"NCT06725277"},{"id":"study-NCT06087510","cat":"studies","name":"Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes","status":"RECRUITING","phase":"Phase 4","sponsor":"Peking University First Hospital","drugs":["esketamine"],"nct":"NCT06087510","nsites":1,"countries":"China","ccs":["CN"],"start":"2024-01-24","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT06087510","sites":["Beijing University First Hospital — Beijing, China"],"conds":["Scoliosis Correction","Postoperative Analgesia","Esketamine","Dexmedetomidine","Chronic Postsurgical Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Dong-Xin Wang, MD, PhD","p":"8610-83572784","e":"wangdongxin@hotmail.com"},"enroll":312,"eid":"NCT06087510"},{"id":"study-NCT06213324","cat":"studies","name":"Neural Circuit Effects of Ketamine in Depression","status":"RECRUITING","phase":"Phase 4","sponsor":"Icahn School of Medicine at Mount Sinai","drugs":["ketamine"],"nct":"NCT06213324","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-01-31","official":"James Murrough, MD/PhD (Icahn School of Medicine at Mount Sinai); Laurel Morris (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT06213324","sites":["Icahn School of Medicine at Mount Sinai — New York, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Sibilla Masieri","e":"sibilla.masieri@mssm.edu"},"enroll":120,"eid":"NCT06213324"},{"id":"study-NCT06125054","cat":"studies","name":"Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction","status":"RECRUITING","phase":"Phase 2","sponsor":"Dr. med. Marcus Herdener","drugs":["ketamine"],"nct":"NCT06125054","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2024-02-05","src":"https://clinicaltrials.gov/study/NCT06125054","sites":["Psychiatric University Hospital Zurich, University of Zurich — Zurich, Switzerland"],"conds":["Cocaine Use Disorder","Cocaine Dependence"],"condg":["Addiction & substance use"],"contact":{"n":"Marcus Herdener, PD Dr. med.","p":"+41583845810","e":"marcus.herdener@bli.uzh.ch"},"enroll":120,"eid":"NCT06125054"},{"id":"study-NCT06067737","cat":"studies","name":"Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder","status":"RECRUITING","phase":"Phase 2","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT06067737","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-02-08","official":"Sandeep Nayak, MD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06067737","sites":["Johns Hopkins Center for Psychedelic and Consciousness Research — Baltimore, United States"],"conds":["Opioid Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Andrew L Gaddis, MD","p":"410-550-0048","e":"gaddis@jhmi.edu"},"enroll":90,"eid":"NCT06067737"},{"id":"study-NCT06394284","cat":"studies","name":"Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral Injury","status":"RECRUITING","phase":"Phase 3","sponsor":"Herzog Hospital","drugs":["MDMA"],"nct":"NCT06394284","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2024-02-18","official":"Anna Harwood-Gross, PhD (Metiv Israel Psychotrauma Center); Pinhas Danon, Prof (Herzog Medical Center)","src":"https://clinicaltrials.gov/study/NCT06394284","sites":["METIV Israel Psychotrauma Center, Herzog Medical Center — Jerusalem, Israel"],"conds":["PTSD, Post Traumatic Stress Disorder","Moral Injury"],"condg":["PTSD & trauma"],"contact":{"n":"Moriya Rahmani, PhD","p":"0097226264889","e":"moriya@metiv.org"},"enroll":60,"eid":"NCT06394284"},{"id":"study-NCT05940324","cat":"studies","name":"Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)","status":"RECRUITING","phase":"Phase 2","sponsor":"Stanford University","drugs":["ketamine"],"nct":"NCT05940324","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-02-24","src":"https://clinicaltrials.gov/study/NCT05940324","sites":["Department of Psychiatry & Behavioral Sciences — Stanford, United States"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"contact":{"n":"Pavithra Mukunda, MS","p":"6504972578","e":"ocdresearch@stanford.edu"},"enroll":150,"eid":"NCT05940324"},{"id":"study-NCT06161805","cat":"studies","name":"Esketamine as Treatment for Chronic Pain Due to Endometriosis: a RCT Study","status":"RECRUITING","phase":"Phase 3","sponsor":"Reinier de Graaf Groep","drugs":["esketamine"],"nct":"NCT06161805","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2024-03-01","src":"https://clinicaltrials.gov/study/NCT06161805","sites":["Nederlandse Endometriose Kliniek, Reinier de Graaf Gasthuis — Delft, Netherlands"],"conds":["Endometriosis","Chronic Pelvic Pain Syndrome"],"condg":["Chronic pain & headache"],"contact":{"n":"Mathijs Blikkendaal, MD, PhD","p":"070 340 1222","e":"M.Blikkendaal@rdgg.nl"},"enroll":56,"eid":"NCT06161805"},{"id":"study-NCT05265546","cat":"studies","name":"Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain","status":"RECRUITING","phase":"Phase 1","sponsor":"University of California, Berkeley","drugs":["psilocybin"],"nct":"NCT05265546","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-03-08","src":"https://clinicaltrials.gov/study/NCT05265546","sites":["University of California, Berkeley — Berkeley, United States"],"conds":["Perception Disorders"],"condg":["Other"],"contact":{"n":"BCSP Staff","p":"(669) 244-2436","e":"bcspresearchsubjects@berkeley.edu"},"enroll":80,"eid":"NCT05265546"},{"id":"study-NCT05995769","cat":"studies","name":"Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder","status":"RECRUITING","phase":"Phase 2","sponsor":"University of Calgary","drugs":["psilocybin"],"nct":"NCT05995769","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2024-03-20","official":"Leah Mayo, PhD (University of Calgary)","src":"https://clinicaltrials.gov/study/NCT05995769","sites":["University of Calgary — Calgary, Canada"],"conds":["Alcohol Use Disorder","Alcoholism"],"condg":["Addiction & substance use"],"contact":{"n":"Kaitlin O'Grady","p":"587-893-0257","e":"pactlab@ucalgary.ca"},"enroll":128,"eid":"NCT05995769"},{"id":"study-NCT05821972","cat":"studies","name":"Nebulized Dexmedetomidine Combined With Ketamine Versus Nebulized Dexmedetomidine for Cleft Palate","status":"RECRUITING","phase":"Phase 4","sponsor":"Assiut University","drugs":["ketamine"],"nct":"NCT05821972","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2024-04-10","src":"https://clinicaltrials.gov/study/NCT05821972","sites":["Assiut University — Asyut, Egypt"],"conds":["Sedation","Emergence Delirium"],"condg":["Other"],"contact":{"n":"Fatma N. Mohamed, M.D.","p":"+201003633992","e":"fatmanabil2012@aun.edu.eg"},"enroll":60,"eid":"NCT05821972"},{"id":"study-NCT05219175","cat":"studies","name":"MDMA for Co-occurring PTSD and OUD After Childbirth","status":"RECRUITING","phase":"Phase 2","sponsor":"University of New Mexico","drugs":["MDMA"],"nct":"NCT05219175","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-04-16","official":"Hadya Khawaja, MS, CIP (UNM Health Sciences Human Research Protections Program)","src":"https://clinicaltrials.gov/study/NCT05219175","sites":["University of New Mexico Health Sciences — Albuquerque, United States"],"conds":["Stress Disorders, Post-Traumatic","Opioid Use Disorder"],"condg":["PTSD & trauma","Addiction & substance use"],"contact":{"n":"Lawrence M Leeman, MD MPH","p":"5054106990","e":"lleeman@salud.unm.edu"},"enroll":15,"eid":"NCT05219175"},{"id":"study-NCT06200155","cat":"studies","name":"Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy","status":"RECRUITING","phase":"Phase 2","sponsor":"M.D. Anderson Cancer Center","drugs":["psilocybin"],"nct":"NCT06200155","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-04-16","official":"Moran Amit, MD (M.D. Anderson Cancer Center)","src":"https://clinicaltrials.gov/study/NCT06200155","sites":["MD Anderson Cancer Center — Houston, United States"],"conds":["Depression, Anxiety","Psilocybin-Assisted Psychotherapy","Advanced Cancer"],"condg":["Depression","Anxiety","Cancer-related distress"],"contact":{"n":"Moran Amit, MD","p":"(713) 794-5304","e":"mamit@mdanderson.org"},"enroll":48,"eid":"NCT06200155"},{"id":"study-NCT06319378","cat":"studies","name":"Cancer Related Major Depression Treated With a Single Dose of Psilocybin","status":"RECRUITING","phase":"Phase 2","sponsor":"Section for Affective Disorders; Northern Stockholm Psychiatry","drugs":["psilocybin"],"nct":"NCT06319378","nsites":4,"countries":"Sweden","ccs":["SE"],"start":"2024-04-19","official":"Johan Lundberg, MD PhD (Norra Stockholms Psykiatri and Karolinska Institutet)","src":"https://clinicaltrials.gov/study/NCT06319378","sites":["region Västra Götaland — Gothenburg, Sweden","Norra Stockholms Psykiatri — Stockholm, Sweden","Psykiatriska Kliniken, Akademiska Sjukhuset — Uppsala, Sweden","Örebro sjukhus — Örebro, Sweden"],"conds":["MDD"],"condg":["Depression"],"contact":{"n":"Johan Lundberg","p":"0812340000","e":"johan.lundberg@ki.se"},"enroll":100,"eid":"NCT06319378"},{"id":"study-NCT06355414","cat":"studies","name":"Psilocybin in Chronic Low Back Pain and Depression","status":"RECRUITING","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT06355414","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-04-22","official":"David B Yaden, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06355414","sites":["Johns Hopkins University School of Medicine — Baltimore, United States"],"conds":["Chronic Low-back Pain","Depression"],"condg":["Depression","Chronic pain & headache"],"contact":{"n":"Arozo Azimi, BA","p":"410-550-1140","e":"LowBackPain@jh.edu"},"enroll":40,"eid":"NCT06355414"},{"id":"study-NCT06410599","cat":"studies","name":"Pharmacologic Treatment Augmentation in Chronic Depression","status":"RECRUITING","phase":"Phase 2","sponsor":"University Hospital Tuebingen","drugs":["ketamine"],"nct":"NCT06410599","nsites":2,"countries":"Germany","ccs":["DE"],"start":"2024-04-29","official":"Martin Walter, Prof. Dr. (Universitätsklinikum Jena - Klinik für Psychiatrie und Psychotherapie); Andreas J Fallgatter, Prof. Dr. (Universitätsklinikum…","src":"https://clinicaltrials.gov/study/NCT06410599","sites":["Universitätsklinikum Tübingen - Klinik für Psychiatrie und Psychotherapie — Tübingen, Germany","Universitätsklinikum Jena - Klinik für Psychiatrie und Psychotherapie — Jena, Germany"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Martin Walter, Prof. Dr.","p":"+493641 9390101","e":"martin.walter@med.uni-jena.de"},"enroll":60,"eid":"NCT06410599"},{"id":"study-NCT06085937","cat":"studies","name":"Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department","status":"RECRUITING","phase":"Phase 1","sponsor":"Lindsay Maguire, MD","drugs":["ketamine"],"nct":"NCT06085937","nsites":2,"countries":"United States","ccs":["US"],"start":"2024-05-01","src":"https://clinicaltrials.gov/study/NCT06085937","sites":["University of Kansas Strawberry Hill Campus — Kansas City, United States","University of Kansas Medical Center Emergency Department — Kansas City, United States"],"conds":["Suicide","Suicidal Ideation","Depression"],"condg":["Depression"],"contact":{"n":"Lindsay Maguire, MD","p":"913-588-3580","e":"lmaguire@kumc.edu"},"enroll":50,"eid":"NCT06085937"},{"id":"study-NCT06364540","cat":"studies","name":"Nebulized Ketamine to Nebulized Fentanyl for Treating Acute Painful Conditions in the ED","status":"RECRUITING","phase":"Phase 4","sponsor":"Antonios Likourezos","drugs":["ketamine"],"nct":"NCT06364540","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-05-01","official":"Sergey Motov, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT06364540","sites":["Maimonides Medical Center — Brooklyn, United States"],"conds":["Pain, Acute"],"condg":["Chronic pain & headache"],"contact":{"n":"Antonios Likourezos, MA, MPH","p":"718-283-6896","e":"alikourezos@maimo.org"},"enroll":150,"eid":"NCT06364540"},{"id":"study-NCT06368492","cat":"studies","name":"The Impact of Psilocybin on Pain in Fibromyalgia Patients","status":"RECRUITING","phase":"N/A","sponsor":"Maastricht University","drugs":["psilocybin"],"nct":"NCT06368492","nsites":2,"countries":"Netherlands","ccs":["NL"],"start":"2024-05-03","official":"Johannes G. Ramaekers, PhD (Maastricht University)","src":"https://clinicaltrials.gov/study/NCT06368492","sites":["Maastricht University — Maastricht, Netherlands","Leiden University Medical Center — Leiden, Netherlands"],"conds":["Fibromyalgia"],"condg":["Chronic pain & headache"],"contact":{"n":"Mauro Cavarra, MSc","p":"‭+310683029784‬","e":"fpn-pim_p137@maastrichtuniversity.nl"},"enroll":35,"eid":"NCT06368492"},{"id":"study-NCT05577247","cat":"studies","name":"Belief Updating in Treatment Resistant Depression","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","drugs":["ketamine"],"nct":"NCT05577247","nsites":1,"countries":"France","ccs":["FR"],"start":"2024-05-13","src":"https://clinicaltrials.gov/study/NCT05577247","sites":["GH Pitié Salpêtrière — Paris, France"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"contact":{"n":"Philippe FOSSATI, PUPH","p":"+33142162891","e":"philippe.fossati@aphp.fr"},"enroll":60,"eid":"NCT05577247"},{"id":"study-NCT06378229","cat":"studies","name":"Psilocybin for Hospitalized Patients with Treatment-resistant Depression","status":"RECRUITING","phase":"Phase 2","sponsor":"University Hospital, Ghent","drugs":["psilocybin"],"nct":"NCT06378229","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2024-05-21","official":"Gilbert Lemmens, Prof. dr. (University Hospital, Ghent)","src":"https://clinicaltrials.gov/study/NCT06378229","sites":["Ghent University Hospital — Ghent, Belgium"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"contact":{"n":"Cisse Geleyn, dr.","p":"003293328742","e":"cisse.geleyn@uzgent.be"},"enroll":100,"eid":"NCT06378229"},{"id":"study-NCT06278779","cat":"studies","name":"Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression","status":"RECRUITING","phase":"Phase 4","sponsor":"The George Institute","drugs":["esketamine","ketamine"],"nct":"NCT06278779","nsites":7,"countries":"Australia","ccs":["AU"],"start":"2024-06-03","official":"Colleen Loo (The University of New South Wales)","src":"https://clinicaltrials.gov/study/NCT06278779","sites":["Royal Prince Alfred Hospital — Camperdown, Australia","Black Dog Institute — Randwick, Australia","Ramsay Clinic Northside — St Leonards, Australia","Ramsay Clinic Lakeside — Warners Bay, Australia","Gold Coast University Hospital — Southport, Australia","Ramsay Clinic Albert Road — Melbourne, Australia","Royal Melbourne Hospital — Parkville, Australia"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"contact":{"n":"Abigail Hansen","p":"80524300","e":"Trek@georgeinstitute.org.au"},"enroll":162,"eid":"NCT06278779"},{"id":"study-NCT06399185","cat":"studies","name":"Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort","status":"RECRUITING","phase":"Phase 4","sponsor":"Peking University First Hospital","drugs":["esketamine"],"nct":"NCT06399185","nsites":2,"countries":"China","ccs":["CN"],"start":"2024-06-06","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT06399185","sites":["Peking University First Hospital — Beijing, China","Peking University Shenzhen Hospital — Shenzhen, China"],"conds":["Urinary Catheter","Catheter-related Bladder Discomfort","Dexmedetomidine","Esketamine"],"condg":["Other"],"contact":{"n":"Rui Zhang, MD","p":"+8618810662529","e":"zhangrui_bjmu@163.com"},"enroll":1740,"eid":"NCT06399185"},{"id":"study-NCT05883540","cat":"studies","name":"Lysergic Acid Diethylamide (LSD) in Palliative Care","status":"RECRUITING","phase":"Phase 2","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD"],"nct":"NCT05883540","nsites":4,"countries":"Switzerland","ccs":["CH"],"start":"2024-06-09","official":"Yasmin Schmid, PD Dr. med. (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05883540","sites":["University Hospital Basel, Division of Clinical Pharmacology and Toxicology — Basel, Switzerland","University Hospital Geneva, Palliative medicine department — Collonge-Bellerive, Switzerland","Spital Uster AG, Division of Internal Medicine — Uster, Switzerland","University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative Care — Zurich, Switzerland"],"conds":["Palliative Care","Pain","Anxiety","Depression","Demoralization","Psychological Distress"],"condg":["Depression","Anxiety","End-of-life & palliative","Chronic pain & headache"],"contact":{"n":"Yasmin Schmid, PD Dr. med.","p":": +41 61 328 68 47","e":"yasmin.schmid@usb.ch"},"enroll":60,"eid":"NCT05883540"},{"id":"study-NCT06427707","cat":"studies","name":"The Effect of Adding Either Propofol or Ketamine to Magnesium and Lidocaine Infusions in Nasal Surgeries.","status":"RECRUITING","phase":"Phase 2/Phase 3","sponsor":"Ain Shams University","drugs":["ketamine"],"nct":"NCT06427707","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2024-06-15","src":"https://clinicaltrials.gov/study/NCT06427707","sites":["Ain Shams University — Cairo, Egypt"],"conds":["Intraoperative Bleeding"],"condg":["Other"],"contact":{"n":"RANIA M Hussien, MD","p":"01000544520","e":"drrania_maamon@med.asu.edu.eg"},"enroll":90,"eid":"NCT06427707"},{"id":"study-NCT06506565","cat":"studies","name":"Low-Dose Ketamine Infusion During Burn Wound Care","status":"RECRUITING","phase":"Phase 4","sponsor":"University of Tennessee","drugs":["ketamine"],"nct":"NCT06506565","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-07-08","src":"https://clinicaltrials.gov/study/NCT06506565","sites":["Regional One Health — Memphis, United States"],"conds":["Burn","Pain","Dissociation","Opioid"],"condg":["Addiction & substance use","Chronic pain & headache"],"contact":{"n":"David M Hill, Pharm.D.","p":"1-901-545-7100","e":"dhill19@uthsc.edu"},"enroll":140,"eid":"NCT06506565"},{"id":"study-NCT06707532","cat":"studies","name":"The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)","status":"RECRUITING","phase":"N/A","sponsor":"4th Military Clinical Hospital with Polyclinic, Poland","drugs":["ketamine"],"nct":"NCT06707532","nsites":1,"countries":"Poland","ccs":["PL"],"start":"2024-08-01","official":"Marek Szamborski, MD (Senior Assistant)","src":"https://clinicaltrials.gov/study/NCT06707532","sites":["4th Military Clinical Hospital with Polyclinic — Wroclaw, Poland"],"conds":["Kidney Failure, Acute","Myopathy; Drugs","Heart Arrhythmia","Succinylcholine Sensitivity","Muscle Relaxation","General Anesthetic Drug Adverse Reaction"],"condg":["Other"],"contact":{"n":"Marek Szamborski, MD","p":"698-448-639","e":"mszamborski@4wsk.pl"},"enroll":32,"eid":"NCT06707532"},{"id":"study-NCT06455293","cat":"studies","name":"Psilocybin Therapy for Depression in Parkinson's Disease","status":"RECRUITING","phase":"Phase 2","sponsor":"Joshua Woolley, MD, PhD","drugs":["psilocybin"],"nct":"NCT06455293","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-08-19","official":"Joshua Woolley, MD,PhD (University of California, San Francisco); Ellen Bradley, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06455293","sites":["University of California, San Francisco — San Francisco, United States"],"conds":["Parkinson Disease","Depression"],"condg":["Depression","Neurology & cognition"],"contact":{"n":"Brigette Sosa","p":"(415) 935-3489","e":"pdp2@ucsf.edu"},"enroll":60,"eid":"NCT06455293"},{"id":"study-NCT05973851","cat":"studies","name":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","phase":"Phase 3","sponsor":"Dr. Inge Winter","drugs":["esketamine","ketamine"],"nct":"NCT05973851","nsites":12,"countries":"Austria; Germany; Greece; Italy; Spain; United Kingdom","ccs":["AT","DE","ES","GB","GR","IT"],"start":"2024-08-31","src":"https://clinicaltrials.gov/study/NCT05973851","sites":["Medical University Innsbruck — Innsbruck, Austria","Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld — Bielefeld, Germany","LWL-Klinik Dortmund, Bereich Forschung & Wissenschaft — Dortmund, Germany","University Hospital Frankfurt am Main - Goethe University — Frankfurt am Main, Germany","Westfälische Wilhelms-Universität Münster — Münster, Germany","Eginition Hospital, department of psychiatry — Athens, Greece","Universita degli Studi di Brescia — Brescia, Italy","University of Cagliari — Cagliari, Italy"],"conds":["Major Depressive Disorder","Treatment Resistant Depression"],"condg":["Depression"],"contact":{"n":"Inge Winter, Dr.","p":"+31875553227","e":"i.winter@umcutrecht.nl"},"enroll":418,"eid":"NCT05973851"},{"id":"study-NCT05770375","cat":"studies","name":"Tolerability of MDMA in Schizophrenia","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Anya Bershad, MD, PhD","drugs":["MDMA"],"nct":"NCT05770375","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-09-01","src":"https://clinicaltrials.gov/study/NCT05770375","sites":["UCLA — Los Angeles, United States"],"conds":["Schizophrenia"],"condg":["Other"],"contact":{"n":"Gerard De Vera","p":"310-794-5577","e":"gdevera@mednet.ucla.edu"},"enroll":20,"eid":"NCT05770375"},{"id":"study-NCT06402955","cat":"studies","name":"Imaging Depression in Parkinson's Disease","status":"RECRUITING","phase":"Phase 2","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT06402955","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-09-01","src":"https://clinicaltrials.gov/study/NCT06402955","sites":["Yale University — New Haven, United States"],"conds":["Parkinson's Disease","Major Depressive Disorder"],"condg":["Depression","Neurology & cognition"],"contact":{"n":"Sophie Holmes","p":"2036854066","e":"sophie.holmes@yale.edu"},"enroll":120,"eid":"NCT06402955"},{"id":"study-NCT06898606","cat":"studies","name":"Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Federal University of Latin American Integration","drugs":["psilocybin"],"nct":"NCT06898606","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2024-09-05","official":"Francisney P Nascimento, 1 (Federal University of Latin American Integration)","src":"https://clinicaltrials.gov/study/NCT06898606","sites":["Federal University of Latin American Integration — Foz do Iguaçu, Brazil"],"conds":["Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Francisney P Nascimento, 1","p":"+55 45 99933-3479","e":"ensaios.clinicos.lcp@unila.edu.br"},"enroll":24,"eid":"NCT06898606"},{"id":"study-NCT06247839","cat":"studies","name":"The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder","status":"RECRUITING","phase":"Phase 3","sponsor":"Sharmin Ghaznavi","drugs":["psilocybin"],"nct":"NCT06247839","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-09-10","official":"Sharmin Ghaznavi, M.D., Ph.D. (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT06247839","sites":["Athinoula A. Martinos Center for Biomedical Imaging — Charlestown, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Artana Arora, B.S.","p":"6177262290","e":"cnpcogneuro@mgh.harvard.edu"},"enroll":20,"eid":"NCT06247839"},{"id":"study-NCT05864053","cat":"studies","name":"(2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Rush University Medical Center","drugs":["ketamine"],"nct":"NCT05864053","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-09-19","official":"Asokumar Buvanendran, MD (Rush University Medical Center)","src":"https://clinicaltrials.gov/study/NCT05864053","sites":["Rush University Medical Center — Chicago, United States"],"conds":["Pain, Neuropathic"],"condg":["Chronic pain & headache"],"contact":{"n":"Robert J McCarthy, Pharm D","p":"3125630448","e":"robert_j_mccarthy@rush.edu"},"enroll":25,"eid":"NCT05864053"},{"id":"study-NCT06001749","cat":"studies","name":"Psilocybin in Cancer Pain Study","status":"RECRUITING","phase":"Phase 2","sponsor":"Yvan Beaussant, MD, MSci","drugs":["psilocybin"],"nct":"NCT06001749","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-09-23","official":"Yvan Beaussant, MD (Dana-Farber Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT06001749","sites":["Dana-Farber Cancer Institute — Boston, United States"],"conds":["Opioid-Related Disorders","Pain Management","Pain Management and Care","Advanced Cancer","Advanced Cancers"],"condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"contact":{"n":"Amani Ingram","p":"8572151476","e":"patresearch@dfci.harvard.edu"},"enroll":15,"eid":"NCT06001749"},{"id":"study-NCT07269964","cat":"studies","name":"At-Home tDCS as Maintenance Therapy","status":"RECRUITING","phase":"N/A","sponsor":"Technical University of Munich","drugs":["esketamine","ketamine"],"nct":"NCT07269964","nsites":2,"countries":"Germany","ccs":["DE"],"start":"2024-10-01","src":"https://clinicaltrials.gov/study/NCT07269964","sites":["Technical University of Munich, TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy, Munich, — München, Germany","Department of Psychiatry and Psychotherapy, Technical University of Munich, University Hospital — München, Germany"],"conds":["MDD","Severe Depression","Major Depressive Episode"],"condg":["Depression"],"contact":{"n":"Ulrike Vogelmann, Dr. med.","p":"+4917661535471","e":"ulrike.vogelmann@mri.tum.de"},"enroll":30,"eid":"NCT07269964"},{"id":"study-NCT06414356","cat":"studies","name":"The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD","status":"RECRUITING","phase":"Phase 4","sponsor":"Margaux M. Salas, PhD","drugs":["ketamine"],"nct":"NCT06414356","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-10-02","src":"https://clinicaltrials.gov/study/NCT06414356","sites":["Brooke Army Medical Center — San Antonio, United States"],"conds":["Neuropathic Pain","PTSD"],"condg":["PTSD & trauma","Chronic pain & headache"],"contact":{"n":"Margaux M Salas, PhD","p":"210-473-7447","e":"margaux.m.salas.ctr@health.mil"},"enroll":30,"eid":"NCT06414356"},{"id":"study-NCT06752759","cat":"studies","name":"Nebulized Ketamine for the Treatment of Major Depressive Disorder","status":"RECRUITING","phase":"Phase 3","sponsor":"Theresa Jacob, PhD, MPH","drugs":["ketamine"],"nct":"NCT06752759","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-10-16","official":"Theresa Jacob, PhD, MPH (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT06752759","sites":["Maimonides Medical Center — Brooklyn, United States"],"conds":["Severe Depression","Moderate Depression","Ketamine","Midazolam","Peripheral Nervous System Agents","Central Nervous System Agents"],"condg":["Depression","Anxiety"],"contact":{"n":"Jessica Poster, MD","p":"718-283-8170","e":"JPoster@maimo.org"},"enroll":40,"eid":"NCT06752759"},{"id":"study-NCT06442423","cat":"studies","name":"Open-Label Psilocybin Study in Transdiagnostic Population","status":"RECRUITING","phase":"Phase 1","sponsor":"Yale University","drugs":["psilocybin"],"nct":"NCT06442423","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-10-17","official":"Benjamin Kelmendi, MD (Yale University); Gabrielle Agin-Liebes, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06442423","sites":["Connecticut Mental Health Center - Yale School of Medicine — New Haven, United States"],"conds":["Transdiagnostic","Depression - Major Depressive Disorder","Anxiety","PTSD Symptoms","PTSD","Substance Use"],"condg":["Depression","Anxiety","PTSD & trauma","Addiction & substance use"],"contact":{"n":"Sarah Shnayder","p":"(203) 737-3404","e":"enact@yale.edu"},"enroll":50,"eid":"NCT06442423"},{"id":"study-NCT06508710","cat":"studies","name":"Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients","status":"RECRUITING","phase":"Phase 3","sponsor":"Assistance Publique - Hôpitaux de Paris","drugs":["ketamine"],"nct":"NCT06508710","nsites":4,"countries":"France","ccs":["FR"],"start":"2024-10-20","official":"Romain COLLE (Service Hospitalo-Universitaire de Psychiatrie - Hôpital Bicêtre)","src":"https://clinicaltrials.gov/study/NCT06508710","sites":["Psychiatry unit — Le Kremlin-Bicêtre, France","EPS Barthélémy Durand — Étampes, France","Bicetre Hospital - CRC — Le Kremlin-Bicêtre, France","CEA/SHFJ — Orsay, France"],"conds":["Major Depressive Episode"],"condg":["Depression"],"contact":{"n":"Romain COLLE","p":"+33145212524","e":"romain.colle@aphp.fr"},"enroll":60,"eid":"NCT06508710"},{"id":"study-NCT06626139","cat":"studies","name":"Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers","status":"RECRUITING","phase":"Phase 2","sponsor":"Robin Carhart-Harris, PhD, MA","drugs":["psilocybin"],"nct":"NCT06626139","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-10-20","official":"Robin Carhart-Harris, PhD (University of California, San Francisco); Jennifer Mitchell, PhD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06626139","sites":["UCSF Mission Bay — San Francisco, United States"],"conds":["Healthy Participants With Lower-than-average Mental…"],"condg":["Healthy volunteers"],"contact":{"n":"Hannes Kettner, MSc","p":"4158495452","e":"setandsetting@ucsf.edu"},"enroll":120,"eid":"NCT06626139"},{"id":"study-NCT06511908","cat":"studies","name":"Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression","status":"RECRUITING","phase":"Phase 2","sponsor":"National Institute of Mental Health (NIMH)","drugs":["ketamine"],"nct":"NCT06511908","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-11-06","official":"Carlos A Zarate, M.D. (National Institute of Mental Health (NIMH))","src":"https://clinicaltrials.gov/study/NCT06511908","sites":["National Institutes of Health Clinical Center — Bethesda, United States"],"conds":["Suicide","Depressive Disorder, Treatment-Resistant","Ketamine","Molecular Mechanisms of Pharmacological Action","Neurotransmitter Agents","Excitatory Amino Acid Agents"],"condg":["Depression"],"contact":{"n":"Solaleh Azimipour","p":"(301) 768-0049","e":"solaleh.azimipour@nih.gov"},"enroll":50,"eid":"NCT06511908"},{"id":"study-NCT06824532","cat":"studies","name":"Veteran's Perceptions of Ketamine-Assisted Psychotherapy for Depression and End-of-Life","status":"RECRUITING","sponsor":"Albany Research Institute, Inc.","drugs":["ketamine"],"nct":"NCT06824532","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-11-08","official":"Caitlin Holley, Ph.D. (Albany Research Institute, Inc.)","src":"https://clinicaltrials.gov/study/NCT06824532","sites":["Stratton VA Medical Center — Albany, United States"],"conds":["Depression"],"condg":["Depression"],"contact":{"n":"Caitlin Holley, Ph.D.","p":"518-626-5365","e":"caitlin.holley@va.gov"},"enroll":30,"eid":"NCT06824532"},{"id":"study-NCT06660381","cat":"studies","name":"Psilocybin-assisted Treatment for Cannabis Use Disorder","status":"RECRUITING","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT06660381","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-11-08","official":"Albert Garcia-Romeu, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06660381","sites":["Johns Hopkins Center for Psychedelic and Consciousness Research — Baltimore, United States"],"conds":["Cannabis Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Ian Geithner, MPS","p":"410-550-1972","e":"igeithn1@jhmi.edu"},"enroll":12,"eid":"NCT06660381"},{"id":"study-NCT06526078","cat":"studies","name":"Cognitive Training as an Adjunct to Ketamine in Real-world Clinics","status":"RECRUITING","phase":"N/A","sponsor":"University of Pittsburgh","drugs":["ketamine"],"nct":"NCT06526078","nsites":3,"countries":"United States","ccs":["US"],"start":"2024-11-12","official":"Rebecca B Price, PhD (University of Pittsburgh)","src":"https://clinicaltrials.gov/study/NCT06526078","sites":["Kaiser Foundation Research Institute, a division of Kaiser Foundation Hospitals — Oakland, United States","University of Illinois at Chicago — Chicago, United States","Baylor College of Medicine — Houston, United States"],"conds":["Depression"],"condg":["Depression"],"contact":{"n":"Rebecca B Price, PhD","p":"412-383-2150","e":"ketclinics@pitt.edu"},"enroll":600,"eid":"NCT06526078"},{"id":"study-NCT06044675","cat":"studies","name":"MDMA-Assisted CBCT for PTSD vs CBCT RCT","status":"RECRUITING","phase":"Phase 2","sponsor":"Remedy","drugs":["MDMA"],"nct":"NCT06044675","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2024-11-15","official":"Paul Uy, MD (Remedy Institute); Anne Wagner, PhD (Remedy Institute)","src":"https://clinicaltrials.gov/study/NCT06044675","sites":["Remedy Institute — Toronto, Canada"],"conds":["Post Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"contact":{"n":"Song Ge","p":"4372914747","e":"research@remedyinstitute.ca"},"enroll":60,"eid":"NCT06044675"},{"id":"study-NCT06399263","cat":"studies","name":"Study of Psilocybin for Anorexia in Young Adults","status":"RECRUITING","phase":"Phase 2","sponsor":"Marissa Raymond-Flesch, MD, MPH","drugs":["psilocybin"],"nct":"NCT06399263","nsites":2,"countries":"United States","ccs":["US"],"start":"2024-11-18","official":"Marissa Raymond-Flesch, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06399263","sites":["University of California, San Francisco — San Francisco, United States","University of California, San Francisco — San Francisco, United States"],"conds":["Anorexia Nervosa"],"condg":["Eating disorders"],"contact":{"n":"Lisa Fredenburg, MS","p":"415-993-2486","e":"psilocybin.an.study@ucsf.edu"},"enroll":40,"eid":"NCT06399263"},{"id":"study-NCT06430541","cat":"studies","name":"Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence","status":"RECRUITING","phase":"Phase 1","sponsor":"University of Colorado, Denver","drugs":["psilocybin"],"nct":"NCT06430541","nsites":2,"countries":"United States","ccs":["US"],"start":"2024-11-21","official":"Stacy Fischer, MD (University of Colorado, Denver)","src":"https://clinicaltrials.gov/study/NCT06430541","sites":["Outpatient CTRC — Aurora, United States","University of Colorado Cancer Center — Aurora, United States"],"conds":["Breast Cancer","Ovarian Cancer"],"condg":["Cancer-related distress"],"contact":{"n":"Mary Mancuso","p":"303-724-5729","e":"mary.mancuso@cuanschutz.edu"},"enroll":20,"eid":"NCT06430541"},{"id":"study-NCT04882839","cat":"studies","name":"Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD","status":"RECRUITING","phase":"Phase 2","sponsor":"Beersheva Mental Health Center","drugs":["psilocybin"],"nct":"NCT04882839","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2024-11-25","official":"Oded Arbel, MD (Beersheva Mental Health Center)","src":"https://clinicaltrials.gov/study/NCT04882839","sites":["Beer Sheva Mental Health Center — Beersheba, Israel"],"conds":["Obsessive-compulsive Disorder"],"condg":["OCD"],"contact":{"n":"Oded Arbel, Dr.","p":"+972506576691","e":"oded.arbel@gmail.com"},"enroll":15,"eid":"NCT04882839"},{"id":"study-NCT06951802","cat":"studies","name":"Endometriosis and Pain Treatment by Intraoperative Administration of Low-dose Ketamine","status":"RECRUITING","phase":"Phase 4","sponsor":"Insel Gruppe AG, University Hospital Bern","drugs":["ketamine"],"nct":"NCT06951802","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2024-12-03","official":"Christian Vetter, MD (Dep. of Anaesthesiology and Pain Medicine, Inselsptial Bern)","src":"https://clinicaltrials.gov/study/NCT06951802","sites":["Inselspital Bern — Bern, Switzerland"],"conds":["Endometriosis"],"condg":["Other"],"contact":{"n":"Christian Vetter, MD","p":"+416343776","e":"christian.vetter@insel.ch"},"enroll":118,"eid":"NCT06951802"},{"id":"study-NCT06732089","cat":"studies","name":"Digital Interventions for Adults with Treatment-Resistant Depression: a Pilot Study","status":"RECRUITING","sponsor":"Unity Health Toronto","drugs":["ketamine"],"nct":"NCT06732089","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2024-12-16","official":"Dr. Srihar Krishnan, Ph.D., Peng., F.C.A.E. (Toronto Metropolitan University); Dr. Wendy Lou, Ph.D. (Dalla Lana School of Public Health, University of Toronto)","src":"https://clinicaltrials.gov/study/NCT06732089","sites":["St. Michael's Hospital, Unity Health Toronto — Toronto, Canada"],"conds":["Major Depressive Disorder (MDD)","Major Depressive Episode","Treatment-Resistant Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Dr. Venkat Bhat, M.D., F.R.C.P.C.","p":"416-360-4000","e":"venkat.bhat@unityhealth.to"},"enroll":200,"eid":"NCT06732089"},{"id":"study-NCT06773143","cat":"studies","name":"Effect of Subanesthetic Dose of Esketamine on Sleep Quality","status":"RECRUITING","phase":"N/A","sponsor":"Nanjing First Hospital, Nanjing Medical University","drugs":["esketamine"],"nct":"NCT06773143","nsites":1,"countries":"China","ccs":["CN"],"start":"2024-12-30","official":"xiaoliang wang (The First Affiliated Hospital with Nanjing Medical University)","src":"https://clinicaltrials.gov/study/NCT06773143","sites":["Nanjing First Hospital — Nanjing, China"],"conds":["Insomnia","Breast Cancer Surgery","Esketamine"],"condg":["Cancer-related distress"],"contact":{"n":"wenwen zhang, Dr","p":"+8615366110306","e":"1395626955@qq.com"},"enroll":184,"eid":"NCT06773143"},{"id":"study-NCT06784388","cat":"studies","name":"Personalized DBS Targeting for Treating Depression","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","drugs":["esketamine"],"nct":"NCT06784388","nsites":1,"countries":"China","ccs":["CN"],"start":"2025-01-05","src":"https://clinicaltrials.gov/study/NCT06784388","sites":["The Second Affiliated Hospital of Zhejiang University School of Medicine — Hangzhou, China"],"conds":["Treatment-resistant Depression (TRD)"],"condg":["Depression"],"contact":{"n":"Junming Zhu, Ph.D.","p":"+86 13968055768","e":"dr.zhujunming@zju.edu.cn"},"enroll":5,"eid":"NCT06784388"},{"id":"study-NCT06559826","cat":"studies","name":"Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression","status":"RECRUITING","phase":"Phase 2","sponsor":"Icahn School of Medicine at Mount Sinai","drugs":["ketamine"],"nct":"NCT06559826","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-01-10","official":"James Murrough, MD, PhD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT06559826","sites":["Icahn School of Medicine at Mount Sinai — New York, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Rachel Fremont, MD, PhD","p":"212-241-6539","e":"rachel.fremont@mssm.edu"},"enroll":70,"eid":"NCT06559826"},{"id":"study-NCT06132178","cat":"studies","name":"Psilocybin rTMS for Treatment Resistant Depression","status":"RECRUITING","phase":"Phase 2","sponsor":"University of Texas at Austin","drugs":["psilocybin"],"nct":"NCT06132178","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-01-10","official":"Gregory A Fonzo, Ph.D. (The University of Texas at Austin)","src":"https://clinicaltrials.gov/study/NCT06132178","sites":["Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 — Austin, United States"],"conds":["Treatment Resistant Depression","MDD","Major Depressive Disorder","Recurrent Depression","Depression"],"condg":["Depression"],"contact":{"n":"Lauren K Enten, B.S.A.","p":"512-495-5856","e":"psychedelics@utexas.edu"},"enroll":100,"eid":"NCT06132178"},{"id":"study-NCT06814522","cat":"studies","name":"Psilocybin-Assisted Therapy for Physician Well-Being and Burnout","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"University of California, San Diego","drugs":["psilocybin"],"nct":"NCT06814522","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-01-13","src":"https://clinicaltrials.gov/study/NCT06814522","sites":["UC San Diego — San Diego, United States"],"conds":["Burnout","Burnout, Healthcare Workers"],"condg":["Other"],"contact":{"n":"Vy Nguyen","p":"619-363-2465","e":"vyn014@health.ucsd.edu"},"enroll":30,"eid":"NCT06814522"},{"id":"study-NCT05403086","cat":"studies","name":"Pragmatic Trial of Psilocybin Therapy in Palliative Care","status":"RECRUITING","phase":"Phase 2","sponsor":"Charles S. Grob, M.D.","drugs":["ketamine","psilocybin"],"nct":"NCT05403086","nsites":5,"countries":"United States","ccs":["US"],"start":"2025-01-19","official":"Charles S. Grob, M.D. (Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center)","src":"https://clinicaltrials.gov/study/NCT05403086","sites":["Marin Cancer Care — Greenbrae, United States","University of California, Los Angeles — Los Angeles, United States","University of San Francisco — San Francisco, United States","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — Torrance, United States","Sunstone Therapies — Rockville, United States"],"conds":["Demoralization"],"condg":["Other"],"contact":{"n":"Charles S. Grob, M.D.","p":"(626) 522-8615","e":"pt2pc@lundquist.org"},"enroll":100,"eid":"NCT05403086"},{"id":"study-NCT06090422","cat":"studies","name":"Ketamine for Combined Depression and Alcohol Use Disorder","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"University Hospital of North Norway","drugs":["ketamine"],"nct":"NCT06090422","nsites":1,"countries":"Norway","ccs":["NO"],"start":"2025-01-20","official":"Ole K Grønli, Assoc Prof (University Hospital of North Norway); Andreas W Blomkvist, M.D. (University Hospital of North Norway)","src":"https://clinicaltrials.gov/study/NCT06090422","sites":["Department of Addiction, University Hospital of North Norway — Tromsø, Norway"],"conds":["Depression","Alcohol Use Disorder"],"condg":["Depression","Addiction & substance use"],"contact":{"n":"Andreas W Blomkvist, M.D.","p":"41694637","e":"andreas.wahl.blomkvist@unn.no"},"enroll":34,"eid":"NCT06090422"},{"id":"study-NCT06789705","cat":"studies","name":"Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls","status":"RECRUITING","phase":"N/A","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT06789705","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2025-01-27","official":"Mirjam Christ-Crain, Prof. (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT06789705","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Central Diabetes Insipidus"],"condg":["Other"],"contact":{"n":"Mirjam Christ-Crain, Prof.","p":"+41 61 265 25 25","e":"Mirjam.Christ-Crain@usb.ch"},"enroll":24,"eid":"NCT06789705"},{"id":"study-NCT06713616","cat":"studies","name":"PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study","status":"RECRUITING","phase":"Phase 3","sponsor":"Yale University","drugs":["esketamine","ketamine"],"nct":"NCT06713616","nsites":8,"countries":"United States","ccs":["US"],"start":"2025-01-27","official":"Samuel Wilkinson, MD (Samuel.Wilkinson@yale.edu)","src":"https://clinicaltrials.gov/study/NCT06713616","sites":["Mood Institute — Milford, United States","Yale School of Medicine — New Haven, United States","Emory University — Atlanta, United States","University of Michigan — Ann Arbor, United States","LifeStance Health — Moore, United States","Athena Care — Nashville, United States","Houston Center for Advanced Psychiatric Treatment — Bellaire, United States","Seattle NTC — Seattle, United States"],"conds":["Depression"],"condg":["Depression"],"contact":{"n":"Cindy Voghell","p":"203-737-4784","e":"Cynthia.Voghell@yale.edu"},"enroll":400,"eid":"NCT06713616"},{"id":"study-NCT05866471","cat":"studies","name":"The ENHANCE Study: taVNS and Psilocybin","status":"RECRUITING","phase":"Phase 1","sponsor":"University of Wisconsin, Madison","drugs":["psilocybin"],"nct":"NCT05866471","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-01-27","official":"Charles Raison, MD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT05866471","sites":["University of Wisconsin - Madison — Madison, United States"],"conds":["Healthy","Psychedelic Experiences","Vagus Nerve Stimulation"],"condg":["Healthy volunteers"],"contact":{"n":"Program Manager","p":"608-265-4987","e":"enhance@psychiatry.wisc.edu"},"enroll":108,"eid":"NCT05866471"},{"id":"study-NCT06888128","cat":"studies","name":"State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma","status":"RECRUITING","phase":"Phase 2","sponsor":"Baylor College of Medicine","drugs":["psilocybin"],"nct":"NCT06888128","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-01-30","src":"https://clinicaltrials.gov/study/NCT06888128","sites":["Baylor College of Medicine — Houston, United States"],"conds":["PTSD"],"condg":["PTSD & trauma"],"contact":{"n":"Lynnette A. Averill, Ph.D.","p":"‪(832) 271-6615","e":"emerging@bcm.edu"},"enroll":15,"eid":"NCT06888128"},{"id":"study-NCT06731647","cat":"studies","name":"Non-steroidal Anti-inflammatory Drugs in Pleurodesis","status":"RECRUITING","phase":"Phase 2","sponsor":"Centre Hospitalier Universitaire, Amiens","drugs":["ketamine"],"nct":"NCT06731647","nsites":1,"countries":"France","ccs":["FR"],"start":"2025-02-01","src":"https://clinicaltrials.gov/study/NCT06731647","sites":["Centre Hospitalier Universitaire d'Amiens — Amiens, France"],"conds":["Non-steroidal Anti-inflammatory Drugs","Pleurodesis","Pneumothorax","Pain Management"],"condg":["Chronic pain & headache"],"contact":{"n":"Florent LEVIEL, MD","p":"33 3 22 08 91 09","e":"leviel.florent@chu-amiens.fr"},"enroll":358,"eid":"NCT06731647"},{"id":"study-NCT06772753","cat":"studies","name":"Investigation of Psychedelic Effects in Psychoactive Substances","status":"RECRUITING","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["MDMA","ketamine","psilocybin"],"nct":"NCT06772753","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-02-05","official":"Frederick Barrett, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06772753","sites":["Johns Hopkins Center for Psychedelic and Consciousness Research — Baltimore, United States"],"conds":["Psychedelic Effects in Healthy Volunteers"],"condg":["Healthy volunteers"],"contact":{"n":"Zach Daily","p":"410-550-9777","e":"zdaily1@jh.edu"},"enroll":50,"eid":"NCT06772753"},{"id":"study-NCT06981494","cat":"studies","name":"Dexmedetomidine Versus Dexmedetomidine and Ketamine (Ketodex) in Ear and Nose Surgeries","status":"RECRUITING","phase":"N/A","sponsor":"Sohag University","drugs":["ketamine"],"nct":"NCT06981494","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2025-02-05","src":"https://clinicaltrials.gov/study/NCT06981494","sites":["Faculty of medicine — Sohag, Egypt"],"conds":["Ear and Nose Surgeries With Hypotensive Anaesthesia e.g…"],"condg":["Other"],"enroll":84,"eid":"NCT06981494"},{"id":"study-NCT06788444","cat":"studies","name":"Efficacy of Esketamine for Patients With Irritable Bowel Syndrome","status":"RECRUITING","phase":"N/A","sponsor":"Beijing Tiantan Hospital","drugs":["esketamine"],"nct":"NCT06788444","nsites":1,"countries":"China","ccs":["CN"],"start":"2025-02-08","src":"https://clinicaltrials.gov/study/NCT06788444","sites":["Beijing Tiantan Hospital — Beijing, China"],"conds":["Irritable Bowel Syndrome"],"condg":["Other"],"enroll":552,"eid":"NCT06788444"},{"id":"study-NCT05837845","cat":"studies","name":"MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder","status":"RECRUITING","phase":"Phase 2","sponsor":"Patricia Suppes","drugs":["MDMA"],"nct":"NCT05837845","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-02-10","official":"Trisha Suppes, MD, PhD (VA Palo Alto Healthcare System / Stanford University); Shannon Wiltsey Stirman, PhD (VA Palo Alto Healthcare System / Stanford…","src":"https://clinicaltrials.gov/study/NCT05837845","sites":["VA Palo Alto Health Care System / Stanford University — Palo Alto, United States"],"conds":["PTSD"],"condg":["PTSD & trauma"],"contact":{"n":"Anna Donnelly","p":"650-849-0161","e":"exploratorytherapeuticslab@stanford.edu"},"enroll":30,"eid":"NCT05837845"},{"id":"study-NCT06668571","cat":"studies","name":"Intravenous Ketamine for Treatment-Resistant Depression","status":"RECRUITING","phase":"Phase 2","sponsor":"Mayo Clinic","drugs":["ketamine"],"nct":"NCT06668571","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-02-10","official":"Balwinder Singh, M.D., M.S. (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT06668571","sites":["Mayo Clinic in Rochester — Rochester, United States"],"conds":["Depressive Disorder, Treatment-Resistant","Treatment Resistant Depression (TRD)"],"condg":["Depression"],"contact":{"n":"Nicole Reinicke","p":"507-422-1835","e":"reinicke.nicole@mayo.edu"},"enroll":30,"eid":"NCT06668571"},{"id":"study-NCT06592833","cat":"studies","name":"Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder","status":"RECRUITING","phase":"Phase 2","sponsor":"Icahn School of Medicine at Mount Sinai","drugs":["psilocybin"],"nct":"NCT06592833","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-02-25","official":"James Murrough (Icahn School of Medicine at Mount Sinai); Rachel Fremont (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT06592833","sites":["Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research — New York, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Depression and Anxiety Center Icahn School of Medicine at Mount Sinai","p":"(212) 241-6539","e":"dac@mssm.edu"},"enroll":60,"eid":"NCT06592833"},{"id":"study-NCT06464146","cat":"studies","name":"Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine","status":"RECRUITING","phase":"Phase 3","sponsor":"Assistance Publique - Hôpitaux de Paris","drugs":["ketamine"],"nct":"NCT06464146","nsites":5,"countries":"France","ccs":["FR"],"start":"2025-02-26","official":"Hélène CHAPPUY, MD, PhD (Assistance Publique - Hôpitaux de Paris)","src":"https://clinicaltrials.gov/study/NCT06464146","sites":["Ambroise Paré Hospital — Boulogne-Billancourt, France","Roger Salengro Hospital — Lille, France","Timone Hospital — Marseille, France","Mère-Enfant Hospital — Nantes, France","Hopital Necker Enfants malades — Paris, France"],"conds":["Limb Injury"],"condg":["Other"],"contact":{"n":"Hélène CHAPPUY, MD, PhD","p":"+33 1 44 49 41 26","e":"helene.chappuy@aphp.fr"},"enroll":300,"eid":"NCT06464146"},{"id":"study-NCT05790239","cat":"studies","name":"MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder","status":"RECRUITING","phase":"Phase 2","sponsor":"Stephen Robert Marder","drugs":["MDMA"],"nct":"NCT05790239","nsites":2,"countries":"United States","ccs":["US"],"start":"2025-03-01","official":"Stephen Marder, MD (VA Greater Los Angeles Healthcare System); Stephanie L Taylor, PhD (VA Greater Los Angeles Healthcare System)","src":"https://clinicaltrials.gov/study/NCT05790239","sites":["VA Greater Los Angeles Healthcare System, Westwood campus — Los Angeles, United States","West Los Angeles Veteran Affairs — Los Angeles, United States"],"conds":["Post Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"contact":{"n":"Stephanie L Taylor, PhD","p":"213-505-1140","e":"Stephanie.Taylor8@va.gov"},"enroll":40,"eid":"NCT05790239"},{"id":"study-NCT06815653","cat":"studies","name":"Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs","status":"RECRUITING","phase":"Phase 1","sponsor":"University College, London","drugs":["psilocybin"],"nct":"NCT06815653","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2025-03-01","src":"https://clinicaltrials.gov/study/NCT06815653","sites":["University College London — London, United Kingdom"],"conds":["Healthy"],"condg":["Healthy volunteers"],"contact":{"n":"Jeremy I Skipper","p":"+44 (0)20 7679 2000","e":"dipp-project@ucl.ac.uk"},"enroll":40,"eid":"NCT06815653"},{"id":"study-NCT06731335","cat":"studies","name":"Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN","status":"RECRUITING","phase":"Phase 2","sponsor":"Unity Health Toronto","drugs":["psilocybin"],"nct":"NCT06731335","nsites":2,"countries":"Canada","ccs":["CA"],"start":"2025-03-05","src":"https://clinicaltrials.gov/study/NCT06731335","sites":["St. Michael's Hospital. Unity Health Toronto — Toronto, Canada","St. Michael's Hospital. Unity Health Toronto — Toronto, Canada"],"conds":["Chronic Neuropathic Pain","Pain Management"],"condg":["Chronic pain & headache"],"enroll":30,"eid":"NCT06731335"},{"id":"study-NCT06767566","cat":"studies","name":"Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery","status":"RECRUITING","phase":"Phase 1","sponsor":"University of Utah","drugs":["ketamine"],"nct":"NCT06767566","nsites":2,"countries":"United States","ccs":["US"],"start":"2025-03-28","official":"Grace Lim, MD, MSc (University of Utah)","src":"https://clinicaltrials.gov/study/NCT06767566","sites":["Magee Womens Hospital of UPMC — Pittsburgh, United States","University of Utah — Salt Lake City, United States"],"conds":["Pain","Postpartum Depression"],"condg":["Depression","Chronic pain & headache"],"contact":{"n":"Natalie Bennion, MPH","p":"385-209-1185","e":"natalie.bennion@utah.edu"},"enroll":50,"eid":"NCT06767566"},{"id":"study-NCT06899334","cat":"studies","name":"Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants","status":"RECRUITING","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD","psilocybin"],"nct":"NCT06899334","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2025-04-01","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT06899334","sites":["University Hospital — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"contact":{"n":"Matthias E Liechti, Prof. Dr. MD","p":"61 328 68 68","e":"matthias.liechti@usb.ch"},"enroll":24,"eid":"NCT06899334"},{"id":"study-NCT06896994","cat":"studies","name":"Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia","status":"RECRUITING","phase":"N/A","sponsor":"Beijing Tiantan Hospital","drugs":["esketamine"],"nct":"NCT06896994","nsites":1,"countries":"China","ccs":["CN"],"start":"2025-04-01","official":"Fang Luo, M.D. (Beijing Tiantan Hospital)","src":"https://clinicaltrials.gov/study/NCT06896994","sites":["Beijing Tiantan Hospital — Beijing, China"],"conds":["Postherpetic Neuralgia"],"condg":["Chronic pain & headache"],"contact":{"n":"Fang Luo, M.D.","p":"+86 13611326978","e":"13611326978@163.com"},"enroll":150,"eid":"NCT06896994"},{"id":"study-NCT06890897","cat":"studies","name":"Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal Neuralgia","status":"RECRUITING","phase":"N/A","sponsor":"Beijing Tiantan Hospital","drugs":["esketamine"],"nct":"NCT06890897","nsites":1,"countries":"China","ccs":["CN"],"start":"2025-04-01","official":"Fang Luo, M.D. (Beijing Tiantan Hospital)","src":"https://clinicaltrials.gov/study/NCT06890897","sites":["Beijing Tiantan Hospital — Beijing, China"],"conds":["Zoster; Herpes, Trigeminal Neuralgia (Etiology)"],"condg":["Chronic pain & headache"],"contact":{"n":"Fang Luo, M.D.","p":"+86 13611326978","e":"13611326978@163.com"},"enroll":174,"eid":"NCT06890897"},{"id":"study-NCT06518720","cat":"studies","name":"Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)","status":"RECRUITING","phase":"Phase 2","sponsor":"Centre for Addiction and Mental Health","drugs":["psilocybin"],"nct":"NCT06518720","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2025-04-01","official":"Ishrat Husain, MBBS, MD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT06518720","sites":["Centre for Addiction and Mental Health — Toronto, Canada"],"conds":["Treatment Resistant Depression","Chronic Pain"],"condg":["Depression","Chronic pain & headache"],"contact":{"n":"Emily Gilbert, MSc","p":"4165358501","e":"emily.gilbert@camh.ca"},"enroll":16,"eid":"NCT06518720"},{"id":"study-NCT06899594","cat":"studies","name":"Psilocybin for Methamphetamine Addiction","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"Kevin Murnane","drugs":["psilocybin"],"nct":"NCT06899594","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-04-04","official":"Kevin S Murnane, PhD (Louisiana State University Health Science Center Shreveport)","src":"https://clinicaltrials.gov/study/NCT06899594","sites":["LSU Health Shreveport — Shreveport, United States"],"conds":["Methamphetamine Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Kevin S Murnane, PhD","p":"(318) 675-7830","e":"kevin.murnane@lsuhs.edu"},"enroll":20,"eid":"NCT06899594"},{"id":"study-NCT06891300","cat":"studies","name":"Understanding and Treating Suicidal Ideation With Ketamine","status":"RECRUITING","phase":"Phase 2/Phase 3","sponsor":"The Royal's Institute of Mental Health Research","drugs":["ketamine"],"nct":"NCT06891300","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2025-04-08","official":"Jennifer Phillips, PhD (University of Ottawa Institute for Mental Health Research at The Royal)","src":"https://clinicaltrials.gov/study/NCT06891300","sites":["Royal Ottawa Mental Health Centre — Ottawa, Canada"],"conds":["Suicidal Ideation","Major Depressive Disorder (MDD)"],"condg":["Depression"],"contact":{"n":"Research Coordinator","p":"613-722-6521","e":"suzannah.wojcik@theroyal.ca"},"enroll":36,"eid":"NCT06891300"},{"id":"study-NCT06656702","cat":"studies","name":"Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT06656702","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-04-09","official":"Ambereen K Mehta, MD, MPH, FAAHPM (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06656702","sites":["Johns Hopkins Center for Psychedelic and Consciousness Research — Baltimore, United States"],"conds":["Amyotrophic Lateral Sclerosis"],"condg":["Other"],"contact":{"n":"Betsy Mosmiller","p":"410-502-0495","e":"emosmil1@jhmi.edu"},"enroll":24,"eid":"NCT06656702"},{"id":"study-NCT06549426","cat":"studies","name":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","status":"RECRUITING","phase":"N/A","sponsor":"University of Twente","drugs":["ketamine"],"nct":"NCT06549426","nsites":21,"countries":"Belgium; Netherlands","ccs":["BE","NL"],"start":"2025-04-10","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","sites":["Hôpital Universitaire de Bruxelles — Brussels, Belgium","Universitair Ziekenhuis Brussel — Brussels, Belgium","Centre Hospitalier Universitaire Marie Curie — Charleroi, Belgium","Centre Hospitalier Chrétien - MontLégia — Liège, Belgium","Centre Hospitalier Universitaire Sart-Tilmant — Liège, Belgium","Centre Hospitalier Universitaire Tivoli — Louvière, Belgium","Centre Hospitalier Universitaire Saint-Pierre — Ottignies, Belgium","Amsterdam University Medical Center — Amsterdam, Netherlands"],"conds":["Coma","Electrographic Status Epilepticus"],"condg":["Neurology & cognition"],"contact":{"n":"Jeannette Hofmeijer, MD","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"enroll":150,"eid":"NCT06549426"},{"id":"study-NCT06733129","cat":"studies","name":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","status":"RECRUITING","phase":"Phase 3","sponsor":"Nantes University Hospital","drugs":["ketamine"],"nct":"NCT06733129","nsites":20,"countries":"France","ccs":["FR"],"start":"2025-04-14","src":"https://clinicaltrials.gov/study/NCT06733129","sites":["Chr Angers — Angers, France","CHRU de Brest Hôpital Cavale Blanche — Brest, France","Ch Louis Pasteur — Chartres, France","CHU Dijon — Dijon, France","CHU Grenoble Alpes — Grenoble, France","CHD Vendée — La Roche-sur-Yon, France","APHP Bicêtre — Le Kremlin-Bicêtre, France","CH Le Mans — Le Mans, France"],"conds":["Rapid Sequence Induction"],"condg":["Other"],"contact":{"n":"Nicolas GRILLOT, MD","p":"02 53 48 22 24","e":"nicolas.grillot@chu-nantes.fr"},"enroll":1218,"eid":"NCT06733129"},{"id":"study-NCT05477459","cat":"studies","name":"LSD to Improve Cluster Headache Impact Trial","status":"RECRUITING","phase":"Phase 2","sponsor":"Radboud University Medical Center","drugs":["LSD"],"nct":"NCT05477459","nsites":2,"countries":"Netherlands","ccs":["NL"],"start":"2025-04-16","official":"Kees Kramers, Prof. (Radboud University Medical Center)","src":"https://clinicaltrials.gov/study/NCT05477459","sites":["Leiden University Medical Center (LUMC) — Leiden, Netherlands","Canisius-Wilhelmina Ziekenhuis (CWZ) — Nijmegen, Netherlands"],"conds":["Chronic Cluster Headache"],"condg":["Chronic pain & headache"],"contact":{"n":"Julia Jansen, MD","p":"+31 24 3658765","e":"julia.jansen@cwz.nl"},"enroll":65,"eid":"NCT05477459"},{"id":"study-NCT06796361","cat":"studies","name":"Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness","status":"RECRUITING","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["psilocybin"],"nct":"NCT06796361","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2025-04-21","src":"https://clinicaltrials.gov/study/NCT06796361","sites":["Clinical Trial Unit — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":16,"eid":"NCT06796361"},{"id":"study-NCT06512220","cat":"studies","name":"Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)","status":"RECRUITING","phase":"Phase 2","sponsor":"Centre for Addiction and Mental Health","drugs":["psilocybin"],"nct":"NCT06512220","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2025-04-21","official":"Ishrat Husain, MBBS, MD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT06512220","sites":["Centre for Addiction and Mental Health — Toronto, Canada"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"contact":{"n":"Emily Gilbert, MSc","p":"416-535-8501","e":"emily.gilbert@camh.ca"},"enroll":12,"eid":"NCT06512220"},{"id":"study-NCT05603104","cat":"studies","name":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","phase":"Phase 3","sponsor":"Dr. Inge Winter","drugs":["esketamine","ketamine"],"nct":"NCT05603104","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2025-04-27","src":"https://clinicaltrials.gov/study/NCT05603104","sites":["Sheba Medical Center — Ramat Gan, Israel"],"conds":["Schizophrenia and Related Disorders","Major Depressive Disorder","Bipolar Depression"],"condg":["Depression","Bipolar"],"contact":{"n":"Inge Winter, Dr.","p":"+31875553227","e":"i.winter@umcutrecht.nl"},"enroll":1254,"eid":"NCT05603104"},{"id":"study-NCT06620276","cat":"studies","name":"ACT_for Alcohol Use Disorder and Depression","status":"RECRUITING","phase":"N/A","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","drugs":["ketamine"],"nct":"NCT06620276","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2025-05-01","official":"Nicolas Garel, MD MSc (Centre Hospitalier d'Université de Montréal)","src":"https://clinicaltrials.gov/study/NCT06620276","sites":["Centre Hospitalier de l&#39;Université de Montréal — Montreal, Canada"],"conds":["Depression - Major Depressive Disorder","Alcohol Use Disorder"],"condg":["Depression","Addiction & substance use"],"contact":{"n":"Nicolas Garel, MD MSc","p":"514-890-8000","e":"nicolas.garel.med@ssss.gouv.qc.ca"},"enroll":30,"eid":"NCT06620276"},{"id":"study-NCT06512194","cat":"studies","name":"Investigation to Understand and Optimize Psilocybin","status":"RECRUITING","phase":"Phase 2","sponsor":"Charles Raison","drugs":["psilocybin"],"nct":"NCT06512194","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-05-13","official":"Charles Raison, MD (Vail Health Behavioral Health)","src":"https://clinicaltrials.gov/study/NCT06512194","sites":["Vail Health Behavioral Health — Edwards, United States"],"conds":["Depression"],"condg":["Depression"],"contact":{"n":"Program Manager","p":"(970) 855-7374","e":"bhic@vailhealth.org"},"enroll":141,"eid":"NCT06512194"},{"id":"study-NCT06997549","cat":"studies","name":"Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments","status":"RECRUITING","sponsor":"Neuronetics","drugs":["esketamine"],"nct":"NCT06997549","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-05-15","official":"Eleanor Cole, PhD (Neuronetics)","src":"https://clinicaltrials.gov/study/NCT06997549","sites":["Neuronetics — Malvern, United States"],"conds":["Depression","OCD","Anxiety Depression"],"condg":["Depression","Anxiety"],"contact":{"n":"Neha Goyal","p":"7635281599","e":"neha.goyal@neurostar.com"},"enroll":12000,"eid":"NCT06997549"},{"id":"study-NCT06969170","cat":"studies","name":"Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder","status":"RECRUITING","phase":"Phase 2","sponsor":"Claudio N Soares","drugs":["psilocybin"],"nct":"NCT06969170","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2025-05-16","src":"https://clinicaltrials.gov/study/NCT06969170","sites":["Kingston General Health Research Institute — Kingston, Canada"],"conds":["Generalized Anxiety Disorder (GAD)"],"condg":["Anxiety"],"contact":{"n":"Claudio N Soares, MD, PhD, FRCPC, MBA","p":"1-613-548-3232","e":"claudio.soares@kingstonhsc.ca"},"enroll":50,"eid":"NCT06969170"},{"id":"study-NCT06464367","cat":"studies","name":"Mechanistic Studies of Psilocybin in Headache Disorders","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"Yale University","drugs":["psilocybin"],"nct":"NCT06464367","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-05-19","src":"https://clinicaltrials.gov/study/NCT06464367","sites":["VA Connecticut Healthcare System — West Haven, United States"],"conds":["Migraine"],"condg":["Chronic pain & headache"],"contact":{"n":"Erik Zorrilla, PhD","p":"203-932-5711","e":"erik.zorrilla@yale.edu"},"enroll":50,"eid":"NCT06464367"},{"id":"study-NCT06801041","cat":"studies","name":"TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors","status":"RECRUITING","phase":"Phase 2","sponsor":"M.D. Anderson Cancer Center","drugs":["psilocybin"],"nct":"NCT06801041","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-05-23","official":"Moran Amit, MD, PHD (M.D. Anderson Cancer Center)","src":"https://clinicaltrials.gov/study/NCT06801041","sites":["The University of Texas M. D. Anderson Cancer Center — Houston, United States"],"conds":["Depression","Anxiety","Cancer"],"condg":["Depression","Anxiety","Cancer-related distress"],"contact":{"n":"Moran Amit, MD, PHD","p":"(713) 794-5304","e":"mamit@mdanderson.org"},"enroll":20,"eid":"NCT06801041"},{"id":"study-NCT06615908","cat":"studies","name":"Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy","status":"RECRUITING","phase":"Phase 1","sponsor":"University of Calgary","drugs":["psilocybin"],"nct":"NCT06615908","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2025-05-27","official":"Chantel T Debert, MD MSc FRCPC (University of Calgary)","src":"https://clinicaltrials.gov/study/NCT06615908","sites":["University of Calgary — Calgary, Canada"],"conds":["Persisting Symptoms After Concussion"],"condg":["Other"],"contact":{"n":"Chantel T Debert, MD MSc FRCPC","p":"(403) 944-4500","e":"cdebert@ucalgary.ca"},"enroll":40,"eid":"NCT06615908"},{"id":"study-NCT06160284","cat":"studies","name":"Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)","status":"RECRUITING","phase":"Phase 1","sponsor":"Yale University","drugs":["psilocybin"],"nct":"NCT06160284","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-05-28","official":"Gustavo Angarita, MD, MHS (Yale University)","src":"https://clinicaltrials.gov/study/NCT06160284","sites":["Yale University — New Haven, United States"],"conds":["Opioid Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Gustavo Angarita, MD, MHS","p":"(203) 974-7536","e":"gustavo.angarita@yale.edu"},"enroll":12,"eid":"NCT06160284"},{"id":"study-NCT06072898","cat":"studies","name":"A Randomized Neuroimaging Trial of Psilocybin in Depression","status":"RECRUITING","phase":"Phase 2","sponsor":"Sunnybrook Health Sciences Centre","drugs":["psilocybin"],"nct":"NCT06072898","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2025-05-28","official":"Sean M Nestor, PhD MD FRCPC (Sunnybrook Health Sciences Centre); Bradley J MacIntosh, PhD (Sunnybrook Research Institute)","src":"https://clinicaltrials.gov/study/NCT06072898","sites":["Sunnybrook Health Sciences Centre — Toronto, Canada"],"conds":["Depressive Disorder","Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"EMBRACE Team","p":"416-480-4085","e":"embrace@sunnybrook.ca"},"enroll":50,"eid":"NCT06072898"},{"id":"study-NCT07706478","cat":"studies","name":"Working Mechanisms and Effectiveness of IV Ketamine-assisted Psychotherapy on Depression in TRD Clients","status":"RECRUITING","sponsor":"Senz","drugs":["ketamine"],"nct":"NCT07706478","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2025-06-01","official":"Rutger Engels (Senz)","src":"https://clinicaltrials.gov/study/NCT07706478","sites":["SENZ — Doorn, Netherlands"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"contact":{"n":"Rutger Engels, dr","p":"+31 343 235300","e":"r.engels@senzggz.nl"},"enroll":120,"eid":"NCT07706478"},{"id":"study-NCT06969937","cat":"studies","name":"Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder","status":"RECRUITING","phase":"Phase 2","sponsor":"Dr. med. Marcus Herdener","drugs":["ketamine"],"nct":"NCT06969937","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2025-06-01","src":"https://clinicaltrials.gov/study/NCT06969937","sites":["Psychiatric University Zurich, University of Zurich — Zurich, Switzerland"],"conds":["Alcohol Abuse/Dependence","Alcohol Use Disorder (AUD)","Alcoholism"],"condg":["Addiction & substance use"],"contact":{"n":"Marcus Herdener, PD Dr. med.","p":"+41583845810","e":"marcus.herdener@bli.uzh.ch"},"enroll":75,"eid":"NCT06969937"},{"id":"study-NCT06994559","cat":"studies","name":"Music as an Adjunct to Ketamine Therapy for Chronic Pain","status":"RECRUITING","phase":"N/A","sponsor":"McGill University","drugs":["ketamine"],"nct":"NCT06994559","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2025-06-01","official":"Mark A Ware, MD (McGill University Health Centre/Research Institute of the McGill University Health Centre); Mathieu Roy, PhD (McGill University)","src":"https://clinicaltrials.gov/study/NCT06994559","sites":["Montreal General Hospital — Montreal, Canada"],"conds":["Chronic Pain","Chronic Noncancer Pain"],"condg":["Cancer-related distress","Chronic pain & headache"],"contact":{"n":"Mark A Ware, MD","p":"1-5149348222","e":"mark.ware@mcgill.ca"},"enroll":25,"eid":"NCT06994559"},{"id":"study-NCT06418178","cat":"studies","name":"Dose Optimization of MDMA-Assisted Therapy for PTSD","status":"RECRUITING","phase":"Phase 2","sponsor":"Bronx VA Medical Center","drugs":["MDMA"],"nct":"NCT06418178","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-06-03","official":"Rachel Yehuda, PhD (James J. Peters VA Medical Center); Amy Lehrner, PhD (James J. Peters VA Medical Center)","src":"https://clinicaltrials.gov/study/NCT06418178","sites":["James J. Peters VA Medical Center — The Bronx, United States"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"contact":{"n":"Amy Lehrner, PhD","p":"718-584-9000","e":"Amy.Lehrner@va.gov"},"enroll":60,"eid":"NCT06418178"},{"id":"study-NCT06405607","cat":"studies","name":"Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial","status":"RECRUITING","phase":"Phase 2","sponsor":"University of Iowa","drugs":["ketamine","psilocybin"],"nct":"NCT06405607","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-06-12","official":"Peggy C Nopoulos, MD (University of Iowa)","src":"https://clinicaltrials.gov/study/NCT06405607","sites":["University of Iowa Health Care — Iowa City, United States"],"conds":["Alcohol Use Disorder","Alcohol Dependence","Alcohol Abuse"],"condg":["Addiction & substance use"],"contact":{"n":"Lindsay E Golden, BS","p":"319-384-5243","e":"lindsay-golden@uiowa.edu"},"enroll":80,"eid":"NCT06405607"},{"id":"study-NCT06782724","cat":"studies","name":"Psilocybin Therapy for Psychological Distress in Palliative Patients","status":"RECRUITING","phase":"Phase 2","sponsor":"University Medical Center Groningen","drugs":["psilocybin"],"nct":"NCT06782724","nsites":4,"countries":"Czechia; Denmark; Netherlands; Portugal","ccs":["CZ","DK","NL","PT"],"start":"2025-07-01","src":"https://clinicaltrials.gov/study/NCT06782724","sites":["National Institute of Mental Health — Prague, Czechia","Bispebjerg Hospital — Copenhagen, Denmark","University Medical Center Groningen — Groningen, Netherlands","Champalimaud Foundation — Lisbon, Portugal"],"conds":["COPD (Chronic Obstructive Pulmonary Disease)","ALS (Amyotrophic Lateral Sclerosis)","MS (Multiple Sclerosis)","Major Depressive Disorder (MDD)","Atypical Parkinson Disease"],"condg":["Depression","Neurology & cognition"],"contact":{"n":"Robert A Schoevers, Professor","p":"050 361 2008","e":"r.a.schoevers@umcg.nl"},"enroll":108,"eid":"NCT06782724"},{"id":"study-NCT07046611","cat":"studies","name":"Ketamine and Levetiracetam as Second-line Antiseizure Medication for Status Epilepticus in Children","status":"RECRUITING","phase":"Phase 2/Phase 3","sponsor":"Sohag University","drugs":["ketamine"],"nct":"NCT07046611","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2025-07-02","src":"https://clinicaltrials.gov/study/NCT07046611","sites":["Department of Pediatrics at Sohag University Hospital — Sohag, Egypt"],"conds":["Generalized Convulsive Status Epilepticus"],"condg":["Neurology & cognition"],"contact":{"n":"Elsayed Abdelkreem, MD, PhD","p":"1114232126","e":"d.elsayedmohammed@med.sohag.edu.eg"},"enroll":124,"eid":"NCT07046611"},{"id":"study-NCT06608277","cat":"studies","name":"Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSD","status":"RECRUITING","phase":"Phase 2","sponsor":"Northwestern University","drugs":["ketamine"],"nct":"NCT06608277","nsites":3,"countries":"United States","ccs":["US"],"start":"2025-07-02","official":"Steven Cohen, MD (Northwestern University)","src":"https://clinicaltrials.gov/study/NCT06608277","sites":["Anesthesiology Pain Medicine Center — Chicago, United States","Walter Reed National Military Medical Center — Bethesda, United States","Womack Army Medical Center — Fort Bragg, United States"],"conds":["Posttraumatic Headache","Posttraumatic Stress Disorder"],"condg":["PTSD & trauma","Chronic pain & headache"],"contact":{"n":"Jordan Wood, BS","p":"312-695-0915","e":"jordan.wood1@northwestern.edu"},"enroll":175,"eid":"NCT06608277"},{"id":"study-NCT06706232","cat":"studies","name":"Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality","status":"RECRUITING","phase":"Phase 2","sponsor":"The University of Texas Health Science Center, Houston","drugs":["psilocybin"],"nct":"NCT06706232","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-07-07","official":"Thomas Meyer, PhD (The University of Texas Health Science Center, Houston)","src":"https://clinicaltrials.gov/study/NCT06706232","sites":["The University of Texas Health Science Center at Houston — Houston, United States"],"conds":["Bipolar II Disorder","Depression, Bipolar","Suicidality"],"condg":["Depression","Bipolar"],"contact":{"n":"Thomas Meyer, PhD","p":"713-486-2643","e":"thomas.d.meyer@uth.tmc.edu"},"enroll":10,"eid":"NCT06706232"},{"id":"study-NCT07088380","cat":"studies","name":"Ketamine Augmentation of ECT in Treatment-Resistant Depression","status":"RECRUITING","phase":"Phase 3","sponsor":"Università Vita-Salute San Raffaele","drugs":["ketamine"],"nct":"NCT07088380","nsites":1,"countries":"Italy","ccs":["IT"],"start":"2025-07-10","official":"Alberto AZ Zangrillo, MD (Università Vita-Salute San Raffaele); Cristina CC Colombo, MD (IRCCS Ospedale San Raffaele Turro)","src":"https://clinicaltrials.gov/study/NCT07088380","sites":["IRCCS Ospedale San Raffaele Turro — Milan, Italy"],"conds":["Major Depressive Disorder","Treatment Resistant Depression"],"condg":["Depression"],"contact":{"n":"Alberto AZ Zangrillo, MD","p":"0226436154","e":"zangrillo.alberto@hsr.it"},"enroll":30,"eid":"NCT07088380"},{"id":"study-NCT07048743","cat":"studies","name":"Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer","status":"RECRUITING","phase":"Phase 2","sponsor":"University Health Network, Toronto","drugs":["psilocybin"],"nct":"NCT07048743","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2025-07-16","official":"Sarah Hales, MD, PhD (Princess Margaret Cancer Centre)","src":"https://clinicaltrials.gov/study/NCT07048743","sites":["Toronto General Hospital — Toronto, Canada"],"conds":["Caregiver Distress"],"condg":["Other"],"contact":{"n":"Sarah Hales, MD, PhD","p":"416-340-4800","e":"uhnpprg@uhn.ca"},"enroll":15,"eid":"NCT07048743"},{"id":"study-NCT07737054","cat":"studies","name":"Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"Tel-Aviv Sourasky Medical Center","drugs":["psilocybin"],"nct":"NCT07737054","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2025-07-22","official":"Talma Hendler, Prof. (Tel Aviv University and Tel Aviv Sourasky Medical Center)","src":"https://clinicaltrials.gov/study/NCT07737054","sites":["Tel Aviv Sourasky Medical Center — Tel Aviv, Israel"],"conds":["Post-Traumatic Stress Disorder, PTSD"],"condg":["PTSD & trauma"],"contact":{"n":"Ayelet Or-Borichev, PhD","p":"+972507941243","e":"ayeletorb@gmail.com"},"enroll":13,"eid":"NCT07737054"},{"id":"study-NCT06597695","cat":"studies","name":"A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Juliana Zambrano, MD, MPH","drugs":["ketamine"],"nct":"NCT06597695","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-07-23","official":"Juliana Zambrano, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT06597695","sites":["Massachusetts General Hospital, Chelsea — Chelsea, United States"],"conds":["Depression"],"condg":["Depression"],"contact":{"n":"Juliana Zambrano, MD","p":"617-726-2000","e":"JZAMBRANO2@mgh.harvard.edu"},"enroll":10,"eid":"NCT06597695"},{"id":"study-NCT06745388","cat":"studies","name":"Magnesium and Cramping","status":"RECRUITING","phase":"Phase 4","sponsor":"Corewell Health East","drugs":["ketamine"],"nct":"NCT06745388","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-07-29","official":"Ray Soto, MD (Corewell Health East)","src":"https://clinicaltrials.gov/study/NCT06745388","sites":["Corewell Health William Beaumont University Hospital — Royal Oak, United States"],"conds":["Uterine Cramps","Postoperative Pain Management","Hysteroscopy"],"condg":["Chronic pain & headache"],"contact":{"n":"Ray Soto, MD","p":"248-898-0833","e":"roy.soto@corewellhealth.org"},"enroll":150,"eid":"NCT06745388"},{"id":"study-NCT06233344","cat":"studies","name":"Mindfulness-Assisted Psychedelic Therapy","status":"RECRUITING","phase":"Phase 2","sponsor":"University of Southern California","drugs":["psilocybin"],"nct":"NCT06233344","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-07-30","official":"Baruch R Cahn, MD, PhD (University of Southern California)","src":"https://clinicaltrials.gov/study/NCT06233344","sites":["Univeristy of Southern California Brain and Creativity Institute — Los Angeles, United States"],"conds":["Mental Health"],"condg":["Other"],"contact":{"n":"Anna Zandueta-Duarte, BA","p":"(323) 442-0938","e":"mindfulness-psilocybin-study@usc.edu"},"enroll":40,"eid":"NCT06233344"},{"id":"study-NCT07339449","cat":"studies","name":"Intraoperative Multimodal Monitoring as a Means in Reducing the Duration of Mechanical Ventilation in High-Risk Patients Undergoing Major Abdominal Procedures - A Pilot Study","status":"RECRUITING","phase":"N/A","sponsor":"University Hospital Dubrava","drugs":["esketamine","ketamine"],"nct":"NCT07339449","nsites":1,"countries":"Croatia","ccs":["HR"],"start":"2025-08-01","official":"Jasminka Peršec, M.D., PhD, Ass. Prof (University Hospital Dubrava); Andrej Šribar, Assoc. Prof., MD, PhD (University Hospital Dubrava)","src":"https://clinicaltrials.gov/study/NCT07339449","sites":["University hospital Dubrava — Zagreb, Croatia"],"conds":["Major Abdominal Surgeries","Mechanical Ventilation"],"condg":["Other"],"contact":{"n":"Marko Pražetina, MD","p":"+385958150841","e":"mprazetina1991@gmail.com"},"enroll":100,"eid":"NCT07339449"},{"id":"study-NCT07095842","cat":"studies","name":"Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)","status":"RECRUITING","phase":"Phase 2/Phase 3","sponsor":"Sohag University","drugs":["ketamine"],"nct":"NCT07095842","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2025-08-03","src":"https://clinicaltrials.gov/study/NCT07095842","sites":["Department of Pediatrics at Sohag University Hospital — Sohag, Egypt"],"conds":["Convulsive Status EPILEPTICUS"],"condg":["Neurology & cognition"],"contact":{"n":"Elsayed Abdelkreem","p":"1114232126","e":"d.elsayedmohammed@med.sohag.edu.eg"},"enroll":668,"eid":"NCT07095842"},{"id":"study-NCT06070649","cat":"studies","name":"The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)","status":"RECRUITING","phase":"Phase 1","sponsor":"Yale University","drugs":["DMT"],"nct":"NCT06070649","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-08-04","official":"Anahita Bassir Nia, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06070649","sites":["Connecticut Mental Health Center — New Haven, United States"],"conds":["Alcohol Use Disorder (AUD)","Alcohol-Related Disorders","Alcohol Use"],"condg":["Addiction & substance use"],"contact":{"n":"Angelina Contreras","p":"(203) 974-7525","e":"angelina.contreras@yale.edu"},"enroll":63,"eid":"NCT06070649"},{"id":"study-NCT06927076","cat":"studies","name":"Antidepressant Response of DMT Masked With Propofol","status":"RECRUITING","phase":"N/A","sponsor":"University Hospital, Basel, Switzerland","drugs":["DMT"],"nct":"NCT06927076","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2025-08-05","official":"Matthias Liechti, Prof. Dr. med. (University Hospital, Basel, Switzerland); Felix Müller, PD Dr. med. (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT06927076","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Major Depressive Disorder","Psychedelic Experiences"],"condg":["Depression"],"contact":{"n":"Joyce Santos de Jesus","p":"+41 61 556 65 02","e":"DMT4D@usb.ch"},"enroll":112,"eid":"NCT06927076"},{"id":"study-NCT06692192","cat":"studies","name":"The RECAP2 Study: Midazolam and Psilocybin","status":"RECRUITING","phase":"Phase 1","sponsor":"University of Wisconsin, Madison","drugs":["psilocybin"],"nct":"NCT06692192","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-08-07","official":"Charles Raison, MD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT06692192","sites":["UW School of Medicine and Public Health — Madison, United States"],"conds":["Psilocybin"],"condg":["Other"],"contact":{"n":"RECAP Study Contact","p":"608-263-4852","e":"recap2@psychiatry.wisc.edu"},"enroll":60,"eid":"NCT06692192"},{"id":"study-NCT07180108","cat":"studies","name":"PRoMiSS: Psilocybin and the Role of Music in Set and Setting","status":"RECRUITING","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT07180108","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-08-12","official":"Frederick S Barrett, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT07180108","sites":["Center for Psychedelics and Consciousness Research in the Behavioral Biology Research Center — Baltimore, United States"],"conds":["Psilocybin","Music Intervention"],"condg":["Other"],"contact":{"n":"David S Rosen, PhD","p":"609-502-8900","e":"drosen9@jh.edu"},"enroll":100,"eid":"NCT07180108"},{"id":"study-NCT06683014","cat":"studies","name":"MDMA in Borderline Personality Disorder","status":"RECRUITING","phase":"Phase 2","sponsor":"Yale University","drugs":["MDMA"],"nct":"NCT06683014","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-09-05","official":"Sarah K Fineberg, MD, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06683014","sites":["Connecticut Mental Health Center — New Haven, United States"],"conds":["Borderline Personality Disorder"],"condg":["Other"],"contact":{"n":"Sarah K Fineberg, MD, PhD","p":"(203) 974-7265","e":"fineberg.lab@yale.edu"},"enroll":10,"eid":"NCT06683014"},{"id":"study-NCT07226570","cat":"studies","name":"Mapping Ibogaine Neural Dynamics in Opioid Use Disorder","status":"RECRUITING","sponsor":"University of California, Irvine","drugs":["ibogaine"],"nct":"NCT07226570","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-09-08","official":"Richard E Harris, PhD (University of California, Irvine, Susan Samueli Integrative Health Institute)","src":"https://clinicaltrials.gov/study/NCT07226570","sites":["Susan Samueli Integrative Health Institute, University of California, Irvine — Irvine, United States"],"conds":["Opioid Use Disorder (OUD)"],"condg":["Addiction & substance use"],"contact":{"n":"Richard E Harris, PhD","p":"949-824-7000","e":"richareh@hs.uci.edu"},"enroll":20,"eid":"NCT07226570"},{"id":"study-NCT05783817","cat":"studies","name":"MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)","status":"RECRUITING","phase":"Phase 2","sponsor":"Carolyn Rodriguez","drugs":["MDMA"],"nct":"NCT05783817","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-09-10","official":"Carolyn Rodriguez, MD, PhD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT05783817","sites":["Stanford University Medical Center — Palo Alto, United States"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"contact":{"n":"Alessa Gaeta, MS","p":"650-723-4095","e":"ocdresearch@stanford.edu"},"enroll":40,"eid":"NCT05783817"},{"id":"study-NCT07230171","cat":"studies","name":"The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia","status":"RECRUITING","phase":"N/A","sponsor":"Beijing Tiantan Hospital","drugs":["esketamine"],"nct":"NCT07230171","nsites":1,"countries":"China","ccs":["CN"],"start":"2025-09-15","src":"https://clinicaltrials.gov/study/NCT07230171","sites":["Beijing Tiantan Hospital, Beijing, Beijing 100070 — Beijing, China"],"conds":["Fibromyalgia","Pregabalin","Esketamine"],"condg":["Chronic pain & headache"],"contact":{"n":"Fang Luo","p":"+8613611326978","e":"15383510462@163.com"},"enroll":92,"eid":"NCT07230171"},{"id":"study-NCT06989957","cat":"studies","name":"Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)","status":"RECRUITING","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["MDMA","psilocybin"],"nct":"NCT06989957","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-09-17","official":"Brandon Weiss, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06989957","sites":["Johns Hopkins Center for Psychedelic and Consciousness Research — Baltimore, United States"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"contact":{"n":"Chloe Ford, MSc","p":"410-550-0237","e":"cford36@jh.edu"},"enroll":40,"eid":"NCT06989957"},{"id":"study-NCT07422519","cat":"studies","name":"Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression","status":"RECRUITING","phase":"N/A","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","drugs":["esketamine"],"nct":"NCT07422519","nsites":1,"countries":"Spain","ccs":["ES"],"start":"2025-09-18","src":"https://clinicaltrials.gov/study/NCT07422519","sites":["Hospital Universitari Vall d'Hebron — Barcelona, Spain"],"conds":["Depression - Major Depressive Disorder","Depression Disorder","Depression Chronic","Treatment-Resistant Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Dr. J. Antoni Ramos-Quiroga","p":"+3493 274 6087","e":"antoni.ramos@vallhebron.cat"},"enroll":30,"eid":"NCT07422519"},{"id":"study-NCT07072728","cat":"studies","name":"Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder","status":"RECRUITING","phase":"Phase 2","sponsor":"Psyence Australia Pty Ltd","drugs":["psilocybin"],"nct":"NCT07072728","nsites":3,"countries":"Australia","ccs":["AU"],"start":"2025-10-01","official":"Clive Ward-Able (Psyence Biomedical)","src":"https://clinicaltrials.gov/study/NCT07072728","sites":["Mind Medicine Australia Clinic — Abbotsford, Australia","Paratus Clinical Research Melbourne — Northcote, Australia","Empax Centre — Leederville, Australia"],"conds":["Adjustment Disorder","Adjustment Disorder With Anxious Mood","Cancer","Cancer Cachexia","Cancer of Endometrium","Cancer of Kidney"],"condg":["Cancer-related distress"],"contact":{"n":"Tim Waugh","p":"+61481354373","e":"tim@psyencebiomed.com"},"enroll":87,"eid":"NCT07072728"},{"id":"study-NCT06798636","cat":"studies","name":"PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"Imperial College London","drugs":["psilocybin"],"nct":"NCT06798636","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2025-10-01","official":"Martina Di Simplicio, Dr (Imperial College London); David Nutt, Prof (Imperial College London)","src":"https://clinicaltrials.gov/study/NCT06798636","sites":["Imperial College London — London, United Kingdom"],"conds":["Self Harm"],"condg":["Other"],"contact":{"n":"Joanna Vamvakopoulou","p":"+44 (0) 7942292199","e":"imagine@imperial.ac.uk"},"enroll":30,"eid":"NCT06798636"},{"id":"study-NCT06786325","cat":"studies","name":"Wellcome Leap Psilocybin for OUD","status":"RECRUITING","phase":"Phase 2","sponsor":"Anna Rose Childress, Ph.D.","drugs":["psilocybin"],"nct":"NCT06786325","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-10-07","src":"https://clinicaltrials.gov/study/NCT06786325","sites":["University of Pennsylvania — Philadelphia, United States"],"conds":["Opioid Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Megan Ivey, MS","p":"2157467712","e":"megan.ivey@pennmedicine.upenn.edu"},"enroll":36,"eid":"NCT06786325"},{"id":"study-NCT05585229","cat":"studies","name":"Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication","status":"RECRUITING","phase":"Phase 2","sponsor":"University of British Columbia","drugs":["psilocybin"],"nct":"NCT05585229","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2025-10-27","official":"W. Francois Louw, MD (University of British Columbia)","src":"https://clinicaltrials.gov/study/NCT05585229","sites":["University of British Columbia - Okanagan Campus — Kelowna, Canada"],"conds":["Opioid Dependence","Chronic Pain"],"condg":["Addiction & substance use","Chronic pain & headache"],"contact":{"n":"W. Francois Louw, MD","p":"250-860-9754","e":"doclouw@mail.ubc.ca"},"enroll":10,"eid":"NCT05585229"},{"id":"study-NCT06367738","cat":"studies","name":"Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults","status":"RECRUITING","phase":"Phase 1","sponsor":"University of California, Berkeley","drugs":["psilocybin"],"nct":"NCT06367738","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-11","src":"https://clinicaltrials.gov/study/NCT06367738","sites":["University of California, Berkeley — Berkeley, United States"],"conds":["Aging"],"condg":["Other"],"contact":{"n":"BCSP Research Staff","p":"(669) 244-2436","e":"bcspresearchsubjects@berkeley.edu"},"enroll":40,"eid":"NCT06367738"},{"id":"study-NCT07490353","cat":"studies","name":"Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects","status":"RECRUITING","phase":"Phase 1","sponsor":"Medical University of Vienna","drugs":["psilocybin"],"nct":"NCT07490353","nsites":1,"countries":"Austria","ccs":["AT"],"start":"2025-11-01","official":"Marie Spies, Priv.-Doz. DDr. (Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General Psychiatry)","src":"https://clinicaltrials.gov/study/NCT07490353","sites":["Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General Psychiatry — Vienna, Austria"],"conds":["Depression - Major Depressive Disorder","Anhedonia"],"condg":["Depression"],"contact":{"n":"Marie Spies, Priv.-Doz. DDr.","p":"+43 1 40400","e":"marie.spies@meduniwien.ac.at"},"enroll":85,"eid":"NCT07490353"},{"id":"study-NCT06903819","cat":"studies","name":"Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients","status":"RECRUITING","phase":"Phase 4","sponsor":"Texas Tech University Health Sciences Center","drugs":["ketamine"],"nct":"NCT06903819","nsites":2,"countries":"United States","ccs":["US"],"start":"2025-11-06","official":"Max Evan Davis, MD (Texas Tech University Health Sciences Center Department of Orthopaedic Surgery,)","src":"https://clinicaltrials.gov/study/NCT06903819","sites":["Texas Tech University Health Sciences Center Lubbock — Lubbock, United States","University Medical Center — Lubbock, United States"],"conds":["Orthopedic Trauma Surgery Patients","Postoperative Pain","Opioid Use","Depression","Post-traumatic Stress Disorder (PTSD)"],"condg":["Depression","PTSD & trauma","Addiction & substance use","Chronic pain & headache"],"contact":{"n":"Evan J Hernandez, MBA","p":"8067436846","e":"evan.j.hernandez@ttuhsc.edu"},"enroll":90,"eid":"NCT06903819"},{"id":"study-NCT07284667","cat":"studies","name":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","status":"RECRUITING","phase":"Phase 2","sponsor":"ACADIA Pharmaceuticals Inc.","drugs":["ketamine"],"nct":"NCT07284667","nsites":26,"countries":"United States","ccs":["US"],"start":"2025-11-14","src":"https://clinicaltrials.gov/study/NCT07284667","sites":["University of Alabama at Birmingham — Birmingham, United States","Inland Psychiatric Medical Group — Chino, United States","Behavioral Research Specialists, LLC — Glendale, United States","Kadima Neuropsychiatry Institute — La Jolla, United States","PNS Clinical Research LLC dba ATP Clinical Research — Orange, United States","Mountain View Clinical Research — Denver, United States","New Access Research and Medical Services, Inc. — Fort Myers, United States","The Medici Medical Research — Hollywood, United States"],"conds":["Major Depressive Disorder (MDD)","Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"enroll":153,"eid":"NCT07284667"},{"id":"study-NCT07247968","cat":"studies","name":"Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"Min Su","drugs":["esketamine"],"nct":"NCT07247968","nsites":2,"countries":"China","ccs":["CN"],"start":"2025-11-25","official":"Su Min (First Affiliated Hospital of Chongqing Medical University)","src":"https://clinicaltrials.gov/study/NCT07247968","sites":["The First Affiliated Hospital of Chongqing Medical University — Chongqing, China","The First Affiliated Hospital of Chongqing Medical University — Chongqing, China"],"conds":["Esketamine","ECT","Depression","Adolescent"],"condg":["Depression"],"contact":{"n":"Xiaoge Han, Master","p":"023-89011061","e":"3164233689@qq.com"},"enroll":220,"eid":"NCT07247968"},{"id":"study-NCT07183748","cat":"studies","name":"Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression","status":"RECRUITING","phase":"Phase 2","sponsor":"Beersheva Mental Health Center","drugs":["psilocybin"],"nct":"NCT07183748","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2025-12-01","src":"https://clinicaltrials.gov/study/NCT07183748","sites":["Mental Health Center Beer Sheva — Beersheba, Israel"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"contact":{"n":"Oded Arbel, MD","p":"+972506576691","e":"oded.arbel@pbsh.health.gov.il"},"enroll":20,"eid":"NCT07183748"},{"id":"study-NCT07303907","cat":"studies","name":"A Phase 2A Trial of DT402 for Autism Spectrum Disorder","status":"RECRUITING","phase":"Phase 2","sponsor":"Definium Therapeutics US, Inc.","drugs":["MDMA"],"nct":"NCT07303907","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-12-03","src":"https://clinicaltrials.gov/study/NCT07303907","sites":["Spectrum Neuroscience and Treatment Institute — New York, United States"],"conds":["Autism Spectrum Disorder","ASD"],"condg":["Other"],"contact":{"n":"Definium Therapeutics Clinical Trials Information Requests","p":"1-332-282-0479","e":"clinicaltrials@definiumtx.com"},"enroll":20,"eid":"NCT07303907"},{"id":"study-NCT06419439","cat":"studies","name":"Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression","status":"RECRUITING","phase":"Phase 2","sponsor":"VA Office of Research and Development","drugs":["ketamine"],"nct":"NCT06419439","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-12-03","official":"Victoria D Powell, MD (VA Ann Arbor Healthcare System, Ann Arbor, MI)","src":"https://clinicaltrials.gov/study/NCT06419439","sites":["VA Ann Arbor Healthcare System, Ann Arbor, MI — Ann Arbor, United States"],"conds":["Chronic Low Back Pain","Depression"],"condg":["Depression","Chronic pain & headache"],"contact":{"n":"Victoria D Powell, MD","p":"(734) 845-3072","e":"Victoria.Powell2@va.gov"},"enroll":44,"eid":"NCT06419439"},{"id":"study-NCT06793397","cat":"studies","name":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","status":"RECRUITING","phase":"Phase 3","sponsor":"Cybin IRL Limited","drugs":["psilocybin"],"nct":"NCT06793397","nsites":79,"countries":"Australia; Czechia; Germany; Greece; Ireland; Poland; United Kingdom; United States","ccs":["AU","CZ","DE","GB","GR","IE","PL","US"],"start":"2025-12-10","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","sites":["UAB Psychiatry and Behavioral Neurology — Birmingham, United States","Lighthouse Psychiatry — Gilbert, United States","Pillar Clinical Research - Little Rock — Little Rock, United States","Behavioral Research Specialists, LLC — Glendale, United States","Sun Valley Research Center — Imperial, United States","CalNeuro Research Group — Los Angeles, United States","Lipov Medical Group — Los Angeles, United States","ATP Clinical Research — Orange, United States"],"conds":["Major Depressive Disorder (MDD)","Depression in Adults","Depression - Major Depressive Disorder","Depression Disorders","Depression Disorder","Depression"],"condg":["Depression"],"contact":{"n":"Clinical Development","p":"877-361-4003","e":"clinicaltrialsinfo@cybin.com"},"enroll":330,"eid":"NCT06793397"},{"id":"study-NCT07079930","cat":"studies","name":"Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers","status":"RECRUITING","phase":"Phase 1","sponsor":"Hadassah Medical Organization","drugs":["psilocybin"],"nct":"NCT07079930","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2025-12-11","src":"https://clinicaltrials.gov/study/NCT07079930","sites":["Hadassah Medical Organization, Jerusalem, Israel — Jerusalem, Israel"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"contact":{"n":"Bernard Lerer, MD","p":"+972-50-7874575","e":"lerer@mail.huji.ac.il"},"enroll":10,"eid":"NCT07079930"},{"id":"study-NCT06796062","cat":"studies","name":"Psilocybin for Opioid Use Disorder (OUD)","status":"RECRUITING","phase":"Phase 2","sponsor":"NYU Langone Health","drugs":["psilocybin"],"nct":"NCT06796062","nsites":5,"countries":"United States","ccs":["US"],"start":"2025-12-17","official":"Michael Bogenschutz, MD (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT06796062","sites":["Duke City Recovery Toolbox — Albuquerque, United States","University of New Mexico — Albuquerque, United States","StartCare — Brooklyn, United States","NYU Langone Health — New York, United States","VIP Community Services, Inc — The Bronx, United States"],"conds":["Opioid Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Michael Bogenschutz, MD","p":"646-501-4026","e":"Michael.bogenschutz@nyulangone.org"},"enroll":480,"eid":"NCT06796062"},{"id":"study-NCT07317232","cat":"studies","name":"Ayahuasca, Esketamine and Premenstrual Symptoms","status":"RECRUITING","phase":"N/A","sponsor":"University of Sao Paulo","drugs":["ayahuasca","esketamine"],"nct":"NCT07317232","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2025-12-20","src":"https://clinicaltrials.gov/study/NCT07317232","sites":["Hospital das Clínicas da FMRP-USP — Ribeirão Preto, Brazil"],"conds":["Healthy Women Volunteers"],"condg":["Healthy volunteers"],"enroll":20,"eid":"NCT07317232"},{"id":"study-NCT07317206","cat":"studies","name":"Ayahuasca, Esketamine and PTSD","status":"RECRUITING","phase":"Phase 2","sponsor":"University of Sao Paulo","drugs":["ayahuasca","esketamine"],"nct":"NCT07317206","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2025-12-20","src":"https://clinicaltrials.gov/study/NCT07317206","sites":["Hospital das Clínicas da FMRP-USP — Ribeirão Preto, Brazil"],"conds":["Posttraumatic Stress Disorder (PTSD)"],"condg":["PTSD & trauma"],"enroll":10,"eid":"NCT07317206"},{"id":"study-NCT07317219","cat":"studies","name":"Ayahuasca, Esketamine and Body Image Perception","status":"RECRUITING","phase":"N/A","sponsor":"University of Sao Paulo","drugs":["ayahuasca","esketamine"],"nct":"NCT07317219","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2025-12-20","src":"https://clinicaltrials.gov/study/NCT07317219","sites":["Hospital das Clínicas da FMRP-USP — Ribeirão Preto, Brazil"],"conds":["Healthy Women Volunteers"],"condg":["Healthy volunteers"],"enroll":20,"eid":"NCT07317219"},{"id":"study-NCT06810310","cat":"studies","name":"Psilocybin on Brain Mechanisms of Motivation in OUD","status":"RECRUITING","phase":"Phase 2","sponsor":"University of Pennsylvania","drugs":["psilocybin"],"nct":"NCT06810310","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-12-22","src":"https://clinicaltrials.gov/study/NCT06810310","sites":["University of Pennsylvania — Philadelphia, United States"],"conds":["Opioid Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Anna Rose Childress, PhD","p":"215-746-1803","e":"childress@pennmedicine.upenn.edu"},"enroll":24,"eid":"NCT06810310"},{"id":"study-NCT07469098","cat":"studies","name":"Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events","status":"RECRUITING","phase":"Phase 2","sponsor":"Sheba Medical Center","drugs":["MDMA"],"nct":"NCT07469098","nsites":2,"countries":"Israel","ccs":["IL"],"start":"2025-12-24","official":"Revital Amiaz (Sheba Medical Center)","src":"https://clinicaltrials.gov/study/NCT07469098","sites":["Mental Health Medical Center Beer Sheva — Beersheba, Israel","Lev-Hasharon Mental Health Medical Center — Pardesiyya, Israel"],"conds":["PTSD"],"condg":["PTSD & trauma"],"contact":{"n":"Revital Amiaz","p":"972542378757","e":"revital.amiaz@sheba.health.gov.il"},"enroll":168,"eid":"NCT07469098"},{"id":"study-NCT07698665","cat":"studies","name":"Ketamine Versus Dexmedetomidine as an Adjuvant in Scalp Block in Supratentorial Brain Tumor Excision Surgeries","status":"RECRUITING","phase":"N/A","sponsor":"Cairo University","drugs":["ketamine"],"nct":"NCT07698665","nsites":2,"countries":"Egypt","ccs":["EG"],"start":"2026-01-01","src":"https://clinicaltrials.gov/study/NCT07698665","sites":["Cairo university — Cairo, Egypt","Cairo university Hospitals. kasralainy — Cairo, Egypt"],"conds":["Regional Anesthesia Morbidity","Supratentorial Brain Tumor","Acute Pain"],"condg":["Chronic pain & headache"],"enroll":90,"eid":"NCT07698665"},{"id":"study-NCT07216404","cat":"studies","name":"Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer","status":"RECRUITING","phase":"Phase 2","sponsor":"Alan Davis","drugs":["psilocybin"],"nct":"NCT07216404","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-01-01","official":"Alan K Davis, PhD (Ohio State University Comprehensive Cancer Center)","src":"https://clinicaltrials.gov/study/NCT07216404","sites":["Ohio State University Comprehensive Cancer Center — Columbus, United States"],"conds":["Lung Non-Small Cell Carcinoma","Unipolar Depression"],"condg":["Depression"],"contact":{"n":"Ohio State University Comprehensive Cancer Center","p":"18002935066","e":"osucccclincaltrials@osumc.edu"},"enroll":10,"eid":"NCT07216404"},{"id":"study-NCT07281352","cat":"studies","name":"RCT of Psilocybin-assisted CBT for Depression","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"University of California, Los Angeles","drugs":["psilocybin"],"nct":"NCT07281352","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-01-05","src":"https://clinicaltrials.gov/study/NCT07281352","sites":["UCLA Semel Institute — Los Angeles, United States"],"conds":["Major Depressive Diorder"],"condg":["Depression"],"contact":{"n":"Shelby Grody","p":"310-825-4354","e":"UCLAPAT@mednet.ucla.edu"},"enroll":50,"eid":"NCT07281352"},{"id":"study-NCT07227454","cat":"studies","name":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","status":"RECRUITING","phase":"Phase 3","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT07227454","nsites":44,"countries":"Brazil; Hungary; Italy; Romania; Spain; Taiwan; United States","ccs":["BR","ES","HU","IT","RO","TW","US"],"start":"2026-01-08","src":"https://clinicaltrials.gov/study/NCT07227454","sites":["University of Alabama at Birmingham — Birmingham, United States","Children's National Medical Center — Washington D.C., United States","Peachford Hospital-Atlanta Behavioral Research — Atlanta, United States","Endeavor Health Evanston Hospital — Evanston, United States","Johns Hopkins University — Baltimore, United States","Boston Childrens Hospital — Boston, United States","Mayo Clinic — Rochester, United States","University of Cincinnati — Cincinnati, United States"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"enroll":258,"eid":"NCT07227454"},{"id":"study-NCT07276542","cat":"studies","name":"Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an…","status":"RECRUITING","phase":"Phase 2/Phase 3","sponsor":"The Ketamine Research Foundation","drugs":["ketamine"],"nct":"NCT07276542","nsites":4,"countries":"United States","ccs":["US"],"start":"2026-01-15","src":"https://clinicaltrials.gov/study/NCT07276542","sites":["Shamynds — Sacramento, United States","Ketamine Research Foundation — San Anselmo, United States","Mystic Health — Santa Monica, United States","Lisa Feierman MD — Albuquerque, United States"],"conds":["Phantom Limb Syndrome With Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Philip E Wolfson, MD","p":"+1-415-785-3797","e":"ketamine.research@gmail.com"},"enroll":30,"eid":"NCT07276542"},{"id":"study-NCT06575075","cat":"studies","name":"Pilot Study of RR-HNK in OCD","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Carolyn Rodriguez","drugs":["ketamine"],"nct":"NCT06575075","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-01-23","official":"Carolyn Rodriguez, MD, PhD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT06575075","sites":["Stanford University School of Medicine — Palo Alto, United States"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"contact":{"n":"Alessa Gaeta, BA","p":"650-723-4095","e":"ocdresearch@stanford.edu"},"enroll":45,"eid":"NCT06575075"},{"id":"study-NCT05474989","cat":"studies","name":"LSD Treatment for Persons With Alcohol Use Disorder","status":"RECRUITING","phase":"Phase 2","sponsor":"Felix Mueller","drugs":["LSD"],"nct":"NCT05474989","nsites":2,"countries":"Switzerland","ccs":["CH"],"start":"2026-01-27","src":"https://clinicaltrials.gov/study/NCT05474989","sites":["University Hospital of Psychiatry, University of Basel — Basel, Switzerland","University Hospital of Psychiatry, University of Bern — Bern, Switzerland"],"conds":["Alcohol Use Disorder (AUD)"],"condg":["Addiction & substance use"],"contact":{"n":"Felix Müller, PD Dr. med.","p":"+41 (0)61 325 5111","e":"felix.mueller@upk.ch"},"enroll":128,"eid":"NCT05474989"},{"id":"study-NCT07063862","cat":"studies","name":"Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)","status":"RECRUITING","phase":"Phase 3","sponsor":"Bruyère Health Research Institute.","drugs":["psilocybin"],"nct":"NCT07063862","nsites":7,"countries":"Canada","ccs":["CA"],"start":"2026-01-28","src":"https://clinicaltrials.gov/study/NCT07063862","sites":["William Osler Health System — Brampton, Canada","Providence Care Hospital — Kingston, Canada","St. Joseph's Healthcare — London, Canada","South Lake Regional Health Centre — Newmarket, Canada","Bruyere Health — Ottawa, Canada","The Ottawa Hospital — Ottawa, Canada","McGill University Health Centre — Montreal, Canada"],"conds":["Psychological Distress"],"condg":["Other"],"contact":{"n":"James Downar, MDCM, MHSc","p":"613-562-6262","e":"jdownar@toh.ca"},"enroll":120,"eid":"NCT07063862"},{"id":"study-NCT07301632","cat":"studies","name":"Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial","status":"RECRUITING","phase":"Phase 2","sponsor":"Unity Health Toronto","drugs":["MDMA"],"nct":"NCT07301632","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2026-01-30","official":"Akash Goel, MD,MPH,FRCPC (Unity Health Toronto)","src":"https://clinicaltrials.gov/study/NCT07301632","sites":["St. Michael's Hospital — Toronto, Canada"],"conds":["Chronic Neuropathic Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Akash Goel, MD,MPH,FRCPC","p":"4168645071","e":"Akash.Goel@unityhealth.to"},"enroll":50,"eid":"NCT07301632"},{"id":"study-NCT07369102","cat":"studies","name":"Esketamine With or Without Integration Therapy for Treatment-Resistant Depression","status":"RECRUITING","phase":"Phase 4","sponsor":"University of Puerto Rico","drugs":["esketamine"],"nct":"NCT07369102","nsites":2,"countries":"Puerto Rico","ccs":["PR"],"start":"2026-02-01","official":"Karen G Gonzalez-Martinez, MD, MSc (University of Puerto Rico, Medical Sciences Campus, Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT07369102","sites":["Pravan Foundation — San Juan, Puerto Rico","University of Puerto Rico, Department of Psychiatry — San Juan, Puerto Rico"],"conds":["Treatment-resistant Depression (TRD)"],"condg":["Depression"],"contact":{"n":"Paulina D Rullan-Farinacci, MD","p":"787-414-3571","e":"paulina.rullan@upr.edu"},"enroll":20,"eid":"NCT07369102"},{"id":"study-NCT06943859","cat":"studies","name":"Ketamine for Opioid Use Disorder","status":"RECRUITING","phase":"Phase 2","sponsor":"University of Maryland, Baltimore","drugs":["ketamine"],"nct":"NCT06943859","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-02-04","official":"Peter Manza, PhD (University of Maryland, Baltimore)","src":"https://clinicaltrials.gov/study/NCT06943859","sites":["University of Maryland Addiction Programs and Affiliated Clinics — Baltimore, United States"],"conds":["Opioid Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Peter Manza, PhD","p":"410-706-2814","e":"peter.manza@som.umaryland.edu"},"enroll":50,"eid":"NCT06943859"},{"id":"study-NCT07053917","cat":"studies","name":"Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability","status":"RECRUITING","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT07053917","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-02-09","official":"Victor Urrutia, M.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT07053917","sites":["Johns Hopkins — Baltimore, United States"],"conds":["Stroke","Chronic Stroke","Intracerebral Haemorrhage","Intracerebral Haemorrhage (ICH)","Intracerebral Hemorrhage Basal Ganglia","Ischemic Stroke"],"condg":["Neurology & cognition"],"contact":{"n":"Steven R Zeiler, M.D., Ph.D.","p":"303-520-7404","e":"sz@jhmi.edu"},"enroll":20,"eid":"NCT07053917"},{"id":"study-NCT07410702","cat":"studies","name":"Correlating EEG Dynamics With Consciousness Alteration Under Anesthesia","status":"RECRUITING","sponsor":"Huazhong University of Science and Technology","drugs":["esketamine","ketamine"],"nct":"NCT07410702","nsites":1,"countries":"China","ccs":["CN"],"start":"2026-02-10","official":"Pu Zhou, PhD. (Huazhong University of Science and Technology)","src":"https://clinicaltrials.gov/study/NCT07410702","sites":["Department of Anaesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology — Wuhan, China"],"conds":["Altered State of Consciousness","General Anesthetics"],"condg":["Other"],"contact":{"n":"Hua Zheng, MD. & PhD.","p":"0086-27-83663173","e":"hzheng@hust.edu.cn"},"enroll":250,"eid":"NCT07410702"},{"id":"study-NCT07102576","cat":"studies","name":"MDMA-Assisted Therapy for Mental Healthcare Providers","status":"RECRUITING","phase":"Phase 1","sponsor":"Rachel Yehuda","drugs":["MDMA"],"nct":"NCT07102576","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-02-11","official":"Tamar Glatman Zaretsky (Mount Sinai Icahn School of Medicine); Rachel Yehuda (Mount Sinai Icahn School of Medicine)","src":"https://clinicaltrials.gov/study/NCT07102576","sites":["The Parsons Research Center for Psychedelic Healing — New York, United States"],"conds":["Mental Wellbeing"],"condg":["Other"],"contact":{"n":"Lily Fischer","p":"862-253-1938","e":"therapistwellbeing@mssm.edu"},"enroll":30,"eid":"NCT07102576"},{"id":"study-NCT07408193","cat":"studies","name":"The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain.","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"National and Kapodistrian University of Athens","drugs":["ketamine"],"nct":"NCT07408193","nsites":1,"countries":"Greece","ccs":["GR"],"start":"2026-03-01","official":"Konstantinos Kalimeris, Assoc Prof of Anesthesiology (National and Kapodistrian University of Athens); Maria Riga, Assis Prof of Anesthesiology (National and…","src":"https://clinicaltrials.gov/study/NCT07408193","sites":["University General Hospital of Athens \"Attikon\" - National and Kapodistrian University of Athens Medical School — Athens, Greece"],"conds":["Opioid-Refractory Chronic Cancer-Related Pain"],"condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"contact":{"n":"Konstantinos Kalimeris MD, PhD, Associate Professor of Anesthesiology, Associate Professor","p":"+302105831997","e":"kkalimeris@med.uoa.gr"},"enroll":24,"eid":"NCT07408193"},{"id":"study-NCT06231563","cat":"studies","name":"Ketamine for Veterans With Parkinson's Disease","status":"RECRUITING","phase":"Phase 2","sponsor":"VA Office of Research and Development","drugs":["ketamine"],"nct":"NCT06231563","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-03-01","official":"Ellen R Bradley, MD (San Francisco VA Medical Center, San Francisco, CA)","src":"https://clinicaltrials.gov/study/NCT06231563","sites":["San Francisco VA Medical Center, San Francisco, CA — San Francisco, United States"],"conds":["Parkinson's Disease"],"condg":["Neurology & cognition"],"contact":{"n":"Ellen R Bradley, MD","p":"(415) 221-4810","e":"ellen.bradley3@va.gov"},"enroll":80,"eid":"NCT06231563"},{"id":"study-NCT07309471","cat":"studies","name":"Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD","status":"RECRUITING","phase":"N/A","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD"],"nct":"NCT07309471","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2026-03-06","official":"Matthias Liechti, Prof.MD (University Hospital of Basel)","src":"https://clinicaltrials.gov/study/NCT07309471","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["LSD Reaction"],"condg":["Other"],"contact":{"n":"Matthias Liechti, Prof. MD","p":"+41 61 328 68 68","e":"matthias.liechti@usb.ch"},"enroll":24,"eid":"NCT07309471"},{"id":"study-NCT06907173","cat":"studies","name":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","status":"RECRUITING","phase":"Phase 3","sponsor":"University of Virginia","drugs":["ketamine"],"nct":"NCT06907173","nsites":63,"countries":"United States","ccs":["US"],"start":"2026-03-06","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","sites":["UAB Hospital — Birmingham, United States","Banner University Medical Center - Tucson Campus — Tucson, United States","UC San Diego Health La Jolla — La Jolla, United States","Ronald Reagan UCLA Medical Center — Los Angeles, United States","Children's Hospital Los Angeles — Los Angeles, United States","Stanford University Medical Center — Palo Alto, United States","UC Davis Medical Center — Sacramento, United States","UC San Diego Health Hillcrest Hospital — San Diego, United States"],"conds":["Status Epilepticus"],"condg":["Neurology & cognition"],"contact":{"n":"Megan Wardius","p":"434-243-6768","e":"mew5j@virginia.edu"},"enroll":770,"eid":"NCT06907173"},{"id":"study-NCT07494214","cat":"studies","name":"Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants","status":"RECRUITING","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT07494214","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2026-03-09","src":"https://clinicaltrials.gov/study/NCT07494214","sites":["Clinical Pharmacology & Toxicology, University Hospital Basel — Basel, Switzerland"],"conds":["Healhty"],"condg":["Other"],"contact":{"n":"Severin B Vogt, Dr. med.","p":"+41 61 268 68 66","e":"severinbenjamin.vogt@usb.ch"},"enroll":20,"eid":"NCT07494214"},{"id":"study-NCT06724289","cat":"studies","name":"Psilocybin for Prolonged Grief Disorder","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"University of Virginia","drugs":["psilocybin"],"nct":"NCT06724289","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-03-24","official":"Jennifer K Penberthy, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06724289","sites":["University of Virginia — Charlottesville, United States"],"conds":["Prolonged Grief Disorder"],"condg":["Other"],"contact":{"n":"Fatma Wise, PhD","p":"(434) 243-0568","e":"uvagrieftrial@uvahealth.org"},"enroll":12,"eid":"NCT06724289"},{"id":"study-NCT07528014","cat":"studies","name":"ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1","status":"RECRUITING","sponsor":"Salma Health, Inc.","drugs":["esketamine","ketamine"],"nct":"NCT07528014","nsites":2,"countries":"United States","ccs":["US"],"start":"2026-03-25","src":"https://clinicaltrials.gov/study/NCT07528014","sites":["Salma Health — La Jolla, United States","Salma Health — Laguna Hills, United States"],"conds":["Depressed Mood"],"condg":["Depression"],"enroll":5000,"eid":"NCT07528014"},{"id":"study-NCT07444788","cat":"studies","name":"Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants","status":"RECRUITING","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["DMT"],"nct":"NCT07444788","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2026-03-31","official":"Severin Vogt, Dr. med. (University Hospital Basel, Division of Clinical Pharmacology and Toxicology)","src":"https://clinicaltrials.gov/study/NCT07444788","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["5-methoxy-dimethyltryptamine (5-MeO-DMT)"],"condg":["Other"],"contact":{"n":"Livio Erne, MSc Drug Sciences","p":"+41613284818","e":"livio.erne@usb.ch"},"enroll":40,"eid":"NCT07444788"},{"id":"study-NCT07009158","cat":"studies","name":"Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Dr. Yuliya Knyahnytska","drugs":["ketamine"],"nct":"NCT07009158","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2026-03-31","src":"https://clinicaltrials.gov/study/NCT07009158","sites":["Providence Care Hospital / Kingston Health Sciences Centre Hotel Dieu Hospital site — Kingston, Canada"],"conds":["Chronic Pain","Posttraumatic Stress Disorder (PTSD)"],"condg":["PTSD & trauma","Chronic pain & headache"],"contact":{"n":"Etienne J Bisson, PhD","p":"16135443400","e":"etienne.bisson@kingstonhsc.ca"},"enroll":30,"eid":"NCT07009158"},{"id":"study-NCT07461532","cat":"studies","name":"Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD","status":"RECRUITING","phase":"N/A","sponsor":"Northern Jiangsu People's Hospital","drugs":["LSD"],"nct":"NCT07461532","nsites":1,"countries":"China","ccs":["CN"],"start":"2026-04-01","official":"Dou-Sheng Bai (Clinical Medical College, Yangzhou University)","src":"https://clinicaltrials.gov/study/NCT07461532","sites":["Clinical Medical College — Yangzhou, China"],"conds":["Cirrhosis","Splenectomy","Portal Vein Thrombosis","Hypertension, Portal"],"condg":["Other"],"contact":{"n":"Guo-Qing Jiang, MD","p":"+8651487373272","e":"jgqing2003@hotmail.com"},"enroll":20,"eid":"NCT07461532"},{"id":"study-NCT06406647","cat":"studies","name":"Rectroclavicular Block in Orthopedic Surgey","status":"RECRUITING","phase":"N/A","sponsor":"New Valley University","drugs":["ketamine"],"nct":"NCT06406647","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2026-04-01","official":"ahmed ismail, lecture (New Valley University)","src":"https://clinicaltrials.gov/study/NCT06406647","sites":["Faculty of Medicine — Asyut, Egypt"],"conds":["Pain Management"],"condg":["Chronic pain & headache"],"contact":{"n":"ahmed ismail, lecture","p":"01097845491","e":"ahmed_ismail87@med.nvu.edu.eg"},"enroll":80,"eid":"NCT06406647"},{"id":"study-NCT06788249","cat":"studies","name":"Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"University of Pennsylvania","drugs":["ketamine"],"nct":"NCT06788249","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-04-01","official":"Jennifer R Goldschmied, PhD (University of Pennsylvania)","src":"https://clinicaltrials.gov/study/NCT06788249","sites":["University of Pennsylvania — Philadelphia, United States"],"conds":["Major Depressive Disorder (MDD)"],"condg":["Depression"],"contact":{"n":"Isabel Koh","p":"215-573-6173","e":"Isabel.Koh@PennMedicine.upenn.edu"},"enroll":10,"eid":"NCT06788249"},{"id":"study-NCT06490731","cat":"studies","name":"Effects of Dexmedetomidine Versus Ketamine on Inflammatory Response and Hemodynamic in Patients","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"New Valley University","drugs":["ketamine"],"nct":"NCT06490731","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2026-04-01","official":"Ahmed Ismail Abdel Sabour, MD (NewValley University)","src":"https://clinicaltrials.gov/study/NCT06490731","sites":["asyut University — Asyut, Egypt"],"conds":["Haemodynamic Rebound"],"condg":["Other"],"contact":{"n":"Ahmed Ismail ABDEL sabour, MD","p":"01097845491","e":"ahmed_ismail87@med.nvu.edu.eg"},"enroll":2,"eid":"NCT06490731"},{"id":"study-NCT07732166","cat":"studies","name":"Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"Pontifícia Universidade Católica do Rio de Janeiro","drugs":["psilocybin"],"nct":"NCT07732166","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2026-04-01","src":"https://clinicaltrials.gov/study/NCT07732166","sites":["Centro de Pesquisas Matteo Ricci — Rio de Janeiro, Brazil"],"conds":["Healthy Adults"],"condg":["Healthy volunteers"],"contact":{"n":"Daniel C Mograbi, PhD","p":"+ 55 21 35272505","e":"mograbilab@gmail.com"},"enroll":100,"eid":"NCT07732166"},{"id":"study-NCT06818994","cat":"studies","name":"Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer","status":"RECRUITING","phase":"Phase 1","sponsor":"Gustavo Vazquez","drugs":["psilocybin"],"nct":"NCT06818994","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2026-04-01","src":"https://clinicaltrials.gov/study/NCT06818994","sites":["Queen's University — Kingston, Canada"],"conds":["Demoralization","Safety"],"condg":["Other"],"contact":{"n":"Gustavo Vazquez, MD, PhD, FRCPC","p":"613-544-4900 x51214","e":"vazquezg@providencecare.ca"},"enroll":15,"eid":"NCT06818994"},{"id":"study-NCT07703722","cat":"studies","name":"Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder","status":"RECRUITING","phase":"Phase 3","sponsor":"Khyber Medical University Peshawar","drugs":["psilocybin"],"nct":"NCT07703722","nsites":3,"countries":"Pakistan","ccs":["PK"],"start":"2026-04-01","official":"Dr Omer Malik, PhD (Khyber Medical University Peshawar, Pakistan); Dr Inayat Shah, PhD* (Khyber Medical University)","src":"https://clinicaltrials.gov/study/NCT07703722","sites":["Institute of Health Science, Khyber Medical University — Islamabad, Pakistan","Hayatabad Medical Complex Peshawar — Peshawar, Pakistan","Khyber Medical University — Peshawar, Pakistan"],"conds":["Major Depressive Disorder","Post-Traumatic Stress Disorder (PTSD)"],"condg":["Depression","PTSD & trauma"],"contact":{"n":"Bushra Riaz, PhD*","p":"+92 3338000744","e":"bushrariaz098@gmail.com"},"enroll":60,"eid":"NCT07703722"},{"id":"study-NCT07516405","cat":"studies","name":"Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","status":"RECRUITING","phase":"Phase 1","sponsor":"University of Colorado, Denver","drugs":["psilocybin"],"nct":"NCT07516405","nsites":6,"countries":"United States","ccs":["US"],"start":"2026-04-01","src":"https://clinicaltrials.gov/study/NCT07516405","sites":["University of California San Francisco (UCSF) Department of Neurology — San Francisco, United States","University of Colorado Anschutz Medical Campus — Aurora, United States","Emory University Brain Health Center — Atlanta, United States","Dana-Farber Cancer Institute — Boston, United States","University of Nebraska Medical Center — Omaha, United States","New York University Langone Health, Center for Psychedelic Medicine — New York, United States"],"conds":["Healthy Volunteer","Older Adults (65-85 Years)"],"condg":["Healthy volunteers"],"contact":{"n":"Mary P Mancuso, MA (dual degrees)","p":"3037245729","e":"inspire@cuanschutz.edu"},"enroll":40,"eid":"NCT07516405"},{"id":"study-NCT07294092","cat":"studies","name":"Ketamine and Propofol NeuroImaging","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"Keith M Vogt","drugs":["ketamine"],"nct":"NCT07294092","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-04-10","official":"Keith M Vogt, MD, PhD (University of Pittsburgh)","src":"https://clinicaltrials.gov/study/NCT07294092","sites":["University of Pittsburgh — Pittsburgh, United States"],"conds":["Anesthesia","Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Keith M Vogt, MD, PhD","p":"4126473147","e":"kev18@pitt.edu"},"enroll":60,"eid":"NCT07294092"},{"id":"study-NCT07563868","cat":"studies","name":"Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression","status":"RECRUITING","phase":"N/A","sponsor":"Massachusetts General Hospital","drugs":["esketamine","ketamine"],"nct":"NCT07563868","nsites":2,"countries":"United States","ccs":["US"],"start":"2026-04-17","official":"Maren Nyer, PhD (Massachusetts General Hospital and Harvard Medical School); Franklin King, MD (Massachusetts General Hospital and Harvard Medical School)","src":"https://clinicaltrials.gov/study/NCT07563868","sites":["Massachusetts General Hospital's Depression and Clinical Research program — Boston, United States","Massachusetts General Hospital — Boston, United States"],"conds":["Treatment Resistant Depression (TRD)"],"condg":["Depression"],"contact":{"n":"Maren Nyer, PhD","p":"6176434897","e":"mnyer@mgh.harvard.edu"},"enroll":20,"eid":"NCT07563868"},{"id":"study-NCT07222007","cat":"studies","name":"Induction Agent Choice With Early Mortality and Prognostic Outcomes in Critically Ill Patients","status":"RECRUITING","sponsor":"Zeliha Alicikus","drugs":["ketamine"],"nct":"NCT07222007","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-04-18","official":"TOLGA SARAÇOĞLU, Prof,MD (Florida University Jacksonville)","src":"https://clinicaltrials.gov/study/NCT07222007","sites":["UF Health Jacksonville (Shands Hospital) — Jacksonville, United States"],"conds":["Critically Ill","Intubation Complication","Oxygenation","Airway Management","Propofol","Ketamine"],"condg":["Other"],"contact":{"n":"TOLGA SARAÇOĞLU, Prof,MD","p":"+1 (904) 524-5932","e":"kemaltolgasaracoglu@gmail.com"},"enroll":4,"eid":"NCT07222007"},{"id":"study-NCT07506395","cat":"studies","name":"Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder","status":"RECRUITING","phase":"Phase 1","sponsor":"University of New Mexico","drugs":["psilocybin"],"nct":"NCT07506395","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-05-01","src":"https://clinicaltrials.gov/study/NCT07506395","sites":["Interdisciplinary Substance Use and Brain Injury (ISUBI) — Albuquerque, United States"],"conds":["PTSD"],"condg":["PTSD & trauma"],"contact":{"n":"Victoria Culkin","e":"vculkin@salud.unm.edu"},"enroll":36,"eid":"NCT07506395"},{"id":"study-NCT06781697","cat":"studies","name":"InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression","status":"RECRUITING","phase":"Phase 3","sponsor":"Sunnybrook Health Sciences Centre","drugs":["ketamine"],"nct":"NCT06781697","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2026-05-03","src":"https://clinicaltrials.gov/study/NCT06781697","sites":["Sunnybrook Health Sciences Centre — Toronto, Canada"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"contact":{"n":"Fahad Alam, MD","p":"416-480-4864","e":"fahad.alam@sunnybrook.ca"},"enroll":31,"eid":"NCT06781697"},{"id":"study-NCT07592689","cat":"studies","name":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","status":"RECRUITING","phase":"Phase 3","sponsor":"Definium Therapeutics US, Inc.","drugs":["LSD"],"nct":"NCT07592689","nsites":30,"countries":"United States","ccs":["US"],"start":"2026-05-10","src":"https://clinicaltrials.gov/study/NCT07592689","sites":["Preferred Research Partners, Inc. — Little Rock, United States","ATP Clinical Research Orange County — Orange, United States","Kadima Neuropsychiatry Institute — San Diego, United States","UCSF Department of Neurology — San Francisco, United States","Psychedelic Science Institute — Santa Monica, United States","Mountain View Clinical Research, Inc — Denver, United States","Clinical Neuroscience Solutions, LLC (Jacksonville) — Jacksonville, United States","K2 Medical Research (Maitland) — Maitland, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Definium Therapeutics Clinical Trials Info Requests","p":"1-332-282-0479","e":"clinicaltrials@definiumtx.com"},"enroll":165,"eid":"NCT07592689"},{"id":"study-NCT07530146","cat":"studies","name":"Comparative Efficacy and Safety of Propofol-Ketamine Combination Versus Propofol Monotherapy in Geriatric Patients Under Invasive Ventilation","status":"RECRUITING","phase":"Phase 3","sponsor":"Helwan University","drugs":["ketamine"],"nct":"NCT07530146","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2026-05-13","src":"https://clinicaltrials.gov/study/NCT07530146","sites":["Kasr Al Aini Hospital — Cairo, Egypt"],"conds":["The Critically Ill Patient is Requiring Intubation","Septic Shock","Pneumonia"],"condg":["Other"],"enroll":70,"eid":"NCT07530146"},{"id":"study-NCT07639359","cat":"studies","name":"Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients","status":"RECRUITING","phase":"Phase 2","sponsor":"Hospital Italiano de Buenos Aires","drugs":["ketamine"],"nct":"NCT07639359","nsites":2,"countries":"Argentina; United States","ccs":["AR","US"],"start":"2026-05-14","official":"Ivan A Huespe, M.D., M.P.H. (Hospital Italiano de Buenos Aires); Devang K Sanghavi, M.B.B.S., M.D. (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT07639359","sites":["Mayo Clinic — Jacksonville, United States","Hospital Italiano de Buenos Aires - Sede Central — Buenos Aires, Argentina"],"conds":["Critical Illness","Depressive Symptoms"],"condg":["Depression"],"contact":{"n":"Ivan A. Huespe, M.D., M.P.H.","p":"+5493425382554","e":"ivan.huespe@hospitalitaliano.org.ar"},"enroll":50,"eid":"NCT07639359"},{"id":"study-NCT06768944","cat":"studies","name":"Subjective Experience Following Psilocybin","status":"RECRUITING","phase":"Phase 2","sponsor":"University of Calgary","drugs":["psilocybin"],"nct":"NCT06768944","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2026-05-15","official":"Leah Mayo, PhD (University of Calgary)","src":"https://clinicaltrials.gov/study/NCT06768944","sites":["University of Calgary — Calgary, Canada"],"conds":["Investigating the Importance of the Subjective Psychedelic…"],"condg":["Other"],"contact":{"n":"Ana Deutsch, MSc","p":"587-893-0257","e":"septrial@ucalgary.ca"},"enroll":128,"eid":"NCT06768944"},{"id":"study-NCT07118839","cat":"studies","name":"MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder","status":"RECRUITING","phase":"Phase 2/Phase 3","sponsor":"VA Office of Research and Development","drugs":["MDMA"],"nct":"NCT07118839","nsites":2,"countries":"United States","ccs":["US"],"start":"2026-05-18","official":"Erica M. Eaton, PhD (Providence VA Medical Center, Providence, RI)","src":"https://clinicaltrials.gov/study/NCT07118839","sites":["VA Connecticut Healthcare System West Haven Campus, West Haven, CT — West Haven, United States","Providence VA Medical Center, Providence, RI — Providence, United States"],"conds":["Post Traumatic Stress Disorder","Alcohol Use Disorder"],"condg":["PTSD & trauma","Addiction & substance use"],"contact":{"n":"Erica M Eaton, PhD","p":"(401) 273-7100","e":"Erica.Eaton@va.gov"},"enroll":80,"eid":"NCT07118839"},{"id":"study-NCT07347405","cat":"studies","name":"Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.","status":"RECRUITING","phase":"Phase 1","sponsor":"Francisco A Moreno","drugs":["psilocybin"],"nct":"NCT07347405","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-05-18","official":"Francisco Moreno, MD (University of Arizona)","src":"https://clinicaltrials.gov/study/NCT07347405","sites":["The Clinical and Translational Sciences Research Center — Tucson, United States"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"contact":{"n":"The clinical and translational research center","p":"(520) 626-8000","e":"OCD@psychiatry.arizona.edu"},"enroll":30,"eid":"NCT07347405"},{"id":"study-NCT07542145","cat":"studies","name":"MDMA Assisted Therapy for BN","status":"RECRUITING","phase":"Phase 1","sponsor":"Icahn School of Medicine at Mount Sinai","drugs":["MDMA"],"nct":"NCT07542145","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-05-22","official":"Tom Hildebrandt, PsyD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT07542145","sites":["Department of Psychiatry, Eating and Weight Disorders Program — New York, United States"],"conds":["Bulimia Nervosa"],"condg":["Eating disorders"],"contact":{"n":"Carson Harran","p":"212-659-8724","e":"carson.harran@mssm.edu"},"enroll":40,"eid":"NCT07542145"},{"id":"study-NCT06902974","cat":"studies","name":"Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD","status":"RECRUITING","phase":"Phase 2","sponsor":"Sunstone Medical","drugs":["psilocybin"],"nct":"NCT06902974","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-05-23","official":"Manish Agrawal, MD, MSC (Sunstone Medical, PC)","src":"https://clinicaltrials.gov/study/NCT06902974","sites":["Sunstone Medical, PC — Rockville, United States"],"conds":["Post Traumatic Stress Disorder","PTSD"],"condg":["PTSD & trauma"],"contact":{"n":"Clinical Evaluation Team","p":"301-750-3401","e":"clinical.specialists@sunstonetherapies.com"},"enroll":70,"eid":"NCT06902974"},{"id":"study-NCT06386003","cat":"studies","name":"Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD","status":"RECRUITING","phase":"Phase 2","sponsor":"Unity Health Toronto","drugs":["psilocybin"],"nct":"NCT06386003","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2026-06","src":"https://clinicaltrials.gov/study/NCT06386003","sites":["St. Michael's Hospital, Unity Health Toronto — Toronto, Canada"],"conds":["Post Traumatic Stress Disorder","PTSD","Chronic PTSD"],"condg":["PTSD & trauma"],"contact":{"n":"Venkat Bhat","p":"416-360-4000","e":"Venkat.Bhat@unityhealth.to"},"enroll":15,"eid":"NCT06386003"},{"id":"study-NCT07120477","cat":"studies","name":"Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention: A Pragmatic Randomized Trial in a Brazilian Municipality (SAVE)","status":"RECRUITING","phase":"Phase 4","sponsor":"University of Sao Paulo","drugs":["esketamine"],"nct":"NCT07120477","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2026-06-01","src":"https://clinicaltrials.gov/study/NCT07120477","sites":["Prefeitura de Indaiatuba — Indaiatuba, Brazil"],"conds":["Suicide Prevention","Ketamine","Crisis Response Plan"],"condg":["Other"],"contact":{"n":"Rodolfo F Damiano, M.D., Ph.D.","p":"+5511933300360","e":"damianorf@usp.br"},"enroll":478,"eid":"NCT07120477"},{"id":"study-NCT06062628","cat":"studies","name":"Ketamine in Severe Traumatic Brain Injury","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"University of Texas Southwestern Medical Center","drugs":["ketamine"],"nct":"NCT06062628","nsites":2,"countries":"United States","ccs":["US"],"start":"2026-06-01","official":"Anna Bashmakov, D.O. (University of Texas Southwestern Medical Center)","src":"https://clinicaltrials.gov/study/NCT06062628","sites":["Parkland Memorial Hospital — Dallas, United States","Parkland Memorial Hospital — Dallas, United States"],"conds":["Traumatic Brain Injury","Traumatic Encephalopathy"],"condg":["PTSD & trauma","Neurology & cognition"],"enroll":10,"eid":"NCT06062628"},{"id":"study-NCT07386730","cat":"studies","name":"A Study of Psychedelics in Healthy Older Adults With Low Well-being","status":"RECRUITING","phase":"Phase 1","sponsor":"Jennifer Mitchell","drugs":["psilocybin"],"nct":"NCT07386730","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-06-01","official":"Lorenzo Pasquini, PhD (University of California, San Francisco); Jennifer Mitchell, PhD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT07386730","sites":["University of California San Francisco, Sandler Neuroscience Building — San Francisco, United States"],"conds":["Anhedonia in Healthy Volunteers","Older Adults (50-90 Years)"],"condg":["Healthy volunteers"],"contact":{"n":"Gabriella Mace","p":"415-707-5399","e":"agingandpsychedelics@ucsf.edu"},"enroll":80,"eid":"NCT07386730"},{"id":"study-NCT07332143","cat":"studies","name":"Psilocybin-Assisted Therapy","status":"RECRUITING","phase":"Phase 2","sponsor":"Emory University","drugs":["psilocybin"],"nct":"NCT07332143","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-06-08","official":"Anna Wise, PhD (Emory University)","src":"https://clinicaltrials.gov/study/NCT07332143","sites":["Emory University Hospital — Atlanta, United States"],"conds":["PTSD"],"condg":["PTSD & trauma"],"contact":{"n":"Anna Wise, PhD","p":"404-712-1035","e":"patstudy@emory.edu"},"enroll":150,"eid":"NCT07332143"},{"id":"study-NCT06943573","cat":"studies","name":"Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder","status":"RECRUITING","phase":"Phase 2","sponsor":"Lakshmi N Yatham","drugs":["psilocybin"],"nct":"NCT06943573","nsites":3,"countries":"Canada","ccs":["CA"],"start":"2026-06-15","official":"Dr. Lakshmi N Yatham (UBC Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT06943573","sites":["Djavad Mowafaghian Centre for Brain Health — Vancouver, Canada","Department of Psychiatry, University of Ottawa, The Ottawa Hospital — Ottawa, Canada","Department of Psychiatry, University of Toronto, University Health Network, — Toronto, Canada"],"conds":["Bipolar II Depression"],"condg":["Depression","Bipolar"],"contact":{"n":"Vy Ngo, B.Sc","p":"604-822-3769","e":"vy.ngo@ubc.ca"},"enroll":90,"eid":"NCT06943573"},{"id":"study-NCT07569159","cat":"studies","name":"MDMA Therapy in Veterans With PTSD","status":"RECRUITING","phase":"Phase 2","sponsor":"Sunstone Medical","drugs":["MDMA"],"nct":"NCT07569159","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-06-30","official":"Manish Agarwal (Sunstone Medical, PC)","src":"https://clinicaltrials.gov/study/NCT07569159","sites":["Sunstone Therapies — Rockville, United States"],"conds":["Post Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"contact":{"n":"Clinical Evaluation Team","p":"(301) 750-3401","e":"clinical.specialists@sunstonetherapies.com"},"enroll":52,"eid":"NCT07569159"},{"id":"study-NCT07210112","cat":"studies","name":"Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)","status":"RECRUITING","phase":"Phase 2","sponsor":"Centre Hospitalier St Anne","drugs":["psilocybin"],"nct":"NCT07210112","nsites":1,"countries":"France","ccs":["FR"],"start":"2026-06-30","official":"Lucie BERKOVITCH, MD (GHU Paris Psychiatrie and Neurosciences - Neuromodulation Institute)","src":"https://clinicaltrials.gov/study/NCT07210112","sites":["GHU Paris Psychiatrie and Neurosciences — Paris, France"],"conds":["Depression - Major Depressive Disorder","Treatment-resistant Depression (TRD)"],"condg":["Depression"],"contact":{"n":"Lucie BERKOVITCH, MD","p":"+33 145657481","e":"l.berkovitch@ghu-paris.fr"},"enroll":112,"eid":"NCT07210112"},{"id":"study-NCT07638553","cat":"studies","name":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","status":"RECRUITING","phase":"Phase 3","sponsor":"Centre Hospitalier Universitaire de Nīmes","drugs":["psilocybin"],"nct":"NCT07638553","nsites":8,"countries":"France","ccs":["FR"],"start":"2026-06-30","official":"Amandine Luquiens (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT07638553","sites":["Centre Hospitalier de la Côte Basque — Bayonne, France","CHU Besançon — Besançon, France","CHU de Bordeaux — Bordeaux, France","CHU Brest — Brest, France","CH Le Vinatier — Bron, France","CHU de Nantes — Nantes, France","CHU de Nîmes — Nîmes, France","CHU Saint-Etienne — Saint-Priest, France"],"conds":["Alcohol Use Disorder","Depressive Sympotoms","Psilocybin"],"condg":["Depression","Addiction & substance use"],"contact":{"n":"Amandine Luquiens","p":"04.66.68.69.98","e":"amandine.luquiens@chu-nimes.fr"},"enroll":172,"eid":"NCT07638553"},{"id":"study-NCT07288151","cat":"studies","name":"MDMA-Assisted Massed Exposure Therapy for PTSD","status":"RECRUITING","phase":"Phase 2","sponsor":"Emory University","drugs":["MDMA"],"nct":"NCT07288151","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-07","official":"Jessica Maples-Keller, PhD (Emory University)","src":"https://clinicaltrials.gov/study/NCT07288151","sites":["Emory Brain Health Center — Atlanta, United States"],"conds":["Post Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"contact":{"n":"Jessica Maples-Keller, PhD","p":"404-712-1035","e":"patstudy@emory.edu"},"enroll":200,"eid":"NCT07288151"},{"id":"study-NCT07747324","cat":"studies","name":"Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"University of Sao Paulo","drugs":["ayahuasca"],"nct":"NCT07747324","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2026-07-01","src":"https://clinicaltrials.gov/study/NCT07747324","sites":["Ribeirão Preto Medical School — Ribeirão Preto, Brazil"],"conds":["Non Epileptic Seizures"],"condg":["Neurology & cognition"],"enroll":15,"eid":"NCT07747324"},{"id":"study-NCT07104916","cat":"studies","name":"Mindfulness-based Psilocybin Therapy for PTSD","status":"RECRUITING","phase":"Phase 2","sponsor":"Anthony P King","drugs":["psilocybin"],"nct":"NCT07104916","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-07-01","src":"https://clinicaltrials.gov/study/NCT07104916","sites":["The Ohio State University Medical Center — Columbus, United States"],"conds":["Post Traumatic Stress Disorder","Depression - Major Depressive Disorder"],"condg":["Depression","PTSD & trauma"],"contact":{"n":"Anthony King, PhD","p":"614 688-9537","e":"anthony.king@osumc.edu"},"enroll":30,"eid":"NCT07104916"},{"id":"study-NCT07211438","cat":"studies","name":"Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression","status":"RECRUITING","phase":"Phase 2","sponsor":"Centre for Addiction and Mental Health","drugs":["psilocybin"],"nct":"NCT07211438","nsites":2,"countries":"Canada","ccs":["CA"],"start":"2026-07-03","official":"Ishrat Husain, MBBS, MD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT07211438","sites":["Toronto Western Hospital (University Health Network) — Toronto, Canada","Centre for Addiction and Mental Health — Toronto, Canada"],"conds":["Treatment-Resistant Depression"],"condg":["Depression"],"contact":{"n":"Emily Gilbert, MSc","p":"416-535-8501","e":"emily.gilbert@camh.ca"},"enroll":40,"eid":"NCT07211438"},{"id":"study-NCT07118332","cat":"studies","name":"Psilocybin as a Treatment for Chronic Pain in Smokers","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"Yale University","drugs":["psilocybin"],"nct":"NCT07118332","nsites":2,"countries":"United States","ccs":["US"],"start":"2026-07-06","src":"https://clinicaltrials.gov/study/NCT07118332","sites":["Department of Veterans Affairs — West Haven, United States","Department of Veterans Affairs — West Haven, United States"],"conds":["Smokers With Chronic Pain"],"condg":["Addiction & substance use","Chronic pain & headache"],"contact":{"n":"Mehmet Sofuoglu, M.D., Ph.D.","p":"203-932-5711","e":"Mehmet.Sofuoglu@va.gov"},"enroll":10,"eid":"NCT07118332"},{"id":"study-NCT07610369","cat":"studies","name":"The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","status":"RECRUITING","phase":"Phase 2","sponsor":"Yale University","drugs":["psilocybin"],"nct":"NCT07610369","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-07-10","official":"Sophie Holmes, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT07610369","sites":["Yale University — New Haven, United States"],"conds":["Depression","Parkinson's Disease (PD)"],"condg":["Depression","Neurology & cognition"],"contact":{"n":"Sophie Holmes, PhD","p":"203-685-4066","e":"sophie.holmes@yale.edu"},"enroll":40,"eid":"NCT07610369"},{"id":"study-NCT07237659","cat":"studies","name":"Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA","status":"RECRUITING","phase":"Phase 1","sponsor":"Neutrolis","drugs":["LSD"],"nct":"NCT07237659","nsites":7,"countries":"United States","ccs":["US"],"start":"2026-07-15","official":"Andreas Reiff, PhD, MD (Neutrolis)","src":"https://clinicaltrials.gov/study/NCT07237659","sites":["Carewell Arthritis Center — Apple Valley, United States","Attune Health Research Inc — Beverly Hills, United States","Covina Arthritis Clinic — Covina, United States","Novamed — Monterey Park, United States","Southland Arthritis Clinic — Riverside, United States","Southland Arthritis Clinic — Temecula, United States","Foothill Arthritis Clinic — Tujunga, United States"],"conds":["SLE (Systemic Lupus)","RA - Rheumatoid Arthritis"],"condg":["Other"],"contact":{"n":"Andreas Reiff, MD, PhD","p":"(626) 264-2734","e":"reiff@neutrolis.com"},"enroll":24,"eid":"NCT07237659"},{"id":"study-NCT07569198","cat":"studies","name":"Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)","status":"RECRUITING","phase":"Phase 2","sponsor":"Joshua Rosenblat","drugs":["ketamine"],"nct":"NCT07569198","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2026-07-16","official":"Joshua D. Rosenblat, MD, MSc (Toronto Western Hospital, Psychiatry)","src":"https://clinicaltrials.gov/study/NCT07569198","sites":["Toronto Western Hospital — Toronto, Canada"],"conds":["Borderline Personality Disorder (BPD)","Treatment-Resistant Major Depressive Disorder","Treatment-resistant Bipolar Depression","Major Depressive Disorder (MDD)","Bipolar Disorder (BD)","Bipolar Disorder I or II"],"condg":["Depression","Bipolar"],"contact":{"n":"Diana Orsini","p":"437-882-9458","e":"ket.dbt@uhn.ca"},"enroll":120,"eid":"NCT07569198"},{"id":"study-NCT07169747","cat":"studies","name":"Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa","status":"RECRUITING","phase":"Phase 2","sponsor":"Region Skane","drugs":["psilocybin"],"nct":"NCT07169747","nsites":1,"countries":"Sweden","ccs":["SE"],"start":"2026-07-20","official":"Pouya Movahed Rad, Associate Professor (Department of Clinical Sciences, Lund University, Sweden)","src":"https://clinicaltrials.gov/study/NCT07169747","sites":["Psykiatrikliniken, Baravägen 1 — Lund, Sweden"],"conds":["Anorexia Nervosa"],"condg":["Eating disorders"],"contact":{"n":"David Sjöström, MD, PhD-student","p":"+46739075390","e":"david.sjostrom@med.lu.se"},"enroll":40,"eid":"NCT07169747"},{"id":"study-NCT07716098","cat":"studies","name":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","status":"RECRUITING","phase":"Phase 3","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT07716098","nsites":22,"countries":"Japan; Taiwan; United States","ccs":["JP","TW","US"],"start":"2026-07-23","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","sites":["Anderson Clinical Research — Redlands, United States","Artemis Institute for Clinical Research — San Diego, United States","Psych Atlanta, P.C. — Marietta, United States","Psychiatric Medicine Associates LLC — Skokie, United States","Neurobehavioral Research Inc — Cedarhurst, United States","The Medical Research Network, LLC — New York, United States","Northwest Clinical Research Center — Bellevue, United States","Kishiro Mental Clinic — Kawasaki, Japan"],"conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"enroll":348,"eid":"NCT07716098"},{"id":"study-NCT07562191","cat":"studies","name":"Inhaled DMT for Major Depressive Disorder","status":"RECRUITING","phase":"Phase 2","sponsor":"Universidade Federal do Rio Grande do Norte","drugs":["DMT"],"nct":"NCT07562191","nsites":5,"countries":"Brazil","ccs":["BR"],"start":"2026-08-01","src":"https://clinicaltrials.gov/study/NCT07562191","sites":["Hospital de Saúde Mental Professor Frota Pinto — Fortaleza, Brazil","Complexo Hospitalar Universitário Professor Edgard Santos, Federal University of Bahia (HUPES-UFBA) — Salvador, Brazil","Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro (IPUB-UFRJ) — Rio de Janeiro, Brazil","Hospital Universitário Onofre Lopes - HUOL - UFRN — Natal, Brazil","Instituto de Psiquiatria - Hospital das Clínicas - IPq - HC - USP — São Paulo, Brazil"],"conds":["MDD","Major Depressive Disorder (MDD)","Major Depression","Suicidal Ideation","Suicide"],"condg":["Depression"],"enroll":140,"eid":"NCT07562191"},{"id":"study-NCT06820723","cat":"studies","name":"A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety","status":"RECRUITING","phase":"Phase 2","sponsor":"Ohio State University","drugs":["psilocybin"],"nct":"NCT06820723","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-08-01","official":"Luan Phan, MD (Ohio State University)","src":"https://clinicaltrials.gov/study/NCT06820723","sites":["The Ohio State University Department of Psychiatry — Columbus, United States"],"conds":["Depression","Anxiety","Major Depressive Disorder"],"condg":["Depression","Anxiety"],"contact":{"n":"Anne-Marie Duchemin","p":"6142935517","e":"anne-marie.duchemin@osumc.edu"},"enroll":40,"eid":"NCT06820723"},{"id":"study-NCT07226232","cat":"studies","name":"Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression","status":"RECRUITING","phase":"Phase 3","sponsor":"VA Office of Research and Development","drugs":["psilocybin"],"nct":"NCT07226232","nsites":5,"countries":"United States","ccs":["US"],"start":"2026-08-03","official":"Lori Lynne Davis, MD AB (Birmingham VA Medical Center, Birmingham, AL)","src":"https://clinicaltrials.gov/study/NCT07226232","sites":["Birmingham VA Medical Center, Birmingham, AL — Birmingham, United States","Tuscaloosa VA Medical Center, Tuscaloosa, AL — Tuscaloosa, United States","VA Portland Health Care System, Portland, OR — Portland, United States","Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA — Philadelphia, United States","VA Puget Sound Health Care System Seattle Division, Seattle, WA — Seattle, United States"],"conds":["Major Depression"],"condg":["Depression"],"contact":{"n":"Lori L Davis, MD AB","p":"(205) 554-3819","e":"lori.davis@va.gov"},"enroll":240,"eid":"NCT07226232"},{"id":"study-NCT07251491","cat":"studies","name":"Psilocybin to Treat Depression in Spinal Cord Injury","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"James J. Peters Veterans Affairs Medical Center","drugs":["psilocybin"],"nct":"NCT07251491","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-08-06","official":"Jill M Wecht, EdD (James J Peters VA Medical Center)","src":"https://clinicaltrials.gov/study/NCT07251491","sites":["James J. Peters Department of Veterans Affairs Medical Center — The Bronx, United States"],"conds":["Spinal Cord Injury","Depression - Major Depressive Disorder","Veteran"],"condg":["Depression"],"contact":{"n":"Thomas W Sutor, PhD","p":"718-584-9000","e":"Thomas.Sutor@mountsinai.org"},"enroll":30,"eid":"NCT07251491"},{"id":"study-NCT07680140","cat":"studies","name":"Biomarker-Guided Antidepressant Selection","status":"RECRUITING","phase":"Phase 4","sponsor":"Weill Medical College of Cornell University","drugs":["ketamine"],"nct":"NCT07680140","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-08-10","official":"Conor Liston, MD, PhD (Weill Medical College of Cornell University)","src":"https://clinicaltrials.gov/study/NCT07680140","sites":["Weill Cornell Medicine — New York, United States"],"conds":["Depression - Major Depressive Disorder","Treatment-resistant Depression (TRD)","rTMS","Ketamine","fMRI"],"condg":["Depression"],"contact":{"n":"Research Coordinator, Interventional Psychiatry Program","p":"646-962-2900","e":"tmsinfo@med.cornell.edu"},"enroll":27,"eid":"NCT07680140"},{"id":"study-NCT07565493","cat":"studies","name":"Psilocybin Administration With 5-HT1a Blockade","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT07565493","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-08-12","official":"Sandeep M Nayak, MD (Center for Psychedelics and Consciousness Research)","src":"https://clinicaltrials.gov/study/NCT07565493","sites":["Center for Psychedelics and Consciousness Research — Baltimore, United States"],"conds":["Psychedelic Effects in Healthy Volunteers"],"condg":["Healthy volunteers"],"contact":{"n":"Zarmeen Zahid, PhD","p":"667-208-8099","e":"psilblock@jh.edu"},"enroll":18,"eid":"NCT07565493"},{"id":"study-NCT07563296","cat":"studies","name":"KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury","status":"RECRUITING","phase":"Phase 2","sponsor":"Irma Fleming","drugs":["ketamine"],"nct":"NCT07563296","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-08-24","official":"Irma Fleming, MD (The University of Utah); Benjamin Lewis, MD (The University of Utah)","src":"https://clinicaltrials.gov/study/NCT07563296","sites":["University of Utah Health — Salt Lake City, United States"],"conds":["PTSD and Trauma-related Symptoms"],"condg":["PTSD & trauma"],"contact":{"n":"Claire Ausbeck, BA","p":"18014033671","e":"claire.ausbeck@hsc.utah.edu"},"enroll":12,"eid":"NCT07563296"},{"id":"study-NCT06899165","cat":"studies","name":"Psilocybin-Assisted Therapy for Intergenerational Trauma","status":"RECRUITING","phase":"Phase 2","sponsor":"Rachel Yehuda","drugs":["psilocybin"],"nct":"NCT06899165","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-08-28","official":"Rachel Yehuda, PhD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT06899165","sites":["The Parsons Research Center for Psychedelic Healing — New York, United States"],"conds":["Psychological Stress","Depression","Anxiety"],"condg":["Depression","Anxiety"],"contact":{"n":"Lauren Lepow, MD, PhD","p":"646-438-5044","e":"lauren.lepow@mountsinai.org"},"enroll":100,"eid":"NCT06899165"},{"id":"study-NCT07570654","cat":"studies","name":"Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","status":"RECRUITING","phase":"Phase 2/Phase 3","sponsor":"COMPASS Pathways","drugs":["psilocybin"],"nct":"NCT07570654","nsites":4,"countries":"United States","ccs":["US"],"start":"2026-09","src":"https://clinicaltrials.gov/study/NCT07570654","sites":["FL — Miami, United States","FL — Orlando, United States","NE — Lincoln, United States","NY — New York, United States"],"conds":["PTSD - Post Traumatic Stress Disorder","PTSD","PTSD Symptoms","PTSD, Post Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"contact":{"n":"Redefine Study Call Center","p":"202-459-9258","e":"TheRedefineStudy@compasspathways.com"},"enroll":300,"eid":"NCT07570654"},{"id":"study-NCT07607938","cat":"studies","name":"Psilocybin as a Novel Therapy for Residual Anhedonia","status":"RECRUITING","phase":"Phase 1","sponsor":"NYU Langone Health","drugs":["psilocybin"],"nct":"NCT07607938","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-09","official":"Joshua Siegel, MD, PhD (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT07607938","sites":["NYU Langone Health — New York, United States"],"conds":["Anhedonia","Emotional Blunting"],"condg":["Other"],"contact":{"n":"Julia Diamond","p":"646-754-4744","e":"Julia.Diamond@nyulangone.org"},"enroll":90,"eid":"NCT07607938"},{"id":"study-NCT06349083","cat":"studies","name":"Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD","status":"RECRUITING","phase":"Phase 2","sponsor":"NYU Langone Health","drugs":["psilocybin"],"nct":"NCT06349083","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-09-01","official":"Michael Bogenschutz, MD (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT06349083","sites":["NYU Langone Health — New York, United States"],"conds":["Alcohol Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Michael Bogenschutz, MD","p":"646-501-4026","e":"Michael.bogenschutz@nyulangone.org"},"enroll":200,"eid":"NCT06349083"},{"id":"study-NCT07369024","cat":"studies","name":"Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults","status":"RECRUITING","phase":"Phase 2","sponsor":"Mohsen Saidinejad","drugs":["ketamine"],"nct":"NCT07369024","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-09-10","src":"https://clinicaltrials.gov/study/NCT07369024","sites":["Harbor UCLA Medical Center — Torrance, United States"],"conds":["Sickle Cell Disease","Vaso-Occlusive Pain Episode in Sickle Cell Disease","Ketamine Infusion","Pain Management","Vaso-Occlusive Crises"],"condg":["Chronic pain & headache"],"contact":{"n":"Cynthia Luo, MD","p":"310-222-2345","e":"cluo2@dhs.lacounty.gov"},"enroll":120,"eid":"NCT07369024"},{"id":"study-NCT06066853","cat":"studies","name":"MDMA-assisted Therapy for Fibromyalgia","status":"RECRUITING","phase":"EARLY_Phase 1","sponsor":"Spaulding Rehabilitation Hospital","drugs":["MDMA"],"nct":"NCT06066853","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-09-15","official":"Vitaly Napadow, PhD (Spaulding Rehabilitation Hospital)","src":"https://clinicaltrials.gov/study/NCT06066853","sites":["Massachusetts General Hospital — Charlestown, United States"],"conds":["Fibromyalgia"],"condg":["Chronic pain & headache"],"contact":{"n":"Lara Gardiner","p":"617-952-6483","e":"lgardiner1@mgb.org"},"enroll":20,"eid":"NCT06066853"},{"id":"study-NCT07610135","cat":"studies","name":"Psilocybin Efficacy With or Without Pimavanserin Pretreatment","status":"RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT07610135","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-10-30","official":"David B. Yaden, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT07610135","sites":["Johns Hopkins Center for Psychedelic and Consciousness Research — Baltimore, United States"],"conds":["Mood (Psychological Function)","Well Being","Mood","Healthy"],"condg":["Healthy volunteers"],"contact":{"n":"Arozo Azimi","p":"410-550-0007","e":"aazimi2@jh.edu"},"enroll":20,"eid":"NCT07610135"},{"id":"study-NCT06988319","cat":"studies","name":"Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study","status":"RECRUITING","phase":"Phase 1","sponsor":"Oregon Health and Science University","drugs":["psilocybin"],"nct":"NCT06988319","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-11-01","src":"https://clinicaltrials.gov/study/NCT06988319","sites":["Oregon Health & Science University — Portland, United States"],"conds":["Chronic Pelvic Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Lynne H Shinto, ND, MPH","p":"(503) 494-5035","e":"shintol@ohsu.edu"},"enroll":15,"eid":"NCT06988319"},{"id":"study-NCT06228391","cat":"studies","name":"Ketamine Treatment for PTSD and MDD in TBI","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Minneapolis Veterans Affairs Medical Center","drugs":["ketamine"],"nct":"NCT06228391","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-03","src":"https://clinicaltrials.gov/study/NCT06228391","sites":["Minneapolis VA Medical Center — Minneapolis, United States"],"conds":["PTSD, Post Traumatic Stress Disorder","Major Depressive Disorder","Traumatic Brain Injury"],"condg":["Depression","PTSD & trauma","Neurology & cognition"],"contact":{"n":"Paulo Shiroma, MD","p":"612-467-2264","e":"paulo.shiroma@va.gov"},"enroll":40,"eid":"NCT06228391"},{"id":"study-NCT03223220","cat":"studies","name":"Quelling of Excitotoxicity in Acute Stroke With Ketamine","status":"NOT_YET_RECRUITING","phase":"Phase 2/Phase 3","sponsor":"Lower Merion Neurology Research Foundation","drugs":["ketamine"],"nct":"NCT03223220","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-07-01","src":"https://clinicaltrials.gov/study/NCT03223220","sites":["Lankenau Medical Center — Wynnewood, United States"],"conds":["Acute Ischemic Stroke"],"condg":["Neurology & cognition"],"contact":{"n":"Sudhir Aggarwal, MD, PhD","p":"4844132572","e":"saggarwal@lowermerionneurology.com"},"enroll":120,"eid":"NCT03223220"},{"id":"study-NCT06727526","cat":"studies","name":"Acupressure's Impact on Pain and Physiological Parameters in Infants Undergoing Cardiac Catheterization","status":"NOT_YET_RECRUITING","phase":"N/A","sponsor":"Baskent University","drugs":["ketamine"],"nct":"NCT06727526","nsites":0,"start":"2024-12-30","src":"https://clinicaltrials.gov/study/NCT06727526","conds":["Cardiac Catheterization"],"condg":["Other"],"contact":{"n":"İlçim Ercan","p":"05534700629","e":"ilcimercan@hotmail.com"},"enroll":35,"eid":"NCT06727526"},{"id":"study-NCT06666010","cat":"studies","name":"PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Filament Health Corp.","drugs":["psilocybin"],"nct":"NCT06666010","nsites":0,"start":"2025-01","src":"https://clinicaltrials.gov/study/NCT06666010","conds":["Stimulant Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Lisa Ranken","p":"250-212-1169","e":"lisa@filament.health"},"enroll":86,"eid":"NCT06666010"},{"id":"study-NCT06729892","cat":"studies","name":"Feasibility of Closed-loop TCI Based on New EEG Baseline in the Presence of Low Dose of Esketamine","status":"NOT_YET_RECRUITING","phase":"Phase 4","sponsor":"bo xu","drugs":["esketamine"],"nct":"NCT06729892","nsites":0,"start":"2025-01-20","official":"BO xu, doctor, chief director (department of anesthesiology, southern theater general hospital of PLA, Guangzhou, China.)","src":"https://clinicaltrials.gov/study/NCT06729892","conds":["General Anesthesia With Propofol","Closed-Loop"],"condg":["Other"],"contact":{"n":"xiaoshan Li, postgraduate","p":"86 + 17820686302","e":"1225564331@qq.com"},"enroll":120,"eid":"NCT06729892"},{"id":"study-NCT06873906","cat":"studies","name":"Deep Parasternal Intercostal Plane Block Versus Erector Spinae Plane Block in Pediatric Cardiac Patients Undergoing Primary Repair of Septal Defects Via Median Sternotomy","status":"NOT_YET_RECRUITING","phase":"Phase 3","sponsor":"Ain Shams University","drugs":["ketamine"],"nct":"NCT06873906","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2025-03-20","src":"https://clinicaltrials.gov/study/NCT06873906","sites":["Faculty of Medicine, Ain Shams University — Cairo, Egypt"],"conds":["Septal Defect"],"condg":["Other"],"contact":{"n":"Sarah A. H. Bakr, Ms degree of Anesthesia","p":"[202] 01062638487","e":"sarahhanee@med.asu.edu.eg"},"enroll":45,"eid":"NCT06873906"},{"id":"study-NCT06665568","cat":"studies","name":"Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients","status":"NOT_YET_RECRUITING","phase":"EARLY_Phase 1","sponsor":"University of Zurich","drugs":["ketamine"],"nct":"NCT06665568","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2025-04","src":"https://clinicaltrials.gov/study/NCT06665568","sites":["University Hospital Zurich — Zurich, Switzerland"],"conds":["Depressive Symptoms Mild to Moderate in Severity","Anxiety","Quality of Life (QOL)","Caregiver Burden","Sleep Quality"],"condg":["Depression","Anxiety"],"contact":{"n":"Caroline Hertler, MD, PhD","p":"+41 43 253 95 59","e":"caroline.hertler@usz.ch"},"enroll":100,"eid":"NCT06665568"},{"id":"study-NCT06914193","cat":"studies","name":"Esketamine Combined With PRF of DRG for Postherpetic Neuralgia","status":"NOT_YET_RECRUITING","phase":"N/A","sponsor":"Beijing Tiantan Hospital","drugs":["esketamine"],"nct":"NCT06914193","nsites":1,"countries":"China","ccs":["CN"],"start":"2025-04-01","src":"https://clinicaltrials.gov/study/NCT06914193","sites":["Beijing Tiantan Hospital — Beijing, China"],"conds":["Postherpetic Neuralgia"],"condg":["Chronic pain & headache"],"contact":{"n":"Fang Luo","p":"+86 13611326978","e":"13611326978@163.com"},"enroll":186,"eid":"NCT06914193"},{"id":"study-NCT06914180","cat":"studies","name":"Esketamine Combined With PRF for Trigeminal Postherpetic Neuralgia","status":"NOT_YET_RECRUITING","phase":"N/A","sponsor":"Beijing Tiantan Hospital","drugs":["esketamine"],"nct":"NCT06914180","nsites":1,"countries":"China","ccs":["CN"],"start":"2025-04-01","src":"https://clinicaltrials.gov/study/NCT06914180","sites":["Beijing Tiantan Hospital — Beijing, China"],"conds":["Postherpetic; Neuralgia, Trigeminal (Etiology)"],"condg":["Chronic pain & headache"],"contact":{"n":"Fang Luo, M.D.","p":"+86 13611326978","e":"13611326978@163.com"},"enroll":174,"eid":"NCT06914180"},{"id":"study-NCT06914206","cat":"studies","name":"Esketamine Combined With PRF of DRG for Acute/Subacute Zoster-associated Pain","status":"NOT_YET_RECRUITING","phase":"N/A","sponsor":"Beijing Tiantan Hospital","drugs":["esketamine"],"nct":"NCT06914206","nsites":1,"countries":"China","ccs":["CN"],"start":"2025-04-01","src":"https://clinicaltrials.gov/study/NCT06914206","sites":["Beijing Tiantan Hospital — Beijing, China"],"conds":["Herpes Zoster"],"condg":["Other"],"contact":{"n":"Fang Luo","p":"+86 13611326978","e":"13611326978@163.com"},"enroll":184,"eid":"NCT06914206"},{"id":"study-NCT06957704","cat":"studies","name":"Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents","status":"NOT_YET_RECRUITING","phase":"Phase 3","sponsor":"Federal University of São Paulo","drugs":["ketamine"],"nct":"NCT06957704","nsites":0,"start":"2025-05","src":"https://clinicaltrials.gov/study/NCT06957704","conds":["Depressive Disorder","Suicidal Ideas"],"condg":["Depression"],"contact":{"n":"Sheila C Caetano, Phd","p":"551197824398","e":"sheila.caetano@unifesp.br"},"enroll":60,"eid":"NCT06957704"},{"id":"study-NCT06935552","cat":"studies","name":"Ketamine and Lidocaine Infusion in Refractory Chronic Migraine","status":"NOT_YET_RECRUITING","phase":"EARLY_Phase 1","sponsor":"Assiut University","drugs":["ketamine"],"nct":"NCT06935552","nsites":0,"start":"2025-06-01","official":"Nageh Fouly Kamel, PhD. (Assiut University); Mohamed Ahmed Abdelhameed, PhD. (Assiut University)","src":"https://clinicaltrials.gov/study/NCT06935552","conds":["Refractory Chronic Migraine"],"condg":["Chronic pain & headache"],"contact":{"n":"AbdElRahman Mohamed Mohamed","p":"+201066586931","e":"hmdmhmmdl1692@gmail.com"},"enroll":44,"eid":"NCT06935552"},{"id":"study-NCT06968624","cat":"studies","name":"Ketamine for Postherpetic Neuralgia With Depression","status":"NOT_YET_RECRUITING","phase":"Phase 4","sponsor":"Huazhong University of Science and Technology","drugs":["esketamine","ketamine"],"nct":"NCT06968624","nsites":0,"start":"2025-06-15","official":"Wei Mei, Phd (Tongji Medical College, Huazhong University of Science and Technology)","src":"https://clinicaltrials.gov/study/NCT06968624","conds":["Depression Disorders","Herpetic Neuralgia"],"condg":["Depression","Chronic pain & headache"],"contact":{"n":"Shuguang Yang, MD","p":"086-027-63639756","e":"ysg101560@hust.edu.cn"},"enroll":50,"eid":"NCT06968624"},{"id":"study-NCT06989567","cat":"studies","name":"A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis","status":"NOT_YET_RECRUITING","phase":"Phase 3","sponsor":"Asklepion Pharmaceuticals, LLC","drugs":["ketamine"],"nct":"NCT06989567","nsites":6,"countries":"United States","ccs":["US"],"start":"2025-07-25","official":"Suvankar Majumdar, MD (Center for Cancer and Blood Disorders, Children's National Hospital)","src":"https://clinicaltrials.gov/study/NCT06989567","sites":["Children's National Hospital — Washington D.C., United States","University of Miami — Coral Gables, United States","Emory University — Atlanta, United States","Johns Hopkins Hospital — Baltimore, United States","Children's Hospital of Michigan — Detroit, United States","East Carolina (University of North Carolina) — Greenville, United States"],"conds":["Sickle Cell Disease"],"condg":["Other"],"contact":{"n":"Gurdyal Kalsi, MD, MFPM (Hon)","p":"+1 410-736-3750","e":"gurdyal.kalsi@asklepionpharm.com"},"enroll":120,"eid":"NCT06989567"},{"id":"study-NCT07153406","cat":"studies","name":"Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","status":"NOT_YET_RECRUITING","phase":"Phase 3","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","drugs":["esketamine","ketamine"],"nct":"NCT07153406","nsites":9,"countries":"Spain","ccs":["ES"],"start":"2025-09-15","official":"Benedicto Crespo Facorro, MD (Fundación para la Gestión de la Investigación en Salud de Sevilla)","src":"https://clinicaltrials.gov/study/NCT07153406","sites":["Clínica Psiquiátrica Padre Menni — Pamplona, Spain","Hospital Vall d'Hebron — Barcelona, Spain","Hospital De La Santa Creu i Sant Pau — Barcelona, Spain","Hospital Mare de Déu de La Mercè — Barcelona, Spain","Hospital Sagrat Cor. Martorell — Barcelona, Spain","Hospital Benito Menni y Fidmag Hermanas Hospitalarias — Barcelona, Spain","Centro Sociosanitario Hermanas Hospitalarias de Palencia — Palencia, Spain","Corporacion Sanitaria Parc Tauli — Sabadell, Spain"],"conds":["Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Clara M Rosso Fernández, MD-PhD","p":"+34955013414","e":"claram.rosso.sspa@juntadeandalucia.es"},"enroll":220,"eid":"NCT07153406"},{"id":"study-NCT07189299","cat":"studies","name":"Microdosing LSD in Women With Premenstrual Disorders","status":"NOT_YET_RECRUITING","phase":"N/A","sponsor":"Friederike Holze","drugs":["LSD"],"nct":"NCT07189299","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2025-10-01","src":"https://clinicaltrials.gov/study/NCT07189299","sites":["Clinical Pharmacology & Toxicology, University Hospital Basel — Basel, Switzerland"],"conds":["PMS","PMDD"],"condg":["Other"],"contact":{"n":"Friederike Holze, Dr.","p":"+41613287735","e":"friederike.holze@usb.ch"},"enroll":150,"eid":"NCT07189299"},{"id":"study-NCT07177235","cat":"studies","name":"Ketamine for the Treatment of Refractory Status Epilepticus","status":"NOT_YET_RECRUITING","phase":"Phase 4","sponsor":"Thomas Jefferson University","drugs":["ketamine"],"nct":"NCT07177235","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-11","official":"Syed O Shah, MD (Thomas Jefferson University)","src":"https://clinicaltrials.gov/study/NCT07177235","sites":["Thomas Jefferson University Hospital — Philadelphia, United States"],"conds":["Refractory Status Epilepticus"],"condg":["Neurology & cognition"],"contact":{"n":"Elizabeth Fletman, DO","p":"215-955-7000","e":"elizabeth.fletman@jefferson.edu"},"enroll":50,"eid":"NCT07177235"},{"id":"study-NCT07247370","cat":"studies","name":"Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL)","status":"NOT_YET_RECRUITING","phase":"Phase 1/Phase 2","sponsor":"South West Sydney Local Health District","drugs":["ketamine"],"nct":"NCT07247370","nsites":1,"countries":"Australia","ccs":["AU"],"start":"2025-12-10","src":"https://clinicaltrials.gov/study/NCT07247370","sites":["Drug Health Services, Royal Prince Alfred Hospital — Sydney, Australia"],"conds":["Alcohol Use Disorder (AUD)","Major Depressive Disorder (MDD)","Comorbidities and Coexisting Conditions"],"condg":["Depression","Addiction & substance use"],"contact":{"n":"Kirsten C Morley, PhD","p":"+61295153636","e":"Kirsten.morley@sydney.edu.au"},"enroll":20,"eid":"NCT07247370"},{"id":"study-NCT07307768","cat":"studies","name":"Ketamine Biomarker Validation","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"Soterix Medical","drugs":["ketamine"],"nct":"NCT07307768","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-12-20","src":"https://clinicaltrials.gov/study/NCT07307768","sites":["Columbia University Irving Medical Center — New York, United States"],"conds":["Treatment Resistant Depression (TRD)"],"condg":["Depression"],"contact":{"n":"Yishai Valter, MS","p":"8889908327","e":"trials@soterixmedical.com"},"enroll":20,"eid":"NCT07307768"},{"id":"study-NCT07250867","cat":"studies","name":"Safety and Efficacy of Lidocaine Versus Ketamine Infusion for Resistant Orofacial Pain","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Assiut University","drugs":["ketamine"],"nct":"NCT07250867","nsites":0,"start":"2026-01","src":"https://clinicaltrials.gov/study/NCT07250867","conds":["Orofacial Pain"],"condg":["Chronic pain & headache"],"enroll":105,"eid":"NCT07250867"},{"id":"study-NCT07180095","cat":"studies","name":"Children of Age 2-6years Undergoing Elective Surgery Will be Divided Into Two Groups Randomly. This Study Aims to Evaluate if Intranasal Dexmedetomidine is Better Than Intranasal Ketamine in Producing Sedation and…","status":"NOT_YET_RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Liaquat National Hospital & Medical College","drugs":["ketamine"],"nct":"NCT07180095","nsites":0,"start":"2026-01-01","src":"https://clinicaltrials.gov/study/NCT07180095","conds":["Sedation","Preoperative Anxiety Experienced by the Pediatric Patient","Anxiolytic Effect","Sedation and Analgesia"],"condg":["Anxiety"],"enroll":60,"eid":"NCT07180095"},{"id":"study-NCT07360327","cat":"studies","name":"Role of Opioid Free Anaesthesia in Elderly Patients Undergoing Elective Coronary Artery Bypass Graft Surgeries With Cardiopulmonary Bypass in Enhanced Recovery After Surgeries","status":"NOT_YET_RECRUITING","phase":"N/A","sponsor":"Ain Shams University","drugs":["ketamine"],"nct":"NCT07360327","nsites":0,"start":"2026-01-01","src":"https://clinicaltrials.gov/study/NCT07360327","conds":["CABG","Dexmedetomidine","Ketamine","Opioid Free Anesthesia","Opioid Based Anesthesia"],"condg":["Addiction & substance use"],"contact":{"n":"Mahmoud Mohamed Abdelrhman mohamed, Assistant lecturer","p":"01024242615","e":"Mahmoudbdel@med.asu.edu.eg"},"enroll":60,"eid":"NCT07360327"},{"id":"study-NCT07126795","cat":"studies","name":"Magnesium Sulfate in Pediatric Burn Dressing Changes","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"Hennepin Healthcare Research Institute","drugs":["ketamine"],"nct":"NCT07126795","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-01-01","src":"https://clinicaltrials.gov/study/NCT07126795","sites":["Hennepin County Medical Center — Minneapolis, United States"],"conds":["Pediatric Burns"],"condg":["Other"],"enroll":10,"eid":"NCT07126795"},{"id":"study-NCT07296328","cat":"studies","name":"Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"NYU Langone Health","drugs":["psilocybin"],"nct":"NCT07296328","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-01-15","official":"Michael Bogenschutz, MD (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT07296328","sites":["NYU Langone Health — New York, United States"],"conds":["Stuttering"],"condg":["Other"],"contact":{"n":"Eric Jackson, PhD","p":"212-992-9470","e":"Ej34@nyu.edu"},"enroll":25,"eid":"NCT07296328"},{"id":"study-NCT07374198","cat":"studies","name":"Effect of Continuous Intraoperative Esketamine Infusion on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Mild-to-Severe Depression","status":"NOT_YET_RECRUITING","phase":"N/A","sponsor":"Chinese PLA General Hospital","drugs":["esketamine"],"nct":"NCT07374198","nsites":0,"start":"2026-01-18","src":"https://clinicaltrials.gov/study/NCT07374198","conds":["Depression","Anxiety","S-ketamine","Breast Cancer"],"condg":["Depression","Anxiety","Cancer-related distress"],"contact":{"n":"WEIDONG MI","p":"133810829","e":"wwdd1962@163.com"},"enroll":142,"eid":"NCT07374198"},{"id":"study-NCT07374211","cat":"studies","name":"Effect of Esketamine on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Severe Depression","status":"NOT_YET_RECRUITING","phase":"N/A","sponsor":"Chinese PLA General Hospital","drugs":["esketamine"],"nct":"NCT07374211","nsites":0,"start":"2026-01-18","src":"https://clinicaltrials.gov/study/NCT07374211","conds":["Depression","Anxiety","S-ketamine","Breast Cancer"],"condg":["Depression","Anxiety","Cancer-related distress"],"contact":{"n":"WEIDONG MI","p":"133810829","e":"wwdd1962@163.com"},"enroll":242,"eid":"NCT07374211"},{"id":"study-NCT07399756","cat":"studies","name":"Mitochondrial Function After Ketamine","status":"NOT_YET_RECRUITING","sponsor":"Sheba Medical Center","drugs":["esketamine","ketamine"],"nct":"NCT07399756","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2026-02","src":"https://clinicaltrials.gov/study/NCT07399756","sites":["Sheba Medical Center — Ramat Gan, Israel"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"revital amiaz, dr","p":"972 035302538","e":"revital.amiaz@sheba.health.gov.il"},"enroll":30,"eid":"NCT07399756"},{"id":"study-NCT07450430","cat":"studies","name":"Optimal Timing of Ketamine Initiation for SCD Pain","status":"NOT_YET_RECRUITING","phase":"Phase 3","sponsor":"Boston Children's Hospital","drugs":["ketamine"],"nct":"NCT07450430","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-02","official":"Natasha Archer (Boston Children's Hospital)","src":"https://clinicaltrials.gov/study/NCT07450430","sites":["Boston Children's Hospital — Brookline, United States"],"conds":["Sickle Cell Disease","Sickle Cell Crisis"],"condg":["Other"],"contact":{"n":"Natasha Archer, MD, MPH","p":"617-355-6000","e":"natasha.archer@childrens.harvard.edu"},"enroll":90,"eid":"NCT07450430"},{"id":"study-NCT07369089","cat":"studies","name":"Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"University of California, San Diego","drugs":["ketamine"],"nct":"NCT07369089","nsites":2,"countries":"United States","ccs":["US"],"start":"2026-02","src":"https://clinicaltrials.gov/study/NCT07369089","sites":["University of California, San Diego — La Jolla, United States","University Of Utah — Salt Lake City, United States"],"conds":["Opioid Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Hannah Pfeffer, LMSW","p":"619-500-4668","e":"hapfeffer@health.ucsd.edu"},"enroll":88,"eid":"NCT07369089"},{"id":"study-NCT06968546","cat":"studies","name":"Sufentanil Versus Ketamine Intranasally in the Management of Severe Acute Trauma-related Pain in Children.","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Fondation Lenval","drugs":["ketamine"],"nct":"NCT06968546","nsites":1,"countries":"France","ccs":["FR"],"start":"2026-02-05","official":"MARCO OLLA, MD (Fondation Lenval Hôpitaux pediatrique Nice chu Lenval)","src":"https://clinicaltrials.gov/study/NCT06968546","sites":["Hôpital lenval — Nice, France"],"conds":["Traumatology","Wounds and Injury","Fractures Bone","Analgesia","Pain","Pain Management"],"condg":["PTSD & trauma","Chronic pain & headache"],"contact":{"n":"Aline JOULIE, PHD","p":"+33492030520","e":"joulie.a@chu-nice.fr"},"enroll":116,"eid":"NCT06968546"},{"id":"study-NCT07405606","cat":"studies","name":"Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Centre for Addiction and Mental Health","drugs":["psilocybin"],"nct":"NCT07405606","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2026-03","src":"https://clinicaltrials.gov/study/NCT07405606","sites":["Centre for Addiction and Mental Health — Toronto, Canada"],"conds":["Major Depressive Disorder (MDD)","Alcohol Use Disorder (AUD)"],"condg":["Depression","Addiction & substance use"],"contact":{"n":"Bernard Le Foll","p":"+14165358501","e":"bernard.lefoll@camh.ca"},"enroll":30,"eid":"NCT07405606"},{"id":"study-NCT07462559","cat":"studies","name":"KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"Helsinki University Central Hospital","drugs":["ketamine"],"nct":"NCT07462559","nsites":1,"countries":"Finland","ccs":["FI"],"start":"2026-03-04","official":"Janne T Backman, MD, PhD (Helsinki University Central Hospital)","src":"https://clinicaltrials.gov/study/NCT07462559","sites":["Department of Clinical Pharmacology — Helsinki, Finland"],"conds":["Drug Drug Interaction"],"condg":["Other"],"contact":{"n":"Janne T Backman, MD, PhD","p":"+35894711","e":"janne.backman@hus.fi"},"enroll":12,"eid":"NCT07462559"},{"id":"study-NCT03606538","cat":"studies","name":"MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT03606538","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-03-29","official":"Janel Long-Boyle, PharmD, PhD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT03606538","sites":["Alliance for Multispecialty Research, LLC. — Knoxville, United States"],"conds":["Pharmacokinetics","Hepatic Impairment"],"condg":["Other"],"contact":{"n":"Recruitment Officer","e":"recruitment@lykospbc.com"},"enroll":16,"eid":"NCT03606538"},{"id":"study-NCT07540494","cat":"studies","name":"Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"GH Research Ireland Limited","drugs":["DMT"],"nct":"NCT07540494","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-04","src":"https://clinicaltrials.gov/study/NCT07540494","sites":["GH Research Clinical Trial Site — Miami, United States"],"conds":["Healthy Adult"],"condg":["Healthy volunteers"],"contact":{"n":"GH Research Limited Clinical Trial Enquiries","p":"+353874503237","e":"clinicaltrials@ghres.com"},"enroll":12,"eid":"NCT07540494"},{"id":"study-NCT07391332","cat":"studies","name":"Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Nantes University Hospital","drugs":["psilocybin"],"nct":"NCT07391332","nsites":1,"countries":"France","ccs":["FR"],"start":"2026-04-01","src":"https://clinicaltrials.gov/study/NCT07391332","sites":["Nantes University Hospital — Nantes, France"],"conds":["Gambling Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Benoit SCHRECK","p":"+33.2.40.84.76.20","e":"benoit.schreck@chu-nantes.fr"},"enroll":30,"eid":"NCT07391332"},{"id":"study-NCT07584902","cat":"studies","name":"A 2×2 Factorial Randomized Controlled Trial for ERCP","status":"NOT_YET_RECRUITING","phase":"N/A","sponsor":"Gang Chen","drugs":["esketamine"],"nct":"NCT07584902","nsites":0,"start":"2026-04-27","src":"https://clinicaltrials.gov/study/NCT07584902","conds":["Biliary and Pancreatic Diseases","Endoscopic Retrograde Cholangiopancreatography (ERCP)"],"condg":["Other"],"contact":{"n":"Xiaocui Lv","p":"13567109477","e":"3412008@zju.edu.cn"},"enroll":236,"eid":"NCT07584902"},{"id":"study-NCT07373535","cat":"studies","name":"Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Kyle Greenway","drugs":["psilocybin"],"nct":"NCT07373535","nsites":2,"countries":"Canada","ccs":["CA"],"start":"2026-05","official":"Kyle T Greenway, MD (Jewish General Hospital)","src":"https://clinicaltrials.gov/study/NCT07373535","sites":["Jewish General Hospital — Montreal, Canada","Jewish General Hospital — Montreal, Canada"],"conds":["Treatment-Resistant Major Depressive Disorder"],"condg":["Depression"],"enroll":16,"eid":"NCT07373535"},{"id":"study-NCT07588334","cat":"studies","name":"Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)","status":"NOT_YET_RECRUITING","sponsor":"Northern Jiangsu People's Hospital","drugs":["LSD"],"nct":"NCT07588334","nsites":1,"countries":"China","ccs":["CN"],"start":"2026-05-01","official":"Guo-Qing Jiang, MD (Clinical Medical College of Yangzhou University)","src":"https://clinicaltrials.gov/study/NCT07588334","sites":["Clinical Medical College of Yangzhou University — Yangzhou, China"],"conds":["Cirrhosis, Liver","Splenectomy; Status","Portal Hypertension","Lipid Profiles"],"condg":["Other"],"contact":{"n":"Guo-Qing Jiang, MD","p":"+8651487373272","e":"jgqing2003@hotmail.com"},"enroll":30,"eid":"NCT07588334"},{"id":"study-NCT07585786","cat":"studies","name":"Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)","status":"NOT_YET_RECRUITING","sponsor":"Northern Jiangsu People's Hospital","drugs":["LSD"],"nct":"NCT07585786","nsites":0,"start":"2026-05-01","official":"Guo-Qing Jiang, MD (Clinical Medical College of Yangzhou University)","src":"https://clinicaltrials.gov/study/NCT07585786","conds":["Cirrhosis, Liver","Splenectomy; Status","Renal Function Abnormal","Portal Hypertension"],"condg":["Other"],"contact":{"n":"Guo-Qing Jiang, MD","p":"+8651487373272","e":"jgqing2003@hotmail.com"},"enroll":30,"eid":"NCT07585786"},{"id":"study-NCT07602153","cat":"studies","name":"Multimodal Pharmacological Study of Clinical Cohorts for Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Mental Health Center","drugs":["esketamine","ketamine"],"nct":"NCT07602153","nsites":0,"start":"2026-05-30","src":"https://clinicaltrials.gov/study/NCT07602153","conds":["Major Depressive Disorder (MDD"],"condg":["Depression"],"enroll":130,"eid":"NCT07602153"},{"id":"study-NCT07555132","cat":"studies","name":"Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls","status":"NOT_YET_RECRUITING","phase":"N/A","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT07555132","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2026-06","official":"Mirjam Christ-Crain, Prof. Dr. med. (University Hospital Basel, Endocrinology, Diabetes and Metabolism)","src":"https://clinicaltrials.gov/study/NCT07555132","sites":["University Hospital Basel, Endocrinology, Diabetes and Metabolism — Basel, Switzerland"],"conds":["Autism Spectrum Disorder"],"condg":["Other"],"contact":{"n":"Mirjam Christ-Crain, Prof. Dr. med.","p":"+41 61 265 25 25","e":"mirjam.christ-crain@usb.ch"},"enroll":40,"eid":"NCT07555132"},{"id":"study-NCT07639099","cat":"studies","name":"Intranasal Esketamine-dexmedetomidine Combination and Postpartum Depression","status":"NOT_YET_RECRUITING","phase":"Phase 4","sponsor":"Peking University First Hospital","drugs":["esketamine"],"nct":"NCT07639099","nsites":1,"countries":"China","ccs":["CN"],"start":"2026-06","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT07639099","sites":["Peking University First Hospital — Beijing, China"],"conds":["Parturients","Depressive Symptoms","Esketamine","Dexmedetomidine","Intranasal Administration","Postpartum Depression"],"condg":["Depression"],"contact":{"n":"Dong-Xin Wang, MD, PhD","p":"010-83572784","e":"wangdongxin@hotmail.com"},"enroll":164,"eid":"NCT07639099"},{"id":"study-NCT07610343","cat":"studies","name":"Intranasal Dexmedetomidine-esketamine on Sleep and Cognition in Older Adults With Mild-to-moderate Cognitive Impairment","status":"NOT_YET_RECRUITING","phase":"Phase 4","sponsor":"Peking University First Hospital","drugs":["esketamine"],"nct":"NCT07610343","nsites":1,"countries":"China","ccs":["CN"],"start":"2026-06","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT07610343","sites":["Peking University First Hospital — Beijing, China"],"conds":["Older Adults","Cognitive Impairment","Sleep Disorders","Dexmedetomidine","Esketamine"],"condg":["Neurology & cognition"],"contact":{"n":"Dong-Xin Wang, MD, PhD","p":"010-83572784","e":"wangdongxin@hotmail.com"},"enroll":60,"eid":"NCT07610343"},{"id":"study-NCT07582120","cat":"studies","name":"Psilocybin-Assisted Therapy as a Treatment for Depression","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Washington University School of Medicine","drugs":["psilocybin"],"nct":"NCT07582120","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-06","src":"https://clinicaltrials.gov/study/NCT07582120","sites":["Washington University School of Medicine — St Louis, United States"],"conds":["Depression"],"condg":["Depression"],"contact":{"n":"Dawnita Reathaford","p":"314-532-5939","e":"dawnita@wustl.edu"},"enroll":50,"eid":"NCT07582120"},{"id":"study-NCT07565909","cat":"studies","name":"Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"University of Washington","drugs":["psilocybin"],"nct":"NCT07565909","nsites":0,"start":"2026-06","official":"Anthony Back, MD (University of Washington)","src":"https://clinicaltrials.gov/study/NCT07565909","conds":["Depression","Anxiety"],"condg":["Depression","Anxiety"],"contact":{"n":"Leslie Thorn","p":"(206) 295-4425","e":"lazthorn@uw.edu"},"enroll":72,"eid":"NCT07565909"},{"id":"study-NCT07490405","cat":"studies","name":"Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism","status":"NOT_YET_RECRUITING","sponsor":"Northern Jiangsu People's Hospital","drugs":["LSD"],"nct":"NCT07490405","nsites":1,"countries":"China","ccs":["CN"],"start":"2026-06-01","src":"https://clinicaltrials.gov/study/NCT07490405","sites":["Northern Jiangsu People's Hospital — Yangzhou, China"],"conds":["Liver Cirrhosis"],"condg":["Other"],"contact":{"n":"Guoqing Jiang, MD","p":"18051060606","e":"jgqing2003@hotmail.com"},"enroll":140,"eid":"NCT07490405"},{"id":"study-NCT07644663","cat":"studies","name":"The Effects of Different Anesthetics on the Brain's Neural Networks","status":"NOT_YET_RECRUITING","phase":"Phase 4","sponsor":"Fudan University","drugs":["esketamine"],"nct":"NCT07644663","nsites":1,"countries":"China","ccs":["CN"],"start":"2026-06-09","src":"https://clinicaltrials.gov/study/NCT07644663","sites":["Fudan University Shanghai Cancer Center — Shanghai, China"],"conds":["Electroencephalogram (EEG)","Anesthesia"],"condg":["Other"],"contact":{"n":"Xiaoge Liu","p":"021-64175590","e":"18516534948@163.com"},"enroll":120,"eid":"NCT07644663"},{"id":"study-NCT07691372","cat":"studies","name":"Pharmacokinetics and Safety of Single-Dose Wafermine™ (Ketamine Sublingual Wafer) in Healthy Subjects","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"iX Biopharma Ltd.","drugs":["ketamine"],"nct":"NCT07691372","nsites":1,"countries":"Australia","ccs":["AU"],"start":"2026-06-09","official":"Janakan Krishnarajah, MD ()","src":"https://clinicaltrials.gov/study/NCT07691372","sites":["Q-Pharm Pty Ltd. — Brisbane, Australia"],"conds":["Healthy Adult Participants"],"condg":["Healthy volunteers"],"contact":{"n":"Janakan Krishnarajah, MD","p":"+61 412 999 004","e":"j.krishnarajah@ixbiopharma.com"},"enroll":14,"eid":"NCT07691372"},{"id":"study-NCT07670507","cat":"studies","name":"Pilot Randomized Control Trial Comparing Oral Ketamine and Oral Oxycodone for Pain Control in Emergency Department Patients","status":"NOT_YET_RECRUITING","phase":"Phase 2/Phase 3","sponsor":"Albany Medical College","drugs":["ketamine"],"nct":"NCT07670507","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-06-24","src":"https://clinicaltrials.gov/study/NCT07670507","sites":["Albany Medical Center Emergency Department — Albany, United States"],"conds":["Pain Management"],"condg":["Chronic pain & headache"],"enroll":60,"eid":"NCT07670507"},{"id":"study-NCT07723066","cat":"studies","name":"Biomarker Discovery for Suicide Precision Circuit Therapeutics","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","drugs":["esketamine","ketamine"],"nct":"NCT07723066","nsites":0,"start":"2026-07","src":"https://clinicaltrials.gov/study/NCT07723066","conds":["Suicidal Thoughts and Behaviors","Major Depressive Episode (MDE)"],"condg":["Depression"],"contact":{"n":"Joan Camprodon, MD, PhD, MPH","p":"617-726-5340","e":"JCAMPRODON@mgh.harvard.edu"},"enroll":60,"eid":"NCT07723066"},{"id":"study-NCT07479550","cat":"studies","name":"Study of Psilocybin Under Anesthesia Controlled by EEG","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Stanford University","drugs":["psilocybin"],"nct":"NCT07479550","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-07","official":"Dr. Boris Heifets, MD, PhD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT07479550","sites":["Stanford University — Stanford, United States"],"conds":["Major Depression"],"condg":["Depression"],"contact":{"n":"Dr. Boris Heifets, MD, PhD","p":"4157161585","e":"bheifets@stanford.edu"},"enroll":10,"eid":"NCT07479550"},{"id":"study-NCT07614581","cat":"studies","name":"Intra-Sessional Autonomic Arc Detection in Ketamine-Assisted Therapy for PTSD: A Signal Characterisation Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Adriaan Dirk van der Wart","drugs":["ketamine"],"nct":"NCT07614581","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2026-07-15","src":"https://clinicaltrials.gov/study/NCT07614581","sites":["Open Medicine Studio — Ganges, Canada"],"conds":["Post-Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":5,"eid":"NCT07614581"},{"id":"study-NCT07753772","cat":"studies","name":"Dexmedetomidine-Esketamine Combination on Depression and Anxiety After Laparoscopic Ureteral Reconstruction","status":"NOT_YET_RECRUITING","phase":"Phase 4","sponsor":"Peking University First Hospital","drugs":["esketamine"],"nct":"NCT07753772","nsites":1,"countries":"China","ccs":["CN"],"start":"2026-08","official":"Dong-Xin Wang (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT07753772","sites":["Peking University First Hospital — Beijing, China"],"conds":["Ureteral Stricture","Dexmedetomidine","Esketamine","Depressive Symptoms","Anxiety"],"condg":["Depression","Anxiety"],"contact":{"n":"Dong-Xin Wang, MD, PhD","p":"8610 83572784","e":"wangdongxin@hotmail.com"},"enroll":658,"eid":"NCT07753772"},{"id":"study-NCT06760533","cat":"studies","name":"Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)","status":"NOT_YET_RECRUITING","phase":"EARLY_Phase 1","sponsor":"NYU Langone Health","drugs":["psilocybin"],"nct":"NCT06760533","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-08","official":"Maysaa El Zoghbi (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT06760533","sites":["NYU Langone Health — New York, United States"],"conds":["IBS - Irritable Bowel Syndrome"],"condg":["Other"],"contact":{"n":"Maysaa El Zoghbi","p":"216-835-7626","e":"Maysaa.ElZoghbi@nyulangone.org"},"enroll":10,"eid":"NCT06760533"},{"id":"study-NCT07682662","cat":"studies","name":"Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis","status":"NOT_YET_RECRUITING","phase":"Phase 4","sponsor":"University of Mississippi Medical Center","drugs":["ketamine"],"nct":"NCT07682662","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-08-01","official":"John N Freeman, MD (University of Mississippi Medical Center)","src":"https://clinicaltrials.gov/study/NCT07682662","sites":["University of Mississippi Medical Center, Pediatric Emergency Department — Jackson, United States"],"conds":["Vaso-Occlusive Pain Episode in Sickle Cell Disease","Sickle Cell Disease (SCD)"],"condg":["Chronic pain & headache"],"contact":{"n":"Cynthia Karlson, Ph.D.","p":"601-984-2723","e":"ckarlson@umc.edu"},"enroll":400,"eid":"NCT07682662"},{"id":"study-NCT07499583","cat":"studies","name":"Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder","status":"NOT_YET_RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Indiana University","drugs":["psilocybin"],"nct":"NCT07499583","nsites":2,"countries":"United States","ccs":["US"],"start":"2026-08-01","official":"Susan K Conroy, PhD (Indiana University)","src":"https://clinicaltrials.gov/study/NCT07499583","sites":["Goodman Hall, Dept of Psychiatry, Indiana University — Indianapolis, United States","The Stark Neuroscience Building (Goodman Hall) — Indianapolis, United States"],"conds":["Treatment Resistant Depression","Substance Use Disorders"],"condg":["Depression","Addiction & substance use"],"contact":{"n":"Susan K Conroy, MD","p":"317-948-5450","e":"sconroy@iu.edu"},"enroll":50,"eid":"NCT07499583"},{"id":"study-NCT07693153","cat":"studies","name":"The Effects of Psilocybin on Social Connectedness","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"Yale University","drugs":["psilocybin"],"nct":"NCT07693153","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-08-31","official":"Anahita Bassir Nia, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT07693153","sites":["Connecticut Mental Health Center — New Haven, United States"],"conds":["Loneliness","Grief"],"condg":["Other"],"contact":{"n":"Anahita Bassir Nia, MD","p":"203-932-5711","e":"anahita.bassirnia@yale.edu"},"enroll":51,"eid":"NCT07693153"},{"id":"study-NCT07745569","cat":"studies","name":"Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"University of New Mexico","drugs":["psilocybin"],"nct":"NCT07745569","nsites":0,"start":"2026-08-31","official":"Davin Quinn, MD (University of New Mexico)","src":"https://clinicaltrials.gov/study/NCT07745569","conds":["PTSD","PTSD - Post Traumatic Stress Disorder","Major Depression","Suicidality"],"condg":["Depression","PTSD & trauma"],"contact":{"n":"Crystal A Garcia","p":"505-272-9552","e":"crabaca@salud.unm.edu"},"enroll":150,"eid":"NCT07745569"},{"id":"study-NCT07836205","cat":"studies","name":"Brain Activity and Changes in Consciousness During General Anesthesia","status":"NOT_YET_RECRUITING","phase":"Phase 4","sponsor":"Beijing Chao Yang Hospital","drugs":["esketamine"],"nct":"NCT07836205","nsites":1,"countries":"China","ccs":["CN"],"start":"2026-09","src":"https://clinicaltrials.gov/study/NCT07836205","sites":["Affiliated Beijing Chaoyang Hospital of Capital Medical University — Beijing, China"],"conds":["General Anesthesia-Induced Altered Consciousness"],"condg":["Other"],"contact":{"n":"Wei","p":"+86 13810678936","e":"changwei.wei@ccmu.edu.cn"},"enroll":320,"eid":"NCT07836205"},{"id":"study-NCT07781462","cat":"studies","name":"Intravenous Infusion of Low Dose Ketamine Versus Dexmedetomedine for Delirium Treatment in Acute Heart Failure","status":"NOT_YET_RECRUITING","phase":"Phase 4","sponsor":"Alexandria University","drugs":["ketamine"],"nct":"NCT07781462","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2026-09","src":"https://clinicaltrials.gov/study/NCT07781462","sites":["Alexandria Main University Hospital (AMUH) — Alexandria, Egypt"],"conds":["Delirium in Intensive Care Unit","Acute Heart Failure (AHF)"],"condg":["Other"],"contact":{"n":"Nada H Abd El-Rahim, PharmD","p":"01008328380","e":"gs-nada.hesham@alexu.edu.eg"},"enroll":150,"eid":"NCT07781462"},{"id":"study-NCT06660017","cat":"studies","name":"Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"University of Oklahoma","drugs":["ketamine"],"nct":"NCT06660017","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-09","official":"Rusha Patel, MD (OU Health Stephenson Cancer Center)","src":"https://clinicaltrials.gov/study/NCT06660017","sites":["OU Health Stephenson Cancer Center — Oklahoma City, United States"],"conds":["Head and Neck Cancer"],"condg":["Cancer-related distress"],"contact":{"n":"Lead Nurse","p":"405-271-8001","e":"SCC-IIT-Office@ouhsc.edu"},"enroll":62,"eid":"NCT06660017"},{"id":"study-NCT07824973","cat":"studies","name":"Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing","status":"NOT_YET_RECRUITING","phase":"N/A","sponsor":"Valdemar Landgren","drugs":["ketamine"],"nct":"NCT07824973","nsites":1,"countries":"Sweden","ccs":["SE"],"start":"2026-09","src":"https://clinicaltrials.gov/study/NCT07824973","sites":["Brain Stimulation Clinic, Skaraborg's Hospital — Skövde, Sweden"],"conds":["Treatment Resistant Depression (TRD)"],"condg":["Depression"],"contact":{"n":"Alexandra Leinonen, MD","p":"+46706371348","e":"alexandra.leinonen@gu.se"},"enroll":120,"eid":"NCT07824973"},{"id":"study-NCT07801703","cat":"studies","name":"Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression","status":"NOT_YET_RECRUITING","phase":"Phase 2/Phase 3","sponsor":"The Royal's Institute of Mental Health Research","drugs":["ketamine"],"nct":"NCT07801703","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2026-09","official":"Jeanne Talbot, MD, PhD (The University of Ottawa Institute of Mental Health Research (IMHR) at The Royal); Jennifer Phillips, PhD (The University of Ottawa…","src":"https://clinicaltrials.gov/study/NCT07801703","sites":["The Royal — Ottawa, Canada"],"conds":["Treatment Resistant Depression","Major Depressive Disorder (MDD)"],"condg":["Depression"],"contact":{"n":"Research Coordinator","p":"613-722-6521","e":"suwojcik@theroyal.ca"},"enroll":60,"eid":"NCT07801703"},{"id":"study-NCT07079852","cat":"studies","name":"The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function","status":"NOT_YET_RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Manoj Doss","drugs":["psilocybin"],"nct":"NCT07079852","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-09","src":"https://clinicaltrials.gov/study/NCT07079852","sites":["The University of Texas at Austin Dell Medical School — Austin, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"contact":{"n":"Manoj Doss, PhD","p":"512-495-5856","e":"manoj.doss@austin.utexas.edu"},"enroll":48,"eid":"NCT07079852"},{"id":"study-NCT07693257","cat":"studies","name":"Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"Jon Dean","drugs":["DMT"],"nct":"NCT07693257","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-09-01","official":"Jon Dean, PhD (UCSD)","src":"https://clinicaltrials.gov/study/NCT07693257","sites":["Altman Clinical and Translational Research Institute — La Jolla, United States"],"conds":["Healthy Participants Study"],"condg":["Healthy volunteers"],"contact":{"n":"Yasmeen Esshaki","p":"619-786-0375","e":"deanlaboratory@health.ucsd.edu"},"enroll":20,"eid":"NCT07693257"},{"id":"study-NCT07112456","cat":"studies","name":"Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Oman Medical Speciality Board","drugs":["ketamine"],"nct":"NCT07112456","nsites":0,"start":"2026-09-01","src":"https://clinicaltrials.gov/study/NCT07112456","conds":["Asthma Acute","Asthma Attack","Asthma Exacerbations"],"condg":["Other"],"enroll":100,"eid":"NCT07112456"},{"id":"study-NCT07099534","cat":"studies","name":"Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"University Hospital, Toulouse","drugs":["ketamine"],"nct":"NCT07099534","nsites":1,"countries":"France","ccs":["FR"],"start":"2026-09-01","src":"https://clinicaltrials.gov/study/NCT07099534","sites":["Toulouse Purpan University Hospital, Head of Psychiatry Clinic in the UF3 department — Toulouse, France"],"conds":["Infusion of Ketamine in Severe Borderline Personality…","Borderline Personality Disorder (BPD)"],"condg":["Other"],"contact":{"n":"Gaël Galliot","p":"+33 (0)5 34 55 76 51","e":"galliot.g@chu-toulouse.fr"},"enroll":38,"eid":"NCT07099534"},{"id":"study-NCT07433452","cat":"studies","name":"The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"Gabriella Gobbi","drugs":["psilocybin"],"nct":"NCT07433452","nsites":0,"start":"2026-09-01","src":"https://clinicaltrials.gov/study/NCT07433452","conds":["Healthy Participants","Placebo - Control","Psilocybin"],"condg":["Healthy volunteers"],"contact":{"n":"Maryam Oraei, MD","p":"+1-514-3984650","e":"maryam.oraei@mcgill.ca"},"enroll":50,"eid":"NCT07433452"},{"id":"study-NCT06992999","cat":"studies","name":"Psilocybin for Treatment of OCD-2","status":"NOT_YET_RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Francisco A Moreno","drugs":["psilocybin"],"nct":"NCT06992999","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-09-08","official":"Francisco Moreno, MD (University of Arizona, College of Medicine, Tucson)","src":"https://clinicaltrials.gov/study/NCT06992999","sites":["University of Arizona-Tucson — Tucson, United States"],"conds":["Obsessive - Compulsive Disorder"],"condg":["OCD"],"contact":{"n":"Esmeralda Terrazas","p":"(520) 626-8000","e":"esmeralda97h@arizona.edu"},"enroll":20,"eid":"NCT06992999"},{"id":"study-NCT07820033","cat":"studies","name":"Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"University Health Network, Toronto","drugs":["psilocybin"],"nct":"NCT07820033","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2026-09-14","src":"https://clinicaltrials.gov/study/NCT07820033","sites":["University Health Network — Toronto, Canada"],"conds":["Advanced Cancer","Stage IV Solid Tumor Cancer","Stage IV Sarcoma of Bone","Stage IV Lymphoma","Stage IV Melanoma","Endocrine Cancer"],"condg":["Cancer-related distress"],"contact":{"n":"Sarah Hales, MD","p":"416-340-4800","e":"UHNPPRG@uhn.ca"},"enroll":46,"eid":"NCT07820033"},{"id":"study-NCT06827054","cat":"studies","name":"Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Roswell Park Cancer Institute","drugs":["psilocybin"],"nct":"NCT06827054","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-09-15","official":"William Alexander (Roswell Park Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT06827054","sites":["Roswell Park Cancer Institute — Buffalo, United States"],"conds":["Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm"],"condg":["Cancer-related distress"],"enroll":20,"eid":"NCT06827054"},{"id":"study-NCT07377981","cat":"studies","name":"Safety and Efficacy of Esketamine - Dexmedetomidine Combination Versus Dexmedetomidine Monotherapy for Hyperactive Delirium in ICU Patients on Non-Invasive Respiratory Support (SEED-NIRS Trial): Study Protocol of a…","status":"NOT_YET_RECRUITING","phase":"Phase 4","sponsor":"The First Affiliated Hospital with Nanjing Medical University","drugs":["esketamine"],"nct":"NCT07377981","nsites":1,"countries":"China","ccs":["CN"],"start":"2026-09-28","src":"https://clinicaltrials.gov/study/NCT07377981","sites":["The First Affiliated Hospital with Nanjing Medical University — Nanjing, China"],"conds":["Dexmedetomidine","Ketamine","Analgesia","Respiratory Therapy","Intensive Care Units (ICUs)","Agitation"],"condg":["Other"],"contact":{"n":"Xiangrong Zuo","p":"+86 13913979197","e":"zuoxiangrong@njmu.edu.cn"},"enroll":356,"eid":"NCT07377981"},{"id":"study-NCT05455996","cat":"studies","name":"MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Nautilus Sanctuary","drugs":["MDMA"],"nct":"NCT05455996","nsites":3,"countries":"United States","ccs":["US"],"start":"2026-10","official":"Willa Hall, Ph.D. (Nautilus Sanctuary); Casey Paleos, M.D. (InnerMost PBC)","src":"https://clinicaltrials.gov/study/NCT05455996","sites":["Memoru — Boulder, United States","InnerMost, PBC — New York, United States","The Pearl Institute — Waynesville, United States"],"conds":["Post-Traumatic Stress Disorder","Adjustment Disorders"],"condg":["PTSD & trauma"],"contact":{"n":"Willa Hall, Ph.D.","p":"9175091497","e":"willa@nautilussanctuary.org"},"enroll":30,"eid":"NCT05455996"},{"id":"study-NCT07648771","cat":"studies","name":"Outcomes Registry After Ketamine Infusions for Chronic Pain: A Longitudinal Evaluation","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","drugs":["ketamine"],"nct":"NCT07648771","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-10","src":"https://clinicaltrials.gov/study/NCT07648771","sites":["Stanford Health Care — Stanford, United States"],"conds":["Chronic Pain","Ketamine"],"condg":["Chronic pain & headache"],"contact":{"n":"Protocol Director","p":"650-264-9442","e":"tlii@stanford.edu"},"enroll":800,"eid":"NCT07648771"},{"id":"study-NCT07435077","cat":"studies","name":"Examining Analgesic Synergy and Efficacy in Trauma Care","status":"NOT_YET_RECRUITING","phase":"Phase 4","sponsor":"Wake Forest University Health Sciences","drugs":["ketamine"],"nct":"NCT07435077","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-10","official":"Matthew Painter, MD, FACS (Wake Forest University Health Sciences)","src":"https://clinicaltrials.gov/study/NCT07435077","sites":["Wake Forest University Health Sciences — Winston-Salem, United States"],"conds":["Opioid Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"D'Ann B Hershel, MS","p":"336-716-1659","e":"Dann.Hershel@wfusm.edu"},"enroll":282,"eid":"NCT07435077"},{"id":"study-NCT07839338","cat":"studies","name":"A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes","status":"NOT_YET_RECRUITING","phase":"Phase 3","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","drugs":["ketamine"],"nct":"NCT07839338","nsites":5,"countries":"India","ccs":["IN"],"start":"2026-10","src":"https://clinicaltrials.gov/study/NCT07839338","sites":["NIMHANS — Bangalore, India","Kasturba Medical College — Udupi, India","MGM Medical College, Mumbai — Mumbai, India","AIIMS, Bhubaneswar — Bhubaneswar, India","Jawaharlal Institute of Postgraduate Medical Education and Research — Puducherry, India"],"conds":["Major Depressive Episode"],"condg":["Depression"],"contact":{"n":"Vikas Menon, MD","p":"+91 8098158528","e":"drvmenon@gmail.com"},"enroll":220,"eid":"NCT07839338"},{"id":"study-NCT07306364","cat":"studies","name":"Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Yale University","drugs":["psilocybin"],"nct":"NCT07306364","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-10","official":"Joao De Aquino, M.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT07306364","sites":["Connecticut Mental Health Center — New Haven, United States"],"conds":["Chronic Low Back Pain (CLBP)","Physical Therapy","Psilocybin"],"condg":["Chronic pain & headache"],"contact":{"n":"Julia Meyerovich, M.S.","p":"203-932-5711","e":"julia.meyerovich@yale.edu"},"enroll":45,"eid":"NCT07306364"},{"id":"study-NCT07360301","cat":"studies","name":"Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"University of Wisconsin, Madison","drugs":["psilocybin"],"nct":"NCT07360301","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-10","official":"Charles Raison, MD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT07360301","sites":["University of Wisconsin — Madison, United States"],"conds":["Well-Being, Psychological","Psychedelic Experiences"],"condg":["Other"],"contact":{"n":"CoPEWell Study Contact","p":"608-263-4852","e":"copewell@psychiatry.wisc.edu"},"enroll":120,"eid":"NCT07360301"},{"id":"study-NCT07503002","cat":"studies","name":"Shortened LSD Intervention for Major Depressive Disorder","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["LSD"],"nct":"NCT07503002","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-10-01","official":"Sandeep Nayak, MD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT07503002","sites":["Johns Hopkins Center for Psychedelic and Consciousness Research — Baltimore, United States"],"conds":["Major Depression Moderate","Major Depression Severe","Major Depression"],"condg":["Depression"],"contact":{"n":"Matthew Nielsen, BA","p":"410-999-8066","e":"slimstudy@jh.edu"},"enroll":10,"eid":"NCT07503002"},{"id":"study-NCT07704762","cat":"studies","name":"Clinical Trial of MDMA-Assisted Therapy for Military Service Members With Posttraumatic Stress Disorder","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"U.S. Army Medical Research and Development Command","drugs":["MDMA"],"nct":"NCT07704762","nsites":0,"start":"2026-10-01","official":"Shannon Ford, MD (WRNMMC)","src":"https://clinicaltrials.gov/study/NCT07704762","conds":["PTSD","Post Traumatic Stress Disorder PTSD","Post Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"contact":{"n":"Alexandra R Tribo","p":"704-997-9460","e":"alexandra.tribo.ctr@usuhs.edu"},"enroll":86,"eid":"NCT07704762"},{"id":"study-NCT07139106","cat":"studies","name":"Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts","status":"NOT_YET_RECRUITING","phase":"Phase 4","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT07139106","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-10-01","src":"https://clinicaltrials.gov/study/NCT07139106","sites":["New York State Psychiatric Institute — New York, United States"],"conds":["Major Depressive Disorder (MDD)"],"condg":["Depression"],"contact":{"n":"Elizabeth A Bartlett, PhD","p":"646-774-7608","e":"BartlettMINDResearch@nyspi.columbia.edu"},"enroll":12,"eid":"NCT07139106"},{"id":"study-NCT07683988","cat":"studies","name":"Oral and Sublingual Ketamine","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"Western University, Canada","drugs":["ketamine"],"nct":"NCT07683988","nsites":0,"start":"2026-10-01","src":"https://clinicaltrials.gov/study/NCT07683988","conds":["Major Depression Severe"],"condg":["Depression"],"contact":{"n":"Rohit Lodhi, MD","p":"+1-519-646-6100","e":"rlodhi2@uwo.ca"},"enroll":10,"eid":"NCT07683988"},{"id":"study-NCT07826988","cat":"studies","name":"Adaptive Platform Trial for Pain Management in Sickle Cell Vaso-Occlusive Crisis","status":"NOT_YET_RECRUITING","phase":"Phase 4","sponsor":"Assistance Publique - Hôpitaux de Paris","drugs":["ketamine"],"nct":"NCT07826988","nsites":0,"start":"2026-10-01","official":"Ségolène GENDREAU, MD, PhD (Assistance public Hôpitaux de Paris)","src":"https://clinicaltrials.gov/study/NCT07826988","conds":["Sickle Cell Disease","Vaso-occlusive Crisis"],"condg":["Other"],"contact":{"n":"Samia BALOUL","p":"01 49 81 33 85","e":"samia.baloul@aphp.fr"},"enroll":400,"eid":"NCT07826988"},{"id":"study-NCT07449351","cat":"studies","name":"Psilocybin Microdosing on Cognition, Mood and Quality of Life","status":"NOT_YET_RECRUITING","phase":"EARLY_Phase 1","sponsor":"Yale University","drugs":["psilocybin"],"nct":"NCT07449351","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-10-01","official":"Godfrey Pearlson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT07449351","sites":["Olin Neuropsychiatry Research Center — Hartford, United States"],"conds":["Psychedelic Microdosing Effects on Mood, Cognition,…"],"condg":["Other"],"contact":{"n":"Godfrey Pearlson, MD","p":"860-545-7757","e":"godfrey.pearlson@hhchealth.org"},"enroll":20,"eid":"NCT07449351"},{"id":"study-NCT06885996","cat":"studies","name":"Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"University of Calgary","drugs":["psilocybin"],"nct":"NCT06885996","nsites":2,"countries":"Canada","ccs":["CA"],"start":"2026-10-01","official":"Sandy Shultz, PhD (The Institute on Aging & Lifelong Health, Faculty of Health, University of Victoria); Leah Mayo, PhD (Parker Psychedelics Research Chair…","src":"https://clinicaltrials.gov/study/NCT06885996","sites":["University of Calgary — Calgary, Canada","The University of British Columbia - Okanagan Campus — Kelowna, Canada"],"conds":["Post Traumatic Stress Disorder PTSD","Intimate Partner Violence (IPV)"],"condg":["PTSD & trauma"],"contact":{"n":"Chantel T Debert, MD MSc FRCPC","p":"403) 944-4500","e":"cdebert@ucalgary.ca"},"enroll":76,"eid":"NCT06885996"},{"id":"study-NCT07504601","cat":"studies","name":"Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"National Center for Complementary and Integrative Health (NCCIH)","drugs":["ketamine"],"nct":"NCT07504601","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-10-07","official":"Lauren Y Atlas, Ph.D. (National Center for Complementary and Integrative Health (NCCIH))","src":"https://clinicaltrials.gov/study/NCT07504601","sites":["National Institutes of Health Clinical Center — Bethesda, United States"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"contact":{"n":"Xue S Davis","p":"(301) 827-8646","e":"xue.davis@nih.gov"},"enroll":92,"eid":"NCT07504601"},{"id":"study-NCT07721467","cat":"studies","name":"Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"National Institute on Aging (NIA)","drugs":["psilocybin"],"nct":"NCT07721467","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-10-07","official":"Dimitrios I Kapogiannis, M.D. (National Institute on Aging (NIA))","src":"https://clinicaltrials.gov/study/NCT07721467","sites":["National Institute of Aging, Clinical Research Unit — Baltimore, United States"],"conds":["Alzheimer's Disease"],"condg":["Neurology & cognition"],"contact":{"n":"Sierra D Kunkosi","p":"(410) 350-3941","e":"sierra.kunkoski@nih.gov"},"enroll":200,"eid":"NCT07721467"},{"id":"study-NCT07590687","cat":"studies","name":"KetAmine and Recovery After Mechanical VentilAtion ( KARMA )","status":"NOT_YET_RECRUITING","phase":"Phase 3","sponsor":"Assistance Publique - Hôpitaux de Paris","drugs":["ketamine"],"nct":"NCT07590687","nsites":1,"countries":"France","ccs":["FR"],"start":"2026-10-19","official":"Romain Prof SONNEVILLE, MD-PHD (APHP)","src":"https://clinicaltrials.gov/study/NCT07590687","sites":["Department of Intensive Care Medicine, APHP.Nord, hôpital Bichat Claude Bernard, — Paris, France"],"conds":["Critical Illness"],"condg":["Other"],"contact":{"n":"Romain Prof SONNEVILLE, MD-PHD","p":"1 40 25 61 39","e":"romain.sonneville@aphp.fr"},"enroll":640,"eid":"NCT07590687"},{"id":"study-NCT07644767","cat":"studies","name":"Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar Depression","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Neurocentrx Pharma Pty Ltd","drugs":["ketamine"],"nct":"NCT07644767","nsites":0,"start":"2026-10-30","official":"Ishrat Husain, MBBS, MD, FRCPsych(UK) FRCP(C) (University Health Network (UHN); Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto)","src":"https://clinicaltrials.gov/study/NCT07644767","conds":["Treatment Resistant Bipolar Depression"],"condg":["Depression","Bipolar"],"enroll":160,"eid":"NCT07644767"},{"id":"study-NCT07791901","cat":"studies","name":"MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"University of Calgary","drugs":["psilocybin"],"nct":"NCT07791901","nsites":2,"countries":"Canada","ccs":["CA"],"start":"2026-10-30","official":"Linda E. Carlson, Ph.D., R.Psych, FCAHS, FABMR (University of Calgary); Ron Shore, MPA, PhD (Queen's University)","src":"https://clinicaltrials.gov/study/NCT07791901","sites":["Arthur Child Comprehensive Cancer Centre — Calgary, Canada","Providence Care Hospital — Kingston, Canada"],"conds":["Advanced Cancer","Demoralization","Existential Distress","Psychological Distress"],"condg":["Cancer-related distress"],"contact":{"n":"Christopher P. Albertyn, PhD","p":"587-231-3984","e":"christopher.albertyn@ucalgary.ca"},"enroll":60,"eid":"NCT07791901"},{"id":"study-NCT07765693","cat":"studies","name":"MDMA-AT for PTSD in Young Adults With Childhood Trauma","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Jenna M. Traynor","drugs":["MDMA"],"nct":"NCT07765693","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-10-31","official":"Jenna M Traynor (Mclean Hospital)","src":"https://clinicaltrials.gov/study/NCT07765693","sites":["McLean Hospital — Belmont, United States"],"conds":["Posttraumatic Stress Disorder (PTSD)"],"condg":["PTSD & trauma"],"contact":{"n":"Alexandra Velev, BA","p":"617-855-3430","e":"avelev@mclean.harvard.edu"},"enroll":15,"eid":"NCT07765693"},{"id":"study-NCT07756736","cat":"studies","name":"Psilocybin Therapy for Methamphetamine Use Disorder and HIV","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Nicky Mehtani, MD, MPH","drugs":["psilocybin"],"nct":"NCT07756736","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-11","official":"Nicky J. Mehtani, MD, MPH (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT07756736","sites":["UCSF at Zuckerberg San Francisco General Hospital — San Francisco, United States"],"conds":["Methamphetamine Use Disorder","Human Immunodeficiency Virus (HIV)"],"condg":["Addiction & substance use"],"contact":{"n":"Eliza Banbury, BA","p":"510-985-3522","e":"prism.trial@ucsf.edu"},"enroll":30,"eid":"NCT07756736"},{"id":"study-NCT07818564","cat":"studies","name":"Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"Brown University","drugs":["psilocybin"],"nct":"NCT07818564","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-11","src":"https://clinicaltrials.gov/study/NCT07818564","sites":["Brown University School of Public Health — Providence, United States"],"conds":["Phase I"],"condg":["Other"],"enroll":24,"eid":"NCT07818564"},{"id":"study-NCT07227909","cat":"studies","name":"NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"M.D. Anderson Cancer Center","drugs":["psilocybin"],"nct":"NCT07227909","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-11-04","official":"Moran Amit, MD (M.D. Anderson Cancer Center)","src":"https://clinicaltrials.gov/study/NCT07227909","sites":["MD Anderson Cancer Center — Houston, United States"],"conds":["Psilocybin","Neuropathy"],"condg":["Other"],"contact":{"n":"Moran Amit, MD","p":"713-794-5304","e":"mamit@mdanderson.org"},"enroll":83,"eid":"NCT07227909"},{"id":"study-NCT07296094","cat":"studies","name":"Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Brigham and Women's Hospital","drugs":["psilocybin"],"nct":"NCT07296094","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-11-15","official":"Joji Suzuki, MD (Brigham and Women's Hospital)","src":"https://clinicaltrials.gov/study/NCT07296094","sites":["Brigham and Women's Hospital — Boston, United States"],"conds":["Alcohol Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Joji Suzuki, MD","p":"617-732-5752","e":"jsuzuki2@bwh.harvard.edu"},"enroll":36,"eid":"NCT07296094"},{"id":"study-NCT07768618","cat":"studies","name":"Electrophysiologic Mechanisms of Ketamine Antidepressant Response","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Emory University","drugs":["ketamine"],"nct":"NCT07768618","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-12","official":"Carl Hacker, MD, PhD (Emory University)","src":"https://clinicaltrials.gov/study/NCT07768618","sites":["Emory University — Atlanta, United States"],"conds":["Epilepsy","Depressive Symptoms"],"condg":["Depression","Neurology & cognition"],"contact":{"n":"Carl Hacker, MD, PhD","p":"404-778-5770","e":"carl.hacker@emory.edu"},"enroll":37,"eid":"NCT07768618"},{"id":"study-NCT07247006","cat":"studies","name":"Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"University of Rochester","drugs":["ketamine"],"nct":"NCT07247006","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-12","src":"https://clinicaltrials.gov/study/NCT07247006","sites":["University of Rochester Medical Center — Rochester, United States"],"conds":["Treatment Resistant Depression (TRD)","Chronic Pain"],"condg":["Depression","Chronic pain & headache"],"contact":{"n":"Pain and Perception Lab","p":"585-275-4424","e":"painlab@urmc.rochester.edu"},"enroll":25,"eid":"NCT07247006"},{"id":"study-NCT07719088","cat":"studies","name":"Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"Charles Raison","drugs":["psilocybin"],"nct":"NCT07719088","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-12","src":"https://clinicaltrials.gov/study/NCT07719088","sites":["Vail Health Behavioral Health — Edwards, United States"],"conds":["Aging","Longevity","Biomarkers of Aging"],"condg":["Other"],"contact":{"n":"BHIC Study Team","p":"970-855-7374","e":"bhic@vailhealth.org"},"enroll":50,"eid":"NCT07719088"},{"id":"study-NCT07792538","cat":"studies","name":"Psilocybin-Assisted Psychotherapy for Veterans With PTSD","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"ARQ National Psychotrauma Centre","drugs":["psilocybin"],"nct":"NCT07792538","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2026-12","official":"Eric Vermetten, MD, PhD (Leiden University Medical Center)","src":"https://clinicaltrials.gov/study/NCT07792538","sites":["ARQ National Psychotrauma Centre / ARQ Centrum'45 — Oegstgeest, Netherlands"],"conds":["Posttraumatic Stress Disorder (PTSD)"],"condg":["PTSD & trauma"],"contact":{"n":"Annika Wirsching, MSc","p":"088 330 5699","e":"a.wirsching@arq.org"},"enroll":12,"eid":"NCT07792538"},{"id":"study-NCT07818720","cat":"studies","name":"MLS101 Study in PMDD","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"MycoMedica Life Sciences PBC","drugs":["psilocybin"],"nct":"NCT07818720","nsites":0,"start":"2026-12","src":"https://clinicaltrials.gov/study/NCT07818720","conds":["Premenstrual Dysphoric Disorder ( PMDD)","PMDD"],"condg":["Other"],"contact":{"n":"Executive Director of Clinical Operations","p":"(732) 690-3185","e":"sbasim@mycomedica.com"},"enroll":32,"eid":"NCT07818720"},{"id":"study-NCT07740512","cat":"studies","name":"Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Polaryx Therapeutics, Inc.","drugs":["LSD"],"nct":"NCT07740512","nsites":0,"start":"2026-12-01","src":"https://clinicaltrials.gov/study/NCT07740512","conds":["Lysosomal Storage Disorders","Sandhoff Disease","Krabbe Disease","CLN2","CLN3"],"condg":["Other"],"contact":{"n":"Minsu Kang, PhD","p":"217-779-7736","e":"minsukang@polaryx.com"},"enroll":24,"eid":"NCT07740512"},{"id":"study-NCT07833761","cat":"studies","name":"ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"University of Minnesota","drugs":["psilocybin"],"nct":"NCT07833761","nsites":2,"countries":"United States","ccs":["US"],"start":"2026-12-01","official":"Ziad Nahas, MD, MSCR (University of Minnesota); Devin H Hanson, PhD, LP (University of Minnesota)","src":"https://clinicaltrials.gov/study/NCT07833761","sites":["M Health Fairview DBT Program — Minneapolis, United States","M Physicians St. Louis Park Clinic — Saint Louis Park, United States"],"conds":["Borderline Personality Disorder","Borderline Personality Pathology","Depressive Symptoms","Emotion Dysregulation","Suicidal Ideation"],"condg":["Depression"],"contact":{"n":"Ziad Nahas, MD, MSCR","p":"952-525-4505","e":"znahas@umn.edu"},"enroll":18,"eid":"NCT07833761"},{"id":"study-NCT07852832","cat":"studies","name":"Effects of Psilocybin on Craving in Nicotine Dependence","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"University of British Columbia","drugs":["psilocybin"],"nct":"NCT07852832","nsites":0,"start":"2027-01","src":"https://clinicaltrials.gov/study/NCT07852832","conds":["Nicotine Dependence"],"condg":["Addiction & substance use"],"contact":{"n":"Christian G Schutz","p":"604-827-4287","e":"christian.schutz@ubc.ca"},"enroll":3,"eid":"NCT07852832"},{"id":"study-NCT07566104","cat":"studies","name":"Group PACBT for Depression","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"University of California, Los Angeles","drugs":["psilocybin"],"nct":"NCT07566104","nsites":1,"countries":"United States","ccs":["US"],"start":"2027-01","src":"https://clinicaltrials.gov/study/NCT07566104","sites":["UCLA Semel Institute — Los Angeles, United States"],"conds":["Depression - Major Depressive Disorder","Psilocybin","Cognitive Behavioral Therapy"],"condg":["Depression","Neurology & cognition"],"enroll":30,"eid":"NCT07566104"},{"id":"study-NCT07728851","cat":"studies","name":"Nebulized Ketamine for Severe Asthma Attacks in Children","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Sultan Qaboos University","drugs":["ketamine"],"nct":"NCT07728851","nsites":1,"countries":"Oman","ccs":["OM"],"start":"2027-01-01","official":"Zahraa Ali Al Lawati (College of Medicine and Health Sciences , Sultan Qaboos University)","src":"https://clinicaltrials.gov/study/NCT07728851","sites":["Sultan Qaboos University Hospital — Muscat, Oman"],"conds":["Asthma Acute","Exacerbation of Allergic Asthma"],"condg":["Other"],"contact":{"n":"Zahra Ali Al Lawati","p":"+96892347374","e":"zlawati@squ.edu.om"},"enroll":60,"eid":"NCT07728851"},{"id":"study-NCT07774702","cat":"studies","name":"Psilocybin for Methamphetamine Use Disorder","status":"NOT_YET_RECRUITING","phase":"Phase 2","sponsor":"Peter Hendricks","drugs":["psilocybin"],"nct":"NCT07774702","nsites":1,"countries":"United States","ccs":["US"],"start":"2027-02-01","official":"Peter S Hendricks, PhD (University of Alabama at Birmingham)","src":"https://clinicaltrials.gov/study/NCT07774702","sites":["University of Alabama at Birmingham — Birmingham, United States"],"conds":["Methamphetamine Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Seher Premani, MPH","p":"205-975-7721","e":"spremani@uab.edu"},"enroll":42,"eid":"NCT07774702"},{"id":"study-NCT07406828","cat":"studies","name":"Psilocybin After Trauma Surgery for Pain","status":"NOT_YET_RECRUITING","phase":"Phase 1","sponsor":"Trent Emerick","drugs":["psilocybin"],"nct":"NCT07406828","nsites":1,"countries":"United States","ccs":["US"],"start":"2027-12-31","official":"Trent D. Emerick (University of Pittsburgh / UPMC)","src":"https://clinicaltrials.gov/study/NCT07406828","sites":["UPMC Presbyterian — Pittsburgh, United States"],"conds":["Pain Management","Postoperative Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Alisha Maslanka, BS, CCRC","p":"4128646779","e":"maslankaaa@upmc.edu"},"enroll":70,"eid":"NCT07406828"},{"id":"study-NCT06916403","cat":"studies","name":"Safety and Efficacy of Ketamine Intravenous Infusions in the Treatment of Fibromyalgia","status":"ENROLLING_BY_INVITATION","sponsor":"Wilderman Medical Clinic","drugs":["ketamine"],"nct":"NCT06916403","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2020-11-30","official":"Igor Wilderman, MD (Wilderman Medical Clinic)","src":"https://clinicaltrials.gov/study/NCT06916403","sites":["Wilderman Medical Clinic — Thornhill, Canada"],"conds":["Fibromyalgia"],"condg":["Chronic pain & headache"],"enroll":50,"eid":"NCT06916403"},{"id":"study-NCT04933149","cat":"studies","name":"Ketamine Infusion for Neuropathic Pain in Brachial Plexus Injuries","status":"ENROLLING_BY_INVITATION","phase":"Phase 4","sponsor":"Mayo Clinic","drugs":["ketamine"],"nct":"NCT04933149","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-12-15","official":"Alexander Shin, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT04933149","sites":["Mayo Clinic in Rochester — Rochester, United States"],"conds":["Brachial Plexus Injury"],"condg":["Other"],"enroll":100,"eid":"NCT04933149"},{"id":"study-NCT05444751","cat":"studies","name":"GA + ESP vs. SA + ESP in Lumbar Decompression Surgeries","status":"ENROLLING_BY_INVITATION","phase":"Phase 3","sponsor":"Hospital for Special Surgery, New York","drugs":["ketamine"],"nct":"NCT05444751","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-03-22","src":"https://clinicaltrials.gov/study/NCT05444751","sites":["Hospital for Special Surgery — New York, United States"],"conds":["Lumbar Disc Herniation","Lumbar Disc Disease","Lumbar Radiculopathy"],"condg":["Other"],"enroll":142,"eid":"NCT05444751"},{"id":"study-NCT06179485","cat":"studies","name":"Effect of Ketamine and Etomidate During RSI on Long Term Outcomes","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","drugs":["ketamine"],"nct":"NCT06179485","nsites":6,"countries":"United States","ccs":["US"],"start":"2022-04-06","src":"https://clinicaltrials.gov/study/NCT06179485","sites":["University of Alabama Hospital — Birmingham, United States","University of Colorado Denver — Aurora, United States","Denver Health Medical Center — Denver, United States","Hennepin County Medical Center — Minneapolis, United States","Wake Forest Baptist Medical Center — Winston-Salem, United States","Vanderbilt University Medical Center — Nashville, United States"],"conds":["Post-Traumatic Stress Disorder","Acute Respiratory Failure"],"condg":["PTSD & trauma"],"enroll":1756,"eid":"NCT06179485"},{"id":"study-NCT05212571","cat":"studies","name":"Long-term Pain Modulation by Intravenous Esketamine in CRPS","status":"ENROLLING_BY_INVITATION","phase":"N/A","sponsor":"Erasmus Medical Center","drugs":["esketamine","ketamine"],"nct":"NCT05212571","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2022-04-19","official":"Frank JP Huygen, MD, PhD (Erasmus MC, Center for Pain Medicine); Thomas Mangnus, MD (Erasmus MC, Center for Pain Medicine)","src":"https://clinicaltrials.gov/study/NCT05212571","sites":["Erasmus MC — Rotterdam, Netherlands"],"conds":["Complex Regional Pain Syndromes","CRPS (Complex Regional Pain Syndromes)"],"condg":["Chronic pain & headache"],"enroll":60,"eid":"NCT05212571"},{"id":"study-NCT05477004","cat":"studies","name":"Observational Study of Ketamine Infusions for the Treatment of Chronic Pain","status":"ENROLLING_BY_INVITATION","sponsor":"Theresa Lii","drugs":["ketamine"],"nct":"NCT05477004","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-06-01","official":"Theresa Lii, MD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT05477004","sites":["Stanford University — Stanford, United States"],"conds":["Chronic Pain"],"condg":["Chronic pain & headache"],"enroll":100,"eid":"NCT05477004"},{"id":"study-NCT05565352","cat":"studies","name":"Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD)","status":"ENROLLING_BY_INVITATION","sponsor":"Medical University of Gdansk","drugs":["esketamine","ketamine"],"nct":"NCT05565352","nsites":1,"countries":"Poland","ccs":["PL"],"start":"2022-09-01","src":"https://clinicaltrials.gov/study/NCT05565352","sites":["Department of Psychiatry, Medical University of Gdańsk — Gdansk, Poland"],"conds":["Major Depressive Disorder","Post Traumatic Stress Disorder","Obsessive-Compulsive Disorder","Somatoform Disorders","Anxiety Disorders","Dissociative Disorder"],"condg":["Depression","Anxiety","PTSD & trauma","OCD"],"enroll":140,"eid":"NCT05565352"},{"id":"study-NCT05570708","cat":"studies","name":"The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training","status":"ENROLLING_BY_INVITATION","phase":"N/A","sponsor":"Felix Mueller","drugs":["LSD","MDMA","psilocybin"],"nct":"NCT05570708","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2022-10-25","official":"Felix Müller, MD (University of Basel)","src":"https://clinicaltrials.gov/study/NCT05570708","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Personal Experience of Substance-assisted Therapy Using…"],"condg":["Addiction & substance use"],"enroll":48,"eid":"NCT05570708"},{"id":"study-NCT06002100","cat":"studies","name":"Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements","status":"ENROLLING_BY_INVITATION","sponsor":"Kernel","drugs":["esketamine","ketamine"],"nct":"NCT06002100","nsites":10,"countries":"United States","ccs":["US"],"start":"2023-08-14","official":"Katherine Perdue, PhD (Kernel)","src":"https://clinicaltrials.gov/study/NCT06002100","sites":["BrainHealth Solutions — Costa Mesa, United States","Kadima Neuropsychiatry Institute — La Jolla, United States","Kaizen Brain Center, LLC — La Jolla, United States","Bespoke Treatment — Los Angeles, United States","UCLA TMS — Los Angeles, United States","Bespoke Treatment — Los Angeles, United States","Acacia Clinics — Sunnyvale, United States","Metro Psychiatry Inc. — Columbus, United States"],"conds":["Depression","Major Depressive Disorder"],"condg":["Depression"],"enroll":540,"eid":"NCT06002100"},{"id":"study-NCT06034821","cat":"studies","name":"Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan","status":"ENROLLING_BY_INVITATION","phase":"Phase 4","sponsor":"Brigham and Women's Hospital","drugs":["ketamine"],"nct":"NCT06034821","nsites":10,"countries":"Canada; United States","ccs":["CA","US"],"start":"2023-10-01","official":"Amit Anand, MD (Brigham and Woman's Hospital, Harvard Medical School)","src":"https://clinicaltrials.gov/study/NCT06034821","sites":["UC San Francisco — San Francisco, United States","Johns Hopkins University — Baltimore, United States","McLean Hospital — Belmont, United States","Massachusetts General Hospital — Boston, United States","Mount Sinai School of Medicine — New York, United States","Cleveland Clinic — Cleveland, United States","University of Pittsburgh — Pittsburgh, United States","UTHealth Houston — Houston, United States"],"conds":["Acute Suicidal Depression (ASD)"],"condg":["Depression"],"enroll":1500,"eid":"NCT06034821"},{"id":"study-NCT05746572","cat":"studies","name":"MDMA Plus Exposure Therapy for PTSD","status":"ENROLLING_BY_INVITATION","phase":"Phase 2","sponsor":"Emory University","drugs":["MDMA"],"nct":"NCT05746572","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-02-13","official":"Jessica Maples-Keller, PhD (Emory University); Barbara O Rothbaum, PhD (Emory University)","src":"https://clinicaltrials.gov/study/NCT05746572","sites":["Emory Brain Health Center — Atlanta, United States"],"conds":["PTSD"],"condg":["PTSD & trauma"],"enroll":40,"eid":"NCT05746572"},{"id":"study-NCT06823024","cat":"studies","name":"Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions","status":"ENROLLING_BY_INVITATION","sponsor":"Psyrin Inc.","drugs":["esketamine","ketamine"],"nct":"NCT06823024","nsites":2,"countries":"United States","ccs":["US"],"start":"2025-02-18","official":"Julianna Olah, B.Sc., M.A., M.Sc., Ph.D. (Psyrin Inc.)","src":"https://clinicaltrials.gov/study/NCT06823024","sites":["Acacia Clinics — Sunnyvale, United States","Fermata Health — New York, United States"],"conds":["Obsessive Compulsive Disorder (OCD)","Bipolar Disorders","Major Depressive Disorder","Post-Traumatic Stress Disorder, PTSD","Generalized Anxiety Disorder (GAD)"],"condg":["Depression","Anxiety","PTSD & trauma","OCD","Bipolar"],"enroll":200,"eid":"NCT06823024"},{"id":"study-NCT06428838","cat":"studies","name":"Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context","status":"ENROLLING_BY_INVITATION","phase":"Phase 3","sponsor":"Dr George Medvedev","drugs":["ketamine"],"nct":"NCT06428838","nsites":2,"countries":"Canada","ccs":["CA"],"start":"2025-05-05","src":"https://clinicaltrials.gov/study/NCT06428838","sites":["Royal Columbian Hospital — New Westminster, Canada","Surrey Memorial Hospital — Surrey, Canada"],"conds":["Migraine","Chronic Migraine"],"condg":["Chronic pain & headache"],"enroll":102,"eid":"NCT06428838"},{"id":"study-NCT06954025","cat":"studies","name":"High-Intensity Inpatient MDMA-Assisted Psychotherapy for PTSD","status":"ENROLLING_BY_INVITATION","phase":"Phase 2","sponsor":"ARQ National Psychotrauma Centre","drugs":["MDMA"],"nct":"NCT06954025","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2025-05-16","src":"https://clinicaltrials.gov/study/NCT06954025","sites":["ARQ National Psychotrauma Centre / ARQ Centrum'45 — Oegstgeest, Netherlands"],"conds":["Posttraumatic Stress Disorder (PTSD)"],"condg":["PTSD & trauma"],"enroll":20,"eid":"NCT06954025"},{"id":"study-NCT06919640","cat":"studies","name":"Psilocybin With Intracranial Neural Sensing","status":"ENROLLING_BY_INVITATION","phase":"Phase 1","sponsor":"Joshua Woolley, MD, PhD","drugs":["psilocybin"],"nct":"NCT06919640","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-06-01","official":"Joshua Woolley, MD/PhD (University of California, San Francisco); Prasad Shirvalkar, MD/PhD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06919640","sites":["University of California, San Francisco — San Francisco, United States"],"conds":["Chronic Pain"],"condg":["Chronic pain & headache"],"enroll":20,"eid":"NCT06919640"},{"id":"study-NCT06736769","cat":"studies","name":"Ketamine Effects on Learning In Eating Disorders","status":"ENROLLING_BY_INVITATION","phase":"Phase 2","sponsor":"Amanda Downey, MD","drugs":["ketamine"],"nct":"NCT06736769","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-06-05","official":"Amanda E. Downey, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06736769","sites":["University of California, San Francisco — San Francisco, United States"],"conds":["Anorexia Nervosa","Atypical Anorexia Nervosa"],"condg":["Eating disorders"],"enroll":20,"eid":"NCT06736769"},{"id":"study-NCT06605105","cat":"studies","name":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","status":"ENROLLING_BY_INVITATION","phase":"Phase 3","sponsor":"Cybin IRL Limited","drugs":["psilocybin"],"nct":"NCT06605105","nsites":49,"countries":"Australia; Greece; Poland; United Kingdom; United States","ccs":["AU","GB","GR","PL","US"],"start":"2025-07-18","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","sites":["Scottsdale Research Institute — Phoenix, United States","Behavioral Research Specialists, LLC — Glendale, United States","Kadima Neuropsychiatry Institute — La Jolla, United States","TRIP Clinic and Psychedelic Science Institute — Los Angeles, United States","CalNeuro Research Group — Los Angeles, United States","Lipov Medical Group — Los Angeles, United States","Excell Research, Inc — Oceanside, United States","Open Mind Collective / UCSF Medical Center - Mount Zion — San Francisco, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":468,"eid":"NCT06605105"},{"id":"study-NCT07345858","cat":"studies","name":"Salivary Oxytocin as a Biomarker of Psychedelic Treatment","status":"ENROLLING_BY_INVITATION","sponsor":"University of Geneva, Switzerland","drugs":["LSD","psilocybin"],"nct":"NCT07345858","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2026-01-05","src":"https://clinicaltrials.gov/study/NCT07345858","sites":["Geneva University Hospitals — Geneva, Switzerland"],"conds":["Major Depressive Disorder (MDD)"],"condg":["Depression"],"enroll":80,"eid":"NCT07345858"},{"id":"study-NCT07396220","cat":"studies","name":"Psychotherapy Combined With Intranasal Esketamine for the Treatment of Suicidal Ideation","status":"ENROLLING_BY_INVITATION","phase":"N/A","sponsor":"University of California, San Diego","drugs":["esketamine"],"nct":"NCT07396220","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-01-09","src":"https://clinicaltrials.gov/study/NCT07396220","sites":["UC San Diego Health - 4S Ranch — San Diego, United States"],"conds":["Suicidal Ideation"],"condg":["Other"],"enroll":56,"eid":"NCT07396220"},{"id":"study-NCT07737990","cat":"studies","name":"Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression","status":"ENROLLING_BY_INVITATION","phase":"N/A","sponsor":"Joshua Rosenblat","drugs":["psilocybin"],"nct":"NCT07737990","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2026-07-01","src":"https://clinicaltrials.gov/study/NCT07737990","sites":["Toronto Western Hospital — Toronto, Canada"],"conds":["Treatment-resistant Depression (TRD)"],"condg":["Depression"],"enroll":65,"eid":"NCT07737990"},{"id":"study-NCT07705022","cat":"studies","name":"Assessing Covert Consciousness During Dexmedetomidine and Ketamine Sedation: An fMRI Study","status":"ENROLLING_BY_INVITATION","phase":"Phase 2","sponsor":"University of Michigan","drugs":["ketamine"],"nct":"NCT07705022","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-08-07","official":"Zirui Huang, PhD (University of Michigan)","src":"https://clinicaltrials.gov/study/NCT07705022","sites":["University of Michigan — Ann Arbor, United States"],"conds":["Healthy","Covert Consciousness"],"condg":["Healthy volunteers"],"enroll":60,"eid":"NCT07705022"},{"id":"study-NCT07810023","cat":"studies","name":"Intramuscular Ketamine for Suicidal Patients in the Evanston Hospital Emergency Department for Suicidal Distress","status":"ENROLLING_BY_INVITATION","phase":"N/A","sponsor":"Endeavor Health","drugs":["ketamine"],"nct":"NCT07810023","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-09-10","src":"https://clinicaltrials.gov/study/NCT07810023","sites":["Endeavor Health Evanston Hospital — Evanston, United States"],"conds":["Suicidal","Suicidal Ideation","Suicidal Ideation and Behavior","Depression / Major Depressive Disorder"],"condg":["Depression"],"enroll":8,"eid":"NCT07810023"},{"id":"study-NCT02734602","cat":"studies","name":"Imaging SV2A in Mood Disorders","status":"ACTIVE_NOT_RECRUITING","phase":"N/A","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT02734602","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-04","official":"Irina Esterlis, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT02734602","sites":["PET Center — New Haven, United States"],"conds":["Major Depressive Disorder","Post-Traumatic Stress Disorder"],"condg":["Depression","PTSD & trauma"],"enroll":130,"eid":"NCT02734602"},{"id":"study-NCT02866071","cat":"studies","name":"Intranasal Ketamine as an Adjunct to Fentanyl for the Prehospital Treatment of Acute Traumatic Pain","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 3","sponsor":"Jason McMullan","drugs":["ketamine"],"nct":"NCT02866071","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-10-03","src":"https://clinicaltrials.gov/study/NCT02866071","sites":["University of Cincinnati Medical Center — Cincinnati, United States"],"conds":["Acute Traumatic Pain"],"condg":["PTSD & trauma","Chronic pain & headache"],"enroll":224,"eid":"NCT02866071"},{"id":"study-NCT03345173","cat":"studies","name":"Facilitating Rapid Naltrexone Initiation","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 3","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT03345173","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-11-25","official":"Elias Dakwar, MD (NYSPI)","src":"https://clinicaltrials.gov/study/NCT03345173","sites":["New York State Psychiatric Institute — New York, United States"],"conds":["Opioid Dependence"],"condg":["Addiction & substance use"],"enroll":100,"eid":"NCT03345173"},{"id":"study-NCT03554174","cat":"studies","name":"Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1","sponsor":"Yale University","drugs":["psilocybin"],"nct":"NCT03554174","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-02-27","official":"Deepak D'Souza, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03554174","sites":["VA Connecticut Healthcare System, West Haven Campus — West Haven, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":18,"eid":"NCT03554174"},{"id":"study-NCT03573349","cat":"studies","name":"Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:","status":"ACTIVE_NOT_RECRUITING","phase":"EARLY_Phase 1","sponsor":"Mayo Clinic","drugs":["ketamine"],"nct":"NCT03573349","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-01-03","official":"Balwinder Singh, MD, MS (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT03573349","sites":["Mayo Clinic in Rochester — Rochester, United States"],"conds":["Major Depressive Disorder","Treatment Resistant Depression","Bipolar Depression"],"condg":["Depression","Bipolar"],"enroll":18,"eid":"NCT03573349"},{"id":"study-NCT07164287","cat":"studies","name":"Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Geneva","drugs":["LSD","psilocybin"],"nct":"NCT07164287","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2020-06-01","src":"https://clinicaltrials.gov/study/NCT07164287","sites":["Geneva University Hospital — Geneva, Switzerland"],"conds":["Major Depressive Disorder (MDD)","Anxiety Disorders","Substance Use Disorder (SUD)","PTSD - Post Traumatic Stress Disorder"],"condg":["Depression","Anxiety","PTSD & trauma","Addiction & substance use"],"enroll":376,"eid":"NCT07164287"},{"id":"study-NCT04589208","cat":"studies","name":"Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1/Phase 2","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT04589208","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-01-01","src":"https://clinicaltrials.gov/study/NCT04589208","sites":["New York State Psychiatric — New York, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":35,"eid":"NCT04589208"},{"id":"study-NCT04410913","cat":"studies","name":"Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"Keith Heinzerling","drugs":["psilocybin"],"nct":"NCT04410913","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-02-18","src":"https://clinicaltrials.gov/study/NCT04410913","sites":["Pacific Treatment & Research in Psychedelics — Santa Monica, United States"],"conds":["Alcohol Use Disorder"],"condg":["Addiction & substance use"],"enroll":20,"eid":"NCT04410913"},{"id":"study-NCT04578938","cat":"studies","name":"Ketamine + Cognitive Training for Suicidality in the Medical Setting","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 4","sponsor":"Rebecca Price","drugs":["ketamine"],"nct":"NCT04578938","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-03-15","official":"Rebecca B Price, PhD (University of Pittsburgh)","src":"https://clinicaltrials.gov/study/NCT04578938","sites":["University of Pittsburgh — Pittsburgh, United States"],"conds":["Suicide, Attempted"],"condg":["Other"],"enroll":200,"eid":"NCT04578938"},{"id":"study-NCT04711915","cat":"studies","name":"Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1","sponsor":"Yale University","drugs":["DMT"],"nct":"NCT04711915","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-03-17","src":"https://clinicaltrials.gov/study/NCT04711915","sites":["Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine — West Haven, United States"],"conds":["Major Depressive Disorder","Depression"],"condg":["Depression"],"enroll":30,"eid":"NCT04711915"},{"id":"study-NCT04781673","cat":"studies","name":"Ketamine vs Lidocaine in Traumatic Rib Fractures","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 4","sponsor":"Brittany Hoyte","drugs":["ketamine"],"nct":"NCT04781673","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-04-01","src":"https://clinicaltrials.gov/study/NCT04781673","sites":["Corewell Health West — Grand Rapids, United States"],"conds":["Rib Fractures","Rib Fracture Multiple","Rib Trauma"],"condg":["PTSD & trauma"],"enroll":74,"eid":"NCT04781673"},{"id":"study-NCT04620759","cat":"studies","name":"Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT04620759","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-04-14","official":"Frederick S Barrett, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT04620759","sites":["Johns Hopkins Center for Psychedelic and Consciousness Research — Baltimore, United States"],"conds":["Major Depressive Disorder","Alcohol Use Disorder"],"condg":["Depression","Addiction & substance use"],"enroll":90,"eid":"NCT04620759"},{"id":"study-NCT07164755","cat":"studies","name":"Measurement of Serum Inflammatory Markers in Patients Treatment-resistant Depression Given Psilocybin","status":"ACTIVE_NOT_RECRUITING","sponsor":"King's College London","drugs":["psilocybin"],"nct":"NCT07164755","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2021-06-21","src":"https://clinicaltrials.gov/study/NCT07164755","sites":["King's College London Institute of Psychiatry, Psychology and Neuroscience — London, United Kingdom"],"conds":["Depression - Major Depressive Disorder"],"condg":["Depression"],"enroll":46,"eid":"NCT07164755"},{"id":"study-NCT04313712","cat":"studies","name":"Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","drugs":["ibogaine"],"nct":"NCT04313712","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-11-15","official":"Nolan Williams, MD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT04313712","sites":["Stanford University School of Medicine — Stanford, United States"],"conds":["Blast or Combat Exposure","Head Injury Trauma"],"condg":["PTSD & trauma"],"enroll":30,"eid":"NCT04313712"},{"id":"study-NCT05065294","cat":"studies","name":"Psilocybin Therapy for Depression in Bipolar II Disorder","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"University of California, San Francisco","drugs":["psilocybin"],"nct":"NCT05065294","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-01-28","official":"Joshua D Woolley, MD,PhD (University of California, San Francisco); David Guard, PhD (San Francisco State University)","src":"https://clinicaltrials.gov/study/NCT05065294","sites":["University of California, San Francisco — San Francisco, United States"],"conds":["Bipolar II Disorder"],"condg":["Bipolar"],"enroll":14,"eid":"NCT05065294"},{"id":"study-NCT05950711","cat":"studies","name":"Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 4","sponsor":"Ohio State University","drugs":["ketamine"],"nct":"NCT05950711","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-03-30","src":"https://clinicaltrials.gov/study/NCT05950711","sites":["Harding Hospital — Columbus, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":21,"eid":"NCT05950711"},{"id":"study-NCT04982796","cat":"studies","name":"Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Portland VA Research Foundation, Inc","drugs":["psilocybin"],"nct":"NCT04982796","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-07-07","official":"Chris Stauffer, MD (Oregon Health and Science University)","src":"https://clinicaltrials.gov/study/NCT04982796","sites":["Portland VA Health Care System — Vancouver, United States"],"conds":["Amphetamine-Related Disorders"],"condg":["Other"],"enroll":30,"eid":"NCT04982796"},{"id":"study-NCT07717866","cat":"studies","name":"Trifecta Research Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Axial Therapeutic Research","drugs":["ibogaine"],"nct":"NCT07717866","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-08-01","official":"I S Kroop (Axial Therapeutic Research)","src":"https://clinicaltrials.gov/study/NCT07717866","sites":["Axial Therapeutic Research — Northridge, United States"],"conds":["PTSD - Post Traumatic Stress Disorder","Cognitive Dysfunction","Brain Injury","Depression - Major Depressive Disorder","Suicidal Ideation"],"condg":["Depression","PTSD & trauma","Neurology & cognition"],"enroll":52,"eid":"NCT07717866"},{"id":"study-NCT05434156","cat":"studies","name":"ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Eleusis Therapeutics","drugs":["psilocybin"],"nct":"NCT05434156","nsites":2,"countries":"United Kingdom","ccs":["GB"],"start":"2022-10-27","official":"Neel Bhatt (MAC Clinical Research)","src":"https://clinicaltrials.gov/study/NCT05434156","sites":["MAC Clinical Research — Liverpool, United Kingdom","MAC Clinical Research — Manchester, United Kingdom"],"conds":["Healthy Volunteers","Major Depressive Disorder","Depression"],"condg":["Depression","Healthy volunteers"],"enroll":84,"eid":"NCT05434156"},{"id":"study-NCT05546658","cat":"studies","name":"Effects of Psilocybin in Obsessive Compulsive Disorder","status":"ACTIVE_NOT_RECRUITING","phase":"EARLY_Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT05546658","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-11-28","official":"David B Yaden, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT05546658","sites":["Johns Hopkins University School of Medicine — Baltimore, United States"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"enroll":35,"eid":"NCT05546658"},{"id":"study-NCT05554094","cat":"studies","name":"Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"Ohio State University","drugs":["psilocybin"],"nct":"NCT05554094","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-01-01","official":"Alan K Davis, PhD (Ohio State University)","src":"https://clinicaltrials.gov/study/NCT05554094","sites":["Ohio State University Department of Psychiatry and Behavioral Health at the Davis Medical Research Center — Columbus, United States"],"conds":["PTSD","Stress Disorders, Traumatic","Stress Disorders, Post-Traumatic","Trauma and Stressor Related Disorders","Mental Disorder"],"condg":["PTSD & trauma"],"enroll":15,"eid":"NCT05554094"},{"id":"study-NCT05559931","cat":"studies","name":"Single and Repeat Doses of DMT in Healthy Subjects","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1","sponsor":"Algernon Pharmaceuticals","drugs":["DMT"],"nct":"NCT05559931","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2023-01-13","official":"Gabriel Jacobs, MD, PhD (Centre for Human Drugs Research)","src":"https://clinicaltrials.gov/study/NCT05559931","sites":["Centre for Human Drug Research — Leiden, Netherlands"],"conds":["Stroke"],"condg":["Neurology & cognition"],"enroll":60,"eid":"NCT05559931"},{"id":"study-NCT05733546","cat":"studies","name":"A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"COMPASS Pathways","drugs":["psilocybin"],"nct":"NCT05733546","nsites":5,"countries":"United States","ccs":["US"],"start":"2023-01-30","src":"https://clinicaltrials.gov/study/NCT05733546","sites":["Kadima Neuropsychiatry Institute — La Jolla, United States","Clinical Neuroscience Solutions Inc — Jacksonville, United States","Sunstone Therapies — Rockville, United States","Elixia MA, LLC — Springfield, United States","Aims Trial — Plano, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":102,"eid":"NCT05733546"},{"id":"study-NCT05711940","cat":"studies","name":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 3","sponsor":"COMPASS Pathways","drugs":["psilocybin"],"nct":"NCT05711940","nsites":116,"countries":"Canada; Czechia; Denmark; France; Germany; Ireland; Netherlands; Poland; Spain; Sweden; United Kingdom; United States","ccs":["CA","CZ","DE","DK","ES","FR","GB","IE","NL","PL","SE","US"],"start":"2023-02-14","src":"https://clinicaltrials.gov/study/NCT05711940","sites":["Lighthouse Psychiatry Scottsdale — Gilbert, United States","Clinical Innovations, Inc. — Bellflower, United States","M3 Wake Research — Encino, United States","The Regents of the University of California - San Diego — La Jolla, United States","Kadima Neuropsychiatry Institute — La Jolla, United States","CalNeuro Research Group, Inc — Los Angeles, United States","Catalina Research Institute, LLC — Montclair, United States","Piedmont Hospital Neuroscience Centre — Oakland, United States"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":572,"eid":"NCT05711940"},{"id":"study-NCT05690503","cat":"studies","name":"Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT05690503","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-03-20","official":"Saleena Subaiya, MD (New York State Psychiatric Institute); Elias Dakwar, MD (New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT05690503","sites":["New York State Psychiatric Institute — New York, United States"],"conds":["Post-acute Sequelae of COVID-19","Depressive Symptoms","Cognitive Dysfunction"],"condg":["Depression","Neurology & cognition"],"enroll":12,"eid":"NCT05690503"},{"id":"study-NCT05370911","cat":"studies","name":"Effects of Repeated Psilocybin Dosing in OCD","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1","sponsor":"Yale University","drugs":["psilocybin"],"nct":"NCT05370911","nsites":2,"countries":"United States","ccs":["US"],"start":"2023-07-20","official":"Benjamin Kelmendi, MD (Yale University); Terence Ching, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT05370911","sites":["Enact Research Collaborative (40 Temple St, 4th Floor) — New Haven, United States","Yale Program for Psychedelic Research — New Haven, United States"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"enroll":28,"eid":"NCT05370911"},{"id":"study-NCT05698511","cat":"studies","name":"Neural and Physiological Correlates of Psychedelic Sub-states","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1","sponsor":"Robin Carhart-Harris, PhD, MA","drugs":["psilocybin"],"nct":"NCT05698511","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-07-31","official":"Robin Carhart-Harris, PhD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT05698511","sites":["University of California, San Francisco — San Francisco, United States"],"conds":["Psychedelic Experiences","Neuroimaging","Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":12,"eid":"NCT05698511"},{"id":"study-NCT05737693","cat":"studies","name":"Enhancing Week-long Psychological Treatment for PTSD With Ketamine","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT05737693","nsites":2,"countries":"Israel; United States","ccs":["IL","US"],"start":"2023-08-21","official":"Ilan Harpaz-Rotem, PhD ABPP (Yale University)","src":"https://clinicaltrials.gov/study/NCT05737693","sites":["Yale University School of Medicine — New Haven, United States","Tel Aviv University — Tel Aviv, Israel"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":350,"eid":"NCT05737693"},{"id":"study-NCT05698394","cat":"studies","name":"Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 4","sponsor":"Peking University First Hospital","drugs":["esketamine"],"nct":"NCT05698394","nsites":4,"countries":"China","ccs":["CN"],"start":"2023-09-09","official":"Dong-Xin Wang, MD,PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT05698394","sites":["Hunan Provincial Maternal and Child Health Care Hospital — Changsha, China","Women's Hospital of Nanjing Medical University — Nanjing, China","Women's Hospital, Zhejiang University School of Medicine — Hangzhou, China","Peking University First Hospital — Beijing, China"],"conds":["Prenatal Depression","Ketamine","Postpartum Depression"],"condg":["Depression"],"enroll":364,"eid":"NCT05698394"},{"id":"study-NCT05947383","cat":"studies","name":"Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"Sunstone Medical","drugs":["psilocybin"],"nct":"NCT05947383","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-10-23","src":"https://clinicaltrials.gov/study/NCT05947383","sites":["Sunstone Medical, PC — Rockville, United States"],"conds":["Cancer","Major Depressive Disorder"],"condg":["Depression","Cancer-related distress"],"enroll":56,"eid":"NCT05947383"},{"id":"study-NCT06062550","cat":"studies","name":"Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 4","sponsor":"Peking University First Hospital","drugs":["esketamine"],"nct":"NCT06062550","nsites":1,"countries":"China","ccs":["CN"],"start":"2023-10-24","official":"Dong-Xin Wang, MD,PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT06062550","sites":["Beijing University First Hospital — Beijing, China"],"conds":["Scoliosis Correction","Esketamine","Dexmedetomidine","Postoperative Analgesia","Chronic Postsurgical Pain"],"condg":["Chronic pain & headache"],"enroll":312,"eid":"NCT06062550"},{"id":"study-NCT05953038","cat":"studies","name":"LSD Occupancy of the Serotonin 2A Receptor in the Human Brain","status":"ACTIVE_NOT_RECRUITING","phase":"EARLY_Phase 1","sponsor":"Copenhagen University Hospital, Rigshospitalet","drugs":["LSD"],"nct":"NCT05953038","nsites":1,"countries":"Denmark","ccs":["DK"],"start":"2023-11-08","official":"Gitte M Knudsen, DMsc, MD (Copenhagen University Hospital, Rigshospitalet)","src":"https://clinicaltrials.gov/study/NCT05953038","sites":["Neurobiology Research Unit, Rigshospitalet — Copenhagen, Denmark"],"conds":["Basic Science"],"condg":["Other"],"enroll":40,"eid":"NCT05953038"},{"id":"study-NCT06041152","cat":"studies","name":"Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"Centre for Addiction and Mental Health","drugs":["psilocybin"],"nct":"NCT06041152","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2023-11-27","official":"Philip Gerretsen, MD, PhD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT06041152","sites":["Centre for Addiction and Mental Health — Toronto, Canada"],"conds":["Amnestic Mild Cognitive Impairment"],"condg":["Neurology & cognition"],"enroll":10,"eid":"NCT06041152"},{"id":"study-NCT05351541","cat":"studies","name":"Psilocybin Therapy for Chronic Low Back Pain","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Joshua Woolley, MD, PhD","drugs":["psilocybin"],"nct":"NCT05351541","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-12-01","official":"Joshua Woolley (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT05351541","sites":["University of California San Francisco — San Francisco, United States"],"conds":["Chronic Low-back Pain"],"condg":["Chronic pain & headache"],"enroll":30,"eid":"NCT05351541"},{"id":"study-NCT04754061","cat":"studies","name":"PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1/Phase 2","sponsor":"Ottawa Hospital Research Institute","drugs":["psilocybin"],"nct":"NCT04754061","nsites":2,"countries":"Canada","ccs":["CA"],"start":"2024-01-08","official":"James Downar, MDCM, MSc (Ottawa Hospital Research Institute)","src":"https://clinicaltrials.gov/study/NCT04754061","sites":["The Ottawa Hospital — Ottawa, Canada","Bruyere Continuing Care — Ottawa, Canada"],"conds":["Depression, Anxiety","Distress, Emotional"],"condg":["Depression","Anxiety"],"enroll":20,"eid":"NCT04754061"},{"id":"study-NCT06206265","cat":"studies","name":"Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"TRYP Therapeutics","drugs":["psilocybin"],"nct":"NCT06206265","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-01-17","official":"Franklin King, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT06206265","sites":["Massachusetts General Hospital — Boston, United States"],"conds":["Irritable Bowel Syndrome"],"condg":["Other"],"enroll":14,"eid":"NCT06206265"},{"id":"study-NCT05625555","cat":"studies","name":"Predictors of Intravenous Ketamine Response in TRD","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 3","sponsor":"Abraham Nunes","drugs":["ketamine"],"nct":"NCT05625555","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2024-01-19","official":"Abraham Nunes, MD PhD MBA FRCPC (Nova Scotia Health Authority)","src":"https://clinicaltrials.gov/study/NCT05625555","sites":["Mood Disorders Program — Halifax, Canada"],"conds":["Treatment Resistant Depression","Major Depressive Disorder","Bipolar Disorder"],"condg":["Depression","Bipolar"],"enroll":40,"eid":"NCT05625555"},{"id":"study-NCT05421065","cat":"studies","name":"Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"Peggy C Nopoulos","drugs":["ketamine","psilocybin"],"nct":"NCT05421065","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-02-02","official":"Peggy C Nopoulos, MD (University of Iowa)","src":"https://clinicaltrials.gov/study/NCT05421065","sites":["University of Iowa — Iowa City, United States"],"conds":["Alcohol Use Disorder"],"condg":["Addiction & substance use"],"enroll":20,"eid":"NCT05421065"},{"id":"study-NCT06341426","cat":"studies","name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"University Health Network, Toronto","drugs":["psilocybin"],"nct":"NCT06341426","nsites":2,"countries":"Canada","ccs":["CA"],"start":"2024-02-05","official":"Joshua Rosenblat, MD, MSc (University Health Network, Toronto)","src":"https://clinicaltrials.gov/study/NCT06341426","sites":["Toronto Western Hospital — Toronto, Canada","Centre for Addiction and Mental Health (CAMH) — Toronto, Canada"],"conds":["Major Depressive Disorder","Depression","Treatment-Resistant Depression","Mood Disorders"],"condg":["Depression"],"enroll":92,"eid":"NCT06341426"},{"id":"study-NCT06308653","cat":"studies","name":"Psilocybin for Major Depressive Disorder (MDD)","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 3","sponsor":"Usona Institute","drugs":["psilocybin"],"nct":"NCT06308653","nsites":29,"countries":"United States","ccs":["US"],"start":"2024-03-13","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","sites":["University of Alabama Clinical Research Unit — Birmingham, United States","Preferred Research Partners-NWA, LLC — Fayetteville, United States","Preferred Research Partners, Inc. — Little Rock, United States","Kadima Neuropsychiatry Institute — La Jolla, United States","West LA VA Medical Center - Mental Health Department — Los Angeles, United States","Pacific Neuroscience Institute (PNI) at Saint John's Physician Partners — Santa Monica, United States","Psychedelic Science Institute — Santa Monica, United States","Mountain View Clinical Research — Denver, United States"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"enroll":238,"eid":"NCT06308653"},{"id":"study-NCT06303739","cat":"studies","name":"Psilocybin-Assisted Therapy in Treatment-Resistant Depression","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 3","sponsor":"University of North Carolina, Chapel Hill","drugs":["psilocybin"],"nct":"NCT06303739","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-04-19","official":"Robert K McClure, MD (Director of Interventional Psychiatry)","src":"https://clinicaltrials.gov/study/NCT06303739","sites":["UNC Chapel Hill Medical Center — Chapel Hill, United States"],"conds":["Refractory Depression","Treatment Resistant Depression"],"condg":["Depression"],"enroll":20,"eid":"NCT06303739"},{"id":"study-NCT06416085","cat":"studies","name":"Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"University Health Network, Toronto","drugs":["psilocybin"],"nct":"NCT06416085","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2024-06-06","official":"Sarah Hales, MD (University Health Network, Toronto)","src":"https://clinicaltrials.gov/study/NCT06416085","sites":["Princess Margaret Cancer Centre — Toronto, Canada"],"conds":["Advanced Cancer","Stage IV Solid Tumor Cancer","Stage IV Sarcoma of Bone","Stage IV Lymphoma","Stage IV Melanoma","Endocrine Cancer"],"condg":["Cancer-related distress"],"enroll":15,"eid":"NCT06416085"},{"id":"study-NCT06407635","cat":"studies","name":"A Study of Psilocybin for PTSD","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT06407635","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-06-07","official":"Sandeep Nayak, MD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06407635","sites":["Johns Hopkins Center for Psychedelic and Consciousness Research — Baltimore, United States"],"conds":["Post Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":20,"eid":"NCT06407635"},{"id":"study-NCT06565494","cat":"studies","name":"MDMA-Assisted Therapy for Pathological Narcissism","status":"ACTIVE_NOT_RECRUITING","phase":"EARLY_Phase 1","sponsor":"University of Washington","drugs":["MDMA"],"nct":"NCT06565494","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-08-27","official":"Anthony Back, MD (University of Washington); Alexa Albert, MD (University of Washington)","src":"https://clinicaltrials.gov/study/NCT06565494","sites":["University of Washington — Seattle, United States"],"conds":["Narcissism"],"condg":["Other"],"enroll":12,"eid":"NCT06565494"},{"id":"study-NCT06496750","cat":"studies","name":"Ketamine for Methamphetamine Use Disorder","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"University of Texas Southwestern Medical Center","drugs":["ketamine"],"nct":"NCT06496750","nsites":5,"countries":"United States","ccs":["US"],"start":"2024-09-11","official":"Madhukar Trivedi, MD (Professor (Tenured))","src":"https://clinicaltrials.gov/study/NCT06496750","sites":["Alameda Health System — San Leandro, United States","Interdisciplinary Substance Use and Brain Injury Facility — Albuquerque, United States","Addiction Institute of Mount Sinai — New York, United States","Prisma Health — Greenville, United States","UT Southwestern Medical Center — Dallas, United States"],"conds":["Substance Use Disorders","Substance Use","Methamphetamine Abuse"],"condg":["Addiction & substance use"],"enroll":120,"eid":"NCT06496750"},{"id":"study-NCT06506019","cat":"studies","name":"Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1","sponsor":"University Health Network, Toronto","drugs":["psilocybin"],"nct":"NCT06506019","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2024-10-09","official":"Joshua Rosenblat, MD, MSc (University Health Network, Toronto)","src":"https://clinicaltrials.gov/study/NCT06506019","sites":["Toronto Western Hospital - University Health Network — Toronto, Canada"],"conds":["Bipolar Depression"],"condg":["Depression","Bipolar"],"enroll":30,"eid":"NCT06506019"},{"id":"study-NCT06117306","cat":"studies","name":"MDMA-assisted Massed Prolonged Exposure for PTSD","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 3","sponsor":"Healing Breakthrough","drugs":["MDMA"],"nct":"NCT06117306","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-10-25","official":"Leslie Morland, Psy.D. (San Diego Veterans Affairs Health System)","src":"https://clinicaltrials.gov/study/NCT06117306","sites":["VA San Diego Healthcare System, San Diego, CA — San Diego, United States"],"conds":["Post-Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":20,"eid":"NCT06117306"},{"id":"study-NCT06069843","cat":"studies","name":"Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"Icahn School of Medicine at Mount Sinai","drugs":["ketamine"],"nct":"NCT06069843","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-11-01","official":"Rachel Fremont, MD, PhD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT06069843","sites":["Icahn School of Medicine at Mount Sinai (Depression and Anxiety Center) — New York, United States"],"conds":["Depression","Mild Cognitive Impairment"],"condg":["Depression","Neurology & cognition"],"enroll":15,"eid":"NCT06069843"},{"id":"study-NCT06731621","cat":"studies","name":"Psilocybin for Treatment-Resistant Depression in Autism","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1","sponsor":"Centre for Addiction and Mental Health","drugs":["psilocybin"],"nct":"NCT06731621","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2024-11-01","official":"Hsiang-Yuan Lin, MD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT06731621","sites":["Centre for Addiction and Mental Health — Toronto, Canada"],"conds":["Treatment Resistant Depression","Autism Spectrum Disorder"],"condg":["Depression"],"enroll":20,"eid":"NCT06731621"},{"id":"study-NCT07199179","cat":"studies","name":"Link Between Reduction of Suicide Ideation by Esketamine in Add-On and Initial Levels of Psychological Pain and Anhedonia","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Montpellier","drugs":["esketamine","ketamine"],"nct":"NCT07199179","nsites":1,"countries":"France","ccs":["FR"],"start":"2024-11-24","src":"https://clinicaltrials.gov/study/NCT07199179","sites":["Chu Montpellier — Montpellier, France"],"conds":["Depression - Major Depressive Disorder","Depression Disorder","Suicide"],"condg":["Depression"],"enroll":456,"eid":"NCT07199179"},{"id":"study-NCT06741228","cat":"studies","name":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 3","sponsor":"Definium Therapeutics US, Inc.","drugs":["LSD"],"nct":"NCT06741228","nsites":34,"countries":"United States","ccs":["US"],"start":"2024-12-11","src":"https://clinicaltrials.gov/study/NCT06741228","sites":["Lighthouse Psychiatry — Gilbert, United States","Scottsdale Research Institute — Scottsdale, United States","Kadima Neuropsychiatry Institute — La Jolla, United States","UCSF Department of Neurology — San Francisco, United States","Psychedelic Science Institute — Santa Monica, United States","Mountain View — Denver, United States","Clinical Neuroscience Solutions Inc. — Jacksonville, United States","Segal Trials — Lauderhill, United States"],"conds":["Generalized Anxiety Disorder"],"condg":["Anxiety"],"enroll":214,"eid":"NCT06741228"},{"id":"study-NCT06564818","cat":"studies","name":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 3","sponsor":"Cybin IRL Limited","drugs":["psilocybin"],"nct":"NCT06564818","nsites":45,"countries":"United States","ccs":["US"],"start":"2024-12-17","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","sites":["Scottsdale Research Institute — Phoenix, United States","Mountain Clinical Trials — Phoenix, United States","Noble Clinical Research — Tucson, United States","Del Sol Research Management — Tucson, United States","CenExel CIT (Clinical Innovations, Inc) — Bellflower, United States","Kadima Neuropsychiatry Institute — La Jolla, United States","Bespoke Treatment/Lipov Medical Group — Los Angeles, United States","Catalina Research Institute — Montclair, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":220,"eid":"NCT06564818"},{"id":"study-NCT07556172","cat":"studies","name":"Clinical Study of Esketamine in Patients With Sepsis Undergoing Invasive Mechanical Ventilation","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 4","sponsor":"Second Affiliated Hospital of Nanchang University","drugs":["esketamine"],"nct":"NCT07556172","nsites":1,"countries":"China","ccs":["CN"],"start":"2025-01-01","src":"https://clinicaltrials.gov/study/NCT07556172","sites":["The Second Affiliated Hospital of Nanchang University — Nanchang, China"],"conds":["Sepsis","Mechanical Ventilation"],"condg":["Other"],"enroll":80,"eid":"NCT07556172"},{"id":"study-NCT06698848","cat":"studies","name":"Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1","sponsor":"Massachusetts General Hospital","drugs":["ketamine"],"nct":"NCT06698848","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-01-01","src":"https://clinicaltrials.gov/study/NCT06698848","sites":["Massachusetts General Hosipital — Boston, United States"],"conds":["Depression","Suicide"],"condg":["Depression"],"enroll":120,"eid":"NCT06698848"},{"id":"study-NCT06317636","cat":"studies","name":"Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 4","sponsor":"Stanford University","drugs":["ketamine"],"nct":"NCT06317636","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-01-28","official":"Theresa Lii, MD, MS (Stanford University)","src":"https://clinicaltrials.gov/study/NCT06317636","sites":["Stanford University — Stanford, United States"],"conds":["Chronic Pain","Depression"],"condg":["Depression","Chronic pain & headache"],"enroll":40,"eid":"NCT06317636"},{"id":"study-NCT06809595","cat":"studies","name":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 3","sponsor":"Definium Therapeutics US, Inc.","drugs":["LSD"],"nct":"NCT06809595","nsites":36,"countries":"Czechia; France; Germany; Poland; United Kingdom; United States","ccs":["CZ","DE","FR","GB","PL","US"],"start":"2025-01-29","src":"https://clinicaltrials.gov/study/NCT06809595","sites":["Preferred Research Partners, Inc. — Little Rock, United States","Psychedelic Science Institute — Los Angeles, United States","West Los Angeles VA Medical Center — Los Angeles, United States","Bradenton Research Center, Inc. — Bradenton, United States","Clinical Neuroscience Solutions, Inc — Orlando, United States","Atlanta Center for Medical Research — Atlanta, United States","Sheppard Pratt Health System — Towson, United States","Adams Clinical Boston — Boston, United States"],"conds":["Generalized Anxiety Disorder"],"condg":["Anxiety"],"enroll":245,"eid":"NCT06809595"},{"id":"study-NCT07189988","cat":"studies","name":"Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Healing Advocacy Fund","drugs":["psilocybin"],"nct":"NCT07189988","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-03-05","official":"Noah Craft, MD (People Science, Inc.)","src":"https://clinicaltrials.gov/study/NCT07189988","sites":["Innertrek Patient Service Center — Portland, United States"],"conds":["Alcohol Use Disorder"],"condg":["Addiction & substance use"],"enroll":20,"eid":"NCT07189988"},{"id":"study-NCT06225232","cat":"studies","name":"Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"McMaster University","drugs":["psilocybin"],"nct":"NCT06225232","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2025-03-21","src":"https://clinicaltrials.gov/study/NCT06225232","sites":["MacAnxiety Research Centre — Hamilton, Canada"],"conds":["Cannabis Use Disorder, Moderate","Cannabis Use Disorder, Severe"],"condg":["Addiction & substance use"],"enroll":16,"eid":"NCT06225232"},{"id":"study-NCT06941844","cat":"studies","name":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 3","sponsor":"Definium Therapeutics US, Inc.","drugs":["LSD"],"nct":"NCT06941844","nsites":22,"countries":"United States","ccs":["US"],"start":"2025-04-14","src":"https://clinicaltrials.gov/study/NCT06941844","sites":["Preferred Research Partners, Inc — Little Rock, United States","Kadima Neuropsychiatry Institute — La Jolla, United States","Psychedelic Science Institute — Santa Monica, United States","Mountain View Clinical Research, Inc — Denver, United States","CNS, LLC (Jacksonville) — Jacksonville, United States","CNS, LLC (Orlando) — Orlando, United States","Charter Research — Orlando, United States","Uptown Research Institute (URI), LLC — Chicago, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":149,"eid":"NCT06941844"},{"id":"study-NCT07463911","cat":"studies","name":"Treatment Response In ECT Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nurdan Sağbaş","drugs":["ketamine"],"nct":"NCT07463911","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2025-05-20","official":"ceyhan M şengül balcı (Pamukkale University)","src":"https://clinicaltrials.gov/study/NCT07463911","sites":["Pamukkale University — Denizli, Turkey"],"conds":["Major Depression","Bipolar Affective Disorder","Bipolar Depression Depressed Phase"],"condg":["Depression","Bipolar"],"enroll":65,"eid":"NCT07463911"},{"id":"study-NCT06853912","cat":"studies","name":"PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"Nathan Brashares Sackett","drugs":["psilocybin"],"nct":"NCT06853912","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-06-01","official":"Nathan B Sackett, MD (University of Washington)","src":"https://clinicaltrials.gov/study/NCT06853912","sites":["University of Washington Center for Novel Therapeutics in Addiction Psychiatry — Seattle, United States"],"conds":["Alcohol Use Disorder (AUD)","PTSD"],"condg":["PTSD & trauma","Addiction & substance use"],"enroll":40,"eid":"NCT06853912"},{"id":"study-NCT07066306","cat":"studies","name":"Effects of Local Ketamine in Orthognathic Procedures","status":"ACTIVE_NOT_RECRUITING","phase":"N/A","sponsor":"Bezmialem Vakif University","drugs":["ketamine"],"nct":"NCT07066306","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2025-06-21","src":"https://clinicaltrials.gov/study/NCT07066306","sites":["Bezmialem Vakıf Universty — Istanbul, Turkey"],"conds":["Dentofacial Deformities","Analgesia","Vomiting, Postoperative","Nausea, Postoperative"],"condg":["Other"],"enroll":40,"eid":"NCT07066306"},{"id":"study-NCT07034950","cat":"studies","name":"Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1/Phase 2","sponsor":"The First Affiliated Hospital of Xiamen University","drugs":["esketamine"],"nct":"NCT07034950","nsites":1,"countries":"China","ccs":["CN"],"start":"2025-06-29","official":"Lijuan Yan (Department of Anesthesiology, The First Affiliated Hospital of Xiamen University)","src":"https://clinicaltrials.gov/study/NCT07034950","sites":["Department of Anesthesiology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, China — Xiamen, China"],"conds":["Hepatic Neoplasm","Hepatic Cancer"],"condg":["Cancer-related distress"],"enroll":79,"eid":"NCT07034950"},{"id":"study-NCT07165262","cat":"studies","name":"Effect of Different Anesthetic Drugs on Electrocorticography (ECOG).","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 3","sponsor":"Children's Cancer Hospital Egypt 57357","drugs":["ketamine"],"nct":"NCT07165262","nsites":2,"countries":"Egypt","ccs":["EG"],"start":"2025-08-18","official":"Suzan A. Abdelrahman, consultant (Children's Cancer Hospital Egypt 57357)","src":"https://clinicaltrials.gov/study/NCT07165262","sites":["Children's Cancer Hospital Egypt 57357 — Cairo, Egypt","Children Cancer Hospital 57357 — Cairo, Egypt"],"conds":["Epilepsy","Brain Tumor"],"condg":["Neurology & cognition"],"enroll":88,"eid":"NCT07165262"},{"id":"study-NCT07057193","cat":"studies","name":"Effect of Different Drugs on Emergency Delirium in Preschool Age Patient","status":"ACTIVE_NOT_RECRUITING","phase":"N/A","sponsor":"Zagazig University","drugs":["ketamine"],"nct":"NCT07057193","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2026-01-15","src":"https://clinicaltrials.gov/study/NCT07057193","sites":["Faculty of Medicine Zagazig University — Zagazig, Egypt"],"conds":["Emergence Delirium, Anesthesia"],"condg":["Other"],"enroll":92,"eid":"NCT07057193"},{"id":"study-NCT07513935","cat":"studies","name":"Comparison of Combined Dexmedetomidine and Ketamine (Ketodex) Versus Dexmedetomidine Alone in Awake Mapping for Deep Brain Stimulation: A Randomized Controlled Trial","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 4","sponsor":"Ain Shams University","drugs":["ketamine"],"nct":"NCT07513935","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2026-03-03","src":"https://clinicaltrials.gov/study/NCT07513935","sites":["Ainshams University — Cairo, Egypt"],"conds":["Intraoperative Awareness"],"condg":["Other"],"enroll":24,"eid":"NCT07513935"},{"id":"study-NCT07396272","cat":"studies","name":"A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"Daniel Lindqvist","drugs":["ketamine"],"nct":"NCT07396272","nsites":1,"countries":"Sweden","ccs":["SE"],"start":"2026-03-13","official":"Daniel Lindqvist, PhD, MD (Region Skane)","src":"https://clinicaltrials.gov/study/NCT07396272","sites":["Adult Psychiatry — Lund, Sweden"],"conds":["Major Depressive Disorder (MDD)"],"condg":["Depression"],"enroll":12,"eid":"NCT07396272"},{"id":"study-NCT07275970","cat":"studies","name":"Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1","sponsor":"Scottsdale Research Institute","drugs":["psilocybin"],"nct":"NCT07275970","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-03-20","src":"https://clinicaltrials.gov/study/NCT07275970","sites":["Scottsdale Research Institute — Scottsdale, United States"],"conds":["PTSD"],"condg":["PTSD & trauma"],"enroll":24,"eid":"NCT07275970"},{"id":"study-NCT07584720","cat":"studies","name":"Study of Midomafetamine in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 1","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT07584720","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-04-23","src":"https://clinicaltrials.gov/study/NCT07584720","sites":["Dr. Vince Clinical Research — Overland Park, United States"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":32,"eid":"NCT07584720"},{"id":"study-NCT07179913","cat":"studies","name":"The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 4","sponsor":"The First Hospital of Jilin University","drugs":["esketamine"],"nct":"NCT07179913","nsites":1,"countries":"China","ccs":["CN"],"start":"2026-05-01","official":"Zhiwen Li, Doctor of Medicine (The First Hospital of Jilin University)","src":"https://clinicaltrials.gov/study/NCT07179913","sites":["Zhiwen Li — Changchun, China"],"conds":["Depressed","Bariatric Surgery"],"condg":["Depression"],"enroll":40,"eid":"NCT07179913"},{"id":"study-NCT07336238","cat":"studies","name":"Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","phase":"Phase 2","sponsor":"University of Washington","drugs":["psilocybin"],"nct":"NCT07336238","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-05-19","official":"Anthony Back, MD (Fred Hutch/University of Washington Cancer Consortium)","src":"https://clinicaltrials.gov/study/NCT07336238","sites":["Fred Hutch/University of Washington Cancer Consortium — Seattle, United States"],"conds":["Anxiety","Depression","Hematopoietic and Lymphatic System Neoplasm","Metastatic Malignant Solid Neoplasm"],"condg":["Depression","Anxiety","Cancer-related distress"],"enroll":18,"eid":"NCT07336238"},{"id":"study-NCT01858103","cat":"studies","name":"BMN 110 US Expanded Access Program","status":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","drugs":["LSD"],"nct":"NCT01858103","nsites":25,"countries":"Puerto Rico; United States","ccs":["PR","US"],"src":"https://clinicaltrials.gov/study/NCT01858103","sites":["Unnamed trial site — Birmingham, United States","Unnamed trial site — Little Rock, United States","Unnamed trial site — Oakland, United States","Unnamed trial site — Orange, United States","Unnamed trial site — Aurora, United States","Unnamed trial site — Washington D.C., United States","Unnamed trial site — Hollywood, United States","Unnamed trial site — Miami, United States"],"conds":["Mucopolysaccharidosis IVA","Morquio A Syndrome","MPS IVA"],"condg":["Other"],"eid":"NCT01858103"},{"id":"study-NCT04438512","cat":"studies","name":"A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD","status":"NO_LONGER_AVAILABLE","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT04438512","nsites":2,"countries":"United States","ccs":["US"],"official":"Manish Agrawal, MD (Sunstone Medical, PC); Caroline Lewis, MD (Pearl Psychedelic Institute)","src":"https://clinicaltrials.gov/study/NCT04438512","sites":["Sunstone Medical, PC — Rockville, United States","Pearl Psychedelic Institute — Waynesville, United States"],"conds":["Post Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"eid":"NCT04438512"},{"id":"study-NCT03829579","cat":"studies","name":"Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)","status":"APPROVED_FOR_MARKETING","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT03829579","nsites":0,"official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03829579","conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"eid":"NCT03829579"},{"id":"study-NCT00588952","cat":"studies","name":"Ketamine/Placebo Family History Positive Study","status":"COMPLETED","phase":"N/A","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT00588952","nsites":1,"countries":"United States","ccs":["US"],"start":"2001-03","official":"Ismene L. Petrakis, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT00588952","sites":["VA Connecticut Healthcare System — West Haven, United States"],"conds":["Alcoholism"],"condg":["Addiction & substance use"],"enroll":99,"eid":"NCT00588952"},{"id":"study-NCT00895804","cat":"studies","name":"Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT00895804","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2001-06","official":"Matthias E Liechti, MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT00895804","sites":["Heffter Research Center, University Hospital of Psychiatry — Zurich, Switzerland"],"conds":["Mood Disorder","Substance-Related Disorders","Amphetamine-Related Disorders"],"condg":["Addiction & substance use"],"enroll":16,"eid":"NCT00895804"},{"id":"study-NCT00978757","cat":"studies","name":"The Effect of Ketamine on Interleukin-6 Synthesis in Hepatic Resections Requiring Temporary Porto-arterial Occlusion","status":"COMPLETED","phase":"Phase 4","sponsor":"Hospital Italiano de Buenos Aires","drugs":["ketamine"],"nct":"NCT00978757","nsites":1,"countries":"Argentina","ccs":["AR"],"start":"2001-06","official":"Francisco C Bonofiglio, MD PhD (Hospital Italiano of Buenos Aires, Argentina)","src":"https://clinicaltrials.gov/study/NCT00978757","sites":["Hospital Italiano de Buenos Aires — Buenos Aires, Argentina"],"conds":["Hepatectomy"],"condg":["Other"],"enroll":42,"eid":"NCT00978757"},{"id":"study-NCT00235768","cat":"studies","name":"The NeXT Study; The Netherlands XTC Toxicity Study","status":"COMPLETED","sponsor":"UMC Utrecht","drugs":["MDMA"],"nct":"NCT00235768","nsites":3,"countries":"Netherlands","ccs":["NL"],"start":"2002-04","official":"Wim van den Brink, MD PhD (University of Amsterdam, Academic Medical Center Amsterdam, Dep of Psychiatry); Nick F Ramsey, PhD (University Medical Center…","src":"https://clinicaltrials.gov/study/NCT00235768","sites":["Bonger Institute of Criminology — Amsterdam, Netherlands","Academic Medical Center Amsterdam — Amsterdam, Netherlands","University Medical Center Utrecht — Utrecht, Netherlands"],"conds":["Ecstasy (Drug)","N-Methyl-3,4-Methylenedioxymethamphetamine","Psychopathology"],"condg":["Addiction & substance use"],"enroll":225,"eid":"NCT00235768"},{"id":"study-NCT00387556","cat":"studies","name":"Ondansetron Reduce Vomiting Associated With Ketamine PSA","status":"COMPLETED","phase":"N/A","sponsor":"University of Colorado, Denver","drugs":["ketamine"],"nct":"NCT00387556","nsites":1,"countries":"United States","ccs":["US"],"start":"2002-12","official":"Joe E Wathen, MD (University of Colorado Health Science Center)","src":"https://clinicaltrials.gov/study/NCT00387556","sites":["The Childrens Hospital — Denver, United States"],"conds":["Conscious Sedation"],"condg":["Other"],"enroll":268,"eid":"NCT00387556"},{"id":"study-NCT00690170","cat":"studies","name":"Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT00690170","nsites":1,"countries":"United States","ccs":["US"],"start":"2002-12","official":"Deepak C D'Souza, M.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT00690170","sites":["Veterans Administration Hospital — West Haven, United States"],"conds":["Healthy Subjects"],"condg":["Healthy volunteers"],"enroll":30,"eid":"NCT00690170"},{"id":"study-NCT00224588","cat":"studies","name":"KETOR: Effects of Peri Operative Administration of Ketamine on Long Term Post Thoracotomy Pain","status":"COMPLETED","phase":"Phase 3","sponsor":"Assistance Publique - Hôpitaux de Paris","drugs":["ketamine"],"nct":"NCT00224588","nsites":1,"countries":"France","ccs":["FR"],"start":"2003-01","official":"Thierry GUENOUN, MD (Assistance Publique - Hôpitaux de Paris)","src":"https://clinicaltrials.gov/study/NCT00224588","sites":["Georges Pompidou European Hospital — Paris, France"],"conds":["Ketamine","Chronic Post Thoracotomy Pain","Thoracotomy","Pain","Neuralgia"],"condg":["Chronic pain & headache"],"enroll":80,"eid":"NCT00224588"},{"id":"study-NCT00205712","cat":"studies","name":"Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids","status":"COMPLETED","phase":"Phase 4","sponsor":"Washington University School of Medicine","drugs":["ketamine"],"nct":"NCT00205712","nsites":1,"countries":"United States","ccs":["US"],"start":"2003-02","official":"John W. Newcomer, M.D. (Washington University School of Medicine and Florida Atlantic University)","src":"https://clinicaltrials.gov/study/NCT00205712","sites":["Washington University School of Medicine, Psychiatry Dept. — St Louis, United States"],"conds":["Psychoses, Substance-Induced"],"condg":["Addiction & substance use"],"enroll":40,"eid":"NCT00205712"},{"id":"study-NCT00300794","cat":"studies","name":"Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia","status":"COMPLETED","phase":"Phase 4","sponsor":"Vilnius University","drugs":["ketamine"],"nct":"NCT00300794","nsites":1,"countries":"Lithuania","ccs":["LT"],"start":"2003-02","official":"Juozas Ivaskevicius, Prof. (Vilnius University Clinic of Anaesthesiology and Intensive Care); Tomas Jovaisa, MD (Vilnius University Clinic of Anaesthesiology…","src":"https://clinicaltrials.gov/study/NCT00300794","sites":["Vilnius University Emergency Hospital — Vilnius, Lithuania"],"conds":["Opiate Dependence"],"condg":["Other"],"enroll":60,"eid":"NCT00300794"},{"id":"study-NCT01447472","cat":"studies","name":"-Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms","status":"COMPLETED","phase":"Phase 1","sponsor":"Parc de Salut Mar","drugs":["MDMA"],"nct":"NCT01447472","nsites":1,"countries":"Spain","ccs":["ES"],"start":"2003-05","official":"Magí Farre, PhD (IMIM-Hospital del Mar (Institut de Recerca Hospital del Mar))","src":"https://clinicaltrials.gov/study/NCT01447472","sites":["IMIM-Hospital del Mar (Institut de Recerca Hospital del Mar) — Barcelona, Spain"],"conds":["Metabolism","Interaction"],"condg":["Other"],"enroll":27,"eid":"NCT01447472"},{"id":"study-NCT01146145","cat":"studies","name":"Efficacity, Safety and Cost of Intravenous Morphine Titration Alone or Combined to Ketamine","status":"COMPLETED","phase":"N/A","sponsor":"Assistance Publique - Hôpitaux de Paris","drugs":["ketamine"],"nct":"NCT01146145","nsites":1,"countries":"France","ccs":["FR"],"start":"2003-05","official":"Hawa Keita (Assistance Publique - Hôpitaux de Paris)","src":"https://clinicaltrials.gov/study/NCT01146145","sites":["Hopital Louis Mourier — Colombes, France"],"conds":["Postoperative Pain"],"condg":["Chronic pain & headache"],"enroll":160,"eid":"NCT01146145"},{"id":"study-NCT01148342","cat":"studies","name":"Neurobiology and Pharmacokinets of Acute MDMA Administration","status":"COMPLETED","phase":"Phase 1","sponsor":"National Institute on Drug Abuse (NIDA)","drugs":["MDMA"],"nct":"NCT01148342","nsites":1,"countries":"United States","ccs":["US"],"start":"2004-02-10","official":"Marilyn Huestis, Ph.D. (National Institute on Drug Abuse (NIDA))","src":"https://clinicaltrials.gov/study/NCT01148342","sites":["National Institute on Drug Abuse, Biomedical Research Center (BRC) — Baltimore, United States"],"conds":["Substance-Related Disorders"],"condg":["Addiction & substance use"],"enroll":187,"eid":"NCT01148342"},{"id":"study-NCT00115102","cat":"studies","name":"Sensory Examination and Pharmacological Modulation of Oral Hyperexcitability in Patients With Atypical Odontalgia and Matched Healthy Controls","status":"COMPLETED","phase":"Phase 4","sponsor":"University of Aarhus","drugs":["esketamine","ketamine"],"nct":"NCT00115102","nsites":1,"countries":"Denmark","ccs":["DK"],"start":"2004-03","official":"Troels Staehelin Jensen, MD, PhD, Dr.Sci (Aarhus University Hospital)","src":"https://clinicaltrials.gov/study/NCT00115102","sites":["Danish Pain Research Center — Aarhus, Denmark"],"conds":["Odontalgia"],"condg":["Other"],"enroll":20,"eid":"NCT00115102"},{"id":"study-NCT00090064","cat":"studies","name":"MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder","status":"COMPLETED","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT00090064","nsites":1,"countries":"United States","ccs":["US"],"start":"2004-03-12","official":"Michael Mithoefer, MD (Private Practice)","src":"https://clinicaltrials.gov/study/NCT00090064","sites":["Offices of Michael Mithoefer MD — Mt. Pleasant, United States"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":23,"eid":"NCT00090064"},{"id":"study-NCT00302744","cat":"studies","name":"Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","drugs":["psilocybin"],"nct":"NCT00302744","nsites":1,"countries":"United States","ccs":["US"],"start":"2004-04","official":"Charles S. Grob, MD (University of California, Los Angeles)","src":"https://clinicaltrials.gov/study/NCT00302744","sites":["Harbor-UCLA Medical Center — Torrance, United States"],"conds":["Anxiety"],"condg":["Anxiety"],"enroll":12,"eid":"NCT00302744"},{"id":"study-NCT00252122","cat":"studies","name":"Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease","status":"TERMINATED","phase":"Phase 4","sponsor":"Children's Hospital of Philadelphia","drugs":["ketamine"],"nct":"NCT00252122","nsites":1,"countries":"United States","ccs":["US"],"start":"2004-06","official":"Arjunan Ganesh, MD (Children's Hospital of Philadelphia)","src":"https://clinicaltrials.gov/study/NCT00252122","sites":["The Children's Hospital of Philadelphia — Philadelphia, United States"],"conds":["Sickle Cell Disease"],"condg":["Other"],"enroll":3,"eid":"NCT00252122"},{"id":"study-NCT00556361","cat":"studies","name":"Use of Ketamine Prior to Cardiopulmonary Bypass in Children","status":"COMPLETED","phase":"Phase 2","sponsor":"Arkansas Children's Hospital Research Institute","drugs":["ketamine"],"nct":"NCT00556361","nsites":1,"countries":"United States","ccs":["US"],"start":"2004-07","official":"Adnan T Bhutta, MD (Arkansas Children's Hospital Research Institute)","src":"https://clinicaltrials.gov/study/NCT00556361","sites":["Arkansas Children's Hospital — Little Rock, United States"],"conds":["Ventricular Septal Defect"],"condg":["Other"],"enroll":24,"eid":"NCT00556361"},{"id":"study-NCT00088699","cat":"studies","name":"Rapid Antidepressant Effects of Ketamine in Major Depression","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"National Institute of Mental Health (NIMH)","drugs":["ketamine"],"nct":"NCT00088699","nsites":1,"countries":"United States","ccs":["US"],"start":"2004-07-26","official":"Carlos A Zarate, M.D. (National Institute of Mental Health (NIMH))","src":"https://clinicaltrials.gov/study/NCT00088699","sites":["National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, United States"],"conds":["Depression","Mood Disorders","Major Depresssion"],"condg":["Depression"],"enroll":67,"eid":"NCT00088699"},{"id":"study-NCT00232492","cat":"studies","name":"Ketamine on Acute Pain in Females and Males","status":"COMPLETED","phase":"Phase 4","sponsor":"Ullevaal University Hospital","drugs":["ketamine"],"nct":"NCT00232492","nsites":1,"countries":"Norway","ccs":["NO"],"start":"2005-01","official":"Lasse A Skoglund, DDS, PhD (Section of Dental Pharmacology and Pharmacotherapy, Faculty of Dentistry, POB 1119 Blindern, University of Oslo, N-0317 Oslo,…","src":"https://clinicaltrials.gov/study/NCT00232492","sites":["Department of Oral and Maxillofacial Surgery, Ullevaal University Hospital — Oslo, Norway"],"conds":["Mouth and Tooth Diseases","Tooth, Impacted"],"condg":["Other"],"enroll":128,"eid":"NCT00232492"},{"id":"study-NCT00437814","cat":"studies","name":"Effect of Ketamine (Ketalar) on Intracranial Pressure","status":"UNKNOWN","phase":"N/A","sponsor":"Rambam Health Care Campus","drugs":["ketamine"],"nct":"NCT00437814","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2005-09","official":"Gad Bar-Joseph, MD (Director, Pediatric ICU, Rambam Medical Center)","src":"https://clinicaltrials.gov/study/NCT00437814","sites":["Pediatric ICU, Rambam Medical Center — Haifa, Israel"],"conds":["Traumatic Brain Injury","Intracranial Hypertension"],"condg":["PTSD & trauma","Neurology & cognition"],"contact":{"n":"Gad Bar-Joseph, MD","p":"972-4-8542855","e":"g_barjoseph@rambam.health.gov.il"},"enroll":30,"eid":"NCT00437814"},{"id":"study-NCT00146926","cat":"studies","name":"Comparison of Three Different Strategies to Prevent Propofol Induced Pain During Infusion","status":"UNKNOWN","phase":"Phase 3","sponsor":"Hospices Civils de Lyon","drugs":["ketamine"],"nct":"NCT00146926","nsites":1,"countries":"France","ccs":["FR"],"start":"2005-09","official":"Vincent PIRIOU, MD (Hospices Civils de Lyon)","src":"https://clinicaltrials.gov/study/NCT00146926","sites":["Grégoire CHATAIN — Lyon, France"],"conds":["Induction of Total Intravenous General Anesthesia"],"condg":["Other"],"enroll":200,"eid":"NCT00146926"},{"id":"study-NCT01947114","cat":"studies","name":"Remifentanil Use in Pediatric Rigid Bronchoscopy","status":"COMPLETED","phase":"Phase 4","sponsor":"Bezmialem Vakif University","drugs":["ketamine"],"nct":"NCT01947114","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2005-11","src":"https://clinicaltrials.gov/study/NCT01947114","sites":["Bezmialem Vakif University Faculty of Medicine — Istanbul, Turkey"],"conds":["Pediatric Rigid Bronchoscopy"],"condg":["Other"],"enroll":40,"eid":"NCT01947114"},{"id":"study-NCT00534586","cat":"studies","name":"Anesthetics and Auditory, Visceral, and Heat Evoked Potentials","status":"COMPLETED","phase":"Phase 4","sponsor":"Technical University of Munich","drugs":["esketamine","ketamine"],"nct":"NCT00534586","nsites":1,"countries":"Germany","ccs":["DE"],"start":"2005-12","official":"Eberhard Kochs, MD (Technical University of Munich)","src":"https://clinicaltrials.gov/study/NCT00534586","sites":["Technische Universität München, Klinikum rechts der Isar, Department of Anesthesiology — Munich, Germany"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":60,"eid":"NCT00534586"},{"id":"study-NCT00254306","cat":"studies","name":"Functional Brain Imaging in Recreational Users of Ecstasy","status":"COMPLETED","sponsor":"Hadassah Medical Organization","drugs":["MDMA"],"nct":"NCT00254306","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2006-01","official":"Yodphat Krausz, MD (Hadassah Medical Organization); Aviv M Weinstein, Ph.D (Hadassah Medical Organization)","src":"https://clinicaltrials.gov/study/NCT00254306","sites":["Dept. of Nuclear Medicine, Hadassah Hospital, Ein Kerem — Jerusalem, Israel"],"conds":["Amphetamine-Related Disorders"],"condg":["Other"],"enroll":18,"eid":"NCT00254306"},{"id":"study-NCT00611897","cat":"studies","name":"N-acetylcysteine and NMDA Antagonist Interactions","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT00611897","nsites":1,"countries":"United States","ccs":["US"],"start":"2006-01","official":"Handan Gunduz-Bruce, M.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT00611897","sites":["VHA Connecticut — West Haven, United States"],"conds":["Cognitive Dysfunction"],"condg":["Neurology & cognition"],"enroll":16,"eid":"NCT00611897"},{"id":"study-NCT01296802","cat":"studies","name":"Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging","status":"COMPLETED","phase":"N/A","sponsor":"University of Zurich","drugs":["MDMA"],"nct":"NCT01296802","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2006-04","official":"Franz X Vollenweider, Prof. (Psychiatric University Hospital, Zurich); Boris B Quednow, Prof (Psychiatric University Hospital, Zurich)","src":"https://clinicaltrials.gov/study/NCT01296802","sites":["University Hospital of Psychiatry Zurich — Zurich, Switzerland"],"conds":["Amphetamine-Related Disorders","Amphetamine Abuse"],"condg":["Other"],"enroll":50,"eid":"NCT01296802"},{"id":"study-NCT00329394","cat":"studies","name":"Systemic Ketamine for the Improvement of Post-Operative Analgesia at the Alcohol-Dependent Patient","status":"SUSPENDED","phase":"Phase 3","sponsor":"University Hospital, Clermont-Ferrand","drugs":["ketamine"],"nct":"NCT00329394","nsites":1,"countries":"France","ccs":["FR"],"start":"2006-04","official":"Nicolas Rascol, Dr (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT00329394","sites":["Clermont-Ferrand University Hospital — Clermont-Ferrand, France"],"conds":["Alcoholic Patient","Carcinological Surgery ORL"],"condg":["Addiction & substance use"],"enroll":56,"eid":"NCT00329394"},{"id":"study-NCT00344682","cat":"studies","name":"Memantine Augmentation of Antidepressants","status":"COMPLETED","phase":"Phase 4","sponsor":"University of Massachusetts, Worcester","drugs":["ketamine"],"nct":"NCT00344682","nsites":1,"countries":"United States","ccs":["US"],"start":"2006-06","official":"Kristina M Deligiannidis, M.D. (University of Massachusetts, Worcester)","src":"https://clinicaltrials.gov/study/NCT00344682","sites":["Center for Psychopharmacologic Research and Treatment (University of Massachusetts Medical School) — Worcester, United States"],"conds":["Depressive Disorder"],"condg":["Depression"],"enroll":31,"eid":"NCT00344682"},{"id":"study-NCT00618397","cat":"studies","name":"Pharmacokinetics of Low Dose Ketamine Infusion","status":"TERMINATED","phase":"Phase 1","sponsor":"University of Texas Southwestern Medical Center","drugs":["ketamine"],"nct":"NCT00618397","nsites":1,"countries":"United States","ccs":["US"],"start":"2006-06","official":"Cindy Darnell, MD (University of Texas)","src":"https://clinicaltrials.gov/study/NCT00618397","sites":["Children's Medical Center Dallas, University of Texas Southwestern — Dallas, United States"],"conds":["Sedation","Opioid Tolerance"],"condg":["Addiction & substance use"],"enroll":5,"eid":"NCT00618397"},{"id":"study-NCT00486902","cat":"studies","name":"Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?","status":"COMPLETED","phase":"N/A","sponsor":"Northwestern University","drugs":["ketamine"],"nct":"NCT00486902","nsites":1,"countries":"United States","ccs":["US"],"start":"2006-07","official":"Cynthia A Wong, M.D. (Northwestern University)","src":"https://clinicaltrials.gov/study/NCT00486902","sites":["Northwestern University — Chicago, United States"],"conds":["Ketamine Adverse Reaction","Effects of; Anesthesia, Spinal and Epidural, in Pregnancy","Complication of Labor and/or Delivery"],"condg":["Other"],"enroll":188,"eid":"NCT00486902"},{"id":"study-NCT00579085","cat":"studies","name":"Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS","status":"COMPLETED","phase":"Phase 2","sponsor":"Drexel University College of Medicine","drugs":["ketamine"],"nct":"NCT00579085","nsites":1,"countries":"United States","ccs":["US"],"start":"2006-09","src":"https://clinicaltrials.gov/study/NCT00579085","sites":["Drexel University College of Medicine Department of Neurology — Philadelphia, United States"],"conds":["Complex Regional Pain Syndrome"],"condg":["Chronic pain & headache"],"enroll":40,"eid":"NCT00579085"},{"id":"study-NCT00353938","cat":"studies","name":"Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder","status":"COMPLETED","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT00353938","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2006-09-13","official":"Peter Oehen, MD (private practice, Biberist, Switzerland)","src":"https://clinicaltrials.gov/study/NCT00353938","sites":["Offices of Peter Oehen MD — Biberist, Switzerland"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":14,"eid":"NCT00353938"},{"id":"study-NCT00419003","cat":"studies","name":"Research Study for Major Depressive Disorder: Investigation of Glutamate Medications","status":"COMPLETED","phase":"Phase 4","sponsor":"Baylor College of Medicine","drugs":["ketamine"],"nct":"NCT00419003","nsites":1,"countries":"United States","ccs":["US"],"start":"2006-12","official":"Sanjay Mathew, MD (Baylor College of Medicine)","src":"https://clinicaltrials.gov/study/NCT00419003","sites":["Mount Sinai School of Medicine — New York, United States"],"conds":["Major Depression"],"condg":["Depression"],"enroll":26,"eid":"NCT00419003"},{"id":"study-NCT00611572","cat":"studies","name":"GABA-glutamate Interactions and Psychosis","status":"COMPLETED","phase":"Phase 1","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT00611572","nsites":1,"countries":"United States","ccs":["US"],"start":"2007-01","official":"Mohini Ranganathan, M.D. (Yale School of Medicine, Associate Professor)","src":"https://clinicaltrials.gov/study/NCT00611572","sites":["VHA Connecticut — West Haven, United States"],"conds":["Cognitive Dysfunction"],"condg":["Neurology & cognition"],"enroll":23,"eid":"NCT00611572"},{"id":"study-NCT01070108","cat":"studies","name":"Escalating Ketamine Doses and Pre-emption","status":"COMPLETED","phase":"N/A","sponsor":"Tel-Aviv Sourasky Medical Center","drugs":["ketamine"],"nct":"NCT01070108","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2007-01","src":"https://clinicaltrials.gov/study/NCT01070108","sites":["Tel Aviv Medical Center — Tel Aviv, Israel"],"conds":["Postoperative Pain Management"],"condg":["Chronic pain & headache"],"enroll":120,"eid":"NCT01070108"},{"id":"study-NCT00252174","cat":"studies","name":"MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer","status":"TERMINATED","phase":"Phase 2","sponsor":"Brigham and Women's Hospital","drugs":["MDMA"],"nct":"NCT00252174","nsites":1,"countries":"United States","ccs":["US"],"start":"2007-02","official":"John H Halpern, MD (Mclean Hospital)","src":"https://clinicaltrials.gov/study/NCT00252174","sites":["McLean Hospital — Belmont, United States"],"conds":["Anxiety Disorder","Cancer"],"condg":["Anxiety","Cancer-related distress"],"enroll":2,"eid":"NCT00252174"},{"id":"study-NCT00899600","cat":"studies","name":"Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain","status":"COMPLETED","phase":"N/A","sponsor":"Dartmouth-Hitchcock Medical Center","drugs":["ketamine"],"nct":"NCT00899600","nsites":1,"countries":"United States","ccs":["US"],"start":"2007-02","official":"Jeffrey A Clark, MD (DHMC)","src":"https://clinicaltrials.gov/study/NCT00899600","sites":["Dartmouth-Hitchcock Medical Center — Lebanon, United States"],"conds":["Chronic Low Back Pain"],"condg":["Chronic pain & headache"],"enroll":102,"eid":"NCT00899600"},{"id":"study-NCT00465595","cat":"studies","name":"Psychopharmacology of Psilocybin in Cancer Patients","status":"COMPLETED","phase":"Phase 2","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT00465595","nsites":1,"countries":"United States","ccs":["US"],"start":"2007-04","official":"Roland R Griffiths, Ph.D. (Johns Hopkins School of Medicine, Psychiatry Dept.)","src":"https://clinicaltrials.gov/study/NCT00465595","sites":["Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Campus — Baltimore, United States"],"conds":["Depressive Symptoms","Anxiety","Cancer"],"condg":["Depression","Anxiety","Cancer-related distress"],"enroll":56,"eid":"NCT00465595"},{"id":"study-NCT00484484","cat":"studies","name":"Ketamine Associated With Opioids in Refractory Cancer Pain Treatment","status":"COMPLETED","phase":"Phase 3","sponsor":"Assistance Publique - Hôpitaux de Paris","drugs":["ketamine"],"nct":"NCT00484484","nsites":1,"countries":"France","ccs":["FR"],"start":"2007-05","official":"Sylvie ROSTAING-RIGATTIERI, MD (Assistance Publique - Hôpitaux de Paris)","src":"https://clinicaltrials.gov/study/NCT00484484","sites":["Hopital Saint Antoine — Paris, France"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":100,"eid":"NCT00484484"},{"id":"study-NCT00402298","cat":"studies","name":"Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel","status":"TERMINATED","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT00402298","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2007-05-27","official":"Moshe Kotler (Director of Psychiatry, Beer Yaakov Mental Health Center)","src":"https://clinicaltrials.gov/study/NCT00402298","sites":["Be'er Ya'akov Mental Health Center — Be’er Ya‘aqov, Israel"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":5,"eid":"NCT00402298"},{"id":"study-NCT00519987","cat":"studies","name":"Multiple Dose Pharmacokinetics of Intranasal Ketamine","status":"COMPLETED","phase":"Phase 1","sponsor":"Javelin Pharmaceuticals","drugs":["ketamine"],"nct":"NCT00519987","nsites":0,"start":"2007-06","official":"Javelin Pharmaceuticals (Javelin Pharmaceuticals)","src":"https://clinicaltrials.gov/study/NCT00519987","conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":18,"eid":"NCT00519987"},{"id":"study-NCT00492388","cat":"studies","name":"Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients","status":"TERMINATED","phase":"Phase 3","sponsor":"Hospira, now a wholly owned subsidiary of Pfizer","drugs":["ketamine"],"nct":"NCT00492388","nsites":1,"countries":"United States","ccs":["US"],"start":"2007-06","official":"Zahid Bajwa, MD (Beth Israel Deaconess Medical Center)","src":"https://clinicaltrials.gov/study/NCT00492388","sites":["Beth Israel Deaconess Medical Center — Boston, United States"],"conds":["Pain","Cancer"],"condg":["Cancer-related distress","Chronic pain & headache"],"enroll":2,"eid":"NCT00492388"},{"id":"study-NCT00476151","cat":"studies","name":"A Study of the Efficacy and Safety of Amitriptyline/Ketamine Topical Cream in Patients With Diabetic Peripheral Neuropathy","status":"COMPLETED","phase":"Phase 2","sponsor":"EpiCept Corporation","drugs":["ketamine"],"nct":"NCT00476151","nsites":1,"countries":"India","ccs":["IN"],"start":"2007-07","official":"Robert H Dworkin, Ph.D. (University of Rochester)","src":"https://clinicaltrials.gov/study/NCT00476151","sites":["Multiple Centers — New Delhi, India"],"conds":["Diabetic Peripheral Neuropathy","Neuralgia"],"condg":["Chronic pain & headache"],"enroll":226,"eid":"NCT00476151"},{"id":"study-NCT00475904","cat":"studies","name":"A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)","status":"COMPLETED","phase":"Phase 2","sponsor":"EpiCept Corporation","drugs":["ketamine"],"nct":"NCT00475904","nsites":1,"countries":"India","ccs":["IN"],"start":"2007-07","official":"Robert H Dworkin, Ph.D. (University of Rochester)","src":"https://clinicaltrials.gov/study/NCT00475904","sites":["Multiple Centers — New Delhi, India"],"conds":["Post Herpetic Neuralgia","PHN","Neuropathy","Nerve Pain"],"condg":["Chronic pain & headache"],"enroll":360,"eid":"NCT00475904"},{"id":"study-NCT00553839","cat":"studies","name":"Pharmacokinetics of Ketamine in Infants and Children","status":"COMPLETED","phase":"N/A","sponsor":"Stanford University","drugs":["ketamine"],"nct":"NCT00553839","nsites":2,"countries":"United States","ccs":["US"],"start":"2007-07","official":"Chandra Ramamoorthy, MBBS, FRCA (Stanford University)","src":"https://clinicaltrials.gov/study/NCT00553839","sites":["Lucile Packard Children's Hospital — Palo Alto, United States","The Children's Hospital — Denver, United States"],"conds":["The Pk of IV Ketamine in Children With Heart Disease"],"condg":["Other"],"enroll":21,"eid":"NCT00553839"},{"id":"study-NCT00520169","cat":"studies","name":"Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine","status":"COMPLETED","phase":"Phase 1","sponsor":"Javelin Pharmaceuticals","drugs":["ketamine"],"nct":"NCT00520169","nsites":1,"countries":"United States","ccs":["US"],"start":"2007-07","official":"Javelin Pharmaceuticals (Javelin Pharmaceuticals)","src":"https://clinicaltrials.gov/study/NCT00520169","sites":["Javelin Pharmaceuticals — Cambridge, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":32,"eid":"NCT00520169"},{"id":"study-NCT00520104","cat":"studies","name":"Determination of Drug Interactions of Certain Nasal Medications With Intranasal Ketamine","status":"UNKNOWN","phase":"Phase 1","sponsor":"Javelin Pharmaceuticals","drugs":["ketamine"],"nct":"NCT00520104","nsites":1,"countries":"United States","ccs":["US"],"start":"2007-08","official":"Javelin Pharmaceuticals (Javelin Pharmaceuticals)","src":"https://clinicaltrials.gov/study/NCT00520104","sites":["Javelin Pharmaceuticals — Cambridge, United States"],"conds":["Pharmacokinetics"],"condg":["Other"],"enroll":48,"eid":"NCT00520104"},{"id":"study-NCT00736307","cat":"studies","name":"Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Royan Institute","drugs":["LSD"],"nct":"NCT00736307","nsites":2,"countries":"Iran","ccs":["IR"],"start":"2007-10","official":"Hamid Gorabi, PhD (Royan institute, Tehran, Iran); Mohammadali Javadi, MD (Labbafinejad Ophthalmic Research Center, Tehran, Iran)","src":"https://clinicaltrials.gov/study/NCT00736307","sites":["Royan Institute — Tehran, Iran","Labbafinejad Ophthalmic Research Center — Tehran, Iran"],"conds":["Limbal Stem Cell Deficiency"],"condg":["Other"],"enroll":10,"eid":"NCT00736307"},{"id":"study-NCT00548964","cat":"studies","name":"Continuation Ketamine in Major Depression","status":"COMPLETED","phase":"Phase 1","sponsor":"James Murrough","drugs":["ketamine"],"nct":"NCT00548964","nsites":1,"countries":"United States","ccs":["US"],"start":"2007-10","official":"James W Murrough, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT00548964","sites":["Icahn School of Medicine at Mount Sinai — New York, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":36,"eid":"NCT00548964"},{"id":"study-NCT00441792","cat":"studies","name":"The Effect of Etomidate on Patient Outcomes After Single Bolus Doses","status":"COMPLETED","phase":"N/A","sponsor":"Advocate Hospital System","drugs":["ketamine"],"nct":"NCT00441792","nsites":1,"countries":"United States","ccs":["US"],"start":"2007-10","official":"Erik B Kulstad, MD, MS (advocate christ medical center)","src":"https://clinicaltrials.gov/study/NCT00441792","sites":["Advocate Christ Medical Center — Oak Lawn, United States"],"conds":["Sepsis","Trauma"],"condg":["PTSD & trauma"],"enroll":122,"eid":"NCT00441792"},{"id":"study-NCT00471445","cat":"studies","name":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","status":"COMPLETED","phase":"Phase 3","sponsor":"Gary Morrow","drugs":["ketamine"],"nct":"NCT00471445","nsites":17,"countries":"United States","ccs":["US"],"start":"2007-10","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","sites":["MBCCOP - Hawaii — Honolulu, United States","MBCCOP - University of Illinois at Chicago — Chicago, United States","CCOP - Central Illinois — Decatur, United States","CCOP - Evanston — Evanston, United States","CCOP - Wichita — Wichita, United States","CCOP - Grand Rapids — Grand Rapids, United States","CCOP - Metro-Minnesota — Saint Louis Park, United States","CCOP - Nevada Cancer Research Foundation — Las Vegas, United States"],"conds":["Neurotoxicity","Pain","Peripheral Neuropathy","Unspecified Adult Solid Tumor, Protocol Specific"],"condg":["Chronic pain & headache"],"enroll":462,"eid":"NCT00471445"},{"id":"study-NCT00566098","cat":"studies","name":"Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","drugs":["LSD"],"nct":"NCT00566098","nsites":1,"countries":"United States","ccs":["US"],"start":"2007-11","official":"Ivan Borrello, MD (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins)","src":"https://clinicaltrials.gov/study/NCT00566098","sites":["Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, United States"],"conds":["Multiple Myeloma and Plasma Cell Neoplasm"],"condg":["Cancer-related distress"],"enroll":26,"eid":"NCT00566098"},{"id":"study-NCT00662883","cat":"studies","name":"Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)","status":"COMPLETED","phase":"Phase 1","sponsor":"Javelin Pharmaceuticals","drugs":["ketamine"],"nct":"NCT00662883","nsites":1,"countries":"United States","ccs":["US"],"start":"2007-11","official":"Javelin Pharmaceuticals, Inc (Javelin Pharmaceuticals)","src":"https://clinicaltrials.gov/study/NCT00662883","sites":["Unnamed trial site — Baltimore, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":18,"eid":"NCT00662883"},{"id":"study-NCT02675530","cat":"studies","name":"Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism","status":"COMPLETED","phase":"Phase 1","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT02675530","nsites":1,"countries":"United States","ccs":["US"],"start":"2007-12","official":"Handan Gunduz-Bruce, M.D. (Yale Medical School)","src":"https://clinicaltrials.gov/study/NCT02675530","sites":["VHA CT — West Haven, United States"],"conds":["Schizophrenia"],"condg":["Other"],"enroll":33,"eid":"NCT02675530"},{"id":"study-NCT00700076","cat":"studies","name":"Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT00700076","nsites":1,"countries":"United States","ccs":["US"],"start":"2008-01-22","official":"Deepak C D'Souza, M.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT00700076","sites":["Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine — West Haven, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":15,"eid":"NCT00700076"},{"id":"study-NCT00920387","cat":"studies","name":"Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety","status":"COMPLETED","phase":"Phase 2","sponsor":"Multidisciplinary Association for Psychedelic Studies","drugs":["LSD"],"nct":"NCT00920387","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2008-02","official":"Peter Gasser, MD (Private practices of Peter Gasser; Swiss Medical Association for Psycholytic Therapy (SAPT))","src":"https://clinicaltrials.gov/study/NCT00920387","sites":["Private Practices of Peter Gasser MD — Solothurn, Switzerland"],"conds":["Anxiety"],"condg":["Anxiety"],"enroll":12,"eid":"NCT00920387"},{"id":"study-NCT00516503","cat":"studies","name":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","status":"COMPLETED","phase":"Phase 3","sponsor":"Alliance for Clinical Trials in Oncology","drugs":["ketamine"],"nct":"NCT00516503","nsites":165,"countries":"United States","ccs":["US"],"start":"2008-02","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","sites":["Mayo Clinic Scottsdale — Scottsdale, United States","Mayo Clinic - Jacksonville — Jacksonville, United States","Rush-Copley Cancer Care Center — Aurora, United States","St. Joseph Medical Center — Bloomington, United States","Graham Hospital — Canton, United States","Memorial Hospital — Carthage, United States","Eureka Community Hospital — Eureka, United States","Galesburg Clinic, PC — Galesburg, United States"],"conds":["Chronic Myeloproliferative Disorders","Leukemia","Lymphoma","Lymphoproliferative Disorder","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes"],"condg":["Cancer-related distress","Chronic pain & headache"],"enroll":208,"eid":"NCT00516503"},{"id":"study-NCT00858624","cat":"studies","name":"Neurophysiology and Pharmacology of Cough Reflex Hypersensitivity","status":"COMPLETED","phase":"N/A","sponsor":"Jacky Smith","drugs":["ketamine"],"nct":"NCT00858624","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2008-02","src":"https://clinicaltrials.gov/study/NCT00858624","sites":["University of Manchester, Education and Research Centre, Wythenshawe Hospital — Manchester, United Kingdom"],"conds":["Chronic Cough"],"condg":["Other"],"enroll":24,"eid":"NCT00858624"},{"id":"study-NCT01807260","cat":"studies","name":"Stepwise Shock Wave Lithotripsy in Pediatric Urolithiasis","status":"COMPLETED","phase":"N/A","sponsor":"TC Erciyes University","drugs":["ketamine"],"nct":"NCT01807260","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2008-03","official":"Deniz Demirci, Prof. (Department of Urology, Erciyes University Medical faculty,)","src":"https://clinicaltrials.gov/study/NCT01807260","sites":["Department of Urology, Erciyes University Medical Faculty, — Kayseri, Turkey"],"conds":["Pediatric Urinary Lithiasis"],"condg":["Other"],"enroll":81,"eid":"NCT01807260"},{"id":"study-NCT00646087","cat":"studies","name":"Ketamine Frequency Treatment for Major Depressive Disorder","status":"WITHDRAWN","phase":"Phase 4","sponsor":"Essentia Health","drugs":["ketamine"],"nct":"NCT00646087","nsites":1,"countries":"United States","ccs":["US"],"start":"2008-03","official":"Micheal Messer, MD (Essentia Health)","src":"https://clinicaltrials.gov/study/NCT00646087","sites":["St. Mary's Duluth Clinic Health System — Duluth, United States"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"eid":"NCT00646087"},{"id":"study-NCT00595530","cat":"studies","name":"Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain","status":"TERMINATED","phase":"Phase 2","sponsor":"Connecticut Children's Medical Center","drugs":["ketamine"],"nct":"NCT00595530","nsites":2,"countries":"United States","ccs":["US"],"start":"2008-03-04","official":"William T Zempsky, MD (Connecticut Children's Medical Center)","src":"https://clinicaltrials.gov/study/NCT00595530","sites":["University of Connecticut Health Center — Farmington, United States","Connecticut Children's Medical Center — Hartford, United States"],"conds":["Sickle Cell Disease"],"condg":["Other"],"enroll":3,"eid":"NCT00595530"},{"id":"study-NCT00661063","cat":"studies","name":"Diabetic Neuropathy Topical Treatment","status":"UNKNOWN","phase":"Phase 3","sponsor":"Irmandade da Santa Casa de Misericordia de Sao Paulo","drugs":["ketamine"],"nct":"NCT00661063","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2008-04","official":"Judymara L Gozzani, Investigator (Santa Casa de São Paulo)","src":"https://clinicaltrials.gov/study/NCT00661063","sites":["Santa Casa de São Paulo — São Paulo, Brazil"],"conds":["Diabetic Neuropathy","Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Judymara L Gozzani, investigator","p":"55-11-3884-0865","e":"gozzani@osite.com.br"},"enroll":200,"eid":"NCT00661063"},{"id":"study-NCT00680433","cat":"studies","name":"Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT)","status":"COMPLETED","phase":"Phase 4","sponsor":"Northside Clinic, Australia","drugs":["ketamine"],"nct":"NCT00680433","nsites":1,"countries":"Australia","ccs":["AU"],"start":"2008-04","official":"Colleen K Loo, MB BS FRANZCP, MD (University of New South Wales)","src":"https://clinicaltrials.gov/study/NCT00680433","sites":["Wesley Hospital — Sydney, Australia"],"conds":["Major Depressive Episode"],"condg":["Depression"],"enroll":83,"eid":"NCT00680433"},{"id":"study-NCT00798083","cat":"studies","name":"Neuropathic Pain Caused by Radiation Therapy","status":"COMPLETED","phase":"Phase 3","sponsor":"British Columbia Cancer Agency","drugs":["ketamine"],"nct":"NCT00798083","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2008-04","official":"Isabella Uzaraga, MD (BC Cancer Agency - Vancouver Island Centre)","src":"https://clinicaltrials.gov/study/NCT00798083","sites":["BC Cancer Agency Vancouver Island BCCA — Victoria, Canada"],"conds":["Neuropathic Pain Secondary to Radiation Therapy"],"condg":["Chronic pain & headache"],"enroll":22,"eid":"NCT00798083"},{"id":"study-NCT00701909","cat":"studies","name":"Pain Medicine for Wound Care Procedures","status":"COMPLETED","phase":"Phase 3","sponsor":"University of California, San Francisco","drugs":["ketamine"],"nct":"NCT00701909","nsites":2,"countries":"Puerto Rico; United States","ccs":["PR","US"],"start":"2008-06","official":"Kathleen A Puntillo, RN, DNSc (Regents of the University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT00701909","sites":["University of California San Francisco — San Francisco, United States","Trauma Hospital Puerto Rico Medical Center — San Juan, Puerto Rico"],"conds":["Wound Care","Pain Intensity","Hyperalgesia","Nausea","Vomiting","Hallucinations"],"condg":["Chronic pain & headache"],"enroll":12,"eid":"NCT00701909"},{"id":"study-NCT00720330","cat":"studies","name":"Lidocaine and Ketamine Versus Standard Care on Acute and Chronic Pain","status":"TERMINATED","phase":"N/A","sponsor":"The Cleveland Clinic","drugs":["ketamine"],"nct":"NCT00720330","nsites":1,"countries":"United States","ccs":["US"],"start":"2008-07","official":"Kenneth Cummings, MD (The Cleveland Clinic); Daniel I Sessler, MD (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT00720330","sites":["Cleveland Clinic/Hillcrest Hospital — Mayfield Heights, United States"],"conds":["Pain","Nausea"],"condg":["Chronic pain & headache"],"enroll":12,"eid":"NCT00720330"},{"id":"study-NCT01600885","cat":"studies","name":"The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects","status":"COMPLETED","phase":"N/A","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT01600885","nsites":3,"countries":"United States","ccs":["US"],"start":"2008-08","official":"John H Krystal, M.D. (Yale University); Naomi R Driesen, Ph.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT01600885","sites":["Connecticut Mental Health Center — New Haven, United States","Yale Magnetic Resonance Research Center — New Haven, United States","Veterans Affairs Hospital — West Haven, United States"],"conds":["NMDA Receptor Function"],"condg":["Other"],"enroll":16,"eid":"NCT01600885"},{"id":"study-NCT01943994","cat":"studies","name":"Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study","status":"COMPLETED","phase":"N/A","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT01943994","nsites":2,"countries":"United States","ccs":["US"],"start":"2008-09","official":"Matthew W Johnson, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT01943994","sites":["Behavioral Pharmacology Research Unit — Baltimore, United States","Neuroimaging Research Branch, NIDA-IRP — Baltimore, United States"],"conds":["Nicotine Dependence"],"condg":["Addiction & substance use"],"enroll":82,"eid":"NCT01943994"},{"id":"study-NCT00833755","cat":"studies","name":"Effect of Ketamine on Opioid-Induced Hyperalgesia","status":"COMPLETED","phase":"N/A","sponsor":"Massachusetts General Hospital","drugs":["ketamine"],"nct":"NCT00833755","nsites":1,"countries":"United States","ccs":["US"],"start":"2008-09","official":"Jianren Mao, M.D., Ph.D. (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT00833755","sites":["Massachusetts General Hospital — Boston, United States"],"conds":["Pain","Chronic Pain","Hyperalgesia"],"condg":["Chronic pain & headache"],"enroll":79,"eid":"NCT00833755"},{"id":"study-NCT00787995","cat":"studies","name":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","status":"TERMINATED","sponsor":"BioMarin Pharmaceutical","drugs":["LSD"],"nct":"NCT00787995","nsites":15,"countries":"Argentina; Brazil; Canada; France; Germany; Italy; Netherlands; Taiwan; United Kingdom; United States","ccs":["AR","BR","CA","DE","FR","GB","IT","NL","TW","US"],"start":"2008-10","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","sites":["Unnamed trial site — Oakland, United States","Unnamed trial site — Chicago, United States","Unnamed trial site — Córdoba, Argentina","Unnamed trial site — Porto Alegre, Brazil","Unnamed trial site — São Paulo, Brazil","Unnamed trial site — Montreal, Canada","Unnamed trial site — Lyon, France","Unnamed trial site — Paris, France"],"conds":["MPS IV A","Mucopolysaccharidosis IVA","Morquio A Syndrome"],"condg":["Other"],"enroll":353,"eid":"NCT00787995"},{"id":"study-NCT00768430","cat":"studies","name":"Optimization of IV Ketamine for Treatment Resistant Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Baylor College of Medicine","drugs":["ketamine"],"nct":"NCT00768430","nsites":2,"countries":"United States","ccs":["US"],"start":"2008-11","official":"Sanjay J. Mathew, MD (Baylor College of Medicine); Dan V Iosifescu, MD,M.Sc. (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT00768430","sites":["Mount Sinai School of Medicine — New York, United States","Michael E. Dabakey VA Medical Center & Baylor College of Medicine — Houston, United States"],"conds":["Major Depressive Disorder (MDD)","Treatment Resistant Depression (TRD)"],"condg":["Depression"],"enroll":73,"eid":"NCT00768430"},{"id":"study-NCT00996411","cat":"studies","name":"Human Psychopharmacology of Salvinorin A","status":"COMPLETED","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["salvinorin A"],"nct":"NCT00996411","nsites":2,"countries":"United States","ccs":["US"],"start":"2008-11","official":"Roland Griffiths, Ph.D. (Johns Hopkins University); Matthew W Johnson, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT00996411","sites":["Behavioral Pharmacology Research Unit, Johnson Hopkins Univ. School of Med. — Baltimore, United States","Behavioral Pharmacology Research Unit — Baltimore, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":14,"eid":"NCT00996411"},{"id":"study-NCT00556387","cat":"studies","name":"Efficacy of Ketamine in Children With Severe Brain Injury for Brain Cell Protection","status":"WITHDRAWN","phase":"Phase 2","sponsor":"University of Arkansas","drugs":["ketamine"],"nct":"NCT00556387","nsites":0,"start":"2008-12","official":"Muayyad Tailounie, MD (Arkansas Children's Hospital Research Institute)","src":"https://clinicaltrials.gov/study/NCT00556387","conds":["Traumatic Brain Injury"],"condg":["PTSD & trauma","Neurology & cognition"],"eid":"NCT00556387"},{"id":"study-NCT00823407","cat":"studies","name":"Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]","status":"COMPLETED","phase":"N/A","sponsor":"California Pacific Medical Center Research Institute","drugs":["MDMA"],"nct":"NCT00823407","nsites":1,"countries":"United States","ccs":["US"],"start":"2009-01","official":"John E Mendelson, MD (CPMC Research Institute)","src":"https://clinicaltrials.gov/study/NCT00823407","sites":["CPMC Addiction & Pharmacology Research Laboratory (APRL) — San Francisco, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":12,"eid":"NCT00823407"},{"id":"study-NCT00749203","cat":"studies","name":"Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)","status":"COMPLETED","phase":"Phase 2","sponsor":"Dennis Charney","drugs":["ketamine"],"nct":"NCT00749203","nsites":1,"countries":"United States","ccs":["US"],"start":"2009-01","official":"Dennis Charney, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT00749203","sites":["Icahn School of Medicine at Mount Sinai — New York, United States"],"conds":["Stress Disorders, Post-Traumatic","PTSD","Depression","Anxiety Disorder"],"condg":["Depression","Anxiety","PTSD & trauma"],"enroll":41,"eid":"NCT00749203"},{"id":"study-NCT00834730","cat":"studies","name":"Comparison of N2O Inhalation and Ketamine in Pediatric PSA","status":"COMPLETED","phase":"Phase 4","sponsor":"Seoul National University Hospital","drugs":["ketamine"],"nct":"NCT00834730","nsites":1,"countries":"South Korea","ccs":["KR"],"start":"2009-01","official":"Jin Hee Lee, Professor (Seoul National University Bundang Hospital)","src":"https://clinicaltrials.gov/study/NCT00834730","sites":["Seoul National University Bundang Hospital — Gyeonggi-do, South Korea"],"conds":["Moderate Sedation","Laceration"],"condg":["Other"],"enroll":32,"eid":"NCT00834730"},{"id":"study-NCT00838305","cat":"studies","name":"Role of Serotonin in Acute and Subacute MDMA Effects","status":"COMPLETED","phase":"N/A","sponsor":"California Pacific Medical Center Research Institute","drugs":["MDMA"],"nct":"NCT00838305","nsites":1,"countries":"United States","ccs":["US"],"start":"2009-02","src":"https://clinicaltrials.gov/study/NCT00838305","sites":["CPMC Research Institute, St.Luke's Hospital — San Francisco, United States"],"conds":["MDMA Mechanism of Action"],"condg":["Other"],"enroll":13,"eid":"NCT00838305"},{"id":"study-NCT00957359","cat":"studies","name":"Psilocybin Cancer Anxiety Study","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"NYU Langone Health","drugs":["psilocybin"],"nct":"NCT00957359","nsites":1,"countries":"United States","ccs":["US"],"start":"2009-02","official":"Stephen Ross, MD (NYU Langone Health); Anthony Bossis, PhD (Co-Principal Investigator NYU Langone School of Medicine)","src":"https://clinicaltrials.gov/study/NCT00957359","sites":["NYU College of Dentistry Bluestone Center for Clinical Research — New York, United States"],"conds":["Cancer"],"condg":["Cancer-related distress"],"enroll":29,"eid":"NCT00957359"},{"id":"study-NCT00847418","cat":"studies","name":"Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["esketamine"],"nct":"NCT00847418","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2009-02","official":"Manuel Haschke, MD (Clinical Pharmacology and Toxicology, University Hospital Basel)","src":"https://clinicaltrials.gov/study/NCT00847418","sites":["Clinical Research Center, University Hospital Basel — Basel, Switzerland"],"conds":["Pain"],"condg":["Chronic pain & headache"],"eid":"NCT00847418"},{"id":"study-NCT01022840","cat":"studies","name":"The Preemptive Analgetic Potency of Low Dose S-Ketamine","status":"COMPLETED","phase":"Phase 3","sponsor":"Medical University of Graz","drugs":["esketamine","ketamine"],"nct":"NCT01022840","nsites":3,"countries":"Austria","ccs":["AT"],"start":"2009-02","official":"Mischa Wejbora, MD (Med. U Graz)","src":"https://clinicaltrials.gov/study/NCT01022840","sites":["Medical University Graz — Graz, Austria","Medical University of Graz — Graz, Austria","Medical University of Graz — Graz, Austria"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":60,"eid":"NCT01022840"},{"id":"study-NCT00822419","cat":"studies","name":"Percutaneous Ketamine Versus Lidocaine for Mid-Sternotomy","status":"UNKNOWN","phase":"Phase 4","sponsor":"Tel-Aviv Sourasky Medical Center","drugs":["ketamine"],"nct":"NCT00822419","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2009-02","src":"https://clinicaltrials.gov/study/NCT00822419","sites":["Tel Aviv Sourasky Medical center — Tel Aviv, Israel"],"conds":["Sternotomy"],"condg":["Other"],"contact":{"n":"Avi A Weinbroum, MD","p":"972-3-697-3237","e":"draviw@tasmc.health.gov.il"},"enroll":75,"eid":"NCT00822419"},{"id":"study-NCT01349231","cat":"studies","name":"Ketamine Infusion for Obsessive-Compulsive Disorder","status":"COMPLETED","phase":"Phase 2","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT01349231","nsites":1,"countries":"United States","ccs":["US"],"start":"2009-02","official":"Michael H Bloch, MD, MS (Yale University)","src":"https://clinicaltrials.gov/study/NCT01349231","sites":["Connecticut Mental Health Center/ YNHH — New Haven, United States"],"conds":["Obsessive-compulsive Disorder"],"condg":["OCD"],"enroll":10,"eid":"NCT01349231"},{"id":"study-NCT00700596","cat":"studies","name":"Effects of Salvinorin A in Healthy Controls","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Yale University","drugs":["salvinorin A"],"nct":"NCT00700596","nsites":1,"countries":"United States","ccs":["US"],"start":"2009-02-12","official":"Mohini Ranganathan, M.D. (Yale University School of Medicine, Dept of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT00700596","sites":["VA Connecticut Healthcare System — West Haven, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":105,"eid":"NCT00700596"},{"id":"study-NCT00957333","cat":"studies","name":"Effects of Ketamine on Human Bladders and Its Possible Mechanisms","status":"COMPLETED","sponsor":"Taipei Medical University WanFang Hospital","drugs":["ketamine"],"nct":"NCT00957333","nsites":1,"countries":"Taiwan","ccs":["TW"],"start":"2009-03","official":"Ruei-Ming Chen, PhD (Taipei Medical University-Wan Fang Hospital)","src":"https://clinicaltrials.gov/study/NCT00957333","sites":["Taipei Medical University-Wan Fang Hospital — Taipei, Taiwan"],"conds":["Cystitis"],"condg":["Other"],"enroll":44,"eid":"NCT00957333"},{"id":"study-NCT00961194","cat":"studies","name":"Oral Ketamine Administration in Patients With Peripheral Neuropathic Pain","status":"COMPLETED","phase":"Phase 2","sponsor":"University Hospital, Toulouse","drugs":["ketamine"],"nct":"NCT00961194","nsites":1,"countries":"France","ccs":["FR"],"start":"2009-03","official":"Nathalie Cantagrel, MD (University Hospital, Toulouse)","src":"https://clinicaltrials.gov/study/NCT00961194","sites":["Service de Neurochirurgie — Toulouse, France"],"conds":["Neuropathic Pain"],"condg":["Chronic pain & headache"],"enroll":22,"eid":"NCT00961194"},{"id":"study-NCT00884949","cat":"studies","name":"A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"BioMarin Pharmaceutical","drugs":["LSD"],"nct":"NCT00884949","nsites":3,"countries":"United Kingdom","ccs":["GB"],"start":"2009-04","official":"Celeste Decker, MD (BioMarin Pharmceutical Inc.)","src":"https://clinicaltrials.gov/study/NCT00884949","sites":["Unnamed trial site — Birmingham, United Kingdom","Unnamed trial site — London, United Kingdom","Unnamed trial site — Manchester, United Kingdom"],"conds":["MPS IV A"],"condg":["Other"],"enroll":20,"eid":"NCT00884949"},{"id":"study-NCT00886886","cat":"studies","name":"Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT00886886","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2009-04","official":"Matthias E Liechti, MD (Department of Internal Medicine, Division of Pharmacology & Toxicology, University Hospital Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT00886886","sites":["University Hospital — Basel, Switzerland"],"conds":["Mood Disorder","Substance-related Disorders","Amphetamine-related Disorders"],"condg":["Addiction & substance use"],"enroll":16,"eid":"NCT00886886"},{"id":"study-NCT01316744","cat":"studies","name":"Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain","status":"UNKNOWN","phase":"Phase 3","sponsor":"University of Glasgow","drugs":["ketamine"],"nct":"NCT01316744","nsites":3,"countries":"United Kingdom","ccs":["GB"],"start":"2009-04","official":"Marie T. Fallon (Edinburgh Cancer Centre at Western General Hospital); Barry J.A. Laird, MD (Edinburgh Cancer Centre at Western General Hospital)","src":"https://clinicaltrials.gov/study/NCT01316744","sites":["Royal Brompton Hospital — London, United Kingdom","Edinburgh Cancer Centre at Western General Hospital — Edinburgh, United Kingdom","Beatson West of Scotland Cancer Centre — Glasgow, United Kingdom"],"conds":["Cancer"],"condg":["Cancer-related distress"],"enroll":214,"eid":"NCT01316744"},{"id":"study-NCT01149824","cat":"studies","name":"Placebo Controlled Study of Sublingual Salvinorin A","status":"COMPLETED","phase":"N/A","sponsor":"California Pacific Medical Center Research Institute","drugs":["salvinorin A"],"nct":"NCT01149824","nsites":0,"start":"2009-06","official":"John Mendelson, MD (California Pacific Medical Center)","src":"https://clinicaltrials.gov/study/NCT01149824","conds":["Pharmaceutical Preparations"],"condg":["Other"],"enroll":8,"eid":"NCT01149824"},{"id":"study-NCT00947791","cat":"studies","name":"Treatment Study of Bipolar Depression","status":"TERMINATED","phase":"Phase 4","sponsor":"Icahn School of Medicine at Mount Sinai","drugs":["ketamine"],"nct":"NCT00947791","nsites":1,"countries":"United States","ccs":["US"],"start":"2009-07","official":"James W Murrough, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT00947791","sites":["Mount Sinai School of Medicine — New York, United States"],"conds":["Bipolar Disorder"],"condg":["Bipolar"],"enroll":1,"eid":"NCT00947791"},{"id":"study-NCT00474110","cat":"studies","name":"Ketamine and Hydromorphone for Patient Controlled Pain Relief in Children's Mucositis","status":"WITHDRAWN","phase":"Phase 3","sponsor":"University of British Columbia","drugs":["ketamine"],"nct":"NCT00474110","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2009-08","official":"Carolyne Montgomery, MD (University of British Columbia); Mark Ansermino, MD (University of British Columbia)","src":"https://clinicaltrials.gov/study/NCT00474110","sites":["BC Children's Hospital — Vancouver, Canada"],"conds":["Mucositis"],"condg":["Other"],"eid":"NCT00474110"},{"id":"study-NCT00956085","cat":"studies","name":"Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder","status":"COMPLETED","phase":"Phase 2","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT00956085","nsites":1,"countries":"United States","ccs":["US"],"start":"2009-08","official":"Carolyn I Rodriguez, M.D., Ph.D. (Stanford University); Helen B Simpson, MD, PhD (NYSPI-Columbia)","src":"https://clinicaltrials.gov/study/NCT00956085","sites":["New York State Psychiatric Institute — New York, United States"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"enroll":12,"eid":"NCT00956085"},{"id":"study-NCT00802282","cat":"studies","name":"Psilocybin and Spiritual Practice","status":"COMPLETED","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT00802282","nsites":1,"countries":"United States","ccs":["US"],"start":"2009-08","official":"Roland R Griffiths, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT00802282","sites":["Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center — Baltimore, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":75,"eid":"NCT00802282"},{"id":"study-NCT01736020","cat":"studies","name":"Developing Anesthesia as Post Traumatic Stress Disorder (PTSD) Therapy","status":"UNKNOWN","phase":"Phase 1","sponsor":"Southern California Institute for Research and Education","drugs":["ketamine"],"nct":"NCT01736020","nsites":1,"countries":"United States","ccs":["US"],"start":"2009-09","official":"Michael T Alkire, MD (University of California, Irvine and Long Beach VA Medical Center)","src":"https://clinicaltrials.gov/study/NCT01736020","sites":["University of California, Irvine — Irvine, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":293,"eid":"NCT01736020"},{"id":"study-NCT01165294","cat":"studies","name":"The Effect of Ketamine on Attentiveness","status":"COMPLETED","phase":"Phase 1","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drugs":["esketamine","ketamine"],"nct":"NCT01165294","nsites":0,"start":"2009-10","official":"Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial (Johnson & Johnson Pharmaceutical Research & Development, L.L.C.)","src":"https://clinicaltrials.gov/study/NCT01165294","conds":["Schizophrenia"],"condg":["Other"],"enroll":24,"eid":"NCT01165294"},{"id":"study-NCT00990067","cat":"studies","name":"Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT00990067","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2009-11","official":"Matthias E Liechti, MD (Department of Internal Medicine, Division of Pharmacology & Toxicology, University Hospital Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT00990067","sites":["Clinical Pharmacology & Toxicology, University Hospital Basel — Basel, Switzerland"],"conds":["Mood Disorder","Substance-Related Disorders","Amphetamine-Related Disorders"],"condg":["Addiction & substance use"],"enroll":16,"eid":"NCT00990067"},{"id":"study-NCT01046630","cat":"studies","name":"Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"AstraZeneca","drugs":["ketamine"],"nct":"NCT01046630","nsites":2,"countries":"United Kingdom","ccs":["GB"],"start":"2009-12","official":"Bill Deakin, Prof (University of Manchester, Neurosciance and Psychiatry Unit, UK); Guy Goodwin, Prof (University of Oxford, Departmentof Psychiatry, UK)","src":"https://clinicaltrials.gov/study/NCT01046630","sites":["Research Site — Manchester, United Kingdom","Research Site — Oxford, United Kingdom"],"conds":["Depression"],"condg":["Depression"],"enroll":128,"eid":"NCT01046630"},{"id":"study-NCT01089361","cat":"studies","name":"Immunomodulatory Properties of Ketamine in Sepsis","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Beth Israel Deaconess Medical Center","drugs":["ketamine"],"nct":"NCT01089361","nsites":1,"countries":"United States","ccs":["US"],"start":"2009-12","official":"Daniel Talmor, MD, MPH (Beth Israel Deaconess Medical Center)","src":"https://clinicaltrials.gov/study/NCT01089361","sites":["Beth Israel Deaconess Medical Center — Boston, United States"],"conds":["Sepsis"],"condg":["Other"],"enroll":19,"eid":"NCT01089361"},{"id":"study-NCT00921765","cat":"studies","name":"Reversal of Ketamine Pharmacodynamic Effects With Naloxone","status":"TERMINATED","phase":"Phase 4","sponsor":"Ullevaal University Hospital","drugs":["ketamine"],"nct":"NCT00921765","nsites":1,"countries":"Norway","ccs":["NO"],"start":"2009-12","official":"Olav Hustveit, MD, PhD (University of Oslo); Elena Landari, DDS (University of Oslo)","src":"https://clinicaltrials.gov/study/NCT00921765","sites":["Ullevaal University Hospital — Oslo, Norway"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":3,"eid":"NCT00921765"},{"id":"study-NCT01325493","cat":"studies","name":"Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia","status":"COMPLETED","phase":"Phase 4","sponsor":"Julia Finkel","drugs":["ketamine"],"nct":"NCT01325493","nsites":1,"countries":"United States","ccs":["US"],"start":"2010-01","official":"Pestieau Sophie, MD (Children's National Research Institute); Finkel C Julie, MD (Children's National Research Institute)","src":"https://clinicaltrials.gov/study/NCT01325493","sites":["Children's National Medical Center — Washington D.C., United States"],"conds":["Idiopathic Scoliosis","Spondylolisthesis"],"condg":["Other"],"enroll":54,"eid":"NCT01325493"},{"id":"study-NCT01045460","cat":"studies","name":"Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant…","status":"COMPLETED","phase":"Phase 2","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","drugs":["LSD"],"nct":"NCT01045460","nsites":1,"countries":"United States","ccs":["US"],"start":"2010-01-15","official":"Ivan Borrello, MD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT01045460","sites":["Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, United States"],"conds":["Multiple Myeloma"],"condg":["Other"],"enroll":36,"eid":"NCT01045460"},{"id":"study-NCT01101659","cat":"studies","name":"Ketamine Challenge Study With JNJ-40411813","status":"COMPLETED","phase":"Phase 1","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drugs":["ketamine"],"nct":"NCT01101659","nsites":1,"countries":"Germany","ccs":["DE"],"start":"2010-02","official":"Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial (Johnson & Johnson Pharmaceutical Research & Development, L.L.C.)","src":"https://clinicaltrials.gov/study/NCT01101659","sites":["Unnamed trial site — Neuss, Germany"],"conds":["Perceptual Disorders","Confusion","Schizophrenia"],"condg":["Other"],"enroll":40,"eid":"NCT01101659"},{"id":"study-NCT00985933","cat":"studies","name":"The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"AstraZeneca","drugs":["ketamine"],"nct":"NCT00985933","nsites":1,"countries":"United States","ccs":["US"],"start":"2010-02","official":"John Krystal (Chair, Department of PsychiatryYale University School of MedicineChief of Psychiatry, Yale-New Haven Hospital)","src":"https://clinicaltrials.gov/study/NCT00985933","sites":["Research Site — New Haven, United States"],"conds":["Healthy","Memory Impairment"],"condg":["Healthy volunteers"],"enroll":20,"eid":"NCT00985933"},{"id":"study-NCT01053403","cat":"studies","name":"Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.","status":"COMPLETED","phase":"N/A","sponsor":"California Pacific Medical Center Research Institute","drugs":["MDMA"],"nct":"NCT01053403","nsites":1,"countries":"United States","ccs":["US"],"start":"2010-04","official":"John Mendelson, MD (CPMC Research Institute)","src":"https://clinicaltrials.gov/study/NCT01053403","sites":["CPMC Addiction & Pharmacology Research Laboratory (APRL) — San Francisco, United States"],"conds":["MDMA Discontinuation Syndrome"],"condg":["Other"],"enroll":12,"eid":"NCT01053403"},{"id":"study-NCT01209845","cat":"studies","name":"Ketamine for Low Mood States in the ER","status":"COMPLETED","phase":"Phase 1","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT01209845","nsites":1,"countries":"United States","ccs":["US"],"start":"2010-04","official":"Gregory L Larkin, MD (Yale University School of Medicine, Department of Emergency Medicine)","src":"https://clinicaltrials.gov/study/NCT01209845","sites":["Yale New Haven Hospital Emergency Department — New Haven, United States"],"conds":["Depression","Suicide Ideation"],"condg":["Depression"],"enroll":14,"eid":"NCT01209845"},{"id":"study-NCT01047241","cat":"studies","name":"Nasal Administration of Sufentanil+Ketamine for Procedure-related Pain in Children","status":"COMPLETED","phase":"Phase 2","sponsor":"Danish University of Pharmaceutical Sciences","drugs":["ketamine"],"nct":"NCT01047241","nsites":1,"countries":"Denmark","ccs":["DK"],"start":"2010-04","official":"Steen W Henneberg, MD DMSc (Copenhagen University Hospital, Rigshospitalet); Kjeld Schmiegelow, MD DMSc (Copenhagen University Hospital Righospitalet)","src":"https://clinicaltrials.gov/study/NCT01047241","sites":["Copenhagen University Hospital Rigshospitalet — Copenhagen, Denmark"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":50,"eid":"NCT01047241"},{"id":"study-NCT01100255","cat":"studies","name":"Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)","status":"COMPLETED","phase":"Phase 2","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT01100255","nsites":1,"countries":"United States","ccs":["US"],"start":"2010-04","official":"Carolyn I. Rodriguez, M.D., Ph.D. (Columbia-NYSPI-RFMH)","src":"https://clinicaltrials.gov/study/NCT01100255","sites":["New York State Psychiatric Institute — New York, United States"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"enroll":15,"eid":"NCT01100255"},{"id":"study-NCT01309581","cat":"studies","name":"Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression","status":"TERMINATED","phase":"N/A","sponsor":"James Murrough","drugs":["ketamine"],"nct":"NCT01309581","nsites":1,"countries":"United States","ccs":["US"],"start":"2010-04","official":"James W Murrough, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT01309581","sites":["Icahn School of Medicine at Mount Sinai — New York, United States"],"conds":["Major Depression","Bipolar Depression"],"condg":["Depression","Bipolar"],"enroll":3,"eid":"NCT01309581"},{"id":"study-NCT01130909","cat":"studies","name":"A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765","status":"TERMINATED","phase":"Phase 1","sponsor":"AstraZeneca","drugs":["ketamine"],"nct":"NCT01130909","nsites":1,"countries":"France","ccs":["FR"],"start":"2010-05","official":"Albena Patroneva, MD (AstraZeneca); Francine Santoro (Forenap)","src":"https://clinicaltrials.gov/study/NCT01130909","sites":["Research Site — Rouffach, France"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":36,"eid":"NCT01130909"},{"id":"study-NCT01135758","cat":"studies","name":"Study of Depression-Ketamine-Brain Function","status":"TERMINATED","phase":"Phase 2","sponsor":"Markus KOSEL","drugs":["ketamine"],"nct":"NCT01135758","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2010-06","official":"Markus Kosel, MD-PhD (Departement of Adult Psychiatry, University Hospital of Geneva)","src":"https://clinicaltrials.gov/study/NCT01135758","sites":["Service de Psychiatrie Adulte, Programme dépression — Geneva, Switzerland"],"conds":["Major Depression"],"condg":["Depression"],"enroll":10,"eid":"NCT01135758"},{"id":"study-NCT01881763","cat":"studies","name":"Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression","status":"COMPLETED","phase":"Phase 4","sponsor":"Northwell Health","drugs":["ketamine"],"nct":"NCT01881763","nsites":1,"countries":"United States","ccs":["US"],"start":"2010-06","official":"Georgios Petrides, M.D. (The Zucker Hillside Hospital)","src":"https://clinicaltrials.gov/study/NCT01881763","sites":["Zucker Hillside Hospital — Glen Oaks, United States"],"conds":["Unipolar Depression","Bipolar Depression"],"condg":["Depression","Bipolar"],"enroll":31,"eid":"NCT01881763"},{"id":"study-NCT01140620","cat":"studies","name":"Effects of Ketamine and Risperidone on Cognition","status":"COMPLETED","phase":"Phase 4","sponsor":"University of Manchester","drugs":["ketamine"],"nct":"NCT01140620","nsites":3,"countries":"United Kingdom","ccs":["GB"],"start":"2010-06","official":"Professor Bill Deakin (University of Manchester)","src":"https://clinicaltrials.gov/study/NCT01140620","sites":["Institute of Psychiatry, King's College London — London, United Kingdom","University of Manchester (Dept of Neuropyschiatry) — Manchester, United Kingdom","School of Psychology, University of Cardiff — Cardiff, United Kingdom"],"conds":["Healthy Volunteers","Schizophrenia"],"condg":["Healthy volunteers"],"enroll":87,"eid":"NCT01140620"},{"id":"study-NCT01155778","cat":"studies","name":"Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Shire","drugs":["LSD"],"nct":"NCT01155778","nsites":2,"countries":"Netherlands; United Kingdom","ccs":["GB","NL"],"start":"2010-06-01","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT01155778","sites":["Emma Children's Hospital, Academic Medical Center — Amsterdam, Netherlands","St. Mary's Hospital — Manchester, United Kingdom"],"conds":["Mucopolysaccharidosis (MPS)"],"condg":["Other"],"enroll":12,"eid":"NCT01155778"},{"id":"study-NCT01136278","cat":"studies","name":"Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT01136278","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2010-07","official":"Matthias E Liechti, MD (Department of Internal Medicine, Division of Pharmacology & Toxicology, University Hospital Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01136278","sites":["Clinical Pharmacology & Toxicology, University Hospital Basel — Basel, Switzerland"],"conds":["Mood Disorder","Substance-Related Disorders","Amphetamine-Related Disorders"],"condg":["Addiction & substance use"],"enroll":16,"eid":"NCT01136278"},{"id":"study-NCT01849419","cat":"studies","name":"Effects of MDMA on Social and Emotional Processing","status":"COMPLETED","phase":"N/A","sponsor":"University of Chicago","drugs":["MDMA"],"nct":"NCT01849419","nsites":1,"countries":"United States","ccs":["US"],"start":"2010-07","official":"Harriet de Wit, PhD (University of Chicago)","src":"https://clinicaltrials.gov/study/NCT01849419","sites":["University of Chicago — Chicago, United States"],"conds":["Drug Addiction"],"condg":["Addiction & substance use"],"enroll":65,"eid":"NCT01849419"},{"id":"study-NCT01301079","cat":"studies","name":"Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia","status":"COMPLETED","phase":"Phase 3","sponsor":"Federal University of São Paulo","drugs":["ketamine"],"nct":"NCT01301079","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2010-09","official":"Plínio da Cunha Leal, PhD (Federal University of São Paulo)","src":"https://clinicaltrials.gov/study/NCT01301079","sites":["Federal University of São Paulo — São Paulo, Brazil"],"conds":["Pain","Hyperalgesia","Inflammatory Response"],"condg":["Chronic pain & headache"],"enroll":60,"eid":"NCT01301079"},{"id":"study-NCT01207206","cat":"studies","name":"Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients","status":"UNKNOWN","phase":"N/A","sponsor":"Tel-Aviv Sourasky Medical Center","drugs":["ketamine"],"nct":"NCT01207206","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2010-10","src":"https://clinicaltrials.gov/study/NCT01207206","sites":["Tel Aviv Sourasky Medical Center, Pain Medicine Unit — Tel Aviv, Israel"],"conds":["Cancer","Pain","Tolerance"],"condg":["Cancer-related distress","Chronic pain & headache"],"contact":{"n":"Silviu Brill, MD","p":"972-3-6974477","e":"silviub@tasmc.health.gov.il"},"enroll":50,"eid":"NCT01207206"},{"id":"study-NCT01242111","cat":"studies","name":"A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","status":"TERMINATED","phase":"Phase 1/Phase 2","sponsor":"BioMarin Pharmaceutical","drugs":["LSD"],"nct":"NCT01242111","nsites":4,"countries":"United Kingdom","ccs":["GB"],"start":"2010-11","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01242111","sites":["Unnamed trial site — Birmingham, United Kingdom","Unnamed trial site — Dumfries, United Kingdom","Unnamed trial site — London, United Kingdom","Unnamed trial site — Manchester, United Kingdom"],"conds":["MPS IV A","Mucopolysaccharidosis IVA","Morquio A Syndrome"],"condg":["Other"],"enroll":20,"eid":"NCT01242111"},{"id":"study-NCT01260649","cat":"studies","name":"N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression","status":"TERMINATED","phase":"Phase 4","sponsor":"Massachusetts General Hospital","drugs":["ketamine"],"nct":"NCT01260649","nsites":1,"countries":"United States","ccs":["US"],"start":"2010-11-01","src":"https://clinicaltrials.gov/study/NCT01260649","sites":["Massachusetts General Hospital — Boston, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":17,"eid":"NCT01260649"},{"id":"study-NCT01211405","cat":"studies","name":"Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder","status":"COMPLETED","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT01211405","nsites":1,"countries":"United States","ccs":["US"],"start":"2010-11-10","official":"Michael Mithoefer, MD (Private Practice)","src":"https://clinicaltrials.gov/study/NCT01211405","sites":["Offices of Michael Mithoefer — Mt. Pleasant, United States"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":26,"eid":"NCT01211405"},{"id":"study-NCT01400204","cat":"studies","name":"Naturalistic Study Into the Hangover Effects of MDMA","status":"COMPLETED","sponsor":"Utrecht Institute for Pharmaceutical Sciences","drugs":["MDMA"],"nct":"NCT01400204","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2010-12","official":"Joris C Verster, PhD (Utrecht University)","src":"https://clinicaltrials.gov/study/NCT01400204","sites":["Utrecht University — Utrecht, Netherlands"],"conds":["Hangover"],"condg":["Other"],"enroll":39,"eid":"NCT01400204"},{"id":"study-NCT01065350","cat":"studies","name":"A Comparison of Ketofol (Ketamine and Propofol Admixture) Versus Propofol as Induction Agents on Hemodynamic Parameters","status":"COMPLETED","phase":"N/A","sponsor":"Mayo Clinic","drugs":["ketamine"],"nct":"NCT01065350","nsites":1,"countries":"United States","ccs":["US"],"start":"2010-12","official":"Nathan J Smischney, MD (Mayo Clinic); Matthew Koff, MD (Dartmouth-Hitchcock Medical Center)","src":"https://clinicaltrials.gov/study/NCT01065350","sites":["Dartmouth Hitchcock Medical Center — Lebanon, United States"],"conds":["Blood Pressure"],"condg":["Other"],"enroll":85,"eid":"NCT01065350"},{"id":"study-NCT01458327","cat":"studies","name":"Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial","status":"COMPLETED","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT01458327","nsites":1,"countries":"United States","ccs":["US"],"start":"2010-12-15","official":"Michael C Mithoefer, MD (Psychiatrist)","src":"https://clinicaltrials.gov/study/NCT01458327","sites":["Offices of Michael Mithoefer — Mt. Pleasant, United States"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":3,"eid":"NCT01458327"},{"id":"study-NCT01270672","cat":"studies","name":"Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)","status":"COMPLETED","phase":"N/A","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT01270672","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2011-01","official":"Matthias E Liechti, MD (Department of Internal Medicine, Division of Pharmacology & Toxicology, University Hospital Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01270672","sites":["Clinical Pharmacology & Toxicology, University Hospital Basel — Basel, Switzerland"],"conds":["Mood Disorder","Substance-Related Disorders","Amphetamine-Related Disorders"],"condg":["Addiction & substance use"],"enroll":16,"eid":"NCT01270672"},{"id":"study-NCT01816958","cat":"studies","name":"Neuromodulation to Facilitate the Effect of Ketamine","status":"COMPLETED","sponsor":"The Neuroscience Center, LLC","drugs":["ketamine"],"nct":"NCT01816958","nsites":1,"countries":"United States","ccs":["US"],"start":"2011-01","official":"Steven R Devore Best, M.D. (The Neuroscience Center)","src":"https://clinicaltrials.gov/study/NCT01816958","sites":["The Neuroscience Center — Deerfield, United States"],"conds":["Depression","Chronic Pain","Substance Abuse"],"condg":["Depression","Addiction & substance use","Chronic pain & headache"],"enroll":35,"eid":"NCT01816958"},{"id":"study-NCT03105765","cat":"studies","name":"Acute and Chronic Pain, Especially Neuropathic Pain, After Thoracotomy and Continuous Application of Ketamine.","status":"COMPLETED","phase":"N/A","sponsor":"Dr. Horst Schmidt Klinik GmbH","drugs":["ketamine"],"nct":"NCT03105765","nsites":1,"countries":"Germany","ccs":["DE"],"start":"2011-01","src":"https://clinicaltrials.gov/study/NCT03105765","sites":["Dr. Horst Schmidt Klinik — Wiesbaden, Germany"],"conds":["Acute Pain","Chronic Pain","Neuropathic Pain"],"condg":["Chronic pain & headache"],"enroll":200,"eid":"NCT03105765"},{"id":"study-NCT01275066","cat":"studies","name":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","status":"COMPLETED","phase":"Phase 3","sponsor":"BioMarin Pharmaceutical","drugs":["LSD"],"nct":"NCT01275066","nsites":28,"countries":"Argentina; Brazil; Canada; Colombia; Denmark; France; Germany; Italy; Japan; Netherlands; Portugal; Qatar; Saudi Arabia; South Korea; Taiwan; United Kingdom; United States","ccs":["AR","BR","CA","CO","DE","DK","FR","GB","IT","JP","KR","NL","PT","QA","SA","TW","US"],"start":"2011-02","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","sites":["Unnamed trial site — Oakland, United States","Unnamed trial site — Wilmington, United States","Unnamed trial site — Washington D.C., United States","Unnamed trial site — Chicago, United States","Unnamed trial site — New York, United States","Unnamed trial site — Seattle, United States","Unnamed trial site — Córdoba, Argentina","Unnamed trial site — Campina Grande, Brazil"],"conds":["MPS IV A"],"condg":["Other"],"enroll":177,"eid":"NCT01275066"},{"id":"study-NCT01790490","cat":"studies","name":"Glutamatergic Modulation of Cocaine-related Deficits","status":"COMPLETED","phase":"Phase 2","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT01790490","nsites":1,"countries":"United States","ccs":["US"],"start":"2011-02","official":"Elias Dakwar, MD (NYSPI/Columbia College of Physicians and Surgeons); Carl Hart, PhD (NYSPI/Columbia College of Physicians and Surgeons)","src":"https://clinicaltrials.gov/study/NCT01790490","sites":["NYSPI — New York, United States"],"conds":["Cocaine Dependence"],"condg":["Addiction & substance use"],"enroll":8,"eid":"NCT01790490"},{"id":"study-NCT01306760","cat":"studies","name":"The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy","status":"COMPLETED","phase":"Phase 4","sponsor":"University of Aberdeen","drugs":["ketamine"],"nct":"NCT01306760","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2011-03","official":"Ian C Reid, PhD (University of Aberdeen)","src":"https://clinicaltrials.gov/study/NCT01306760","sites":["Royal Cornhill Hospital, NHS Grampian — Aberdeen, United Kingdom"],"conds":["Depression"],"condg":["Depression"],"enroll":40,"eid":"NCT01306760"},{"id":"study-NCT01299727","cat":"studies","name":"Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)","status":"TERMINATED","phase":"Phase 1/Phase 2","sponsor":"Shire","drugs":["LSD"],"nct":"NCT01299727","nsites":2,"countries":"Netherlands; United Kingdom","ccs":["GB","NL"],"start":"2011-03-01","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT01299727","sites":["Emma Children's Hospital, Academic Medical Center — Amsterdam, Netherlands","St. Mary's Hospital — Manchester, United Kingdom"],"conds":["Sanfilippo Syndrome"],"condg":["Other"],"enroll":12,"eid":"NCT01299727"},{"id":"study-NCT01094990","cat":"studies","name":"Efficacy of Dexamethasone for Prevent Vomiting in Leukemic Children Who Receive Intrathecal Chemotherapy","status":"COMPLETED","phase":"Phase 4","sponsor":"CHANCHAI TRAIVAREE","drugs":["ketamine"],"nct":"NCT01094990","nsites":2,"countries":"Thailand","ccs":["TH"],"start":"2011-04","official":"chanchai traivaree, MD (Phramongkutklao College of Medicine and Hospital)","src":"https://clinicaltrials.gov/study/NCT01094990","sites":["Phramongkutklao hospital — Bangkok, Thailand","Phramongkutklao Hospital — Bangkok, Thailand"],"conds":["Acute Leukemic Patients in Children"],"condg":["Other"],"enroll":32,"eid":"NCT01094990"},{"id":"study-NCT01244880","cat":"studies","name":"Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects","status":"TERMINATED","phase":"Phase 1","sponsor":"Pfizer","drugs":["ketamine"],"nct":"NCT01244880","nsites":3,"countries":"United States","ccs":["US"],"start":"2011-04","official":"Pfizer CT.gov Call Center (Pfizer)","src":"https://clinicaltrials.gov/study/NCT01244880","sites":["Pfizer Investigational Site — New Haven, United States","Pfizer Investigational Site — New Haven, United States","Pfizer Investigational Site — New Haven, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":4,"eid":"NCT01244880"},{"id":"study-NCT01339065","cat":"studies","name":"The Effect of Ketamine on Production of Inflammatory Markers in Post Operative Patients in Mulago Hospital","status":"UNKNOWN","phase":"Phase 4","sponsor":"Makerere University","drugs":["ketamine"],"nct":"NCT01339065","nsites":1,"countries":"Uganda","ccs":["UG"],"start":"2011-04","src":"https://clinicaltrials.gov/study/NCT01339065","sites":["Mulago Hospital National Refferal, surgical wards — Kampala, Uganda"],"conds":["Post Operative Inflammatory Marker Levels"],"condg":["Other"],"enroll":30,"eid":"NCT01339065"},{"id":"study-NCT01404754","cat":"studies","name":"Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT01404754","nsites":3,"countries":"United States","ccs":["US"],"start":"2011-04-09","official":"Michael M Mithoefer, MD (Resilient Pharmaceuticals)","src":"https://clinicaltrials.gov/study/NCT01404754","sites":["Aguazul Bluewater, Inc. — Boulder, United States","Santa Fe MDMA Therapy Training, LLC — Santa Fe, United States","Zen Therapeutic Solutions — Mt. Pleasant, United States"],"conds":["Psychological Effects of Study Drug"],"condg":["Other"],"enroll":107,"eid":"NCT01404754"},{"id":"study-NCT01506921","cat":"studies","name":"Racemic Ketamine Versus S-ketamine With Arterial Spin Labeling (ASL)-MRI in Healthy Volunteers","status":"COMPLETED","phase":"N/A","sponsor":"Lund University","drugs":["esketamine","ketamine"],"nct":"NCT01506921","nsites":1,"countries":"Sweden","ccs":["SE"],"start":"2011-05","official":"Jonas Åkeson, profesor (Lund University)","src":"https://clinicaltrials.gov/study/NCT01506921","sites":["Deprtment of radiology, SUS, Malmö — Malmö, Sweden"],"conds":["Healthy","Abnormal Vascular Flow"],"condg":["Healthy volunteers"],"enroll":14,"eid":"NCT01506921"},{"id":"study-NCT01369680","cat":"studies","name":"Oral Ketamine for Control of Chronic Pain in Children","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Rochester","drugs":["ketamine"],"nct":"NCT01369680","nsites":1,"countries":"United States","ccs":["US"],"start":"2011-05","official":"David Korones, MD (University of Rochester)","src":"https://clinicaltrials.gov/study/NCT01369680","sites":["University of Rochester — Rochester, United States"],"conds":["Chronic Pain"],"condg":["Chronic pain & headache"],"enroll":12,"eid":"NCT01369680"},{"id":"study-NCT01955070","cat":"studies","name":"Use of a Multimedia Presentation for Informed Consent","status":"COMPLETED","phase":"N/A","sponsor":"Nationwide Children's Hospital","drugs":["ketamine"],"nct":"NCT01955070","nsites":1,"countries":"United States","ccs":["US"],"start":"2011-05","official":"Sandra P Spencer, MD (Nationwide Childrens, Department of Emergency Medicine)","src":"https://clinicaltrials.gov/study/NCT01955070","sites":["Nationwide Childrens — Columbus, United States"],"conds":["Improving Informed Consent Process"],"condg":["Other"],"enroll":184,"eid":"NCT01955070"},{"id":"study-NCT01385904","cat":"studies","name":"Blood Levels of Ketamine in Patients Using Topical Application of 10% Ketamine Gel for Neuropathic Pain","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","drugs":["ketamine"],"nct":"NCT01385904","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2011-06","official":"Patricia Morley- Forster, MD, FRCPC (Western University, Canada)","src":"https://clinicaltrials.gov/study/NCT01385904","sites":["Pain Clinic, St. Joseph's Health Care London Hospitals — London, Canada"],"conds":["Neuropathic Pain."],"condg":["Chronic pain & headache"],"contact":{"n":"Patricia Morley-Forster, MD, FRCPC","p":"(519) 646-6000","e":"pat.morley-forster@sjhc.london.on.ca"},"enroll":15,"eid":"NCT01385904"},{"id":"study-NCT01377831","cat":"studies","name":"Study of Ketamine Administered Intravenously and by Sublingual Wafer","status":"COMPLETED","sponsor":"iX Biopharma Ltd.","drugs":["ketamine"],"nct":"NCT01377831","nsites":1,"countries":"Australia","ccs":["AU"],"start":"2011-06","official":"Pual Rolan (Pain and Anaesthesia Research Clinic - PARC)","src":"https://clinicaltrials.gov/study/NCT01377831","sites":["Pain and Anaesthesia Research Clinic (PARC), Royal Adelaide Hospital — Adelaide, Australia"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":8,"eid":"NCT01377831"},{"id":"study-NCT01415427","cat":"studies","name":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","status":"COMPLETED","phase":"Phase 3","sponsor":"BioMarin Pharmaceutical","drugs":["LSD"],"nct":"NCT01415427","nsites":43,"countries":"Argentina; Brazil; Canada; Colombia; Denmark; France; Germany; Italy; Japan; Netherlands; Norway; Portugal; Qatar; Saudi Arabia; South Korea; Spain; Taiwan; Turkey (Türkiye); United Kingdom; United States","ccs":["AR","BR","CA","CO","DE","DK","ES","FR","GB","IT","JP","KR","NL","NO","PT","QA","SA","TR","TW","US"],"start":"2011-07","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","sites":["Unnamed trial site — Phoenix, United States","Unnamed trial site — Oakland, United States","Unnamed trial site — Orange, United States","Unnamed trial site — Wilmington, United States","Unnamed trial site — Washington D.C., United States","Unnamed trial site — Orlando, United States","Unnamed trial site — Honolulu, United States","Unnamed trial site — Chicago, United States"],"conds":["Mucopolysaccharidosis IV A","Morquio A Syndrome","MPS IVA"],"condg":["Other"],"enroll":173,"eid":"NCT01415427"},{"id":"study-NCT01386177","cat":"studies","name":"Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT01386177","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2011-07","official":"Matthias E Liechti, MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01386177","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Mood Disorder","Substance-Related Disorders","Amphetamine-Related Disorders"],"condg":["Addiction & substance use"],"enroll":16,"eid":"NCT01386177"},{"id":"study-NCT02429011","cat":"studies","name":"MRI Studies of Emotion in Depression","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","drugs":["ketamine"],"nct":"NCT02429011","nsites":1,"countries":"United States","ccs":["US"],"start":"2011-07-15","official":"James Murrough, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT02429011","sites":["Icahn School of Medicine at Mount Sinai — New York, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":135,"eid":"NCT02429011"},{"id":"study-NCT01394757","cat":"studies","name":"Network Dysfunction, Schizophrenia and Pharmacological Magnetic Resonance Imaging (phMRI)","status":"COMPLETED","phase":"N/A","sponsor":"Medical University of Vienna","drugs":["esketamine"],"nct":"NCT01394757","nsites":1,"countries":"Austria","ccs":["AT"],"start":"2011-08","official":"Rupert Lanzenberger, A/Prof., MD (Department of Psychiatry and Psychotherapy, Medical University of Vienna)","src":"https://clinicaltrials.gov/study/NCT01394757","sites":["Department of Psychiatry and Psychotherapy, Medical University of Vienna — Vienna, Austria"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":52,"eid":"NCT01394757"},{"id":"study-NCT01535976","cat":"studies","name":"Ketamine Infusion and Hypoventilation","status":"COMPLETED","phase":"N/A","sponsor":"Northwestern University","drugs":["ketamine"],"nct":"NCT01535976","nsites":1,"countries":"United States","ccs":["US"],"start":"2011-08","official":"Gildasio De Oliveira, MD (Northwestern University)","src":"https://clinicaltrials.gov/study/NCT01535976","sites":["Prentice Womens Hospital — Chicago, United States"],"conds":["Hypoventilation"],"condg":["Other"],"enroll":54,"eid":"NCT01535976"},{"id":"study-NCT01567852","cat":"studies","name":"Use of Ketamine vs Methohexital for Electroconvulsive Therapy (ECT) on Patient Recovery and Re-orientation Time","status":"COMPLETED","phase":"N/A","sponsor":"University of New Mexico","drugs":["ketamine"],"nct":"NCT01567852","nsites":1,"countries":"United States","ccs":["US"],"start":"2011-08","official":"Tony Yen, MD (University of New Mexico)","src":"https://clinicaltrials.gov/study/NCT01567852","sites":["University of New Mexico — Albuquerque, United States"],"conds":["Post-anesthesia Recovery","Orientation"],"condg":["Other"],"enroll":20,"eid":"NCT01567852"},{"id":"study-NCT01441505","cat":"studies","name":"A Study of Ketamine as an Antidepressant","status":"UNKNOWN","phase":"Phase 2","sponsor":"The University of New South Wales","drugs":["ketamine"],"nct":"NCT01441505","nsites":1,"countries":"Australia","ccs":["AU"],"start":"2011-09","official":"Colleen K Loo, MB BS FRANZCP MD (University of New South Wales)","src":"https://clinicaltrials.gov/study/NCT01441505","sites":["Wesley Hospital — Kogarah, Australia"],"conds":["Major Depressive Episode"],"condg":["Depression"],"contact":{"n":"Angelo Alonzo","p":"61 02 9382 3720","e":"TMSandDCS@unsw.edu.au"},"enroll":42,"eid":"NCT01441505"},{"id":"study-NCT01435213","cat":"studies","name":"Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Turku","drugs":["ketamine"],"nct":"NCT01435213","nsites":2,"countries":"Finland","ccs":["FI"],"start":"2011-09","official":"Juha Rinne, MD, PhD (University of Turku)","src":"https://clinicaltrials.gov/study/NCT01435213","sites":["University of Turku, Clinical Research Services Turku CRST — Turku, Finland","University of Turku, Turku PET Centre — Turku, Finland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":10,"eid":"NCT01435213"},{"id":"study-NCT01515956","cat":"studies","name":"Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)","status":"COMPLETED","phase":"Phase 2","sponsor":"BioMarin Pharmaceutical","drugs":["LSD"],"nct":"NCT01515956","nsites":5,"countries":"Italy; Taiwan; United Kingdom; United States","ccs":["GB","IT","TW","US"],"start":"2011-10","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01515956","sites":["Unnamed trial site — Oakland, United States","Unnamed trial site — Manhasset, United States","Unnamed trial site — Monza, Italy","Unnamed trial site — Taipei, Taiwan","Unnamed trial site — Central Manchester, United Kingdom"],"conds":["Mucopolysaccharidosis IVA","Morquio A Syndrome","MPS IVA"],"condg":["Other"],"enroll":15,"eid":"NCT01515956"},{"id":"study-NCT01546051","cat":"studies","name":"A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"BrainCells Inc.","drugs":["ketamine"],"nct":"NCT01546051","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2011-10","official":"Principal Investigator (PRA Health Sciences)","src":"https://clinicaltrials.gov/study/NCT01546051","sites":["PRA International — Zuidlaren, Netherlands"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":31,"eid":"NCT01546051"},{"id":"study-NCT01304147","cat":"studies","name":"Intranasal Ketamine in Treatment-Resistant Depression","status":"COMPLETED","phase":"N/A","sponsor":"James Murrough","drugs":["ketamine"],"nct":"NCT01304147","nsites":1,"countries":"United States","ccs":["US"],"start":"2011-10","official":"James W Murrough, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT01304147","sites":["Icahn School of Medicine at Mount Sinai — New York, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":20,"eid":"NCT01304147"},{"id":"study-NCT01477242","cat":"studies","name":"The Effect of Ondansetron During Intramuscular Ketamine Use in Children: A Trial in Emergency Department","status":"UNKNOWN","phase":"N/A","sponsor":"Seoul National University Hospital","drugs":["ketamine"],"nct":"NCT01477242","nsites":1,"countries":"South Korea","ccs":["KR"],"start":"2011-11","official":"Do Kyun Kim, M.D. (Seoul National University Hospital)","src":"https://clinicaltrials.gov/study/NCT01477242","sites":["Seoul National University Hospital — Seoul, South Korea"],"conds":["Sedation and Analgesia","Side Effect of Drug"],"condg":["Other"],"contact":{"n":"Do Kyun Kim, M.D.","p":"82-2-2072-0238","e":"birdbeak@naver.com"},"enroll":266,"eid":"NCT01477242"},{"id":"study-NCT01465685","cat":"studies","name":"Emotional Effects of Methylphenidate and MDMA in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT01465685","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2011-12","official":"Matthias E Liechti, MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01465685","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":16,"eid":"NCT01465685"},{"id":"study-NCT02378415","cat":"studies","name":"Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression","status":"TERMINATED","phase":"Phase 1","sponsor":"United States Naval Medical Center, San Diego","drugs":["ketamine"],"nct":"NCT02378415","nsites":1,"countries":"United States","ccs":["US"],"start":"2011-12","official":"Robert E Lovern, MD (United States Naval Medical Center, San Diego)","src":"https://clinicaltrials.gov/study/NCT02378415","sites":["Naval Medical Center San Diego — San Diego, United States"],"conds":["Acute Depression"],"condg":["Depression"],"enroll":20,"eid":"NCT02378415"},{"id":"study-NCT02233452","cat":"studies","name":"Methadone and Ketamine for Neuropathic Pain Treatment","status":"COMPLETED","phase":"Phase 4","sponsor":"Universidade Federal de Santa Maria","drugs":["esketamine","ketamine"],"nct":"NCT02233452","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2012-01","official":"Juliano Ferreira, PhD (Federal University of Santa Catarina)","src":"https://clinicaltrials.gov/study/NCT02233452","sites":["University Hospital in Santa Maria — Santa Maria, Brazil"],"conds":["Neuropathic Pain"],"condg":["Chronic pain & headache"],"enroll":37,"eid":"NCT02233452"},{"id":"study-NCT01501786","cat":"studies","name":"Does Ketamine Attenuate Depression of Respiratory and Cardiac Functions","status":"COMPLETED","phase":"N/A","sponsor":"Ibaraki Children's Hospital","drugs":["ketamine"],"nct":"NCT01501786","nsites":1,"countries":"Japan","ccs":["JP"],"start":"2012-01","official":"Kazuhiko Okuyama, MD (Ibaraki Children's Hospital); Yuki Takeda, MD (Ibaraki Children's Hospital)","src":"https://clinicaltrials.gov/study/NCT01501786","sites":["Ibaraki Children's Hospital — Mito, Japan"],"conds":["Congenital Heart Disease","Sedated for Cardiac Catheterization"],"condg":["Other"],"enroll":150,"eid":"NCT01501786"},{"id":"study-NCT01507181","cat":"studies","name":"Ketamine For Suicidal Ideation","status":"COMPLETED","phase":"Phase 4","sponsor":"James Murrough","drugs":["ketamine"],"nct":"NCT01507181","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-01","official":"James Murrough, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT01507181","sites":["Icahn School of Medicine at Mount Sinai — New York, United States"],"conds":["Suicidal Ideation"],"condg":["Other"],"enroll":24,"eid":"NCT01507181"},{"id":"study-NCT01500018","cat":"studies","name":"Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214","status":"WITHDRAWN","phase":"Phase 1","sponsor":"AstraZeneca","drugs":["ketamine"],"nct":"NCT01500018","nsites":0,"start":"2012-01","official":"Hans A Eriksson, MD (AstraZeneca Kvzmbergagatan 12, 15185,Sodertalje, Sweden); Pierre Geoffroy, MDCM, MSC, FCFP (Syneos Health)","src":"https://clinicaltrials.gov/study/NCT01500018","conds":["Drug Abuse","Healthy"],"condg":["Healthy volunteers"],"eid":"NCT01500018"},{"id":"study-NCT01534494","cat":"studies","name":"Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence","status":"COMPLETED","phase":"Phase 2","sponsor":"University of New Mexico","drugs":["psilocybin"],"nct":"NCT01534494","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-01","official":"Michael P Bogenschutz, M.D. (University of New Mexico)","src":"https://clinicaltrials.gov/study/NCT01534494","sites":["University of New Mexico Health Sciences Center — Albuquerque, United States"],"conds":["Alcohol Dependence"],"condg":["Addiction & substance use"],"enroll":10,"eid":"NCT01534494"},{"id":"study-NCT00979693","cat":"studies","name":"Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Multidisciplinary Association for Psychedelic Studies","drugs":["psilocybin"],"nct":"NCT00979693","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-01","official":"Sameet Kumar, Ph.D (Psycho-oncologist, Mount Sinai Comprehensive Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00979693","sites":["Mount Sinai Comprehensive Cancer Center — Miami Beach, United States"],"conds":["Anxiety","Stage IV Melanoma"],"condg":["Anxiety"],"eid":"NCT00979693"},{"id":"study-NCT03415191","cat":"studies","name":"The Pre-Emptive Administration Of Ketamine for Controlling Post-thoracotomy Pain","status":"COMPLETED","phase":"N/A","sponsor":"University of Campania Luigi Vanvitelli","drugs":["ketamine"],"nct":"NCT03415191","nsites":1,"countries":"Italy","ccs":["IT"],"start":"2012-01-05","official":"Alfonso Fiorelli, MD, PhD (University of Campania Luigi Vanvitelli)","src":"https://clinicaltrials.gov/study/NCT03415191","sites":["Alfonso Fiorelli — Naples, Italy"],"conds":["Post Thoracotomy Pain"],"condg":["Chronic pain & headache"],"enroll":75,"eid":"NCT03415191"},{"id":"study-NCT07811713","cat":"studies","name":"Effect of LSD on Renal Function in Cirrhotic Patients With Portal Hypertension","status":"COMPLETED","sponsor":"Northern Jiangsu People's Hospital","drugs":["LSD"],"nct":"NCT07811713","nsites":0,"start":"2012-02","official":"guoqing jiang (Clinical Medical College, Yangzhou University)","src":"https://clinicaltrials.gov/study/NCT07811713","conds":["Cirrhosis, Liver","Splenectomy; Status","Renal Function Abnormal","Portal Hypertension"],"condg":["Other"],"enroll":496,"eid":"NCT07811713"},{"id":"study-NCT02342366","cat":"studies","name":"Characterization of the Prosocial and Prosexual Effects of GHB","status":"COMPLETED","phase":"N/A","sponsor":"University of Zurich","drugs":["MDMA"],"nct":"NCT02342366","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2012-02","official":"Erich Seifritz, Professor (University of Zurich)","src":"https://clinicaltrials.gov/study/NCT02342366","sites":["Hospital for Psychiatry, University of Zurich — Zurich, Switzerland"],"conds":["Depressive Disorder, Major","Bipolar Disorder","Autistic Disorder"],"condg":["Depression","Bipolar"],"enroll":19,"eid":"NCT02342366"},{"id":"study-NCT01538745","cat":"studies","name":"Low Dose Ketamine (LDK) Versus Morphine for Acute Pain Control in the Emergency Department","status":"COMPLETED","phase":"Phase 4","sponsor":"Brooke Army Medical Center","drugs":["ketamine"],"nct":"NCT01538745","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-02","official":"Joshua P Miller, MD (United States Air Force)","src":"https://clinicaltrials.gov/study/NCT01538745","sites":["Brooke Army Medical Center — San Antonio, United States"],"conds":["Abdomen, Acute","Other Acute Pain","Flank Pain","Back Pain","Musculoskeletal Pain"],"condg":["Chronic pain & headache"],"enroll":45,"eid":"NCT01538745"},{"id":"study-NCT01573741","cat":"studies","name":"Study of Ketamine as an Antidepressant in Major Depressive Disorder","status":"UNKNOWN","phase":"Phase 1/Phase 2","sponsor":"Shi Jinyun","drugs":["ketamine"],"nct":"NCT01573741","nsites":1,"countries":"China","ccs":["CN"],"start":"2012-02","official":"Jianjun Yang, Dr (Department of Anesthesiology, Jinling Hospital, School of Medicine, Nanjing University)","src":"https://clinicaltrials.gov/study/NCT01573741","sites":["The PLA 102nd Hospital and mental health center of military — Changzhou, China"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Qin zhi Gao, MD","p":"051983064728","e":"gzq_102@hotmail.com"},"enroll":35,"eid":"NCT01573741"},{"id":"study-NCT01535937","cat":"studies","name":"The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence","status":"TERMINATED","phase":"Phase 1/Phase 2","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT01535937","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-02","official":"Herbert Kleber, M.D. (NYSPI); Elias Dakwar, MD (New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT01535937","sites":["New York State Psychiatric Institute — New York, United States"],"conds":["Cocaine Dependence"],"condg":["Addiction & substance use"],"enroll":55,"eid":"NCT01535937"},{"id":"study-NCT01558063","cat":"studies","name":"Ketamine in the Treatment of Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Columbia University","drugs":["ketamine"],"nct":"NCT01558063","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-02","official":"Michael F. Grunebaum, M.D. (Columbia University)","src":"https://clinicaltrials.gov/study/NCT01558063","sites":["New York State Psychiatric Institute — New York, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":38,"eid":"NCT01558063"},{"id":"study-NCT01870219","cat":"studies","name":"Effects of Sevoflurane and Ketamine on QT in Electroconvulsive Therapy","status":"COMPLETED","phase":"Phase 4","sponsor":"Inonu University","drugs":["ketamine"],"nct":"NCT01870219","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2012-02","official":"Feray Erdil, MD (Associated Prof Dr)","src":"https://clinicaltrials.gov/study/NCT01870219","sites":["Turgut Ozal Medical Center — Malatya, Turkey"],"conds":["Major Depression","Electroconvulsive Therapy"],"condg":["Depression"],"enroll":24,"eid":"NCT01870219"},{"id":"study-NCT01548703","cat":"studies","name":"A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"BrainCells Inc.","drugs":["ketamine"],"nct":"NCT01548703","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2012-02","official":"Salah Hadi, MD (PRA Health Sciences)","src":"https://clinicaltrials.gov/study/NCT01548703","sites":["PRA International — Zuidlaren, Netherlands"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":30,"eid":"NCT01548703"},{"id":"study-NCT01566448","cat":"studies","name":"Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash","status":"COMPLETED","phase":"Phase 2","sponsor":"Aaron Cumpston, PharmD, BCOP","drugs":["ketamine"],"nct":"NCT01566448","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-02","official":"Aaron Cumpston, PharmD (West Virginia University)","src":"https://clinicaltrials.gov/study/NCT01566448","sites":["West Virginia University Hospitals Mary Babb Randolph Cancer Center — Morgantown, United States"],"conds":["Mucositis"],"condg":["Other"],"enroll":30,"eid":"NCT01566448"},{"id":"study-NCT01551329","cat":"studies","name":"Ketamine for Depression and Alcohol Dependence","status":"COMPLETED","phase":"Phase 1","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT01551329","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-03","official":"Ismene Petrakis, M.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT01551329","sites":["VA CT Healthcare Systems — West Haven, United States"],"conds":["Depression","Alcohol Dependence"],"condg":["Depression","Addiction & substance use"],"enroll":5,"eid":"NCT01551329"},{"id":"study-NCT01557712","cat":"studies","name":"Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks","status":"COMPLETED","phase":"Phase 3","sponsor":"University Hospital, Grenoble","drugs":["ketamine"],"nct":"NCT01557712","nsites":1,"countries":"France","ccs":["FR"],"start":"2012-03","src":"https://clinicaltrials.gov/study/NCT01557712","sites":["Centre hospitalier universitaire — Grenoble, France"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":25,"eid":"NCT01557712"},{"id":"study-NCT01609062","cat":"studies","name":"Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome","status":"TERMINATED","phase":"Phase 2","sponsor":"BioMarin Pharmaceutical","drugs":["LSD"],"nct":"NCT01609062","nsites":11,"countries":"Canada; Germany; United Kingdom; United States","ccs":["CA","DE","GB","US"],"start":"2012-04","official":"Adam Shaywitz, MD PhD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01609062","sites":["Unnamed trial site — Oakland, United States","Unnamed trial site — Chicago, United States","Unnamed trial site — New York, United States","Unnamed trial site — Houston, United States","Unnamed trial site — Calgary, Canada","Unnamed trial site — Toronto, Canada","Unnamed trial site — Montreal, Canada","Unnamed trial site — Sherbrook, Canada"],"conds":["Mucopolysaccharidosis IVA","Morquio A Syndrome","MPS IVA"],"condg":["Other"],"enroll":25,"eid":"NCT01609062"},{"id":"study-NCT01948336","cat":"studies","name":"The Effects of Dexmedetomidine on Early Stage Renal Functions in Pediatric Patients","status":"COMPLETED","phase":"Phase 4","sponsor":"TC Erciyes University","drugs":["ketamine"],"nct":"NCT01948336","nsites":0,"start":"2012-04","official":"Adnan Bayram, Asst. Prof. (TC Erciyes University)","src":"https://clinicaltrials.gov/study/NCT01948336","conds":["Renal Function Disorder","Hemodynamic Instability"],"condg":["Other"],"enroll":60,"eid":"NCT01948336"},{"id":"study-NCT02648412","cat":"studies","name":"Pupillary Dilation After Incremental Tetanic Stimulations Under Ketamine Sedation","status":"COMPLETED","phase":"N/A","sponsor":"Pr Isabelle CONSTANT","drugs":["ketamine"],"nct":"NCT02648412","nsites":1,"countries":"France","ccs":["FR"],"start":"2012-04","official":"Isabelle Constant, PHD (University Hospital Armand Trousseau)","src":"https://clinicaltrials.gov/study/NCT02648412","sites":["Departement d'anesthesie Hopital Armand Trousseau — Paris, France"],"conds":["Pain","Anesthesia"],"condg":["Chronic pain & headache"],"enroll":24,"eid":"NCT02648412"},{"id":"study-NCT01524237","cat":"studies","name":"A Study of LY2979165 and LY2140023 in Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"Eli Lilly and Company","drugs":["ketamine"],"nct":"NCT01524237","nsites":2,"countries":"United Kingdom","ccs":["GB"],"start":"2012-04","official":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) (Eli Lilly and Company)","src":"https://clinicaltrials.gov/study/NCT01524237","sites":["For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — London, United Kingdom","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — London, United Kingdom"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":52,"eid":"NCT01524237"},{"id":"study-NCT01179009","cat":"studies","name":"Treatment Resistant Depression (Pilot)","status":"COMPLETED","phase":"N/A","sponsor":"Washington University School of Medicine","drugs":["ketamine"],"nct":"NCT01179009","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-04","official":"Eric Lenze, MD (Washington University School of Medicine); John W Newcomer, MD (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT01179009","sites":["Washington University School of Medicine — St Louis, United States"],"conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"enroll":20,"eid":"NCT01179009"},{"id":"study-NCT01669642","cat":"studies","name":"Study to Find the Dose of Rapidly Administered Ketamine for Brief Painful Procedures in Children","status":"COMPLETED","phase":"N/A","sponsor":"Washington University School of Medicine","drugs":["ketamine"],"nct":"NCT01669642","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-04","official":"sri s chinta, MD (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT01669642","sites":["St Louis Children's hospital, Washington university — St Louis, United States"],"conds":["Abscess","Fracture"],"condg":["Other"],"enroll":111,"eid":"NCT01669642"},{"id":"study-NCT01582945","cat":"studies","name":"Ketamine Infusion for Treatment-resistant Major Depressive Disorder","status":"COMPLETED","phase":"N/A","sponsor":"Massachusetts General Hospital","drugs":["ketamine"],"nct":"NCT01582945","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-04","official":"Cristina Cusin, MD (MGH Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT01582945","sites":["Depression Clinical and Research Program - MGH — Boston, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":14,"eid":"NCT01582945"},{"id":"study-NCT02664922","cat":"studies","name":"Anesthetic Techniques in EP Patients","status":"TERMINATED","phase":"Phase 4","sponsor":"University of California, Los Angeles","drugs":["ketamine"],"nct":"NCT02664922","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-05","official":"Aman Mahajan, MD, PhD (University of California, Los Angeles)","src":"https://clinicaltrials.gov/study/NCT02664922","sites":["Ronald Reagan UCLA Medical Center — Los Angeles, United States"],"conds":["Cardiac Disease"],"condg":["Other"],"enroll":35,"eid":"NCT02664922"},{"id":"study-NCT02512055","cat":"studies","name":"Ketamine Tolerance in Children After Repeated Administrations During Radiotherapy Sessions","status":"COMPLETED","phase":"Phase 4","sponsor":"Baskent University","drugs":["ketamine"],"nct":"NCT02512055","nsites":0,"start":"2012-05","src":"https://clinicaltrials.gov/study/NCT02512055","conds":["Conscious Sedation Failure During Procedure"],"condg":["Other"],"enroll":33,"eid":"NCT02512055"},{"id":"study-NCT01602185","cat":"studies","name":"Study of NMDA Antagonists and Neuropathic Pain","status":"COMPLETED","phase":"Phase 2","sponsor":"University Hospital, Clermont-Ferrand","drugs":["ketamine"],"nct":"NCT01602185","nsites":1,"countries":"France","ccs":["FR"],"start":"2012-05","official":"Gisèle PICKERING (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT01602185","sites":["CHU Clermont-Ferrand — Clermont-Ferrand, France"],"conds":["Neuropathic Pain"],"condg":["Chronic pain & headache"],"enroll":7,"eid":"NCT01602185"},{"id":"study-NCT01887990","cat":"studies","name":"Treatment of Suicidal Ideation With Intravenous Ketamine Infusion","status":"COMPLETED","phase":"N/A","sponsor":"University of Alabama at Birmingham","drugs":["ketamine"],"nct":"NCT01887990","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-05","official":"Cheryl B McCullumsmith, MD PhD (University of Alabama at Birmingham)","src":"https://clinicaltrials.gov/study/NCT01887990","sites":["University of Alabama Birmingham — Birmingham, United States"],"conds":["Depression","Suicidal Ideation"],"condg":["Depression"],"enroll":18,"eid":"NCT01887990"},{"id":"study-NCT01691092","cat":"studies","name":"PET Imaging of mGLuR5 With Drug Challenge","status":"COMPLETED","phase":"N/A","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT01691092","nsites":3,"countries":"United States","ccs":["US"],"start":"2012-06","official":"Irina Esterlis, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT01691092","sites":["Connecticut Mental Health Center — New Haven, United States","Yale University Magnetic Resonance Research Center (MRRC) — New Haven, United States","Yale University PET Center — New Haven, United States"],"conds":["Major Depressive Disorder","Post-Traumatic Stress Disorder (PTSD)"],"condg":["Depression","PTSD & trauma"],"enroll":79,"eid":"NCT01691092"},{"id":"study-NCT01371110","cat":"studies","name":"Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder","status":"TERMINATED","phase":"Phase 1/Phase 2","sponsor":"Wayne Goodman MD","drugs":["ketamine"],"nct":"NCT01371110","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-06","official":"Wayne K Goodman, MD (Baylor College of Medicine (previously Icahn School of Medicine at Mount Sinai)); Kyle Lapidus, MD ((previously Icahn School of Medicine…","src":"https://clinicaltrials.gov/study/NCT01371110","sites":["Clinical Research Centers at Icahn School of Medicine at Mount Sinai — New York, United States"],"conds":["Obsessive Compulsive Disorder"],"condg":["OCD"],"enroll":3,"eid":"NCT01371110"},{"id":"study-NCT01700829","cat":"studies","name":"Ketamine in the Treatment of Suicidal Depression","status":"COMPLETED","phase":"Phase 4","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT01700829","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-06","official":"Michael F. Grunebaum, M.D. (Columbia University/New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT01700829","sites":["Columbia University/New York State Psychiatric Institute — New York, United States"],"conds":["Major Depressive Disorder","Suicidal Ideation"],"condg":["Depression"],"enroll":82,"eid":"NCT01700829"},{"id":"study-NCT01640080","cat":"studies","name":"A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT01640080","nsites":9,"countries":"Belgium; Germany; Poland","ccs":["BE","DE","PL"],"start":"2012-06-27","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01640080","sites":["Unnamed trial site — Dave, Belgium","Unnamed trial site — Ghent, Belgium","Unnamed trial site — Kortenberg, Belgium","Unnamed trial site — Lede, Belgium","Unnamed trial site — Berlin, Germany","Unnamed trial site — Freiburg im Breisgau, Germany","Unnamed trial site — Mainz, Germany","Unnamed trial site — München, Germany"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":30,"eid":"NCT01640080"},{"id":"study-NCT01504659","cat":"studies","name":"Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder","status":"TERMINATED","phase":"Phase 2/Phase 3","sponsor":"Juvenile Bipolar Research Foundation","drugs":["ketamine"],"nct":"NCT01504659","nsites":4,"countries":"United States","ccs":["US"],"start":"2012-07","official":"Demitri Papolos, MD (Juvenile Bipolar Research Foundation)","src":"https://clinicaltrials.gov/study/NCT01504659","sites":["Individual homes of subjects — Not Predetermined, United States","Juvenile Bipolar Research Foundation — Maplewood, United States","Individual homes of subjects — Not Predetermined, United States","Individual homes of subjects — Not Predetermined, United States"],"conds":["Bipolar Disorder"],"condg":["Bipolar"],"enroll":5,"eid":"NCT01504659"},{"id":"study-NCT01697319","cat":"studies","name":"Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation","status":"TERMINATED","phase":"Phase 2","sponsor":"BioMarin Pharmaceutical","drugs":["LSD"],"nct":"NCT01697319","nsites":7,"countries":"Germany; United Kingdom; United States","ccs":["DE","GB","US"],"start":"2012-08","official":"Celeste Decker, M.D. (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01697319","sites":["Children's Hospital & Research Center Oakland — Oakland, United States","Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, United States","Universitätsklinikum Hamburg — Hamburg, Germany","University Medical Center Mainz, Center of Pediatric and Adolescent Medicine Villa Metabolica — Mainz, Germany","NIHR/Wellcome Trust Birmingham CRF, Queen Elizabeth Hospital — Birmingham, United Kingdom","Central Manchester University Hospitals NHS Foundation Trust — Manchester, United Kingdom","Salford Royal NHS Foundation Trust — Salford, United Kingdom"],"conds":["Mucopolysaccharidosis IVA","Morquio A Syndrome","MPS IVA"],"condg":["Other"],"enroll":16,"eid":"NCT01697319"},{"id":"study-NCT01616407","cat":"studies","name":"Effects of MDMA and Methylphenidate on Social Cognition","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT01616407","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2012-08","official":"Matthias E Liechti, MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01616407","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Social Cognition"],"condg":["Other"],"enroll":30,"eid":"NCT01616407"},{"id":"study-NCT01680172","cat":"studies","name":"Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer","status":"TERMINATED","phase":"Phase 2","sponsor":"Mayo Clinic","drugs":["ketamine"],"nct":"NCT01680172","nsites":2,"countries":"United States","ccs":["US"],"start":"2012-08","official":"Robert P. Bright, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT01680172","sites":["Mayo Clinic in Arizona — Scottsdale, United States","Yuma Regional Medical Center — Yuma, United States"],"conds":["Cancer","Depression","Anxiety"],"condg":["Depression","Anxiety","Cancer-related distress"],"enroll":5,"eid":"NCT01680172"},{"id":"study-NCT01794975","cat":"studies","name":"Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Turku","drugs":["ketamine"],"nct":"NCT01794975","nsites":1,"countries":"Finland","ccs":["FI"],"start":"2012-08","official":"Juha Rinne, PhD (Turku PET Centre)","src":"https://clinicaltrials.gov/study/NCT01794975","sites":["Clinical Research Services Turku (CRST) / Turku PET Centre — Turku, Finland"],"conds":["Changes in Striatal [11C]ORM-13070 Binding."],"condg":["Other"],"enroll":8,"eid":"NCT01794975"},{"id":"study-NCT01627782","cat":"studies","name":"A Study of Ketamine in Patients With Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Janssen Research & Development, LLC","drugs":["ketamine"],"nct":"NCT01627782","nsites":13,"countries":"United States","ccs":["US"],"start":"2012-08-06","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01627782","sites":["Unnamed trial site — Birmingham, United States","Unnamed trial site — Little Rock, United States","Unnamed trial site — Centennial, United States","Unnamed trial site — Hartford, United States","Unnamed trial site — New Haven, United States","Unnamed trial site — Atlanta, United States","Unnamed trial site — Rockville, United States","Unnamed trial site — Marlton, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":68,"eid":"NCT01627782"},{"id":"study-NCT01740492","cat":"studies","name":"Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department","status":"COMPLETED","phase":"Phase 1","sponsor":"Rhode Island Hospital","drugs":["ketamine"],"nct":"NCT01740492","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-09","official":"Francesca Beaudoin, MD (Rhode Island Hospital)","src":"https://clinicaltrials.gov/study/NCT01740492","sites":["Rhode Island Hospital — Providence, United States"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":75,"eid":"NCT01740492"},{"id":"study-NCT02817477","cat":"studies","name":"Intranasal Ketamine for Acute Traumatic Pain","status":"COMPLETED","phase":"Phase 4","sponsor":"Tel Aviv Medical Center","drugs":["ketamine"],"nct":"NCT02817477","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2012-09","official":"Pinchas Halpern, MD (Tel Aviv Medical Center)","src":"https://clinicaltrials.gov/study/NCT02817477","sites":["Tel Aviv Medical Center — Tel Aviv, Israel"],"conds":["Acute Pain"],"condg":["Chronic pain & headache"],"enroll":90,"eid":"NCT02817477"},{"id":"study-NCT01169025","cat":"studies","name":"Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients","status":"WITHDRAWN","phase":"N/A","sponsor":"University of Utah","drugs":["ketamine"],"nct":"NCT01169025","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-09","official":"Scott T Youngquist, MD, MS (University of Utah)","src":"https://clinicaltrials.gov/study/NCT01169025","sites":["University of Utah Medical Center — Salt Lake City, United States"],"conds":["Trauma","Pain"],"condg":["PTSD & trauma","Chronic pain & headache"],"eid":"NCT01169025"},{"id":"study-NCT01780259","cat":"studies","name":"A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT01780259","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2012-12","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01780259","sites":["Unnamed trial site — Merksem, Belgium"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":58,"eid":"NCT01780259"},{"id":"study-NCT01951963","cat":"studies","name":"Sub-dissociative Ketamine for the Management of Acute Pediatric Pain","status":"COMPLETED","phase":"Phase 4","sponsor":"HealthPartners Institute","drugs":["ketamine"],"nct":"NCT01951963","nsites":1,"countries":"United States","ccs":["US"],"start":"2012-12","official":"Aaron M Burnett, MD (Regions Hospital)","src":"https://clinicaltrials.gov/study/NCT01951963","sites":["Regions Hospital — Saint Paul, United States"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":77,"eid":"NCT01951963"},{"id":"study-NCT01749098","cat":"studies","name":"A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"Biogen","drugs":["ketamine"],"nct":"NCT01749098","nsites":2,"countries":"United States","ccs":["US"],"start":"2012-12","official":"Medical Director (Biogen)","src":"https://clinicaltrials.gov/study/NCT01749098","sites":["Pfizer Investigational Site — New Haven, United States","Pfizer Investigational Site — West Haven, United States"],"conds":["Schizophrenia"],"condg":["Other"],"enroll":29,"eid":"NCT01749098"},{"id":"study-NCT01771874","cat":"studies","name":"Influence of Bupropion on the Effects of MDMA","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT01771874","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2013-01","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01771874","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Healthy","Substance-related Disorders"],"condg":["Addiction & substance use","Healthy volunteers"],"enroll":16,"eid":"NCT01771874"},{"id":"study-NCT01768767","cat":"studies","name":"Trial of Ketamine and Lithium Therapy in Bipolar Depression","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT01768767","nsites":0,"start":"2013-01","official":"Chadi Abdallah, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT01768767","conds":["Bipolar Depression"],"condg":["Depression","Bipolar"],"eid":"NCT01768767"},{"id":"study-NCT01755169","cat":"studies","name":"Ketamine in Chronic Kid's (KiCK) Pain","status":"TERMINATED","phase":"Phase 2","sponsor":"Medical University of South Carolina","drugs":["ketamine"],"nct":"NCT01755169","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-01","official":"Amy-Lee Bredlau, MD (Medical University of South Carolina)","src":"https://clinicaltrials.gov/study/NCT01755169","sites":["Medical University of South Carolina — Charleston, United States"],"conds":["Chronic Pain"],"condg":["Chronic pain & headache"],"enroll":7,"eid":"NCT01755169"},{"id":"study-NCT01667926","cat":"studies","name":"Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder","status":"COMPLETED","phase":"N/A","sponsor":"Massachusetts General Hospital","drugs":["ketamine"],"nct":"NCT01667926","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-01","official":"Cristina Cusin, M.D. (MGH Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT01667926","sites":["Depression Clinical and Reseach Program - MGH — Boston, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":37,"eid":"NCT01667926"},{"id":"study-NCT01827020","cat":"studies","name":"Effect of Ketamine Addition to Lidocaine in Rhinoplasty","status":"COMPLETED","phase":"Phase 4","sponsor":"Inonu University","drugs":["ketamine"],"nct":"NCT01827020","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2013-01","official":"Mukadder Sanli, MD (Turgut Ozal Medical Center)","src":"https://clinicaltrials.gov/study/NCT01827020","sites":["Turgut Ozal Medical Center — Malatya, Turkey"],"conds":["Nose Deformities, Acquired"],"condg":["Other"],"enroll":90,"eid":"NCT01827020"},{"id":"study-NCT01689740","cat":"studies","name":"Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD","status":"COMPLETED","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT01689740","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2013-01-17","official":"Moshe Kotler (Beer Yaakov Hospital)","src":"https://clinicaltrials.gov/study/NCT01689740","sites":["Beer Yaakov Hospital — Be’er Ya‘aqov, Israel"],"conds":["Posttraumatic Stress Disorder (PTSD)"],"condg":["PTSD & trauma"],"enroll":10,"eid":"NCT01689740"},{"id":"study-NCT01833897","cat":"studies","name":"NMDA Antagonists in Bipolar Depression","status":"COMPLETED","phase":"Phase 4","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT01833897","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-03","official":"Joshua T Kantrowitz, MD (New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT01833897","sites":["New York State Psychiatric Institute — New York, United States"],"conds":["Bipolar Disorder"],"condg":["Bipolar"],"enroll":8,"eid":"NCT01833897"},{"id":"study-NCT01835262","cat":"studies","name":"Low Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department","status":"COMPLETED","phase":"Phase 4","sponsor":"Antonios Likourezos","drugs":["ketamine"],"nct":"NCT01835262","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-04","official":"Sergey Motov, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT01835262","sites":["Maimonides Medical Center — Brooklyn, United States"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":90,"eid":"NCT01835262"},{"id":"study-NCT03842800","cat":"studies","name":"Characterizing Clinical and Pharmacological Neuroimaging Biomarkers","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT03842800","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-04-01","official":"Alan Anticevic, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03842800","sites":["Magnetic Resonance Research Center — New Haven, United States"],"conds":["Cognitive Impairment"],"condg":["Neurology & cognition"],"enroll":143,"eid":"NCT03842800"},{"id":"study-NCT01945047","cat":"studies","name":"Action of Ketamine in Treatment-Resistant Depression","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"University of Ottawa","drugs":["ketamine"],"nct":"NCT01945047","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2013-05","official":"Pierre Blier, M.D, Ph.D (University of Ottawa)","src":"https://clinicaltrials.gov/study/NCT01945047","sites":["Institute of Mental Health Research, Royal Ottawa Hospital — Ottawa, Canada"],"conds":["Treatment-resistant Depression"],"condg":["Depression"],"enroll":46,"eid":"NCT01945047"},{"id":"study-NCT01988311","cat":"studies","name":"Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators","status":"COMPLETED","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT01988311","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-05","official":"Roland R Griffiths, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT01988311","sites":["Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center — Baltimore, United States"],"conds":["Psilocybin","Hallucinogens","Pharmacologic Actions","Central Nervous System Agents","Therapeutic Uses","Psychotropic Drugs"],"condg":["Other"],"enroll":10,"eid":"NCT01988311"},{"id":"study-NCT01793610","cat":"studies","name":"Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD","status":"COMPLETED","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT01793610","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-05-13","official":"Marcela d'Otalora, MA, LPC (Private Practice)","src":"https://clinicaltrials.gov/study/NCT01793610","sites":["Offices of Marcela d'Otalora — Boulder, United States"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":29,"eid":"NCT01793610"},{"id":"study-NCT01878942","cat":"studies","name":"Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD"],"nct":"NCT01878942","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2013-06","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01878942","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":16,"eid":"NCT01878942"},{"id":"study-NCT02049411","cat":"studies","name":"Ketamine and Changes of the Short Portable Mental Status Questionnaire","status":"COMPLETED","phase":"Phase 2","sponsor":"Instituto Mexicano del Seguro Social","drugs":["ketamine"],"nct":"NCT02049411","nsites":1,"countries":"Mexico","ccs":["MX"],"start":"2013-06","official":"Dulce M. Rascon, M.D (Instituto Mexicano del Seguro Social); Maria E. Ocharan, PhD. (Instituto Politecnico Nacional)","src":"https://clinicaltrials.gov/study/NCT02049411","sites":["Centro Medico Nacional Siglo XXI. UMAE Hospital de Especialidades — Mexico City, Mexico"],"conds":["Postoperative Cognitive Dysfunction"],"condg":["Neurology & cognition"],"enroll":80,"eid":"NCT02049411"},{"id":"study-NCT02048423","cat":"studies","name":"An Open Prospective Trial of IV Ketamine in Suicidal Adolescents","status":"UNKNOWN","phase":"Phase 2/Phase 3","sponsor":"Nationwide Children's Hospital","drugs":["ketamine"],"nct":"NCT02048423","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-06","official":"Robert A Kowatch, MD, PhD (OSU Medical Center/Nationwide Childrens Hospital)","src":"https://clinicaltrials.gov/study/NCT02048423","sites":["Nationwide Children's Hospital — Columbus, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Robert A Kowatch, MD, PhD","p":"614-355-2872","e":"robert.kowatch@nationwidechildrens.org"},"enroll":10,"eid":"NCT02048423"},{"id":"study-NCT01809340","cat":"studies","name":"The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression","status":"TERMINATED","phase":"Phase 2","sponsor":"Janssen Research & Development, LLC","drugs":["ketamine"],"nct":"NCT01809340","nsites":12,"countries":"Belgium; France; Netherlands; Spain","ccs":["BE","ES","FR","NL"],"start":"2013-06","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01809340","sites":["Unnamed trial site — Duffel, Belgium","Unnamed trial site — Lede, Belgium","Unnamed trial site — Leuven, Belgium","Unnamed trial site — Besançon, France","Unnamed trial site — Clermont-Ferrand, France","Unnamed trial site — Nîmes, France","Unnamed trial site — Leiden, Netherlands","Unnamed trial site — Alicante, Spain"],"conds":["Depressive Disorder"],"condg":["Depression"],"enroll":29,"eid":"NCT01809340"},{"id":"study-NCT03257800","cat":"studies","name":"Laryngeal Mask Insertion Conditions And Hemodynamic Effects","status":"COMPLETED","phase":"N/A","sponsor":"Leila mansali stambouli","drugs":["ketamine"],"nct":"NCT03257800","nsites":1,"countries":"Tunisia","ccs":["TN"],"start":"2013-06-01","official":"leila Mansali Stambouli, MD PhD (university Hospital of Fattouma Bourguiba, Monastir, TUNISIA)","src":"https://clinicaltrials.gov/study/NCT03257800","sites":["University Hospital of Fattouma Bourguiba — Monastir, Tunisia"],"conds":["Laryngeal Masks"],"condg":["Other"],"enroll":120,"eid":"NCT03257800"},{"id":"study-NCT06310850","cat":"studies","name":"The Effect of Preprocedural Subanesthetic Ketamine on Pain and Anxiety","status":"COMPLETED","phase":"Phase 3","sponsor":"Ankara Ataturk Sanatorium Training and Research Hospital","drugs":["ketamine"],"nct":"NCT06310850","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2013-06-01","official":"Onur KÜÇÜK, specialist (Ankara Ataturk Sanatorium Training and Research Hospital)","src":"https://clinicaltrials.gov/study/NCT06310850","sites":["Ankara Atatürk Sanatorium Training and Research Hospital — Ankara, Turkey"],"conds":["Epidural Catheterization","Thoracic","Procedural Pain"],"condg":["Chronic pain & headache"],"enroll":60,"eid":"NCT06310850"},{"id":"study-NCT01900847","cat":"studies","name":"Ketamine and Morphine Versus Morphine Alone for the Treatment of Acute Pain in the Emergency Department","status":"TERMINATED","phase":"N/A","sponsor":"University of Arizona","drugs":["ketamine"],"nct":"NCT01900847","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-06-01","src":"https://clinicaltrials.gov/study/NCT01900847","sites":["University of Arizona Health Network University Campus 1501 North Campbell Ave — Tucson, United States"],"conds":["Acute Pain"],"condg":["Chronic pain & headache"],"enroll":17,"eid":"NCT01900847"},{"id":"study-NCT02037035","cat":"studies","name":"Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT02037035","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-07","official":"Lynnette Averill, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT02037035","sites":["Yale Depression Research Program — New Haven, United States"],"conds":["Depression"],"condg":["Depression"],"enroll":36,"eid":"NCT02037035"},{"id":"study-NCT01880593","cat":"studies","name":"Ketamine Plus Lithium in Treatment-Resistant Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Icahn School of Medicine at Mount Sinai","drugs":["ketamine"],"nct":"NCT01880593","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-07","official":"James W Murrough, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT01880593","sites":["Icahn School of Medicine at Mount Sinai — New York, United States"],"conds":["Depression"],"condg":["Depression"],"enroll":34,"eid":"NCT01880593"},{"id":"study-NCT01879826","cat":"studies","name":"Pediatric Laser Acupuncture and Renal Biopsy","status":"COMPLETED","phase":"N/A","sponsor":"University of California, San Francisco","drugs":["ketamine"],"nct":"NCT01879826","nsites":2,"countries":"United States","ccs":["US"],"start":"2013-07","official":"Cynthia Kim, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT01879826","sites":["University of California San Francisco Hospital — San Francisco, United States","University of California, San Francisco — San Francisco, United States"],"conds":["Pain","Anxiety"],"condg":["Anxiety","Chronic pain & headache"],"enroll":81,"eid":"NCT01879826"},{"id":"study-NCT04751175","cat":"studies","name":"Management of Pain in Lumbar Arthrodesis","status":"COMPLETED","phase":"Phase 4","sponsor":"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta","drugs":["ketamine"],"nct":"NCT04751175","nsites":1,"countries":"Spain","ccs":["ES"],"start":"2013-07-04","official":"Emili Leon, MD (Hospital Dr Josep Trueta and Hospital Santa Caterina)","src":"https://clinicaltrials.gov/study/NCT04751175","sites":["Hospital Dr Josep Trueta — Girona, Spain"],"conds":["Pain, Postoperative"],"condg":["Chronic pain & headache"],"enroll":128,"eid":"NCT04751175"},{"id":"study-NCT01892189","cat":"studies","name":"Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults","status":"COMPLETED","phase":"Phase 1","sponsor":"Takeda","drugs":["ketamine"],"nct":"NCT01892189","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-08","official":"Medical Director (Takeda Development Center Americas, Inc. (Note: This product was divested to Axsome in 2026))","src":"https://clinicaltrials.gov/study/NCT01892189","sites":["The Brain Institute, University of Utah — Salt Lake City, United States"],"conds":["Ketamine-Induced Brain Activity Changes","Psychotic-like Symptoms"],"condg":["Other"],"enroll":27,"eid":"NCT01892189"},{"id":"study-NCT01626755","cat":"studies","name":"Prevention of Phantom Limb Pain After Transtibial Amputation","status":"TERMINATED","phase":"N/A","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","drugs":["ketamine"],"nct":"NCT01626755","nsites":9,"countries":"Austria; Belgium; Netherlands; Spain; United States","ccs":["AT","BE","ES","NL","US"],"start":"2013-08","official":"Markus Hollmann, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands); Philipp Lirk, MD PhD (Dept. of…","src":"https://clinicaltrials.gov/study/NCT01626755","sites":["Massachusetts General Hospital, Dept. of Anesthesiology, Perioperative and Pain Medicine — Boston, United States","General Hospital Klagenfurt — Klagenfurt, Austria","Innsbruck Medical University Hospital — Innsbruck, Austria","Ziekenhuis Oost Limburg — Genk, Belgium","Academic Medical Center, University of Amsterdam — Amsterdam, Netherlands","Westfriesgasthuis — Hoorn, Netherlands","Erasmus Medical Center — Rotterdam, Netherlands","Canisius Wilhelmus Ziekenhuis — Nijmegen, Netherlands"],"conds":["Phantom Limb Pain","Chronic Pain","Prevention"],"condg":["Chronic pain & headache"],"enroll":12,"eid":"NCT01626755"},{"id":"study-NCT02766192","cat":"studies","name":"TIMBER Psychotherapy and Ketamine Single Infusion in Chronic PTSD","status":"UNKNOWN","phase":"N/A","sponsor":"The Cooper Health System","drugs":["ketamine"],"nct":"NCT02766192","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-08","official":"Basant Pradhan, MD (Cooper Health System)","src":"https://clinicaltrials.gov/study/NCT02766192","sites":["Cooper University Hospital — Camden, United States"],"conds":["PTSD"],"condg":["PTSD & trauma"],"contact":{"n":"Jean Smith, PhD","p":"856-757-7814","e":"jean-smith@cooperhealth.edu"},"enroll":50,"eid":"NCT02766192"},{"id":"study-NCT01942356","cat":"studies","name":"Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor","status":"COMPLETED","phase":"N/A","sponsor":"The University of Texas Health Science Center at San Antonio","drugs":["ketamine"],"nct":"NCT01942356","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-09","official":"Erik Boatman, M.D. (University of Texas)","src":"https://clinicaltrials.gov/study/NCT01942356","sites":["University Hospital — San Antonio, United States"],"conds":["Acute Cholecystitis","Chronic Cholecystitis"],"condg":["Other"],"enroll":4,"eid":"NCT01942356"},{"id":"study-NCT02489630","cat":"studies","name":"Low Dose Ketamine as an Adjunct to Opiates for Acute Pain in the Emergency Department","status":"COMPLETED","phase":"Phase 4","sponsor":"Carilion Clinic","drugs":["ketamine"],"nct":"NCT02489630","nsites":0,"start":"2013-09","official":"Corey R Heitz, MD (Physician)","src":"https://clinicaltrials.gov/study/NCT02489630","conds":["Acute Pain","Pain"],"condg":["Chronic pain & headache"],"enroll":116,"eid":"NCT02489630"},{"id":"study-NCT02410460","cat":"studies","name":"Anesthetics in Rhytidoplasty - A Comparison Study","status":"COMPLETED","phase":"N/A","sponsor":"Mercy Facial Plastic Surgery Center","drugs":["ketamine"],"nct":"NCT02410460","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-09","src":"https://clinicaltrials.gov/study/NCT02410460","sites":["Mercy Facial Plastic Surgery Center — Springfield, United States"],"conds":["Rhytidoplasty"],"condg":["Other"],"enroll":30,"eid":"NCT02410460"},{"id":"study-NCT01868802","cat":"studies","name":"Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population","status":"UNKNOWN","phase":"Phase 2","sponsor":"Paul J. Lamothe","drugs":["ketamine"],"nct":"NCT01868802","nsites":1,"countries":"Mexico","ccs":["MX"],"start":"2013-09","official":"Paul J Lamothe, M.D. (American British Cowdray Medical Center); David N Lopez-Garza, M.D. (American British Cowdray Medical Center)","src":"https://clinicaltrials.gov/study/NCT01868802","sites":["ABC Neurological Center — Mexico City, Mexico"],"conds":["Depressive Disorder,","Treatment-Resistant Depression"],"condg":["Depression"],"contact":{"n":"Paul J Lamothe, M.D.","p":"+52 (55) 11031750","e":"paul@lamothe.com"},"enroll":60,"eid":"NCT01868802"},{"id":"study-NCT01944293","cat":"studies","name":"Ketamine for Suicidality in Bipolar Depression","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT01944293","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-09","official":"Michael F Grunebaum, M.D. (Columbia Unviversity/New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT01944293","sites":["Columbia University/New York State Psychiatric Institute — New York, United States"],"conds":["Bipolar Disorder","Major Depressive Episode","Suicidal Ideation"],"condg":["Depression","Bipolar"],"enroll":16,"eid":"NCT01944293"},{"id":"study-NCT01951911","cat":"studies","name":"Effectiveness of Ketamine in Malignant Neuropathic Pain Relief","status":"WITHDRAWN","phase":"Phase 3","sponsor":"Haukeland University Hospital","drugs":["ketamine"],"nct":"NCT01951911","nsites":1,"countries":"Norway","ccs":["NO"],"start":"2013-09","official":"Rae F Bell, M.D. PhD. (Pain Clinic, Haukeland University Hospital, 5021 Bergen, Norway)","src":"https://clinicaltrials.gov/study/NCT01951911","sites":["Haukeland University Hospital — Bergen, Norway"],"conds":["Pain, Intractable"],"condg":["Chronic pain & headache"],"eid":"NCT01951911"},{"id":"study-NCT01938079","cat":"studies","name":"Pharmacokinetic Alterations During ECMO","status":"COMPLETED","phase":"N/A","sponsor":"Columbia University","drugs":["ketamine"],"nct":"NCT01938079","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-09","official":"Daniel Brodie, MD (Columbia University)","src":"https://clinicaltrials.gov/study/NCT01938079","sites":["NewYork-Presbyterian Hospital — New York, United States"],"conds":["Acute Respiratory Failure"],"condg":["Other"],"enroll":20,"eid":"NCT01938079"},{"id":"study-NCT01951508","cat":"studies","name":"Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT01951508","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2013-10","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01951508","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Healthy","Substance-related Disorder","Mood Disorder"],"condg":["Addiction & substance use","Healthy volunteers"],"enroll":24,"eid":"NCT01951508"},{"id":"study-NCT02060929","cat":"studies","name":"A Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02060929","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2013-10","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02060929","sites":["Unnamed trial site — Merksem, Belgium"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":14,"eid":"NCT02060929"},{"id":"study-NCT02063620","cat":"studies","name":"The Effect of Anesthetic Agents Management on ECG Changes of Patients Who Were Operated Under RIVA","status":"COMPLETED","phase":"N/A","sponsor":"Duzce University","drugs":["ketamine"],"nct":"NCT02063620","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2013-10","official":"Gokce Akman Kose (Duzce University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT02063620","sites":["Duzce Univercity Medical Fauculty — Düzce, Turkey"],"conds":["Qt Interval, Variation in"],"condg":["Other"],"enroll":60,"eid":"NCT02063620"},{"id":"study-NCT02145169","cat":"studies","name":"Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study","status":"COMPLETED","phase":"N/A","sponsor":"Albert Einstein Healthcare Network","drugs":["ketamine"],"nct":"NCT02145169","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-10","official":"Paul Dominici, MD (Albert Einstein Healthcare Network)","src":"https://clinicaltrials.gov/study/NCT02145169","sites":["Albert Einstein Healthcare Network — Philadelphia, United States"],"conds":["Emergence Reaction","Procedural Sedation"],"condg":["Other"],"enroll":20,"eid":"NCT02145169"},{"id":"study-NCT03736980","cat":"studies","name":"Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self","status":"COMPLETED","phase":"N/A","sponsor":"University of Zurich","drugs":["psilocybin"],"nct":"NCT03736980","nsites":0,"start":"2013-10-01","src":"https://clinicaltrials.gov/study/NCT03736980","conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":140,"eid":"NCT03736980"},{"id":"study-NCT01980303","cat":"studies","name":"A Study to Assess the Pharmacokinetics of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT01980303","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-11","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01980303","sites":["Unnamed trial site — Cypress, United States"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":29,"eid":"NCT01980303"},{"id":"study-NCT02099006","cat":"studies","name":"Novel Topical Therapies for the Treatment of Genital Pain","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"University of Rochester","drugs":["ketamine"],"nct":"NCT02099006","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-11","official":"Adrienne D Bonham, MD (University of Rochester)","src":"https://clinicaltrials.gov/study/NCT02099006","sites":["University of Rochester — Rochester, United States"],"conds":["Female Genital Diseases"],"condg":["Other"],"enroll":9,"eid":"NCT02099006"},{"id":"study-NCT01988922","cat":"studies","name":"CYP2B6 Polymorphisms in Ketamine","status":"COMPLETED","phase":"N/A","sponsor":"Washington University School of Medicine","drugs":["ketamine"],"nct":"NCT01988922","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-11","official":"Lesley Rao, MD (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT01988922","sites":["Washington University School of Medicine — St Louis, United States"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":30,"eid":"NCT01988922"},{"id":"study-NCT02062658","cat":"studies","name":"Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)","status":"COMPLETED","phase":"Phase 2","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT02062658","nsites":1,"countries":"United States","ccs":["US"],"start":"2013-12","official":"H Blair Simpson, MD, PhD (Columbia-NYSPI-RFMH)","src":"https://clinicaltrials.gov/study/NCT02062658","sites":["New York State Psychiatric Insitute — New York, United States"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"enroll":10,"eid":"NCT02062658"},{"id":"study-NCT02368782","cat":"studies","name":"Effects of Ketamine and Propofol in Otoacoustic Emissions (OAE) in Children","status":"COMPLETED","sponsor":"Istanbul University","drugs":["ketamine"],"nct":"NCT02368782","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2013-12","src":"https://clinicaltrials.gov/study/NCT02368782","sites":["Istanbul University Cerrahpasa Medical Faculty — Istanbul, Turkey"],"conds":["Normal Healthy Ears","Ketamine and Propofol Effects on Hemodynamics","Ketamine and Propofol Effects on TEOAE and DPOAE"],"condg":["Healthy volunteers"],"enroll":30,"eid":"NCT02368782"},{"id":"study-NCT02106325","cat":"studies","name":"Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients","status":"COMPLETED","phase":"Phase 2","sponsor":"NYU Langone Health","drugs":["ketamine"],"nct":"NCT02106325","nsites":2,"countries":"United States","ccs":["US"],"start":"2013-12","official":"Stephen Ross, MD (NYU Langone Health); K. Casey Paleos, MD (New York Unversity School of Medicine)","src":"https://clinicaltrials.gov/study/NCT02106325","sites":["Bellevue Hospital Center — New York, United States","NYU Langone Medical Center/Tisch Hospital — New York, United States"],"conds":["Depression"],"condg":["Depression"],"enroll":21,"eid":"NCT02106325"},{"id":"study-NCT01997801","cat":"studies","name":"Ketamine in Robot-assisted Thyroidectomy","status":"UNKNOWN","phase":"N/A","sponsor":"Seoul National University Hospital","drugs":["ketamine"],"nct":"NCT01997801","nsites":1,"countries":"South Korea","ccs":["KR"],"start":"2013-12","official":"Hee-Pyoung Park, PhD (Seoul National University of Hospital)","src":"https://clinicaltrials.gov/study/NCT01997801","sites":["Seoul National University Hospital — Seoul, South Korea"],"conds":["Thyroid","Acute Pain","Chronic Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Hee-Pyoung Park, PhD","p":"+82-10-2971-7647","e":"hppark@snu.ac.kr"},"enroll":64,"eid":"NCT01997801"},{"id":"study-NCT02102802","cat":"studies","name":"Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD","status":"COMPLETED","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT02102802","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-01","official":"Michael C Mithoefer, MD (Private Practice)","src":"https://clinicaltrials.gov/study/NCT02102802","sites":["Offices of Michael Mithoefer — Mt. Pleasant, United States"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":10,"eid":"NCT02102802"},{"id":"study-NCT02012335","cat":"studies","name":"Ketamine Use in Electroconvulsive Therapy","status":"WITHDRAWN","phase":"N/A","sponsor":"Hospital de Clinicas de Porto Alegre","drugs":["ketamine"],"nct":"NCT02012335","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2014-01","src":"https://clinicaltrials.gov/study/NCT02012335","sites":["Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA) — Porto Alegre, Brazil"],"conds":["Depression"],"condg":["Depression"],"eid":"NCT02012335"},{"id":"study-NCT01969227","cat":"studies","name":"The Effects of Ketamine on Respiratory Stimulation and Transpulmonary Pressures","status":"COMPLETED","phase":"N/A","sponsor":"Massachusetts General Hospital","drugs":["ketamine"],"nct":"NCT01969227","nsites":2,"countries":"United States","ccs":["US"],"start":"2014-01","official":"Lorenzo Berra, MD (Massachusetts General Hospital); Matthias Eikermann, MD, PhD (Beth Israel Deaconess Medical Center)","src":"https://clinicaltrials.gov/study/NCT01969227","sites":["Massachusetts General Hospital — Boston, United States","Beth Israel Deaconess Medical Center — Boston, United States"],"conds":["Mechanical Ventilation","Airway Patency","Respiratory Depression"],"condg":["Depression"],"enroll":15,"eid":"NCT01969227"},{"id":"study-NCT02037503","cat":"studies","name":"The Effect of Ketamine on Mechanises Underlying Suicidal Ideation and Drug-resistant Major Depression","status":"UNKNOWN","phase":"Phase 3","sponsor":"Tel-Aviv Sourasky Medical Center","drugs":["ketamine"],"nct":"NCT02037503","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2014-01","src":"https://clinicaltrials.gov/study/NCT02037503","sites":["Tel Aviv Sourasky Medical Center — Tel Aviv, Israel"],"conds":["Suicidal Ideation","Major Depressive Disorder","Healthy Participants"],"condg":["Depression","Healthy volunteers"],"contact":{"n":"Talma Hendler, MD","p":"97236973953"},"enroll":100,"eid":"NCT02037503"},{"id":"study-NCT03764267","cat":"studies","name":"MAC vs TIVA Ambulatory Breast Augmentation","status":"COMPLETED","phase":"Phase 3","sponsor":"Ain Shams University","drugs":["ketamine"],"nct":"NCT03764267","nsites":0,"start":"2014-01-01","src":"https://clinicaltrials.gov/study/NCT03764267","conds":["Breast Diseases"],"condg":["Other"],"enroll":80,"eid":"NCT03764267"},{"id":"study-NCT01998958","cat":"studies","name":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT01998958","nsites":25,"countries":"Belgium; Japan; United States","ccs":["BE","JP","US"],"start":"2014-01-27","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","sites":["Unnamed trial site — Birmingham, United States","Unnamed trial site — Garden Grove, United States","Unnamed trial site — Hartford, United States","Unnamed trial site — Jacksonville, United States","Unnamed trial site — Tampa, United States","Unnamed trial site — Atlanta, United States","Unnamed trial site — Chicago, United States","Unnamed trial site — Hoffman Estates, United States"],"conds":["Treatment Resistant Depressive Disorder"],"condg":["Depression"],"enroll":108,"eid":"NCT01998958"},{"id":"study-NCT02120235","cat":"studies","name":"Investigating Lysosomal Storage Diseases in Minority Groups","status":"UNKNOWN","sponsor":"O & O Alpan LLC","drugs":["LSD"],"nct":"NCT02120235","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-02","src":"https://clinicaltrials.gov/study/NCT02120235","sites":["O&O Alpan, LLC — Fairfax, United States"],"conds":["Lysosomal Storage Disorders","Gaucher Disease","Fabry Disease","Pompe Disease","Niemann-Pick Disease"],"condg":["Other"],"contact":{"n":"Ozlem Goker-Alpan, M.D.","p":"571-308-1900","e":"ogokeralpan@oandoalpan.com"},"enroll":20000,"eid":"NCT02120235"},{"id":"study-NCT02914769","cat":"studies","name":"Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Universidade Federal do Rio Grande do Norte","drugs":["ayahuasca"],"nct":"NCT02914769","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2014-02","official":"Draulio B de Araujo, Ph.D (Brain Institute - UFRN)","src":"https://clinicaltrials.gov/study/NCT02914769","sites":["Draulio B de Araujo — Natal, Brazil"],"conds":["Major Depression"],"condg":["Depression"],"enroll":35,"eid":"NCT02914769"},{"id":"study-NCT02000206","cat":"studies","name":"Comparison of Propofol/Alfentanil With Propofol/Ketamine","status":"UNKNOWN","phase":"N/A","sponsor":"Rabin Medical Center","drugs":["ketamine"],"nct":"NCT02000206","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2014-02","official":"Mordechai R Kramer, MD (Rabin Medical Center)","src":"https://clinicaltrials.gov/study/NCT02000206","sites":["Pulmonary Institute, Rabin Medical Center, Beilinson Hospital — Petah Tikva, Israel"],"conds":["Lung Disease"],"condg":["Other"],"contact":{"n":"Yair Manevich, MD","e":"yair.manevich@gmail.com"},"enroll":80,"eid":"NCT02000206"},{"id":"study-NCT01957410","cat":"studies","name":"A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder","status":"TERMINATED","phase":"Phase 2","sponsor":"Janssen Research & Development, LLC","drugs":["ketamine"],"nct":"NCT01957410","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-02","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01957410","sites":["Unnamed trial site — Durham, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":13,"eid":"NCT01957410"},{"id":"study-NCT02072083","cat":"studies","name":"Intranasal Dexmedetomidine vs Midazolam-ketamine Combination for Premedication of Pediatric Patients","status":"COMPLETED","phase":"Phase 4","sponsor":"TC Erciyes University","drugs":["ketamine"],"nct":"NCT02072083","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2014-02","official":"Müge Yüce Yıldırım, resident (erciyes univercity)","src":"https://clinicaltrials.gov/study/NCT02072083","sites":["Erciyes university hospital — Kayseri, Turkey"],"conds":["Premedication","Oculocardiac Reflex"],"condg":["Other"],"enroll":60,"eid":"NCT02072083"},{"id":"study-NCT02726867","cat":"studies","name":"Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus","status":"WITHDRAWN","phase":"Phase 3","sponsor":"Mid-Atlantic Epilepsy and Sleep Center, LLC","drugs":["ketamine"],"nct":"NCT02726867","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-02","official":"Pavel Klein, M.D. (Mid-Atlantic Epilepsy and Sleep Center)","src":"https://clinicaltrials.gov/study/NCT02726867","sites":["MidAtlantic Epilepsy and Sleep Center — Bethesda, United States"],"conds":["Epilepsy","Status Epilepticus"],"condg":["Neurology & cognition"],"eid":"NCT02726867"},{"id":"study-NCT02060526","cat":"studies","name":"Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease","status":"COMPLETED","phase":"Phase 2","sponsor":"Shire","drugs":["LSD"],"nct":"NCT02060526","nsites":10,"countries":"Argentina; France; Germany; Italy; Netherlands; Spain; United Kingdom; United States","ccs":["AR","DE","ES","FR","GB","IT","NL","US"],"start":"2014-02-26","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT02060526","sites":["Los Angeles Biomedical Research — Torrance, United States","University of Minnesota Department of Pediatrics — Minneapolis, United States","University of North Carolina — Chapel Hill, United States","Hospital Universitario Austral A Unidad de Investigacion — Buenos Aires, Argentina","Chu Bicetre — Le Kremlin-Bicêtre, France","Universitätsklinikum Hamburg Eppendorf — Hamburg, Germany","U.O.S Malattie Metaboliche Rare Clinical Pediatrica — Monza, Italy","Academisch Medisch Centrum — Amsterdam, Netherlands"],"conds":["Sanfilippo Syndrome"],"condg":["Other"],"enroll":21,"eid":"NCT02060526"},{"id":"study-NCT02082327","cat":"studies","name":"A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"Amicus Therapeutics","drugs":["LSD"],"nct":"NCT02082327","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2014-03","official":"Medical Monitor Clinical Research (Amicus Therapeutics)","src":"https://clinicaltrials.gov/study/NCT02082327","sites":["PRA International — Groningen, Netherlands"],"conds":["Fabry Disease"],"condg":["Other"],"enroll":31,"eid":"NCT02082327"},{"id":"study-NCT02129088","cat":"studies","name":"A Pharmacokinetic, Safety and Tolerability Study of Esketamine in Healthy Elderly and Adult Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02129088","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2014-03","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02129088","sites":["Unnamed trial site — Merksem, Belgium"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":34,"eid":"NCT02129088"},{"id":"study-NCT02087202","cat":"studies","name":"Hyperalgesia and NMDA Receptor Antagonist","status":"UNKNOWN","phase":"N/A","sponsor":"Seoul National University Bundang Hospital","drugs":["ketamine"],"nct":"NCT02087202","nsites":0,"start":"2014-03","src":"https://clinicaltrials.gov/study/NCT02087202","conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":90,"eid":"NCT02087202"},{"id":"study-NCT02033434","cat":"studies","name":"Pre-hospital Care With Intra-Nasal Ketamine for Transport (PRECINKT): A Pilot Study","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Calgary","drugs":["ketamine"],"nct":"NCT02033434","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2014-03-01","official":"Gary Andolfatto, MD (University of British Columbia)","src":"https://clinicaltrials.gov/study/NCT02033434","sites":["Whistler Blackcomb — Whistler, Canada"],"conds":["Pain","Traumatic Limb Injury"],"condg":["PTSD & trauma","Chronic pain & headache"],"enroll":30,"eid":"NCT02033434"},{"id":"study-NCT02033707","cat":"studies","name":"Effects of Hallucinogens and Other Drugs on Mood and Performance","status":"COMPLETED","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["LSD","MDMA","ketamine","mescaline","psilocybin","salvinorin A"],"nct":"NCT02033707","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-04","official":"Roland R Griffiths, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT02033707","sites":["Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center — Baltimore, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":20,"eid":"NCT02033707"},{"id":"study-NCT02701933","cat":"studies","name":"Effects of Ketamine on Eye Movements, Perception and Brain Function","status":"COMPLETED","phase":"N/A","sponsor":"University of Bonn","drugs":["ketamine"],"nct":"NCT02701933","nsites":1,"countries":"Germany","ccs":["DE"],"start":"2014-04","official":"Ulrich Ettinger, PhD (Department of Psychology, University of Bonn)","src":"https://clinicaltrials.gov/study/NCT02701933","sites":["University of Bonn — Bonn, Germany"],"conds":["Functional Neuroimaging"],"condg":["Other"],"enroll":24,"eid":"NCT02701933"},{"id":"study-NCT02103881","cat":"studies","name":"Ketamine Versus Haloperidol for Severe Agitation Outside the Hospital","status":"WITHDRAWN","phase":"Phase 4","sponsor":"Hennepin Healthcare Research Institute","drugs":["ketamine"],"nct":"NCT02103881","nsites":0,"start":"2014-04","src":"https://clinicaltrials.gov/study/NCT02103881","conds":["Agitation"],"condg":["Other"],"eid":"NCT02103881"},{"id":"study-NCT02016664","cat":"studies","name":"Plasma Concentration of Ketamine and Norketamine .","status":"COMPLETED","phase":"N/A","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","drugs":["ketamine"],"nct":"NCT02016664","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2014-04","official":"Patricia Morley-Foster, MD, FRCPC (Department of Anesthesia and Perioperative Medicine, Western University, Canada.)","src":"https://clinicaltrials.gov/study/NCT02016664","sites":["St.Joseph's Health Care, Western University — London, Canada"],"conds":["Chronic Pain"],"condg":["Chronic pain & headache"],"enroll":12,"eid":"NCT02016664"},{"id":"study-NCT02105415","cat":"studies","name":"Ketamine / Propofol Admixture \"Ketofol\" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Mayo Clinic","drugs":["ketamine"],"nct":"NCT02105415","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-04","official":"Nathan J Smischney, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT02105415","sites":["Mayo Clinic — Rochester, United States"],"conds":["Critical Illness"],"condg":["Other"],"enroll":160,"eid":"NCT02105415"},{"id":"study-NCT02008396","cat":"studies","name":"Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults","status":"COMPLETED","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT02008396","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-04-11","official":"Charles S. Grob, MD (University of California, Los Angeles)","src":"https://clinicaltrials.gov/study/NCT02008396","sites":["Los Angeles Biomedical Research Institute — Torrance, United States"],"conds":["Social Anxiety in Autistic Adults"],"condg":["Anxiety"],"enroll":12,"eid":"NCT02008396"},{"id":"study-NCT02145091","cat":"studies","name":"Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators","status":"COMPLETED","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT02145091","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-05","src":"https://clinicaltrials.gov/study/NCT02145091","sites":["Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center — Baltimore, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":40,"eid":"NCT02145091"},{"id":"study-NCT02610712","cat":"studies","name":"Clinical Trial of the Use of Ketamine in Treatment Resistant Depression","status":"UNKNOWN","phase":"Phase 4","sponsor":"National Institute of Neurology and Neurosurgery, Mexico","drugs":["ketamine"],"nct":"NCT02610712","nsites":1,"countries":"Mexico","ccs":["MX"],"start":"2014-05","official":"Rodrigo Pérez-Esparza, MD (National Institute of Neurology and Neurosurgery, Mexico); Jesús Ramírez-Bermúdez, MD, MSc (National Institute of Neurology and…","src":"https://clinicaltrials.gov/study/NCT02610712","sites":["National Institute of Neurology and Neurosurgery — Mexico City, Mexico"],"conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"contact":{"n":"Rodrigo Pérez-Esparza, MD","p":"56063822","e":"dr.rodrigope@gmail.com"},"enroll":20,"eid":"NCT02610712"},{"id":"study-NCT02134951","cat":"studies","name":"Biomarker Assessment of Glutamatergic Target Engagement","status":"COMPLETED","phase":"Phase 4","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT02134951","nsites":3,"countries":"United States","ccs":["US"],"start":"2014-05","official":"Jeffrey A Lieberman, MD (New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT02134951","sites":["University of California Davis — Sacramento, United States","Yale University — New Haven, United States","New York State Psychiatric Institute — New York, United States"],"conds":["Healthy Controls"],"condg":["Healthy volunteers"],"enroll":65,"eid":"NCT02134951"},{"id":"study-NCT02133001","cat":"studies","name":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be…","status":"COMPLETED","phase":"Phase 2","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02133001","nsites":14,"countries":"United States","ccs":["US"],"start":"2014-05-23","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02133001","sites":["Unnamed trial site — Birmingham, United States","Unnamed trial site — San Diego, United States","Unnamed trial site — Hartford, United States","Unnamed trial site — New Haven, United States","Unnamed trial site — Atlanta, United States","Unnamed trial site — Iowa City, United States","Unnamed trial site — Baltimore, United States","Unnamed trial site — Towson, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":68,"eid":"NCT02133001"},{"id":"study-NCT02154334","cat":"studies","name":"Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02154334","nsites":1,"countries":"Germany","ccs":["DE"],"start":"2014-06","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02154334","sites":["Unnamed trial site — Hanover, Germany"],"conds":["Allergic Rhinitis"],"condg":["Other"],"enroll":47,"eid":"NCT02154334"},{"id":"study-NCT02094378","cat":"studies","name":"A Study to Evaluate the Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02094378","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2014-06","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02094378","sites":["Unnamed trial site — Leiden, Netherlands"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":24,"eid":"NCT02094378"},{"id":"study-NCT02165488","cat":"studies","name":"Frequent Ketamine Use and Gastrointestinal, Liver and Biliary Sequelae","status":"COMPLETED","sponsor":"The University of Hong Kong","drugs":["ketamine"],"nct":"NCT02165488","nsites":1,"countries":"Hong Kong","ccs":["HK"],"start":"2014-06","src":"https://clinicaltrials.gov/study/NCT02165488","sites":["The University of Hong Kong — Hong Kong, Hong Kong"],"conds":["Gastritis","Peptic Ulcer Disease","Cholangiopathy","Liver Fibrosis"],"condg":["Other"],"enroll":100,"eid":"NCT02165488"},{"id":"study-NCT02165449","cat":"studies","name":"Biomarkers of Fast Acting Therapies in Major Depression","status":"COMPLETED","phase":"Phase 1","sponsor":"University of California, Los Angeles","drugs":["ketamine"],"nct":"NCT02165449","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-06","official":"Katherine Narr, Ph.D. (Geffen School of Medicine, University of California, Los Angeles (UCLA))","src":"https://clinicaltrials.gov/study/NCT02165449","sites":["Geffen School of Medicine, UCLA — Los Angeles, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":60,"eid":"NCT02165449"},{"id":"study-NCT02061293","cat":"studies","name":"A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence","status":"COMPLETED","phase":"Phase 2","sponsor":"NYU Langone Health","drugs":["psilocybin"],"nct":"NCT02061293","nsites":2,"countries":"United States","ccs":["US"],"start":"2014-06","official":"Michael P Bogenschutz, MD (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT02061293","sites":["University of New Mexico Health Sciences Center — Albuquerque, United States","Clinical and Translational Science Institute, NYU Langone Medical Center — New York, United States"],"conds":["Alcohol Dependence"],"condg":["Addiction & substance use"],"enroll":95,"eid":"NCT02061293"},{"id":"study-NCT02163707","cat":"studies","name":"UW Psilocybin Pharmacokinetics Study","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Wisconsin, Madison","drugs":["psilocybin"],"nct":"NCT02163707","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-06","official":"Paul Hutson, PharmD (University of Wisconsin, School of Pharmacy)","src":"https://clinicaltrials.gov/study/NCT02163707","sites":["University of Wisconsin, School of Pharmacy — Madison, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":12,"eid":"NCT02163707"},{"id":"study-NCT02931786","cat":"studies","name":"Effects of Propofol and Ketofol on Core Body Temperature in MRI","status":"COMPLETED","phase":"N/A","sponsor":"Istanbul University","drugs":["ketamine"],"nct":"NCT02931786","nsites":0,"start":"2014-08","src":"https://clinicaltrials.gov/study/NCT02931786","conds":["Children"],"condg":["Other"],"enroll":90,"eid":"NCT02931786"},{"id":"study-NCT02494830","cat":"studies","name":"Single Dose Administration of Ketamine 10, 20, 40 and 80 mg and 5 mg Solution for Infusion in 15 Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"University Medicine Greifswald","drugs":["ketamine"],"nct":"NCT02494830","nsites":1,"countries":"Germany","ccs":["DE"],"start":"2014-08","official":"Werner Siegmund, Prof (Department of Clinical Pharmacology)","src":"https://clinicaltrials.gov/study/NCT02494830","sites":["Department of Clinical Pharmacology, Ernst-Moritz-Arndt-University Greifswald — Greifswald, Germany"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":15,"eid":"NCT02494830"},{"id":"study-NCT04057989","cat":"studies","name":"Retrospective Evaluation of Ketamine Effectiveness for the Treatment of Acute Battlefield Related Pain","status":"COMPLETED","sponsor":"Defense and Veterans Center for Integrative Pain Management","drugs":["ketamine"],"nct":"NCT04057989","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-08","official":"Michael Kent, MD (Walter Reed National Military Medical Center)","src":"https://clinicaltrials.gov/study/NCT04057989","sites":["Walter Reed National Military Medical Center — Bethesda, United States"],"conds":["Pain, Acute","Analgesia","Amputation, Traumatic","Post Traumatic Stress Disorder","Trauma, Brain"],"condg":["PTSD & trauma","Chronic pain & headache"],"enroll":80,"eid":"NCT04057989"},{"id":"study-NCT02219867","cat":"studies","name":"Ketamine Infusions for Major Depression Disorder","status":"UNKNOWN","phase":"N/A","sponsor":"Sheba Medical Center","drugs":["ketamine"],"nct":"NCT02219867","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2014-08","src":"https://clinicaltrials.gov/study/NCT02219867","sites":["Sheba MC — Ramat Gan, Israel"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"enroll":10,"eid":"NCT02219867"},{"id":"study-NCT03644719","cat":"studies","name":"Effectiveness of a Brief Cognitive and Behavioral Skills Program on Stage Transitions for Chronic Ketamine Abusers","status":"COMPLETED","phase":"N/A","sponsor":"National Taiwan University","drugs":["ketamine"],"nct":"NCT03644719","nsites":0,"start":"2014-08-19","official":"Tony Szu-Hsien Lee, Ph.D. (Health Promotion and Health Education)","src":"https://clinicaltrials.gov/study/NCT03644719","conds":["Substance Use Disorders"],"condg":["Addiction & substance use"],"enroll":409,"eid":"NCT03644719"},{"id":"study-NCT02232789","cat":"studies","name":"Abuse Liability and Human Pharmacology of Mephedrone","status":"COMPLETED","phase":"Phase 1","sponsor":"Parc de Salut Mar","drugs":["MDMA"],"nct":"NCT02232789","nsites":1,"countries":"Spain","ccs":["ES"],"start":"2014-09","official":"Magi Farre, MD, PhD (Parc de Salut Mar)","src":"https://clinicaltrials.gov/study/NCT02232789","sites":["Institut Hospital del Mar d'Investigacions Mèdiques-IMIM. Parc de Salut Mar. — Barcelona, Spain"],"conds":["Amphetamine-Related Disorders"],"condg":["Other"],"enroll":12,"eid":"NCT02232789"},{"id":"study-NCT02228239","cat":"studies","name":"Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02228239","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2014-09","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02228239","sites":["Unnamed trial site — Leiden, Netherlands"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":26,"eid":"NCT02228239"},{"id":"study-NCT02220400","cat":"studies","name":"Ketamine Prevent POCD","status":"UNKNOWN","phase":"N/A","sponsor":"RenJi Hospital","drugs":["ketamine"],"nct":"NCT02220400","nsites":3,"countries":"China","ccs":["CN"],"start":"2014-09","src":"https://clinicaltrials.gov/study/NCT02220400","sites":["Shanghai Tongji Hospital — Shanghai, China","Renji Hospital, School of Medicine, Shanghai Jiaotong University — Shanghai, China","Shanghai Pudong New Area People's Hospital — Shanghai, China"],"conds":["Necrosis of Femoral Head","Knee Osteoarthritis"],"condg":["Other"],"enroll":484,"eid":"NCT02220400"},{"id":"study-NCT04656886","cat":"studies","name":"Ketamine's Actions on Rumination Mechanisms as an Antidepressant","status":"COMPLETED","phase":"N/A","sponsor":"King's College London","drugs":["ketamine"],"nct":"NCT04656886","nsites":0,"start":"2014-09","src":"https://clinicaltrials.gov/study/NCT04656886","conds":["Remission in Depression"],"condg":["Depression"],"enroll":37,"eid":"NCT04656886"},{"id":"study-NCT02234011","cat":"studies","name":"A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder","status":"TERMINATED","phase":"Phase 2","sponsor":"Mclean Hospital","drugs":["ketamine"],"nct":"NCT02234011","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-09","official":"Brian P Brennan, M.D. (Mclean Hospital)","src":"https://clinicaltrials.gov/study/NCT02234011","sites":["McLean Hospital — Belmont, United States"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"enroll":1,"eid":"NCT02234011"},{"id":"study-NCT02094898","cat":"studies","name":"Ketamine for Depression and Suicide Risk","status":"COMPLETED","phase":"Phase 2","sponsor":"Mayo Clinic","drugs":["ketamine"],"nct":"NCT02094898","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-09","official":"William V Bobo, MD (Consultant - Psychiatry)","src":"https://clinicaltrials.gov/study/NCT02094898","sites":["Mayo Clinic — Rochester, United States"],"conds":["Depression","Suicide"],"condg":["Depression"],"enroll":12,"eid":"NCT02094898"},{"id":"study-NCT02078817","cat":"studies","name":"Ketamine in Adolescents With Treatment-Resistant Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"University of Minnesota","drugs":["ketamine"],"nct":"NCT02078817","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-09","src":"https://clinicaltrials.gov/study/NCT02078817","sites":["University of Minnesota — Minneapolis, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":14,"eid":"NCT02078817"},{"id":"study-NCT02206776","cat":"studies","name":"Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD","status":"TERMINATED","phase":"Phase 2","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT02206776","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-09","official":"Carolyn I Rodriguez, M.D., Ph.D. (Stanford University)","src":"https://clinicaltrials.gov/study/NCT02206776","sites":["New York State Psychiatric Institute — New York, United States"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"enroll":2,"eid":"NCT02206776"},{"id":"study-NCT02235012","cat":"studies","name":"Cognitive Biases Under Ketamine","status":"COMPLETED","phase":"N/A","sponsor":"Centre Hospitalier St Anne","drugs":["ketamine"],"nct":"NCT02235012","nsites":1,"countries":"France","ccs":["FR"],"start":"2014-09-08","official":"Raphaël GAILLARD (Centre Hospitalier St Anne)","src":"https://clinicaltrials.gov/study/NCT02235012","sites":["Centre Hospitalier Sainte Anne — Paris, France"],"conds":["Healthy Subjects"],"condg":["Healthy volunteers"],"enroll":84,"eid":"NCT02235012"},{"id":"study-NCT02452060","cat":"studies","name":"Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"NYU Langone Health","drugs":["ketamine"],"nct":"NCT02452060","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-10","official":"Jing Wang, MD, PHD (NYU School of Medicine)","src":"https://clinicaltrials.gov/study/NCT02452060","sites":["NYU Langone Medical Center — New York, United States"],"conds":["Pain","Postoperative Depression"],"condg":["Depression","Chronic pain & headache"],"enroll":90,"eid":"NCT02452060"},{"id":"study-NCT02232347","cat":"studies","name":"Ketamine and Glutamate After Brain Injury : a Microdialysis Study","status":"UNKNOWN","phase":"Phase 2","sponsor":"Pierre-Julien CUNGI","drugs":["ketamine"],"nct":"NCT02232347","nsites":1,"countries":"France","ccs":["FR"],"start":"2014-10","official":"Ambroise MONTCRIOL, MD (Direction Centrale du Service de Santé des Armées)","src":"https://clinicaltrials.gov/study/NCT02232347","sites":["Sainte Anne Military Teaching Hospital — Toulon, France"],"conds":["Head Trauma"],"condg":["PTSD & trauma"],"contact":{"n":"Ambroise MONTCRIOL, MD","p":"0483162358","e":"ambroise.montcriol@free.fr"},"enroll":20,"eid":"NCT02232347"},{"id":"study-NCT01958593","cat":"studies","name":"Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD","status":"TERMINATED","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT01958593","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2014-10-14","official":"Ingrid Pacey, MBBS FRCP[C] (University of Victoria)","src":"https://clinicaltrials.gov/study/NCT01958593","sites":["Offices of Dr. Ingrid Pacey MBBS FRCP[C] — Vancouver, Canada"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":6,"eid":"NCT01958593"},{"id":"study-NCT02303847","cat":"studies","name":"Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting","status":"UNKNOWN","phase":"Phase 3","sponsor":"University of Washington","drugs":["ketamine"],"nct":"NCT02303847","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-11","official":"Lucinda Grande, MD (University of Washington Department of Family Medicine)","src":"https://clinicaltrials.gov/study/NCT02303847","sites":["Pioneer Family Practice — Lacey, United States"],"conds":["Chronic Pain"],"condg":["Chronic pain & headache"],"enroll":32,"eid":"NCT02303847"},{"id":"study-NCT02308969","cat":"studies","name":"Neuronal Correlates of Altered States of Consciousness","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD"],"nct":"NCT02308969","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2014-12","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT02308969","sites":["University Hospital — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":24,"eid":"NCT02308969"},{"id":"study-NCT03050541","cat":"studies","name":"Effects of MDMA on Emotional and Social Memories","status":"COMPLETED","phase":"N/A","sponsor":"University of Chicago","drugs":["MDMA"],"nct":"NCT03050541","nsites":0,"start":"2014-12","official":"Harriet de Wit, PhD (University of Chicago); David Gallo, PhD (University of Chicago)","src":"https://clinicaltrials.gov/study/NCT03050541","conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":84,"eid":"NCT03050541"},{"id":"study-NCT02345148","cat":"studies","name":"Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly and and Healthy Younger Adult Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02345148","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2014-12","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02345148","sites":["Unnamed trial site — Merksem, Belgium"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":16,"eid":"NCT02345148"},{"id":"study-NCT04053400","cat":"studies","name":"Evaluating Ketamine and Psychological Sequelae","status":"COMPLETED","sponsor":"Defense and Veterans Center for Integrative Pain Management","drugs":["ketamine"],"nct":"NCT04053400","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-12","src":"https://clinicaltrials.gov/study/NCT04053400","sites":["Walter Reed National Military Medical Center — Bethesda, United States"],"conds":["Pain, Ketamine Infusion, Psychologic Sequelae"],"condg":["Chronic pain & headache"],"enroll":159,"eid":"NCT04053400"},{"id":"study-NCT02307591","cat":"studies","name":"Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)","status":"WITHDRAWN","phase":"Phase 2/Phase 3","sponsor":"Emergency NGO Onlus","drugs":["ketamine"],"nct":"NCT02307591","nsites":0,"start":"2014-12","src":"https://clinicaltrials.gov/study/NCT02307591","conds":["Ebola Virus Disease"],"condg":["Other"],"eid":"NCT02307591"},{"id":"study-NCT02356965","cat":"studies","name":"Study Testing Ketamine Sublingual Wafer After Wisdom Tooth Extraction","status":"COMPLETED","phase":"Phase 2","sponsor":"iX Biopharma Ltd.","drugs":["ketamine"],"nct":"NCT02356965","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-12","official":"Derek D Muse, MD (Jean Brown Research)","src":"https://clinicaltrials.gov/study/NCT02356965","sites":["Jean Brown Research — Salt Lake City, United States"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":80,"eid":"NCT02356965"},{"id":"study-NCT02398136","cat":"studies","name":"To Test the Potential Efficacy of Repeated Intranasal Administration of Ketamine as a Treatment for PTSD","status":"WITHDRAWN","phase":"Phase 2/Phase 3","sponsor":"Adriana Feder","drugs":["ketamine"],"nct":"NCT02398136","nsites":0,"start":"2014-12","official":"Adriana Feder, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT02398136","conds":["PTSD"],"condg":["PTSD & trauma"],"eid":"NCT02398136"},{"id":"study-NCT01920555","cat":"studies","name":"Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)","status":"COMPLETED","phase":"Phase 2","sponsor":"Massachusetts General Hospital","drugs":["ketamine"],"nct":"NCT01920555","nsites":6,"countries":"United States","ccs":["US"],"start":"2014-12","official":"Maurizio Fava, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT01920555","sites":["Stanford University — Palo Alto, United States","Yale University — New Haven, United States","Massachusetts General Hospital — Boston, United States","Mount Sinai School of Medicine — New York, United States","University of Texas Southwestern — Dallas, United States","Baylor College of Medicine — Houston, United States"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":99,"eid":"NCT01920555"},{"id":"study-NCT02313337","cat":"studies","name":"The Comparison of Different Administration Routes of Pediatric Premedication","status":"UNKNOWN","phase":"Phase 4","sponsor":"Second Affiliated Hospital of Xi'an Jiaotong University","drugs":["ketamine"],"nct":"NCT02313337","nsites":0,"start":"2014-12","official":"NIU XIAOLI (The second affiliated hospital of xi 'an jiaotong university)","src":"https://clinicaltrials.gov/study/NCT02313337","conds":["Anesthesia"],"condg":["Other"],"enroll":80,"eid":"NCT02313337"},{"id":"study-NCT02317341","cat":"studies","name":"Effect of Ketamine on Fatigue Following Cancer Therapy","status":"TERMINATED","phase":"EARLY_Phase 1","sponsor":"National Institute of Nursing Research (NINR)","drugs":["ketamine"],"nct":"NCT02317341","nsites":1,"countries":"United States","ccs":["US"],"start":"2014-12-13","official":"Leorey N Saligan, C.R.N.P. (National Institute of Nursing Research (NINR))","src":"https://clinicaltrials.gov/study/NCT02317341","sites":["National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, United States"],"conds":["Cancer","Fatigue","Ketamine"],"condg":["Cancer-related distress"],"enroll":2,"eid":"NCT02317341"},{"id":"study-NCT02343289","cat":"studies","name":"A Study to Evaluate the Absolute Bioavailability of Intranasal and Oral Esketamine and the Effects of Clarithromycin on the Pharmacokinetics of Intranasal Esketamine in Healthy Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02343289","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2015-01","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02343289","sites":["Unnamed trial site — Merksem, Belgium"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":18,"eid":"NCT02343289"},{"id":"study-NCT03609190","cat":"studies","name":"A Multimodal Neuroimaging Study of Brain Activation Patterns Under Ketamine","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Psychiatric University Hospital, Zurich","drugs":["esketamine","ketamine"],"nct":"NCT03609190","nsites":0,"start":"2015-01","src":"https://clinicaltrials.gov/study/NCT03609190","conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":10,"eid":"NCT03609190"},{"id":"study-NCT02305394","cat":"studies","name":"Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy","status":"UNKNOWN","phase":"Phase 4","sponsor":"First Affiliated Hospital of Chongqing Medical University","drugs":["ketamine"],"nct":"NCT02305394","nsites":1,"countries":"China","ccs":["CN"],"start":"2015-01","official":"Su Min (First Affiliated Hospital of Chongqing Medical University)","src":"https://clinicaltrials.gov/study/NCT02305394","sites":["China,Chongqing The First Affiliated Hospital of Chongqing Medical University — Chongqing, China"],"conds":["Depressive Symptoms","Impaired Cognition","Electroconvulsive Therapy"],"condg":["Depression"],"contact":{"n":"Qibin Chen, Master","p":"023-89011061","e":"403497559@qq.com"},"enroll":132,"eid":"NCT02305394"},{"id":"study-NCT02306759","cat":"studies","name":"Ketamine For Acute Treatment of Pain in Emergency Department","status":"COMPLETED","phase":"Phase 4","sponsor":"The Brooklyn Hospital Center","drugs":["ketamine"],"nct":"NCT02306759","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-01","official":"Billy Sin, Pharm.D. (The Brooklyn Hospital Center)","src":"https://clinicaltrials.gov/study/NCT02306759","sites":["The Brooklyn Hospital Center — Brooklyn, United States"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":60,"eid":"NCT02306759"},{"id":"study-NCT02527083","cat":"studies","name":"Influence of Anesthetic Technique on Acute and Chronic Neuropathic Pain","status":"COMPLETED","phase":"Phase 4","sponsor":"VA Pittsburgh Healthcare System","drugs":["ketamine"],"nct":"NCT02527083","nsites":0,"start":"2015-01","src":"https://clinicaltrials.gov/study/NCT02527083","conds":["Acute Pain","Chronic Pain","Hernia","Anesthesia, Intravenous","Anesthesia, Intratracheal"],"condg":["Chronic pain & headache"],"enroll":10,"eid":"NCT02527083"},{"id":"study-NCT02336308","cat":"studies","name":"A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn Patients","status":"WITHDRAWN","phase":"Phase 4","sponsor":"University of Colorado, Denver","drugs":["ketamine"],"nct":"NCT02336308","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-01","official":"Robert MacLaren, PharmD, MPH (University of Colorado, Denver)","src":"https://clinicaltrials.gov/study/NCT02336308","sites":["University of Colorado — Aurora, United States"],"conds":["Thermal Hyperalgesia","Anxiety","Pain"],"condg":["Anxiety","Chronic pain & headache"],"eid":"NCT02336308"},{"id":"study-NCT02651792","cat":"studies","name":"Ketamine- Propofol Versus Pethidine- Propofol in ERCP","status":"COMPLETED","phase":"Phase 2","sponsor":"Assiut University","drugs":["ketamine"],"nct":"NCT02651792","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2015-01","official":"Mostafa S Abbas, MD (Assiut University)","src":"https://clinicaltrials.gov/study/NCT02651792","sites":["Al Rajhy liver hospital — Asyut, Egypt"],"conds":["Sedation in ERCP"],"condg":["Other"],"enroll":50,"eid":"NCT02651792"},{"id":"study-NCT02461927","cat":"studies","name":"Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"VA Office of Research and Development","drugs":["ketamine"],"nct":"NCT02461927","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-01-01","official":"Gihyun Yoon, MD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT02461927","sites":["VA Connecticut Healthcare System West Haven Campus, West Haven, CT — West Haven, United States"],"conds":["Major Depressive Disorder","Alcohol Use Disorder"],"condg":["Depression","Addiction & substance use"],"enroll":65,"eid":"NCT02461927"},{"id":"study-NCT02083926","cat":"studies","name":"Ketamine Infusion for Social Anxiety Disorder","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT02083926","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-01-02","official":"Michael H. Bloch, MD, MS (Yale University)","src":"https://clinicaltrials.gov/study/NCT02083926","sites":["Connecticut Mental Health Center — New Haven, United States"],"conds":["Social Anxiety Disorder"],"condg":["Anxiety"],"enroll":18,"eid":"NCT02083926"},{"id":"study-NCT02289248","cat":"studies","name":"Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine","status":"COMPLETED","phase":"Phase 1","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT02289248","nsites":2,"countries":"United States","ccs":["US"],"start":"2015-02","official":"Samuel Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT02289248","sites":["Connecticut Mental Health Center — New Haven, United States","Yale Psychiatric Hospital — New Haven, United States"],"conds":["Depression"],"condg":["Depression"],"enroll":16,"eid":"NCT02289248"},{"id":"study-NCT02373449","cat":"studies","name":"Ketamine and fMRI for Neuropathic Pain","status":"COMPLETED","phase":"N/A","sponsor":"University Health Network, Toronto","drugs":["ketamine"],"nct":"NCT02373449","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2015-02","official":"Anuj Bhatia (UHN)","src":"https://clinicaltrials.gov/study/NCT02373449","sites":["Toronto Western Hospital — Toronto, Canada"],"conds":["Neuralgia"],"condg":["Chronic pain & headache"],"enroll":39,"eid":"NCT02373449"},{"id":"study-NCT02591017","cat":"studies","name":"Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain Outpatients","status":"TERMINATED","phase":"Phase 3","sponsor":"University Hospital, Basel, Switzerland","drugs":["ketamine"],"nct":"NCT02591017","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2015-02","official":"Wilhelm Ruppen, PD Dr. med. (Pain Relief Unit and Anaesthesiology, University Hospital Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT02591017","sites":["Pain Relief Unit and Anaesthesiology, University Hospital Basel — Basel, Switzerland"],"conds":["Cancer: Breakthrough Pain","Cancer: Extreme Pain on Movement"],"condg":["Cancer-related distress","Chronic pain & headache"],"enroll":11,"eid":"NCT02591017"},{"id":"study-NCT02659085","cat":"studies","name":"Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Pouya Movahed Rad","drugs":["ketamine"],"nct":"NCT02659085","nsites":1,"countries":"Sweden","ccs":["SE"],"start":"2015-02","official":"Pouya Movahed Rad, MD, PhD (Dept of Clinical Sciences Lund, Faculty of Medicine Lund University, Sweden)","src":"https://clinicaltrials.gov/study/NCT02659085","sites":["Department of Psychiatry — Lund, Sweden"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"enroll":198,"eid":"NCT02659085"},{"id":"study-NCT02451072","cat":"studies","name":"The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers","status":"COMPLETED","phase":"N/A","sponsor":"Psychiatric University Hospital, Zurich","drugs":["LSD"],"nct":"NCT02451072","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2015-03","official":"Franz X. Vollenweider, Prof. Dr. (Center for Psychiatric Research, Department of Psychiatry, Psychotherapy and Psychosomatic, Psychiatric Hospital, University…","src":"https://clinicaltrials.gov/study/NCT02451072","sites":["Center for Psychiatric Research, Department of Psychiatry, Psychotherapy and Psychosomatic, Psychiatric Hospital, University of Zurich — Zurich, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":25,"eid":"NCT02451072"},{"id":"study-NCT02401139","cat":"studies","name":"Ketamine Trial for the Treatment of Depression","status":"COMPLETED","phase":"Phase 1","sponsor":"The University of New South Wales","drugs":["ketamine"],"nct":"NCT02401139","nsites":2,"countries":"Australia","ccs":["AU"],"start":"2015-03","official":"Colleen K Loo, MBBS, MD (University of New South Wales)","src":"https://clinicaltrials.gov/study/NCT02401139","sites":["Brain & Mind Research Institute (BMRI), University of Sydney — Camperdown, Australia","Black Dog Institute, University of New South Wales — Sydney, Australia"],"conds":["Unipolar Depression"],"condg":["Depression"],"enroll":10,"eid":"NCT02401139"},{"id":"study-NCT02422290","cat":"studies","name":"Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT02422290","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-03","official":"Pablo Goldberg, M.D. (Columbia University/NYSPI)","src":"https://clinicaltrials.gov/study/NCT02422290","sites":["New York State Psychiatric Institute/Columbia University — New York, United States"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"enroll":5,"eid":"NCT02422290"},{"id":"study-NCT02258204","cat":"studies","name":"Ketamine for Thrombolysis in Acute Ischemic Stroke","status":"UNKNOWN","phase":"Phase 1/Phase 2","sponsor":"University Hospital, Caen","drugs":["ketamine"],"nct":"NCT02258204","nsites":1,"countries":"France","ccs":["FR"],"start":"2015-03","src":"https://clinicaltrials.gov/study/NCT02258204","sites":["CHU Caen — Caen, France"],"conds":["Stroke"],"condg":["Neurology & cognition"],"enroll":50,"eid":"NCT02258204"},{"id":"study-NCT02243813","cat":"studies","name":"Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion","status":"COMPLETED","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT02243813","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-03","official":"Roland R Griffiths, Ph.D. (JHUSOM)","src":"https://clinicaltrials.gov/study/NCT02243813","sites":["Behavioral Biology Research Center, Johns Hopkins Bayview — Baltimore, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":24,"eid":"NCT02243813"},{"id":"study-NCT02378740","cat":"studies","name":"Ketamine in Patients Undergoing Anterior Cervical Discectomy and Fusion","status":"WITHDRAWN","phase":"Phase 4","sponsor":"Northwestern University","drugs":["ketamine"],"nct":"NCT02378740","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-04","official":"Natalie Moreland, MD (Northwestern University)","src":"https://clinicaltrials.gov/study/NCT02378740","sites":["Northwestern Memorial Hospital — Chicago, United States"],"conds":["Anesthesia","Pain","Surgery"],"condg":["Chronic pain & headache"],"eid":"NCT02378740"},{"id":"study-NCT02431663","cat":"studies","name":"Ketamine in Refractory Convulsive Status Epilepticus","status":"TERMINATED","phase":"Phase 3","sponsor":"Meyer Children's Hospital IRCCS","drugs":["ketamine"],"nct":"NCT02431663","nsites":1,"countries":"Italy","ccs":["IT"],"start":"2015-04","official":"Anna Rosati, MD, PhD (Children's Hospital A. Meyer of Firenze, Italy)","src":"https://clinicaltrials.gov/study/NCT02431663","sites":["Anna Rosati — Florence, Italy"],"conds":["Status Epilepticus"],"condg":["Neurology & cognition"],"enroll":57,"eid":"NCT02431663"},{"id":"study-NCT02583217","cat":"studies","name":"Effect of Ketamine+Propofol vs Remifentanyl+Propofol on Laryngeal Mask Insertion Conditions","status":"COMPLETED","sponsor":"Ankara University","drugs":["ketamine"],"nct":"NCT02583217","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2015-04","official":"CIGDEM YILDIRIM GUCLU, MD (Ankara University)","src":"https://clinicaltrials.gov/study/NCT02583217","sites":["Cigdem Yildirim Guclu — Ankara, Turkey"],"conds":["Surgery"],"condg":["Other"],"enroll":50,"eid":"NCT02583217"},{"id":"study-NCT02299440","cat":"studies","name":"Effects of Ketamine in the Acute Phase of Suicidal Ideation","status":"COMPLETED","phase":"Phase 3","sponsor":"Centre Hospitalier Universitaire de Nīmes","drugs":["ketamine"],"nct":"NCT02299440","nsites":9,"countries":"France","ccs":["FR"],"start":"2015-04","official":"Mocrane Abbar, MD (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT02299440","sites":["CHU de Clermont Ferrand - Hôpital Gabriel-Montpied — Clermont-Ferrand, France","CHRU de Lille - Hôpital Michel Fontan — Lille, France","CHRU de Montpellier - Hôpital Lapeyronie — Montpellier, France","Clinique Les Sophoras — Nîmes, France","CHRU de Nîmes - Hôpital Universitaire Carémeau — Nîmes, France","APHP - Hôpital Lariboisière — Paris, France","Centre Hospitalier Sainte-Anne — Paris, France","CMME Centre Hospitalier Sainte Anne — Paris, France"],"conds":["Suicidal Ideation"],"condg":["Other"],"enroll":156,"eid":"NCT02299440"},{"id":"study-NCT02414932","cat":"studies","name":"Ketamine for Depression Relapse Prevention Following ECT","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"St Patrick's Hospital, Ireland","drugs":["ketamine"],"nct":"NCT02414932","nsites":1,"countries":"Ireland","ccs":["IE"],"start":"2015-04","official":"Declan M McLoughlin (St Patrick's Hospital/Trinity College)","src":"https://clinicaltrials.gov/study/NCT02414932","sites":["St Patrick's University Hospital — Dublin, Ireland"],"conds":["Depression"],"condg":["Depression"],"enroll":6,"eid":"NCT02414932"},{"id":"study-NCT02421263","cat":"studies","name":"The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals","status":"COMPLETED","phase":"Phase 1","sponsor":"NYU Langone Health","drugs":["psilocybin"],"nct":"NCT02421263","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-04","official":"Anthony Bossis, PhD (New York University); Stephen Ross, MD (New York University)","src":"https://clinicaltrials.gov/study/NCT02421263","sites":["NYU Langone Medical Center/Tisch Hospital — New York, United States"],"conds":["Religious or Spiritual Problem"],"condg":["Other"],"enroll":12,"eid":"NCT02421263"},{"id":"study-NCT02294162","cat":"studies","name":"Pain Relief for Submucosal Resection of Nasal Septum in Adults Does Ketamine Have a Pre-Emptive Effect?","status":"WITHDRAWN","phase":"N/A","sponsor":"Western Galilee Hospital-Nahariya","drugs":["ketamine"],"nct":"NCT02294162","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2015-04-01","src":"https://clinicaltrials.gov/study/NCT02294162","sites":["Galillee medical center — Nahariya, Israel"],"conds":["Nasal Obstruction"],"condg":["Other"],"eid":"NCT02294162"},{"id":"study-NCT02363270","cat":"studies","name":"Ketamine: Comparison of IV Push vs. IV Drip","status":"COMPLETED","phase":"N/A","sponsor":"Antonios Likourezos","drugs":["ketamine"],"nct":"NCT02363270","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-04-01","official":"Sergey Motov, MD (Maimonides Medical Center); John Marshall, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT02363270","sites":["Maimonides Medical Center — Brooklyn, United States"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":48,"eid":"NCT02363270"},{"id":"study-NCT02360280","cat":"studies","name":"Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"VA Office of Research and Development","drugs":["ketamine"],"nct":"NCT02360280","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-04-01","official":"Paulo R Shiroma, MD (Minneapolis VA Health Care System, Minneapolis, MN)","src":"https://clinicaltrials.gov/study/NCT02360280","sites":["Minneapolis VA Health Care System, Minneapolis, MN — Minneapolis, United States"],"conds":["Treatment-resistant Depression"],"condg":["Depression"],"enroll":62,"eid":"NCT02360280"},{"id":"study-NCT02418195","cat":"studies","name":"miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome","status":"COMPLETED","phase":"Phase 2","sponsor":"University of Alabama at Birmingham","drugs":["ketamine"],"nct":"NCT02418195","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-04-20","official":"Yogesh Dwivedi, Ph.D. (University of Alabama at Birmingham); Richard C Shelton, M.D. (University of Alabama at Birmingham)","src":"https://clinicaltrials.gov/study/NCT02418195","sites":["University of Alabama at Birmingham — Birmingham, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":247,"eid":"NCT02418195"},{"id":"study-NCT02577250","cat":"studies","name":"Ketamine Infusions for PTSD and Treatment-Resistant Depression","status":"COMPLETED","phase":"Phase 1","sponsor":"Minneapolis Veterans Affairs Medical Center","drugs":["ketamine"],"nct":"NCT02577250","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-05","official":"Paulo Shiroma, MD (Minneapolis Veterans Affairs Medical Center); Cristina S Albott, MD,MA (Minneapolis Veterans Affairs Medical Center)","src":"https://clinicaltrials.gov/study/NCT02577250","sites":["Minneapolis Va Health Care System, Minneapolis MN — Minneapolis, United States"],"conds":["Depressive Disorder, Treatment-Resistant","Stress Disorders, Post-Traumatic"],"condg":["Depression","PTSD & trauma"],"enroll":20,"eid":"NCT02577250"},{"id":"study-NCT02037126","cat":"studies","name":"Psilocybin-facilitated Treatment for Cocaine Use","status":"COMPLETED","phase":"Phase 2","sponsor":"University of Alabama at Birmingham","drugs":["psilocybin"],"nct":"NCT02037126","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-05","official":"Peter S. Hendricks, Ph.D. (UAB Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT02037126","sites":["UAB Outpatient Clinical Research Unit — Birmingham, United States"],"conds":["Cocaine-Related Disorders"],"condg":["Addiction & substance use"],"enroll":40,"eid":"NCT02037126"},{"id":"study-NCT02388321","cat":"studies","name":"Pediatric Ketamine Study for Pain Management","status":"TERMINATED","phase":"Phase 4","sponsor":"Antonios Likourezos","drugs":["ketamine"],"nct":"NCT02388321","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-05-01","official":"Sabina Zavolkovskaya, MD (Maimonides Medical Center); Sergey Motov, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT02388321","sites":["Maimonides Medical Center — Brooklyn, United States"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":22,"eid":"NCT02388321"},{"id":"study-NCT02427568","cat":"studies","name":"MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness","status":"COMPLETED","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT02427568","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-05-14","official":"Philip Wolfson, MD (Private Practice)","src":"https://clinicaltrials.gov/study/NCT02427568","sites":["Offices of Philip Wolfson MD — San Anselmo, United States"],"conds":["Anxiety"],"condg":["Anxiety"],"enroll":18,"eid":"NCT02427568"},{"id":"study-NCT02311777","cat":"studies","name":"Pre-operative Pregabalin and Ketamine to Prevent Phantom Pain","status":"WITHDRAWN","phase":"Phase 3","sponsor":"University of Texas Southwestern Medical Center","drugs":["ketamine"],"nct":"NCT02311777","nsites":2,"countries":"United States","ccs":["US"],"start":"2015-05-15","official":"Dawood H Nasir, MD (University of Texas Southwestern Medical Center)","src":"https://clinicaltrials.gov/study/NCT02311777","sites":["Parkland Health Hospital System — Dallas, United States","UTSW, Parkland Hospital — Dallas, United States"],"conds":["Phantom Pain"],"condg":["Chronic pain & headache"],"eid":"NCT02311777"},{"id":"study-NCT02397889","cat":"studies","name":"Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Icahn School of Medicine at Mount Sinai","drugs":["ketamine"],"nct":"NCT02397889","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-05-18","official":"Adriana Feder, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT02397889","sites":["Depression and Anxiety Center (DAC) — New York, United States"],"conds":["Posttraumatic Stress Disorder (PTSD)"],"condg":["PTSD & trauma"],"enroll":30,"eid":"NCT02397889"},{"id":"study-NCT02434939","cat":"studies","name":"Low-dose Ketamine vs Morphine for Vaso-occlusive Crisis in Sicklers","status":"COMPLETED","phase":"Phase 4","sponsor":"Makerere University","drugs":["ketamine"],"nct":"NCT02434939","nsites":1,"countries":"Uganda","ccs":["UG"],"start":"2015-06","official":"Felix A. Lubega, MBChB (Makerere University, College of Health Sciences, Department of Anesthesia and Critical Care); Tonny S. Luggya, MMed (Makerere…","src":"https://clinicaltrials.gov/study/NCT02434939","sites":["Sickle Cell clinic, Mulago Hospital Complex — Kampala, Uganda"],"conds":["Sickle Cell Crisis","Acute Pain"],"condg":["Chronic pain & headache"],"enroll":240,"eid":"NCT02434939"},{"id":"study-NCT01892995","cat":"studies","name":"Ketamine for Acute Suicidal Ideation in the Emergency Department: Randomized Controlled Trial","status":"UNKNOWN","phase":"N/A","sponsor":"Brooke Army Medical Center","drugs":["ketamine"],"nct":"NCT01892995","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-06","src":"https://clinicaltrials.gov/study/NCT01892995","sites":["Brooke Army Medical Center — Fort Sam Houston, United States"],"conds":["Suicide"],"condg":["Other"],"contact":{"n":"Steven G Schauer, DO","p":"2109160808","e":"sgschauer@gmail.com"},"enroll":53,"eid":"NCT01892995"},{"id":"study-NCT02708849","cat":"studies","name":"The Sustained Effects of Ketamine","status":"TERMINATED","phase":"Phase 1","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT02708849","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-06","official":"Chadi Abdallah, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT02708849","sites":["Yale Center for Clinical Investigation, Yale University — New Haven, United States"],"conds":["Mental Disorders"],"condg":["Other"],"enroll":3,"eid":"NCT02708849"},{"id":"study-NCT03000413","cat":"studies","name":"Ketamine Efficacy for Acute Severe Bronchospasm in ICU: MACANUDO Trial","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Hospital Nossa Senhora da Conceicao","drugs":["ketamine"],"nct":"NCT03000413","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2015-06-04","src":"https://clinicaltrials.gov/study/NCT03000413","sites":["Hospital Nossa Senhora da Conceição — Porto Alegre, Brazil"],"conds":["Critical Illness","Asthma","Bronchospasm"],"condg":["Other"],"enroll":45,"eid":"NCT03000413"},{"id":"study-NCT04421105","cat":"studies","name":"A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years","status":"COMPLETED","phase":"Phase 1","sponsor":"Eleusis Therapeutics","drugs":["LSD"],"nct":"NCT04421105","nsites":0,"start":"2015-06-29","official":"Research and Development Director (Eleusis Therapeutics)","src":"https://clinicaltrials.gov/study/NCT04421105","conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":48,"eid":"NCT04421105"},{"id":"study-NCT02501941","cat":"studies","name":"Spreading Depolarization and Ketamine Suppression","status":"COMPLETED","phase":"Phase 1","sponsor":"University of New Mexico","drugs":["ketamine"],"nct":"NCT02501941","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-07","official":"Andrew P Carlson, MD (University of New Mexico)","src":"https://clinicaltrials.gov/study/NCT02501941","sites":["University of New Mexico — Albuquerque, United States"],"conds":["Cortical Spreading Depolarization","Cortical Spreading Depression","Subarachoid Hemorrhage","Traumatic Brain Injury"],"condg":["Depression","PTSD & trauma","Neurology & cognition"],"enroll":10,"eid":"NCT02501941"},{"id":"study-NCT02295787","cat":"studies","name":"Intranasal Ketamine for Late-Life Depression and Suicidal Ideation","status":"WITHDRAWN","phase":"Phase 4","sponsor":"Massachusetts General Hospital","drugs":["ketamine"],"nct":"NCT02295787","nsites":0,"start":"2015-07","official":"Dawn F Ionescu, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT02295787","conds":["Depression","Suicide","Suicidal Ideation"],"condg":["Depression"],"eid":"NCT02295787"},{"id":"study-NCT02525978","cat":"studies","name":"Heart Rate Variability in Depression","status":"COMPLETED","phase":"N/A","sponsor":"Emory University","drugs":["ketamine"],"nct":"NCT02525978","nsites":3,"countries":"United States","ccs":["US"],"start":"2015-07","official":"Andrea Crowell, MD (Emory University)","src":"https://clinicaltrials.gov/study/NCT02525978","sites":["Emory University Hospital — Atlanta, United States","12 Executive Park Drive — Atlanta, United States","Emory University at Wesley Woods Hospital — Atlanta, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":8,"eid":"NCT02525978"},{"id":"study-NCT02522377","cat":"studies","name":"Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression","status":"COMPLETED","phase":"N/A","sponsor":"The Cleveland Clinic","drugs":["ketamine"],"nct":"NCT02522377","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-08","official":"Murat Altinay, MD (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT02522377","sites":["Cleveland Clinic Foundation Center for Behavioral Health — Cleveland, United States"],"conds":["Treatment Resistant Depression","Major Depressive Disorder","Severe Depression"],"condg":["Depression"],"enroll":15,"eid":"NCT02522377"},{"id":"study-NCT02497066","cat":"studies","name":"Efficacy Study Comparing Compounded Topical Pain Creams vs. Placebo for Treating Pain Symptoms","status":"COMPLETED","phase":"Phase 3","sponsor":"Walter Reed National Military Medical Center","drugs":["ketamine"],"nct":"NCT02497066","nsites":0,"start":"2015-08-05","official":"Robert E Brutcher, PharmD,Ph.D. (WRNMMC)","src":"https://clinicaltrials.gov/study/NCT02497066","conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":399,"eid":"NCT02497066"},{"id":"study-NCT02418585","cat":"studies","name":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 3","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02418585","nsites":48,"countries":"Czechia; Germany; Poland; Spain; United States","ccs":["CZ","DE","ES","PL","US"],"start":"2015-08-07","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","sites":["Unnamed trial site — Birmingham, United States","Unnamed trial site — Orange, United States","Unnamed trial site — San Rafael, United States","Unnamed trial site — Maitland, United States","Unnamed trial site — Atlanta, United States","Unnamed trial site — Chicago, United States","Unnamed trial site — Gaithersburg, United States","Unnamed trial site — Boston, United States"],"conds":["Treatment-resistant Depression"],"condg":["Depression"],"enroll":236,"eid":"NCT02418585"},{"id":"study-NCT02417064","cat":"studies","name":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 3","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02417064","nsites":90,"countries":"Belgium; Brazil; Canada; Estonia; France; Hungary; Mexico; Slovakia; United States","ccs":["BE","BR","CA","EE","FR","HU","MX","SK","US"],"start":"2015-08-10","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","sites":["Unnamed trial site — Birmingham, United States","Unnamed trial site — Little Rock, United States","Unnamed trial site — Garden Grove, United States","Unnamed trial site — Orange, United States","Unnamed trial site — San Diego, United States","Unnamed trial site — San Marcos, United States","Unnamed trial site — San Rafael, United States","Unnamed trial site — Bradenton, United States"],"conds":["Treatment-resistant Depression"],"condg":["Depression"],"enroll":346,"eid":"NCT02417064"},{"id":"study-NCT02729805","cat":"studies","name":"Intraoperative Ketamine on Chronic Pain After Mastectomy","status":"SUSPENDED","phase":"Phase 4","sponsor":"The University of Hong Kong","drugs":["ketamine"],"nct":"NCT02729805","nsites":1,"countries":"Hong Kong","ccs":["HK"],"start":"2015-08-18","official":"Stanley SC Wong, MBBS (The University of Hong Kong)","src":"https://clinicaltrials.gov/study/NCT02729805","sites":["The University of Hong Kong — Hong Kong, Hong Kong"],"conds":["Chronic Pain"],"condg":["Chronic pain & headache"],"enroll":135,"eid":"NCT02729805"},{"id":"study-NCT02422186","cat":"studies","name":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 3","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02422186","nsites":69,"countries":"Belgium; Brazil; Bulgaria; Finland; France; Lithuania; Poland; South Africa; Spain; Sweden; United Kingdom; United States","ccs":["BE","BG","BR","ES","FI","FR","GB","LT","PL","SE","US","ZA"],"start":"2015-08-20","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","sites":["Unnamed trial site — San Diego, United States","Unnamed trial site — New Haven, United States","Unnamed trial site — Miami, United States","Unnamed trial site — Marietta, United States","Unnamed trial site — Iowa City, United States","Unnamed trial site — Baltimore, United States","Unnamed trial site — Watertown, United States","Unnamed trial site — New York, United States"],"conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"enroll":139,"eid":"NCT02422186"},{"id":"study-NCT02435030","cat":"studies","name":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","status":"COMPLETED","sponsor":"ZevraDenmark","drugs":["LSD"],"nct":"NCT02435030","nsites":16,"countries":"Denmark; France; Germany; Italy; Poland; Spain; Switzerland; United Kingdom","ccs":["CH","DE","DK","ES","FR","GB","IT","PL"],"start":"2015-09","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","sites":["University Hospital Copenhagen (Rigshospitalet) — Copenhagen, Denmark","CHU de Montpellier — Montpellier, France","Hôpital Trousseau — Paris, France","Villa Metabolica Mainz — Mainz, Germany","Klinikum der Universistat, Munchen — Munich, Germany","Istituto Carlo Besta (Milano) — Milan, Italy","Azienda Ospedaliera San Gerardo — Monza, Italy","Università Federico II — Naples, Italy"],"conds":["Niemann-Pick Disease, Type C"],"condg":["Other"],"enroll":35,"eid":"NCT02435030"},{"id":"study-NCT02556060","cat":"studies","name":"Lamotrigine for Ketamine Dependence Trial","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Taipei City Hospital","drugs":["ketamine"],"nct":"NCT02556060","nsites":1,"countries":"Taiwan","ccs":["TW"],"start":"2015-09","official":"Shih-Ku Lin, MD (Taipei City Hospital)","src":"https://clinicaltrials.gov/study/NCT02556060","sites":["Taipei City Hospital and Psychiatric Center — Taipei, Taiwan"],"conds":["Addiction"],"condg":["Addiction & substance use"],"enroll":30,"eid":"NCT02556060"},{"id":"study-NCT01613820","cat":"studies","name":"Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder","status":"WITHDRAWN","phase":"N/A","sponsor":"Massachusetts General Hospital","drugs":["ketamine"],"nct":"NCT01613820","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-09","official":"Cristina Cusin, M.D. (MGH Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT01613820","sites":["Depression Clinical and Reseach Program - MGH — Boston, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"eid":"NCT01613820"},{"id":"study-NCT02497287","cat":"studies","name":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 3","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02497287","nsites":109,"countries":"Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Finland; France; Germany; Lithuania; Malaysia; Mexico; Poland; South Africa; South Korea; Spain; Sweden; Taiwan; Turkey (Türkiye); United Kingdom; United States","ccs":["AR","AT","AU","BE","BG","BR","DE","ES","FI","FR","GB","KR","LT","MX","MY","PL","SE","TR","TW","US","ZA"],"start":"2015-09-30","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","sites":["Unnamed trial site — New Haven, United States","Unnamed trial site — Miami, United States","Unnamed trial site — Marietta, United States","Unnamed trial site — Iowa City, United States","Unnamed trial site — Wichita, United States","Unnamed trial site — Baltimore, United States","Unnamed trial site — Watertown, United States","Unnamed trial site — Cedarhurst, United States"],"conds":["Treatment-resistant Depression"],"condg":["Depression"],"enroll":802,"eid":"NCT02497287"},{"id":"study-NCT02568176","cat":"studies","name":"Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02568176","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2015-10","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02568176","sites":["Unnamed trial site — Merksem, Belgium"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":71,"eid":"NCT02568176"},{"id":"study-NCT02541396","cat":"studies","name":"A Study Of The Effectiveness Of Wafermine Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy","status":"COMPLETED","phase":"Phase 2","sponsor":"iX Biopharma Ltd.","drugs":["ketamine"],"nct":"NCT02541396","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-10","src":"https://clinicaltrials.gov/study/NCT02541396","sites":["Jean Brown Research — Salt Lake City, United States"],"conds":["Acute Pain"],"condg":["Chronic pain & headache"],"enroll":72,"eid":"NCT02541396"},{"id":"study-NCT02579928","cat":"studies","name":"Ketamine Infusion for Adolescent Depression and Anxiety","status":"COMPLETED","phase":"Phase 4","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT02579928","nsites":2,"countries":"United States","ccs":["US"],"start":"2015-10","official":"Michael H. Bloch, MD MS (Yale University)","src":"https://clinicaltrials.gov/study/NCT02579928","sites":["Hospital Research Unit at the Yale New Haven Hospital — New Haven, United States","Yale Child Study Center — New Haven, United States"],"conds":["Major Depressive Disorder","Anxiety Disorder"],"condg":["Depression","Anxiety"],"enroll":17,"eid":"NCT02579928"},{"id":"study-NCT02493868","cat":"studies","name":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 3","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02493868","nsites":155,"countries":"Belgium; Brazil; Canada; Czechia; Estonia; France; Germany; Hungary; Mexico; Poland; Slovakia; Spain; Sweden; Turkey (Türkiye); United States","ccs":["BE","BR","CA","CZ","DE","EE","ES","FR","HU","MX","PL","SE","SK","TR","US"],"start":"2015-10-01","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","sites":["Unnamed trial site — Birmingham, United States","Unnamed trial site — Little Rock, United States","Unnamed trial site — Anaheim, United States","Unnamed trial site — Garden Grove, United States","Unnamed trial site — Glendale, United States","Unnamed trial site — Oakland, United States","Unnamed trial site — Orange, United States","Unnamed trial site — San Diego, United States"],"conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"enroll":719,"eid":"NCT02493868"},{"id":"study-NCT02556606","cat":"studies","name":"Ketamine for Treatment Resistant Late-Life Depression","status":"COMPLETED","phase":"Phase 3","sponsor":"VA Office of Research and Development","drugs":["ketamine"],"nct":"NCT02556606","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-10-01","official":"Sanjay Mathew, MD (Michael E. DeBakey VA Medical Center, Houston, TX)","src":"https://clinicaltrials.gov/study/NCT02556606","sites":["Michael E. DeBakey VA Medical Center, Houston, TX — Houston, United States"],"conds":["Treatment Resistant Depressive Disorder"],"condg":["Depression"],"enroll":33,"eid":"NCT02556606"},{"id":"study-NCT05674669","cat":"studies","name":"A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"Eleusis Therapeutics","drugs":["LSD"],"nct":"NCT05674669","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2015-10-20","official":"Director of Research and Development (Eleusis Therapeutics)","src":"https://clinicaltrials.gov/study/NCT05674669","sites":["PAREXEL, Early Phase Clinical Unit — London, United Kingdom"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":32,"eid":"NCT05674669"},{"id":"study-NCT02467517","cat":"studies","name":"Ketamine and Neuropathic Pain","status":"UNKNOWN","phase":"Phase 2","sponsor":"University Hospital, Clermont-Ferrand","drugs":["ketamine"],"nct":"NCT02467517","nsites":1,"countries":"France","ccs":["FR"],"start":"2015-11","official":"Gisèle PICKERING (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT02467517","sites":["CHU de Clermont-Ferrand — Clermont-Ferrand, France"],"conds":["Neuropathic Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Patrick LACARIN","p":"04 73 75 11 95","e":"placarin@chu-clermontferrand.fr"},"enroll":22,"eid":"NCT02467517"},{"id":"study-NCT02417298","cat":"studies","name":"Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department","status":"TERMINATED","phase":"N/A","sponsor":"Billy Sin","drugs":["ketamine"],"nct":"NCT02417298","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-11","official":"Michael Hochberg, MD (The Brooklyn Hospital Center)","src":"https://clinicaltrials.gov/study/NCT02417298","sites":["The Brooklyn Hospital Center — Brooklyn, United States"],"conds":["Pain","Sickle Cell Disorder"],"condg":["Chronic pain & headache"],"enroll":12,"eid":"NCT02417298"},{"id":"study-NCT02562820","cat":"studies","name":"An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome","status":"TERMINATED","phase":"Phase 1","sponsor":"The Cleveland Clinic","drugs":["ketamine"],"nct":"NCT02562820","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-11","official":"Daniel Sessler, MD (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT02562820","sites":["Cleveland Clinic — Cleveland, United States"],"conds":["Rett Syndrome"],"condg":["Other"],"enroll":4,"eid":"NCT02562820"},{"id":"study-NCT02954562","cat":"studies","name":"Correlates of Anxiety Associated With a Life-threatening Illness","status":"COMPLETED","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT02954562","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-11-07","official":"Michael Silver (University of California, Berkeley)","src":"https://clinicaltrials.gov/study/NCT02954562","sites":["University of California - Berkeley — Berkeley, United States"],"conds":["Anxiety"],"condg":["Anxiety"],"enroll":12,"eid":"NCT02954562"},{"id":"study-NCT02611505","cat":"studies","name":"A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02611505","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-11-30","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02611505","sites":["Unnamed trial site — Knoxville, United States"],"conds":["Hepatic Impairment","Normal Hepatic Function"],"condg":["Other"],"enroll":24,"eid":"NCT02611505"},{"id":"study-NCT02661061","cat":"studies","name":"Ketamine for Relapse Prevention in Recurrent Depressive Disorder","status":"TERMINATED","phase":"Phase 1","sponsor":"St Patrick's Hospital, Ireland","drugs":["ketamine"],"nct":"NCT02661061","nsites":1,"countries":"Ireland","ccs":["IE"],"start":"2015-12","official":"Declan McLoughlin (University of Dublin, Trinity College)","src":"https://clinicaltrials.gov/study/NCT02661061","sites":["St Patrick's University Hospital — Dublin, Ireland"],"conds":["Depression","Relapse","Recurrent Depressive Disorder","Major Depressive Disorder"],"condg":["Depression"],"enroll":9,"eid":"NCT02661061"},{"id":"study-NCT02422303","cat":"studies","name":"Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms","status":"TERMINATED","phase":"N/A","sponsor":"The University of Texas Health Science Center at San Antonio","drugs":["ketamine"],"nct":"NCT02422303","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-12","official":"Bonny C Gillis, M.D. (Department of Anesthesiology UTHSCSA)","src":"https://clinicaltrials.gov/study/NCT02422303","sites":["University Hospital — San Antonio, United States"],"conds":["Depression","Major Depressive Disorder"],"condg":["Depression"],"enroll":12,"eid":"NCT02422303"},{"id":"study-NCT02521415","cat":"studies","name":"IN Sub-Dissociative Ketamine vs IN Fentanyl","status":"COMPLETED","phase":"Phase 2","sponsor":"Wake Forest University Health Sciences","drugs":["ketamine"],"nct":"NCT02521415","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-12","official":"Stacy Reynolds, MD (Carolinas Medical Center)","src":"https://clinicaltrials.gov/study/NCT02521415","sites":["Carolinas Medical Center Main - Levine Children's Hospital Emergency Department — Charlotte, United States"],"conds":["Bone Fracture"],"condg":["Other"],"enroll":87,"eid":"NCT02521415"},{"id":"study-NCT02573714","cat":"studies","name":"Sub-dissociative Intranasal Ketamine for Pediatric Sickle Cell Pain Crises","status":"UNKNOWN","phase":"N/A","sponsor":"Cameroon Baptist Convention Health","drugs":["ketamine"],"nct":"NCT02573714","nsites":2,"countries":"Cameroon; Tanzania","ccs":["CM","TZ"],"start":"2015-12","official":"Ernest Nshom, MD (Cameroon Baptist Convention Health); Michael Runyon, MD (Carolinas Medical Center)","src":"https://clinicaltrials.gov/study/NCT02573714","sites":["Mbingo Baptist Hospital — Bamenda, Cameroon","Muhimbili National Hospital — Dar es Salaam, Tanzania"],"conds":["Sickle Cell Disease"],"condg":["Other"],"contact":{"n":"James R Young, MD","p":"704-578-5078","e":"james.young@carolinashealthcare.org"},"enroll":160,"eid":"NCT02573714"},{"id":"study-NCT02727998","cat":"studies","name":"Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy","status":"TERMINATED","phase":"Phase 2","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT02727998","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-12","official":"Ilan Harpaz-Rotem, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT02727998","sites":["Yale University School of Medicine — New Haven, United States"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":28,"eid":"NCT02727998"},{"id":"study-NCT02606084","cat":"studies","name":"A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02606084","nsites":2,"countries":"United States","ccs":["US"],"start":"2015-12-04","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02606084","sites":["Unnamed trial site — Miami, United States","Unnamed trial site — Knoxville, United States"],"conds":["Renal Impairment","Healthy"],"condg":["Healthy volunteers"],"enroll":32,"eid":"NCT02606084"},{"id":"study-NCT02611921","cat":"studies","name":"Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder","status":"COMPLETED","phase":"Phase 1","sponsor":"Children's Hospital Medical Center, Cincinnati","drugs":["ketamine"],"nct":"NCT02611921","nsites":1,"countries":"United States","ccs":["US"],"start":"2015-12-22","official":"Logan K Wink, MD (Children's Hospital Medical Center, Cincinnati)","src":"https://clinicaltrials.gov/study/NCT02611921","sites":["Cincinnati Childrens Hospital Medical Center — Cincinnati, United States"],"conds":["Autism Spectrum Disorder"],"condg":["Other"],"enroll":21,"eid":"NCT02611921"},{"id":"study-NCT02624401","cat":"studies","name":"The Neural Mechanisms of Anesthesia and Human Consciousness (Part 6)","status":"COMPLETED","phase":"Phase 4","sponsor":"University of Turku","drugs":["esketamine","ketamine"],"nct":"NCT02624401","nsites":1,"countries":"Finland","ccs":["FI"],"start":"2016-01","official":"Harry Scheinin, MD (Turku PET Centre, University of Turku, Turku, Finland)","src":"https://clinicaltrials.gov/study/NCT02624401","sites":["Turku PET Centre — Turku, Finland"],"conds":["Anesthesia","Unconsciousness"],"condg":["Other"],"enroll":160,"eid":"NCT02624401"},{"id":"study-NCT03017248","cat":"studies","name":"Low-dose Ketamine for Acute Pain in the Emergency Department","status":"UNKNOWN","phase":"Phase 1","sponsor":"Faculty of Medicine, Sousse","drugs":["ketamine"],"nct":"NCT03017248","nsites":1,"countries":"Tunisia","ccs":["TN"],"start":"2016-01","official":"Hajer KRAIEM, MD (Faculty of medicine of Sousse)","src":"https://clinicaltrials.gov/study/NCT03017248","sites":["Faculty of medicine of Sousse — Sousse, Tunisia"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":125,"eid":"NCT03017248"},{"id":"study-NCT02646709","cat":"studies","name":"The Effect of Different Dose of Ketamine With Low Dose Rocuronium in Children","status":"UNKNOWN","phase":"Phase 4","sponsor":"Ajou University School of Medicine","drugs":["ketamine"],"nct":"NCT02646709","nsites":0,"start":"2016-01","official":"Go Un Roh, MD (Ajou University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT02646709","conds":["Inguinal Hernia"],"condg":["Other"],"contact":{"n":"Go Un Roh, MD","p":"82-31-219-6435","e":"gone7968@aumc.ac.kr"},"enroll":60,"eid":"NCT02646709"},{"id":"study-NCT02593643","cat":"studies","name":"Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Sunnybrook Health Sciences Centre","drugs":["ketamine"],"nct":"NCT02593643","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2016-01","src":"https://clinicaltrials.gov/study/NCT02593643","sites":["Sunnybook Health Sciences Centre — Toronto, Canada"],"conds":["Major Depressive Disorder","Bipolar I Disorder","Bipolar II Disorder","Bipolar Depression","Suicidal Ideation"],"condg":["Depression","Bipolar"],"enroll":9,"eid":"NCT02593643"},{"id":"study-NCT03780556","cat":"studies","name":"Lornoxicam With Low Dose Ketamine Versus Pethidine to Control Pain of Acute Renal Colic","status":"COMPLETED","phase":"N/A","sponsor":"Ain Shams University","drugs":["ketamine"],"nct":"NCT03780556","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2016-01-02","src":"https://clinicaltrials.gov/study/NCT03780556","sites":["ِAin Shams University hospitals — Cairo, Egypt"],"conds":["Renal Colic"],"condg":["Other"],"enroll":120,"eid":"NCT03780556"},{"id":"study-NCT02636218","cat":"studies","name":"Ketamine Infusion in Neurologic Deficit","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Unity Health Toronto","drugs":["ketamine"],"nct":"NCT02636218","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2016-01-26","official":"Andrew Baker, MD, FRCPC (Unity Health Toronto)","src":"https://clinicaltrials.gov/study/NCT02636218","sites":["St Michael's Hospital — Toronto, Canada"],"conds":["Subarachnoid Hemorrhage"],"condg":["Other"],"enroll":9,"eid":"NCT02636218"},{"id":"study-NCT02697071","cat":"studies","name":"Ketamine for Acute Migraine in the Emergency Department","status":"COMPLETED","phase":"N/A","sponsor":"Carilion Clinic","drugs":["ketamine"],"nct":"NCT02697071","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-02","official":"Corey Corey, MD (Carilion Clinic)","src":"https://clinicaltrials.gov/study/NCT02697071","sites":["Carilion Roanoke Memorial Emergency Department — Roanoke, United States"],"conds":["Headache"],"condg":["Chronic pain & headache"],"enroll":34,"eid":"NCT02697071"},{"id":"study-NCT03221569","cat":"studies","name":"Ketamine v. Ketorolac for Management of Generalized Tension Type Headache","status":"UNKNOWN","phase":"Phase 4","sponsor":"The Brooklyn Hospital Center","drugs":["ketamine"],"nct":"NCT03221569","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-02-01","src":"https://clinicaltrials.gov/study/NCT03221569","sites":["The Brooklyn Hospital Center — Brooklyn, United States"],"conds":["Migraine"],"condg":["Chronic pain & headache"],"contact":{"n":"Billy Sin, PharmD","p":"718-250-5000","e":"bsin@tbh.org"},"enroll":60,"eid":"NCT03221569"},{"id":"study-NCT02846519","cat":"studies","name":"Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of…","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02846519","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-02-26","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02846519","sites":["Unnamed trial site — Cypress, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":66,"eid":"NCT02846519"},{"id":"study-NCT02741622","cat":"studies","name":"Brain Derived Neurotropic Factor Response to Aerobic Exercise Intensity in Depressive Patients.","status":"COMPLETED","phase":"N/A","sponsor":"St. Olavs Hospital","drugs":["LSD"],"nct":"NCT02741622","nsites":1,"countries":"Norway","ccs":["NO"],"start":"2016-03","official":"Pål Sandvik, MD (St.Olavs University Hospital, Østmarka)","src":"https://clinicaltrials.gov/study/NCT02741622","sites":["St.Olavs university Hospital, Departement of Østmarka — Trondheim, Norway"],"conds":["Depressive Disorder","Depressive Disorder, Major"],"condg":["Depression"],"enroll":21,"eid":"NCT02741622"},{"id":"study-NCT02674295","cat":"studies","name":"A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02674295","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-03","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02674295","sites":["Unnamed trial site — Madison, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":8,"eid":"NCT02674295"},{"id":"study-NCT02544607","cat":"studies","name":"Ketamine for Depression: An MRI Study","status":"COMPLETED","phase":"Phase 4","sponsor":"Massachusetts General Hospital","drugs":["ketamine"],"nct":"NCT02544607","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-03","official":"Cristina Cusin, M.D. (MGH)","src":"https://clinicaltrials.gov/study/NCT02544607","sites":["Massachusetts General Hospital — Boston, United States"],"conds":["Depression","Anxious Depression","Major Depressive Disorder"],"condg":["Depression"],"enroll":25,"eid":"NCT02544607"},{"id":"study-NCT02487485","cat":"studies","name":"Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects","status":"COMPLETED","phase":"Phase 2","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT02487485","nsites":2,"countries":"United States","ccs":["US"],"start":"2016-03","official":"Chadi Abdallah, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT02487485","sites":["Yale New Haven Hospital — New Haven, United States","West Haven Veterans Affairs — West Haven, United States"],"conds":["Depression"],"condg":["Depression"],"enroll":23,"eid":"NCT02487485"},{"id":"study-NCT02752724","cat":"studies","name":"Ketamine Anesthesia for Improvement of Depression in ECT","status":"COMPLETED","phase":"N/A","sponsor":"VA Puget Sound Health Care System","drugs":["ketamine"],"nct":"NCT02752724","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-03","official":"Anna Borisovskaya, MD (Puget Sound VA Medical Center, Dept of Psychiatry); Irene Rozet, MD (Puget Sound VA Medical Center, Dept of Anesthesiology)","src":"https://clinicaltrials.gov/study/NCT02752724","sites":["VA Puget Sound Health Care System — Seattle, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":52,"eid":"NCT02752724"},{"id":"study-NCT02657031","cat":"studies","name":"The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine","status":"COMPLETED","phase":"Phase 4","sponsor":"University Medical Center of Southern Nevada","drugs":["ketamine"],"nct":"NCT02657031","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-03-17","official":"Joseph A Zitek, MD (Unviersity of Nevada School of Medicine)","src":"https://clinicaltrials.gov/study/NCT02657031","sites":["University Medical Center of Southern Nevada — Las Vegas, United States"],"conds":["Headache"],"condg":["Chronic pain & headache"],"enroll":54,"eid":"NCT02657031"},{"id":"study-NCT02682225","cat":"studies","name":"Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine","ketamine"],"nct":"NCT02682225","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-03-25","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02682225","sites":["Unnamed trial site — Salt Lake City, United States"],"conds":["Drug Abuse"],"condg":["Other"],"enroll":55,"eid":"NCT02682225"},{"id":"study-NCT03865550","cat":"studies","name":"Post-op Ketamine Study","status":"UNKNOWN","phase":"N/A","sponsor":"Rothman Institute Orthopaedics","drugs":["ketamine"],"nct":"NCT03865550","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-03-28","src":"https://clinicaltrials.gov/study/NCT03865550","sites":["Rothman Institute — Philadelphia, United States"],"conds":["Osteo Arthritis Knee"],"condg":["Other"],"enroll":75,"eid":"NCT03865550"},{"id":"study-NCT02778880","cat":"studies","name":"Pain Reduction With Intranasal Medications for Extremity Injuries","status":"COMPLETED","phase":"Phase 3","sponsor":"Children's Hospital Medical Center, Cincinnati","drugs":["ketamine"],"nct":"NCT02778880","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-03-31","official":"Theresa M Frey, MD (Children's Hospital Medical Center, Cincinnati); Matthew R Mittiga, MD (Children's Hospital Medical Center, Cincinnati)","src":"https://clinicaltrials.gov/study/NCT02778880","sites":["Cincinnati Children's Hospital Medical Center — Cincinnati, United States"],"conds":["Pain","Traumatic Limb Injury"],"condg":["PTSD & trauma","Chronic pain & headache"],"enroll":90,"eid":"NCT02778880"},{"id":"study-NCT02909049","cat":"studies","name":"Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy","status":"COMPLETED","phase":"Phase 4","sponsor":"Complexo Hospitalario Universitario de A Coruña","drugs":["ketamine"],"nct":"NCT02909049","nsites":1,"countries":"Spain","ccs":["ES"],"start":"2016-04","official":"Jose L Ponce, MD (Complejo Hospitalario Universitario, A Coruña)","src":"https://clinicaltrials.gov/study/NCT02909049","sites":["Jose Luis Ponce Diaz-Reixa — A Coruña, Spain"],"conds":["Prostatic Cancer"],"condg":["Cancer-related distress"],"enroll":100,"eid":"NCT02909049"},{"id":"study-NCT02644629","cat":"studies","name":"Intra-nasal vs. Intra-venous Ketamine Administration","status":"COMPLETED","phase":"Phase 4","sponsor":"Shalvata Mental Health Center","drugs":["ketamine"],"nct":"NCT02644629","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2016-04","official":"Aviv Segev, MD (Shalvata MHC)","src":"https://clinicaltrials.gov/study/NCT02644629","sites":["Shalvata MHC — Hod HaSharon, Israel"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":45,"eid":"NCT02644629"},{"id":"study-NCT02673372","cat":"studies","name":"Geriatric Ketamine for Pain Management Study","status":"COMPLETED","phase":"Phase 4","sponsor":"Antonios Likourezos","drugs":["ketamine"],"nct":"NCT02673372","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-04","official":"Sergey Motov, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT02673372","sites":["Maimonides Medical Center — Brooklyn, United States"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":60,"eid":"NCT02673372"},{"id":"study-NCT02655692","cat":"studies","name":"CAP-Ketamine for Antidepressant Resistant PTSD","status":"COMPLETED","phase":"Phase 2","sponsor":"VA Office of Research and Development","drugs":["ketamine"],"nct":"NCT02655692","nsites":3,"countries":"United States","ccs":["US"],"start":"2016-04-18","official":"John H. Krystal, MD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT02655692","sites":["VA Connecticut Healthcare System West Haven Campus, West Haven, CT — West Haven, United States","Minneapolis VA Health Care System, Minneapolis, MN — Minneapolis, United States","Brooke Army Medical Center — San Antonio, United States"],"conds":["PTSD","Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":163,"eid":"NCT02655692"},{"id":"study-NCT02717052","cat":"studies","name":"Positron Emission Tomography Assessment of Ketamine Binding of the Serotonin Transporter","status":"UNKNOWN","phase":"Phase 2","sponsor":"Medical University of Vienna","drugs":["esketamine","ketamine"],"nct":"NCT02717052","nsites":1,"countries":"Austria","ccs":["AT"],"start":"2016-05","official":"Rupert Lanzenberger, Prof. (Department of Psychiatry and Psychotherapy, Medical University of Vienna)","src":"https://clinicaltrials.gov/study/NCT02717052","sites":["Department of Psychiatry and Psychotherapy, Medical University of Vienna — Vienna, Austria"],"conds":["Depression","Ketamine"],"condg":["Depression"],"contact":{"n":"Rupert Lanzenberger, Prof.","p":"014040035760","e":"rupert.lanzenberger@meduniwien.ac.at"},"enroll":74,"eid":"NCT02717052"},{"id":"study-NCT02587130","cat":"studies","name":"Ketamine and Refractory Painful Care in a Palliative Unit","status":"TERMINATED","phase":"Phase 4","sponsor":"Lille Catholic University","drugs":["ketamine"],"nct":"NCT02587130","nsites":1,"countries":"France","ccs":["FR"],"start":"2016-05","official":"Marie Danel Delerue, MD (Groupment des Hôpitaux de l'Institut Catholique de Lille)","src":"https://clinicaltrials.gov/study/NCT02587130","sites":["GHICL — Lomme, France"],"conds":["Intractable Pain","Intensive Care","Pressure Ulcer","Pain Management"],"condg":["Chronic pain & headache"],"enroll":8,"eid":"NCT02587130"},{"id":"study-NCT03081416","cat":"studies","name":"\"THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the…","status":"COMPLETED","phase":"Phase 3","sponsor":"Brooke Army Medical Center","drugs":["ketamine"],"nct":"NCT03081416","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-05","src":"https://clinicaltrials.gov/study/NCT03081416","sites":["Brooke Army Medical Center — San Antonio, United States"],"conds":["Headache","Intranasal Ketamine"],"condg":["Chronic pain & headache"],"enroll":80,"eid":"NCT03081416"},{"id":"study-NCT03658330","cat":"studies","name":"Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder","status":"COMPLETED","phase":"Phase 2","sponsor":"VA Connecticut Healthcare System","drugs":["ketamine"],"nct":"NCT03658330","nsites":0,"start":"2016-05","official":"Gihyun Yoon, MD (VA Connecticut Healthcare System)","src":"https://clinicaltrials.gov/study/NCT03658330","conds":["Major Depressive Disorder","Alcohol Use Disorder"],"condg":["Depression","Addiction & substance use"],"enroll":5,"eid":"NCT03658330"},{"id":"study-NCT03043430","cat":"studies","name":"Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients","status":"TERMINATED","phase":"Phase 4","sponsor":"Brooke Army Medical Center","drugs":["ketamine"],"nct":"NCT03043430","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-05","official":"Nadia M Pearson, MD (Faculty Physician)","src":"https://clinicaltrials.gov/study/NCT03043430","sites":["San Antonio Military Medical Center — Fort Sam Houston, United States"],"conds":["Anxiety","Pediatric ALL","Procedural Anxiety"],"condg":["Anxiety"],"enroll":10,"eid":"NCT03043430"},{"id":"study-NCT03541408","cat":"studies","name":"Preventative Delirium Protocol in Elderly Patients","status":"COMPLETED","phase":"N/A","sponsor":"Rush University Medical Center","drugs":["ketamine"],"nct":"NCT03541408","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-05-01","official":"Asokumar Buvanendran, MD (Rush University Medical Center)","src":"https://clinicaltrials.gov/study/NCT03541408","sites":["Rush University Medical Center — Chicago, United States"],"conds":["Delirium"],"condg":["Other"],"enroll":263,"eid":"NCT03541408"},{"id":"study-NCT03296345","cat":"studies","name":"Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis","status":"COMPLETED","phase":"Phase 2","sponsor":"UCSF Benioff Children's Hospital Oakland","drugs":["ketamine"],"nct":"NCT03296345","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-06","official":"Jonathan B Cooper-Sood, MD (Children's Hospital and Research Center of Oakland)","src":"https://clinicaltrials.gov/study/NCT03296345","sites":["UCSF Benioff Children's Hospital and Research Center Oakland — Oakland, United States"],"conds":["Sickle Cell Disease","Vaso-Occlusive Crisis"],"condg":["Other"],"enroll":62,"eid":"NCT03296345"},{"id":"study-NCT02772211","cat":"studies","name":"D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression","status":"UNKNOWN","phase":"Phase 4","sponsor":"Sheba Medical Center","drugs":["ketamine"],"nct":"NCT02772211","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2016-06","src":"https://clinicaltrials.gov/study/NCT02772211","sites":["Psychiatry Clinic - Sheba Medical Center — Ramat Gan, Israel"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"contact":{"n":"Revital Amiaz, MD","p":"+972-542378757","e":"revital.amiaz@sheba.health.gov.il"},"enroll":60,"eid":"NCT02772211"},{"id":"study-NCT02652507","cat":"studies","name":"Dexmedetomidine and Ketamine in MRI","status":"COMPLETED","phase":"Phase 1","sponsor":"Children's Hospital Medical Center, Cincinnati","drugs":["ketamine"],"nct":"NCT02652507","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-06","official":"Mohamed Mahmoud, MD (Children's Hospital Medical Center, Cincinnati)","src":"https://clinicaltrials.gov/study/NCT02652507","sites":["Cincinnati Children's Hospital Medical Center — Cincinnati, United States"],"conds":["Magnetic Resonance Imaging"],"condg":["Other"],"enroll":22,"eid":"NCT02652507"},{"id":"study-NCT03790618","cat":"studies","name":"Effect of Stimulant Drugs on Social Perception","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Chicago","drugs":["MDMA"],"nct":"NCT03790618","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-06-01","src":"https://clinicaltrials.gov/study/NCT03790618","sites":["University of Chicago — Chicago, United States"],"conds":["Healthy","MDMA ('Ecstasy')"],"condg":["Healthy volunteers"],"enroll":36,"eid":"NCT03790618"},{"id":"study-NCT03109418","cat":"studies","name":"Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea","status":"TERMINATED","phase":"Phase 2/Phase 3","sponsor":"University of Alabama at Birmingham","drugs":["ketamine"],"nct":"NCT03109418","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-06-02","official":"Peter A Nagi, MD (University of Alabama at Birmingham)","src":"https://clinicaltrials.gov/study/NCT03109418","sites":["UAB Department of Anesthesiology and Perioperative Medicine — Birmingham, United States"],"conds":["Sleep Apnea","Obstructive Sleep Apnea","Postoperative Complications"],"condg":["Other"],"enroll":9,"eid":"NCT03109418"},{"id":"study-NCT02782104","cat":"studies","name":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 3","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02782104","nsites":173,"countries":"Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Czechia; Estonia; Finland; France; Germany; Hungary; Lithuania; Malaysia; Mexico; Poland; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Turkey (Türkiye); United Kingdom; United States","ccs":["AR","AT","AU","BE","BG","BR","CA","CZ","DE","EE","ES","FI","FR","GB","HU","KR","LT","MX","MY","PL","SE","SK","TR","TW","US","ZA"],"start":"2016-06-09","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","sites":["Unnamed trial site — Birmingham, United States","Unnamed trial site — Little Rock, United States","Unnamed trial site — Garden Grove, United States","Unnamed trial site — Glendale, United States","Unnamed trial site — Oakland, United States","Unnamed trial site — Orange, United States","Unnamed trial site — San Diego, United States","Unnamed trial site — San Rafael, United States"],"conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"enroll":1148,"eid":"NCT02782104"},{"id":"study-NCT02669043","cat":"studies","name":"Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects","status":"TERMINATED","phase":"N/A","sponsor":"Massachusetts General Hospital","drugs":["ketamine"],"nct":"NCT02669043","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-07","official":"Dawn Ionescu, M.D. (MGH)","src":"https://clinicaltrials.gov/study/NCT02669043","sites":["Massachusetts General Hospital — Boston, United States"],"conds":["Depression"],"condg":["Depression"],"enroll":8,"eid":"NCT02669043"},{"id":"study-NCT02848963","cat":"studies","name":"Comparison of Ketamine-propofol Combinations","status":"COMPLETED","phase":"Phase 4","sponsor":"Cukurova University","drugs":["ketamine"],"nct":"NCT02848963","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2016-07","official":"Dilek Özcengiz, Professor (Cukurova University)","src":"https://clinicaltrials.gov/study/NCT02848963","sites":["Cukurova University — Adana, Turkey"],"conds":["Agitation","Postoperative Pain"],"condg":["Chronic pain & headache"],"enroll":75,"eid":"NCT02848963"},{"id":"study-NCT02801292","cat":"studies","name":"Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease","status":"UNKNOWN","phase":"Phase 3","sponsor":"Augusta University","drugs":["ketamine"],"nct":"NCT02801292","nsites":0,"start":"2016-07","official":"George Hsu, MD (Augusta University)","src":"https://clinicaltrials.gov/study/NCT02801292","conds":["Sickle Cell Disease"],"condg":["Other"],"contact":{"n":"George Hsu, MD","p":"404-556-7250","e":"ghsu@augusta.edu"},"enroll":20,"eid":"NCT02801292"},{"id":"study-NCT02857361","cat":"studies","name":"Crossover Study to Evaluate the PK Effects of Two Different Wafer Administration Protocols.","status":"COMPLETED","phase":"Phase 2","sponsor":"iX Biopharma Ltd.","drugs":["ketamine"],"nct":"NCT02857361","nsites":1,"countries":"Australia","ccs":["AU"],"start":"2016-07","official":"Sam Salman, MD (iX Biopharma)","src":"https://clinicaltrials.gov/study/NCT02857361","sites":["Linear Clinical Research — Nedlands, Australia"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":10,"eid":"NCT02857361"},{"id":"study-NCT02839928","cat":"studies","name":"Nasal Ketamine for Minor Procedures in Children","status":"UNKNOWN","phase":"N/A","sponsor":"Kaplan Medical Center","drugs":["ketamine"],"nct":"NCT02839928","nsites":0,"start":"2016-07","official":"Eric Scheier, MD (Physician, pediatric emergency department)","src":"https://clinicaltrials.gov/study/NCT02839928","conds":["Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Eric Scheier","p":"4103586230","e":"eric.scheier@gmail.com"},"enroll":20,"eid":"NCT02839928"},{"id":"study-NCT02737605","cat":"studies","name":"A Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02737605","nsites":1,"countries":"Germany","ccs":["DE"],"start":"2016-07-01","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02737605","sites":["Unnamed trial site — Berlin, Germany"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":62,"eid":"NCT02737605"},{"id":"study-NCT02876172","cat":"studies","name":"MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT02876172","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-07-03","official":"Michael C Mithoefer, MD (Private Practice)","src":"https://clinicaltrials.gov/study/NCT02876172","sites":["Offices of Michael Mithoefer MD — Mt. Pleasant, United States"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":12,"eid":"NCT02876172"},{"id":"study-NCT03319238","cat":"studies","name":"OBSERVATIONAL STUDY OF THE MANAGEMENT OF PATIENTS WITH CHRONIC PAIN","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","drugs":["ketamine"],"nct":"NCT03319238","nsites":1,"countries":"France","ccs":["FR"],"start":"2016-07-07","official":"Gisèle PICKERING (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT03319238","sites":["CHU Clermont-Ferrand — Clermont-Ferrand, France"],"conds":["Chronic Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Patrick LACARIN","p":"04 73 75 11 95","e":"placarin@chu-clermontferrand.fr"},"enroll":1000,"eid":"NCT03319238"},{"id":"study-NCT02735343","cat":"studies","name":"The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine","status":"TERMINATED","phase":"Phase 3","sponsor":"Mike O'Callaghan Military Hospital","drugs":["ketamine"],"nct":"NCT02735343","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-08","official":"Christopher Pitotti, MD (Mike O'Callaghan Federal Medical Center)","src":"https://clinicaltrials.gov/study/NCT02735343","sites":["Mike O'Callaghan Federal Medical Center — Nellis Air Force Base, United States"],"conds":["Headache"],"condg":["Chronic pain & headache"],"enroll":5,"eid":"NCT02735343"},{"id":"study-NCT02635282","cat":"studies","name":"IN Ketamine Vs IN Midazolam and Fentanyl for Abscess I&D","status":"COMPLETED","phase":"Phase 4","sponsor":"University of Tennessee","drugs":["ketamine"],"nct":"NCT02635282","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-08","src":"https://clinicaltrials.gov/study/NCT02635282","sites":["Le Bonheur Children's Hospital — Memphis, United States"],"conds":["Abscess","Pain"],"condg":["Chronic pain & headache"],"enroll":19,"eid":"NCT02635282"},{"id":"study-NCT02418702","cat":"studies","name":"A Study to Decrease Suicidal Thinking Using Ketamine","status":"WITHDRAWN","phase":"Phase 3","sponsor":"United States Naval Medical Center, San Diego","drugs":["ketamine"],"nct":"NCT02418702","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-08","official":"Marc A Capobianco (United States Naval Medical Center, San Diego)","src":"https://clinicaltrials.gov/study/NCT02418702","sites":["Naval Medical Center San Diego — San Diego, United States"],"conds":["Depression","Suicide"],"condg":["Depression"],"eid":"NCT02418702"},{"id":"study-NCT02183272","cat":"studies","name":"Emergency Ketamine Treatment of Suicidal Ideation","status":"UNKNOWN","phase":"Phase 2/Phase 3","sponsor":"University of Cincinnati","drugs":["ketamine"],"nct":"NCT02183272","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-08","official":"Cheryl McCullumsmith, MD PhD (University of Cincinnati)","src":"https://clinicaltrials.gov/study/NCT02183272","sites":["University of Cincinnati — Cincinnati, United States"],"conds":["Depression","Suicidal Ideation","Suicidal Impulses"],"condg":["Depression"],"contact":{"n":"Faryal Mallick","p":"513-558-4997","e":"mallicfl@ucmail.uc.edu"},"enroll":60,"eid":"NCT02183272"},{"id":"study-NCT02857777","cat":"studies","name":"Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02857777","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-08-09","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02857777","sites":["Unnamed trial site — Cypress, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":37,"eid":"NCT02857777"},{"id":"study-NCT02442739","cat":"studies","name":"Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers","status":"WITHDRAWN","phase":"EARLY_Phase 1","sponsor":"Cedars-Sinai Medical Center","drugs":["ketamine"],"nct":"NCT02442739","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-08-15","official":"Scott Irwin, MD, PhD (Cedars-Sinal Medical Center)","src":"https://clinicaltrials.gov/study/NCT02442739","sites":["Cedars-Sinai Medical Center — Los Angeles, United States"],"conds":["Head and Neck Cancer","Pancreatic Cancer","Depression"],"condg":["Depression","Cancer-related distress"],"eid":"NCT02442739"},{"id":"study-NCT02624596","cat":"studies","name":"Understanding How Ketamine Brings About Rapid Improvement in OCD","status":"COMPLETED","phase":"Phase 2","sponsor":"Stanford University","drugs":["ketamine"],"nct":"NCT02624596","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-08-16","official":"Carolyn I Rodriguez, MD, PhD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT02624596","sites":["Stanford University — Stanford, United States"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"enroll":120,"eid":"NCT02624596"},{"id":"study-NCT03134066","cat":"studies","name":"Neurocognitive Features of Patients With Treatment-Resistant Depression","status":"COMPLETED","sponsor":"Massachusetts General Hospital","drugs":["ketamine"],"nct":"NCT03134066","nsites":0,"start":"2016-09","src":"https://clinicaltrials.gov/study/NCT03134066","conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":13,"eid":"NCT03134066"},{"id":"study-NCT02911597","cat":"studies","name":"Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)","status":"COMPLETED","phase":"Phase 1","sponsor":"Stanford University","drugs":["ketamine"],"nct":"NCT02911597","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-09","official":"Alan Schatzberg, MD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT02911597","sites":["Stanford University — Stanford, United States"],"conds":["Depression"],"condg":["Depression"],"enroll":16,"eid":"NCT02911597"},{"id":"study-NCT02924090","cat":"studies","name":"Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression","status":"UNKNOWN","phase":"Phase 4","sponsor":"University of Manitoba","drugs":["ketamine"],"nct":"NCT02924090","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2016-09","official":"Ian McIntyre, MD, MSc (University of Manitoba); Michael Harrington, MD (University of Manitoba)","src":"https://clinicaltrials.gov/study/NCT02924090","sites":["Health Sciences Centre — Winnipeg, Canada"],"conds":["Depression"],"condg":["Depression"],"contact":{"n":"Ian McIntyre, MD, MSc","p":"204 787-1414","e":"ian.mcintyre@umanitoba.ca"},"enroll":48,"eid":"NCT02924090"},{"id":"study-NCT02783430","cat":"studies","name":"Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"University Hospital, Lille","drugs":["ketamine"],"nct":"NCT02783430","nsites":9,"countries":"France","ccs":["FR"],"start":"2016-09-08","official":"Antoine LEMAIRE, MD (Hospital of Valenciennes)","src":"https://clinicaltrials.gov/study/NCT02783430","sites":["Chu Amiens Picardie — Amiens, France","Ch Calais — Calais, France","Maison Medicale Jean Xxiii - Lille — Lille, France","University Hospital, — Lille, France","Groupt Hopitaux Instit Catho de Lille - Lomme — Lomme, France","C.H de Roubaix — Roubaix, France","Ch Ghpso Senlis — Senlis, France","Ch Tourcoing — Tourcoing, France"],"conds":["Depression"],"condg":["Depression"],"enroll":42,"eid":"NCT02783430"},{"id":"study-NCT02935959","cat":"studies","name":"Premedication With Nebulized Ketamine,Dexmedetomidine Versus Midazolam in Oncologic Preschool Children","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Assiut University","drugs":["ketamine"],"nct":"NCT02935959","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2016-10","official":"fatma a elsherif, lecturer (South Egypt Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT02935959","sites":["Assiut University — Asyut, Egypt"],"conds":["Oncological Children"],"condg":["Cancer-related distress"],"enroll":90,"eid":"NCT02935959"},{"id":"study-NCT02935725","cat":"studies","name":"A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males","status":"COMPLETED","phase":"Phase 1","sponsor":"Autifony Therapeutics Limited","drugs":["ketamine"],"nct":"NCT02935725","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2016-10","official":"Bill Deakin, Prof (University of Manchester)","src":"https://clinicaltrials.gov/study/NCT02935725","sites":["University Of Manchester — London, United Kingdom"],"conds":["Schizophrenia"],"condg":["Other"],"enroll":22,"eid":"NCT02935725"},{"id":"study-NCT02649231","cat":"studies","name":"Ketamine for Reduction of Alcoholic Relapse","status":"COMPLETED","phase":"Phase 2","sponsor":"University College, London","drugs":["ketamine"],"nct":"NCT02649231","nsites":2,"countries":"United Kingdom","ccs":["GB"],"start":"2016-10","official":"Celia Morgan, Ph.D. (UCL)","src":"https://clinicaltrials.gov/study/NCT02649231","sites":["NIHR Exeter Clinical Research Facility — Exeter, United Kingdom","NIHR UCLH Clinical Research Facility — London, United Kingdom"],"conds":["Primary Alcohol Use Disorder"],"condg":["Addiction & substance use"],"enroll":96,"eid":"NCT02649231"},{"id":"study-NCT02919579","cat":"studies","name":"A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT02919579","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2016-10-07","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02919579","sites":["Unnamed trial site — Leiden, Netherlands"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"enroll":27,"eid":"NCT02919579"},{"id":"study-NCT02935595","cat":"studies","name":"Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients","status":"COMPLETED","phase":"Phase 2","sponsor":"The University of Texas Health Science Center, Houston","drugs":["ketamine"],"nct":"NCT02935595","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-10-14","official":"Sudhakar Selvaraj, MBBS, DPhil (University of Texas)","src":"https://clinicaltrials.gov/study/NCT02935595","sites":["Harris County Psychiatric Center — Houston, United States"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":9,"eid":"NCT02935595"},{"id":"study-NCT02882711","cat":"studies","name":"The UTHealth Ketamine Project","status":"TERMINATED","phase":"Phase 2","sponsor":"The University of Texas Health Science Center, Houston","drugs":["ketamine"],"nct":"NCT02882711","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-11-07","official":"Salih Selek, MD (The University of Texas Health Science Center, Houston)","src":"https://clinicaltrials.gov/study/NCT02882711","sites":["The University of Texas Health Science Center at Houston — Houston, United States"],"conds":["Treatment Resistant Depression","Major Depressive Disorder","Bipolar Disorder"],"condg":["Depression","Bipolar"],"enroll":10,"eid":"NCT02882711"},{"id":"study-NCT03088384","cat":"studies","name":"Ketamine Infusion Therapy for PTSD in Combat Veterans","status":"COMPLETED","sponsor":"Klarisana Physician Services PLLC","drugs":["ketamine"],"nct":"NCT03088384","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-11-28","src":"https://clinicaltrials.gov/study/NCT03088384","sites":["Klarisana — San Antonio, United States"],"conds":["Stress Disorders, Post-Traumatic"],"condg":["PTSD & trauma"],"enroll":30,"eid":"NCT03088384"},{"id":"study-NCT02990975","cat":"studies","name":"Transversus Abdominis Plane Block In Children","status":"UNKNOWN","phase":"N/A","sponsor":"Erzincan University","drugs":["ketamine"],"nct":"NCT02990975","nsites":0,"start":"2016-12","official":"ilke kupeli (Erzincan University)","src":"https://clinicaltrials.gov/study/NCT02990975","conds":["Intra-operative Anesthesia"],"condg":["Other"],"enroll":60,"eid":"NCT02990975"},{"id":"study-NCT02981173","cat":"studies","name":"Psilocybin for the Treatment of Cluster Headache","status":"COMPLETED","phase":"Phase 1","sponsor":"Yale University","drugs":["psilocybin"],"nct":"NCT02981173","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-12-05","src":"https://clinicaltrials.gov/study/NCT02981173","sites":["VA Connecticut Healthcare System — West Haven, United States"],"conds":["Cluster Headache"],"condg":["Chronic pain & headache"],"enroll":25,"eid":"NCT02981173"},{"id":"study-NCT03633253","cat":"studies","name":"The \"Motoric Cognitive Risk\" Syndrome in the Quebec Population","status":"UNKNOWN","sponsor":"Jewish General Hospital","drugs":["LSD"],"nct":"NCT03633253","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2016-12-07","src":"https://clinicaltrials.gov/study/NCT03633253","sites":["Jewish General Hospital — Montreal, Canada"],"conds":["Cognition Disorders in Old Age","Dementia"],"condg":["Neurology & cognition"],"enroll":1741,"eid":"NCT03633253"},{"id":"study-NCT02918318","cat":"studies","name":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Janssen Pharmaceutical K.K.","drugs":["esketamine"],"nct":"NCT02918318","nsites":43,"countries":"Japan","ccs":["JP"],"start":"2016-12-12","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","sites":["Unnamed trial site — Akita, Japan","Unnamed trial site — Fukui-shi, Japan","Unnamed trial site — Fukuoka, Japan","Unnamed trial site — Gunma, Japan","Unnamed trial site — Hachinohe-shi, Japan","Unnamed trial site — Hachioji-shi, Japan","Unnamed trial site — Hirakata, Japan","Unnamed trial site — Hiratsuka-shi, Japan"],"conds":["Depression"],"condg":["Depression"],"enroll":202,"eid":"NCT02918318"},{"id":"study-NCT02836288","cat":"studies","name":"Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for Cancer","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Scott A. Irwin, MD, PhD","drugs":["ketamine"],"nct":"NCT02836288","nsites":1,"countries":"United States","ccs":["US"],"start":"2016-12-20","official":"Scott Irwin, MD, PhD (Cedars-Sinal Medical Center)","src":"https://clinicaltrials.gov/study/NCT02836288","sites":["Cedars-Sinai Medical Center — Los Angeles, United States"],"conds":["Cancer","Depression"],"condg":["Depression","Cancer-related distress"],"enroll":4,"eid":"NCT02836288"},{"id":"study-NCT02962999","cat":"studies","name":"Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation","status":"COMPLETED","phase":"Phase 4","sponsor":"Cukurova University","drugs":["ketamine"],"nct":"NCT02962999","nsites":2,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2017-01","official":"Feride Karacaer, Specialist (Cukurova University)","src":"https://clinicaltrials.gov/study/NCT02962999","sites":["Cukurova University — Adana, Turkey","Cukurova University Faculty of Medicine Research Hospital — Adana, Turkey"],"conds":["Chronic Obstructive Pulmonary Disease Mild","Chronic Obstructive Pulmonary Disease Moderate","Chronic Obstructive Pulmonary Disease Severe","Lungcancer","Anesthesia"],"condg":["Cancer-related distress"],"enroll":30,"eid":"NCT02962999"},{"id":"study-NCT03027362","cat":"studies","name":"Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression","status":"COMPLETED","phase":"N/A","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT03027362","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-01","official":"Samuel Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03027362","sites":["Yale University — New Haven, United States"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"enroll":28,"eid":"NCT03027362"},{"id":"study-NCT03915938","cat":"studies","name":"Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Hospital de Clinicas de Porto Alegre","drugs":["esketamine","ketamine"],"nct":"NCT03915938","nsites":0,"start":"2017-01-02","official":"Wolnei Caumo, MD, PhD (Hospital de Clinicas de Porto Alegre)","src":"https://clinicaltrials.gov/study/NCT03915938","conds":["Acute Pain","Chronic Pain, Widespread","Schizophrenia"],"condg":["Chronic pain & headache"],"enroll":24,"eid":"NCT03915938"},{"id":"study-NCT03499886","cat":"studies","name":"Low-Dose Intravenous Ketamine Bolus Versus Conventional Technique","status":"UNKNOWN","phase":"Phase 2/Phase 3","sponsor":"Isfahan University of Medical Sciences","drugs":["ketamine"],"nct":"NCT03499886","nsites":2,"countries":"Iran","ccs":["IR"],"start":"2017-01-17","official":"Mehdi Nasr Isfahani, M.D. (Isfahan University of Medical Sciences)","src":"https://clinicaltrials.gov/study/NCT03499886","sites":["Al-Zahra University Hospital — Isfahan, Iran","Mehdi Nasr Isfahani — Isfahan, Iran"],"conds":["Procedural Sedation"],"condg":["Other"],"contact":{"n":"Mehdi Nasr Isfahani, M.D.","p":"+989132034381","e":"mni.papillon@gmail.com"},"enroll":198,"eid":"NCT03499886"},{"id":"study-NCT03053830","cat":"studies","name":"Open Label Ketamine Treatment for Major Depressive Disorder in Veterans","status":"COMPLETED","phase":"Phase 2","sponsor":"VA Connecticut Healthcare System","drugs":["ketamine"],"nct":"NCT03053830","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-01-31","src":"https://clinicaltrials.gov/study/NCT03053830","sites":["VA Healthcare System — West Haven, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":11,"eid":"NCT03053830"},{"id":"study-NCT02532153","cat":"studies","name":"The Impact of Ketamine on the Reward Circuitry of Suicidal Patients","status":"WITHDRAWN","phase":"Phase 3","sponsor":"Massachusetts General Hospital","drugs":["ketamine"],"nct":"NCT02532153","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-02","official":"Dawn Ionescu, M.D. (MGH)","src":"https://clinicaltrials.gov/study/NCT02532153","sites":["Massachusetts General Hospital — Boston, United States"],"conds":["Suicidal Ideation","Suicide"],"condg":["Other"],"eid":"NCT02532153"},{"id":"study-NCT03019822","cat":"studies","name":"Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD","MDMA"],"nct":"NCT03019822","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2017-02-01","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT03019822","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":28,"eid":"NCT03019822"},{"id":"study-NCT03102736","cat":"studies","name":"Ketamine and Nitroprusside for Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Icahn School of Medicine at Mount Sinai","drugs":["ketamine"],"nct":"NCT03102736","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-02-14","official":"James Murrough, MD, PhD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT03102736","sites":["Icahn School of Medicine at Mount Sinai — New York, United States"],"conds":["Depression"],"condg":["Depression"],"enroll":40,"eid":"NCT03102736"},{"id":"study-NCT03053947","cat":"studies","name":"Pain Free Laceration Repairs Using Intra-nasal Ketamine","status":"COMPLETED","phase":"Phase 2","sponsor":"Evelyne D.Trottier","drugs":["ketamine"],"nct":"NCT03053947","nsites":2,"countries":"Canada","ccs":["CA"],"start":"2017-02-16","official":"Evelyne D Trottier, MD, FRCPC (St. Justine's Hospital)","src":"https://clinicaltrials.gov/study/NCT03053947","sites":["Sickkids — Toronto, Canada","St. Justine's Hospital — Montreal, Canada"],"conds":["Laceration"],"condg":["Other"],"enroll":42,"eid":"NCT03053947"},{"id":"study-NCT03001843","cat":"studies","name":"Ketamine vs Hydromorphone","status":"COMPLETED","phase":"Phase 4","sponsor":"University of Florida","drugs":["ketamine"],"nct":"NCT03001843","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-02-22","official":"David M Smyth, MSN (Shands Hospital at the University of Florida)","src":"https://clinicaltrials.gov/study/NCT03001843","sites":["University of Florida — Gainesville, United States"],"conds":["Laparoscopic Gastric Bypass","Obesity","Pain, Postoperative"],"condg":["Chronic pain & headache"],"enroll":54,"eid":"NCT03001843"},{"id":"study-NCT03679390","cat":"studies","name":"The Electroencephalogram and Clinical Effect of Ketamine","status":"TERMINATED","phase":"N/A","sponsor":"National Taiwan University Hospital","drugs":["ketamine"],"nct":"NCT03679390","nsites":1,"countries":"Taiwan","ccs":["TW"],"start":"2017-03-01","src":"https://clinicaltrials.gov/study/NCT03679390","sites":["National Taiwan University Hospital — Taipei, Taiwan"],"conds":["Electroencephalogram","Consciousness, Loss of"],"condg":["Other"],"enroll":17,"eid":"NCT03679390"},{"id":"study-NCT02997722","cat":"studies","name":"The Effect of Ketamine on the Length of Hospital Stay of Patients Hospitalized With Suicidal Ideation.","status":"TERMINATED","phase":"Phase 4","sponsor":"Allen Richert","drugs":["ketamine"],"nct":"NCT02997722","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-03-02","official":"Allen C Richert, MD (University of Mississippi Medical Center)","src":"https://clinicaltrials.gov/study/NCT02997722","sites":["University of Mississippi Medical Center — Jackson, United States"],"conds":["Suicidal Ideation"],"condg":["Other"],"enroll":4,"eid":"NCT02997722"},{"id":"study-NCT03060070","cat":"studies","name":"Ketamine Versus Dexmedetomidine With Local Anesthetic in TAP Block","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Assiut University","drugs":["ketamine"],"nct":"NCT03060070","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2017-03-10","src":"https://clinicaltrials.gov/study/NCT03060070","sites":["South Egypt Cancer Institute — Asyut, Egypt"],"conds":["Postoperative Analgesia","Lower Abdominal Cancer"],"condg":["Cancer-related distress"],"enroll":90,"eid":"NCT03060070"},{"id":"study-NCT03181763","cat":"studies","name":"Evaluation of MDMA on Startle Response","status":"COMPLETED","phase":"Phase 1","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT03181763","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-03-14","official":"Barbara Rothbaum (Emory University)","src":"https://clinicaltrials.gov/study/NCT03181763","sites":["Emory University — Atlanta, United States"],"conds":["Startle Response"],"condg":["Other"],"enroll":34,"eid":"NCT03181763"},{"id":"study-NCT03040024","cat":"studies","name":"Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients","status":"TERMINATED","phase":"Phase 4","sponsor":"Emory University","drugs":["ketamine"],"nct":"NCT03040024","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-03-17","official":"Vanessa Moll, PhD (Emory University)","src":"https://clinicaltrials.gov/study/NCT03040024","sites":["Emory University Hospital Midtown — Atlanta, United States"],"conds":["Otolaryngeal Cancer"],"condg":["Cancer-related distress"],"enroll":71,"eid":"NCT03040024"},{"id":"study-NCT04414800","cat":"studies","name":"Intranasal Ketamine Versus Intranasal Fentanyl","status":"COMPLETED","phase":"Phase 3","sponsor":"Isfahan University of Medical Sciences","drugs":["ketamine"],"nct":"NCT04414800","nsites":1,"countries":"Iran","ccs":["IR"],"start":"2017-04-01","src":"https://clinicaltrials.gov/study/NCT04414800","sites":["Al-Zahra University Hospital — Isfahan, Iran"],"conds":["Multiple Trauma","Pain, Acute"],"condg":["PTSD & trauma","Chronic pain & headache"],"enroll":125,"eid":"NCT04414800"},{"id":"study-NCT03095222","cat":"studies","name":"Exploring the Safety and Efficacy of Low-dose Ketamine Infusions for Pain Control in Acute Burn Injury","status":"WITHDRAWN","phase":"Phase 4","sponsor":"University of Kansas Medical Center","drugs":["ketamine"],"nct":"NCT03095222","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-04-01","official":"Andrea Nicol, MD (University of Kansas Medical Center)","src":"https://clinicaltrials.gov/study/NCT03095222","sites":["University of Kansas Medical Center — Kansas City, United States"],"conds":["Pain"],"condg":["Chronic pain & headache"],"eid":"NCT03095222"},{"id":"study-NCT03113968","cat":"studies","name":"ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Bo Hu","drugs":["ketamine"],"nct":"NCT03113968","nsites":5,"countries":"United States","ccs":["US"],"start":"2017-04-07","official":"Amit Anand, MD (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT03113968","sites":["Yale School of Medicine — New Haven, United States","Johns Hopkins University School of Medicine — Baltimore, United States","Mount Sinai — New York, United States","Cleveland Clinic — Cleveland, United States","Baylor College of Medicine — Houston, United States"],"conds":["Treatment Resistant Depression","Electroconvulsive Therapy","ECT","Ketamine","Psychiatric Disorder","Depression"],"condg":["Depression"],"enroll":403,"eid":"NCT03113968"},{"id":"study-NCT02992496","cat":"studies","name":"Investigation of Antidepressant Efficacy of Oral Ketamine Treatment","status":"UNKNOWN","phase":"Phase 2","sponsor":"Medical University of Vienna","drugs":["ketamine"],"nct":"NCT02992496","nsites":1,"countries":"Austria","ccs":["AT"],"start":"2017-04-24","src":"https://clinicaltrials.gov/study/NCT02992496","sites":["Department of Psychiatry and Psychotherapy, Medical University of Vienna — Vienna, Austria"],"conds":["Major Depressive Episode"],"condg":["Depression"],"enroll":60,"eid":"NCT02992496"},{"id":"study-NCT02920528","cat":"studies","name":"Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain","status":"COMPLETED","phase":"Phase 3","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","drugs":["ketamine"],"nct":"NCT02920528","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-05-01","official":"David Tanen, MD (Los Angeles Biomedical Institute)","src":"https://clinicaltrials.gov/study/NCT02920528","sites":["Emergency Department, Harbor-UCLA Medical Center — Torrance, United States"],"conds":["Chronic Pain"],"condg":["Chronic pain & headache"],"enroll":106,"eid":"NCT02920528"},{"id":"study-NCT03194594","cat":"studies","name":"Dexamethasone and Ketamine on Change of Postoperative Mood","status":"COMPLETED","phase":"Phase 4","sponsor":"Wonkwang University Hospital","drugs":["ketamine"],"nct":"NCT03194594","nsites":1,"countries":"South Korea","ccs":["KR"],"start":"2017-05-02","official":"Cheol Lee, M.D.,Ph.D (Wonkwang UH)","src":"https://clinicaltrials.gov/study/NCT03194594","sites":["WonwangUH — Iksan, South Korea"],"conds":["Depressive Symptoms"],"condg":["Depression"],"enroll":93,"eid":"NCT03194594"},{"id":"study-NCT03115489","cat":"studies","name":"Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus","status":"WITHDRAWN","phase":"Phase 2/Phase 3","sponsor":"University of Alabama at Birmingham","drugs":["ketamine"],"nct":"NCT03115489","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-05-04","official":"Vinodkumar Singh, MD (University of Alabama at Birmingham)","src":"https://clinicaltrials.gov/study/NCT03115489","sites":["UAB Department of Anesthesiology and Perioperative Medicine — Birmingham, United States"],"conds":["Refractory Epilepsy"],"condg":["Neurology & cognition"],"eid":"NCT03115489"},{"id":"study-NCT02950233","cat":"studies","name":"Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial","status":"TERMINATED","phase":"Phase 3","sponsor":"Population Health Research Institute","drugs":["ketamine"],"nct":"NCT02950233","nsites":2,"countries":"Canada; United States","ccs":["CA","US"],"start":"2017-05-04","official":"PJ Devereaux, MD, PhD (McMaster University)","src":"https://clinicaltrials.gov/study/NCT02950233","sites":["Cleveland Clinic — Cleveland, United States","St. Joseph's Healthcare — Hamilton, Canada"],"conds":["Pain, Postoperative"],"condg":["Chronic pain & headache"],"enroll":27,"eid":"NCT02950233"},{"id":"study-NCT03096444","cat":"studies","name":"Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine","status":"TERMINATED","phase":"Phase 2","sponsor":"Gil Yosipovitch","drugs":["ketamine"],"nct":"NCT03096444","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-05-23","official":"Gil Yosipovitch, MD (University of Miami)","src":"https://clinicaltrials.gov/study/NCT03096444","sites":["University of Miami — Miami, United States"],"conds":["Pruritus"],"condg":["Other"],"enroll":13,"eid":"NCT03096444"},{"id":"study-NCT03164590","cat":"studies","name":"Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines","status":"COMPLETED","phase":"Phase 4","sponsor":"Assiut University","drugs":["ketamine"],"nct":"NCT03164590","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2017-06-01","official":"fatma el sherif, MD (South Egypt Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT03164590","sites":["South Egypt Cancer instIitute — Asyut, Egypt"],"conds":["Endometrial Adenocarcinoma"],"condg":["Other"],"enroll":60,"eid":"NCT03164590"},{"id":"study-NCT03165149","cat":"studies","name":"Effect of a Topical Ketamine on Acute and Chronic Pain, Dose Finding","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Assiut University","drugs":["ketamine"],"nct":"NCT03165149","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2017-06-01","src":"https://clinicaltrials.gov/study/NCT03165149","sites":["South Egypt Cancer Instuite — Asyut, Egypt"],"conds":["Breast Cancer"],"condg":["Cancer-related distress"],"enroll":90,"eid":"NCT03165149"},{"id":"study-NCT03156504","cat":"studies","name":"The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.","status":"COMPLETED","phase":"Phase 4","sponsor":"Mayo Clinic","drugs":["ketamine"],"nct":"NCT03156504","nsites":4,"countries":"United States","ccs":["US"],"start":"2017-06-01","official":"Mark A Frye, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT03156504","sites":["Johns Hopkins Hospital — Baltimore, United States","University of Michigan — Ann Arbor, United States","Mayo Clinic — Rochester, United States","University of Cincinnati Medical Center — Cincinnati, United States"],"conds":["Major Depression","Bipolar I Disorder","Bipolar II Disorder","Unipolar Depression"],"condg":["Depression","Bipolar"],"enroll":75,"eid":"NCT03156504"},{"id":"study-NCT03039192","cat":"studies","name":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including…","status":"COMPLETED","phase":"Phase 3","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT03039192","nsites":56,"countries":"Bulgaria; Estonia; Germany; Hungary; Malaysia; Slovakia; South Africa; South Korea; Spain; Taiwan; United States","ccs":["BG","DE","EE","ES","HU","KR","MY","SK","TW","US","ZA"],"start":"2017-06-09","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","sites":["UAB Department of Psychiatry and Behavioral Neurobiology — Birmingham, United States","Metropolitan Neuro Behavioral Institute — Chandler, United States","Collaborative NeuroScience Network — Garden Grove, United States","Yale University — New Haven, United States","Rush University — Chicago, United States","Alexian Behavioral Health Hospital — Hoffman Estates, United States","University of Louisville Department of Psychiatry — Louisville, United States","LSU Health Sciences Center New Orleans — New Orleans, United States"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"enroll":226,"eid":"NCT03039192"},{"id":"study-NCT03097133","cat":"studies","name":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including…","status":"COMPLETED","phase":"Phase 3","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT03097133","nsites":61,"countries":"Argentina; Austria; Belgium; Brazil; Canada; Czechia; France; Lithuania; Poland; Spain; Turkey (Türkiye); United States","ccs":["AR","AT","BE","BR","CA","CZ","ES","FR","LT","PL","TR","US"],"start":"2017-06-15","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","sites":["University of California San Diego/Psychiatry — San Diego, United States","Sharp Mesa Vista Hospital — San Diego, United States","University of Conneticut School of Medicine — Farmington, United States","University of Miami Health System — Miami, United States","Innovative Clinical Research Inc — North Miami, United States","University of South Florida — Tampa, United States","Atlanta Behavioral Research, LLC — Atlanta, United States","Memorial Medical Center — Springfield, United States"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"enroll":230,"eid":"NCT03097133"},{"id":"study-NCT03153579","cat":"studies","name":"LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders","status":"COMPLETED","phase":"Phase 2","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD"],"nct":"NCT03153579","nsites":2,"countries":"Switzerland","ccs":["CH"],"start":"2017-06-23","official":"Peter Gasser, MD (Private Practice)","src":"https://clinicaltrials.gov/study/NCT03153579","sites":["University Hospital Basel — Basel, Switzerland","Private Practice P.Gasser — Solothurn, Switzerland"],"conds":["Patients","Anxiety Disorders"],"condg":["Anxiety"],"enroll":46,"eid":"NCT03153579"},{"id":"study-NCT03141658","cat":"studies","name":"Effects of TS-134 on Ketamine-induced BOLD Signals in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"Taisho Pharmaceutical R&D Inc.","drugs":["ketamine"],"nct":"NCT03141658","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-06-28","official":"Jeffrey A Lieberman, MD (New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT03141658","sites":["New York State Psychiatric Institute — New York, United States"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":63,"eid":"NCT03141658"},{"id":"study-NCT03979105","cat":"studies","name":"Cardiovascular Safety After Continuous Ketamine Infusion","status":"COMPLETED","sponsor":"Universidad de Antioquia","drugs":["ketamine"],"nct":"NCT03979105","nsites":2,"countries":"Colombia","ccs":["CO"],"start":"2017-07-01","official":"Adriana M Cadavid, MD (Anesthesiology Investigator)","src":"https://clinicaltrials.gov/study/NCT03979105","sites":["hospital universitario San Vicente Fundacion — Medellín, Colombia","Adriana Cadavid, MD — Medellín, Colombia"],"conds":["Pain","Ketamine Adverse Reaction","Postoperative Pain"],"condg":["Chronic pain & headache"],"enroll":300,"eid":"NCT03979105"},{"id":"study-NCT03090776","cat":"studies","name":"Prevention of Post Mastectomy With Intraoperative Ketamine","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Brigham and Women's Hospital","drugs":["ketamine"],"nct":"NCT03090776","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-07-01","official":"Kristin L Schreiber, MD/PhD (Brigham and Women's Hospital)","src":"https://clinicaltrials.gov/study/NCT03090776","sites":["Brigham and Women's Hospital — Boston, United States"],"conds":["Pain, Postoperative","Post-Mastectomy Chronic Pain Syndrome"],"condg":["Chronic pain & headache"],"enroll":264,"eid":"NCT03090776"},{"id":"study-NCT03525912","cat":"studies","name":"Neuropsychiatric and Cardiovascular Side Effects in Ketamine Analgesic Infusions","status":"COMPLETED","phase":"N/A","sponsor":"Universidad de Antioquia","drugs":["ketamine"],"nct":"NCT03525912","nsites":1,"countries":"Colombia","ccs":["CO"],"start":"2017-07-01","official":"Adriana M Cadavid, MD (Anesthesiology professor)","src":"https://clinicaltrials.gov/study/NCT03525912","sites":["hospital universitario San Vicente Fundacion — Medellín, Colombia"],"conds":["Pain, Postoperative","Ketamine Adverse Reaction"],"condg":["Chronic pain & headache"],"enroll":101,"eid":"NCT03525912"},{"id":"study-NCT03088306","cat":"studies","name":"Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Johns Hopkins University","drugs":["ketamine"],"nct":"NCT03088306","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-07-01","official":"Richard L Skolasky, ScD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT03088306","sites":["Johns Hopkins University School of Medicine — Baltimore, United States"],"conds":["Lumbar Spinal Stenosis","Lumbar Spinal Instability","Lumbar Spine Degeneration"],"condg":["Other"],"enroll":49,"eid":"NCT03088306"},{"id":"study-NCT02971605","cat":"studies","name":"Persisting Effects of Psilocybin","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT02971605","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-07-01","official":"Frederick S Barrett, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT02971605","sites":["Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center — Baltimore, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":13,"eid":"NCT02971605"},{"id":"study-NCT03086148","cat":"studies","name":"Ketamine and Postoperative Depressive Symptom-PASSION","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Beijing Tiantan Hospital","drugs":["ketamine"],"nct":"NCT03086148","nsites":1,"countries":"China","ccs":["CN"],"start":"2017-07-05","official":"Ruquan Han, M.D., Ph.D (Department of Anesthesiology, Beijing Tiantan Hospital)","src":"https://clinicaltrials.gov/study/NCT03086148","sites":["Beijing TianTan Hospital — Beijing, China"],"conds":["Ketamine; Depressive Symptom; Neurosurgery; Perioperative…"],"condg":["Depression"],"enroll":84,"eid":"NCT03086148"},{"id":"study-NCT03146806","cat":"studies","name":"Intranasal (NAS) Ketamine for Cancer Pain","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Emory University","drugs":["ketamine"],"nct":"NCT03146806","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-07-25","official":"Vinita Singh, MD (Emory University)","src":"https://clinicaltrials.gov/study/NCT03146806","sites":["Winship Cancer Institute — Atlanta, United States"],"conds":["Cancer","Pain"],"condg":["Cancer-related distress","Chronic pain & headache"],"enroll":10,"eid":"NCT03146806"},{"id":"study-NCT03554915","cat":"studies","name":"Ketamine Versus Midazolam for Prehospital Agitation","status":"COMPLETED","sponsor":"Hennepin Healthcare Research Institute","drugs":["ketamine"],"nct":"NCT03554915","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-08-01","src":"https://clinicaltrials.gov/study/NCT03554915","sites":["Hennepin County Medical Center — Minneapolis, United States"],"conds":["Agitation"],"condg":["Other"],"enroll":314,"eid":"NCT03554915"},{"id":"study-NCT03586154","cat":"studies","name":"Combined Intra-articular Shoulder Injection and Stellate Ganglion Block in Chronic Post-mastectomy Shoulder Pain","status":"COMPLETED","phase":"Phase 4","sponsor":"Mansoura University","drugs":["ketamine"],"nct":"NCT03586154","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2017-08-01","official":"Mohamed Tahan, MD (Professor of Anesthesia, Medical Faculty, Mansoura University)","src":"https://clinicaltrials.gov/study/NCT03586154","sites":["MansouraU — Al Mansurah, Egypt"],"conds":["Breast Neoplasms"],"condg":["Cancer-related distress"],"enroll":70,"eid":"NCT03586154"},{"id":"study-NCT03284307","cat":"studies","name":"UNderstanding CONSciousness Connectedness and Intraoperative Unresponsiveness Study","status":"COMPLETED","phase":"Phase 4","sponsor":"University of Wisconsin, Madison","drugs":["ketamine"],"nct":"NCT03284307","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-08-10","official":"Robert A Pearce, MD, PhD (Professor and chair of Anesthesiology at UW- Madison)","src":"https://clinicaltrials.gov/study/NCT03284307","sites":["UW Hospital and Clinics — Madison, United States"],"conds":["Unconsciousness","Consciousness"],"condg":["Other"],"enroll":35,"eid":"NCT03284307"},{"id":"study-NCT03181529","cat":"studies","name":"Effects of Psilocybin in Major Depressive Disorder","status":"COMPLETED","phase":"Phase 2","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT03181529","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-08-10","official":"Roland R Griffiths, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT03181529","sites":["Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center — Baltimore, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":27,"eid":"NCT03181529"},{"id":"study-NCT03246971","cat":"studies","name":"Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain","status":"COMPLETED","phase":"Phase 2","sponsor":"iX Biopharma Ltd.","drugs":["ketamine"],"nct":"NCT03246971","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-08-24","src":"https://clinicaltrials.gov/study/NCT03246971","sites":["Lotus Clinical Research — Pasadena, United States"],"conds":["Acute Pain","Bunion","Abdominoplasty"],"condg":["Chronic pain & headache"],"enroll":125,"eid":"NCT03246971"},{"id":"study-NCT03207165","cat":"studies","name":"Milrinone Versus Dobutamine in Critically Ill Patients","status":"COMPLETED","phase":"Phase 4","sponsor":"Ottawa Heart Institute Research Corporation","drugs":["LSD"],"nct":"NCT03207165","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2017-08-30","official":"Benjamin M Hibbert, MD, PhD (Ottawa Heart Institute Research Corporation)","src":"https://clinicaltrials.gov/study/NCT03207165","sites":["University of Ottawa Heart Institute — Ottawa, Canada"],"conds":["Low Cardiac Output Syndrome","Cardiogenic Shock","Acute Coronary Syndrome","Pulmonary Edema"],"condg":["Other"],"enroll":192,"eid":"NCT03207165"},{"id":"study-NCT03247998","cat":"studies","name":"GA vs. CS for Endovascular Stroke Therapy","status":"UNKNOWN","phase":"N/A","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","drugs":["ketamine"],"nct":"NCT03247998","nsites":0,"start":"2017-08-31","official":"Miguel Arango (London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's)","src":"https://clinicaltrials.gov/study/NCT03247998","conds":["Stroke","Endovascular Repair","Anesthesia"],"condg":["Neurology & cognition"],"contact":{"n":"Miguel Arango","p":"519-685-8500","e":"miguel.arango@lhsc.on.ca"},"enroll":20,"eid":"NCT03247998"},{"id":"study-NCT03249025","cat":"studies","name":"Lidocaine-Ketamine for Management of Chronic Pain","status":"UNKNOWN","phase":"N/A","sponsor":"Hamilton Health Sciences Corporation","drugs":["ketamine"],"nct":"NCT03249025","nsites":0,"start":"2017-09-01","official":"Michael Gofeld, MD, FRCPC (Michael G. DeGroote Pain Clinic, Hamilton Health Sciences)","src":"https://clinicaltrials.gov/study/NCT03249025","conds":["Chronic Pain Syndrome"],"condg":["Chronic pain & headache"],"contact":{"n":"Lisa Patterson, BA","p":"905-521-5100","e":"pattersl@hhsc.ca"},"enroll":72,"eid":"NCT03249025"},{"id":"study-NCT03273231","cat":"studies","name":"The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection","status":"UNKNOWN","phase":"N/A","sponsor":"Yonsei University","drugs":["ketamine"],"nct":"NCT03273231","nsites":1,"countries":"South Korea","ccs":["KR"],"start":"2017-09-01","src":"https://clinicaltrials.gov/study/NCT03273231","sites":["Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine — Seoul, South Korea"],"conds":["Colorectal Cancer"],"condg":["Cancer-related distress"],"contact":{"n":"Jin Sun Cho, MD","p":"82-2-2228-5448","e":"chjs0214@yuhs.ac"},"enroll":100,"eid":"NCT03273231"},{"id":"study-NCT03256162","cat":"studies","name":"Ketamine as an Adjunctive Therapy for Major Depression","status":"COMPLETED","phase":"Phase 1","sponsor":"St Patrick's Hospital, Ireland","drugs":["ketamine"],"nct":"NCT03256162","nsites":1,"countries":"Ireland","ccs":["IE"],"start":"2017-09-07","official":"Declan M McLoughlin, PhD (St Patrick's Mental Health Services and Trinity College Dublin)","src":"https://clinicaltrials.gov/study/NCT03256162","sites":["St Patrick's University Hospital — Dublin, Ireland"],"conds":["Major Depressive Episode","Unipolar Depression","Bipolar Depression"],"condg":["Depression","Bipolar"],"enroll":25,"eid":"NCT03256162"},{"id":"study-NCT03149991","cat":"studies","name":"A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)","status":"COMPLETED","phase":"Phase 4","sponsor":"Massachusetts General Hospital","drugs":["ketamine"],"nct":"NCT03149991","nsites":6,"countries":"United States","ccs":["US"],"start":"2017-09-14","official":"Maurizio Fava, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT03149991","sites":["Collaborative Neuroscience Network, LLC. — Garden Grove, United States","Pacific Research Partners, LLC — Oakland, United States","Rush University Medical Center — Chicago, United States","Massachusetts General Hospital, Depression Clinical and Research Program — Boston, United States","Nathan Kline Institute for Psychiatric Research — Orangeburg, United States","Montefiore Medical Center — The Bronx, United States"],"conds":["Depression"],"condg":["Depression"],"enroll":51,"eid":"NCT03149991"},{"id":"study-NCT03298906","cat":"studies","name":"A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT03298906","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2017-09-26","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03298906","sites":["Clinical Pharmacology Unit — Merksem, Belgium"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":16,"eid":"NCT03298906"},{"id":"study-NCT03185819","cat":"studies","name":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal…","status":"COMPLETED","phase":"Phase 2","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT03185819","nsites":51,"countries":"Belgium; Brazil; Bulgaria; France; Hungary; Italy; Poland; Spain; United States","ccs":["BE","BG","BR","ES","FR","HU","IT","PL","US"],"start":"2017-10-05","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","sites":["Institute of Living/ Hartford Hospital — Hartford, United States","Yale University — New Haven, United States","Atlanta Behavioral Research, LLC — Atlanta, United States","Rush University Medical Center — Chicago, United States","Neuroscience Research Institute — Winfield, United States","Beacon Medical Group Clinical Research — South Bend, United States","University of Iowa, Carver College of Medicine — Iowa City, United States","Lake Charles Clinical Trials — Lake Charles, United States"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"enroll":147,"eid":"NCT03185819"},{"id":"study-NCT02987985","cat":"studies","name":"Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy","status":"COMPLETED","phase":"Phase 3","sponsor":"University of Saskatchewan","drugs":["ketamine"],"nct":"NCT02987985","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2017-10-15","official":"Jon Gamble, MD (University of Saskatchewan)","src":"https://clinicaltrials.gov/study/NCT02987985","sites":["Royal University Hospital — Saskatoon, Canada"],"conds":["Anesthesia","General Anesthesia","Analgesics, Opioid","Postoperative Complications","Pathologic Processes","Physiologic Effects of Drugs"],"condg":["Depression","Addiction & substance use"],"enroll":50,"eid":"NCT02987985"},{"id":"study-NCT03341689","cat":"studies","name":"Psilocybin for the Treatment of Migraine Headache","status":"COMPLETED","phase":"Phase 1","sponsor":"Yale University","drugs":["psilocybin"],"nct":"NCT03341689","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-11-01","src":"https://clinicaltrials.gov/study/NCT03341689","sites":["VA Connecticut Healthcare System, West Haven Campus — West Haven, United States"],"conds":["Migraine Headache"],"condg":["Chronic pain & headache"],"enroll":14,"eid":"NCT03341689"},{"id":"study-NCT04123652","cat":"studies","name":"Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain","status":"COMPLETED","phase":"Phase 4","sponsor":"Allevio Pain Management Clinic","drugs":["ketamine"],"nct":"NCT04123652","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2017-11-05","official":"Ramin Safakish, MD.FRCPC (Allevio Pain Management Clinic)","src":"https://clinicaltrials.gov/study/NCT04123652","sites":["Allevio Pain Management Clinic — Toronto, Canada"],"conds":["Chronic Neuropathic Pain and Fibromyalgia"],"condg":["Chronic pain & headache"],"enroll":162,"eid":"NCT04123652"},{"id":"study-NCT03282123","cat":"studies","name":"Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","status":"COMPLETED","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT03282123","nsites":12,"countries":"United States","ccs":["US"],"start":"2017-11-16","official":"Michael C Mithoefer, MD (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03282123","sites":["New School Research LLC — North Hollywood, United States","San Francisco Insight and Integration Center — San Francisco, United States","University of California San Francisco — San Francisco, United States","Aguazul-Blue Water Inc. — Boulder, United States","Wholeness Center — Fort Collins, United States","University of Connecticut — Farmington, United States","Ray Worthy Psychiatry LLC — New Orleans, United States","Trauma Research Foundation — Brookline, United States"],"conds":["PTSD"],"condg":["PTSD & trauma"],"enroll":38,"eid":"NCT03282123"},{"id":"study-NCT03632915","cat":"studies","name":"Pharmacokinetics of Antiepileptics in Patients on CRRT","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","drugs":["ketamine"],"nct":"NCT03632915","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-11-20","official":"Neeraj Badjatia, MD (University of Maryland, College Park)","src":"https://clinicaltrials.gov/study/NCT03632915","sites":["University of Maryland Medical Center — Baltimore, United States"],"conds":["Acute Kidney Injury","Renal Insufficiency","Renal Failure","Pharmacokinetics"],"condg":["Other"],"enroll":18,"eid":"NCT03632915"},{"id":"study-NCT03832309","cat":"studies","name":"Techniques to Reduce the Severity and Frequency of Emergent Reactions","status":"TERMINATED","phase":"N/A","sponsor":"CHRISTUS Health","drugs":["ketamine"],"nct":"NCT03832309","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-11-21","official":"Paul Crapo, DO (CHRISTUS Health)","src":"https://clinicaltrials.gov/study/NCT03832309","sites":["CHRISTUS Health — Corpus Christi, United States"],"conds":["Analgesia"],"condg":["Other"],"enroll":38,"eid":"NCT03832309"},{"id":"study-NCT03336541","cat":"studies","name":"Low-dose Ketamine and Postpartum Depression in Parturients With Prenatal Depression","status":"COMPLETED","phase":"Phase 4","sponsor":"Peking University First Hospital","drugs":["ketamine"],"nct":"NCT03336541","nsites":1,"countries":"China","ccs":["CN"],"start":"2017-11-23","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT03336541","sites":["Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital — Beijing, China"],"conds":["Perinatal Depression","Ketamine","Cesarean Delivery","Postpartum Depression"],"condg":["Depression"],"enroll":64,"eid":"NCT03336541"},{"id":"study-NCT03321136","cat":"studies","name":"Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD"],"nct":"NCT03321136","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2017-11-28","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT03321136","sites":["University Hospital — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":16,"eid":"NCT03321136"},{"id":"study-NCT03290963","cat":"studies","name":"Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine","status":"WITHDRAWN","phase":"Phase 2","sponsor":"William V. Bobo, M.D.","drugs":["ketamine"],"nct":"NCT03290963","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-11-30","official":"William V Bobo (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT03290963","sites":["Mayo Clinic in Rochester — Rochester, United States"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"eid":"NCT03290963"},{"id":"study-NCT03421275","cat":"studies","name":"Intranasal Esketamine and Fentanyl for Pain in Minor Trauma","status":"UNKNOWN","phase":"Phase 4","sponsor":"Anna Meuronen, MD","drugs":["esketamine"],"nct":"NCT03421275","nsites":1,"countries":"Finland","ccs":["FI"],"start":"2017-12-01","official":"Anna Meuronen, MD,PhD (consultant)","src":"https://clinicaltrials.gov/study/NCT03421275","sites":["Hyvinkää Hospital — Hyvinkää, Finland"],"conds":["Acute Pain Due to Trauma"],"condg":["PTSD & trauma","Chronic pain & headache"],"contact":{"n":"Anna Meuronen, MD,PhD","p":"+35819458711","e":"anna.meuronen@hus.fi"},"enroll":105,"eid":"NCT03421275"},{"id":"study-NCT03237286","cat":"studies","name":"Intravenous Ketamine Plus Neurocognitive Training for Depression","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Rebecca Price","drugs":["ketamine"],"nct":"NCT03237286","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-12-01","src":"https://clinicaltrials.gov/study/NCT03237286","sites":["Western Psychiatric Institute and Clinic — Pittsburgh, United States"],"conds":["Depression"],"condg":["Depression"],"enroll":154,"eid":"NCT03237286"},{"id":"study-NCT03407872","cat":"studies","name":"Safety and Pharmacokinetic Study of Inhaled Esketamine in Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"Celon Pharma SA","drugs":["esketamine"],"nct":"NCT03407872","nsites":1,"countries":"Poland","ccs":["PL"],"start":"2017-12-09","src":"https://clinicaltrials.gov/study/NCT03407872","sites":["BioResearch Group Sp. z o.o. — Kajetany, Poland"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":63,"eid":"NCT03407872"},{"id":"study-NCT03418714","cat":"studies","name":"Effects of Salvinorin A on Brain Function","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Johns Hopkins University","drugs":["salvinorin A"],"nct":"NCT03418714","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-12-14","official":"Frederick S Barrett, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT03418714","sites":["Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center — Baltimore, United States"],"conds":["Drug Effect"],"condg":["Other"],"enroll":13,"eid":"NCT03418714"},{"id":"study-NCT03305055","cat":"studies","name":"RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn Pain","status":"TERMINATED","phase":"Phase 4","sponsor":"Johns Hopkins University","drugs":["ketamine"],"nct":"NCT03305055","nsites":1,"countries":"United States","ccs":["US"],"start":"2017-12-16","official":"James A Fauerbach, PhD (Johns Hopkins University SOM); Kevin Gerold, DOJD (Johns Hopkins University SOM)","src":"https://clinicaltrials.gov/study/NCT03305055","sites":["Johns Hopkins Burn Center — Baltimore, United States"],"conds":["Acute Pain","Wound Care","Posttraumatic Stress Disorder"],"condg":["PTSD & trauma","Chronic pain & headache"],"enroll":4,"eid":"NCT03305055"},{"id":"study-NCT02860117","cat":"studies","name":"Ketamine Continuous Infusion on Opioid Consumption and Pain Management in Severe Burned Patients","status":"WITHDRAWN","phase":"Phase 3","sponsor":"University of Sao Paulo General Hospital","drugs":["ketamine"],"nct":"NCT02860117","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2018-01","official":"Claudia Palmeira, MD, PhD (University of Sao Paulo General Hospital)","src":"https://clinicaltrials.gov/study/NCT02860117","sites":["Hospital das Clínicas da FMUSP — São Paulo, Brazil"],"conds":["Pain, Burning"],"condg":["Chronic pain & headache"],"eid":"NCT02860117"},{"id":"study-NCT03233035","cat":"studies","name":"Low Dose Ketamine Intra Nasal Traumatology","status":"COMPLETED","phase":"Phase 2","sponsor":"University of Monastir","drugs":["ketamine"],"nct":"NCT03233035","nsites":2,"countries":"Tunisia","ccs":["TN"],"start":"2018-01-01","official":"Nouira Semir, Professor (university Hospital of Monastir)","src":"https://clinicaltrials.gov/study/NCT03233035","sites":["Nouira Samir — Monastir, Tunisia","Emergency department of university hospital Fattouma Bourguiba of Monastir — Monastir, Tunisia"],"conds":["Trauma"],"condg":["PTSD & trauma"],"enroll":1102,"eid":"NCT03233035"},{"id":"study-NCT03431285","cat":"studies","name":"Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients","status":"COMPLETED","phase":"N/A","sponsor":"Imam Abdulrahman Bin Faisal University","drugs":["ketamine"],"nct":"NCT03431285","nsites":1,"countries":"Saudi Arabia","ccs":["SA"],"start":"2018-01-01","official":"Mohammed SS Alshahrani, MD (King Fahad Hospital of the University -Imam Abdulrahman Bin Faisal University - (Dammam University))","src":"https://clinicaltrials.gov/study/NCT03431285","sites":["Imam Abdulrahman Bin Faisal University — Dammam, Saudi Arabia"],"conds":["Sickle Cell Crisis"],"condg":["Other"],"enroll":278,"eid":"NCT03431285"},{"id":"study-NCT02950467","cat":"studies","name":"Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors","status":"COMPLETED","phase":"Phase 1","sponsor":"Joshua Woolley","drugs":["psilocybin"],"nct":"NCT02950467","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-01-05","official":"Joshua Woolley, MD,PhD (University of California, San Francisco); Brian Anderson, MD,MSc (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT02950467","sites":["University of California, San Francisco — San Francisco, United States"],"conds":["Distress","Depression","Grief"],"condg":["Depression"],"enroll":30,"eid":"NCT02950467"},{"id":"study-NCT04322968","cat":"studies","name":"Ketamine Infusion for Comorbid PTSD and Chronic Pain","status":"COMPLETED","phase":"Phase 3","sponsor":"VA Ann Arbor Healthcare System","drugs":["ketamine"],"nct":"NCT04322968","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-01-09","src":"https://clinicaltrials.gov/study/NCT04322968","sites":["Ann Arbor VA Medical Center — Ann Arbor, United States"],"conds":["PTSD","Chronic Pain"],"condg":["PTSD & trauma","Chronic pain & headache"],"enroll":41,"eid":"NCT04322968"},{"id":"study-NCT02974010","cat":"studies","name":"Sequential Therapy for the Treatment of Severe Bipolar Depression.","status":"COMPLETED","phase":"Phase 2","sponsor":"NeuroRx, Inc.","drugs":["ketamine"],"nct":"NCT02974010","nsites":4,"countries":"United States","ccs":["US"],"start":"2018-01-15","official":"Andrew Nierenberg, MD (Massachusetts General Hospital); Daniel C Javitt, MD (NeuroRx, Inc.)","src":"https://clinicaltrials.gov/study/NCT02974010","sites":["Research Site, Birmingham — Birmingham, United States","Research Site, Fort Lauderdale — Fort Lauderdale, United States","Research Site, Charlotte — Charlotte, United States","Research Site, Houston — Houston, United States"],"conds":["Bipolar Depression","Suicidal Ideas","Suicidal Ideation","Suicide, Attempted"],"condg":["Depression","Bipolar"],"enroll":22,"eid":"NCT02974010"},{"id":"study-NCT03434366","cat":"studies","name":"Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder","status":"SUSPENDED","phase":"Phase 2","sponsor":"Guangzhou Women and Children's Medical Center","drugs":["ketamine"],"nct":"NCT03434366","nsites":1,"countries":"China","ccs":["CN"],"start":"2018-01-20","official":"Qing Zhao, Doctor (Guangzhou Women and Children's Medical Center)","src":"https://clinicaltrials.gov/study/NCT03434366","sites":["Guangzhou Women and Children Medical Center — Guangzhou, China"],"conds":["Autism Spectrum Disorder"],"condg":["Other"],"enroll":50,"eid":"NCT03434366"},{"id":"study-NCT02823977","cat":"studies","name":"Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal","status":"WITHDRAWN","phase":"Phase 4","sponsor":"University of Colorado, Denver","drugs":["ketamine"],"nct":"NCT02823977","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-02","official":"Robert MacLaren, PharmD, MPH (University of Colorado, Denver)","src":"https://clinicaltrials.gov/study/NCT02823977","sites":["University of Colorado Hospital — Aurora, United States"],"conds":["Alcohol Withdrawal"],"condg":["Addiction & substance use"],"eid":"NCT02823977"},{"id":"study-NCT03458143","cat":"studies","name":"Respiratory Depression During an Analgosedation Combining Remifentanil and Ketamine in TCI for Oocyte Retrieval","status":"UNKNOWN","sponsor":"Erasme University Hospital","drugs":["ketamine"],"nct":"NCT03458143","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2018-02-12","official":"Peres-Bota Iulia, student (Erasme University Hospital); Barvais Luc, MDPhD (Erasme University Hospital)","src":"https://clinicaltrials.gov/study/NCT03458143","sites":["Erasme University Hospital — Brussels, Belgium"],"conds":["Oocyte Retrieval","Sedation, Conscious","Ventilatory Depression"],"condg":["Depression"],"contact":{"n":"barvais luc, MD PhD","p":"+3225553919","e":"luc.barvais@erasme.ulb.ac.be"},"enroll":20,"eid":"NCT03458143"},{"id":"study-NCT03312894","cat":"studies","name":"Efficacy and Safety of TAK-653 in Treatment-Resistant Depression","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Millennium Pharmaceuticals, Inc.","drugs":["ketamine"],"nct":"NCT03312894","nsites":0,"start":"2018-02-15","official":"Medical Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT03312894","conds":["Treatment-Resistant Depression"],"condg":["Depression"],"eid":"NCT03312894"},{"id":"study-NCT03395314","cat":"studies","name":"Ketamine in Borderline Personality Disorder","status":"TERMINATED","phase":"Phase 2","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT03395314","nsites":2,"countries":"United States","ccs":["US"],"start":"2018-02-15","official":"Sarah Fineberg, MD/PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03395314","sites":["Connecticut Mental Health Center — New Haven, United States","Yale New Haven Hospital — New Haven, United States"],"conds":["Borderline Personality Disorder"],"condg":["Other"],"enroll":22,"eid":"NCT03395314"},{"id":"study-NCT03513822","cat":"studies","name":"Ketamine's Efficiency in the Treatment of Chronic Pain: Kynurenin Pathway","status":"UNKNOWN","phase":"Phase 3","sponsor":"Redar","drugs":["ketamine"],"nct":"NCT03513822","nsites":1,"countries":"France","ccs":["FR"],"start":"2018-02-16","official":"Didier Bouhassira, Md, PhD (INSERM U987)","src":"https://clinicaltrials.gov/study/NCT03513822","sites":["Raymond Poincaré Hospital — Garches, France"],"conds":["Neuralgia","Chronic Pain","Inflammation"],"condg":["Chronic pain & headache"],"contact":{"n":"Cyril QUEMENEUR, Resident","p":"0033681193981","e":"c.quemeneur@gmx.com"},"enroll":48,"eid":"NCT03513822"},{"id":"study-NCT03469089","cat":"studies","name":"Touchscreen-based Cognitive Tests in Healthy Volunteers","status":"UNKNOWN","phase":"Phase 1","sponsor":"University of Eastern Finland","drugs":["ketamine"],"nct":"NCT03469089","nsites":1,"countries":"Finland","ccs":["FI"],"start":"2018-03-12","official":"Markus M Forsberg, PhD (University of Eastern Finland)","src":"https://clinicaltrials.gov/study/NCT03469089","sites":["University of Eastern Finland, Clinical Research Centre, Brain Research Unit — Kuopio, Finland"],"conds":["Cognitive Symptom","Schizophrenia"],"condg":["Neurology & cognition"],"enroll":16,"eid":"NCT03469089"},{"id":"study-NCT03485287","cat":"studies","name":"Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)","status":"COMPLETED","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT03485287","nsites":2,"countries":"Canada","ccs":["CA"],"start":"2018-03-13","official":"Michael Mithoefer (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03485287","sites":["British Columbia Centre on Substance Abuse — Vancouver, Canada","Dr. Simon Amar, LLC — Montreal, Canada"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":4,"eid":"NCT03485287"},{"id":"study-NCT04234776","cat":"studies","name":"Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression","status":"UNKNOWN","phase":"Phase 4","sponsor":"University of Sao Paulo","drugs":["ketamine"],"nct":"NCT04234776","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2018-04-03","official":"Ricardo A Moreno, MD, PhD (Department and Institute of Psychiatry, University of Sao Paulo)","src":"https://clinicaltrials.gov/study/NCT04234776","sites":["Núcleo de Pesquisas em Saúde Mental — Blumenau, Brazil"],"conds":["Depressive Disorder"],"condg":["Depression"],"enroll":88,"eid":"NCT04234776"},{"id":"study-NCT03473431","cat":"studies","name":"Effect of Ketamine in Depressive Symptoms of Elderly Patients With Visual Impairment.","status":"COMPLETED","phase":"N/A","sponsor":"Instituto Mexicano del Seguro Social","drugs":["ketamine"],"nct":"NCT03473431","nsites":1,"countries":"Mexico","ccs":["MX"],"start":"2018-04-15","official":"DULCE RASCON MARTINEZ, M.D (imss)","src":"https://clinicaltrials.gov/study/NCT03473431","sites":["Centro Medico Nacional Siglo XXI. UMAE Hospital de Especialidades — Mexico City, Mexico"],"conds":["Depression in Old Age","Ketamine"],"condg":["Depression"],"enroll":90,"eid":"NCT03473431"},{"id":"study-NCT04158778","cat":"studies","name":"Bristol Imperial MDMA in Alcoholism Study","status":"UNKNOWN","phase":"Phase 1","sponsor":"Imperial College London","drugs":["MDMA"],"nct":"NCT04158778","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2018-04-18","official":"Prof Nutt (Imperial College London)","src":"https://clinicaltrials.gov/study/NCT04158778","sites":["Study Center: University of Bristol — Bristol, United Kingdom"],"conds":["Alcohol Use Disorder"],"condg":["Addiction & substance use"],"enroll":20,"eid":"NCT04158778"},{"id":"study-NCT03790358","cat":"studies","name":"Mood Effects of Serotonin Agonists","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Chicago","drugs":["LSD","MDMA"],"nct":"NCT03790358","nsites":2,"countries":"United States","ccs":["US"],"start":"2018-05-01","src":"https://clinicaltrials.gov/study/NCT03790358","sites":["Matthew Bona — Chicago, United States","University of Chicago — Chicago, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":80,"eid":"NCT03790358"},{"id":"study-NCT03539887","cat":"studies","name":"Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse","status":"COMPLETED","phase":"Phase 3","sponsor":"The University of Texas Health Science Center, Houston","drugs":["ketamine"],"nct":"NCT03539887","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-05-01","official":"Rodrigo Machado-Vieira, MD, PhD, MSc (The University of Texas Health Science Center, Houston)","src":"https://clinicaltrials.gov/study/NCT03539887","sites":["The University of Texas Health Science Center at Houston — Houston, United States"],"conds":["Suicidal Ideation","Depression","Alcohol Abuse"],"condg":["Depression","Addiction & substance use"],"enroll":33,"eid":"NCT03539887"},{"id":"study-NCT03434041","cat":"studies","name":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 3","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT03434041","nsites":30,"countries":"China; United States","ccs":["CN","US"],"start":"2018-05-25","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","sites":["Atlanta Center for Medical Research — Atlanta, United States","Biomedical Research Foundation of Northwest Louisiana — Shreveport, United States","CBH Health — Gaithersburg, United States","Adams Clinical — Watertown, United States","The Medical Research Network, LLC — New York, United States","IPS Research Company — Oklahoma City, United States","Beijing Anding Hospital of Capital Medical University — Beijing, China","Beijing HuiLong Guan Hospital — Beijing, China"],"conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"enroll":252,"eid":"NCT03434041"},{"id":"study-NCT03375671","cat":"studies","name":"Rapid Agitation Control With Ketamine in the Emergency Department","status":"COMPLETED","phase":"Phase 2","sponsor":"David Barbic","drugs":["ketamine"],"nct":"NCT03375671","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2018-05-29","official":"David Barbic, MD MSc FRCPC, (University of British Columbia)","src":"https://clinicaltrials.gov/study/NCT03375671","sites":["St. Paul's Hospital Emergency Department — Vancouver, Canada"],"conds":["Violent Aggressive Behavior","Ketamine"],"condg":["Other"],"enroll":81,"eid":"NCT03375671"},{"id":"study-NCT02967640","cat":"studies","name":"Does Subacromial Injection With Glutamate Receptor Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy?","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Helse Møre og Romsdal HF","drugs":["ketamine"],"nct":"NCT02967640","nsites":1,"countries":"Norway","ccs":["NO"],"start":"2018-05-30","official":"Oystein B Lian, md phd (Helse Nord-Trøndelag HF)","src":"https://clinicaltrials.gov/study/NCT02967640","sites":["Department of Orthopedic Surgery, Kristiansund Hospital — Kristiansund, Norway"],"conds":["Rotator Cuff Tendinitis","Chronic Pain"],"condg":["Chronic pain & headache"],"enroll":14,"eid":"NCT02967640"},{"id":"study-NCT03362073","cat":"studies","name":"Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients","status":"TERMINATED","phase":"Phase 2","sponsor":"Pusan National University Yangsan Hospital","drugs":["ketamine"],"nct":"NCT03362073","nsites":1,"countries":"South Korea","ccs":["KR"],"start":"2018-06-01","official":"Kwonoh Park, MD, PhD (Pusan National University Yangsan Hospital)","src":"https://clinicaltrials.gov/study/NCT03362073","sites":["Pusan National University Yangsan Hospital — Yangsan, South Korea"],"conds":["Ketamine","Refractory Cancer Pain"],"condg":["Cancer-related distress","Chronic pain & headache"],"enroll":20,"eid":"NCT03362073"},{"id":"study-NCT03485339","cat":"studies","name":"Substance Misuse To Psychosis for Ketamine (SToP-K)","status":"COMPLETED","sponsor":"The University of Hong Kong","drugs":["ketamine"],"nct":"NCT03485339","nsites":2,"countries":"Hong Kong","ccs":["HK"],"start":"2018-06-12","official":"albert KK Chung, MBBS(HK) (The University of Hong Kong)","src":"https://clinicaltrials.gov/study/NCT03485339","sites":["Queen Mary Hospital — Hong Kong, Hong Kong","Western Psychiatric Centre — Hong Kong, Hong Kong"],"conds":["Ketamine Abuse","Psychotic Disorders","Substance Use Disorders","Schizophrenia","Genetic Predisposition"],"condg":["Addiction & substance use"],"enroll":162,"eid":"NCT03485339"},{"id":"study-NCT03470675","cat":"studies","name":"Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries","status":"COMPLETED","phase":"Phase 4","sponsor":"Northwestern University","drugs":["ketamine"],"nct":"NCT03470675","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-06-27","official":"Feyce Peralta, MD (Northwestern University)","src":"https://clinicaltrials.gov/study/NCT03470675","sites":["Northwestern University — Chicago, United States"],"conds":["Pain","Postpartum Depression"],"condg":["Depression","Chronic pain & headache"],"enroll":67,"eid":"NCT03470675"},{"id":"study-NCT03812055","cat":"studies","name":"Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders","status":"UNKNOWN","sponsor":"Lysosomal and Rare Disorders Research and Treatment Center, Inc.","drugs":["LSD"],"nct":"NCT03812055","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-07-06","official":"Margarita M Ivanova, PhD (LDRTC); Ozlem Goker-Alpan, MD (LDRTC)","src":"https://clinicaltrials.gov/study/NCT03812055","sites":["LDRTC — Fairfax, United States"],"conds":["Lysosomal Storage Diseases"],"condg":["Other"],"contact":{"n":"Margarita M Ivanova, PhD","p":"7032616220","e":"mivanova@ldrtc.org"},"enroll":50,"eid":"NCT03812055"},{"id":"study-NCT03410446","cat":"studies","name":"Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care","status":"COMPLETED","phase":"Phase 2","sponsor":"University Health Network, Toronto","drugs":["ketamine"],"nct":"NCT03410446","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2018-07-16","official":"Madeline Li, M.D. (Princess Margaret Cancer Centre)","src":"https://clinicaltrials.gov/study/NCT03410446","sites":["Princess Margaret Cancer Centre — Toronto, Canada"],"conds":["Depression","Cancer","Palliative Care"],"condg":["Depression","End-of-life & palliative","Cancer-related distress"],"enroll":22,"eid":"NCT03410446"},{"id":"study-NCT03498391","cat":"studies","name":"A Study of Human Multi-Sensory Integration","status":"SUSPENDED","phase":"Phase 2","sponsor":"University of Pennsylvania","drugs":["ketamine"],"nct":"NCT03498391","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-07-30","official":"Max Kelz, MD, PhD (University of Pennsylvania)","src":"https://clinicaltrials.gov/study/NCT03498391","sites":["University of Pennsylvania, Perelman School of Medicine — Philadelphia, United States"],"conds":["Anesthesia Awareness"],"condg":["Other"],"enroll":40,"eid":"NCT03498391"},{"id":"study-NCT03500289","cat":"studies","name":"Ketamine for Treatment of MS Fatigue","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Johns Hopkins University","drugs":["ketamine"],"nct":"NCT03500289","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-08-10","official":"Bardia Nourbakhsh, MD, MAS (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT03500289","sites":["Johns Hopkins University — Baltimore, United States"],"conds":["Multiple Sclerosis","Fatigue"],"condg":["Other"],"enroll":18,"eid":"NCT03500289"},{"id":"study-NCT03649334","cat":"studies","name":"Ketamine-ketorolac Versus Fentanyl- Ketorolac I.M in Children During Bone Marrow Biopsy","status":"COMPLETED","phase":"Phase 4","sponsor":"Mansoura University","drugs":["ketamine"],"nct":"NCT03649334","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2018-08-26","official":"Enas A Abd el Motlb, MD (Assisitant Professor)","src":"https://clinicaltrials.gov/study/NCT03649334","sites":["Mansoura University — Al Mansurah, Egypt"],"conds":["Hematological Malignancy (Leukemia- Lymphoma)"],"condg":["Other"],"enroll":80,"eid":"NCT03649334"},{"id":"study-NCT03647579","cat":"studies","name":"Dexmedetomidine Versus Midazolam Added to Ketamine in Pediatric Patients Undergoing Bone Marrow Aspiration and Biopsy","status":"COMPLETED","phase":"N/A","sponsor":"Assiut University","drugs":["ketamine"],"nct":"NCT03647579","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2018-08-30","src":"https://clinicaltrials.gov/study/NCT03647579","sites":["South Egypt Cancer Institute, Assiut University — Asyut, Egypt"],"conds":["Procedural Sedation and Analgesia During Bone Marrow…"],"condg":["Other"],"enroll":100,"eid":"NCT03647579"},{"id":"study-NCT03380442","cat":"studies","name":"Psilocybin and Depression","status":"UNKNOWN","phase":"Phase 2","sponsor":"University of Helsinki","drugs":["ketamine","psilocybin"],"nct":"NCT03380442","nsites":0,"start":"2018-09","src":"https://clinicaltrials.gov/study/NCT03380442","conds":["Severe Depression"],"condg":["Depression"],"contact":{"n":"Mona E Moisala, PhD","p":"504480044","e":"mona.moisala@helsinki.fi"},"enroll":60,"eid":"NCT03380442"},{"id":"study-NCT04856124","cat":"studies","name":"Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine","status":"COMPLETED","sponsor":"Psych Atlanta","drugs":["esketamine"],"nct":"NCT04856124","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-09-01","src":"https://clinicaltrials.gov/study/NCT04856124","sites":["PsychAtlanta — Marietta, United States"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":10,"eid":"NCT04856124"},{"id":"study-NCT05444036","cat":"studies","name":"Caudal Ketamine-bupivacaine More Effective Than Bupivacaine-saline","status":"COMPLETED","phase":"Phase 1","sponsor":"Egymedicalpedia","drugs":["ketamine"],"nct":"NCT05444036","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2018-09-01","official":"Nirvana Elshalakany, Professor (Department of Anesthesia and I.C.U. faculty of Medicine October six university, Egypt)","src":"https://clinicaltrials.gov/study/NCT05444036","sites":["October 6 University Hospital — Giza, Egypt"],"conds":["Surgery","Pediatric Surgery"],"condg":["Other"],"enroll":60,"eid":"NCT05444036"},{"id":"study-NCT04021433","cat":"studies","name":"Ketamine for Treatment Resistant MDD","status":"UNKNOWN","phase":"N/A","sponsor":"Hadassah Medical Organization","drugs":["ketamine"],"nct":"NCT04021433","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2018-09-01","src":"https://clinicaltrials.gov/study/NCT04021433","sites":["Hadassah Hebrew University Medical Center — Jerusalem, Israel"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"contact":{"n":"Moshe Isserles, MD","p":"00972 2 6777184","e":"moshay@hadassah.org.il"},"enroll":20,"eid":"NCT04021433"},{"id":"study-NCT03502421","cat":"studies","name":"Ketamine Sickle Cell Disease","status":"WITHDRAWN","phase":"Phase 3","sponsor":"University of South Florida","drugs":["ketamine"],"nct":"NCT03502421","nsites":0,"start":"2018-09-01","official":"Enrico Camporesi, MD (University of South Florida)","src":"https://clinicaltrials.gov/study/NCT03502421","conds":["SC Disease","Pain, Chronic"],"condg":["Chronic pain & headache"],"eid":"NCT03502421"},{"id":"study-NCT03528512","cat":"studies","name":"IN Ketamine vs IN Midazolam and Fentanyl for Laceration Repair","status":"TERMINATED","phase":"Phase 4","sponsor":"Corewell Health East","drugs":["ketamine"],"nct":"NCT03528512","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-09-04","official":"Kelly Levasseur, DO (Corewell Health East)","src":"https://clinicaltrials.gov/study/NCT03528512","sites":["Beaumont Hospital - Royal Oak — Royal Oak, United States"],"conds":["Laceration of Skin"],"condg":["Other"],"enroll":5,"eid":"NCT03528512"},{"id":"study-NCT03666390","cat":"studies","name":"Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide","status":"UNKNOWN","phase":"N/A","sponsor":"Taipei Veterans General Hospital, Taiwan","drugs":["ketamine"],"nct":"NCT03666390","nsites":1,"countries":"Taiwan","ccs":["TW"],"start":"2018-09-10","official":"Mu-Hong Chen, M.D. (Taipei Veterans General Hospital, Taiwan)","src":"https://clinicaltrials.gov/study/NCT03666390","sites":["Taipei Veterans General Hospital — Taipei, Taiwan"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Mu-Hong Chen, M.D.","p":"886 -2- 28712121","e":"kremer7119@gmail.com"},"enroll":48,"eid":"NCT03666390"},{"id":"study-NCT03664622","cat":"studies","name":"Ketamine Versus Morphine Change Pain Profile","status":"COMPLETED","phase":"N/A","sponsor":"Cairo University","drugs":["ketamine"],"nct":"NCT03664622","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2018-09-15","official":"hassan Ali (Cairo University)","src":"https://clinicaltrials.gov/study/NCT03664622","sites":["Cairo University — Cairo, Egypt"],"conds":["Acute Pain"],"condg":["Chronic pain & headache"],"enroll":160,"eid":"NCT03664622"},{"id":"study-NCT03771586","cat":"studies","name":"A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"Supernus Pharmaceuticals, Inc.","drugs":["ketamine"],"nct":"NCT03771586","nsites":2,"countries":"United States","ccs":["US"],"start":"2018-09-24","src":"https://clinicaltrials.gov/study/NCT03771586","sites":["Sage Investigational Site — Long Beach, United States","Sage Investigational Site — Berlin, United States"],"conds":["Healthy Volunteer"],"condg":["Healthy volunteers"],"enroll":22,"eid":"NCT03771586"},{"id":"study-NCT03742557","cat":"studies","name":"Evaluation of Schemes of Administration of Intravenous Ketamine in Depression","status":"UNKNOWN","phase":"Phase 3","sponsor":"National Institute of Neurology and Neurosurgery, Mexico","drugs":["ketamine"],"nct":"NCT03742557","nsites":1,"countries":"Mexico","ccs":["MX"],"start":"2018-10-01","official":"Rodrigo Pérez-Esparza, M.D., M.Sc. (National Institute of Neurology and Neurosurgery, Mexico)","src":"https://clinicaltrials.gov/study/NCT03742557","sites":["Instituto Nacional de Neurología y Neurocirugía (National Institute of Neurology and Neurosurgery) — Mexico City, Mexico"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"contact":{"n":"Rodrigo Pérez-Esparza, M.D., M.Sc.","p":"+5256063822","e":"dr.rodrigope@gmail.com"},"enroll":30,"eid":"NCT03742557"},{"id":"study-NCT03714620","cat":"studies","name":"Sub-dissociative Dose Ketamine Dosing Study","status":"COMPLETED","phase":"Phase 4","sponsor":"Loyola University","drugs":["ketamine"],"nct":"NCT03714620","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-10-15","official":"Shannon Lovett, MD (Loyola University Chicago, LUMC)","src":"https://clinicaltrials.gov/study/NCT03714620","sites":["Loyola University Medical Center — Maywood, United States"],"conds":["Acute Pain"],"condg":["Chronic pain & headache"],"enroll":98,"eid":"NCT03714620"},{"id":"study-NCT03674671","cat":"studies","name":"Ketamine Versus Electroconvulsive Therapy in Depression","status":"SUSPENDED","phase":"Phase 3","sponsor":"University of Ottawa","drugs":["ketamine"],"nct":"NCT03674671","nsites":4,"countries":"Canada","ccs":["CA"],"start":"2018-10-29","official":"Pierre Blier, MD, PhD (The Royal's Institute of Mental Health Research)","src":"https://clinicaltrials.gov/study/NCT03674671","sites":["Providence Care Hospital — Kingston, Canada","Royal Ottawa Mental Health Centre — Ottawa, Canada","University Health Network — Toronto, Canada","Ontario Shores Centre for Mental Health Sciences — Whitby, Canada"],"conds":["Depressive Disorder, Major","Bipolar Depression"],"condg":["Depression","Bipolar"],"enroll":240,"eid":"NCT03674671"},{"id":"study-NCT03933865","cat":"studies","name":"Acute Pain Management in Patients on Opioid Replacement Therapy","status":"TERMINATED","phase":"Phase 1","sponsor":"University of California, San Francisco","drugs":["ketamine"],"nct":"NCT03933865","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-10-31","official":"D. Andrew Tompkins, MD MHS (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT03933865","sites":["Zuckerberg San Francisco General Hospital — San Francisco, United States"],"conds":["Opioid-use Disorder","Pain, Acute"],"condg":["Addiction & substance use","Chronic pain & headache"],"enroll":1,"eid":"NCT03933865"},{"id":"study-NCT03711734","cat":"studies","name":"Acupuncture ACL (Anterior Cruciate Ligament)","status":"COMPLETED","phase":"N/A","sponsor":"Hospital for Special Surgery, New York","drugs":["ketamine"],"nct":"NCT03711734","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-11-01","official":"Stephanie Cheng, MD (Hospital for Special Surgey)","src":"https://clinicaltrials.gov/study/NCT03711734","sites":["Hospital for Special Surgery — New York, United States"],"conds":["ACL","ACL Injury","Anterior Cruciate Ligament Injury","Anterior Cruciate Ligament Rupture","Anesthesia"],"condg":["Other"],"enroll":40,"eid":"NCT03711734"},{"id":"study-NCT03799900","cat":"studies","name":"Assessment of Abuse Potential of Rapastinel in Humans","status":"COMPLETED","phase":"Phase 1","sponsor":"Naurex, Inc, an affiliate of Allergan plc","drugs":["ketamine"],"nct":"NCT03799900","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-11-01","official":"Sheng Fang Su (Allergan)","src":"https://clinicaltrials.gov/study/NCT03799900","sites":["Vince and Associates Clinical Research Inc — Overland Park, United States"],"conds":["Human Abuse Potential"],"condg":["Other"],"enroll":72,"eid":"NCT03799900"},{"id":"study-NCT03814733","cat":"studies","name":"Assessment of Effect of Rapastinel on Driving Performance","status":"COMPLETED","phase":"Phase 1","sponsor":"Naurex, Inc, an affiliate of Allergan plc","drugs":["ketamine"],"nct":"NCT03814733","nsites":2,"countries":"Canada; United States","ccs":["CA","US"],"start":"2018-11-05","official":"Sheng Fang Su (Allergan)","src":"https://clinicaltrials.gov/study/NCT03814733","sites":["Collaborative Neuroscience Network — San Clemente, United States","Algorithme Pharma — Aurora, Canada"],"conds":["Driving Performance"],"condg":["Other"],"enroll":107,"eid":"NCT03814733"},{"id":"study-NCT03770780","cat":"studies","name":"A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"Supernus Pharmaceuticals, Inc.","drugs":["ketamine"],"nct":"NCT03770780","nsites":2,"countries":"United States","ccs":["US"],"start":"2018-11-12","src":"https://clinicaltrials.gov/study/NCT03770780","sites":["Sage Investigational Site — Long Beach, United States","Sage Investigational Site — Berlin, United States"],"conds":["Healthy Volunteer"],"condg":["Healthy volunteers"],"enroll":19,"eid":"NCT03770780"},{"id":"study-NCT03356483","cat":"studies","name":"Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.","status":"COMPLETED","phase":"Phase 1","sponsor":"Yale University","drugs":["psilocybin"],"nct":"NCT03356483","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-11-13","official":"Benjamin Kelmendi, MD (Yale University); Christopher Pittenger, MD, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03356483","sites":["Connecticut Mental Health Center — New Haven, United States"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"enroll":31,"eid":"NCT03356483"},{"id":"study-NCT03729973","cat":"studies","name":"Comparing Efficacy Preoperative Nebulized: Ketamine , Mgspo4 ,and Lidocaine In Attenuating Endotracheal Sore Throat","status":"COMPLETED","phase":"Phase 3","sponsor":"Zagazig University","drugs":["ketamine"],"nct":"NCT03729973","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2018-11-15","official":"Alshaimaa Kamel, MD (Zagazig University)","src":"https://clinicaltrials.gov/study/NCT03729973","sites":["Zagazig University Hospitsals — Zagazig, Egypt"],"conds":["Sore Throat"],"condg":["Other"],"enroll":100,"eid":"NCT03729973"},{"id":"study-NCT06189027","cat":"studies","name":"Epigenetics and MDMA-Assisted Psychotherapy for PTSD","status":"COMPLETED","phase":"Phase 3","sponsor":"University of Southern California","drugs":["MDMA"],"nct":"NCT06189027","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-11-20","official":"Rael Cahn, MD, PhD (University of Southern California)","src":"https://clinicaltrials.gov/study/NCT06189027","sites":["Univeristy of Southern California — Los Angeles, United States"],"conds":["PTSD"],"condg":["PTSD & trauma"],"enroll":45,"eid":"NCT06189027"},{"id":"study-NCT03537014","cat":"studies","name":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","status":"COMPLETED","phase":"Phase 3","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT03537014","nsites":15,"countries":"Canada; Israel; United States","ccs":["CA","IL","US"],"start":"2018-11-21","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","sites":["New School Research LLT — North Hollywood, United States","San Francisco Insight and Integration Center — San Francisco, United States","University of California San Francisco — San Francisco, United States","Aguazul-Blue Water Inc. — Boulder, United States","Wholeness Center — Fort Collins, United States","Ray Worthy Psychiatry LLC — New Orleans, United States","Trauma Research Foundation — Boston, United States","New York University — New York, United States"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":100,"eid":"NCT03537014"},{"id":"study-NCT03753737","cat":"studies","name":"Personality Disorders and Substance Use Disorders in a Sexual Context in the Man Having Sex With Other Men Population","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","drugs":["ketamine"],"nct":"NCT03753737","nsites":1,"countries":"France","ccs":["FR"],"start":"2018-11-22","src":"https://clinicaltrials.gov/study/NCT03753737","sites":["CSAPA - Service Hépato-gastroentérologie — Lyon, France"],"conds":["Substance Use Disorders"],"condg":["Addiction & substance use"],"enroll":94,"eid":"NCT03753737"},{"id":"study-NCT03367533","cat":"studies","name":"Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial","status":"COMPLETED","phase":"Phase 1","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT03367533","nsites":1,"countries":"United States","ccs":["US"],"start":"2018-11-29","official":"John Krystal, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03367533","sites":["Yale University — New Haven, United States"],"conds":["Depressive Disorder, Major","Post Traumatic Stress Disorder","Bipolar Disorder"],"condg":["Depression","PTSD & trauma","Bipolar"],"enroll":13,"eid":"NCT03367533"},{"id":"study-NCT03666494","cat":"studies","name":"Ketamine Co-induction for Patients With Major Depressive Disorder","status":"UNKNOWN","phase":"Phase 4","sponsor":"University of Saskatchewan","drugs":["ketamine"],"nct":"NCT03666494","nsites":0,"start":"2018-12","official":"Jonathan Gamble, MD (University of Saskatchewan)","src":"https://clinicaltrials.gov/study/NCT03666494","conds":["Ketamine","Depression","Anesthesia"],"condg":["Depression"],"contact":{"n":"Jonathan Gamble, MD","p":"306-655-1183","e":"j_gamble@yahoo.com"},"enroll":50,"eid":"NCT03666494"},{"id":"study-NCT03808259","cat":"studies","name":"A Study to Investigate the Different Modes of (S) Ketamine Administration in Healthy Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine","ketamine"],"nct":"NCT03808259","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2018-12-20","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03808259","sites":["Clinical Pharmacology Unit — Merksem, Belgium"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":96,"eid":"NCT03808259"},{"id":"study-NCT03844906","cat":"studies","name":"A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"Supernus Pharmaceuticals, Inc.","drugs":["ketamine"],"nct":"NCT03844906","nsites":2,"countries":"United States","ccs":["US"],"start":"2018-12-27","src":"https://clinicaltrials.gov/study/NCT03844906","sites":["Sage Investigational Site — Long Beach, United States","Sage Investigational Site — Berlin, United States"],"conds":["Healthy Volunteer"],"condg":["Healthy volunteers"],"enroll":40,"eid":"NCT03844906"},{"id":"study-NCT03721900","cat":"studies","name":"Ketamine for Major Depressive Disorder","status":"UNKNOWN","phase":"Phase 1","sponsor":"Shenox Pharmaceuticals, LLC","drugs":["ketamine"],"nct":"NCT03721900","nsites":3,"countries":"United States","ccs":["US"],"start":"2018-12-28","official":"Mason Freeman, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT03721900","sites":["Clinical Research Site — Gaithersburg, United States","Clinical Research Site — Boston, United States","Clinical Research Site — Dayton, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":14,"eid":"NCT03721900"},{"id":"study-NCT03671070","cat":"studies","name":"Role of Low Dose Epinephrine Boluses In Acute Hypotension","status":"UNKNOWN","phase":"N/A","sponsor":"Assiut University","drugs":["ketamine"],"nct":"NCT03671070","nsites":0,"start":"2019-01-01","src":"https://clinicaltrials.gov/study/NCT03671070","conds":["Hypotension and Shock"],"condg":["Other"],"contact":{"n":"Maher M Ahmed, Professer","p":"+201062052802","e":"maher61ahmed@aun.edu.eg"},"enroll":50,"eid":"NCT03671070"},{"id":"study-NCT03300947","cat":"studies","name":"Psilocybin for Treatment of Obsessive Compulsive Disorder","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Arizona","drugs":["psilocybin"],"nct":"NCT03300947","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-01-02","official":"Francisco A. Moreno, MD (Professor of Psychiatry and Associate Vice President, Diversity and Inclusion)","src":"https://clinicaltrials.gov/study/NCT03300947","sites":["University of Arizona — Tucson, United States"],"conds":["Obsessive-compulsive Disorder (OCD)"],"condg":["OCD"],"enroll":15,"eid":"NCT03300947"},{"id":"study-NCT03429075","cat":"studies","name":"Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms","status":"COMPLETED","phase":"Phase 2","sponsor":"Imperial College London","drugs":["psilocybin"],"nct":"NCT03429075","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2019-01-07","official":"David J Nutt, Medicine (Imperial College London)","src":"https://clinicaltrials.gov/study/NCT03429075","sites":["Imperial College Hammersmith campus — London, United Kingdom"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"enroll":59,"eid":"NCT03429075"},{"id":"study-NCT04162028","cat":"studies","name":"Pre-hospital Nebulized Ketamine for Pain","status":"WITHDRAWN","phase":"Phase 4","sponsor":"Antonios Likourezos","drugs":["ketamine"],"nct":"NCT04162028","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-01-15","src":"https://clinicaltrials.gov/study/NCT04162028","sites":["Maimonides Medical Center — Brooklyn, United States"],"conds":["Pain"],"condg":["Chronic pain & headache"],"eid":"NCT04162028"},{"id":"study-NCT03756129","cat":"studies","name":"Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Novartis Pharmaceuticals","drugs":["ketamine"],"nct":"NCT03756129","nsites":12,"countries":"Spain; United States","ccs":["ES","US"],"start":"2019-02-08","src":"https://clinicaltrials.gov/study/NCT03756129","sites":["Novartis Investigative Site — Birmingham, United States","Novartis Investigative Site — Garden Grove, United States","Novartis Investigative Site — Oakland, United States","Novartis Investigative Site — Bradenton, United States","Novartis Investigative Site — Atlanta, United States","Novartis Investigative Site — Skokie, United States","Novartis Investigative Site — Rockville, United States","Novartis Investigative Site — Berlin, United States"],"conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"enroll":70,"eid":"NCT03756129"},{"id":"study-NCT03792672","cat":"studies","name":"A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)","status":"COMPLETED","phase":"Phase 1","sponsor":"Neurocrine Biosciences","drugs":["ketamine"],"nct":"NCT03792672","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2019-02-11","official":"Medical Director (Millennium Pharmaceuticals, Inc.)","src":"https://clinicaltrials.gov/study/NCT03792672","sites":["CHDR — Leiden, Netherlands"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":24,"eid":"NCT03792672"},{"id":"study-NCT04281628","cat":"studies","name":"Comparison Between Low-dose Ketamine Infusion and Intravenous Morphine","status":"COMPLETED","phase":"Phase 4","sponsor":"Cairo University","drugs":["ketamine"],"nct":"NCT04281628","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2019-02-21","official":"amr wahadan, MD (lecture)","src":"https://clinicaltrials.gov/study/NCT04281628","sites":["Faculty of Medicine, Cairo University. — Cairo, Egypt"],"conds":["Ketamine"],"condg":["Other"],"enroll":80,"eid":"NCT04281628"},{"id":"study-NCT03965858","cat":"studies","name":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Celon Pharma SA","drugs":["esketamine"],"nct":"NCT03965858","nsites":12,"countries":"Poland","ccs":["PL"],"start":"2019-02-25","src":"https://clinicaltrials.gov/study/NCT03965858","sites":["Wojewodzki Szpital im. Jana Pawła II — Bełchatów, Poland","Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych — Bolesławiec, Poland","Samodzielny Publiczny Psychiatryczny Zaklad Opieki Zdrowotnej — Choroszcz, Poland","Szpital Miejski — Elblag, Poland","Uniwersyteckie Centrum Kliniczne — Gdansk, Poland","Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych — Gmina Świecie, Poland","Gornoslaskie Centrum Medyczne — Katowice, Poland","Specjalistyczny Psychiatryczny Zespol Opieki Zdrowotnej — Lodz, Poland"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":88,"eid":"NCT03965858"},{"id":"study-NCT04242914","cat":"studies","name":"The Effect of Intravenous Ketamine on Non Suicidal Self Injuries.","status":"UNKNOWN","phase":"Phase 1/Phase 2","sponsor":"Tel-Aviv Sourasky Medical Center","drugs":["ketamine"],"nct":"NCT04242914","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2019-02-25","official":"Miki Bloch, Prof. (Tel Aviv University)","src":"https://clinicaltrials.gov/study/NCT04242914","sites":["Psychiatric Service, Tel-Aviv Sourasky Medical Center — Tel Aviv, Israel"],"conds":["Non Suicidal Self Injury"],"condg":["Other"],"contact":{"n":"Lior Dvorak, M.D.","p":"972527360974","e":"liordv@tlvmc.gov.il"},"enroll":30,"eid":"NCT04242914"},{"id":"study-NCT03775200","cat":"studies","name":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"COMPASS Pathways","drugs":["psilocybin"],"nct":"NCT03775200","nsites":25,"countries":"Canada; Czechia; Denmark; Germany; Ireland; Netherlands; Portugal; Spain; United Kingdom; United States","ccs":["CA","CZ","DE","DK","ES","GB","IE","NL","PT","US"],"start":"2019-03-01","src":"https://clinicaltrials.gov/study/NCT03775200","sites":["Kadima Neuropsychiatry Institute — La Jolla, United States","Altman Clinical and Translational Research Institute, University of California — San Diego, United States","Stanford Department of Psychiatry — Stanford, United States","Mood and Anxiety Disorders Program Emory University School of Medicine — Atlanta, United States","Ray Worthy Psychiatry LLC — New Orleans, United States","Sheppard Pratt Health System — Baltimore, United States","New York State Psychiatric Institute — New York, United States","UT Center of Excellence on Mood Disorders, University of Texas Health Science Center — Houston, United States"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":233,"eid":"NCT03775200"},{"id":"study-NCT04011592","cat":"studies","name":"Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression","status":"TERMINATED","phase":"Phase 2","sponsor":"The University of Texas Health Science Center, Houston","drugs":["ketamine"],"nct":"NCT04011592","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-03-04","official":"Sudhakar Selvaraj, 713-486-2837 (UTHealth Science Center at Houston)","src":"https://clinicaltrials.gov/study/NCT04011592","sites":["The University of Texas Health Science Center at Houston — Houston, United States"],"conds":["Post Partum Depression"],"condg":["Depression"],"enroll":1,"eid":"NCT04011592"},{"id":"study-NCT03860831","cat":"studies","name":"Intranasal Ketamine and Midazolam Mixture for Procedural Sedation in Children With Mental Disabilities:","status":"UNKNOWN","phase":"Phase 1","sponsor":"Ain Shams University","drugs":["ketamine"],"nct":"NCT03860831","nsites":2,"countries":"Egypt","ccs":["EG"],"start":"2019-03-06","src":"https://clinicaltrials.gov/study/NCT03860831","sites":["Sanaa Farag Mahmoud — Cairo, Egypt","Ainshams hospitals — Cairo, Egypt"],"conds":["Procedural Sedation"],"condg":["Other"],"contact":{"n":"dean of faculty of medicine, MD","p":"0020224821894","e":"dean@med.asu.edu.eg"},"enroll":40,"eid":"NCT03860831"},{"id":"study-NCT03715127","cat":"studies","name":"Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept","status":"COMPLETED","phase":"Phase 2","sponsor":"University of Zurich","drugs":["psilocybin"],"nct":"NCT03715127","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2019-03-11","src":"https://clinicaltrials.gov/study/NCT03715127","sites":["Psychiatrische Universitätsklinik Zürich — Zurich, Switzerland"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"enroll":55,"eid":"NCT03715127"},{"id":"study-NCT03633058","cat":"studies","name":"A Study to Evaluate Ketamine for the Treatment of Rett Syndrome","status":"COMPLETED","phase":"Phase 2","sponsor":"Rett Syndrome Research Trust","drugs":["ketamine"],"nct":"NCT03633058","nsites":7,"countries":"United States","ccs":["US"],"start":"2019-03-12","official":"Jeffrey Neul, MD, PhD (Vanderbilt University Medical Center); Jana von Hehn, PhD (Rett Syndrome Research Trust)","src":"https://clinicaltrials.gov/study/NCT03633058","sites":["University of Alabama Birmingham School of Medicine — Birmingham, United States","Children's Hospital Colorado — Aurora, United States","Rush University Medical Center — Chicago, United States","Boston Children's Hospital — Boston, United States","Children's Hospital of Philadelphia — Philadelphia, United States","Vanderbilt University Medical Center — Nashville, United States","Texas Children's Hospital — Houston, United States"],"conds":["Rett Syndrome"],"condg":["Other"],"enroll":23,"eid":"NCT03633058"},{"id":"study-NCT04640831","cat":"studies","name":"Safety of GH001 in Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"GH Research Ireland Limited","drugs":["DMT"],"nct":"NCT04640831","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2019-03-13","official":"GH Research Clinical Team (GH Research Ireland Limited)","src":"https://clinicaltrials.gov/study/NCT04640831","sites":["Clinical Trial Site — Maastricht, Netherlands"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":22,"eid":"NCT04640831"},{"id":"study-NCT03896256","cat":"studies","name":"Ketamine for Refractory Chronic Migraine: a Pilot Study","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Thomas Jefferson University","drugs":["ketamine"],"nct":"NCT03896256","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-03-22","src":"https://clinicaltrials.gov/study/NCT03896256","sites":["Thomas Jefferson University Hospital — Philadelphia, United States"],"conds":["Migraine Headache With Intractable Migraine"],"condg":["Chronic pain & headache"],"enroll":6,"eid":"NCT03896256"},{"id":"study-NCT03604744","cat":"studies","name":"Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD","psilocybin"],"nct":"NCT03604744","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2019-03-27","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT03604744","sites":["Clinical Pharmacology & Toxicology, University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":28,"eid":"NCT03604744"},{"id":"study-NCT03965871","cat":"studies","name":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Celon Pharma SA","drugs":["esketamine"],"nct":"NCT03965871","nsites":12,"countries":"Poland","ccs":["PL"],"start":"2019-03-28","src":"https://clinicaltrials.gov/study/NCT03965871","sites":["Wojewodzki Szpital im. Jana Pawła II — Bełchatów, Poland","Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych — Bolesławiec, Poland","Samodzielny Publiczny Psychiatryczny Zaklad Opieki Zdrowotnej — Choroszcz, Poland","Szpital Miejski — Elblag, Poland","Uniwersyteckie Centrum Kliniczne — Gdansk, Poland","Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych — Gmina Świecie, Poland","Gornoslaskie Centrum Medyczne — Katowice, Poland","Specjalistyczny Psychiatryczny Zespol Opieki Zdrowotnej — Lodz, Poland"],"conds":["Bipolar Depression"],"condg":["Depression","Bipolar"],"enroll":88,"eid":"NCT03965871"},{"id":"study-NCT03852797","cat":"studies","name":"Spontaneous and Oxytocin-induced Contractility After Exposure to Intravenous Anesthetic Agents: an In-vitro Study in Human Myometrium","status":"COMPLETED","phase":"N/A","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","drugs":["ketamine"],"nct":"NCT03852797","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2019-03-28","official":"Mrinalini Balki, MD (MOUNT SINAI HOSPITAL)","src":"https://clinicaltrials.gov/study/NCT03852797","sites":["Mount Sinai Hospital — Toronto, Canada"],"conds":["Postpartum Hemorrhage"],"condg":["Other"],"enroll":33,"eid":"NCT03852797"},{"id":"study-NCT03806985","cat":"studies","name":"Effects of Psilocybin in Concussion Headache","status":"TERMINATED","phase":"Phase 1","sponsor":"Yale University","drugs":["psilocybin"],"nct":"NCT03806985","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-03-28","src":"https://clinicaltrials.gov/study/NCT03806985","sites":["VA Connecticut Healthcare System — West Haven, United States"],"conds":["Post-Traumatic Headache"],"condg":["PTSD & trauma","Chronic pain & headache"],"enroll":12,"eid":"NCT03806985"},{"id":"study-NCT04427605","cat":"studies","name":"Efficacy and Safety of Continuous Infusion of Ketamine in Pediatric Intensive Care Unit (KISS Study)","status":"COMPLETED","sponsor":"Azienda Ospedaliera di Padova","drugs":["ketamine"],"nct":"NCT04427605","nsites":1,"countries":"Italy","ccs":["IT"],"start":"2019-04-01","official":"angela amigoni, MD (Azienda Ospedaliera di Padova); andrea pettenazzo, MD (Azienda Ospedaliera di Padova)","src":"https://clinicaltrials.gov/study/NCT04427605","sites":["Azienda Ospedale Università Padova — Padova, Italy"],"conds":["Analgesia","Ketamine Toxicity","Bronchospasm","Sedation Complication"],"condg":["Other"],"enroll":57,"eid":"NCT04427605"},{"id":"study-NCT03502551","cat":"studies","name":"ED Treatment of Suicidal Patients With Ketamine Infusion","status":"WITHDRAWN","phase":"Phase 2","sponsor":"University of California, Davis","drugs":["ketamine"],"nct":"NCT03502551","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-04-01","official":"Aimee Moulin, MD (University of California, Davis)","src":"https://clinicaltrials.gov/study/NCT03502551","sites":["University of California Davis Medical Center — Sacramento, United States"],"conds":["Suicide","Suicidal Ideation"],"condg":["Other"],"eid":"NCT03502551"},{"id":"study-NCT03960658","cat":"studies","name":"Ketamine and Prolonged Exposure in PTSD","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Minneapolis Veterans Affairs Medical Center","drugs":["ketamine"],"nct":"NCT03960658","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-04-03","official":"Paulo R Shiroma, MD (Minneapolis Veterans Affairs Medical Center)","src":"https://clinicaltrials.gov/study/NCT03960658","sites":["Minneapolis VA Medical Center — Minneapolis, United States"],"conds":["Post-traumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":12,"eid":"NCT03960658"},{"id":"study-NCT03788889","cat":"studies","name":"Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine","status":"WITHDRAWN","phase":"Phase 4","sponsor":"Santa Barbara Cottage Hospital","drugs":["ketamine"],"nct":"NCT03788889","nsites":0,"start":"2019-04-12","official":"Noah Stites-Hallet, MD (Santa Barbara Cottage Hospital)","src":"https://clinicaltrials.gov/study/NCT03788889","conds":["Alcohol Withdrawal Syndrome"],"condg":["Addiction & substance use"],"eid":"NCT03788889"},{"id":"study-NCT03909607","cat":"studies","name":"Nebulized Sub-dissociative Dose Ketamine for Treating Pain","status":"COMPLETED","phase":"Phase 4","sponsor":"Antonios Likourezos","drugs":["ketamine"],"nct":"NCT03909607","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-04-16","official":"Sergey Motov, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT03909607","sites":["Maimonides Medical Center — Brooklyn, United States"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":120,"eid":"NCT03909607"},{"id":"study-NCT03934710","cat":"studies","name":"Mood Effects of Serotonin Agonists Extended","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Chicago","drugs":["LSD"],"nct":"NCT03934710","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-04-20","official":"Harriet de Wit (University of Chicago)","src":"https://clinicaltrials.gov/study/NCT03934710","sites":["Matthew Bona — Chicago, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":56,"eid":"NCT03934710"},{"id":"study-NCT04508894","cat":"studies","name":"Ketamine Versus Dexmedetomidine in Supraclavicular Brachial Plexus Block","status":"COMPLETED","phase":"N/A","sponsor":"Minia University","drugs":["ketamine"],"nct":"NCT04508894","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2019-04-21","official":"Haidy S Mansour, MD (assistant professor of Anesthesia and Surgical Intensive Care)","src":"https://clinicaltrials.gov/study/NCT04508894","sites":["Minya University — Minya, Egypt"],"conds":["Supraclavicular Brachial Plexus Block"],"condg":["Other"],"enroll":75,"eid":"NCT04508894"},{"id":"study-NCT03631875","cat":"studies","name":"Co-induction Ketamine-propofol: Effects on Laryngeal Mask Airway Insertion Conditions in Children","status":"COMPLETED","phase":"Phase 4","sponsor":"University Hospital, Mahdia","drugs":["ketamine"],"nct":"NCT03631875","nsites":1,"countries":"Tunisia","ccs":["TN"],"start":"2019-05-01","official":"ali majdoub, professor (Ministery of Health)","src":"https://clinicaltrials.gov/study/NCT03631875","sites":["Mahdia University Hospital — Mahdia, Tunisia"],"conds":["Anesthesia Intubation Complication"],"condg":["Other"],"enroll":120,"eid":"NCT03631875"},{"id":"study-NCT03947099","cat":"studies","name":"Ketamine Infusion Therapy for the Treatment of PTSD in Paramedics","status":"COMPLETED","sponsor":"Klarisana Physician Services PLLC","drugs":["ketamine"],"nct":"NCT03947099","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-05-02","official":"Carl J Bonnett, MD (Klarisana Physician Services PLLC)","src":"https://clinicaltrials.gov/study/NCT03947099","sites":["Klarisana — San Antonio, United States"],"conds":["Stress Disorders, Post-Traumatic","Anxiety Disorders"],"condg":["Anxiety","PTSD & trauma"],"enroll":7,"eid":"NCT03947099"},{"id":"study-NCT03896230","cat":"studies","name":"Ketamine for Pain in the Emergency Department","status":"TERMINATED","phase":"Phase 4","sponsor":"Hackensack Meridian Health","drugs":["ketamine"],"nct":"NCT03896230","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-05-03","src":"https://clinicaltrials.gov/study/NCT03896230","sites":["Hackensack University Medical Center — Hackensack, United States"],"conds":["Acute Pain"],"condg":["Chronic pain & headache"],"enroll":11,"eid":"NCT03896230"},{"id":"study-NCT03969316","cat":"studies","name":"Transversus Abdominis Plane Block Versus Quadratus Lumborum Block in The Pediatric Population Undergoing Orchiopexy","status":"COMPLETED","phase":"N/A","sponsor":"Istanbul University - Cerrahpasa","drugs":["ketamine"],"nct":"NCT03969316","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2019-05-10","official":"Ozgecan P Zanbak, MD (Istanbul University - Cerrahpasa); Ayse C Tutuncu, MD,Prof (Istanbul University - Cerrahpasa)","src":"https://clinicaltrials.gov/study/NCT03969316","sites":["Istanbul University - Cerrahpasa — Istanbul, Turkey"],"conds":["Pain, Postoperative"],"condg":["Chronic pain & headache"],"enroll":102,"eid":"NCT03969316"},{"id":"study-NCT03950817","cat":"studies","name":"Nebulized Sub-dissociative Dose Ketamine at Three Different Dosing Regimens for Treating Acute Pain in the Pediatric ED","status":"COMPLETED","phase":"Phase 4","sponsor":"Antonios Likourezos","drugs":["ketamine"],"nct":"NCT03950817","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-05-13","official":"John Marshall, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT03950817","sites":["Maimonides Medical Center — Brooklyn, United States"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":80,"eid":"NCT03950817"},{"id":"study-NCT03977675","cat":"studies","name":"The Role of HNKs in the Antidepressant Effect of Ketamine","status":"TERMINATED","phase":"Phase 1","sponsor":"Columbia University","drugs":["ketamine"],"nct":"NCT03977675","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-05-15","official":"Michael Grunebaum, MD (New York Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT03977675","sites":["New York State Psychiatric Institute — New York, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":8,"eid":"NCT03977675"},{"id":"study-NCT05209217","cat":"studies","name":"Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder","status":"UNKNOWN","sponsor":"Mclean Hospital","drugs":["ketamine"],"nct":"NCT05209217","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-06-04","official":"Martin H Teicher, MD, PhD (Mclean Hospital)","src":"https://clinicaltrials.gov/study/NCT05209217","sites":["McLean Hospital — Belmont, United States"],"conds":["Bipolar Disorder"],"condg":["Bipolar"],"contact":{"n":"Elizabeth A Bolger, MA","p":"617-855-2964","e":"lbolger@mclean.harvard.edu"},"enroll":20,"eid":"NCT05209217"},{"id":"study-NCT05320991","cat":"studies","name":"Effects of Ketamine on Mentalizing and Metacognition in Healthy Volunteers","status":"COMPLETED","phase":"Phase 4","sponsor":"University Hospital, Bonn","drugs":["ketamine"],"nct":"NCT05320991","nsites":1,"countries":"Germany","ccs":["DE"],"start":"2019-06-15","src":"https://clinicaltrials.gov/study/NCT05320991","sites":["Department of Psychiatry and Psychotherapy, University Hospital Bonn — Bonn, Germany"],"conds":["Ketamine-Induced Psychotic Disorder","Social Cognition","Theory of Mind"],"condg":["Other"],"enroll":70,"eid":"NCT05320991"},{"id":"study-NCT03396601","cat":"studies","name":"NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression","status":"UNKNOWN","phase":"Phase 3","sponsor":"NeuroRx, Inc.","drugs":["ketamine"],"nct":"NCT03396601","nsites":2,"countries":"United States","ccs":["US"],"start":"2019-06-25","official":"Martin Brecher, MD (VP, Clinical Development, NeuroRx, Inc.)","src":"https://clinicaltrials.gov/study/NCT03396601","sites":["Research Centers of America — Hollywood, United States","JP Smith Hospital — Fort Worth, United States"],"conds":["Bipolar Depression","Suicidal Ideation"],"condg":["Depression","Bipolar"],"enroll":150,"eid":"NCT03396601"},{"id":"study-NCT04216888","cat":"studies","name":"Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Dan Iosifescu","drugs":["ketamine"],"nct":"NCT04216888","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-06-26","official":"Dan Iosifescu, MD, MSc (Nathan Kline Institute)","src":"https://clinicaltrials.gov/study/NCT04216888","sites":["Nathan Kline Institute — Orangeburg, United States"],"conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"enroll":9,"eid":"NCT04216888"},{"id":"study-NCT04099771","cat":"studies","name":"Ketamine for Mood Disorders With Suicidal Ideation","status":"UNKNOWN","phase":"EARLY_Phase 1","sponsor":"The Miriam Hospital","drugs":["ketamine"],"nct":"NCT04099771","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-07-01","official":"Francesca Beaudoin, MD PhD (Rhode Island Hospital)","src":"https://clinicaltrials.gov/study/NCT04099771","sites":["The Miriam Hospital — Providence, United States"],"conds":["Depressive Disorder, Major","Suicidal Ideation"],"condg":["Depression"],"contact":{"n":"Principal Investigator","p":"4014444000","e":"Kelly.Wong@Lifespan.org"},"enroll":20,"eid":"NCT04099771"},{"id":"study-NCT03912974","cat":"studies","name":"Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["psilocybin"],"nct":"NCT03912974","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2019-07-04","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT03912974","sites":["University Hospital Basel, Clinical Trial Unit — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":27,"eid":"NCT03912974"},{"id":"study-NCT03897361","cat":"studies","name":"Stem Cell Gene Therapy for Cystinosis","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"University of California, San Diego","drugs":["LSD"],"nct":"NCT03897361","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-07-08","official":"Stephanie Cherqui, Ph.D. (University of California, San Diego)","src":"https://clinicaltrials.gov/study/NCT03897361","sites":["University of California San Diego — La Jolla, United States"],"conds":["Lysosomal Storage Diseases","Cystinosis"],"condg":["Other"],"enroll":7,"eid":"NCT03897361"},{"id":"study-NCT03889756","cat":"studies","name":"Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy","status":"TERMINATED","phase":"Phase 2/Phase 3","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT03889756","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-07-17","official":"Michael H. Bloch, MD (Yale University); Jennifer Dwyer, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03889756","sites":["Yale Child Study Center — New Haven, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":3,"eid":"NCT03889756"},{"id":"study-NCT06021756","cat":"studies","name":"Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson's Disease","status":"UNKNOWN","phase":"Phase 1","sponsor":"University of Arizona","drugs":["ketamine"],"nct":"NCT06021756","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-07-28","official":"Scott J Sherman (University of Arizona Health Sciences Center - Dep. of Neurology)","src":"https://clinicaltrials.gov/study/NCT06021756","sites":["Scott J Sherman — Tucson, United States"],"conds":["Levodopa-Induced Dyskinesia","Parkinson's Disease"],"condg":["Neurology & cognition"],"enroll":9,"eid":"NCT06021756"},{"id":"study-NCT03051945","cat":"studies","name":"Endogenous Opioid Modulation by Ketamine","status":"WITHDRAWN","phase":"Phase 3","sponsor":"University of Utah","drugs":["ketamine"],"nct":"NCT03051945","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-08","src":"https://clinicaltrials.gov/study/NCT03051945","sites":["Huntsman Cancer Institute — Salt Lake City, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"eid":"NCT03051945"},{"id":"study-NCT04013958","cat":"studies","name":"Comparison of Treatment by IM Ketamine to IV Ketamine in Patients With Renal Colic","status":"UNKNOWN","phase":"Phase 3","sponsor":"Tel-Aviv Sourasky Medical Center","drugs":["ketamine"],"nct":"NCT04013958","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2019-08-01","src":"https://clinicaltrials.gov/study/NCT04013958","sites":["Tel Aviv Sourasky Medical Center, department of Emergency Medicine — Tel Aviv, Israel"],"conds":["Acute Pain","Renal Colic"],"condg":["Chronic pain & headache"],"contact":{"n":"Daniel Trotzky, MD","p":"+97236973829","e":"danieltro@tlvmc.gov.il"},"enroll":100,"eid":"NCT04013958"},{"id":"study-NCT03962725","cat":"studies","name":"Avoiding Neuromuscular Blockers to Reduce Complications","status":"TERMINATED","phase":"Phase 4","sponsor":"Beth Israel Deaconess Medical Center","drugs":["ketamine"],"nct":"NCT03962725","nsites":2,"countries":"United States","ccs":["US"],"start":"2019-08-07","official":"Maximilian S Schaefer, MD (Beth Israel Deaconess Medical Center)","src":"https://clinicaltrials.gov/study/NCT03962725","sites":["Massachusetts General Hospital — Boston, United States","Beth Israel Deaconess Medical Center — Boston, United States"],"conds":["Respiratory Failure","Respiratory Infection","Aspiration Pneumonia","Pneumonitis","Atelectasis","Bronchospasm"],"condg":["Other"],"enroll":3,"eid":"NCT03962725"},{"id":"study-NCT04053036","cat":"studies","name":"Effects of Drugs on Responses to Brain and Emotional Processes","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University of Chicago","drugs":["MDMA"],"nct":"NCT04053036","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-08-08","official":"Harriet de Wit (Principal Investigator)","src":"https://clinicaltrials.gov/study/NCT04053036","sites":["University of Chicago — Chicago, United States"],"conds":["Autism Spectrum Disorder","Healthy"],"condg":["Healthy volunteers"],"enroll":22,"eid":"NCT04053036"},{"id":"study-NCT04824157","cat":"studies","name":"Ketamine IV Classic Protocol : Five Years Follow up","status":"COMPLETED","sponsor":"Sheba Medical Center","drugs":["ketamine"],"nct":"NCT04824157","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2019-08-08","src":"https://clinicaltrials.gov/study/NCT04824157","sites":["The Chaim Sheba Medical Center — Tel Litwinsky, Israel"],"conds":["Major Depressive Disorder","Drug Abuse","Medications","Relapse"],"condg":["Depression"],"enroll":11,"eid":"NCT04824157"},{"id":"study-NCT04173962","cat":"studies","name":"Effect of Ketamine on Laboratory-induced Stress in Healthy Subjects","status":"COMPLETED","phase":"Phase 2","sponsor":"Icahn School of Medicine at Mount Sinai","drugs":["ketamine"],"nct":"NCT04173962","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-08-08","official":"James Murrough, MD, PhD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT04173962","sites":["Icahn School of Medicine at Mount Sinai — New York, United States"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":24,"eid":"NCT04173962"},{"id":"study-NCT03475277","cat":"studies","name":"Stanford Regulating Circuits of the Brain Study- Ketamine","status":"COMPLETED","sponsor":"Stanford University","drugs":["ketamine"],"nct":"NCT03475277","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-08-19","official":"Leanne M Williams, PhD (Study PI)","src":"https://clinicaltrials.gov/study/NCT03475277","sites":["Stanford Psychiatry — Palo Alto, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":13,"eid":"NCT03475277"},{"id":"study-NCT04016740","cat":"studies","name":"The PATHFINDER Study: A Feasibility Trial","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Beth Israel Deaconess Medical Center","drugs":["ketamine"],"nct":"NCT04016740","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-08-20","official":"Balachundhar Subramaniam, MD, MPH (Beth Israel Deaconess Medical Center)","src":"https://clinicaltrials.gov/study/NCT04016740","sites":["Beth Israel Deaconess Medical Center — Boston, United States"],"conds":["Coronary Artery Disease","Delirium"],"condg":["Other"],"enroll":22,"eid":"NCT04016740"},{"id":"study-NCT03861988","cat":"studies","name":"Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery","status":"COMPLETED","phase":"Phase 4","sponsor":"Stanford University","drugs":["ketamine"],"nct":"NCT03861988","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-08-22","official":"Boris D Heifets, MD, PhD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT03861988","sites":["Stanford University — Stanford, United States"],"conds":["Major Depressive Disorder","Surgery","Orthopedic Disorder"],"condg":["Depression"],"enroll":45,"eid":"NCT03861988"},{"id":"study-NCT04052568","cat":"studies","name":"Effects of Psilocybin in Anorexia Nervosa","status":"COMPLETED","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT04052568","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-08-26","official":"Roland Griffiths, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT04052568","sites":["Behavioral Pharmacology Research Unit — Baltimore, United States"],"conds":["Anorexia Nervosa"],"condg":["Eating disorders"],"enroll":22,"eid":"NCT04052568"},{"id":"study-NCT03336398","cat":"studies","name":"Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus","status":"COMPLETED","phase":"Phase 2","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT03336398","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-09-01","official":"Diana Martinez (NYSPI/Columbia University)","src":"https://clinicaltrials.gov/study/NCT03336398","sites":["1051 Riverside Drive — New York, United States"],"conds":["Tinnitus"],"condg":["Other"],"enroll":42,"eid":"NCT03336398"},{"id":"study-NCT06185127","cat":"studies","name":"Dexmedetomidine-ketamine Combination Versus Fentanyl-midazolam During Bronchoscopy","status":"COMPLETED","phase":"Phase 3","sponsor":"University of Patras","drugs":["ketamine"],"nct":"NCT06185127","nsites":1,"countries":"Greece","ccs":["GR"],"start":"2019-09-01","official":"Sotirios Fouzas, MD, PhD (University of Patras)","src":"https://clinicaltrials.gov/study/NCT06185127","sites":["Naval Hospital — Athens, Greece"],"conds":["Lung Diseases","Diagnosis","Anesthesia"],"condg":["Other"],"enroll":50,"eid":"NCT06185127"},{"id":"study-NCT04048226","cat":"studies","name":"Dexmedetomidine-Ketamine Infusion in Breast Surgeries","status":"COMPLETED","phase":"Phase 4","sponsor":"Tanta University","drugs":["ketamine"],"nct":"NCT04048226","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2019-09-01","official":"Sameh Ismaiel, M.D (Lecturer of Anesthesia and Intensive Care, Tanta University)","src":"https://clinicaltrials.gov/study/NCT04048226","sites":["Tanta University hospitals — Tanta, Egypt"],"conds":["Total Intravenous Anesthesia"],"condg":["Other"],"enroll":103,"eid":"NCT04048226"},{"id":"study-NCT04814888","cat":"studies","name":"3D Airway Model for Pediatric Patients","status":"COMPLETED","sponsor":"Pusan National University Yangsan Hospital","drugs":["ketamine"],"nct":"NCT04814888","nsites":1,"countries":"South Korea","ccs":["KR"],"start":"2019-09-03","official":"Hee Young Kim (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University)","src":"https://clinicaltrials.gov/study/NCT04814888","sites":["Pusan National University Yangsan Hospital — Yangsan, South Korea"],"conds":["Congenital Heart Disease"],"condg":["Other"],"enroll":35,"eid":"NCT04814888"},{"id":"study-NCT04103892","cat":"studies","name":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","status":"COMPLETED","phase":"Phase 2","sponsor":"Clexio Biosciences Ltd.","drugs":["esketamine","ketamine"],"nct":"NCT04103892","nsites":46,"countries":"Puerto Rico; United States","ccs":["PR","US"],"start":"2019-09-05","src":"https://clinicaltrials.gov/study/NCT04103892","sites":["Clinical Site 126 — Bentonville, United States","Clinical Site 120 — Little Rock, United States","Clinical Site 129 — Little Rock, United States","Clinical Site 141 — Anaheim, United States","Clinical Site 115 — Bellflower, United States","Clinical Site 132 — Lafayette, United States","Clinical Site 117 — Oakland, United States","Clinical Site 113 — Oceanside, United States"],"conds":["Adjunctive Treatment of Major Depressive Disorder"],"condg":["Depression"],"enroll":146,"eid":"NCT04103892"},{"id":"study-NCT04070521","cat":"studies","name":"EEG Monitoring in the Emergency Department","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","drugs":["ketamine"],"nct":"NCT04070521","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-09-06","official":"Patrick L Purdon, Ph.D. (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT04070521","sites":["Massachusetts General Hospital — Boston, United States"],"conds":["Drug Overdose","Substance Abuse","Alcohol Abuse"],"condg":["Addiction & substance use"],"enroll":10,"eid":"NCT04070521"},{"id":"study-NCT04471818","cat":"studies","name":"Ketamine or Placebo in Patients With Major Depression and Advanced Cancer","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Instituto Nacional de Cancerologia de Mexico","drugs":["ketamine"],"nct":"NCT04471818","nsites":1,"countries":"Mexico","ccs":["MX"],"start":"2019-09-19","src":"https://clinicaltrials.gov/study/NCT04471818","sites":["Instituto Nacional de Cancerología (INCan) — Mexico City, Mexico"],"conds":["Major Depressive Disorder","Advanced Cancer"],"condg":["Depression","Cancer-related distress"],"enroll":19,"eid":"NCT04471818"},{"id":"study-NCT04199468","cat":"studies","name":"THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis","status":"COMPLETED","phase":"Phase 1","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT04199468","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-09-24","official":"Rajiv Radhakrishnan, M.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT04199468","sites":["VA Connecticut Healthcare System — West Haven, United States"],"conds":["Cannabis","Ketamine"],"condg":["Addiction & substance use"],"enroll":22,"eid":"NCT04199468"},{"id":"study-NCT04032301","cat":"studies","name":"Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Minnesota","drugs":["ketamine"],"nct":"NCT04032301","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-09-30","official":"Cristina S Albott, MD, MA (Minneapolis Veterans Affairs Medical Center)","src":"https://clinicaltrials.gov/study/NCT04032301","sites":["Minneapolis Veterans Affairs Health Care System — Minneapolis, United States"],"conds":["Post-Traumatic Stress Disorders","Major Depressive Disorder"],"condg":["Depression","PTSD & trauma"],"enroll":67,"eid":"NCT04032301"},{"id":"study-NCT06191770","cat":"studies","name":"Comparison of Morphine With Nalbuphine in a Multimodal Approach for Pain Relief in Patients Undergoing Gynecological Procedures: Randomized Controlled Double Blind Clinical Trial","status":"COMPLETED","phase":"N/A","sponsor":"Aga Khan University Hospital, Pakistan","drugs":["ketamine"],"nct":"NCT06191770","nsites":1,"countries":"Pakistan","ccs":["PK"],"start":"2019-10-01","src":"https://clinicaltrials.gov/study/NCT06191770","sites":["Gauhar Afshan — Karachi, Pakistan"],"conds":["Pain, Acute"],"condg":["Chronic pain & headache"],"enroll":66,"eid":"NCT06191770"},{"id":"study-NCT04022226","cat":"studies","name":"EEG Characteristics in ECT","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University of New Mexico","drugs":["ketamine"],"nct":"NCT04022226","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-10-01","src":"https://clinicaltrials.gov/study/NCT04022226","sites":["University of New Mexico Mental Health Center — Albuquerque, United States"],"conds":["Electroconvulsive Therapy","Direct Current Electroencephalogram","Ketamine","Spreadind Depression"],"condg":["Depression"],"enroll":11,"eid":"NCT04022226"},{"id":"study-NCT04120870","cat":"studies","name":"Comparison of Ketamine and Etomidate During Rapid Sequence Intubation in Trauma Patients","status":"TERMINATED","phase":"N/A","sponsor":"Ajou University School of Medicine","drugs":["ketamine"],"nct":"NCT04120870","nsites":1,"countries":"South Korea","ccs":["KR"],"start":"2019-10-01","official":"In Kyong Yi, MD (Ajou University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT04120870","sites":["Ajou university school of medicine — Suwon, South Korea"],"conds":["Trauma","Shock, Traumatic"],"condg":["PTSD & trauma"],"enroll":10,"eid":"NCT04120870"},{"id":"study-NCT03527316","cat":"studies","name":"Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT03527316","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2019-10-18","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT03527316","sites":["Clinical Pharmacology & Toxicology, University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":30,"eid":"NCT03527316"},{"id":"study-NCT04266288","cat":"studies","name":"Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department","status":"COMPLETED","phase":"Phase 4","sponsor":"MercyOne Des Moines Medical Center","drugs":["ketamine"],"nct":"NCT04266288","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-10-18","official":"Kathryn Bress, PharmD (MercyOne Des Moines Medical Center); Adnan Iqbal, MD (MercyOne Des Moines Medical Center)","src":"https://clinicaltrials.gov/study/NCT04266288","sites":["MercyOne Des Moines Medical Center — Des Moines, United States"],"conds":["Depression","Depression Severe","Depression Acute","Depression and Suicide","Suicidal Ideation"],"condg":["Depression"],"enroll":29,"eid":"NCT04266288"},{"id":"study-NCT04108234","cat":"studies","name":"A Study of HR071603(Ketamine Nasal Spray) in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","drugs":["ketamine"],"nct":"NCT04108234","nsites":1,"countries":"China","ccs":["CN"],"start":"2019-10-24","src":"https://clinicaltrials.gov/study/NCT04108234","sites":["Beijing AnDing hospital affiliated to Capital Medical University — Beijing, China"],"conds":["Depression"],"condg":["Depression"],"enroll":50,"eid":"NCT04108234"},{"id":"study-NCT03866252","cat":"studies","name":"LSD Therapy for Persons Suffering From Major Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD"],"nct":"NCT03866252","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2019-11-01","official":"Dr. med. Felix Müller, MD (Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT03866252","sites":["Universitäre Psychiatrische Kliniken — Basel, Switzerland"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":60,"eid":"NCT03866252"},{"id":"study-NCT04698603","cat":"studies","name":"Clinical Study of GH001 in Depression","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"GH Research Ireland Limited","drugs":["DMT"],"nct":"NCT04698603","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2019-11-12","official":"GH Research Clinical Team (GH Research Ireland Limited)","src":"https://clinicaltrials.gov/study/NCT04698603","sites":["Clinical Trial Site — Maastricht, Netherlands"],"conds":["Treatment Resistant Depression","Major Depressive Disorder","Depression"],"condg":["Depression"],"enroll":16,"eid":"NCT04698603"},{"id":"study-NCT05386069","cat":"studies","name":"Does a Non-Opioid Multimodal Pain (NOMO) Protocol Decrease Narcotic Use","status":"COMPLETED","phase":"Phase 3","sponsor":"Prisma Health-Upstate","drugs":["ketamine"],"nct":"NCT05386069","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-11-15","official":"Hema Brazell, MD (Prisma Health)","src":"https://clinicaltrials.gov/study/NCT05386069","sites":["Prisma Health - Upstate — Greenville, United States"],"conds":["Opioid Use"],"condg":["Addiction & substance use"],"enroll":10,"eid":"NCT05386069"},{"id":"study-NCT03959852","cat":"studies","name":"Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain","status":"TERMINATED","phase":"Phase 4","sponsor":"Mercy Health Ohio","drugs":["ketamine"],"nct":"NCT03959852","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-11-18","official":"David Gemmel (Director of Research)","src":"https://clinicaltrials.gov/study/NCT03959852","sites":["St. Elizabeth Boardman Hospital — Boardman, United States"],"conds":["Pain, Acute"],"condg":["Chronic pain & headache"],"enroll":6,"eid":"NCT03959852"},{"id":"study-NCT04179266","cat":"studies","name":"Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"CCH Pharmaceuticals","drugs":["ketamine"],"nct":"NCT04179266","nsites":1,"countries":"Denmark","ccs":["DK"],"start":"2019-11-20","src":"https://clinicaltrials.gov/study/NCT04179266","sites":["Danish Headache Center — Glostrup Municipality, Denmark"],"conds":["Cluster Headache"],"condg":["Chronic pain & headache"],"enroll":23,"eid":"NCT04179266"},{"id":"study-NCT03511833","cat":"studies","name":"Comparison of Treatment by IN Ketamine to IV Morphine in Acute Pain","status":"UNKNOWN","phase":"Phase 3","sponsor":"Tel-Aviv Sourasky Medical Center","drugs":["ketamine"],"nct":"NCT03511833","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2019-12","src":"https://clinicaltrials.gov/study/NCT03511833","sites":["Tel Aviv Sourasky Medical Center, department of Emergency Medicine — Tel Aviv, Israel"],"conds":["Acute Traumatic Pain"],"condg":["PTSD & trauma","Chronic pain & headache"],"contact":{"n":"Pinchas Halpern, MD","p":"+97236973829","e":"DR_HALPERIN@tlvmc.gov.il"},"enroll":120,"eid":"NCT03511833"},{"id":"study-NCT03436121","cat":"studies","name":"Single-dose Ketamine for the Reduction of Pain and Depression in the Emergency Department","status":"WITHDRAWN","phase":"Phase 2/Phase 3","sponsor":"Maria Pacella","drugs":["ketamine"],"nct":"NCT03436121","nsites":0,"start":"2019-12","official":"Maria L Pacella, PhD (University of Pittsburgh)","src":"https://clinicaltrials.gov/study/NCT03436121","conds":["Acute Pain","Depression"],"condg":["Depression","Chronic pain & headache"],"eid":"NCT03436121"},{"id":"study-NCT03852160","cat":"studies","name":"A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant…","status":"WITHDRAWN","phase":"Phase 3","sponsor":"Janssen-Cilag International NV","drugs":["esketamine"],"nct":"NCT03852160","nsites":0,"start":"2019-12-01","official":"Janssen-Cilag International NV Clinical Trial (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT03852160","conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"eid":"NCT03852160"},{"id":"study-NCT04209296","cat":"studies","name":"Chart Review of Patients Undergoing Ketamine Infusions","status":"COMPLETED","sponsor":"Brain and Cognition Discovery Foundation","drugs":["esketamine","ketamine"],"nct":"NCT04209296","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2019-12-03","official":"Roger S McIntyre, MD (Brain and Cognition Discovery Foundation)","src":"https://clinicaltrials.gov/study/NCT04209296","sites":["Canadian Rapid Treatment Centre of Excellence — Mississauga, Canada"],"conds":["Major Depressive Disorder","Bipolar Disorder","Obsessive-Compulsive Disorder","Post Traumatic Stress Disorder"],"condg":["Depression","PTSD & trauma","OCD","Bipolar"],"enroll":891,"eid":"NCT04209296"},{"id":"study-NCT04226963","cat":"studies","name":"A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders","status":"COMPLETED","sponsor":"Medical University of Gdansk","drugs":["ketamine"],"nct":"NCT04226963","nsites":1,"countries":"Poland","ccs":["PL"],"start":"2019-12-04","src":"https://clinicaltrials.gov/study/NCT04226963","sites":["Department of Psychiatry, Medical University of Gdańsk — Gdansk, Poland"],"conds":["Treatment Resistant Depression","Bipolar Depression","Ketamine","Major Depressive Disorder"],"condg":["Depression","Bipolar"],"enroll":80,"eid":"NCT04226963"},{"id":"study-NCT04238039","cat":"studies","name":"Ketamine Long Therm Follow Up Study","status":"UNKNOWN","sponsor":"The Chaim Sheba Medical Center","drugs":["ketamine"],"nct":"NCT04238039","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2019-12-14","src":"https://clinicaltrials.gov/study/NCT04238039","sites":["Revital Amiaz — Ramat Gan, Israel"],"conds":["Followin Ketamine Treatment"],"condg":["Other"],"enroll":16,"eid":"NCT04238039"},{"id":"study-NCT04698772","cat":"studies","name":"Patient Satisfaction With Subdissociative Dose Ketamine Versus Morphine for Emergency Department Pain Control","status":"COMPLETED","sponsor":"CHRISTUS Health","drugs":["ketamine"],"nct":"NCT04698772","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-12-19","official":"Rebekka Lee, DO (CHRISTUS Health)","src":"https://clinicaltrials.gov/study/NCT04698772","sites":["CHRISTUS — Corpus Christi, United States"],"conds":["Abdominal Pain"],"condg":["Chronic pain & headache"],"enroll":32,"eid":"NCT04698772"},{"id":"study-NCT04150757","cat":"studies","name":"Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED","status":"TERMINATED","phase":"Phase 3","sponsor":"Abigail Nixon","drugs":["ketamine"],"nct":"NCT04150757","nsites":2,"countries":"United States","ccs":["US"],"start":"2019-12-19","src":"https://clinicaltrials.gov/study/NCT04150757","sites":["Jacobi Medical Center — The Bronx, United States","JACOBI — The Bronx, United States"],"conds":["Sickle Cell Disease","Vaso-Occlusive Pain Episode in Sickle Cell Disease","Vaso-occlusive Crisis","Ketamine","Intranasal Ketamine","Analgesia"],"condg":["Chronic pain & headache"],"enroll":5,"eid":"NCT04150757"},{"id":"study-NCT04154150","cat":"studies","name":"Ketamine + Cognitive Training for Suicidality in the Medical Setting: Pilot","status":"TERMINATED","phase":"Phase 4","sponsor":"Rebecca Price","drugs":["ketamine"],"nct":"NCT04154150","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-12-19","src":"https://clinicaltrials.gov/study/NCT04154150","sites":["University of Pittsburgh — Pittsburgh, United States"],"conds":["Suicide, Attempted"],"condg":["Other"],"enroll":16,"eid":"NCT04154150"},{"id":"study-NCT04285684","cat":"studies","name":"The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"The Ketamine Research Foundation","drugs":["ketamine"],"nct":"NCT04285684","nsites":1,"countries":"United States","ccs":["US"],"start":"2019-12-20","official":"Philip E Wolfson, MD (Ketamine Research Foundation)","src":"https://clinicaltrials.gov/study/NCT04285684","sites":["Ketamine Research Foundation — San Anselmo, United States"],"conds":["Ketamine","Lactation"],"condg":["Other"],"enroll":4,"eid":"NCT04285684"},{"id":"study-NCT03338205","cat":"studies","name":"The Role of Ketamine as an Adjuvant Therapy for Children With Acute Status Asthmaticus","status":"WITHDRAWN","phase":"Phase 3","sponsor":"Augusta University","drugs":["ketamine"],"nct":"NCT03338205","nsites":0,"start":"2020-01","src":"https://clinicaltrials.gov/study/NCT03338205","conds":["Status Asthmaticus"],"condg":["Other"],"eid":"NCT03338205"},{"id":"study-NCT07097025","cat":"studies","name":"2-Year Study of Vagus Nerve Stimulation for Higher-Grade Treatment-Resistant Depression: Clinical Outcomes and Policy Recommendation","status":"COMPLETED","sponsor":"Dr.Yoav Domany","drugs":["esketamine","ketamine"],"nct":"NCT07097025","nsites":2,"countries":"Israel","ccs":["IL"],"start":"2020-01-01","src":"https://clinicaltrials.gov/study/NCT07097025","sites":["Maaynei Hayeshua medical center — Bnei Brak, Israel","Lev Hasharon Medical Center — Netanya, Israel"],"conds":["Treatment Resistant Depression (TRD)","Depression - Major Depressive Disorder","Bipolar Depression"],"condg":["Depression","Bipolar"],"enroll":19,"eid":"NCT07097025"},{"id":"study-NCT03788694","cat":"studies","name":"Intranasal Ketamine for Suicidal Ideation in Veterans","status":"WITHDRAWN","phase":"EARLY_Phase 1","sponsor":"Bronx Veterans Medical Research Foundation, Inc","drugs":["ketamine"],"nct":"NCT03788694","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-01-01","src":"https://clinicaltrials.gov/study/NCT03788694","sites":["James J. Peters VA Medical Center — The Bronx, United States"],"conds":["Suicidal Ideation"],"condg":["Other"],"eid":"NCT03788694"},{"id":"study-NCT04082858","cat":"studies","name":"Ketamine Interleaved With Electroconvulsive Therapy for Depression","status":"TERMINATED","phase":"Phase 1","sponsor":"St Patrick's Hospital, Ireland","drugs":["ketamine"],"nct":"NCT04082858","nsites":1,"countries":"Ireland","ccs":["IE"],"start":"2020-01-06","official":"Declan McLoughlin, PhD (St Patrick's Hospital)","src":"https://clinicaltrials.gov/study/NCT04082858","sites":["St Patrick's University Hospital — Dublin, Ireland"],"conds":["Depression"],"condg":["Depression"],"enroll":3,"eid":"NCT04082858"},{"id":"study-NCT03560102","cat":"studies","name":"Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer","status":"TERMINATED","phase":"N/A","sponsor":"Kantonsspital Winterthur KSW","drugs":["ketamine"],"nct":"NCT03560102","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2020-01-13","official":"Christoph A Binkert, MD (Kantonsspital Winterthur KSW)","src":"https://clinicaltrials.gov/study/NCT03560102","sites":["Kantonsspital Winterthur — Winterthur, Switzerland"],"conds":["Breast Cancer, Invasive Ductal"],"condg":["Cancer-related distress"],"enroll":1,"eid":"NCT03560102"},{"id":"study-NCT04260607","cat":"studies","name":"Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department","status":"TERMINATED","phase":"Phase 3","sponsor":"Naval Medical Center Camp Lejeune","drugs":["ketamine"],"nct":"NCT04260607","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-01-14","official":"Nathan H Butler, DO (Naval Medical Center Camp Lejeune)","src":"https://clinicaltrials.gov/study/NCT04260607","sites":["Naval Medical Center Camp Lejeune — Marine Corps Base Camp Lejeune, United States"],"conds":["Suicide","Suicide Threat","Depression Severe"],"condg":["Depression"],"enroll":1,"eid":"NCT04260607"},{"id":"study-NCT04280055","cat":"studies","name":"Prophylactic Effects of Psilocybin on Chronic Cluster Headache","status":"TERMINATED","phase":"Phase 1/Phase 2","sponsor":"Gitte Moos Knudsen","drugs":["psilocybin"],"nct":"NCT04280055","nsites":1,"countries":"Denmark","ccs":["DK"],"start":"2020-01-21","official":"Gitte Moos Knudsen, MD, DMSc (Neurobiology Research Unit, Rigshospitalet)","src":"https://clinicaltrials.gov/study/NCT04280055","sites":["Neurobiology Research Unit, Rigshospitalet — Copenhagen, Denmark"],"conds":["Cluster Headache"],"condg":["Chronic pain & headache"],"enroll":10,"eid":"NCT04280055"},{"id":"study-NCT03866174","cat":"studies","name":"A Study of Psilocybin for Major Depressive Disorder (MDD)","status":"COMPLETED","phase":"Phase 2","sponsor":"Usona Institute","drugs":["psilocybin"],"nct":"NCT03866174","nsites":11,"countries":"United States","ccs":["US"],"start":"2020-01-23","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT03866174","sites":["University of California, San Francisco — San Francisco, United States","Pacific Neuroscience Institute — Santa Monica, United States","Yale University — New Haven, United States","Segal Trials — Lauderhill, United States","Emory University — Atlanta, United States","Great Lakes Clinical Trials — Chicago, United States","Johns Hopkins University — Baltimore, United States","Hassman Research Institute — Berlin, United States"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"enroll":347,"eid":"NCT03866174"},{"id":"study-NCT04803448","cat":"studies","name":"Patient Doctor Lies","status":"COMPLETED","phase":"N/A","sponsor":"University of Utah","drugs":["MDMA"],"nct":"NCT04803448","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-02-12","official":"Mark Keith, PhD (Brigham Young University)","src":"https://clinicaltrials.gov/study/NCT04803448","sites":["Brigham Young University — Provo, United States"],"conds":["Patient Lying","Privacy Statements","Risk Statements","Benefit Statements","Patient Lie Detection"],"condg":["Other"],"enroll":619,"eid":"NCT04803448"},{"id":"study-NCT04282746","cat":"studies","name":"A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine","ketamine"],"nct":"NCT04282746","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2020-02-18","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04282746","sites":["SGS Life Science Services — Antwerp, Belgium"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":17,"eid":"NCT04282746"},{"id":"study-NCT04156035","cat":"studies","name":"Ketamine-Induced Brain Changes and Their Modulation by Lamotrigine","status":"COMPLETED","phase":"N/A","sponsor":"Charite University, Berlin, Germany","drugs":["ketamine"],"nct":"NCT04156035","nsites":1,"countries":"Germany","ccs":["DE"],"start":"2020-03-10","official":"Simone Grimm, PhD (Medical School Berlin)","src":"https://clinicaltrials.gov/study/NCT04156035","sites":["Medical School Berlin — Berlin, Germany"],"conds":["Emotions"],"condg":["Other"],"enroll":75,"eid":"NCT04156035"},{"id":"study-NCT05604794","cat":"studies","name":"A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health","status":"COMPLETED","phase":"Phase 4","sponsor":"Field Trip Health","drugs":["ketamine"],"nct":"NCT05604794","nsites":11,"countries":"Canada; United States","ccs":["CA","US"],"start":"2020-03-13","official":"Ryan Yermus, MD (Field Trip Health); Chris Lo, PhD (University of Toronto)","src":"https://clinicaltrials.gov/study/NCT05604794","sites":["LA Centre — Los Angeles, United States","San Diego Centre — San Diego, United States","Washington DC Centre — Washington D.C., United States","Atlanta Centre — Atlanta, United States","Chicago Centre — Chicago, United States","NYC Centre — New York, United States","Houston Centre — Houston, United States","Seattle Centre — Seattle, United States"],"conds":["Depression","Anxiety","Post Traumatic Stress Disorder"],"condg":["Depression","Anxiety","PTSD & trauma"],"enroll":1806,"eid":"NCT05604794"},{"id":"study-NCT04769297","cat":"studies","name":"Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic","status":"UNKNOWN","phase":"Phase 4","sponsor":"Limbic Medical","drugs":["ketamine"],"nct":"NCT04769297","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-04-15","official":"Andre Atoian, MD (Limbic Medical)","src":"https://clinicaltrials.gov/study/NCT04769297","sites":["Limbic Medical — Toluca Lake, United States"],"conds":["Acute Stress Disorder"],"condg":["Other"],"enroll":30,"eid":"NCT04769297"},{"id":"study-NCT04365985","cat":"studies","name":"Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19","status":"TERMINATED","phase":"Phase 2","sponsor":"Corewell Health East","drugs":["ketamine"],"nct":"NCT04365985","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-04-29","official":"Matthew Sims, MD PhD (Beaumont Health)","src":"https://clinicaltrials.gov/study/NCT04365985","sites":["William Beaumont Hospital — Royal Oak, United States"],"conds":["COVID-19","Acute Respiratory Distress Syndrome","Severe Acute Respiratory Syndrome (SARS)","Coronavirus Infections"],"condg":["Other"],"enroll":70,"eid":"NCT04365985"},{"id":"study-NCT04352621","cat":"studies","name":"Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)","status":"UNKNOWN","phase":"Phase 4","sponsor":"University of Cincinnati","drugs":["ketamine"],"nct":"NCT04352621","nsites":0,"start":"2020-05-01","src":"https://clinicaltrials.gov/study/NCT04352621","conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Jade Lord","p":"513-558-4997","e":"lordje@ucmail.uc.edu"},"enroll":20,"eid":"NCT04352621"},{"id":"study-NCT04205890","cat":"studies","name":"Intravenous Ketamine Effects on Functional Neuroanatomy","status":"WITHDRAWN","phase":"Phase 1","sponsor":"Neurological Associates of West Los Angeles","drugs":["ketamine"],"nct":"NCT04205890","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-05-02","official":"Sheldon Jordan, MD (The Neurological Associates of West Los Angeles); Taylor Kuhn, PhD (The Neurological Associates of West Los Angeles)","src":"https://clinicaltrials.gov/study/NCT04205890","sites":["Neurological Associates of West Los Angeles — Santa Monica, United States"],"conds":["Depression"],"condg":["Depression"],"eid":"NCT04205890"},{"id":"study-NCT04227756","cat":"studies","name":"Comparative Acute Effects of LSD, Psilocybin and Mescaline","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD","mescaline","psilocybin"],"nct":"NCT04227756","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2020-05-19","official":"Matthias E. Liechti, Prof. (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT04227756","sites":["University Hospital Basel, Clinical Trial Unit — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":32,"eid":"NCT04227756"},{"id":"study-NCT04141501","cat":"studies","name":"Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients","status":"COMPLETED","phase":"Phase 2","sponsor":"University of Zurich","drugs":["psilocybin"],"nct":"NCT04141501","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2020-06-08","official":"Katrin Preller, Dr. (Psychiatric University Clinic)","src":"https://clinicaltrials.gov/study/NCT04141501","sites":["Psychiatrische Universitätsklinik Zürich — Zurich, Switzerland"],"conds":["Alcohol Use Disorder"],"condg":["Addiction & substance use"],"enroll":37,"eid":"NCT04141501"},{"id":"study-NCT03927378","cat":"studies","name":"Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression","status":"COMPLETED","phase":"N/A","sponsor":"Peking University First Hospital","drugs":["esketamine","ketamine"],"nct":"NCT03927378","nsites":7,"countries":"China","ccs":["CN"],"start":"2020-06-19","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT03927378","sites":["Peking University First Hospital — Beijing, China","Beijing Tiantan Hospital — Beijing, China","Peking University International Hospital — Beijing, China","Hunan Provincial Maternal and Child Health Care Hospital — Changsha, China","Huaian Maternal and Child Health Care Hospital — Huaian, China","Nanjing Maternal and Child Health Care Hospital — Nanjing, China","Women's Hospital School Of Medicine Zhejiang University — Hanzhou, China"],"conds":["Prenatal Depression","Ketamine","Postpartum Depression"],"condg":["Depression"],"enroll":364,"eid":"NCT03927378"},{"id":"study-NCT04414943","cat":"studies","name":"Low-dose S-ketamine in Women With Prenatal Depression","status":"COMPLETED","phase":"N/A","sponsor":"Peking University First Hospital","drugs":["esketamine","ketamine"],"nct":"NCT04414943","nsites":7,"countries":"China","ccs":["CN"],"start":"2020-06-19","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT04414943","sites":["Peking University First Hospital — Beijing, China","Beijing Tiantan Hospital — Beijing, China","Peking University International Hospital — Beijing, China","Hunan Provincial Maternal and Child Health Care Hospital — Changsha, China","Huaian Maternal and Child Health Care Hospital — Huaian, China","Nanjing Maternal and Child Health Care Hospital — Nanjing, China","Women's Hospital School Of Medicine Zhejiang University — Hangzhou, China"],"conds":["Prenatal Depression","Ketamine","Postpartum Depression"],"condg":["Depression"],"enroll":364,"eid":"NCT04414943"},{"id":"study-NCT04300621","cat":"studies","name":"A Study of Different Oral Thin Film (S)-Ketamine Formulations for Sublingual Administration in Healthy Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine","ketamine"],"nct":"NCT04300621","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2020-06-19","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04300621","sites":["SGS Life Science Services — Antwerp, Belgium"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":16,"eid":"NCT04300621"},{"id":"study-NCT04030169","cat":"studies","name":"Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study","status":"COMPLETED","phase":"Phase 2","sponsor":"MAPS Europe B.V.","drugs":["MDMA"],"nct":"NCT04030169","nsites":6,"countries":"Czechia; Germany; Netherlands; Norway; United Kingdom","ccs":["CZ","DE","GB","NL","NO"],"start":"2020-06-24","official":"Prof. Dr. Eric Vermetten, MD (Leiden University Medical Center)","src":"https://clinicaltrials.gov/study/NCT04030169","sites":["NUDZ - National Institute of Mental Health — Klecany, Czechia","Charité - Universitätsmedizin, Berlin Campus Benjamin Franklin — Berlin, Germany","Stichting Centrum '45/Arq — Oegstgeest, Netherlands","Sykehuset Østfold Hf, DPS Norder — Moss, Norway","University Hospital of Wales - Research Facility — Cardiff, United Kingdom","The Institute of Psychiatry, Psychology and Neuroscience — London, United Kingdom"],"conds":["PTSD"],"condg":["PTSD & trauma"],"enroll":21,"eid":"NCT04030169"},{"id":"study-NCT05796232","cat":"studies","name":"Pharmacogenetics of Ketamine in Children","status":"UNKNOWN","sponsor":"IRCCS Burlo Garofolo","drugs":["ketamine"],"nct":"NCT05796232","nsites":1,"countries":"Italy","ccs":["IT"],"start":"2020-06-26","official":"Egidio Barbi, MD (IRCCS materno infantile Burlo Garofolo)","src":"https://clinicaltrials.gov/study/NCT05796232","sites":["IRCCS Burlo Garofolo — Trieste, Italy"],"conds":["Procedural Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Egidio Barbi, MD","p":"+390403785251","e":"egidio.barbi@burlo.trieste.it"},"enroll":250,"eid":"NCT05796232"},{"id":"study-NCT04283058","cat":"studies","name":"Low Dose Ketamine Infusion for the Treatment of Resistant Depression","status":"WITHDRAWN","sponsor":"Loma Linda University","drugs":["ketamine"],"nct":"NCT04283058","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-06-29","official":"Patricia Radovich, PhD (Loma Linda University Medical Center)","src":"https://clinicaltrials.gov/study/NCT04283058","sites":["Loma Linda University Medical Center — Loma Linda, United States"],"conds":["Depression"],"condg":["Depression"],"eid":"NCT04283058"},{"id":"study-NCT04353921","cat":"studies","name":"PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder","status":"TERMINATED","sponsor":"Usona Institute","drugs":["psilocybin"],"nct":"NCT04353921","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-06-30","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT04353921","sites":["Innovative Clinical Research, Inc. (formerly Segal Trials) — Lauderhill, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":26,"eid":"NCT04353921"},{"id":"study-NCT04330183","cat":"studies","name":"Low Dose Ketamine and Acute Pain Crisis","status":"COMPLETED","phase":"Phase 4","sponsor":"Rhode Island Hospital","drugs":["ketamine"],"nct":"NCT04330183","nsites":2,"countries":"United States","ccs":["US"],"start":"2020-07-01","official":"Taneisha Wison, MD, ScM (Brown Emergency Medicine)","src":"https://clinicaltrials.gov/study/NCT04330183","sites":["Rhode Island Hospital — Providence, United States","The Miriam Hospital — Providence, United States"],"conds":["Sickle Cell Crisis"],"condg":["Other"],"enroll":20,"eid":"NCT04330183"},{"id":"study-NCT04129086","cat":"studies","name":"Ketamine for Acute Pain Management After Trauma","status":"COMPLETED","phase":"Phase 4","sponsor":"The University of Texas Health Science Center, Houston","drugs":["ketamine"],"nct":"NCT04129086","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-07-01","official":"John P Harvin, MD (The University of Texas Health Science Center, Houston)","src":"https://clinicaltrials.gov/study/NCT04129086","sites":["The University of Texas Health Science Center at Houston — Houston, United States"],"conds":["Trauma Injury","Pain","Opioid Use"],"condg":["PTSD & trauma","Addiction & substance use","Chronic pain & headache"],"enroll":305,"eid":"NCT04129086"},{"id":"study-NCT04997967","cat":"studies","name":"Ketofol Versus Propofol in Urgent ERCP for Acute Cholangitis","status":"UNKNOWN","phase":"Phase 4","sponsor":"Assiut University","drugs":["ketamine"],"nct":"NCT04997967","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2020-07-01","official":"Haidi Ramadan, PhD (faculty of medicine)","src":"https://clinicaltrials.gov/study/NCT04997967","sites":["Assiut University — Asyut, Egypt"],"conds":["Conscious Sedation Failure During Procedure"],"condg":["Other"],"contact":{"n":"Haidi Ramadan, Phd","p":"+201028186710","e":"haidikaram@aun.edu.eg"},"enroll":100,"eid":"NCT04997967"},{"id":"study-NCT03853577","cat":"studies","name":"Characterization of Altered Waking States of Consciousness in Healthy Humans","status":"COMPLETED","phase":"N/A","sponsor":"University of Zurich","drugs":["psilocybin"],"nct":"NCT03853577","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2020-07-08","official":"Franz X. Vollenweider, Prof, MD (Psychiatric Hospital, University of Zurich)","src":"https://clinicaltrials.gov/study/NCT03853577","sites":["Psychiatrische Universitätsklinik Zürich — Zurich, Switzerland"],"conds":["Altered Waking States of Consciousness in Healthy Humans"],"condg":["Healthy volunteers"],"enroll":25,"eid":"NCT03853577"},{"id":"study-NCT06165848","cat":"studies","name":"Effects Of Different Anesthesia Applications On Mood, Depression, And Anxiety Levels In Burn Patients","status":"COMPLETED","sponsor":"T.C. Sağlık Bakanlığı Ankara Bilkent Şehir Hastanesi","drugs":["ketamine"],"nct":"NCT06165848","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2020-07-09","official":"Ayça Tuba Özcan (Ankara Bilkent Şehir Hastanesi)","src":"https://clinicaltrials.gov/study/NCT06165848","sites":["Ankara Bilkent Şehir Hastanesi — Ankara, Turkey"],"conds":["Burn Unspecified Degree","Deep Sedation"],"condg":["Other"],"enroll":67,"eid":"NCT06165848"},{"id":"study-NCT04682782","cat":"studies","name":"Intraoperative Small-dose Esketamine Infusion for Pain Control in Burn Patients","status":"UNKNOWN","phase":"Phase 4","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","drugs":["esketamine"],"nct":"NCT04682782","nsites":1,"countries":"China","ccs":["CN"],"start":"2020-07-14","official":"Min YAN, MD (2nd Affiliated Hospital, School of Medicine, Zhejiang University, China)","src":"https://clinicaltrials.gov/study/NCT04682782","sites":["2nd affiliated hospital, School of Medicine, Zhejiang Universtiy, China — Hangzhou, China"],"conds":["Burns"],"condg":["Other"],"contact":{"n":"Qingyu SHI, MD","p":"+8613777564585","e":"shiqinyu_001@zju.edu.cn"},"enroll":26,"eid":"NCT04682782"},{"id":"study-NCT04485702","cat":"studies","name":"Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine","status":"COMPLETED","phase":"Phase 1","sponsor":"Melt Pharmaceuticals","drugs":["ketamine"],"nct":"NCT04485702","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-07-20","official":"Cynthia Zamora, MD (Worldwide Clinical Trials)","src":"https://clinicaltrials.gov/study/NCT04485702","sites":["WWCT — San Antonio, United States"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":17,"eid":"NCT04485702"},{"id":"study-NCT04519957","cat":"studies","name":"Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)","status":"COMPLETED","sponsor":"COMPASS Pathways","drugs":["psilocybin"],"nct":"NCT04519957","nsites":8,"countries":"Czechia; Ireland; Netherlands; United Kingdom; United States","ccs":["CZ","GB","IE","NL","US"],"start":"2020-07-20","src":"https://clinicaltrials.gov/study/NCT04519957","sites":["Kadima Neuropsychiatry Institute — La Jolla, United States","Altman Clinical and Translational Research Institute, University of California — San Diego, United States","Mood and Anxiety Disorders Program Emory University School of Medicine — Atlanta, United States","UT Center of Excellence on Mood Disorders, University of Texas Health Science Center — Houston, United States","National Institute of Mental Health Czech Republic — Klecany, Czechia","Sheaf House, Tallaght Hospital — Dublin, Ireland","Groningen University Medical Centre — Groningen, Netherlands","Kings College London, Institute of Psychiatry, Psychology and Neurology — London, United Kingdom"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":66,"eid":"NCT04519957"},{"id":"study-NCT04399070","cat":"studies","name":"The Effect of S-ketamine for Patients Undergoing Electroconvulsive Therapy (ECT)","status":"UNKNOWN","phase":"N/A","sponsor":"Yan Qiu","drugs":["esketamine","ketamine"],"nct":"NCT04399070","nsites":1,"countries":"China","ccs":["CN"],"start":"2020-08-01","official":"Guizhi Du, Doctor (West China Hospital of Sichuan University, Department of Anesthesiology)","src":"https://clinicaltrials.gov/study/NCT04399070","sites":["West China Hospital of Sichuan University, Department of Anesthesiology — Chengdu, China"],"conds":["Depression, Bipolar","Depression, Unipolar","Major Depressive Disorder","Manic-Depressive - Now Depressed"],"condg":["Depression","Bipolar"],"contact":{"n":"Yan Qiu, Doctor","p":"+8618980606269","e":"qiuyan_mz@126.com"},"enroll":150,"eid":"NCT04399070"},{"id":"study-NCT04116528","cat":"studies","name":"Opiate Suicide Study in Patients With Major Depression","status":"COMPLETED","phase":"Phase 3","sponsor":"Stanford University","drugs":["ketamine"],"nct":"NCT04116528","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-08-01","official":"Alan F. Schatzberg (Stanford University)","src":"https://clinicaltrials.gov/study/NCT04116528","sites":["Stanford University School of Medicine — Stanford, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":50,"eid":"NCT04116528"},{"id":"study-NCT04739865","cat":"studies","name":"The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"COMPASS Pathways","drugs":["psilocybin"],"nct":"NCT04739865","nsites":2,"countries":"Ireland; United States","ccs":["IE","US"],"start":"2020-08-10","official":"Guy Goodwin (University of Oxford)","src":"https://clinicaltrials.gov/study/NCT04739865","sites":["Kadima Neuropsychiatry Institute — La Jolla, United States","Sheaf House, Tallaght Hospital — Dublin, Ireland"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":19,"eid":"NCT04739865"},{"id":"study-NCT04239963","cat":"studies","name":"Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression","status":"COMPLETED","sponsor":"Mclean Hospital","drugs":["ketamine"],"nct":"NCT04239963","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-08-17","official":"Diego Pizzagalli, PhD (Mclean Hospital)","src":"https://clinicaltrials.gov/study/NCT04239963","sites":["McLean Hospital — Belmont, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":60,"eid":"NCT04239963"},{"id":"study-NCT04388774","cat":"studies","name":"Low-Dose Ketamine in Children With ADNP Syndrome","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Alexander Kolevzon","drugs":["ketamine"],"nct":"NCT04388774","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-08-19","official":"Alexander Kolevzon, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT04388774","sites":["Icahn School of Medicine at Mount Sinai — New York, United States"],"conds":["ADNP Syndrome"],"condg":["Other"],"enroll":10,"eid":"NCT04388774"},{"id":"study-NCT04338321","cat":"studies","name":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With…","status":"COMPLETED","phase":"Phase 3","sponsor":"Janssen-Cilag International NV","drugs":["esketamine"],"nct":"NCT04338321","nsites":171,"countries":"Argentina; Austria; Belgium; Brazil; Bulgaria; Czechia; Denmark; Finland; Germany; Greece; Hungary; Israel; Kazakhstan; Malaysia; Netherlands; Norway; Poland; Portugal; South Africa; South Korea; Sweden; Taiwan; Turkey (Türkiye); United Arab Emirates","ccs":["AE","AR","AT","BE","BG","BR","CZ","DE","DK","FI","GR","HU","IL","KR","KZ","MY","NL","NO","PL","PT","SE","TR","TW","ZA"],"start":"2020-08-21","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","sites":["Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales — Buenos Aires, Argentina","FunDaMos — Buenos Aires, Argentina","CEN Consultorios Especializados en Neurociencias — Córdoba, Argentina","Fundacion Lennox — Córdoba, Argentina","Instituto Medico DAMIC — Córdoba, Argentina","Sanatorio Prof Leon S Morra S A — Córdoba, Argentina","Instituto de Neurociencias San Agustin — La Plata, Argentina","C I A P Centro de investigacion y Asistencia en Psiquiatria — Rosario, Argentina"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"enroll":676,"eid":"NCT04338321"},{"id":"study-NCT05506787","cat":"studies","name":"The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease","status":"COMPLETED","phase":"Phase 4","sponsor":"Jinling Hospital, China","drugs":["esketamine"],"nct":"NCT05506787","nsites":1,"countries":"China","ccs":["CN"],"start":"2020-09-01","official":"Ji Qing (Anesthesiology Department, Jinling Hospital Affiliated to Nanjing University)","src":"https://clinicaltrials.gov/study/NCT05506787","sites":["Anesthesiology Department, Jinling Hospital Affiliated to Nanjing University — Nanjing, China"],"conds":["Crohn Disease","Depression","Esketamine"],"condg":["Depression"],"enroll":120,"eid":"NCT05506787"},{"id":"study-NCT04101474","cat":"studies","name":"Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality","status":"COMPLETED","phase":"N/A","sponsor":"Assiut University","drugs":["ketamine"],"nct":"NCT04101474","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2020-09-01","src":"https://clinicaltrials.gov/study/NCT04101474","sites":["Assiut university — Asyut, Egypt"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":36,"eid":"NCT04101474"},{"id":"study-NCT04593563","cat":"studies","name":"The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder","status":"UNKNOWN","phase":"Phase 2","sponsor":"Maryland Oncology Hematology, PA","drugs":["psilocybin"],"nct":"NCT04593563","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-09-01","src":"https://clinicaltrials.gov/study/NCT04593563","sites":["Maryland Oncology Hematology PA — Rockville, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":30,"eid":"NCT04593563"},{"id":"study-NCT04077437","cat":"studies","name":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","status":"COMPLETED","phase":"Phase 3","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT04077437","nsites":14,"countries":"Israel; United States","ccs":["IL","US"],"start":"2020-09-02","src":"https://clinicaltrials.gov/study/NCT04077437","sites":["New School Research — Los Angeles, United States","San Francisco Insight and Integration Center — San Francisco, United States","UCSF — San Francisco, United States","Aguazul Bluewater, Inc. — Boulder, United States","Wholeness Center — Fort Collins, United States","University of Connecticut — Farmington, United States","Ray Worthy Psychiatry LLC — New Orleans, United States","Trauma Research Foundation — Boston, United States"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":121,"eid":"NCT04077437"},{"id":"study-NCT04544228","cat":"studies","name":"Ketamine or Neostigmine for Serratus Anterior Plane Block in Modified Radical Mastectomy","status":"COMPLETED","phase":"N/A","sponsor":"Cairo University","drugs":["ketamine"],"nct":"NCT04544228","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2020-09-05","official":"Bassant abdelhamid, M.D. (Cairo University)","src":"https://clinicaltrials.gov/study/NCT04544228","sites":["Faculty of medicine-Cairo University — Cairo, Egypt"],"conds":["Postoperative Pain"],"condg":["Chronic pain & headache"],"enroll":90,"eid":"NCT04544228"},{"id":"study-NCT04476446","cat":"studies","name":"An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives","status":"COMPLETED","phase":"Phase 3","sponsor":"Janssen-Cilag, S.A.","drugs":["esketamine"],"nct":"NCT04476446","nsites":8,"countries":"Mexico","ccs":["MX"],"start":"2020-09-08","official":"Janssen-Cilag, S.A. Clinical Trial (Janssen-Cilag, S.A.)","src":"https://clinicaltrials.gov/study/NCT04476446","sites":["Clínica de Ansiedad, Depresión y Estrés CADE, S. de R.L. de C.V. — Guadalajara, Mexico","Gabipros SC. — Mexico City, Mexico","Avalon Vinculación Médica En Salud Mental — Mexico City, Mexico","Hospital Espanol — Mexico City, Mexico","Ketamine Mexico S. de RL. de C.V. — Mexico City, Mexico","Ángel Alberto Ruiz Chow — México, Mexico","Especialidades en Neuropsiquiatría de México S.C. — México, Mexico","Clínica de Interdisciplinas Congnitivo Conductuales — México, Mexico"],"conds":["Depression"],"condg":["Depression"],"enroll":41,"eid":"NCT04476446"},{"id":"study-NCT04488874","cat":"studies","name":"Sodium Lactate and Brain Relaxation (LSD)","status":"COMPLETED","phase":"Phase 3","sponsor":"Centre Hospitalier Universitaire de Besancon","drugs":["LSD"],"nct":"NCT04488874","nsites":1,"countries":"France","ccs":["FR"],"start":"2020-09-29","src":"https://clinicaltrials.gov/study/NCT04488874","sites":["CHU de Besançon — Besançon, France"],"conds":["Sodium Lactate","Intracranial Hypertension","Brain Relaxation"],"condg":["Other"],"enroll":50,"eid":"NCT04488874"},{"id":"study-NCT05586126","cat":"studies","name":"AnaConDa-therapy in COVID-19 Patients","status":"TERMINATED","sponsor":"Jeroen Bosch Ziekenhuis","drugs":["esketamine","ketamine"],"nct":"NCT05586126","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2020-10-01","official":"D. van Nieuwenhuizen, RN (Jeroen Bosch Hospital)","src":"https://clinicaltrials.gov/study/NCT05586126","sites":["Jeroen Bosch Ziekenhuis — 's-Hertogenbosch, Netherlands"],"conds":["COVID-19","SARS CoV-2"],"condg":["Other"],"enroll":42,"eid":"NCT05586126"},{"id":"study-NCT04527757","cat":"studies","name":"Duration of Anaesthesia Induction in Paediatric Patients: Prospective Observational Trial","status":"COMPLETED","sponsor":"Brno University Hospital","drugs":["ketamine"],"nct":"NCT04527757","nsites":1,"countries":"Czechia","ccs":["CZ"],"start":"2020-10-01","official":"Petr Štourač, prof. MD., Ph.D. (Faculty of medicince Masaryk University and University Hospital Brno)","src":"https://clinicaltrials.gov/study/NCT04527757","sites":["University Hospital Brno — Brno, Czechia"],"conds":["Anaesthesia Induction"],"condg":["Other"],"enroll":1000,"eid":"NCT04527757"},{"id":"study-NCT04700592","cat":"studies","name":"A Comparison of Gabapentin and Ketamine in Acute and Chronic Pain After Inguinal Hernia Repair","status":"COMPLETED","phase":"N/A","sponsor":"University Tunis El Manar","drugs":["ketamine"],"nct":"NCT04700592","nsites":1,"countries":"Tunisia","ccs":["TN"],"start":"2020-10-02","official":"mechaal benali, PROFESSOR (university manar Tunis tunisia)","src":"https://clinicaltrials.gov/study/NCT04700592","sites":["Mechaal Benali — Nabeul, Tunisia"],"conds":["Chronic Pain Following Surgical Procedure for Cancer"],"condg":["Cancer-related distress","Chronic pain & headache"],"enroll":60,"eid":"NCT04700592"},{"id":"study-NCT04587778","cat":"studies","name":"Imaging Neural Correlates of Ketamine Using PET/MR","status":"UNKNOWN","phase":"Phase 1","sponsor":"Medical University of Vienna","drugs":["esketamine","ketamine"],"nct":"NCT04587778","nsites":1,"countries":"Austria","ccs":["AT"],"start":"2020-10-05","src":"https://clinicaltrials.gov/study/NCT04587778","sites":["Medical University of Vienna — Vienna, Austria"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Rupert Lanzenberger, Prof.","p":"004314040035760","e":"rupert.lanzenberger@meduniwien.ac.at"},"enroll":65,"eid":"NCT04587778"},{"id":"study-NCT04091971","cat":"studies","name":"Ketamine Treatment Effects on Synaptic Plasticity in Depression","status":"COMPLETED","phase":"Phase 4","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT04091971","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-10-09","official":"Jeffrey Miller, MD (New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT04091971","sites":["New York State Psychiatric Institute/Columbia University — New York, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":9,"eid":"NCT04091971"},{"id":"study-NCT04436250","cat":"studies","name":"ESKETamine for FIBromyalgia Treatment","status":"TERMINATED","phase":"N/A","sponsor":"Grand Hôpital de Charleroi","drugs":["esketamine","ketamine"],"nct":"NCT04436250","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2020-10-10","official":"Jean-Paul Lechat, MD (Grand Hôpital de Charleroi)","src":"https://clinicaltrials.gov/study/NCT04436250","sites":["Grand Hôpital de Charleroi — Gilly, Belgium"],"conds":["Fibromyalgia"],"condg":["Chronic pain & headache"],"enroll":23,"eid":"NCT04436250"},{"id":"study-NCT04558294","cat":"studies","name":"Effect of Ketanserin After LSD Administration","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD"],"nct":"NCT04558294","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2020-10-16","official":"Matthias E Liechti, Dr., MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT04558294","sites":["Clinical Pharmacology & Toxicology, University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":24,"eid":"NCT04558294"},{"id":"study-NCT04576637","cat":"studies","name":"Neurophysiological Monitoring and Videolaryngoscopy","status":"UNKNOWN","phase":"N/A","sponsor":"Rabin Medical Center","drugs":["ketamine"],"nct":"NCT04576637","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2020-10-21","official":"Leonid O Eidelman (Rabin Medical Center)","src":"https://clinicaltrials.gov/study/NCT04576637","sites":["Rabin Medical Center/Beilinson Campus — Petah Tikva, Israel"],"conds":["Postsynaptic Potential Summation"],"condg":["Other"],"contact":{"n":"Leonid Eidelman","p":"97239376850","e":"leidelman@clalit.org.il"},"enroll":20,"eid":"NCT04576637"},{"id":"study-NCT04504175","cat":"studies","name":"Ketamine for Older Adults Pilot","status":"COMPLETED","phase":"Phase 4","sponsor":"Washington University School of Medicine","drugs":["ketamine"],"nct":"NCT04504175","nsites":5,"countries":"Canada; United States","ccs":["CA","US"],"start":"2020-10-22","official":"Eric Lenze, MD (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT04504175","sites":["UCLA Late-Life Mood, Stress, and Wellness Research Program — Los Angeles, United States","Washington University School of Medicine Healthy Mind Lab — St Louis, United States","Columbia University Adult and Late Life Depression Clinic — New York, United States","UPMC Late-Life Depression, Evaluation, Prevention, and Treatment Program — Pittsburgh, United States","University Health Network — Toronto, Canada"],"conds":["Treatment Resistant Depression","Refractory Depression","Therapy-Resistant Depression","Late Life Depression","Geriatric Depression"],"condg":["Depression"],"enroll":25,"eid":"NCT04504175"},{"id":"study-NCT04003948","cat":"studies","name":"Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification","status":"COMPLETED","phase":"Phase 2","sponsor":"International Center for Ethnobotanical Education, Research, and Service","drugs":["ibogaine"],"nct":"NCT04003948","nsites":1,"countries":"Spain","ccs":["ES"],"start":"2020-10-28","official":"José Carlos Bouso, PhD (International Center for Ethnobotanical Education, Research, and Service); Tre Borràs, MD (Hospital Universitari Sant Joan de Reus)","src":"https://clinicaltrials.gov/study/NCT04003948","sites":["Hospital Universitari Sant Joan — Reus, Spain"],"conds":["Drug Dependence","Drug Use Disorders","Opioid Dependence"],"condg":["Addiction & substance use"],"enroll":20,"eid":"NCT04003948"},{"id":"study-NCT04429685","cat":"studies","name":"The Effects of Low Dose Ketamine on Cardiovascular Function","status":"TERMINATED","phase":"Phase 1","sponsor":"University of Texas Southwestern Medical Center","drugs":["ketamine"],"nct":"NCT04429685","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-11-01","src":"https://clinicaltrials.gov/study/NCT04429685","sites":["University of Texas Southwestern Medical Center — Dallas, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":6,"eid":"NCT04429685"},{"id":"study-NCT05046275","cat":"studies","name":"MCR Syndrome in Quebec : Results From NuAge Study","status":"UNKNOWN","sponsor":"Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal","drugs":["LSD"],"nct":"NCT05046275","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2020-11-03","src":"https://clinicaltrials.gov/study/NCT05046275","sites":["CRIUGM — Montreal, Canada"],"conds":["Motoric Cognitive Risk Syndrome","Aging Disorder"],"condg":["Neurology & cognition"],"enroll":1741,"eid":"NCT05046275"},{"id":"study-NCT04599855","cat":"studies","name":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 4","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT04599855","nsites":54,"countries":"United States","ccs":["US"],"start":"2020-11-04","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","sites":["UAB Department of Psychiatry and Behavioral Neurobiology — Birmingham, United States","UAB Huntsville Regional Medical Campus — Huntsville, United States","Preferred Research Partners — Little Rock, United States","Behavioral Research Specialists LLC — Glendale, United States","CalNeuro Research — Los Angeles, United States","Pacific Research Partners — Oakland, United States","Anderson Clinical Research — Redlands, United States","University of California at San Diego — San Diego, United States"],"conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"enroll":477,"eid":"NCT04599855"},{"id":"study-NCT04080453","cat":"studies","name":"Pro-inflammatory Role of Blood Platelets in Critically Ill Patients With Septic Shock.","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","drugs":["LSD"],"nct":"NCT04080453","nsites":1,"countries":"France","ccs":["FR"],"start":"2020-11-09","official":"Antoine DEWITTE, Dr (University Hospital, Bordeaux)","src":"https://clinicaltrials.gov/study/NCT04080453","sites":["Hôpital Haut Lévêque — Pessac, France"],"conds":["Septic Shock"],"condg":["Other"],"enroll":202,"eid":"NCT04080453"},{"id":"study-NCT04281017","cat":"studies","name":"Effect of Position and Anesthetic Choice in Intraocular Pressure in Robotic GYN (Gynecologic) Oncology Patients","status":"COMPLETED","phase":"Phase 4","sponsor":"University of Florida","drugs":["ketamine"],"nct":"NCT04281017","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-11-10","official":"Sonia Mehta, MD (University of Florida)","src":"https://clinicaltrials.gov/study/NCT04281017","sites":["University of Florida — Gainesville, United States"],"conds":["Intraocular Pressure","Oncology"],"condg":["Cancer-related distress"],"enroll":22,"eid":"NCT04281017"},{"id":"study-NCT04666623","cat":"studies","name":"Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain","status":"WITHDRAWN","phase":"Phase 2","sponsor":"University Hospital, Basel, Switzerland","drugs":["esketamine"],"nct":"NCT04666623","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2020-11-25","official":"Benito Benitez, MD (University Hospital Basel, Klinik für Mund-, Kiefer- und Gesichtschirurgie)","src":"https://clinicaltrials.gov/study/NCT04666623","sites":["University Hospital Basel, Klinik für Mund-, Kiefer- und Gesichtschirurgie — Basel, Switzerland"],"conds":["Cancer Pain"],"condg":["Cancer-related distress","Chronic pain & headache"],"eid":"NCT04666623"},{"id":"study-NCT04664530","cat":"studies","name":"The Study on the Esketamine in the Treatment of Postherpetic Neuralgia","status":"UNKNOWN","phase":"Phase 4","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","drugs":["esketamine"],"nct":"NCT04664530","nsites":1,"countries":"China","ccs":["CN"],"start":"2020-11-25","official":"Min Yan, Doctor (The second affiliated hospital of Zhejiang University hangzhou, Zhejiang, China)","src":"https://clinicaltrials.gov/study/NCT04664530","sites":["The Second Affiliated Hospital of Zhejiang University anesthesiology department — Hangzhou, China"],"conds":["Postherpetic Neuralgia","Esketamine"],"condg":["Chronic pain & headache"],"contact":{"n":"Lieju Wang, Master","p":"18758131223","e":"11518264@zju.edu.cn"},"enroll":48,"eid":"NCT04664530"},{"id":"study-NCT04876066","cat":"studies","name":"Use of Transmucosal Ketamine in Post Stroke Depression","status":"UNKNOWN","phase":"Phase 1","sponsor":"West Virginia University","drugs":["ketamine"],"nct":"NCT04876066","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-11-30","src":"https://clinicaltrials.gov/study/NCT04876066","sites":["WVU Medicine — Morgantown, United States"],"conds":["Post-stroke Depression"],"condg":["Depression","Neurology & cognition"],"contact":{"n":"Amelia Adcock","p":"(304) 293-3527","e":"akadcock@hsc.wvu.edu"},"enroll":21,"eid":"NCT04876066"},{"id":"study-NCT04716335","cat":"studies","name":"Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Psychiatric University Hospital, Zurich","drugs":["DMT"],"nct":"NCT04716335","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2020-12-01","src":"https://clinicaltrials.gov/study/NCT04716335","sites":["Psychiatric University Hospital — Zurich, Switzerland"],"conds":["Emotions","Mood","Cognitive Function 1, Social","Empathy"],"condg":["Neurology & cognition"],"enroll":34,"eid":"NCT04716335"},{"id":"study-NCT04602221","cat":"studies","name":"A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine","status":"COMPLETED","phase":"Phase 1","sponsor":"Boehringer Ingelheim","drugs":["ketamine"],"nct":"NCT04602221","nsites":2,"countries":"United States","ccs":["US"],"start":"2020-12-01","src":"https://clinicaltrials.gov/study/NCT04602221","sites":["Collaborative Neuroscience Research, LLC — Long Beach, United States","Hassman Research Institute — Marlton, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":40,"eid":"NCT04602221"},{"id":"study-NCT04767035","cat":"studies","name":"Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine","status":"COMPLETED","phase":"Phase 1","sponsor":"Melt Pharmaceuticals","drugs":["ketamine"],"nct":"NCT04767035","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-12-01","src":"https://clinicaltrials.gov/study/NCT04767035","sites":["Worldwide Clinical Trials — San Antonio, United States"],"conds":["Procedural Sedation"],"condg":["Other"],"enroll":25,"eid":"NCT04767035"},{"id":"study-NCT05190952","cat":"studies","name":"Dexamethasone & Ketamine as Adjuvants to Bupivacaine for Incisional Infiltration in Pediatric Abdominal Operations","status":"COMPLETED","phase":"N/A","sponsor":"Ain Shams University","drugs":["ketamine"],"nct":"NCT05190952","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2020-12-05","src":"https://clinicaltrials.gov/study/NCT05190952","sites":["Ain Shams university hospitals — Cairo, Egypt"],"conds":["Pediatric ALL"],"condg":["Other"],"enroll":150,"eid":"NCT05190952"},{"id":"study-NCT04600089","cat":"studies","name":"Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI","status":"COMPLETED","phase":"Phase 2","sponsor":"Eric Johnson","drugs":["ketamine"],"nct":"NCT04600089","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-12-08","official":"Anna Rockich, Pharm D (University of Kentucky); Samuel Tyagi, MD (University of Kentucky)","src":"https://clinicaltrials.gov/study/NCT04600089","sites":["University of Kentucky Medical Center — Lexington, United States"],"conds":["Descending Aortic Dissection","Postoperative Pain","Thoracoabdominal Aortic Aneurysm"],"condg":["Chronic pain & headache"],"enroll":21,"eid":"NCT04600089"},{"id":"study-NCT04177706","cat":"studies","name":"Ketamine for the Treatment of Opioid Use Disorder and Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Medical University of South Carolina","drugs":["ketamine"],"nct":"NCT04177706","nsites":1,"countries":"United States","ccs":["US"],"start":"2020-12-17","official":"Jennifer Jones, MD (Medical University of South Carolina)","src":"https://clinicaltrials.gov/study/NCT04177706","sites":["Medical University of South Carolina — Charleston, United States"],"conds":["Depression","Opioid-use Disorder","Opioid Abuse"],"condg":["Depression","Addiction & substance use"],"enroll":21,"eid":"NCT04177706"},{"id":"study-NCT04669665","cat":"studies","name":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","status":"COMPLETED","phase":"Phase 2","sponsor":"Seelos Therapeutics, Inc.","drugs":["ketamine"],"nct":"NCT04669665","nsites":21,"countries":"United States","ccs":["US"],"start":"2020-12-17","src":"https://clinicaltrials.gov/study/NCT04669665","sites":["Seelos Investigational Site — Orange, United States","Seelos Investigational Site — Panorama City, United States","Seelos Investigational Site — San Diego, United States","Seelos Investigational Site — Hollywood, United States","Seelos Investigational Site — Miami, United States","Seelos Investigational Site — Miami Lakes, United States","Seelos Investigational Site — Miramar, United States","Seelos Investigational Site — Oakland Park, United States"],"conds":["Depressive Disorder, Major","Suicidal"],"condg":["Depression"],"enroll":164,"eid":"NCT04669665"},{"id":"study-NCT04516902","cat":"studies","name":"Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD","MDMA"],"nct":"NCT04516902","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2021-01-01","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT04516902","sites":["University Hospital Basel, Clinical Trial Unit — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":24,"eid":"NCT04516902"},{"id":"study-NCT06185426","cat":"studies","name":"Histopathological, Biochemical And Electrophysiological Evaluation Of Single Or Combined Use Of Diode Laser/Steroid Treatment On Facial Nerve Injury","status":"UNKNOWN","phase":"EARLY_Phase 1","sponsor":"Recep Tayyip Erdogan University","drugs":["ketamine"],"nct":"NCT06185426","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2021-01-01","official":"zeynep gümrükçü, Associate Professor (RTEU)","src":"https://clinicaltrials.gov/study/NCT06185426","sites":["RTEU Faculty of Dentistry — Rize, Turkey"],"conds":["Nerve Injury","Laser Therapy","Methylprednisolone","Facial Nerve Injuries"],"condg":["Other"],"enroll":35,"eid":"NCT06185426"},{"id":"study-NCT05218161","cat":"studies","name":"Hemodynamic Effect of Dexmedetomidine Alone With Dexmedetomidine Plus Ketamine Combination in CABG","status":"UNKNOWN","phase":"N/A","sponsor":"Chaudhry Pervaiz Elahi Institute of Cardiology","drugs":["ketamine"],"nct":"NCT05218161","nsites":1,"countries":"Pakistan","ccs":["PK"],"start":"2021-01-01","official":"Dr Shumaila Rai, FCPS (Chaudhry Pervaiz Elahi Institute of Cardiology)","src":"https://clinicaltrials.gov/study/NCT05218161","sites":["CPEIC — Multan, Pakistan"],"conds":["Hemodynamic Instability"],"condg":["Other"],"enroll":40,"eid":"NCT05218161"},{"id":"study-NCT04630964","cat":"studies","name":"The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density","status":"COMPLETED","phase":"Phase 2","sponsor":"Section for Affective Disorders; Northern Stockholm Psychiatry","drugs":["psilocybin"],"nct":"NCT04630964","nsites":1,"countries":"Sweden","ccs":["SE"],"start":"2021-01-01","src":"https://clinicaltrials.gov/study/NCT04630964","sites":["Northern Stockholm Spychiatry Clinic — Stockholm, Sweden"],"conds":["Major Depressive Disorder","Depression"],"condg":["Depression"],"enroll":35,"eid":"NCT04630964"},{"id":"study-NCT04701866","cat":"studies","name":"Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in Depression","status":"COMPLETED","phase":"N/A","sponsor":"Douglas Mental Health University Institute","drugs":["ketamine"],"nct":"NCT04701866","nsites":2,"countries":"Canada","ccs":["CA"],"start":"2021-01-11","official":"Stéphane Richard-Devantoy, MD, PhD (Douglas Mental Health University Insitute)","src":"https://clinicaltrials.gov/study/NCT04701866","sites":["Jewish General Hospital — Montreal, Canada","Douglas Mental Health University Institute — Montreal, Canada"],"conds":["Depressive Disorder, Treatment-Resistant","Depressive Disorder, Major","Unipolar Depression","Depression, Bipolar"],"condg":["Depression","Bipolar"],"enroll":32,"eid":"NCT04701866"},{"id":"study-NCT04711005","cat":"studies","name":"Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine","status":"COMPLETED","phase":"Phase 1","sponsor":"National Institute of Mental Health (NIMH)","drugs":["ketamine"],"nct":"NCT04711005","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-01-11","official":"Shruti Raja, MD, MHS (Duke University)","src":"https://clinicaltrials.gov/study/NCT04711005","sites":["Duke Early Phase Clinical Research — Durham, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":74,"eid":"NCT04711005"},{"id":"study-NCT04562779","cat":"studies","name":"Inpatient Single Dose Interventions for Alcohol Use Disorder","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Denver Health and Hospital Authority","drugs":["ketamine"],"nct":"NCT04562779","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-01-19","src":"https://clinicaltrials.gov/study/NCT04562779","sites":["Denver Health Medical Center — Denver, United States"],"conds":["Alcohol Use Disorder, Severe"],"condg":["Addiction & substance use"],"enroll":44,"eid":"NCT04562779"},{"id":"study-NCT04274361","cat":"studies","name":"Ketamine for Pain Control After Severe Traumatic Injury","status":"COMPLETED","phase":"N/A","sponsor":"Medical College of Wisconsin","drugs":["ketamine"],"nct":"NCT04274361","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-01-20","official":"Thomas Carver, MD (Medical College of WI)","src":"https://clinicaltrials.gov/study/NCT04274361","sites":["Froedtert Hospital — Milwaukee, United States"],"conds":["Hospital Inpatient Trauma Injury","Pain Management"],"condg":["PTSD & trauma","Chronic pain & headache"],"enroll":93,"eid":"NCT04274361"},{"id":"study-NCT05160220","cat":"studies","name":"Naturalistic Study of Microdosing With Psilocybin","status":"COMPLETED","phase":"N/A","sponsor":"National Council of Scientific and Technical Research, Argentina","drugs":["psilocybin"],"nct":"NCT05160220","nsites":1,"countries":"Argentina","ccs":["AR"],"start":"2021-01-20","official":"Enzo Tagliazucchi, PhD (National Council of Scientific and Technical Research, Argentina)","src":"https://clinicaltrials.gov/study/NCT05160220","sites":["Instituto de Fisica de Buenos Aires (IFIBA) — Buenos Aires, Argentina"],"conds":["Cognitive Change","Creativity","Mood Change","Sleep"],"condg":["Neurology & cognition"],"enroll":34,"eid":"NCT05160220"},{"id":"study-NCT04695405","cat":"studies","name":"Pharmacogenetics Associated With IV Ketamine","status":"COMPLETED","sponsor":"Brain and Cognition Discovery Foundation","drugs":["ketamine"],"nct":"NCT04695405","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2021-01-21","official":"Joshua D Rosenblat, MD, MSc (Canadian Rapid Treatment Center of Excellence)","src":"https://clinicaltrials.gov/study/NCT04695405","sites":["Canadian Rapid Treatment Centre of Excellence — Mississauga, Canada"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":85,"eid":"NCT04695405"},{"id":"study-NCT04712071","cat":"studies","name":"Ketamine in Veterans With Gulf War Illness","status":"TERMINATED","phase":"EARLY_Phase 1","sponsor":"Baylor College of Medicine","drugs":["ketamine"],"nct":"NCT04712071","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-02-01","official":"Marijn Lijffijt, PhD (Baylor College of Medicine)","src":"https://clinicaltrials.gov/study/NCT04712071","sites":["Marijn Lijffijt — Houston, United States"],"conds":["Gulf War Syndrome"],"condg":["Other"],"enroll":1,"eid":"NCT04712071"},{"id":"study-NCT04459234","cat":"studies","name":"Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC","status":"COMPLETED","sponsor":"Centre Leon Berard","drugs":["ketamine"],"nct":"NCT04459234","nsites":12,"countries":"France","ccs":["FR"],"start":"2021-02-02","official":"Gisèle CHVETZOFF, MD (Centre Leon Berard)","src":"https://clinicaltrials.gov/study/NCT04459234","sites":["Institut Bergonié — Bordeaux, France","Centre François Baclesse — Caen, France","Centre Jean Perrin — Clermont-Ferrand, France","Centre Leon Berard — Lyon, France","Institut Paoli Calmettes — Marseille, France","Institut de Cancérologie de Montpellier — Montpellier, France","Institut Curie — Paris, France","Institut Godinot — Reims, France"],"conds":["Cancer","Chronic Pain","Neuropathic Pain","Opioid Use"],"condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"enroll":81,"eid":"NCT04459234"},{"id":"study-NCT04673383","cat":"studies","name":"SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Small Pharma Ltd","drugs":["DMT"],"nct":"NCT04673383","nsites":2,"countries":"United Kingdom","ccs":["GB"],"start":"2021-02-04","official":"David Erritzoe, MD (Imperial College London); Malcolm Boyce, MD (Hammersmith Medicines Research)","src":"https://clinicaltrials.gov/study/NCT04673383","sites":["MAC Clinical Research — Liverpool, United Kingdom","Hammersmith Medicines Research — London, United Kingdom"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":66,"eid":"NCT04673383"},{"id":"study-NCT04648137","cat":"studies","name":"Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls","status":"COMPLETED","phase":"N/A","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT04648137","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2021-02-05","official":"Mirjam Christ-Crain, Prof. Dr. med. (Endocrinology, Diabetes and Metabolism, University Hospital Basel)","src":"https://clinicaltrials.gov/study/NCT04648137","sites":["University Hospital Basel, Endocrinology, Diabetes and Metabolism — Basel, Switzerland"],"conds":["Diabetes Insipidus"],"condg":["Other"],"enroll":30,"eid":"NCT04648137"},{"id":"study-NCT04746079","cat":"studies","name":"Positive Imagery Therapy and the Incidence of Emergence Reactions With the Use of Ketamine","status":"UNKNOWN","phase":"N/A","sponsor":"Mercy Health Ohio","drugs":["ketamine"],"nct":"NCT04746079","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-02-05","official":"Todd Bolotin, MD (Bon Secours Mercy Health)","src":"https://clinicaltrials.gov/study/NCT04746079","sites":["Mercy Health St Elizabeth Youngstown — Youngstown, United States"],"conds":["Procedural Sedation","Emergence Delirium"],"condg":["Other"],"contact":{"n":"Todd Bolotin, MD","p":"(330) 219-3838","e":"tbolotin@gmail.com"},"enroll":180,"eid":"NCT04746079"},{"id":"study-NCT04640636","cat":"studies","name":"IM Ketamine vs Midazolam for Suicidal ER Patients","status":"SUSPENDED","phase":"Phase 4","sponsor":"New York State Psychiatric Institute","drugs":["ketamine"],"nct":"NCT04640636","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-02-09","official":"Michael Grunebaum, MD (New York State Psychiatric Institute/Columbia University Irving Medical Center)","src":"https://clinicaltrials.gov/study/NCT04640636","sites":["Comprehensive Psychiatric Emergency Department of Columbia University Medical Center — New York, United States"],"conds":["Depression, Unipolar","Depression, Bipolar","Suicidal Ideation"],"condg":["Depression","Bipolar"],"enroll":90,"eid":"NCT04640636"},{"id":"study-NCT04850937","cat":"studies","name":"Effect of Low-dose Esketamine on Postoperative Depression in Patients With Breast Cancer","status":"COMPLETED","phase":"N/A","sponsor":"Yangzhou University","drugs":["esketamine"],"nct":"NCT04850937","nsites":1,"countries":"China","ccs":["CN"],"start":"2021-02-10","official":"LIU M YU (Yangzhou University)","src":"https://clinicaltrials.gov/study/NCT04850937","sites":["Affiliated hospital of yangzhou university — Yangzhou, China"],"conds":["Depression"],"condg":["Depression"],"enroll":90,"eid":"NCT04850937"},{"id":"study-NCT04425473","cat":"studies","name":"Esketamine and Perioperative Depressive Symptoms","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Beijing Tiantan Hospital","drugs":["esketamine"],"nct":"NCT04425473","nsites":1,"countries":"China","ccs":["CN"],"start":"2021-02-19","official":"Ruquan Han, M.D., Ph D. (Beijing Tiantan Hospital)","src":"https://clinicaltrials.gov/study/NCT04425473","sites":["Beijing Tiantan Hospital, Capital Medical University — Beijing, China"],"conds":["Depressive Symptoms","Esketamine","Perioperative Complication","Major Surgery"],"condg":["Depression"],"enroll":435,"eid":"NCT04425473"},{"id":"study-NCT04656301","cat":"studies","name":"Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder","status":"COMPLETED","phase":"Phase 2","sponsor":"New York State Psychiatric Institute","drugs":["psilocybin"],"nct":"NCT04656301","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-02-26","official":"Franklin Schneier, MD (Research Foundation for Mental Hygiene/NY State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT04656301","sites":["New York State Psychiatric Institute, 1051 Riverside Drive — New York, United States"],"conds":["Body Dysmorphic Disorders"],"condg":["Other"],"enroll":12,"eid":"NCT04656301"},{"id":"study-NCT05066282","cat":"studies","name":"Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD","status":"COMPLETED","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT05066282","nsites":4,"countries":"Canada; Israel; United States","ccs":["CA","IL","US"],"start":"2021-03-01","official":"Jennifer Mitchell, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT05066282","sites":["USCF — San Francisco, United States","Dr. Simon Amar Inc — Montreal, Canada","Beer Yaakov Mental Health Center — Be’er Ya‘aqov, Israel","Tel Hashomer — Tel Aviv, Israel"],"conds":["PTSD"],"condg":["PTSD & trauma"],"enroll":186,"eid":"NCT05066282"},{"id":"study-NCT04010266","cat":"studies","name":"RelieVRx for Total Knee Arthroplasty (TKA) for the Reduction of Acute Postoperative Pain and Opioid Use","status":"COMPLETED","phase":"N/A","sponsor":"AppliedVR Inc.","drugs":["ketamine"],"nct":"NCT04010266","nsites":3,"countries":"United States","ccs":["US"],"start":"2021-03-01","official":"Dr. Michael Suk (Geisinger Clinic)","src":"https://clinicaltrials.gov/study/NCT04010266","sites":["Geisinger Medical Center — Danville, United States","Geisinger Wyoming Valley Medical Center — Wilkes-Barre, United States","Geisinger South Wilkes Barre — Wilkes-Barre, United States"],"conds":["Opioid Use","Arthropathy of Knee","Pain, Postoperative"],"condg":["Addiction & substance use","Chronic pain & headache"],"enroll":63,"eid":"NCT04010266"},{"id":"study-NCT05163366","cat":"studies","name":"Oral Morphine Versus Ketamine in Pain Management","status":"COMPLETED","phase":"Phase 3","sponsor":"Mbarara University of Science and Technology","drugs":["ketamine"],"nct":"NCT05163366","nsites":2,"countries":"Uganda","ccs":["UG"],"start":"2021-03-01","official":"ALICE G. ATAI, MbChB (Mbarara University of Science and Technology)","src":"https://clinicaltrials.gov/study/NCT05163366","sites":["Mbarara Regional Referral Hospital — Mbarara, Uganda","Mbarara Regional Referral Hospital — Mbarara, Uganda"],"conds":["Pain, Procedural"],"condg":["Chronic pain & headache"],"enroll":44,"eid":"NCT05163366"},{"id":"study-NCT04433858","cat":"studies","name":"An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)","status":"UNKNOWN","phase":"Phase 2","sponsor":"Sheppard Pratt Health System","drugs":["psilocybin"],"nct":"NCT04433858","nsites":2,"countries":"United States","ccs":["US"],"start":"2021-03-01","official":"Scott Aaronson, MD (Sheppard Pratt Health System)","src":"https://clinicaltrials.gov/study/NCT04433858","sites":["VA Palo Alto Healthcare System/Stanford Medicine — Palo Alto, United States","Sheppard Pratt Health System — Baltimore, United States"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":27,"eid":"NCT04433858"},{"id":"study-NCT04433845","cat":"studies","name":"The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.","status":"UNKNOWN","phase":"Phase 2","sponsor":"Sheppard Pratt Health System","drugs":["psilocybin"],"nct":"NCT04433845","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-03-01","official":"Scott Aaronson, MD (Sheppard Pratt Health System)","src":"https://clinicaltrials.gov/study/NCT04433845","sites":["Sheppard Pratt — Baltimore, United States"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":15,"eid":"NCT04433845"},{"id":"study-NCT04760652","cat":"studies","name":"Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention","status":"COMPLETED","phase":"N/A","sponsor":"Yale University","drugs":["esketamine","ketamine"],"nct":"NCT04760652","nsites":3,"countries":"United States","ccs":["US"],"start":"2021-03-05","official":"Samuel T Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT04760652","sites":["UAB Medicine | Heersink School of Medicine — Birmingham, United States","Yale University — New Haven, United States","Emory University — Atlanta, United States"],"conds":["Depression and Suicide"],"condg":["Depression"],"enroll":93,"eid":"NCT04760652"},{"id":"study-NCT04714359","cat":"studies","name":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","status":"COMPLETED","phase":"Phase 3","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT04714359","nsites":15,"countries":"Canada; Israel; United States","ccs":["CA","IL","US"],"start":"2021-03-08","src":"https://clinicaltrials.gov/study/NCT04714359","sites":["New School Research — Los Angeles, United States","San Francisco Insight and Integration Center — San Francisco, United States","UCSF — San Francisco, United States","Aguazul-Blue Water Inc. — Boulder, United States","Wholeness Center — Fort Collins, United States","Ray Worthy Psychiatry — New Orleans, United States","Trauma Research Foundation — Boston, United States","NYU — New York, United States"],"conds":["PTSD"],"condg":["PTSD & trauma"],"enroll":87,"eid":"NCT04714359"},{"id":"study-NCT04560660","cat":"studies","name":"Ketamine-enhanced Prolonged Exposure Therapy in PTSD","status":"COMPLETED","phase":"Phase 2","sponsor":"VA Office of Research and Development","drugs":["ketamine"],"nct":"NCT04560660","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-03-09","official":"Paulo R Shiroma, MD (Minneapolis VA Health Care System, Minneapolis, MN)","src":"https://clinicaltrials.gov/study/NCT04560660","sites":["Minneapolis VA Health Care System, Minneapolis, MN — Minneapolis, United States"],"conds":["PTSD"],"condg":["PTSD & trauma"],"enroll":73,"eid":"NCT04560660"},{"id":"study-NCT04807335","cat":"studies","name":"Study of CT001 in Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"Cessatech A/S","drugs":["ketamine"],"nct":"NCT04807335","nsites":1,"countries":"Denmark","ccs":["DK"],"start":"2021-03-17","official":"Mads Werner, MD (Copenhagen University Hospital, Rigshospitalet)","src":"https://clinicaltrials.gov/study/NCT04807335","sites":["Dantrials — Copenhagen, Denmark"],"conds":["Bioavailability"],"condg":["Other"],"enroll":14,"eid":"NCT04807335"},{"id":"study-NCT05029401","cat":"studies","name":"A Study of Oral Ibogaine in Opioid Withdrawal","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"atai Therapeutics, Inc.","drugs":["ibogaine"],"nct":"NCT05029401","nsites":2,"countries":"United Kingdom","ccs":["GB"],"start":"2021-04-01","src":"https://clinicaltrials.gov/study/NCT05029401","sites":["MAC Clinical Research Manchester (Early Phase Unit), Neuroscience Centre of Excellence — Manchester, United Kingdom","Hammersmith Medicines Research (HMR) Limited — London, United Kingdom"],"conds":["Opiate Withdrawal Syndrome"],"condg":["Other"],"enroll":116,"eid":"NCT05029401"},{"id":"study-NCT05063097","cat":"studies","name":"Addiction in Intensive Cardiac Care Units","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","drugs":["MDMA"],"nct":"NCT05063097","nsites":1,"countries":"France","ccs":["FR"],"start":"2021-04-06","official":"Jean-Guillaume DILLINGER, MD,PhD (Lariboisière Hospital, APHP, Paris)","src":"https://clinicaltrials.gov/study/NCT05063097","sites":["CHU Lariboisière, APHP, Cardiology — Paris, France"],"conds":["Intensive Care Unit Syndrome","Drug Abuse","Substance-Related Disorders","Cardiovascular Events","Cardiac Disease"],"condg":["Addiction & substance use"],"enroll":1500,"eid":"NCT05063097"},{"id":"study-NCT04714541","cat":"studies","name":"Modified Ketogenic Diet and Ketamine for Anorexia Nervosa","status":"COMPLETED","phase":"Phase 1","sponsor":"Homeostasis Therapeutics, LLC","drugs":["ketamine"],"nct":"NCT04714541","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-04-12","official":"Lori Calabrese, MD (Innovative Psychiatry So Windsor); Lori Calabrese, MD (Innovative Psychiatry, So Windsor)","src":"https://clinicaltrials.gov/study/NCT04714541","sites":["Lori Calabrese MD Innovative Psychiatry — South Windsor, United States"],"conds":["Anorexia Nervosa"],"condg":["Eating disorders"],"enroll":5,"eid":"NCT04714541"},{"id":"study-NCT04852484","cat":"studies","name":"Morphine Versus Ketamine as Adjuvants in Paravertebral Blocks","status":"UNKNOWN","phase":"N/A","sponsor":"Aretaieion University Hospital","drugs":["ketamine"],"nct":"NCT04852484","nsites":2,"countries":"Greece","ccs":["GR"],"start":"2021-04-16","official":"Kassiani Theodoraki, PhD, DESA (Aretaieion University Hospital)","src":"https://clinicaltrials.gov/study/NCT04852484","sites":["Aretaieion University Hospital — Athens, Greece","KAT General Hospital of Athens — Athens, Greece"],"conds":["Pain, Postoperative","Pain, Acute","Pain, Chronic","Pain, Neuropathic","Morphine","Ketamine"],"condg":["Chronic pain & headache"],"enroll":90,"eid":"NCT04852484"},{"id":"study-NCT04860713","cat":"studies","name":"An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute Headache","status":"COMPLETED","phase":"Phase 4","sponsor":"Antonios Likourezos","drugs":["ketamine"],"nct":"NCT04860713","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-04-22","official":"Leily Naraghi, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT04860713","sites":["Maimonides Medical Center — Brooklyn, United States"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":5,"eid":"NCT04860713"},{"id":"study-NCT04860804","cat":"studies","name":"A Comparison of Proprietary Formulations of Oral Ketamine + Aspirin and Oral Ketamine Alone for Musculoskeletal Pain","status":"COMPLETED","phase":"Phase 4","sponsor":"Antonios Likourezos","drugs":["ketamine"],"nct":"NCT04860804","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-04-22","official":"Leily Naraghi Bagher Pour, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT04860804","sites":["Maimonides Medical Center — Brooklyn, United States"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":60,"eid":"NCT04860804"},{"id":"study-NCT04829318","cat":"studies","name":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","status":"COMPLETED","phase":"Phase 4","sponsor":"Janssen-Cilag Ltd.","drugs":["esketamine"],"nct":"NCT04829318","nsites":59,"countries":"Argentina; Belgium; Bulgaria; Czechia; Finland; Germany; Greece; Hungary; Malaysia; Poland; South Africa; South Korea; Taiwan; Turkey (Türkiye)","ccs":["AR","BE","BG","CZ","DE","FI","GR","HU","KR","MY","PL","TR","TW","ZA"],"start":"2021-04-26","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","sites":["FunDaMos — Buenos Aires, Argentina","CEN Consultorios Especializados en Neurociencias — Córdoba, Argentina","Fundacion Lennox — Córdoba, Argentina","Instituto Medico DAMIC — Córdoba, Argentina","Sanatorio Prof Leon S Morra S A — Córdoba, Argentina","Instituto de Neurociencias San Agustin — La Plata, Argentina","C I A P Centro de investigacion y Asistencia en Psiquiatria — Rosario, Argentina","Anima — Alken, Belgium"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"enroll":183,"eid":"NCT04829318"},{"id":"study-NCT04843462","cat":"studies","name":"Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray","status":"UNKNOWN","phase":"N/A","sponsor":"Lukas Pezawas","drugs":["esketamine"],"nct":"NCT04843462","nsites":1,"countries":"Austria","ccs":["AT"],"start":"2021-04-29","official":"Markus Dold, MD., Priv.Doz. (Medical University of Vienna); Gabriele Fischer, MD, Prof. (Medical University of Vienna)","src":"https://clinicaltrials.gov/study/NCT04843462","sites":["Medical University Vienna — Vienna, Austria"],"conds":["Major Depressive Disorder","Therapy Resistant Depression"],"condg":["Depression"],"contact":{"n":"Lukas M Pezawas, MD, Prof.","p":"004314040035470","e":"lukas.pezawas@meduniwien.ac.at"},"enroll":70,"eid":"NCT04843462"},{"id":"study-NCT04837170","cat":"studies","name":"Safety and Efficacy Evaluation of S (+) - Ketamine in Adults","status":"UNKNOWN","phase":"Phase 4","sponsor":"Chinese PLA General Hospital","drugs":["esketamine","ketamine"],"nct":"NCT04837170","nsites":0,"start":"2021-05-01","official":"Weidong Mi, MD (Chinese PLA General Hospital)","src":"https://clinicaltrials.gov/study/NCT04837170","conds":["Postoperative Pain","Adults","Anesthesia"],"condg":["Chronic pain & headache"],"contact":{"n":"Weidong Mi, MD","p":"8613381082966","e":"wwdd1962@aliyun.com"},"enroll":12000,"eid":"NCT04837170"},{"id":"study-NCT04847245","cat":"studies","name":"Esketamine Adjuvant Therapy for Patients With Chronic Visceral Pain Comorbid Major Depressive Disorder","status":"UNKNOWN","phase":"N/A","sponsor":"Peking University","drugs":["esketamine"],"nct":"NCT04847245","nsites":0,"start":"2021-05-01","src":"https://clinicaltrials.gov/study/NCT04847245","conds":["Chronic Visceral Pain","Major Depressive Disorder"],"condg":["Depression","Chronic pain & headache"],"contact":{"n":"Tianmei SI, PhD., MD","p":"86-1062723748","e":"si.tian-mei@163.com"},"enroll":80,"eid":"NCT04847245"},{"id":"study-NCT04860661","cat":"studies","name":"Esketamine on Postpartum Depression in Cesarean Section Women","status":"COMPLETED","phase":"N/A","sponsor":"Ailin Luo","drugs":["esketamine"],"nct":"NCT04860661","nsites":1,"countries":"China","ccs":["CN"],"start":"2021-05-01","official":"Ailin luo, Dr. (Department of Anesthesiology of Tongji Hospital)","src":"https://clinicaltrials.gov/study/NCT04860661","sites":["Tongji Hospital — Wuhan, China"],"conds":["Esketamine","Postpartum Depression"],"condg":["Depression"],"enroll":336,"eid":"NCT04860661"},{"id":"study-NCT05249309","cat":"studies","name":"Naturalistic Study of Ketamine in the Treatment of Depression","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","drugs":["ketamine"],"nct":"NCT05249309","nsites":2,"countries":"Brazil","ccs":["BR"],"start":"2021-05-01","official":"Ana P Anzolin, Master (Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre); Keila Maria M Ceresér, PhD (Laboratory of Molecular…","src":"https://clinicaltrials.gov/study/NCT05249309","sites":["Hospital Moinhos de Vento — Porto Alegre, Brazil","Hospital de Clinicas de Porto Alegre — Porto Alegre, Brazil"],"conds":["Major Depressive Disorder","Bipolar Disorder","Bipolar Depression","Bipolar I Disorder","Bipolar II Disorder","Affective Disorder"],"condg":["Depression","Bipolar"],"enroll":90,"eid":"NCT05249309"},{"id":"study-NCT05383313","cat":"studies","name":"Psilocybin Versus Ketamine in Treatment-Resistant Depression","status":"UNKNOWN","phase":"Phase 2","sponsor":"National Institute of Mental Health, Czech Republic","drugs":["ketamine","psilocybin"],"nct":"NCT05383313","nsites":1,"countries":"Czechia","ccs":["CZ"],"start":"2021-05-01","src":"https://clinicaltrials.gov/study/NCT05383313","sites":["National Institute of Mental Health — Klecany, Czechia"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"contact":{"n":"Vivian Winkler, MD","p":"+420773137373","e":"vivian.winkler@nudz.cz"},"enroll":60,"eid":"NCT05383313"},{"id":"study-NCT04661514","cat":"studies","name":"Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy","status":"COMPLETED","phase":"Phase 2","sponsor":"University of California, San Diego","drugs":["psilocybin"],"nct":"NCT04661514","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-05-01","src":"https://clinicaltrials.gov/study/NCT04661514","sites":["Altman Clinical and Translational Research Institute — La Jolla, United States"],"conds":["Anorexia Nervosa"],"condg":["Eating disorders"],"enroll":16,"eid":"NCT04661514"},{"id":"study-NCT04842045","cat":"studies","name":"Pilot RECAP Study in Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Wisconsin, Madison","drugs":["psilocybin"],"nct":"NCT04842045","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-05-21","official":"Christopher R Nicholas, MD,PHD (University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United State, 53715)","src":"https://clinicaltrials.gov/study/NCT04842045","sites":["UWHealth, 600 Highland Avenue — Madison, United States"],"conds":["Psychedelic Experiences","Amnesia"],"condg":["Other"],"enroll":8,"eid":"NCT04842045"},{"id":"study-NCT04505189","cat":"studies","name":"Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Imperial College London","drugs":["psilocybin"],"nct":"NCT04505189","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2021-05-28","src":"https://clinicaltrials.gov/study/NCT04505189","sites":["Imperial College Hammersmith campus — London, United Kingdom"],"conds":["Anorexia Nervosa"],"condg":["Eating disorders"],"enroll":21,"eid":"NCT04505189"},{"id":"study-NCT04621110","cat":"studies","name":"Intranasal Versus Intravenous Drug in Painful Procedure for Outpatient Oncologic Participants","status":"UNKNOWN","phase":"Phase 3","sponsor":"University of Sao Paulo General Hospital","drugs":["ketamine"],"nct":"NCT04621110","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2021-06-01","src":"https://clinicaltrials.gov/study/NCT04621110","sites":["ITACI - Instituto de Tratamento do Câncer Infantil/ ICR HCFMUSP — São Paulo, Brazil"],"conds":["Pediatric Cancer","Analgesia","Procedural Pain"],"condg":["Cancer-related distress","Chronic pain & headache"],"contact":{"n":"Clarissa A Archanjo, M.D.","p":"+5511964593842","e":"clarissa.archanjo@yahoo.com.br"},"enroll":60,"eid":"NCT04621110"},{"id":"study-NCT04501653","cat":"studies","name":"Precision Functional Brain Mapping in Psilocybin","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Washington University School of Medicine","drugs":["psilocybin"],"nct":"NCT04501653","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-06-01","src":"https://clinicaltrials.gov/study/NCT04501653","sites":["Washington University — St Louis, United States"],"conds":["Psilocybin"],"condg":["Other"],"enroll":11,"eid":"NCT04501653"},{"id":"study-NCT04889664","cat":"studies","name":"Adding Trauma-focused Psychotherapy to Ketamine Treatment for Chronic PTSD","status":"COMPLETED","phase":"Phase 2","sponsor":"Icahn School of Medicine at Mount Sinai","drugs":["ketamine"],"nct":"NCT04889664","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-06-04","official":"Adriana Feder, MD (Depression and Anxiety Center, Icahn School of Medicine at Mount Sinai); Oneysha Brown, BA (Depression and Anxiety Center, Icahn School of…","src":"https://clinicaltrials.gov/study/NCT04889664","sites":["Depression and Anxiety Center, Icahn School of Medicine at Mount Sinai — Manhattan, United States"],"conds":["PTSD"],"condg":["PTSD & trauma"],"enroll":16,"eid":"NCT04889664"},{"id":"study-NCT04670081","cat":"studies","name":"Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Central Institute of Mental Health, Mannheim","drugs":["psilocybin"],"nct":"NCT04670081","nsites":2,"countries":"Germany","ccs":["DE"],"start":"2021-06-10","official":"Gerhard Gründer, Prof. Dr. (Central Institute of Mental Health, Mannheim)","src":"https://clinicaltrials.gov/study/NCT04670081","sites":["Charité Berlin, Campus Mitte, Department of Psychiatry and Psychotherapy — Berlin, Germany","Central Institute of Mental Health (CIMH) — Mannheim, Germany"],"conds":["Treatment-resistant Depression"],"condg":["Depression"],"enroll":144,"eid":"NCT04670081"},{"id":"study-NCT04353024","cat":"studies","name":"Effects of Dimethyltryptamine in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["DMT"],"nct":"NCT04353024","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2021-06-18","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT04353024","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":31,"eid":"NCT04353024"},{"id":"study-NCT05163691","cat":"studies","name":"Pharmacokinetics of GH001 in Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"GH Research Ireland Limited","drugs":["DMT"],"nct":"NCT05163691","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2021-06-21","official":"GH Research Clinical Team (GH Research Ireland Limited)","src":"https://clinicaltrials.gov/study/NCT05163691","sites":["GH Research Clinical Trial Site — Groningen, Netherlands"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":46,"eid":"NCT05163691"},{"id":"study-NCT04959253","cat":"studies","name":"Psilocybin in Depression Resistant to Standard Treatments","status":"COMPLETED","phase":"Phase 2","sponsor":"King's College London","drugs":["psilocybin"],"nct":"NCT04959253","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2021-06-21","official":"James Rucker, MD PhD (King's College London)","src":"https://clinicaltrials.gov/study/NCT04959253","sites":["Clinical Research Facility, King's College Hospital — London, United Kingdom"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":60,"eid":"NCT04959253"},{"id":"study-NCT04938713","cat":"studies","name":"Comparison of Ketamine and Esketamine in Patients Suffering From Fibromyalgia Syndrome.","status":"UNKNOWN","phase":"N/A","sponsor":"Centre Hospitalier Universitaire de Charleroi","drugs":["esketamine","ketamine"],"nct":"NCT04938713","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2021-07-01","official":"Brice Constant, MD (Centre Universitaire de Charleroi)","src":"https://clinicaltrials.gov/study/NCT04938713","sites":["CHU de Charleroi — Lodelinsart, Belgium"],"conds":["Fibromyalgia"],"condg":["Chronic pain & headache"],"contact":{"n":"Brice Constant, MD","p":"0032477504934","e":"briceconstant@hotmail.com"},"enroll":50,"eid":"NCT04938713"},{"id":"study-NCT04658420","cat":"studies","name":"A Single Ketamine Infusion Combined With Music for Suicidal Ideation","status":"UNKNOWN","phase":"Phase 2","sponsor":"The University of Texas Health Science Center at Tyler","drugs":["ketamine"],"nct":"NCT04658420","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-07-01","official":"Richard Idell, MD (University of Texas Health Science Center at Tyler)","src":"https://clinicaltrials.gov/study/NCT04658420","sites":["UT Health East Texas — Tyler, United States"],"conds":["Suicidal Ideation","Depressive Episode"],"condg":["Depression"],"contact":{"n":"Richard Idell, MD","p":"2816088348","e":"richard.idell@uthct.edu"},"enroll":200,"eid":"NCT04658420"},{"id":"study-NCT05056038","cat":"studies","name":"Lateral Versus Posterior Quadratus Lumborum Block in The Pediatric Patients Undergoing Orchiopexy","status":"COMPLETED","phase":"N/A","sponsor":"Istanbul University - Cerrahpasa","drugs":["ketamine"],"nct":"NCT05056038","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2021-07-01","official":"Ayşe Çiğdem Tütüncü, Prof. (Istanbul University - Cerrahpasa)","src":"https://clinicaltrials.gov/study/NCT05056038","sites":["Istanbul University - Cerrahpasa — Istanbul, Turkey"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":103,"eid":"NCT05056038"},{"id":"study-NCT05719506","cat":"studies","name":"A Comparative Evaluation of Nebulized Dexmedetomidine and Nebulized Ketamine as a Premedication in Pediatric Surgeries","status":"COMPLETED","phase":"Phase 4","sponsor":"Tanta University","drugs":["ketamine"],"nct":"NCT05719506","nsites":2,"countries":"Egypt","ccs":["EG"],"start":"2021-07-21","src":"https://clinicaltrials.gov/study/NCT05719506","sites":["Tanta University Hospitals — Tanta, Egypt","Tanta University — Tanta, Egypt"],"conds":["Anesthesia Refusal"],"condg":["Other"],"enroll":60,"eid":"NCT05719506"},{"id":"study-NCT04141696","cat":"studies","name":"A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"National Institute of Nursing Research (NINR)","drugs":["ketamine"],"nct":"NCT04141696","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-07-26","official":"Leorey N Saligan, C.R.N.P. (National Institute of Nursing Research (NINR))","src":"https://clinicaltrials.gov/study/NCT04141696","sites":["National Institutes of Health Clinical Center — Bethesda, United States"],"conds":["Fatigue"],"condg":["Other"],"enroll":10,"eid":"NCT04141696"},{"id":"study-NCT04843982","cat":"studies","name":"Immunoinflammatory Regulation of Esketamine in Septic Patients","status":"TERMINATED","phase":"Phase 4","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","drugs":["esketamine"],"nct":"NCT04843982","nsites":1,"countries":"China","ccs":["CN"],"start":"2021-07-28","official":"Shiying Yuan, PhD, MD (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology)","src":"https://clinicaltrials.gov/study/NCT04843982","sites":["Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, China"],"conds":["Esketamine","Sepsis","Inflammatory Response","Immunosuppression"],"condg":["Other"],"enroll":10,"eid":"NCT04843982"},{"id":"study-NCT04924257","cat":"studies","name":"ECT vs. Esketamine","status":"WITHDRAWN","phase":"Phase 3","sponsor":"Medical University Innsbruck","drugs":["esketamine"],"nct":"NCT04924257","nsites":1,"countries":"Austria","ccs":["AT"],"start":"2021-07-28","src":"https://clinicaltrials.gov/study/NCT04924257","sites":["Medical University Innsbruck — Innsbruck, Austria"],"conds":["Treatment Resistant Depression","Major Depressive Disorder"],"condg":["Depression"],"eid":"NCT04924257"},{"id":"study-NCT04264026","cat":"studies","name":"MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD","status":"COMPLETED","phase":"Phase 2","sponsor":"VA Loma Linda Health Care System","drugs":["MDMA"],"nct":"NCT04264026","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-07-29","official":"Shannon Remick, MD (Staff Psychiatrist)","src":"https://clinicaltrials.gov/study/NCT04264026","sites":["VA Loma Linda Health Care System — Loma Linda, United States"],"conds":["Post Traumatic Stress Disorder","Combat Stress Disorders"],"condg":["PTSD & trauma"],"enroll":5,"eid":"NCT04264026"},{"id":"study-NCT04777110","cat":"studies","name":"The Effectiveness and Safety of Esketamine in Modified Electroconvulsive Therapy","status":"UNKNOWN","phase":"EARLY_Phase 1","sponsor":"First Affiliated Hospital of Chongqing Medical University","drugs":["esketamine"],"nct":"NCT04777110","nsites":0,"start":"2021-08","src":"https://clinicaltrials.gov/study/NCT04777110","conds":["Esketamine","ECT","Depression"],"condg":["Depression"],"enroll":396,"eid":"NCT04777110"},{"id":"study-NCT05123716","cat":"studies","name":"Drug Effects on Interpersonal Interaction","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University of Chicago","drugs":["MDMA"],"nct":"NCT05123716","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-08-01","src":"https://clinicaltrials.gov/study/NCT05123716","sites":["University of Chicago — Chicago, United States"],"conds":["Interaction, Social"],"condg":["Other"],"enroll":30,"eid":"NCT05123716"},{"id":"study-NCT04771767","cat":"studies","name":"Combined Ketamine and eCBT Intervention for PTSD","status":"UNKNOWN","phase":"Phase 2","sponsor":"Queen's University","drugs":["ketamine"],"nct":"NCT04771767","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2021-08-01","official":"Taras Reshetukha, MD (Queen's University)","src":"https://clinicaltrials.gov/study/NCT04771767","sites":["Queen's University — Kingston, Canada"],"conds":["Post-Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"contact":{"n":"Aaron E Philipp-Muller, B.Sc.","p":"416-939-3164","e":"19aepm1@queensu.ca"},"enroll":16,"eid":"NCT04771767"},{"id":"study-NCT05648526","cat":"studies","name":"Neuroprotective Effects of ACTH4-10PRO8-GLY9-PRO10","status":"COMPLETED","phase":"N/A","sponsor":"Universitas Sumatera Utara","drugs":["ketamine"],"nct":"NCT05648526","nsites":1,"countries":"Indonesia","ccs":["ID"],"start":"2021-08-01","src":"https://clinicaltrials.gov/study/NCT05648526","sites":["Faculty of Medicine Universitas Sumatera Utara — Medan, Indonesia"],"conds":["Ketamine-Induced Neurotoxicity"],"condg":["Other"],"enroll":42,"eid":"NCT05648526"},{"id":"study-NCT04218539","cat":"studies","name":"Repeat Dosing of Psilocybin in Migraine Headache","status":"COMPLETED","phase":"Phase 1","sponsor":"Yale University","drugs":["psilocybin"],"nct":"NCT04218539","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-08-10","src":"https://clinicaltrials.gov/study/NCT04218539","sites":["VA Connecticut Healthcare System — West Haven, United States"],"conds":["Migraine Headache"],"condg":["Chronic pain & headache"],"enroll":18,"eid":"NCT04218539"},{"id":"study-NCT04849013","cat":"studies","name":"Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["mescaline"],"nct":"NCT04849013","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2021-08-11","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT04849013","sites":["University Hospital Basel, Clinical Trial Unit — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":16,"eid":"NCT04849013"},{"id":"study-NCT04905121","cat":"studies","name":"Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)","status":"TERMINATED","phase":"Phase 1","sponsor":"Beckley Psytech Limited","drugs":["psilocybin"],"nct":"NCT04905121","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2021-08-11","src":"https://clinicaltrials.gov/study/NCT04905121","sites":["King's College London — London, United Kingdom"],"conds":["Short Lasting Unilateral Neuralgiform Headache Attacks"],"condg":["Chronic pain & headache"],"enroll":4,"eid":"NCT04905121"},{"id":"study-NCT04932434","cat":"studies","name":"Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease","status":"COMPLETED","phase":"Phase 2","sponsor":"Joshua Woolley, MD, PhD","drugs":["psilocybin"],"nct":"NCT04932434","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-08-15","official":"Joshua Woolley, MD/PhD (University of California, San Francisco); Ellen Bradley, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT04932434","sites":["University of California, San Francisco — San Francisco, United States"],"conds":["Parkinson Disease","Depression","Anxiety"],"condg":["Depression","Anxiety","Neurology & cognition"],"enroll":12,"eid":"NCT04932434"},{"id":"study-NCT04850911","cat":"studies","name":"Reward Emotion Learning and Ketamine Study","status":"UNKNOWN","phase":"N/A","sponsor":"University of Oxford","drugs":["ketamine"],"nct":"NCT04850911","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2021-08-25","official":"Catherine Harmer, PhD (University of Oxford)","src":"https://clinicaltrials.gov/study/NCT04850911","sites":["University of Oxford — Oxford, United Kingdom"],"conds":["Depression","Major Depressive Disorder","Treatment Resistant Depression"],"condg":["Depression"],"contact":{"n":"Erdem Pulcu, PhD","p":"01865613154","e":"erdem.pulcu@psych.ox.ac.uk"},"enroll":70,"eid":"NCT04850911"},{"id":"study-NCT04424225","cat":"studies","name":"Visual Surround Suppression and Perceptual Expectation Under Psilocybin","status":"TERMINATED","phase":"Phase 1","sponsor":"University of Minnesota","drugs":["psilocybin"],"nct":"NCT04424225","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-08-30","official":"Jessica Nielson, PhD (University of Minnesota); Link Swanson, PhD(c) (University of Minnesota)","src":"https://clinicaltrials.gov/study/NCT04424225","sites":["University of Minnesota — Minneapolis, United States"],"conds":["Perception Disturbance","Visual Suppression","Psychedelic Experiences"],"condg":["Other"],"enroll":10,"eid":"NCT04424225"},{"id":"study-NCT05026203","cat":"studies","name":"Effectiveness of Ketamine Treatment for Three Consecutive Days in Depression","status":"COMPLETED","phase":"Phase 4","sponsor":"Mahidol University","drugs":["ketamine"],"nct":"NCT05026203","nsites":1,"countries":"Thailand","ccs":["TH"],"start":"2021-09-01","src":"https://clinicaltrials.gov/study/NCT05026203","sites":["Keerati Pattanaseri — Bangkok, Thailand"],"conds":["Depression"],"condg":["Depression"],"enroll":24,"eid":"NCT05026203"},{"id":"study-NCT05097261","cat":"studies","name":"Ketamine in Acute Brain Injury Patients.","status":"UNKNOWN","phase":"Phase 4","sponsor":"Geert Meyfroidt, MD, PhD","drugs":["ketamine"],"nct":"NCT05097261","nsites":8,"countries":"Belgium","ccs":["BE"],"start":"2021-09-06","official":"Geert Meyfroidt, MD PhD (Associate Professor of Medicine)","src":"https://clinicaltrials.gov/study/NCT05097261","sites":["Imelda Bonheiden — Bonheiden, Belgium","AZ Sint-Jan — Bruges, Belgium","Jessa Ziekenhuis — Hasselt, Belgium","UZLeuven — Leuven, Belgium","CHR de la Citadelle Liège — Liège, Belgium","CHU de Liège — Liège, Belgium","AZ Delta — Roeselare, Belgium","AZ Turnhout — Turnhout, Belgium"],"conds":["Brain Injuries, Traumatic"],"condg":["PTSD & trauma","Neurology & cognition"],"contact":{"n":"Liese Mebis, PhD","p":"003216343125","e":"liese.mebis@uzleuven.be"},"enroll":100,"eid":"NCT05097261"},{"id":"study-NCT05103319","cat":"studies","name":"Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","drugs":["ketamine"],"nct":"NCT05103319","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2021-09-07","official":"Tobias Schneider, Dr. med. (Department of Anesthesiology University of Basel (USB))","src":"https://clinicaltrials.gov/study/NCT05103319","sites":["Department of Anesthesiology, University of Basel (USB) — Basel, Switzerland"],"conds":["Chronic Pain"],"condg":["Chronic pain & headache"],"enroll":319,"eid":"NCT05103319"},{"id":"study-NCT04939649","cat":"studies","name":"Ketamine As an Adjunctive Therapy for Major Depression (2)","status":"COMPLETED","phase":"Phase 3","sponsor":"University of Dublin, Trinity College","drugs":["ketamine"],"nct":"NCT04939649","nsites":1,"countries":"Ireland","ccs":["IE"],"start":"2021-09-13","official":"Declan M McLoughlin, PhD (University of Dublin, Trinity College and St Patrick's Mental Health Services)","src":"https://clinicaltrials.gov/study/NCT04939649","sites":["St Patrick's Univeristy Hospital — Dublin, Ireland"],"conds":["Major Depressive Episode","Unipolar Depression","Bipolar Depression"],"condg":["Depression","Bipolar"],"enroll":63,"eid":"NCT04939649"},{"id":"study-NCT04814381","cat":"studies","name":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","status":"COMPLETED","phase":"Phase 4","sponsor":"University Hospital, Clermont-Ferrand","drugs":["ketamine"],"nct":"NCT04814381","nsites":14,"countries":"France","ccs":["FR"],"start":"2021-09-15","official":"Xavier MOISSET (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT04814381","sites":["CH Annecy Genevois — Annecy, France","Polyclinique Jean Villar — Bruges, France","CHU de Clermont-Ferrand — Clermont-Ferrand, France","CHRU De Lille — Lille, France","Hospices civils de Lyon, Hôpital Pierre Wertheimer — Lyon, France","AP-HM Marseille — Marseille, France","Clinique Beau Soleil — Montpellier, France","CHU de Montpellier — Montpellier, France"],"conds":["Refractory Chronic Cluster Headache"],"condg":["Chronic pain & headache"],"enroll":93,"eid":"NCT04814381"},{"id":"study-NCT05042765","cat":"studies","name":"Entheogen Resurgence","status":"COMPLETED","sponsor":"Vireo Health","drugs":["ayahuasca"],"nct":"NCT05042765","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-09-16","official":"Stephen Dahmer, ND (Resurgent Biosciences, Inc.)","src":"https://clinicaltrials.gov/study/NCT05042765","sites":["Vireo Health of New York — Queens, United States"],"conds":["Psychedelic Experiences"],"condg":["Other"],"enroll":102,"eid":"NCT05042765"},{"id":"study-NCT04916548","cat":"studies","name":"Repeated Neurocognitive Measurements in Depressed Patients","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Rebecca Price","drugs":["ketamine"],"nct":"NCT04916548","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-09-16","src":"https://clinicaltrials.gov/study/NCT04916548","sites":["Western Psychiatric Institute and Clinic — Pittsburgh, United States"],"conds":["Depression, Unipolar"],"condg":["Depression"],"enroll":15,"eid":"NCT04916548"},{"id":"study-NCT05049343","cat":"studies","name":"Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"Supernus Pharmaceuticals, Inc.","drugs":["ketamine"],"nct":"NCT05049343","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-09-21","src":"https://clinicaltrials.gov/study/NCT05049343","sites":["Sage Investigational Site — Newark, United States"],"conds":["Healthy Volunteer"],"condg":["Healthy volunteers"],"enroll":22,"eid":"NCT05049343"},{"id":"study-NCT05032833","cat":"studies","name":"Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"Beckley Psytech Limited","drugs":["DMT"],"nct":"NCT05032833","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2021-09-22","src":"https://clinicaltrials.gov/study/NCT05032833","sites":["King's College London — London, United Kingdom"],"conds":["Pharmacokinetics in Healthy Adults"],"condg":["Healthy volunteers"],"enroll":36,"eid":"NCT05032833"},{"id":"study-NCT04977674","cat":"studies","name":"Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"King's College London","drugs":["ketamine"],"nct":"NCT04977674","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2021-09-27","src":"https://clinicaltrials.gov/study/NCT04977674","sites":["King's College London — London, United Kingdom"],"conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"enroll":27,"eid":"NCT04977674"},{"id":"study-NCT04009759","cat":"studies","name":"Influence of Morphine or Ketamine or Saline Applied During In-hospital Cardiopulmonary Resuscitation on Early Survival","status":"UNKNOWN","phase":"Phase 1","sponsor":"University Hospital, Akershus","drugs":["esketamine","ketamine"],"nct":"NCT04009759","nsites":0,"start":"2021-10-01","src":"https://clinicaltrials.gov/study/NCT04009759","conds":["Cardiac Arrest"],"condg":["Other"],"contact":{"n":"Vladimir Kuklin, dr med","p":"+4798838024","e":"vkuklin@me.com"},"enroll":240,"eid":"NCT04009759"},{"id":"study-NCT06236113","cat":"studies","name":"Low Dose Ketamine for Blunt Thoracic Trauma","status":"COMPLETED","phase":"Phase 4","sponsor":"North Memorial Health Care","drugs":["ketamine"],"nct":"NCT06236113","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-10-01","official":"Michaela A West, MD, PhD (North Memorial Health); Joseph Farhat, MD (North Memorial Health)","src":"https://clinicaltrials.gov/study/NCT06236113","sites":["North Memorial Health Hospital — Robbinsdale, United States"],"conds":["Blunt Injury of Thorax","Multiple Rib Fractures, Involving Three Ribs"],"condg":["Other"],"enroll":50,"eid":"NCT06236113"},{"id":"study-NCT05071352","cat":"studies","name":"Adjuvant Continuous Infusion of Nefopam Versus Standard of Care in Mechanically Ventilated Critically Ill Patients: Randomized Double-blind Controlled Study","status":"COMPLETED","phase":"Phase 3","sponsor":"Cairo University","drugs":["ketamine"],"nct":"NCT05071352","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2021-10-01","official":"Mohammed Gamal Abdelraouf Amer, Pharm D (Cairo University)","src":"https://clinicaltrials.gov/study/NCT05071352","sites":["Cairo University Hospitals (Kasr Alainy) — Cairo, Egypt"],"conds":["Analgesia","Critical Illness","Mechanical Ventilation","Sedation"],"condg":["Other"],"enroll":60,"eid":"NCT05071352"},{"id":"study-NCT05067244","cat":"studies","name":"A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)","status":"COMPLETED","phase":"Phase 2","sponsor":"Remedy","drugs":["MDMA"],"nct":"NCT05067244","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2021-10-04","official":"Alison Bruni, MD (Remedy Institute); Anne Wagner, PhD (Remedy Institute)","src":"https://clinicaltrials.gov/study/NCT05067244","sites":["Remedy Institute — Toronto, Canada"],"conds":["Post Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":10,"eid":"NCT05067244"},{"id":"study-NCT04947085","cat":"studies","name":"Comparison of Nebulized Ketamine to Intravenous Sub-Dissociative Dose Ketamine for Pain","status":"COMPLETED","phase":"Phase 4","sponsor":"Antonios Likourezos","drugs":["ketamine"],"nct":"NCT04947085","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-10-04","official":"Sergey Motov, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT04947085","sites":["Maimonides Medical Center — Brooklyn, United States"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":150,"eid":"NCT04947085"},{"id":"study-NCT04522804","cat":"studies","name":"Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University of Utah","drugs":["psilocybin"],"nct":"NCT04522804","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-10-04","official":"Anna Beck, MD (Huntsman Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT04522804","sites":["Huntsman Cancer Institute — Salt Lake City, United States"],"conds":["Cancer"],"condg":["Cancer-related distress"],"enroll":12,"eid":"NCT04522804"},{"id":"study-NCT04912115","cat":"studies","name":"Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia","status":"SUSPENDED","phase":"Phase 2","sponsor":"PharmaTher Inc.","drugs":["ketamine"],"nct":"NCT04912115","nsites":7,"countries":"United States","ccs":["US"],"start":"2021-10-05","official":"Study Director (PharmaTher Inc.)","src":"https://clinicaltrials.gov/study/NCT04912115","sites":["Investigative Site #7 — Tucson, United States","Investigative Site #2 — Chula Vista, United States","Investigative Site #1 — Fountain Valley, United States","Investigative Site #3 — Miami, United States","Investigative Site #6 — Miami, United States","Investigative Site #5 — Rolling Meadows, United States","Investigative Site #4 — Plymouth, United States"],"conds":["Dyskinesias","Movement Disorders","Central Nervous System Diseases","Nervous System Diseases","Neurologic Manifestations"],"condg":["Other"],"enroll":30,"eid":"NCT04912115"},{"id":"study-NCT05060068","cat":"studies","name":"Effect of Intravenous S-ketamine on Opioid Consumption","status":"COMPLETED","phase":"N/A","sponsor":"The Second Hospital of Anhui Medical University","drugs":["esketamine","ketamine"],"nct":"NCT05060068","nsites":1,"countries":"China","ccs":["CN"],"start":"2021-10-07","official":"Ye Zhang, M.D., Ph. D. (The Second Hospital of Anhui Medical University)","src":"https://clinicaltrials.gov/study/NCT05060068","sites":["Second Affiliated Hospital of Anhui Medical University — Hefei, China"],"conds":["Breast Cancer Surgery"],"condg":["Cancer-related distress"],"enroll":345,"eid":"NCT05060068"},{"id":"study-NCT05752409","cat":"studies","name":"Comparison of Esketamine-Propofol and Fentanyl-Propofol","status":"UNKNOWN","phase":"N/A","sponsor":"Eye & ENT Hospital of Fudan University","drugs":["esketamine"],"nct":"NCT05752409","nsites":1,"countries":"China","ccs":["CN"],"start":"2021-10-08","official":"Fang Tan (Anesthesiology Department of Affiliated Eye and ENT Hospital, Fudan University)","src":"https://clinicaltrials.gov/study/NCT05752409","sites":["Anesthesiology Department of Affiliated Eye and ENT Hospital, Fudan University — Shanghai, China"],"conds":["Hemodynamics"],"condg":["Other"],"contact":{"n":"Fang Tan, Phd","p":"8613611716000","e":"tanfang@eentanesthesia.com"},"enroll":120,"eid":"NCT05752409"},{"id":"study-NCT04303325","cat":"studies","name":"Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI)","status":"UNKNOWN","phase":"Phase 4","sponsor":"China Medical University, China","drugs":["esketamine"],"nct":"NCT04303325","nsites":1,"countries":"China","ccs":["CN"],"start":"2021-10-08","src":"https://clinicaltrials.gov/study/NCT04303325","sites":["the First Hospital of China Medical University — Shenyang, China"],"conds":["Depression"],"condg":["Depression"],"enroll":72,"eid":"NCT04303325"},{"id":"study-NCT06150859","cat":"studies","name":"Ayahuasca Assisted Psychotherapy for Grief","status":"UNKNOWN","phase":"Phase 2","sponsor":"Beckley Med Foundation","drugs":["ayahuasca"],"nct":"NCT06150859","nsites":1,"countries":"Spain","ccs":["ES"],"start":"2021-10-15","official":"Magi Farré (Hospital German Trials I Pujol)","src":"https://clinicaltrials.gov/study/NCT06150859","sites":["Institut de Recerca Holistica de Montserat (Irehom) — Barcelona, Spain"],"conds":["Bereavement"],"condg":["Other"],"enroll":84,"eid":"NCT06150859"},{"id":"study-NCT07710027","cat":"studies","name":"Identification of a Safe and Non-Psychedelic Dose of Psilocybin","status":"COMPLETED","phase":"Phase 1","sponsor":"Diamond Therapeutics Inc.","drugs":["psilocybin"],"nct":"NCT07710027","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2021-10-19","src":"https://clinicaltrials.gov/study/NCT07710027","sites":["BioPharma Services Inc. — Toronto, Canada"],"conds":["Healthy Controls"],"condg":["Healthy volunteers"],"enroll":56,"eid":"NCT07710027"},{"id":"study-NCT05870501","cat":"studies","name":"Synaptic Imaging and Network Activity in Treatment Resistant Depression","status":"COMPLETED","phase":"N/A","sponsor":"King's College London","drugs":["ketamine"],"nct":"NCT05870501","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2021-10-20","official":"Mitul Mehta, PhD (King's College London)","src":"https://clinicaltrials.gov/study/NCT05870501","sites":["The Institute of Psychiatry, Psychology & Neuroscience, King's College London — London, United Kingdom"],"conds":["Depressive Disorder","Depressive Disorder, Major","Depressive Disorder, Treatment-Resistant","Bipolar Disorder","Bipolar Disorder I","Bipolar Disorder II"],"condg":["Depression","Bipolar"],"enroll":56,"eid":"NCT05870501"},{"id":"study-NCT05137938","cat":"studies","name":"Intranasal Ketamine in Ultra-REsistant Depression (SURE-ECT Non Responders)","status":"COMPLETED","phase":"N/A","sponsor":"Centre for Addiction and Mental Health","drugs":["ketamine"],"nct":"NCT05137938","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2021-10-25","official":"Yuliya Knyahnytska, MD, PhD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT05137938","sites":["Centre for Addiction and Mental Health — Toronto, Canada"],"conds":["Depression"],"condg":["Depression"],"enroll":25,"eid":"NCT05137938"},{"id":"study-NCT04060108","cat":"studies","name":"Stanford Regulating Circuits of the Brain Study - MDMA","status":"COMPLETED","sponsor":"Stanford University","drugs":["MDMA"],"nct":"NCT04060108","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-11-02","official":"Leanne M Williams, PhD (Stanford PI)","src":"https://clinicaltrials.gov/study/NCT04060108","sites":["Stanford Psychiatry and Behavioral Sciences Department — Palo Alto, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":22,"eid":"NCT04060108"},{"id":"study-NCT04650074","cat":"studies","name":"Effectiveness of Ketamine Administered by Mesotherapy in Complex Regional Pain Syndrome Type 1 (CRPS1)","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Hospices Civils de Lyon","drugs":["ketamine"],"nct":"NCT04650074","nsites":1,"countries":"France","ccs":["FR"],"start":"2021-11-05","src":"https://clinicaltrials.gov/study/NCT04650074","sites":["Department of orthopedic surgery and trauma emergencies of the lower limb, Edouard Herriot Hospital, Hospices Civils de Lyon — Lyon, France"],"conds":["Neuropathic Pain","Complex Regional Pain Syndrome Type 1"],"condg":["Chronic pain & headache"],"enroll":31,"eid":"NCT04650074"},{"id":"study-NCT04784143","cat":"studies","name":"Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD","status":"TERMINATED","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT04784143","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-11-08","official":"Rachel Yehuda (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT04784143","sites":["James J. Peters VA Medical Center — The Bronx, United States"],"conds":["PTSD"],"condg":["PTSD & trauma"],"enroll":26,"eid":"NCT04784143"},{"id":"study-NCT05095792","cat":"studies","name":"Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG)","status":"TERMINATED","sponsor":"Entheon Biomedical Corp.","drugs":["ketamine"],"nct":"NCT05095792","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-11-09","official":"Steven Levine, MD (Heading Health)","src":"https://clinicaltrials.gov/study/NCT05095792","sites":["Heading Health — Austin, United States"],"conds":["Treatment-resistant Depression"],"condg":["Depression"],"enroll":1,"eid":"NCT05095792"},{"id":"study-NCT05029466","cat":"studies","name":"Psilocybin for Treatment-Resistant Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Brain and Cognition Discovery Foundation","drugs":["psilocybin"],"nct":"NCT05029466","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2021-11-19","official":"Joshua D Rosenblat, MD, MSc (Canadian Rapid Treatment Centre of Excellence)","src":"https://clinicaltrials.gov/study/NCT05029466","sites":["Canadian Rapid Treatment Centre of Excellence (CRTCE) — Mississauga, Canada"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":30,"eid":"NCT05029466"},{"id":"study-NCT04944017","cat":"studies","name":"Ketamine for the Treatment of Depression in Parkinson's Disease","status":"COMPLETED","phase":"Phase 2","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT04944017","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-11-23","official":"Sophie E. Holmes, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT04944017","sites":["Yale New Haven Hospital — New Haven, United States"],"conds":["Parkinson's Disease","Depression"],"condg":["Depression","Neurology & cognition"],"enroll":51,"eid":"NCT04944017"},{"id":"study-NCT05488171","cat":"studies","name":"Abuse Potential and Human Pharmacology of Methylone","status":"UNKNOWN","phase":"Phase 1","sponsor":"Germans Trias i Pujol Hospital","drugs":["MDMA"],"nct":"NCT05488171","nsites":1,"countries":"Spain","ccs":["ES"],"start":"2021-12-01","official":"Magi Farré, MD, PhD (Germans Trias i Pujol Hospital)","src":"https://clinicaltrials.gov/study/NCT05488171","sites":["Germans Trias i Pujol Hospital — Badalona, Spain"],"conds":["Substance Use","Healthy Subjects"],"condg":["Addiction & substance use","Healthy volunteers"],"enroll":17,"eid":"NCT05488171"},{"id":"study-NCT04847206","cat":"studies","name":"Effects of MDMA-like Substances in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT04847206","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2021-12-01","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT04847206","sites":["University Hospital Basel, Clinical Trial Unit — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":23,"eid":"NCT04847206"},{"id":"study-NCT05155969","cat":"studies","name":"Intravenous Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery","status":"UNKNOWN","phase":"N/A","sponsor":"Anshi Wu","drugs":["esketamine"],"nct":"NCT05155969","nsites":2,"countries":"China","ccs":["CN"],"start":"2021-12-01","official":"Anshi Wu Wu, Ph.D (Beijing Chao-Yang Hospital, Capital Medical Unive)","src":"https://clinicaltrials.gov/study/NCT05155969","sites":["Beijing Chaoyang Hospital, Capital Medical University — Beijing, China","Beijing Chaoyang Hospital — Beijing, China"],"conds":["Postoperative Depression"],"condg":["Depression"],"contact":{"n":"Anshi Wu Wu, Ph.D","p":"+861085351330","e":"wuanshi1965@163.com"},"enroll":80,"eid":"NCT05155969"},{"id":"study-NCT05274230","cat":"studies","name":"Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy","status":"UNKNOWN","phase":"N/A","sponsor":"Apollo Neuroscience, Inc.","drugs":["MDMA"],"nct":"NCT05274230","nsites":1,"countries":"United States","ccs":["US"],"start":"2021-12-08","official":"Belinda Tan, MD PhD (The Board of Medicine)","src":"https://clinicaltrials.gov/study/NCT05274230","sites":["Apollo Neuroscience, Inc. — Pittsburgh, United States"],"conds":["Stress Disorders, Post-Traumatic"],"condg":["PTSD & trauma"],"contact":{"n":"Nicole Grinsell, MS","p":"8559220057","e":"nicole@apolloneuro.com"},"enroll":200,"eid":"NCT05274230"},{"id":"study-NCT05149586","cat":"studies","name":"Impact of Low Dose Ketamine Infusion in Septic Patient on Non-invasive Estimators of ICP","status":"COMPLETED","sponsor":"Zagazig University","drugs":["ketamine"],"nct":"NCT05149586","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2021-12-10","src":"https://clinicaltrials.gov/study/NCT05149586","sites":["Zagazig university — Zagazig, Egypt"],"conds":["Intracranial Pressure Changes"],"condg":["Other"],"enroll":100,"eid":"NCT05149586"},{"id":"study-NCT05200936","cat":"studies","name":"Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial","status":"COMPLETED","phase":"Phase 2","sponsor":"Definium Therapeutics US, Inc.","drugs":["LSD"],"nct":"NCT05200936","nsites":2,"countries":"Netherlands; Switzerland","ccs":["CH","NL"],"start":"2021-12-17","official":"Kim Kuypers (Maastricht University); Matthias Liechti (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05200936","sites":["Maastricht University — Maastricht, Netherlands","University Hospital Basel — Basel, Switzerland"],"conds":["ADHD","Attention Deficit Disorder"],"condg":["Other"],"enroll":53,"eid":"NCT05200936"},{"id":"study-NCT04005209","cat":"studies","name":"Ketamine Infusion for Sickle Cell Pain Crisis","status":"WITHDRAWN","phase":"Phase 4","sponsor":"Duke University","drugs":["ketamine"],"nct":"NCT04005209","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-01","src":"https://clinicaltrials.gov/study/NCT04005209","sites":["Duke Hospital — Durham, United States"],"conds":["Anemia; Sickle-Cell, With Crisis","Acute Pain"],"condg":["Chronic pain & headache"],"eid":"NCT04005209"},{"id":"study-NCT04386538","cat":"studies","name":"Effect of a Low Starch Diet in Patients With Ankylosing Spondylitis","status":"UNKNOWN","phase":"N/A","sponsor":"Universidade do Porto","drugs":["LSD"],"nct":"NCT04386538","nsites":1,"countries":"Portugal","ccs":["PT"],"start":"2022-01-03","official":"Alexandra MT Cardoso, MD (Universidade do Porto); Maria Leonor Silva, PhD (Centro de Investigação Interdisciplinar Egas Moniz)","src":"https://clinicaltrials.gov/study/NCT04386538","sites":["Instituto Português de Reumatologia — Lisbon, Portugal"],"conds":["Spondyloarthritis","Ankylosing Spondylitis"],"condg":["Other"],"contact":{"n":"Alexandra MT Cardoso, MD","p":"+351926142356","e":"alexandra.cardoso@gmail.com"},"enroll":150,"eid":"NCT04386538"},{"id":"study-NCT05193318","cat":"studies","name":"KAP for Depression in Abstinent Opioid Users","status":"TERMINATED","phase":"Phase 2","sponsor":"Medical University of South Carolina","drugs":["ketamine"],"nct":"NCT05193318","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-01-13","official":"Eric T Dobson, MD (Medical University of South Carolina)","src":"https://clinicaltrials.gov/study/NCT05193318","sites":["Medical University of South Carolina Centerspace — Charleston, United States"],"conds":["Opioid Use Disorder, Severe, in Sustained Remission","Opioid Use Disorder, Severe, in Early Remission","Major Depressive Disorder"],"condg":["Depression","Addiction & substance use"],"enroll":5,"eid":"NCT05193318"},{"id":"study-NCT05756621","cat":"studies","name":"Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest","status":"COMPLETED","sponsor":"University of Milano Bicocca","drugs":["ketamine"],"nct":"NCT05756621","nsites":10,"countries":"Italy","ccs":["IT"],"start":"2022-01-15","official":"Simone Beretta, MD, PhD (University of Milano Bicocca); Matteo Pozzi, MD (Fondazione IRCCS Gerardo dei Tintori Monza)","src":"https://clinicaltrials.gov/study/NCT05756621","sites":["ASST Spedali Civili Brescia — Brescia, Italy","Ospedale Centrale di Bolzano — Bolzano, Italy","Ospedale G. Brotzu — Cagliari, Italy","Ospedale M. Bufalini — Cesena, Italy","AOU Careggi — Florence, Italy","Fondazione IRCCS San Gerardo dei Tintori Monza — Monza, Italy","Azienda Ospedaliero-Universitaria di Modena — Modena, Italy","Azienda Ospedaliero-Universitaria di Parma — Parma, Italy"],"conds":["Status Epilepticus","Cardiac Arrest"],"condg":["Neurology & cognition"],"enroll":84,"eid":"NCT05756621"},{"id":"study-NCT05175781","cat":"studies","name":"Sedation for Non-invasive Ventilation in Blunt Chest Trauma","status":"COMPLETED","phase":"N/A","sponsor":"Aswan University Hospital","drugs":["ketamine"],"nct":"NCT05175781","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2022-01-18","src":"https://clinicaltrials.gov/study/NCT05175781","sites":["AHU — Aswān, Egypt"],"conds":["Chest Trauma"],"condg":["PTSD & trauma"],"enroll":45,"eid":"NCT05175781"},{"id":"study-NCT05297422","cat":"studies","name":"Axillary Approach to Brachial Plexus Blockade Using Ketamine, Regional Versus Intravenous Administration","status":"UNKNOWN","phase":"N/A","sponsor":"National and Kapodistrian University of Athens","drugs":["ketamine"],"nct":"NCT05297422","nsites":1,"countries":"Greece","ccs":["GR"],"start":"2022-01-20","official":"Theodoros Xanthos, Professor (National and Kapodistrian University of Athens)","src":"https://clinicaltrials.gov/study/NCT05297422","sites":["National and Kapodistrian University of Athens — Athens, Greece"],"conds":["Branchial Plexus Blockade","Anesthesia"],"condg":["Other"],"contact":{"n":"Demetra Solomou","p":"+306987707097","e":"Demetra_Sol@hotmail.com"},"enroll":81,"eid":"NCT05297422"},{"id":"study-NCT04613453","cat":"studies","name":"Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine","status":"TERMINATED","phase":"Phase 2","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT04613453","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-01-21","official":"Michael Bloch, MD MS (Yale University)","src":"https://clinicaltrials.gov/study/NCT04613453","sites":["Yale New Haven Hospital — New Haven, United States"],"conds":["Adolescent Suicide","Adolescent Depression"],"condg":["Depression"],"enroll":12,"eid":"NCT04613453"},{"id":"study-NCT05105061","cat":"studies","name":"Intramuscular Ketamine for Suicidal Ideation","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Icahn School of Medicine at Mount Sinai","drugs":["ketamine"],"nct":"NCT05105061","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-02","official":"Matthew Klein (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT05105061","sites":["Icahn School of Medicine at Mount Sinai — New York, United States"],"conds":["Suicidal Ideation"],"condg":["Other"],"eid":"NCT05105061"},{"id":"study-NCT05402189","cat":"studies","name":"Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioids in…","status":"UNKNOWN","phase":"Phase 1","sponsor":"Ain Shams University","drugs":["ketamine"],"nct":"NCT05402189","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2022-02-01","src":"https://clinicaltrials.gov/study/NCT05402189","sites":["Faculty of Medicine Ain Shams University — Cairo, Egypt"],"conds":["Ketodex Versus Opioids Based Anaesthesia in Cleft Palate…"],"condg":["Addiction & substance use"],"contact":{"n":"Marwa M Mohamed, Lecturer","p":"01000205686","e":"marwaemam600@gmail.com"},"enroll":50,"eid":"NCT05402189"},{"id":"study-NCT05414422","cat":"studies","name":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","status":"COMPLETED","phase":"Phase 2","sponsor":"Perception Neuroscience","drugs":["ketamine"],"nct":"NCT05414422","nsites":21,"countries":"Germany; Poland; United States","ccs":["DE","PL","US"],"start":"2022-02-01","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","sites":["Preferred Research Partners — Little Rock, United States","CNS Network — Garden Grove, United States","Kadima Neuropsychiatry Institute — La Jolla, United States","Synergy San Diego — Lemon Grove, United States","NRC Research Institute — Orange, United States","Premier Clinical Research Institute Inc. — Miami, United States","Psych Atlanta — Marietta, United States","Hassman Research Institute — Berlin, United States"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":102,"eid":"NCT05414422"},{"id":"study-NCT05168735","cat":"studies","name":"Ketamine + Mindfulness for Depression","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Rebecca Price","drugs":["ketamine"],"nct":"NCT05168735","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-02-01","official":"Rebecca Price, PhD (University of Pittsburgh)","src":"https://clinicaltrials.gov/study/NCT05168735","sites":["Western Psychiatric Institute and Clinic — Pittsburgh, United States"],"conds":["Depression, Unipolar"],"condg":["Depression"],"enroll":43,"eid":"NCT05168735"},{"id":"study-NCT05347849","cat":"studies","name":"Single Ascending Dose Study With BPL-003 in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"Beckley Psytech Limited","drugs":["DMT"],"nct":"NCT05347849","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2022-02-14","official":"VP & Head of Clinical Development, PhD (Beckley Psytech Ltd)","src":"https://clinicaltrials.gov/study/NCT05347849","sites":["Hammersmith Medicines Research — London, United Kingdom"],"conds":["Pharmacokinetics in Healthy Adults"],"condg":["Healthy volunteers"],"enroll":62,"eid":"NCT05347849"},{"id":"study-NCT05229913","cat":"studies","name":"Effects of Esketamine on Postpartum Depression","status":"UNKNOWN","phase":"Phase 4","sponsor":"Qinghai University","drugs":["esketamine"],"nct":"NCT05229913","nsites":0,"start":"2022-02-20","official":"Wang Xuejun, director (Department of Anesthesiology, Qinghai Red Cross Hospital)","src":"https://clinicaltrials.gov/study/NCT05229913","conds":["Postpartum Depression"],"condg":["Depression"],"contact":{"n":"Wang Xuejun, director","p":"+86 18997159111","e":"wangxuejunhsz9111@163.com"},"enroll":500,"eid":"NCT05229913"},{"id":"study-NCT05775393","cat":"studies","name":"Effects of Adding Dexamethasone Plus Ketamine to Bupivacine in Serrtatus Plane Block","status":"UNKNOWN","phase":"N/A","sponsor":"National Cancer Institute, Egypt","drugs":["ketamine"],"nct":"NCT05775393","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2022-02-20","src":"https://clinicaltrials.gov/study/NCT05775393","sites":["Ahmed Fakher — Cairo, Egypt"],"conds":["Post Operative Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Ahmed Fakher","p":"+201097419966","e":"ahmezfakhr66@gmail.com"},"enroll":60,"eid":"NCT05775393"},{"id":"study-NCT06131970","cat":"studies","name":"The Effectiveness of Continuous Ketamine Infusion (KONTINUE)","status":"COMPLETED","sponsor":"Centre Hospitalier Princesse Grace","drugs":["ketamine"],"nct":"NCT06131970","nsites":1,"countries":"Monaco","ccs":["MC"],"start":"2022-02-22","src":"https://clinicaltrials.gov/study/NCT06131970","sites":["Centre Hospitalier Princesse Grace — Monaco, Monaco"],"conds":["Chronic Pain"],"condg":["Chronic pain & headache"],"enroll":80,"eid":"NCT06131970"},{"id":"study-NCT05074823","cat":"studies","name":"Comparing Three Different Doses of Intrathecal Ketamine","status":"COMPLETED","phase":"Phase 4","sponsor":"Assiut University","drugs":["ketamine"],"nct":"NCT05074823","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2022-02-26","src":"https://clinicaltrials.gov/study/NCT05074823","sites":["Assiut University hospital — Asyut, Egypt"],"conds":["Ketamine Causing Adverse Effects in Therapeutic Use"],"condg":["Other"],"enroll":105,"eid":"NCT05074823"},{"id":"study-NCT04751812","cat":"studies","name":"Venous Cannulation Pain to Guide Choice of Anesthetic Method","status":"COMPLETED","phase":"N/A","sponsor":"Region Halland","drugs":["esketamine","ketamine"],"nct":"NCT04751812","nsites":1,"countries":"Sweden","ccs":["SE"],"start":"2022-03-01","official":"Anna KM Persson, PhD, MD (Region Halland)","src":"https://clinicaltrials.gov/study/NCT04751812","sites":["Halland Hospital Halmstad — Halmstad, Sweden"],"conds":["Pain, Postoperative","Pain Prediction","Laparoscopic Surgery","Venous Cannulation Pain","Anesthesia Opioid Free"],"condg":["Addiction & substance use","Chronic pain & headache"],"enroll":270,"eid":"NCT04751812"},{"id":"study-NCT06398834","cat":"studies","name":"Esketamine and Butorphanol for Post-Lobectomy Pain","status":"COMPLETED","phase":"Phase 4","sponsor":"Second People's Hospital of Hefei City","drugs":["esketamine"],"nct":"NCT06398834","nsites":1,"countries":"China","ccs":["CN"],"start":"2022-03-01","official":"Xianwen Hu, PhD (The Second Hospital of Anhui Medical University); Wensheng He, MD (The Second People's Hospital of Hefei)","src":"https://clinicaltrials.gov/study/NCT06398834","sites":["The Second People's Hospital of Hefei — Hefei, China"],"conds":["Esketamine","Pain","Post-thoracotomy Pain Syndrome","Thoracic Diseases"],"condg":["Chronic pain & headache"],"enroll":223,"eid":"NCT06398834"},{"id":"study-NCT05217706","cat":"studies","name":"Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department","status":"UNKNOWN","phase":"EARLY_Phase 1","sponsor":"Rady Children's Hospital, San Diego","drugs":["ketamine"],"nct":"NCT05217706","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-03-01","src":"https://clinicaltrials.gov/study/NCT05217706","sites":["Rady Children's Hospital San Diego — San Diego, United States"],"conds":["Depression","Suicidal Ideation"],"condg":["Depression"],"contact":{"n":"Tatyana Vayngortin, MD","p":"8589668036","e":"tvayngortin@rchsd.org"},"enroll":30,"eid":"NCT05217706"},{"id":"study-NCT05256264","cat":"studies","name":"Machine-learning Algorithm to Differentiate Intraoperative Ketamine Dosing Based on Electroencephalographic Density Spectrum Array Analysis","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","drugs":["ketamine"],"nct":"NCT05256264","nsites":1,"countries":"Taiwan","ccs":["TW"],"start":"2022-03-01","official":"Chien-Kun Ting, MD, PhD (Taipei Veterans General Hospital, Taiwan)","src":"https://clinicaltrials.gov/study/NCT05256264","sites":["Taipei Veterans General Hospital — Taipei, Taiwan"],"conds":["Electroencephalographic Density Spectrum Array Analysis","Density Spectrum Array","Ketamine","Multimodal General Anesthesia"],"condg":["Other"],"contact":{"n":"Hui Zen Hee","p":"+886928507736","e":"huizen.hee@gmail.com"},"enroll":90,"eid":"NCT05256264"},{"id":"study-NCT05163496","cat":"studies","name":"Frontline Clinician Psilocybin Study","status":"COMPLETED","phase":"Phase 3","sponsor":"University of Washington","drugs":["psilocybin"],"nct":"NCT05163496","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-03-03","official":"Anthony Back, MD (University of Washington)","src":"https://clinicaltrials.gov/study/NCT05163496","sites":["University of Washington — Seattle, United States"],"conds":["Burnout, Caregiver","Burnout, Professional","COVID-19","Depression","Post Traumatic Stress Disorder","Moral Injury"],"condg":["Depression","PTSD & trauma"],"enroll":30,"eid":"NCT05163496"},{"id":"study-NCT04950608","cat":"studies","name":"Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care","status":"COMPLETED","phase":"Phase 2","sponsor":"Yvan Beaussant, MD, MSci","drugs":["psilocybin"],"nct":"NCT04950608","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-03-09","official":"Yvan Beaussant, MD (Dana-Farber Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT04950608","sites":["Care Dimensions — Danvers, United States"],"conds":["Hospice","Psilocybin","Demoralization","Terminal Illness","Cancer-related Problem/Condition","Psychotherapy"],"condg":["End-of-life & palliative","Cancer-related distress"],"enroll":15,"eid":"NCT04950608"},{"id":"study-NCT05289440","cat":"studies","name":"Esketamine Administration on Recovery Quality After Radical Mastectomy","status":"COMPLETED","phase":"N/A","sponsor":"Anqing Municipal Hospital","drugs":["esketamine"],"nct":"NCT05289440","nsites":1,"countries":"China","ccs":["CN"],"start":"2022-03-15","src":"https://clinicaltrials.gov/study/NCT05289440","sites":["Department of Anqing Hospital Anesthesiology — Anqing, China"],"conds":["Esketamine and the Quality of Recovery"],"condg":["Other"],"enroll":105,"eid":"NCT05289440"},{"id":"study-NCT05045378","cat":"studies","name":"Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 4","sponsor":"Taipei Veterans General Hospital, Taiwan","drugs":["ketamine"],"nct":"NCT05045378","nsites":1,"countries":"Taiwan","ccs":["TW"],"start":"2022-03-15","official":"Mu-Hong Chen, M.D., Ph.D. (Taipei Veterans General Hospital, Taiwan)","src":"https://clinicaltrials.gov/study/NCT05045378","sites":["Taipei Veterans General Hospital, Taiwan — Taipei, Taiwan"],"conds":["Treatment-resistant Depression","Major Depressive Disorder"],"condg":["Depression"],"enroll":12,"eid":"NCT05045378"},{"id":"study-NCT05035927","cat":"studies","name":"Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder","status":"COMPLETED","phase":"Phase 2","sponsor":"TRYP Therapeutics","drugs":["psilocybin"],"nct":"NCT05035927","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-03-16","official":"Jennifer Miller, MD (University of Florida)","src":"https://clinicaltrials.gov/study/NCT05035927","sites":["University of Florida — Gainesville, United States"],"conds":["Binge Eating Disorder"],"condg":["Eating disorders"],"enroll":5,"eid":"NCT05035927"},{"id":"study-NCT04865653","cat":"studies","name":"LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD"],"nct":"NCT04865653","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2022-03-17","official":"Matthias E Liechti, MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT04865653","sites":["Clinical Pharmacology & Toxicology, University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":20,"eid":"NCT04865653"},{"id":"study-NCT05220410","cat":"studies","name":"The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation","status":"COMPLETED","phase":"Phase 2","sponsor":"Sheppard Pratt Health System","drugs":["psilocybin"],"nct":"NCT05220410","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-03-28","official":"Scott Aaronson, MD (Sheppard Pratt Health System)","src":"https://clinicaltrials.gov/study/NCT05220410","sites":["Sheppard Pratt Health System — Baltimore, United States"],"conds":["Treatment Resistant Depression","Suicidal Ideation"],"condg":["Depression"],"enroll":20,"eid":"NCT05220410"},{"id":"study-NCT05288764","cat":"studies","name":"Effect of Ketamine on BIS Values","status":"COMPLETED","sponsor":"University of Padova","drugs":["ketamine"],"nct":"NCT05288764","nsites":1,"countries":"Italy","ccs":["IT"],"start":"2022-03-31","src":"https://clinicaltrials.gov/study/NCT05288764","sites":["ULSS 2 Marca Trevigiana — Treviso, Italy"],"conds":["Anesthesia Brain Monitoring","Ketamine"],"condg":["Other"],"enroll":14,"eid":"NCT05288764"},{"id":"study-NCT05180149","cat":"studies","name":"Personality and Drug Use (PDU)","status":"WITHDRAWN","sponsor":"Quantified Citizen Technologies Inc.","drugs":["LSD","MDMA","ayahuasca","ibogaine","ketamine","mescaline","psilocybin"],"nct":"NCT05180149","nsites":0,"start":"2022-04","official":"Kim PC Kuypers, PhD (Maastricht University)","src":"https://clinicaltrials.gov/study/NCT05180149","conds":["Personality"],"condg":["Other"],"eid":"NCT05180149"},{"id":"study-NCT07099235","cat":"studies","name":"Chart Review of Patients Undergoing Ketamine Treatments for Depression","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","drugs":["esketamine","ketamine"],"nct":"NCT07099235","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2022-04-01","src":"https://clinicaltrials.gov/study/NCT07099235","sites":["Ontario Ketamine and Infusion Centre - Toronto Site — Mississauga, Canada"],"conds":["Depression - Major Depressive Disorder"],"condg":["Depression"],"enroll":250,"eid":"NCT07099235"},{"id":"study-NCT05752110","cat":"studies","name":"Effects of Subanesthetic Dose of Ketamine Given on Postoperative Mood in Patients Undergoing Fractional Curettage","status":"COMPLETED","phase":"Phase 4","sponsor":"Istanbul Training and Research Hospital","drugs":["ketamine"],"nct":"NCT05752110","nsites":2,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2022-04-01","official":"Mehmet TOPTAS, Ass.Prof.Dr (Istanbul Training and Research Hospital)","src":"https://clinicaltrials.gov/study/NCT05752110","sites":["Istanbul Training and Research Hospital — Istanbul, Turkey","IstanbulTRH — Istanbul, Turkey"],"conds":["Ketamine","Minor Surgical Procedure","Total Mood Score","Woman"],"condg":["Other"],"enroll":140,"eid":"NCT05752110"},{"id":"study-NCT05294835","cat":"studies","name":"Ketamine and Epigenetic Aging","status":"UNKNOWN","phase":"Phase 2","sponsor":"TruDiagnostic","drugs":["ketamine"],"nct":"NCT05294835","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-04-01","src":"https://clinicaltrials.gov/study/NCT05294835","sites":["Wild Health — Lexington, United States"],"conds":["Depression","Post Traumatic Stress Disorder"],"condg":["Depression","PTSD & trauma"],"contact":{"n":"Jessica Klunder","p":"(615) 278-6394","e":"jessica.klunder@wildhealth.com"},"enroll":20,"eid":"NCT05294835"},{"id":"study-NCT05051449","cat":"studies","name":"Ketamine for OUD and Comorbid Depression (OUDCD)","status":"TERMINATED","phase":"Phase 1","sponsor":"University of Maryland, Baltimore","drugs":["ketamine"],"nct":"NCT05051449","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-04-04","official":"Annabelle Belcher, PhD (University of Maryland, Baltimore)","src":"https://clinicaltrials.gov/study/NCT05051449","sites":["University of Maryland Baltimore — Baltimore, United States"],"conds":["Opioid Use Disorder","Depressive Disorder"],"condg":["Depression","Addiction & substance use"],"enroll":5,"eid":"NCT05051449"},{"id":"study-NCT05283408","cat":"studies","name":"The Clinical Study of Dexmedetomidine and Esketamine Combined Infusion Undergoing Modified Radical Mastectomy","status":"COMPLETED","phase":"N/A","sponsor":"Anqing Municipal Hospital","drugs":["esketamine"],"nct":"NCT05283408","nsites":1,"countries":"China","ccs":["CN"],"start":"2022-04-10","src":"https://clinicaltrials.gov/study/NCT05283408","sites":["Department of Anqing Hospital Anesthesiology — Anqing, China"],"conds":["Dexmedetomidine, Esketamine, Postoperative Pain and…"],"condg":["Chronic pain & headache"],"enroll":135,"eid":"NCT05283408"},{"id":"study-NCT05530668","cat":"studies","name":"Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective MAOI","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","drugs":["esketamine","ketamine"],"nct":"NCT05530668","nsites":1,"countries":"France","ccs":["FR"],"start":"2022-04-11","src":"https://clinicaltrials.gov/study/NCT05530668","sites":["Service de physiologie - Explorations fonctionnelles - CHU de Strasbourg - France — Strasbourg, France"],"conds":["Depression Anxiety Disorder"],"condg":["Depression","Anxiety"],"enroll":13,"eid":"NCT05530668"},{"id":"study-NCT05138068","cat":"studies","name":"Social Anxiety MDMA-Assisted Therapy Investigation","status":"COMPLETED","phase":"Phase 2","sponsor":"Jason B Luoma","drugs":["MDMA"],"nct":"NCT05138068","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-04-13","official":"Jason B Luoma, Ph.D. (Portland Psychotherapy Clinic, Research, and Training Center)","src":"https://clinicaltrials.gov/study/NCT05138068","sites":["Portland Psychotherapy Clinic, Research, & Training Center — Portland, United States"],"conds":["Social Anxiety Disorder"],"condg":["Anxiety"],"enroll":90,"eid":"NCT05138068"},{"id":"study-NCT04834427","cat":"studies","name":"Safety and Efficacy Evaluation of S (+) - Ketamine in Children","status":"UNKNOWN","phase":"Phase 4","sponsor":"Chinese PLA General Hospital","drugs":["esketamine","ketamine"],"nct":"NCT04834427","nsites":1,"countries":"China","ccs":["CN"],"start":"2022-04-20","official":"Weidong Mi, MD (Chinese PLA General Hospital)","src":"https://clinicaltrials.gov/study/NCT04834427","sites":["Chinese PLA General Hospital — Beijing, China"],"conds":["S-ketamine","Esketamine","Acute Pain","Postoperative Pain","Analgesia","Hyperalgesia"],"condg":["Depression","Anxiety","Chronic pain & headache"],"enroll":3000,"eid":"NCT04834427"},{"id":"study-NCT05233566","cat":"studies","name":"Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial","status":"COMPLETED","phase":"Phase 3","sponsor":"Washington University School of Medicine","drugs":["ketamine"],"nct":"NCT05233566","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-04-25","src":"https://clinicaltrials.gov/study/NCT05233566","sites":["Washington University School of Medicine — St Louis, United States"],"conds":["Postoperative Depression"],"condg":["Depression"],"enroll":32,"eid":"NCT05233566"},{"id":"study-NCT06370130","cat":"studies","name":"Different Dose of Esketamine Inhibiting Response to Laryngeal Mask Airway Insertion","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Aerospace Center Hospital","drugs":["esketamine"],"nct":"NCT06370130","nsites":1,"countries":"China","ccs":["CN"],"start":"2022-05-01","src":"https://clinicaltrials.gov/study/NCT06370130","sites":["Liang-Yuan Lu — Beijing, China"],"conds":["Anesthesia"],"condg":["Other"],"enroll":58,"eid":"NCT06370130"},{"id":"study-NCT05343507","cat":"studies","name":"Ketamine to Treat Patients With Post-comatose Disorders of Consciousness","status":"UNKNOWN","phase":"Phase 2/Phase 3","sponsor":"University of Liege","drugs":["ketamine"],"nct":"NCT05343507","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2022-05-01","official":"Olivia Gosseries, PhD (Coma Science Group (ULiege) & Centre du Cerveau2 (CHU Liege))","src":"https://clinicaltrials.gov/study/NCT05343507","sites":["Centre Hospitalier Neurologique William Lennox — Ottignies-Louvain-la-Neuve, Belgium"],"conds":["Disorder of Consciousness"],"condg":["Other"],"contact":{"n":"Paolo Cardone, MSc","p":"0456309880","e":"p.cardone@uliege.be"},"enroll":30,"eid":"NCT05343507"},{"id":"study-NCT05214417","cat":"studies","name":"Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy","status":"UNKNOWN","phase":"Phase 2","sponsor":"The Ketamine Research Foundation","drugs":["ketamine"],"nct":"NCT05214417","nsites":0,"start":"2022-05-01","official":"Philip E Wolfson, MD (Ketamine Research Foundation)","src":"https://clinicaltrials.gov/study/NCT05214417","conds":["Illness Terminal"],"condg":["Other"],"contact":{"n":"Philip E Wolfson, MD","p":"415-550-1700","e":"ketamine.research@gmail.com"},"enroll":120,"eid":"NCT05214417"},{"id":"study-NCT05177419","cat":"studies","name":"Effects of LSD on Neuroplasticity in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Fribourg","drugs":["LSD"],"nct":"NCT05177419","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2022-05-02","src":"https://clinicaltrials.gov/study/NCT05177419","sites":["University of Fribourg — Fribourg, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":45,"eid":"NCT05177419"},{"id":"study-NCT05646303","cat":"studies","name":"Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","status":"UNKNOWN","phase":"Phase 2","sponsor":"Clairvoyant Therapeutics","drugs":["psilocybin"],"nct":"NCT05646303","nsites":12,"countries":"Canada; Finland","ccs":["CA","FI"],"start":"2022-05-02","official":"Hannu Alho, MD (Addiktum Oy)","src":"https://clinicaltrials.gov/study/NCT05646303","sites":["Sabi Mind — Calgary, Canada","Okanagan Clinical Trials — Kelowna, Canada","Centre for Neurology Studies — Surrey, Canada","University of British Columbia, Department of Psychiatry, BRAIN Lab — Vancouver, Canada","Centricity Research — Halifax, Canada","MacAnxiety Research Centre — Hamilton, Canada","Department of Psychiatry, Queen's University — Kingston, Canada","Centre for Addiction and Mental Health — Toronto, Canada"],"conds":["Alcohol Use Disorder"],"condg":["Addiction & substance use"],"enroll":128,"eid":"NCT05646303"},{"id":"study-NCT05177146","cat":"studies","name":"Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression","status":"COMPLETED","phase":"N/A","sponsor":"Centre for Addiction and Mental Health","drugs":["ketamine"],"nct":"NCT05177146","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2022-05-04","official":"Yuliya Knyahnytska, MD, PhD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT05177146","sites":["Centre for Addiction and Mental Health — Toronto, Canada"],"conds":["Bipolar Disorder (BD)","Suicidality"],"condg":["Bipolar"],"enroll":16,"eid":"NCT05177146"},{"id":"study-NCT05046184","cat":"studies","name":"Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets","status":"COMPLETED","phase":"Phase 2","sponsor":"University of Texas Southwestern Medical Center","drugs":["ketamine"],"nct":"NCT05046184","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-05-05","src":"https://clinicaltrials.gov/study/NCT05046184","sites":["UT Southwestern Medical Center — Dallas, United States"],"conds":["Major Depressive Disorder","Healthy Controls"],"condg":["Depression","Healthy volunteers"],"enroll":165,"eid":"NCT05046184"},{"id":"study-NCT05379959","cat":"studies","name":"Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University of Chicago","drugs":["MDMA"],"nct":"NCT05379959","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-05-11","src":"https://clinicaltrials.gov/study/NCT05379959","sites":["University of Chicago — Chicago, United States"],"conds":["Stimulant Use","MDMA ('Ecstasy')","Social Behavior","Motivation"],"condg":["Addiction & substance use"],"enroll":43,"eid":"NCT05379959"},{"id":"study-NCT06297915","cat":"studies","name":"Infusion Treatments of Chronic Peripheral Neuropathic Pain","status":"COMPLETED","sponsor":"Hacettepe University","drugs":["ketamine"],"nct":"NCT06297915","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2022-05-17","official":"Gokhan Sucu, MD (HACETTEPE UNIVERSİTY)","src":"https://clinicaltrials.gov/study/NCT06297915","sites":["Hacettepe University — Ankara, Turkey"],"conds":["Neuropathic Pain"],"condg":["Chronic pain & headache"],"enroll":102,"eid":"NCT06297915"},{"id":"study-NCT04928703","cat":"studies","name":"Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"ERP Biomarker Qualification Consortium","drugs":["ketamine"],"nct":"NCT04928703","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-05-26","official":"Marco Cecchi, PhD (The ERP Biomarker Qualification Consortium)","src":"https://clinicaltrials.gov/study/NCT04928703","sites":["Hassman Research Institute — Marlton, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":33,"eid":"NCT04928703"},{"id":"study-NCT05317689","cat":"studies","name":"Comparing the Effects of Psilocin and Psilocybin in Healthy Adults","status":"UNKNOWN","phase":"Phase 1","sponsor":"University of California, San Francisco","drugs":["psilocybin"],"nct":"NCT05317689","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-05-26","official":"Joshua Woolley, MD/PhD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT05317689","sites":["University of California, San Francisco — San Francisco, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":20,"eid":"NCT05317689"},{"id":"study-NCT04538573","cat":"studies","name":"Virtual Reality MObility for Burn Patients","status":"UNKNOWN","phase":"N/A","sponsor":"St. Justine's Hospital","drugs":["ketamine"],"nct":"NCT04538573","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2022-05-27","official":"Sylvie Le May, PhD (St. Justine's Hospital)","src":"https://clinicaltrials.gov/study/NCT04538573","sites":["St. Justine's Hospital — Montreal, Canada"],"conds":["Pediatric Burns"],"condg":["Other"],"contact":{"n":"Sylvie Le May, PhD","p":"514-345-4931","e":"sylvie.lemay@umontreal.ca"},"enroll":20,"eid":"NCT04538573"},{"id":"study-NCT05422001","cat":"studies","name":"Low-dose KETamine as an Adjunct to MOrphine for Acute Pain in the ED","status":"TERMINATED","phase":"Phase 4","sponsor":"University of Aarhus","drugs":["esketamine","ketamine"],"nct":"NCT05422001","nsites":1,"countries":"Denmark","ccs":["DK"],"start":"2022-05-31","official":"Stine F Galili, MD (Aarhus University Hospital)","src":"https://clinicaltrials.gov/study/NCT05422001","sites":["Aarhus University Hospital — Aarhus N, Denmark"],"conds":["Acute Pain","Opioid Use"],"condg":["Addiction & substance use","Chronic pain & headache"],"enroll":116,"eid":"NCT05422001"},{"id":"study-NCT05573568","cat":"studies","name":"Clinical Study of DMT in Healthy Adults","status":"COMPLETED","phase":"Phase 1","sponsor":"Biomind Labs Inc.","drugs":["DMT"],"nct":"NCT05573568","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2022-06-01","src":"https://clinicaltrials.gov/study/NCT05573568","sites":["Hospital Universitário Onofre Lopes — Natal, Brazil"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":27,"eid":"NCT05573568"},{"id":"study-NCT05320120","cat":"studies","name":"Investigation of Intranasal Ketamine Related Changes in Attentional Brain Networks With Functional and Structural MRI","status":"COMPLETED","phase":"Phase 1","sponsor":"Rupert Lanzenberger","drugs":["esketamine"],"nct":"NCT05320120","nsites":1,"countries":"Austria","ccs":["AT"],"start":"2022-06-01","src":"https://clinicaltrials.gov/study/NCT05320120","sites":["Department of Psychiatry and Psychotherapy — Vienna, Austria"],"conds":["Ketamine Treatment"],"condg":["Other"],"enroll":33,"eid":"NCT05320120"},{"id":"study-NCT05315271","cat":"studies","name":"Supraclavicular Brachial Plexus Block During Upper Limb Surgeries","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Sohag University","drugs":["ketamine"],"nct":"NCT05315271","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2022-06-01","src":"https://clinicaltrials.gov/study/NCT05315271","sites":["Sohag University — Sohag, Egypt"],"conds":["Brachial Plexus Block"],"condg":["Other"],"enroll":60,"eid":"NCT05315271"},{"id":"study-NCT04955470","cat":"studies","name":"Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics","status":"TERMINATED","phase":"Phase 1/Phase 2","sponsor":"University of British Columbia","drugs":["ketamine"],"nct":"NCT04955470","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2022-06-01","official":"Quynh Doan, PhD MHSc MD (University of British Columbia)","src":"https://clinicaltrials.gov/study/NCT04955470","sites":["BC Children's Hospital — Vancouver, Canada"],"conds":["Suicidal Ideation"],"condg":["Other"],"enroll":15,"eid":"NCT04955470"},{"id":"study-NCT05320107","cat":"studies","name":"The Effect of Ketamine on Aesthetics and Role for Antidepressant Effects","status":"UNKNOWN","phase":"Phase 1","sponsor":"Medical University of Vienna","drugs":["ketamine"],"nct":"NCT05320107","nsites":1,"countries":"Austria","ccs":["AT"],"start":"2022-06-01","src":"https://clinicaltrials.gov/study/NCT05320107","sites":["Medical University of Vienna — Vienna, Austria"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Rupert Lanzenberger, MD","p":"0043 1 40400","e":"rupert.lanzenberger@meduniwien.ac.at"},"enroll":60,"eid":"NCT05320107"},{"id":"study-NCT05312151","cat":"studies","name":"The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","status":"COMPLETED","phase":"Phase 2","sponsor":"COMPASS Pathways","drugs":["psilocybin"],"nct":"NCT05312151","nsites":3,"countries":"United Kingdom; United States","ccs":["GB","US"],"start":"2022-06-10","src":"https://clinicaltrials.gov/study/NCT05312151","sites":["Sunstone Therapies — Rockville, United States","Icahn School of Medicine at Mount Sinai — New York, United States","Kings College London, Institute of Psychiatry, Psychology and Neurology — London, United Kingdom"],"conds":["Post Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":22,"eid":"NCT05312151"},{"id":"study-NCT05379179","cat":"studies","name":"Ketamine Pilot Study","status":"TERMINATED","phase":"Phase 4","sponsor":"Meghan Spyres","drugs":["ketamine"],"nct":"NCT05379179","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-06-20","official":"Meghan Spyres, MD (University of Arizona)","src":"https://clinicaltrials.gov/study/NCT05379179","sites":["Banner - University Medical Center, Phoenix campus — Phoenix, United States"],"conds":["Rattlesnake Envenomation"],"condg":["Other"],"enroll":3,"eid":"NCT05379179"},{"id":"study-NCT05416073","cat":"studies","name":"Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma","status":"UNKNOWN","phase":"Phase 4","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","drugs":["esketamine"],"nct":"NCT05416073","nsites":1,"countries":"China","ccs":["CN"],"start":"2022-06-22","official":"Huang He, MD (The Second Affiliated Hospital, Chongqing Medical University); Huang yan, MD (The Second Affiliated Hospital, Chongqing Medical University)","src":"https://clinicaltrials.gov/study/NCT05416073","sites":["The Second Affiliated Hospital, Chongqing Medical University — Chongqing, China"],"conds":["Hepatocellular Carcinoma","Transarterial Chemoembolization","Hepatic Arterial Infusion Chemotherapy","Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Duan Guang you, MD","p":"18323376014","e":"duangy@hospital.cqmu.edu.cn"},"enroll":70,"eid":"NCT05416073"},{"id":"study-NCT05478278","cat":"studies","name":"An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics","status":"COMPLETED","phase":"Phase 1","sponsor":"Usona Institute","drugs":["psilocybin"],"nct":"NCT05478278","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-06-22","src":"https://clinicaltrials.gov/study/NCT05478278","sites":["Altasciences Clinical Kansas, Inc — Overland Park, United States"],"conds":["QTc Interval","Pharmacokinetics"],"condg":["Other"],"enroll":60,"eid":"NCT05478278"},{"id":"study-NCT06219928","cat":"studies","name":"Comparison of the Effects of Dexmedetomidine and Ketamine Infusion on the Inflammatory Response in Liver Resection","status":"COMPLETED","phase":"N/A","sponsor":"Ataturk University","drugs":["ketamine"],"nct":"NCT06219928","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2022-06-30","src":"https://clinicaltrials.gov/study/NCT06219928","sites":["Ataturk University — Erzurum, Turkey"],"conds":["Inflammation","Analgesia"],"condg":["Other"],"enroll":45,"eid":"NCT06219928"},{"id":"study-NCT05809609","cat":"studies","name":"Glutamate Emotion Memory Study","status":"UNKNOWN","phase":"N/A","sponsor":"University of Oxford","drugs":["ketamine"],"nct":"NCT05809609","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2022-07-01","official":"Catherine Harmer, DPhil (University of Oxford)","src":"https://clinicaltrials.gov/study/NCT05809609","sites":["Department of Psychiatry, University of Oxford — Oxford, United Kingdom"],"conds":["Treatment Resistant Depression","Depression","Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Sara Costi, MD","p":"01865 618303","e":"sara.costi@psych.ox.ac.uk"},"enroll":60,"eid":"NCT05809609"},{"id":"study-NCT05305105","cat":"studies","name":"Effects of Psilocybin in Post-Treatment Lyme Disease","status":"COMPLETED","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT05305105","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-07-01","official":"Albert Garcia-Romeu, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT05305105","sites":["Behavioral Pharmacology Research Unit — Baltimore, United States"],"conds":["Post-Treatment Lyme Disease","Chronic Lyme Disease","Lyme Disease, Chronic"],"condg":["Other"],"enroll":20,"eid":"NCT05305105"},{"id":"study-NCT05004896","cat":"studies","name":"Ketamine for Treatment-Resistant Bipolar Disorder","status":"COMPLETED","phase":"Phase 2","sponsor":"Joshua Rosenblat","drugs":["ketamine"],"nct":"NCT05004896","nsites":3,"countries":"Canada","ccs":["CA"],"start":"2022-07-04","official":"Joshua Rosenblat, MD, MSc (Toronto Western Hospital, Psychiatry)","src":"https://clinicaltrials.gov/study/NCT05004896","sites":["Toronto General Hospital — Toronto, Canada","Toronto Western Hospital — Toronto, Canada","Ontario Shores Centre for Mental Health Sciences — Whitby, Canada"],"conds":["Bipolar Disorder","Bipolar Depression","Bipolar I Disorder","Bipolar II Disorder"],"condg":["Depression","Bipolar"],"enroll":71,"eid":"NCT05004896"},{"id":"study-NCT05487885","cat":"studies","name":"Anhedonia, Development, and Emotions: Phenotyping and Therapeutics","status":"COMPLETED","phase":"Phase 4","sponsor":"Erika Forbes","drugs":["ketamine"],"nct":"NCT05487885","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-07-22","official":"Erika E Forbes, PhD (University of Pittsburgh)","src":"https://clinicaltrials.gov/study/NCT05487885","sites":["Loeffler Building — Pittsburgh, United States"],"conds":["Depression","Anhedonia"],"condg":["Depression"],"enroll":123,"eid":"NCT05487885"},{"id":"study-NCT05147402","cat":"studies","name":"Food Effects on Bioavailability of MDMA in Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT05147402","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-07-28","official":"William B Smith, M.D. (Alliance for Multispecialty Research)","src":"https://clinicaltrials.gov/study/NCT05147402","sites":["Alliance for Multispecialty Research LLC — Knoxville, United States"],"conds":["Pharmacokinetics"],"condg":["Other"],"enroll":14,"eid":"NCT05147402"},{"id":"study-NCT04968938","cat":"studies","name":"Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT04968938","nsites":0,"start":"2022-08","official":"Devon Christie, MD (Department of Medicine, University of British Columbia)","src":"https://clinicaltrials.gov/study/NCT04968938","conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"eid":"NCT04968938"},{"id":"study-NCT04939987","cat":"studies","name":"Opioid-Free Pain Control Regiment Following Robotic Radical Prostatectomy","status":"WITHDRAWN","phase":"Phase 2/Phase 3","sponsor":"Wake Forest University Health Sciences","drugs":["ketamine"],"nct":"NCT04939987","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-08","official":"Ram Pathak, MD (Wake Forest Health Sciences)","src":"https://clinicaltrials.gov/study/NCT04939987","sites":["Wake Forest Health Sciences — Winston-Salem, United States"],"conds":["Radical Prostatectomies"],"condg":["Other"],"eid":"NCT04939987"},{"id":"study-NCT05635955","cat":"studies","name":"Remimazolam Versus Propofol for Painless Abortion","status":"COMPLETED","phase":"Phase 2","sponsor":"Maternal and Child Health Hospital of Hubei Province","drugs":["esketamine"],"nct":"NCT05635955","nsites":1,"countries":"China","ccs":["CN"],"start":"2022-08-01","official":"Na Li, MD (Maternal and Child Health Hospital of Hubei Province)","src":"https://clinicaltrials.gov/study/NCT05635955","sites":["Maternal and Child Health Hospital of Hubei Province — Wuhan, China"],"conds":["Anesthesia","Abortion Early"],"condg":["Other"],"enroll":100,"eid":"NCT05635955"},{"id":"study-NCT05385783","cat":"studies","name":"A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Cybin IRL Limited","drugs":["psilocybin"],"nct":"NCT05385783","nsites":3,"countries":"United States","ccs":["US"],"start":"2022-08-02","official":"Amir Inamdar, MBBS,DNB,MFPM (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT05385783","sites":["CenExel ACMR — Atlanta, United States","iResearch Atlanta — Decatur, United States","Clinilabs Drug Development Corporation — Eatontown, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":57,"eid":"NCT05385783"},{"id":"study-NCT05887310","cat":"studies","name":"In Vitro Modeling of Drug-resistant Psychiatric Disorders Using Induced Pluripotent Cells","status":"UNKNOWN","sponsor":"University of Milano Bicocca","drugs":["esketamine","ketamine"],"nct":"NCT05887310","nsites":1,"countries":"Italy","ccs":["IT"],"start":"2022-08-05","src":"https://clinicaltrials.gov/study/NCT05887310","sites":["Fondazione IRCCS San Gerardo di Monza — Monza, Italy"],"conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"enroll":50,"eid":"NCT05887310"},{"id":"study-NCT04833816","cat":"studies","name":"Ketamine Low dOse Evaluation on Morphine Consumption in Traumatic Patient","status":"COMPLETED","phase":"Phase 3","sponsor":"Assistance Publique Hopitaux De Marseille","drugs":["ketamine"],"nct":"NCT04833816","nsites":1,"countries":"France","ccs":["FR"],"start":"2022-08-05","official":"Jean Olivier ARNAUD (AP-HM)","src":"https://clinicaltrials.gov/study/NCT04833816","sites":["Service Anesthésie Réanimation - Hôpital nord — Marseille, France"],"conds":["Traumatic Injury"],"condg":["PTSD & trauma"],"enroll":140,"eid":"NCT04833816"},{"id":"study-NCT05895318","cat":"studies","name":"Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD","status":"COMPLETED","sponsor":"Albany Research Institute, Inc.","drugs":["MDMA"],"nct":"NCT05895318","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-08-08","official":"Caitlin Holley, Ph.D. (Stratton VA Medical Center)","src":"https://clinicaltrials.gov/study/NCT05895318","sites":["Stratton VA Medical Center — Albany, United States"],"conds":["Post Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":30,"eid":"NCT05895318"},{"id":"study-NCT05339074","cat":"studies","name":"Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Joshua Rosenblat","drugs":["ketamine"],"nct":"NCT05339074","nsites":3,"countries":"Canada","ccs":["CA"],"start":"2022-08-11","official":"Joshua Rosenblat, MD, MSc (Toronto Western Hospital, Psychiatry)","src":"https://clinicaltrials.gov/study/NCT05339074","sites":["Toronto General Hospital — Toronto, Canada","Toronto Western Hospital — Toronto, Canada","Ontario Shores Centre for Mental Health Sciences — Whitby, Canada"],"conds":["Bipolar Disorder","Bipolar Depression","Bipolar I Disorder","Bipolar II Disorder"],"condg":["Depression","Bipolar"],"enroll":41,"eid":"NCT05339074"},{"id":"study-NCT05548075","cat":"studies","name":"Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action","status":"UNKNOWN","sponsor":"Imperial College London","drugs":["psilocybin"],"nct":"NCT05548075","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2022-08-15","official":"David Nutt (Imperial College London)","src":"https://clinicaltrials.gov/study/NCT05548075","sites":["Imperial College London — London, United Kingdom"],"conds":["Fibromyalgia"],"condg":["Chronic pain & headache"],"enroll":20,"eid":"NCT05548075"},{"id":"study-NCT05407064","cat":"studies","name":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","status":"COMPLETED","phase":"Phase 2","sponsor":"Definium Therapeutics US, Inc.","drugs":["LSD"],"nct":"NCT05407064","nsites":22,"countries":"United States","ccs":["US"],"start":"2022-08-24","src":"https://clinicaltrials.gov/study/NCT05407064","sites":["Preferred Research Partners — Little Rock, United States","Irvine Center for Clinical Research — Irvine, United States","Kadima Neuropsychiatry Institute — La Jolla, United States","Pacific Neuroscience Institute — Santa Monica, United States","Mountain View Clinical Research — Denver, United States","Wholeness Center — Fort Collins, United States","Segal Trials — Lauderhill, United States","CNS Healthcare - Orlando — Orlando, United States"],"conds":["Anxiety Generalized"],"condg":["Anxiety"],"enroll":198,"eid":"NCT05407064"},{"id":"study-NCT05019885","cat":"studies","name":"The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy","status":"COMPLETED","phase":"Phase 2","sponsor":"Madeline Fields","drugs":["ketamine"],"nct":"NCT05019885","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-08-26","official":"Madeline Fields, MD (Icahn School of Medicine); Lara Marcuse, MD (Icahn School of Medicine)","src":"https://clinicaltrials.gov/study/NCT05019885","sites":["Mount Sinai Hospital — New York, United States"],"conds":["Drug Resistant Epilepsy","Medically Refractory Epilepsy","Refractory Epilepsy"],"condg":["Neurology & cognition"],"enroll":12,"eid":"NCT05019885"},{"id":"study-NCT05468047","cat":"studies","name":"Ketamine Therapy Experiential Education Study","status":"UNKNOWN","phase":"EARLY_Phase 1","sponsor":"Integrative Psychiatry Institute","drugs":["ketamine"],"nct":"NCT05468047","nsites":0,"start":"2022-09","src":"https://clinicaltrials.gov/study/NCT05468047","conds":["Psychedelic Experiences","Therapeutic Alliance","Psychology, Perceptual"],"condg":["Other"],"enroll":500,"eid":"NCT05468047"},{"id":"study-NCT05268497","cat":"studies","name":"A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression","status":"WITHDRAWN","phase":"Phase 1","sponsor":"Janssen Research & Development, LLC","drugs":["esketamine"],"nct":"NCT05268497","nsites":5,"countries":"United States","ccs":["US"],"start":"2022-09-01","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT05268497","sites":["Yale University — New Haven, United States","Rush University Medical Center — Chicago, United States","University of Chicago — Chicago, United States","Sheppard Pratt Health System — Baltimore, United States","University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience — Cincinnati, United States"],"conds":["Depression"],"condg":["Depression"],"eid":"NCT05268497"},{"id":"study-NCT05137587","cat":"studies","name":"Importance of Integrated Pulmonary Index in Pediatric Bronchoscopy","status":"COMPLETED","phase":"N/A","sponsor":"Marmara University","drugs":["ketamine"],"nct":"NCT05137587","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2022-09-01","official":"Ruslan Abdullayev (Marmara University Department of Anesthesiology and Reanimation)","src":"https://clinicaltrials.gov/study/NCT05137587","sites":["Marmara University School of Medicine — Istanbul, Turkey"],"conds":["Monitored Anesthesia Care","Respiratory Monitoring"],"condg":["Other"],"enroll":60,"eid":"NCT05137587"},{"id":"study-NCT04220125","cat":"studies","name":"Preoperative Ketamine and Perioperative Depression","status":"WITHDRAWN","phase":"Phase 4","sponsor":"Northwestern University","drugs":["ketamine"],"nct":"NCT04220125","nsites":0,"start":"2022-09-01","official":"Charles Hogue, MD (Northwestern University)","src":"https://clinicaltrials.gov/study/NCT04220125","conds":["Depressive Disorder"],"condg":["Depression"],"eid":"NCT04220125"},{"id":"study-NCT05508594","cat":"studies","name":"Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Cessatech A/S","drugs":["ketamine"],"nct":"NCT05508594","nsites":1,"countries":"Denmark","ccs":["DK"],"start":"2022-09-05","src":"https://clinicaltrials.gov/study/NCT05508594","sites":["DanTrials — Copenhagen, Denmark"],"conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":220,"eid":"NCT05508594"},{"id":"study-NCT04989972","cat":"studies","name":"Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Wake Network, Inc.","drugs":["psilocybin"],"nct":"NCT04989972","nsites":1,"countries":"Jamaica","ccs":["JM"],"start":"2022-09-15","official":"Roger Gibson (Faculty of Medical Sciences UWI Mona); Sharon White (Wake Network, Inc.)","src":"https://clinicaltrials.gov/study/NCT04989972","sites":["FMS Department of Psychiatry — Kingston, Jamaica"],"conds":["Anxiety and Depression"],"condg":["Depression","Anxiety"],"eid":"NCT04989972"},{"id":"study-NCT05381974","cat":"studies","name":"The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Massachusetts General Hospital","drugs":["psilocybin"],"nct":"NCT05381974","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-09-15","official":"Sharmin Ghaznavi, MD, PhD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT05381974","sites":["Athinoula A. Martinos Center for Biomedical Imaging — Charlestown, United States"],"conds":["Treatment-Resistant Major Depressive Disorder"],"condg":["Depression"],"eid":"NCT05381974"},{"id":"study-NCT05331131","cat":"studies","name":"Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Northwell Health","drugs":["ketamine"],"nct":"NCT05331131","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-09-19","official":"Bhupesh Parashar, MD, DrPH (Northwell Health)","src":"https://clinicaltrials.gov/study/NCT05331131","sites":["Center for Advanced Medicine — Lake Success, United States"],"conds":["Cancer of Head and Neck","Mucositis Oral","Pharyngeal Mucositis"],"condg":["Cancer-related distress"],"eid":"NCT05331131"},{"id":"study-NCT05823454","cat":"studies","name":"Consciousness-specific Brain Network Connection of Propofol Sedation and Prolonged Disorders of Consciousness","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","drugs":["esketamine","ketamine"],"nct":"NCT05823454","nsites":1,"countries":"China","ccs":["CN"],"start":"2022-09-30","src":"https://clinicaltrials.gov/study/NCT05823454","sites":["Beijing Tiantan Hospital, Capital Medical University — Beijing, China"],"conds":["Consciousness Disorder"],"condg":["Other"],"enroll":200,"eid":"NCT05823454"},{"id":"study-NCT05277636","cat":"studies","name":"Acute Effects of R- and S-MDMA in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT05277636","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2022-10-01","official":"Matthias E Liechti, MD (University Hospital Basel, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05277636","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":24,"eid":"NCT05277636"},{"id":"study-NCT05582213","cat":"studies","name":"Effect of Ketamine Versus Sevoflurane On The Right Ventricular Pressure","status":"COMPLETED","phase":"N/A","sponsor":"Ain Shams University","drugs":["ketamine"],"nct":"NCT05582213","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2022-10-01","src":"https://clinicaltrials.gov/study/NCT05582213","sites":["Ain Shams University — Cairo, Egypt"],"conds":["Congenital Pulmonary Stenosis"],"condg":["Other"],"enroll":40,"eid":"NCT05582213"},{"id":"study-NCT05464264","cat":"studies","name":"Auditory MMN EEG in TRD in Response to Ketamine","status":"UNKNOWN","sponsor":"Unity Health Toronto","drugs":["ketamine"],"nct":"NCT05464264","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2022-10-03","src":"https://clinicaltrials.gov/study/NCT05464264","sites":["St. Michael's Hospital — Toronto, Canada"],"conds":["Treatment-resistant Depression (TRD)"],"condg":["Depression"],"contact":{"n":"Venkat Bhat, MD MSc","p":"416-360-4000","e":"Venkat.Bhat@unityhealth.to"},"enroll":30,"eid":"NCT05464264"},{"id":"study-NCT04592809","cat":"studies","name":"Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents","status":"COMPLETED","phase":"Phase 3","sponsor":"University of Texas Southwestern Medical Center","drugs":["ketamine"],"nct":"NCT04592809","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-10-03","official":"Madhukar Trivedi, MD (University of Texas Southwestern Medical Center)","src":"https://clinicaltrials.gov/study/NCT04592809","sites":["UT Southwestern Medical Center — Dallas, United States"],"conds":["Suicide, Attempted","Suicide and Depression","Suicide Threat"],"condg":["Depression"],"enroll":50,"eid":"NCT04592809"},{"id":"study-NCT05243329","cat":"studies","name":"Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder","status":"UNKNOWN","phase":"Phase 2","sponsor":"Halucenex Life Sciences Inc.","drugs":["psilocybin"],"nct":"NCT05243329","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2022-10-03","official":"Lisa Batten, PhD (Halucenex Life Sciences); Paige Stevens, MD (Contracted)","src":"https://clinicaltrials.gov/study/NCT05243329","sites":["Halucenex Life Sciences Inc. — Windsor, Canada"],"conds":["Treatment Resistant Disorders","Post Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":20,"eid":"NCT05243329"},{"id":"study-NCT05224336","cat":"studies","name":"Psilocybin-assisted Therapy for Phantom Limb Pain","status":"COMPLETED","phase":"Phase 1","sponsor":"University of California, San Diego","drugs":["psilocybin"],"nct":"NCT05224336","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-10-03","src":"https://clinicaltrials.gov/study/NCT05224336","sites":["University of California, San Diego — San Diego, United States"],"conds":["Phantom Limb Pain"],"condg":["Chronic pain & headache"],"enroll":10,"eid":"NCT05224336"},{"id":"study-NCT05481736","cat":"studies","name":"Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study","status":"COMPLETED","phase":"Phase 2","sponsor":"COMPASS Pathways","drugs":["psilocybin"],"nct":"NCT05481736","nsites":5,"countries":"Ireland; United Kingdom; United States","ccs":["GB","IE","US"],"start":"2022-10-12","src":"https://clinicaltrials.gov/study/NCT05481736","sites":["Altman Clinical and Translational Research Institute — San Diego, United States","Sheppard Pratt Health System — Baltimore, United States","Dell Medical School — Austin, United States","Tallaght University Hospital — Dublin, Ireland","Kings College London, Institute of Psychiatry, Psychology and Neurology — London, United Kingdom"],"conds":["Anorexia Nervosa"],"condg":["Eating disorders"],"enroll":32,"eid":"NCT05481736"},{"id":"study-NCT05323019","cat":"studies","name":"Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression","status":"TERMINATED","phase":"Phase 2","sponsor":"Zylorion Health","drugs":["esketamine","ketamine"],"nct":"NCT05323019","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2022-10-13","official":"Pierre Chue, MBBCh (Amygdala Associates)","src":"https://clinicaltrials.gov/study/NCT05323019","sites":["City Center Pharmacy and Medical Clinic — Edmonton, Canada"],"conds":["Treatment Resistant Major Depressive Disorder"],"condg":["Depression"],"enroll":6,"eid":"NCT05323019"},{"id":"study-NCT05086250","cat":"studies","name":"Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Cedars-Sinai Medical Center","drugs":["ketamine"],"nct":"NCT05086250","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-10-20","official":"Scott Irwin, MD, PhD (Cedars-Sinai Medical Center)","src":"https://clinicaltrials.gov/study/NCT05086250","sites":["Cedars-Sinai Medical Center — Los Angeles, United States"],"conds":["Anxiety","Pancreatic Cancer"],"condg":["Anxiety","Cancer-related distress"],"enroll":12,"eid":"NCT05086250"},{"id":"study-NCT05175430","cat":"studies","name":"Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD"],"nct":"NCT05175430","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2022-10-24","official":"Matthias E Liechti, Dr., MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05175430","sites":["Clinical Pharmacology & Toxicology, University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":24,"eid":"NCT05175430"},{"id":"study-NCT06258031","cat":"studies","name":"PsilOCD: A Pharmacological-Challenge Feasibility Study","status":"COMPLETED","phase":"Phase 1","sponsor":"Imperial College London","drugs":["psilocybin"],"nct":"NCT06258031","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2022-10-28","official":"Professor David Nutt (Imperial College London); Dr David Erritzoe (Imperial College London)","src":"https://clinicaltrials.gov/study/NCT06258031","sites":["CIPPRes Clinic — London, United Kingdom"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"enroll":19,"eid":"NCT06258031"},{"id":"study-NCT07212946","cat":"studies","name":"Ayahuasca and Esketamine for Major Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"University of Sao Paulo","drugs":["ayahuasca","esketamine"],"nct":"NCT07212946","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2022-10-30","src":"https://clinicaltrials.gov/study/NCT07212946","sites":["Hospital das Clínicas da FMRP-USP — Ribeirão Preto, Brazil"],"conds":["Major Depression Severe"],"condg":["Depression"],"enroll":22,"eid":"NCT07212946"},{"id":"study-NCT03380728","cat":"studies","name":"Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial","status":"COMPLETED","phase":"Phase 2","sponsor":"University of Sao Paulo","drugs":["ibogaine"],"nct":"NCT03380728","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2022-10-30","official":"Rafael dos Santos, PhD (Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo); Jaime…","src":"https://clinicaltrials.gov/study/NCT03380728","sites":["Ribeirão Preto Medical School — Ribeirão Preto, Brazil"],"conds":["Alcoholism"],"condg":["Addiction & substance use"],"enroll":9,"eid":"NCT03380728"},{"id":"study-NCT05591001","cat":"studies","name":"Effects of Anesthetic Infusion on the Amplitude of Motor Evoked Potential in Pediatrics Undergoing Tethered Spinal Cord Surgeries","status":"COMPLETED","phase":"Phase 1","sponsor":"Cairo University","drugs":["ketamine"],"nct":"NCT05591001","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2022-10-30","src":"https://clinicaltrials.gov/study/NCT05591001","sites":["Amany Hassan Saleh — Giza, Egypt"],"conds":["Tethered Cord"],"condg":["Other"],"enroll":46,"eid":"NCT05591001"},{"id":"study-NCT05516823","cat":"studies","name":"Personality and Drug Use","status":"UNKNOWN","sponsor":"Psychedelic Data Society","drugs":["LSD","MDMA","ayahuasca","ibogaine","ketamine","mescaline","psilocybin"],"nct":"NCT05516823","nsites":0,"start":"2022-11","official":"Kim PC Kuypers, PhD (Maastricht University)","src":"https://clinicaltrials.gov/study/NCT05516823","conds":["No Conditions Study Focus on Substance Use and Personality"],"condg":["Addiction & substance use"],"contact":{"n":"Maggie K Kiraga, MSc","p":"4373249251","e":"maggie@quantifiedcitizen.com"},"enroll":1000,"eid":"NCT05516823"},{"id":"study-NCT05502211","cat":"studies","name":"A Comparison Between Ketamine-lidocaine Versus Ketamine-fentanyl for Induction on the Hemodynamic Effects in Patients With Coronary Artery Disease","status":"UNKNOWN","phase":"N/A","sponsor":"Kasr El Aini Hospital","drugs":["ketamine"],"nct":"NCT05502211","nsites":2,"countries":"Egypt","ccs":["EG"],"start":"2022-11-01","official":"Ayman Abougabal, MD (lecturer of anesthesia Kasr Al Ainy hospital)","src":"https://clinicaltrials.gov/study/NCT05502211","sites":["Kasr Al Ainy — Cairo, Egypt","Kasr al ainy — Cairo, Egypt"],"conds":["Induction of General Anesthesia"],"condg":["Other"],"contact":{"n":"Ayman Abougabal, MD","p":"01020671408","e":"ayman.abougabal@kasralainy.edu.eg"},"enroll":100,"eid":"NCT05502211"},{"id":"study-NCT05506982","cat":"studies","name":"Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain","status":"COMPLETED","phase":"Phase 1","sponsor":"Emory University","drugs":["psilocybin"],"nct":"NCT05506982","nsites":2,"countries":"United States","ccs":["US"],"start":"2022-11-01","official":"Ali J. Zarrabi, MD (Emory University Hospital/Winship Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT05506982","sites":["Emory University/Winship Cancer Institute — Atlanta, United States","Brain Health Center at Executive Park — Atlanta, United States"],"conds":["Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm"],"condg":["Cancer-related distress"],"enroll":11,"eid":"NCT05506982"},{"id":"study-NCT05451095","cat":"studies","name":"A Study in Healthy Men to Test Whether BI 474121 Can Reverse the Memory Problems Caused by Ketamine","status":"WITHDRAWN","phase":"Phase 1","sponsor":"Boehringer Ingelheim","drugs":["ketamine"],"nct":"NCT05451095","nsites":0,"start":"2022-11-07","src":"https://clinicaltrials.gov/study/NCT05451095","conds":["Healthy"],"condg":["Healthy volunteers"],"eid":"NCT05451095"},{"id":"study-NCT05384678","cat":"studies","name":"Acute Dose-dependent Effects of DMT in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["DMT"],"nct":"NCT05384678","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2022-11-15","official":"Matthias E Liechti, MD (University Hospital Basel, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05384678","sites":["Universtity Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":24,"eid":"NCT05384678"},{"id":"study-NCT05828199","cat":"studies","name":"The Effect of Intraoperative Infusion of Dexmedetomidine Versus Low Dose Ketamine","status":"UNKNOWN","phase":"Phase 1","sponsor":"Al-Azhar University","drugs":["ketamine"],"nct":"NCT05828199","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2022-12-01","official":"Essam Ali, Professor (Al-Azhar University, Faculty of medicine for boys)","src":"https://clinicaltrials.gov/study/NCT05828199","sites":["Faculty of Medicine, Al-Azhar University — Cairo, Egypt"],"conds":["Nasal Polyps","Nasal Septum, Irregular","Functional Endoscopic Sinus Surgery"],"condg":["Other"],"contact":{"n":"Ahmed Gamal, assist.lect","p":"01099549595","e":"ahmedgamal.226@azhar.edu.eg"},"enroll":80,"eid":"NCT05828199"},{"id":"study-NCT05615948","cat":"studies","name":"Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression","status":"COMPLETED","phase":"Phase 4","sponsor":"Theresa Jacob, PhD, MPH","drugs":["ketamine"],"nct":"NCT05615948","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-12-06","official":"Theresa Jacob, PhD, MPH (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT05615948","sites":["Maimonides Medical Center — Brooklyn, United States"],"conds":["Treatment Resistant Depression","Major Depressive Disorder","Analgesia","Ketamine","Peripheral Nervous System Agents","Central Nervous System Depressants"],"condg":["Depression"],"enroll":15,"eid":"NCT05615948"},{"id":"study-NCT05643066","cat":"studies","name":"Esketamine-propofol Versus Propofol for Flexible Bronchoscopy","status":"COMPLETED","phase":"Phase 4","sponsor":"Fujian Provincial Hospital","drugs":["esketamine"],"nct":"NCT05643066","nsites":1,"countries":"China","ccs":["CN"],"start":"2022-12-07","official":"Xiaochun Zheng, MD (Fujian Provincial Hospital)","src":"https://clinicaltrials.gov/study/NCT05643066","sites":["Fujian provincial hospital — Fuzhou, China"],"conds":["Postoperative Recovery"],"condg":["Other"],"enroll":246,"eid":"NCT05643066"},{"id":"study-NCT05651126","cat":"studies","name":"Psilocybin in Adults With and Without Autism Spectrum Disorder","status":"COMPLETED","phase":"N/A","sponsor":"King's College London","drugs":["psilocybin"],"nct":"NCT05651126","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2022-12-12","src":"https://clinicaltrials.gov/study/NCT05651126","sites":["King's College London — London, United Kingdom"],"conds":["Autism Spectrum Disorder"],"condg":["Other"],"enroll":67,"eid":"NCT05651126"},{"id":"study-NCT05553691","cat":"studies","name":"SPL026 With or Without SSRIs in Participants With MDD","status":"COMPLETED","phase":"Phase 1","sponsor":"Small Pharma Ltd","drugs":["DMT"],"nct":"NCT05553691","nsites":2,"countries":"United Kingdom","ccs":["GB"],"start":"2022-12-13","official":"Fabian Devlin, MD (MAC Clinical Research); Neel Bhatt, MD (MAC Clinical Research)","src":"https://clinicaltrials.gov/study/NCT05553691","sites":["Mac Clinical Research — Manchester, United Kingdom","MAC Clinical Research — Liverpool, United Kingdom"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":18,"eid":"NCT05553691"},{"id":"study-NCT05753956","cat":"studies","name":"Safety and Pharmacokinetics of GH002 in Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"GH Research Ireland Limited","nct":"NCT05753956","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2022-12-22","src":"https://clinicaltrials.gov/study/NCT05753956","sites":["GH Research Clinical Trial Site — Groningen, Netherlands"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":64,"eid":"NCT05753956"},{"id":"study-NCT05698095","cat":"studies","name":"Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"Usona Institute","drugs":["DMT"],"nct":"NCT05698095","nsites":1,"countries":"United States","ccs":["US"],"start":"2022-12-27","src":"https://clinicaltrials.gov/study/NCT05698095","sites":["Altasciences Clinical Kansas, Inc — Overland Park, United States"],"conds":["Pharmacokinetics","Safety","Tolerability"],"condg":["Other"],"enroll":54,"eid":"NCT05698095"},{"id":"study-NCT05571176","cat":"studies","name":"KetaMoHydBup: Pharmacokinetic Interaction of S-ketamine, Morphine, Hydromorphone and Buprenorphine","status":"UNKNOWN","phase":"Phase 1","sponsor":"Elina Brinck","drugs":["esketamine","ketamine"],"nct":"NCT05571176","nsites":0,"start":"2023-01","official":"Tuomas Lilius, MD, PhD (University of Helsinki)","src":"https://clinicaltrials.gov/study/NCT05571176","conds":["The Effect of S-ketamine on Pharmacokinetics of Morphine,…"],"condg":["Other"],"contact":{"n":"Elina CV Brinck, MD, PhD","p":"+358504286267","e":"elina.brinck@hus.fi"},"enroll":12,"eid":"NCT05571176"},{"id":"study-NCT05506462","cat":"studies","name":"An EEG Study of Intravenous Ketamine for Major Depression Disorder","status":"UNKNOWN","phase":"Phase 4","sponsor":"Ehave Inc.","drugs":["ketamine"],"nct":"NCT05506462","nsites":0,"start":"2023-01","official":"Jeffrey D Kamlet, MD (Tristar Wellness)","src":"https://clinicaltrials.gov/study/NCT05506462","conds":["Major Depressive Disorder"],"condg":["Depression"],"contact":{"n":"Jeffrey D Kamlet, MD","p":"305 604 9595","e":"jeffrey@tristarwell.com"},"enroll":35,"eid":"NCT05506462"},{"id":"study-NCT05252598","cat":"studies","name":"Mood and Cognitive Effects of Psilocybin in Healthy Participants","status":"WITHDRAWN","phase":"EARLY_Phase 1","sponsor":"Optimi Health Corporation","drugs":["psilocybin"],"nct":"NCT05252598","nsites":0,"start":"2023-01","official":"Valerie Taylor, MD/PhD (University of Calgary)","src":"https://clinicaltrials.gov/study/NCT05252598","conds":["Mood Disturbance","Mood Change","Sleep Disturbance","Drug Effect","Psychedelic Experiences","Health, Subjective"],"condg":["Anxiety"],"eid":"NCT05252598"},{"id":"study-NCT05670184","cat":"studies","name":"The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality","status":"UNKNOWN","phase":"Phase 1/Phase 2","sponsor":"Maastricht University","drugs":["LSD"],"nct":"NCT05670184","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2023-01-01","official":"Johannes G Ramaekers, PhD (Maastricht University)","src":"https://clinicaltrials.gov/study/NCT05670184","sites":["Maastricht University — Maastricht, Netherlands"],"conds":["Prosocial Behavior"],"condg":["Other"],"contact":{"n":"Natasha Mason, PhD","p":"+31 43 3881382","e":"natasha.mason@maastrichtuniversity.nl"},"enroll":60,"eid":"NCT05670184"},{"id":"study-NCT05802979","cat":"studies","name":"Ketamine Versus Neostigmine as Adjuvants to Bupivacaine During Ultrasound-guided Serratus Anterior Block","status":"UNKNOWN","phase":"Phase 3","sponsor":"Ain Shams University","drugs":["ketamine"],"nct":"NCT05802979","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2023-01-01","official":"Mohammed S Abd El Aziz, M.D. (AinShams University)","src":"https://clinicaltrials.gov/study/NCT05802979","sites":["AinShams University Hospitals — Cairo, Egypt"],"conds":["Post Operative Pain"],"condg":["Chronic pain & headache"],"enroll":80,"eid":"NCT05802979"},{"id":"study-NCT05786365","cat":"studies","name":"Comparison of Emergence/Dysphoric Reaction Frequency of Using 2 Different Doses Ketamine","status":"COMPLETED","sponsor":"Aksaray University Training and Research Hospital","drugs":["ketamine"],"nct":"NCT05786365","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2023-01-01","official":"Kamil Kokulu, M.D. (Aksaray UTRH)","src":"https://clinicaltrials.gov/study/NCT05786365","sites":["Çağrı Türkücü — Aksaray, Turkey"],"conds":["Sedation Complication"],"condg":["Other"],"enroll":108,"eid":"NCT05786365"},{"id":"study-NCT05671913","cat":"studies","name":"Scheduled Intranasal Ketamine","status":"WITHDRAWN","phase":"EARLY_Phase 1","sponsor":"Sanford Health","drugs":["ketamine"],"nct":"NCT05671913","nsites":0,"start":"2023-01-01","src":"https://clinicaltrials.gov/study/NCT05671913","conds":["Pain","Trauma"],"condg":["PTSD & trauma","Chronic pain & headache"],"eid":"NCT05671913"},{"id":"study-NCT05594667","cat":"studies","name":"Effect of SSRIs on Response to Psilocybin Therapy","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Cybin Therapeutics Inc.","drugs":["psilocybin"],"nct":"NCT05594667","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2023-01-01","official":"Reginald Peters, MD (Upstream)","src":"https://clinicaltrials.gov/study/NCT05594667","sites":["Centre for Neurology Studies x Upstream — Abbotsford British Columbia, Canada"],"conds":["Depression","Major Depressive Disorder","Mild Depression","Moderate Depression","Depressive Disorder"],"condg":["Depression"],"eid":"NCT05594667"},{"id":"study-NCT05557643","cat":"studies","name":"PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Utah","drugs":["psilocybin"],"nct":"NCT05557643","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-01-02","src":"https://clinicaltrials.gov/study/NCT05557643","sites":["Huntsman Mental Health Institute — Salt Lake City, United States"],"conds":["Depression","Burnout, Professional"],"condg":["Depression"],"enroll":24,"eid":"NCT05557643"},{"id":"study-NCT05670561","cat":"studies","name":"Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma","status":"UNKNOWN","phase":"Phase 4","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","drugs":["esketamine"],"nct":"NCT05670561","nsites":1,"countries":"China","ccs":["CN"],"start":"2023-01-05","official":"Huang He, MD (The Second Affiliated Hospital, Chongqing Medical University)","src":"https://clinicaltrials.gov/study/NCT05670561","sites":["The Second Affiliated Hospital, Chongqing Medical University — Chongqing, China"],"conds":["Hepatocellular Carcinoma","Transcatheter Arterial Chemoembolization","Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Duan Guang you, MD","p":"18323376014","e":"duangy@hospital.cqmu.edu.cn"},"enroll":60,"eid":"NCT05670561"},{"id":"study-NCT05438758","cat":"studies","name":"Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Zylorion Health","drugs":["esketamine","ketamine"],"nct":"NCT05438758","nsites":0,"start":"2023-01-15","official":"Pierre Chue, MBBCh (Amygdala Associates Inc.)","src":"https://clinicaltrials.gov/study/NCT05438758","conds":["Treatment Resistant Major Depressive Disorder"],"condg":["Depression"],"eid":"NCT05438758"},{"id":"study-NCT05624268","cat":"studies","name":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","status":"COMPLETED","phase":"Phase 3","sponsor":"COMPASS Pathways","drugs":["psilocybin"],"nct":"NCT05624268","nsites":40,"countries":"United States","ccs":["US"],"start":"2023-01-24","src":"https://clinicaltrials.gov/study/NCT05624268","sites":["University of Arizona College of Medicine - Tuscon — Tuscon, United States","ProScience Research Group — Culver City, United States","Collaborative Neuroscience Network, LLC — Garden Grove, United States","Kadima Neuropsychiatry Institute — La Jolla, United States","University California San Diego — La Jolla, United States","California Center for Psychedelic Therapy — Los Angeles, United States","CalNeuro Research Group, Inc — Los Angeles, United States","Clarity Clinical Research, LLC — Los Angeles, United States"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":258,"eid":"NCT05624268"},{"id":"study-NCT05829486","cat":"studies","name":"Integrated Pulmonary Index in Gastroscopic Procedures","status":"UNKNOWN","sponsor":"Gaziosmanpasa Research and Education Hospital","drugs":["ketamine"],"nct":"NCT05829486","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2023-02-06","official":"zuhal çavuş, MD (gaziosmanpasa TREH); döndü genç moralar, MD (gaziosmanpasa TREH)","src":"https://clinicaltrials.gov/study/NCT05829486","sites":["Gaziosmanpaşa TREH — Istanbul, Turkey"],"conds":["Endoscopy"],"condg":["Other"],"contact":{"n":"sibel bektas, MD","p":"02129453030","e":"sibel-bektas@yahoo.com"},"enroll":60,"eid":"NCT05829486"},{"id":"study-NCT05522673","cat":"studies","name":"[11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine","status":"TERMINATED","phase":"Phase 1","sponsor":"National Institute of Mental Health (NIMH)","drugs":["ketamine"],"nct":"NCT05522673","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-02-08","official":"Robert B Innis, M.D. (National Institute of Mental Health (NIMH))","src":"https://clinicaltrials.gov/study/NCT05522673","sites":["National Institutes of Health Clinical Center — Bethesda, United States"],"conds":["Depression"],"condg":["Depression"],"enroll":1,"eid":"NCT05522673"},{"id":"study-NCT04718792","cat":"studies","name":"Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study","status":"UNKNOWN","phase":"Phase 2","sponsor":"Anders Fink-Jensen, MD, DMSci","drugs":["psilocybin"],"nct":"NCT04718792","nsites":1,"countries":"Denmark","ccs":["DK"],"start":"2023-02-09","official":"Anders Fink-Jensen, Professor (Professor)","src":"https://clinicaltrials.gov/study/NCT04718792","sites":["Psychiatric Center Copenhagen — Copenhagen, Denmark"],"conds":["Alcohol Use Disorder (AUD)"],"condg":["Addiction & substance use"],"enroll":10,"eid":"NCT04718792"},{"id":"study-NCT05719909","cat":"studies","name":"Testing the Effectiveness of Cognitive Training Among Depressed Patients Receiving Esketamine Treatment","status":"SUSPENDED","phase":"N/A","sponsor":"University of Pittsburgh","drugs":["esketamine","ketamine"],"nct":"NCT05719909","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-02-14","src":"https://clinicaltrials.gov/study/NCT05719909","sites":["Western Psychiatric Institute and Clinic — Pittsburgh, United States"],"conds":["Depression"],"condg":["Depression"],"enroll":40,"eid":"NCT05719909"},{"id":"study-NCT05780216","cat":"studies","name":"Mindfulness and Psychedelics","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Milan Scheidegger","drugs":["ayahuasca"],"nct":"NCT05780216","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2023-02-20","official":"Milan Scheidegger, MD, PhD (Psychiatric University Hospital, Zurich)","src":"https://clinicaltrials.gov/study/NCT05780216","sites":["Psychiatric University Hospital Zurich — Zurich, Switzerland"],"conds":["Healthy Participants"],"condg":["Healthy volunteers"],"enroll":40,"eid":"NCT05780216"},{"id":"study-NCT07072117","cat":"studies","name":"Intranasal Dexmedetomidine, Ketamine or Midazolam for Anxiety and Respiratory Complications in Children","status":"COMPLETED","phase":"N/A","sponsor":"Zagazig University","drugs":["ketamine"],"nct":"NCT07072117","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2023-02-20","official":"Amira Saeed Kenawy, MD (Faculty of Medicine - Zagazig University)","src":"https://clinicaltrials.gov/study/NCT07072117","sites":["Faculty of Medicine - Zagazig University — Zagazig, Egypt"],"conds":["Adenotonsillectomy"],"condg":["Other"],"enroll":148,"eid":"NCT07072117"},{"id":"study-NCT05751304","cat":"studies","name":"A Comparative Study Between Intrathecal Dexmedetomidine VS Ketamine With Intrathecal Bupivacaine in Orthopedic Lower Limb Surgeries.","status":"UNKNOWN","phase":"N/A","sponsor":"Sohag University","drugs":["ketamine"],"nct":"NCT05751304","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2023-03-01","src":"https://clinicaltrials.gov/study/NCT05751304","sites":["Sohag University Hospital — Sohag, Egypt"],"conds":["Bone Fracture"],"condg":["Other"],"contact":{"n":"zeyad A Ali, Resident","p":"01159596946","e":"zeyadahmed@med.sohag.edu.eg"},"enroll":100,"eid":"NCT05751304"},{"id":"study-NCT05874245","cat":"studies","name":"Effect of Oral Dexmedetomidine, Ketamine, Or Midazolam as Preioperative Medications.","status":"UNKNOWN","phase":"Phase 4","sponsor":"Menoufia University","drugs":["ketamine"],"nct":"NCT05874245","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2023-03-01","src":"https://clinicaltrials.gov/study/NCT05874245","sites":["Menoufia university hospitails — Shibīn al Kawm, Egypt"],"conds":["Anesthesia"],"condg":["Other"],"contact":{"n":"Ahmed Abosayar, Assisstant lecturer","p":"+201064070141","e":"Aabosayar@gmail.com"},"enroll":222,"eid":"NCT05874245"},{"id":"study-NCT05804708","cat":"studies","name":"Phase 2 Clinical Trial of GH001 in Postpartum Depression","status":"TERMINATED","phase":"Phase 2","sponsor":"GH Research Ireland Limited","drugs":["DMT"],"nct":"NCT05804708","nsites":4,"countries":"Netherlands; United Kingdom","ccs":["GB","NL"],"start":"2023-03-02","src":"https://clinicaltrials.gov/study/NCT05804708","sites":["Amsterdam UMC — Amsterdam, Netherlands","Clerkenwell Health — London, United Kingdom","St. Pancras Clinical Research — London, United Kingdom","Sheffield Health and Social Care NHS Foundation — Sheffield, United Kingdom"],"conds":["Postpartum Depression","Postnatal Depression"],"condg":["Depression"],"enroll":10,"eid":"NCT05804708"},{"id":"study-NCT05322954","cat":"studies","name":"Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder","status":"TERMINATED","phase":"Phase 1","sponsor":"University of Wisconsin, Madison","drugs":["psilocybin"],"nct":"NCT05322954","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-03-03","official":"Christopher Nicholas, PhD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT05322954","sites":["University of Wisconsin — Madison, United States"],"conds":["Methamphetamine Use Disorder","Substance-Related Disorders","Chemically-Induced Disorders","Substance Use Disorders","Stimulant-Use Disorder"],"condg":["Addiction & substance use"],"enroll":5,"eid":"NCT05322954"},{"id":"study-NCT05581797","cat":"studies","name":"Psilocybin-assisted Interpersonal Therapy for Depression","status":"COMPLETED","phase":"N/A","sponsor":"University of Otago","drugs":["psilocybin"],"nct":"NCT05581797","nsites":1,"countries":"New Zealand","ccs":["NZ"],"start":"2023-03-15","official":"Cameron Lacey, PhD (University of Otago)","src":"https://clinicaltrials.gov/study/NCT05581797","sites":["University of Otago — Christchurch, New Zealand"],"conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"enroll":5,"eid":"NCT05581797"},{"id":"study-NCT05786833","cat":"studies","name":"Dexmedetomidine vs Ketofol on Delirium in Children Undergoing Congenital Inguinal Hernia Repair","status":"UNKNOWN","phase":"N/A","sponsor":"Tanta University","drugs":["ketamine"],"nct":"NCT05786833","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2023-03-20","src":"https://clinicaltrials.gov/study/NCT05786833","sites":["Nada Maged Shaheen — Tanta, Egypt"],"conds":["Dexmedetomidine","Ketofol","Delirium","Hernia"],"condg":["Other"],"contact":{"n":"Nada M Shaheen, Master","p":"+201006151953","e":"nada169730_pg@med.tanta.edu.eg"},"enroll":60,"eid":"NCT05786833"},{"id":"study-NCT05779657","cat":"studies","name":"Combined Ketamine and Midazolam for Generalized Convulsive Status Epilepticus","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"Sohag University","drugs":["ketamine"],"nct":"NCT05779657","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2023-03-21","official":"Abdelrahim A Sadek, MD, PhD (Faculty of Medicine, Sohag University)","src":"https://clinicaltrials.gov/study/NCT05779657","sites":["Sohag University Hospital — Sohag, Egypt"],"conds":["Generalized Convulsive Status Epilepticus"],"condg":["Neurology & cognition"],"enroll":144,"eid":"NCT05779657"},{"id":"study-NCT04513314","cat":"studies","name":"Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium","status":"WITHDRAWN","phase":"Phase 4","sponsor":"University of Miami","drugs":["ketamine"],"nct":"NCT04513314","nsites":0,"start":"2023-03-28","official":"Dominique L Musselman, MD (University of Miami)","src":"https://clinicaltrials.gov/study/NCT04513314","conds":["Covid19","Hyperactive Delirium","Pneumonia, Viral"],"condg":["Other"],"eid":"NCT04513314"},{"id":"study-NCT05832255","cat":"studies","name":"An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome","status":"SUSPENDED","phase":"Phase 2","sponsor":"Nova Mentis Life Science Corp","drugs":["psilocybin"],"nct":"NCT05832255","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2023-03-28","official":"David Crowley, MD (KGK Science Inc.); Marvin Hausman, MD (Nova Mentis Life Science Corp)","src":"https://clinicaltrials.gov/study/NCT05832255","sites":["KGK Science Inc. — London, Canada"],"conds":["Fragile X Syndrome","Behavior","Cognitive Dysfunction"],"condg":["Neurology & cognition"],"enroll":10,"eid":"NCT05832255"},{"id":"study-NCT05809804","cat":"studies","name":"Median Effective Dose of Esketamine Pretreatment to Prevent Sufentanil-induced Cough","status":"UNKNOWN","phase":"N/A","sponsor":"Yangzhou University","drugs":["esketamine"],"nct":"NCT05809804","nsites":0,"start":"2023-04-01","src":"https://clinicaltrials.gov/study/NCT05809804","conds":["Sufentanil","Esketamine"],"condg":["Other"],"enroll":30,"eid":"NCT05809804"},{"id":"study-NCT05799729","cat":"studies","name":"Effect of Ketamine Infusion on BIS Values","status":"COMPLETED","sponsor":"University of Padova","drugs":["ketamine"],"nct":"NCT05799729","nsites":1,"countries":"Italy","ccs":["IT"],"start":"2023-04-01","src":"https://clinicaltrials.gov/study/NCT05799729","sites":["Treviso Regional Hospital — Treviso, Italy"],"conds":["Anesthesia Brain Monitoring","Ketamine"],"condg":["Other"],"enroll":40,"eid":"NCT05799729"},{"id":"study-NCT05811221","cat":"studies","name":"Application of Different Modes of Esketamine Administration in Pediatric Day Circumcision","status":"UNKNOWN","phase":"N/A","sponsor":"Yangzhou University","drugs":["esketamine"],"nct":"NCT05811221","nsites":0,"start":"2023-04-02","src":"https://clinicaltrials.gov/study/NCT05811221","conds":["Pain"],"condg":["Chronic pain & headache"],"enroll":70,"eid":"NCT05811221"},{"id":"study-NCT05839509","cat":"studies","name":"Phase 2 Clinical Trial of GH001 in Bipolar II Disorder","status":"TERMINATED","phase":"Phase 2","sponsor":"GH Research Ireland Limited","drugs":["DMT"],"nct":"NCT05839509","nsites":7,"countries":"Germany; Netherlands; United Kingdom","ccs":["DE","GB","NL"],"start":"2023-04-06","src":"https://clinicaltrials.gov/study/NCT05839509","sites":["Investigational Site — Dresden, Germany","Investigational Site — Frankfurt, Germany","Investigational Site — Münster, Germany","Investigational Site — Leiden, Netherlands","Investigational Site — Maastricht, Netherlands","Investigational Site — London, United Kingdom","Investigation Site — Oxford, United Kingdom"],"conds":["Bipolar II Disorder"],"condg":["Bipolar"],"enroll":6,"eid":"NCT05839509"},{"id":"study-NCT05220046","cat":"studies","name":"Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Nebraska","drugs":["psilocybin"],"nct":"NCT05220046","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-04-10","official":"Lou Lukas, MD (University of Nebraska)","src":"https://clinicaltrials.gov/study/NCT05220046","sites":["University of Nebraska Medical Center — Omaha, United States"],"conds":["Pancreas Cancer","Biliary Tract Cancer","Psychological Distress","Gastrointestinal Cancer"],"condg":["Cancer-related distress"],"enroll":18,"eid":"NCT05220046"},{"id":"study-NCT05229055","cat":"studies","name":"Intranasal Ketamine Versus Subcutaneous Ketamine for Treatment of Post-traumatic Acute Pain in the Emergency Department ( INVESCK )","status":"COMPLETED","phase":"Phase 2/Phase 3","sponsor":"University of Monastir","drugs":["ketamine"],"nct":"NCT05229055","nsites":1,"countries":"Tunisia","ccs":["TN"],"start":"2023-04-15","official":"Nouira Semir, Professor (University of Monastir)","src":"https://clinicaltrials.gov/study/NCT05229055","sites":["university of Monastir — Monastir, Tunisia"],"conds":["Acute Pain"],"condg":["Chronic pain & headache"],"enroll":1000,"eid":"NCT05229055"},{"id":"study-NCT05597878","cat":"studies","name":"Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy","status":"TERMINATED","phase":"Phase 2/Phase 3","sponsor":"Wake Forest University Health Sciences","drugs":["ketamine"],"nct":"NCT05597878","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-04-18","official":"Ashok Hemal, MD (Atrium Health Wake Forest Baptist Comprehensive Cancer Center)","src":"https://clinicaltrials.gov/study/NCT05597878","sites":["Atrium Health Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, United States"],"conds":["Pain Management","Opioid Use","Prostate Cancer"],"condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"enroll":58,"eid":"NCT05597878"},{"id":"study-NCT06232291","cat":"studies","name":"Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant Depression","status":"COMPLETED","sponsor":"Medical University of Gdansk","drugs":["ketamine"],"nct":"NCT06232291","nsites":1,"countries":"Poland","ccs":["PL"],"start":"2023-04-21","src":"https://clinicaltrials.gov/study/NCT06232291","sites":["Medical University of Gdańsk — Gdansk, Poland"],"conds":["Treatment-Resistant Depression","Major Depressive Disorder"],"condg":["Depression"],"enroll":3,"eid":"NCT06232291"},{"id":"study-NCT05901012","cat":"studies","name":"Safety and Tolerability of DMT in Healthy Adults","status":"COMPLETED","phase":"Phase 1","sponsor":"Universidade Federal do Rio Grande do Norte","drugs":["DMT"],"nct":"NCT05901012","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2023-04-26","official":"Draulio B. Araujo, Ph.D (Universidade Federal do Rio Grande do Norte)","src":"https://clinicaltrials.gov/study/NCT05901012","sites":["Hospital Universitário Onofre Lopes — Natal, Brazil"],"conds":["Safety Issues","Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":25,"eid":"NCT05901012"},{"id":"study-NCT05826327","cat":"studies","name":"Effects of Epidural Labor Analgesia With Esketamine on the Incidence of Postpartum Depression in Parturients","status":"UNKNOWN","phase":"Phase 4","sponsor":"Women's Hospital School Of Medicine Zhejiang University","drugs":["esketamine"],"nct":"NCT05826327","nsites":1,"countries":"China","ccs":["CN"],"start":"2023-05-01","official":"Weiguo Lyv, Dr (Women's Hospital School Of Medicine Zhejiang University)","src":"https://clinicaltrials.gov/study/NCT05826327","sites":["Women's hospital, school of medicine, Zhejiang university — Hangzhou, China"],"conds":["Postpartum Depression"],"condg":["Depression"],"contact":{"n":"Xinzhong Chen, Dr","p":"0571-8999100","e":"chenxinz@zju.edu.cn"},"enroll":364,"eid":"NCT05826327"},{"id":"study-NCT05796791","cat":"studies","name":"Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Medical University of South Carolina","drugs":["ketamine"],"nct":"NCT05796791","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-05-02","src":"https://clinicaltrials.gov/study/NCT05796791","sites":["Medical University of South Carolina — Charleston, United States"],"conds":["Tobacco Use","Smoking Cessation","Nicotine Dependence"],"condg":["Addiction & substance use"],"enroll":7,"eid":"NCT05796791"},{"id":"study-NCT05829603","cat":"studies","name":"Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"Reconnect Labs","drugs":["DMT"],"nct":"NCT05829603","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2023-05-05","official":"Erich Seifritz, Prof (Psychiatric University Hospital, Zurich)","src":"https://clinicaltrials.gov/study/NCT05829603","sites":["University Hospital of Psychiatry Zurich — Zurich, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":16,"eid":"NCT05829603"},{"id":"study-NCT05855798","cat":"studies","name":"Ketamine and Magnesium in Erector Spinae Plane Block","status":"COMPLETED","phase":"Phase 4","sponsor":"Cukurova University","drugs":["ketamine"],"nct":"NCT05855798","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2023-05-10","src":"https://clinicaltrials.gov/study/NCT05855798","sites":["Cukurova University — Adana, Turkey"],"conds":["Postoperative Analgesia"],"condg":["Other"],"enroll":60,"eid":"NCT05855798"},{"id":"study-NCT05837000","cat":"studies","name":"Dexmedetomidine, Ketamine and Magnesium Sulphate in Caudal Block for Hypospadias Repair","status":"UNKNOWN","phase":"Phase 4","sponsor":"Kafrelsheikh University","drugs":["ketamine"],"nct":"NCT05837000","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2023-05-15","official":"Kafrelsheikh University (Research ethics committee - Kafrelsheikh University)","src":"https://clinicaltrials.gov/study/NCT05837000","sites":["Karelsheikh University Hospital — Kafr ash Shaykh, Egypt"],"conds":["Preemptive Analgesia","Dexmedetomidine","Ketamine","Magnesium Sulphate","Hypospadias","Pediatrics"],"condg":["Other"],"contact":{"n":"Gamal MD Hendawy Shams, MD","p":"00201095927971","e":"gamal.shams@yahoo.com"},"enroll":75,"eid":"NCT05837000"},{"id":"study-NCT05906121","cat":"studies","name":"Lidocaine and Ketamine Levels in Plasma After Simultaneous Lidocaine/Ketamine Infusions","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","drugs":["ketamine"],"nct":"NCT05906121","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2023-05-16","official":"Wilhelm Ruppen, Prof. (Department of Anaesthesiology, University Hospital of Basel (USB))","src":"https://clinicaltrials.gov/study/NCT05906121","sites":["Department of Anaesthesiology, University Hospital of Basel (USB) — Basel, Switzerland"],"conds":["Chronic Pain"],"condg":["Chronic pain & headache"],"enroll":15,"eid":"NCT05906121"},{"id":"study-NCT05800860","cat":"studies","name":"A Trial of GH001 in Patients With Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"GH Research Ireland Limited","drugs":["DMT"],"nct":"NCT05800860","nsites":11,"countries":"Czechia; Germany; Ireland; Netherlands; Poland; Spain","ccs":["CZ","DE","ES","IE","NL","PL"],"start":"2023-05-24","src":"https://clinicaltrials.gov/study/NCT05800860","sites":["Investigational site — Pilsen, Czechia","Investigational site — Prague, Czechia","Investigational Site — Dresden, Germany","Investigational Site — Frankfurt, Germany","Investigational Site — Münster, Germany","Investigational site — Dublin, Ireland","Investigational Site — Galway, Ireland","Investigational Site — Maastricht, Netherlands"],"conds":["Treatment-resistant Depression"],"condg":["Depression"],"enroll":81,"eid":"NCT05800860"},{"id":"study-NCT05378555","cat":"studies","name":"Oral Ketamine for Treatment of Vaso-Occlusive Pain","status":"COMPLETED","phase":"Phase 1","sponsor":"Boston Children's Hospital","drugs":["ketamine"],"nct":"NCT05378555","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-05-26","src":"https://clinicaltrials.gov/study/NCT05378555","sites":["Boston Children's Hospital — Boston, United States"],"conds":["Vaso-occlusive Crisis"],"condg":["Other"],"enroll":10,"eid":"NCT05378555"},{"id":"study-NCT05468840","cat":"studies","name":"Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation","status":"UNKNOWN","phase":"Phase 3","sponsor":"University of Ottawa","drugs":["ketamine"],"nct":"NCT05468840","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2023-06","src":"https://clinicaltrials.gov/study/NCT05468840","sites":["CHEO — Ottawa, Canada"],"conds":["Suicidal Ideation"],"condg":["Other"],"contact":{"n":"Michael Schlegelmilch, MD, MPH","p":"1-613-737-7600","e":"mschlegelmilch@cheo.on.ca"},"enroll":20,"eid":"NCT05468840"},{"id":"study-NCT05467761","cat":"studies","name":"Bioavailability Study of Psilocybin in Normal Adults","status":"WITHDRAWN","phase":"Phase 1","sponsor":"University of Wisconsin, Madison","drugs":["psilocybin"],"nct":"NCT05467761","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-06","official":"Christopher Nicholas, PhD (University of Wisconsin, Madison); Paul Hutson, PharmD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT05467761","sites":["University of Wisconsin — Madison, United States"],"conds":["Healthy"],"condg":["Healthy volunteers"],"eid":"NCT05467761"},{"id":"study-NCT05876481","cat":"studies","name":"Evaluation of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans","status":"UNKNOWN","phase":"Phase 2","sponsor":"Combat Stress","drugs":["psilocybin"],"nct":"NCT05876481","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2023-06","official":"Prof. Dominic Murphy (Combat Stress)","src":"https://clinicaltrials.gov/study/NCT05876481","sites":["Combat Stress — Leatherhead, United Kingdom"],"conds":["PTSD"],"condg":["PTSD & trauma"],"contact":{"n":"Prof. Dominic Murphy","p":"01372 587 017","e":"dominic.murphy@combatstress.org.uk"},"enroll":8,"eid":"NCT05876481"},{"id":"study-NCT05951387","cat":"studies","name":"Dexmedetomidine Versus Dexmedetomidine with Ketamine in Mechanically Ventilated ARDS Patients","status":"COMPLETED","phase":"Phase 4","sponsor":"Benha University","drugs":["ketamine"],"nct":"NCT05951387","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2023-06-01","official":"Marwa Elnaggar, MD (Benha University, Faculty of medicine)","src":"https://clinicaltrials.gov/study/NCT05951387","sites":["Benha university — Banhā, Egypt"],"conds":["Haemodynamic Instability"],"condg":["Other"],"enroll":60,"eid":"NCT05951387"},{"id":"study-NCT06035900","cat":"studies","name":"Evaluation of Safety, Rate and Extent of Absorption of Psilocin Mucate","status":"COMPLETED","phase":"Phase 1","sponsor":"Lobe Sciences Ltd.","drugs":["psilocybin"],"nct":"NCT06035900","nsites":1,"countries":"Jordan","ccs":["JO"],"start":"2023-06-21","official":"Ahmad Abdulkhaleq, MD (Arab Pharmaceutical Industry Pharmaceutical Research)","src":"https://clinicaltrials.gov/study/NCT06035900","sites":["Pharmaceutical Research Unit — Amman, Jordan"],"conds":["Side Effect of Drug"],"condg":["Other"],"enroll":10,"eid":"NCT06035900"},{"id":"study-NCT05227612","cat":"studies","name":"Psilocybin-assisted CBT for Depression","status":"COMPLETED","phase":"Phase 1","sponsor":"University of California, Los Angeles","drugs":["psilocybin"],"nct":"NCT05227612","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-06-27","src":"https://clinicaltrials.gov/study/NCT05227612","sites":["UCLA Semel Institute — Los Angeles, United States"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":16,"eid":"NCT05227612"},{"id":"study-NCT05847686","cat":"studies","name":"Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"University of Washington","drugs":["psilocybin"],"nct":"NCT05847686","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-06-27","official":"Anthony Back (Fred Hutch/University of Washington Cancer Consortium)","src":"https://clinicaltrials.gov/study/NCT05847686","sites":["Fred Hutch/University of Washington Cancer Consortium — Seattle, United States"],"conds":["Hematopoietic and Lymphatic System Neoplasm","Metastatic Malignant Solid Neoplasm"],"condg":["Cancer-related distress"],"enroll":55,"eid":"NCT05847686"},{"id":"study-NCT05943028","cat":"studies","name":"Effect of Subanesthetic Dose Esketamine on Propofol-refentanil Closed-loop Targeted Controlled Infusion","status":"UNKNOWN","phase":"EARLY_Phase 1","sponsor":"bo xu","drugs":["esketamine"],"nct":"NCT05943028","nsites":0,"start":"2023-07-01","official":"Shengchao Li, Graduate (The First Clinical College of Southern Medical University)","src":"https://clinicaltrials.gov/study/NCT05943028","conds":["Esketamine"],"condg":["Other"],"contact":{"n":"Bo Xu, professor","p":"+8613802738125","e":"xubo333@hotmail.com"},"enroll":48,"eid":"NCT05943028"},{"id":"study-NCT05601648","cat":"studies","name":"PET Synaptogenesis After Psilocybin In DEpression Recovery","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Washington University School of Medicine","drugs":["psilocybin"],"nct":"NCT05601648","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-07-01","src":"https://clinicaltrials.gov/study/NCT05601648","sites":["Washington University School of Medicine — St Louis, United States"],"conds":["Major Depressive Disorder","Anhedonia"],"condg":["Depression"],"eid":"NCT05601648"},{"id":"study-NCT05710237","cat":"studies","name":"Does Psilocybin Require Psychedelic Effects to Treat Depression?","status":"COMPLETED","phase":"Phase 2","sponsor":"Centre for Addiction and Mental Health","drugs":["psilocybin"],"nct":"NCT05710237","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2023-07-01","official":"M. Ishrat Husain, MBBS, MD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT05710237","sites":["Centre for Addiction and Mental Health — Toronto, Canada"],"conds":["Treatment-resistant Depression"],"condg":["Depression"],"enroll":41,"eid":"NCT05710237"},{"id":"study-NCT06012916","cat":"studies","name":"Brain Network Dynamics of Depression During Esketamine Treatment","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","drugs":["esketamine"],"nct":"NCT06012916","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-07-03","official":"Flavio Frohlich, PhD (University of North Carolina, Chapel Hill)","src":"https://clinicaltrials.gov/study/NCT06012916","sites":["Carolina Center for Neurostimulation — Chapel Hill, United States"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"enroll":8,"eid":"NCT06012916"},{"id":"study-NCT05855876","cat":"studies","name":"Reversal of Battle-Related Aging (ROBRA) in a Special Operations Forces Cohort","status":"UNKNOWN","sponsor":"Stella Center","drugs":["ketamine"],"nct":"NCT05855876","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-07-05","official":"Eugene Lipov, MD (Stella Center)","src":"https://clinicaltrials.gov/study/NCT05855876","sites":["Stella Center — Westmont, United States"],"conds":["Post-Traumatic Stress Disorder","Traumatic Brain Injury"],"condg":["PTSD & trauma","Neurology & cognition"],"enroll":20,"eid":"NCT05855876"},{"id":"study-NCT05933213","cat":"studies","name":"Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis","status":"UNKNOWN","phase":"Phase 4","sponsor":"Xiangya Hospital of Central South University","drugs":["mescaline"],"nct":"NCT05933213","nsites":0,"start":"2023-07-06","official":"LUO HUI, Doctor (Xiangya Hospital of Central South University)","src":"https://clinicaltrials.gov/study/NCT05933213","conds":["Lupus Nephritis"],"condg":["Other"],"contact":{"n":"LUO HUI, Doctor","p":"+86-13974871326","e":"luohuihn@sina.com"},"enroll":205,"eid":"NCT05933213"},{"id":"study-NCT05259943","cat":"studies","name":"Microdosing Psychedelics to Improve Mood","status":"COMPLETED","phase":"Phase 2","sponsor":"Rotem Petranker","drugs":["psilocybin"],"nct":"NCT05259943","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2023-07-15","src":"https://clinicaltrials.gov/study/NCT05259943","sites":["Psych Research — Toronto, Canada"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":39,"eid":"NCT05259943"},{"id":"study-NCT05948683","cat":"studies","name":"Prosocial Effects of MDMA","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University of Chicago","drugs":["MDMA"],"nct":"NCT05948683","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-07-21","official":"Harriet de Wit (University of Chicago)","src":"https://clinicaltrials.gov/study/NCT05948683","sites":["University of Chicago — Chicago, United States"],"conds":["MDMA ('Ecstasy')","Social Interaction"],"condg":["Other"],"enroll":33,"eid":"NCT05948683"},{"id":"study-NCT05970380","cat":"studies","name":"Effect of Erector Spinae Plane Block in Patients Scheduled for Kyphoplasty","status":"COMPLETED","sponsor":"Bozyaka Training and Research Hospital","drugs":["ketamine"],"nct":"NCT05970380","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2023-07-25","official":"Halide H Şahinkaya, MD (Izmir Bozyaka Training and Research Hospital); Alper Tabanlı, MD (Izmir Bozyaka Training and Research Hospital)","src":"https://clinicaltrials.gov/study/NCT05970380","sites":["Izmir Bozyaka Training and Research Hospital — Izmir, Turkey"],"conds":["Erector Spinae Plane Block"],"condg":["Other"],"enroll":61,"eid":"NCT05970380"},{"id":"study-NCT05957302","cat":"studies","name":"Hemodynamic Effects of Bolus of Ketamine Versus Fentanyl in Patients With Septic Shock","status":"COMPLETED","phase":"N/A","sponsor":"Cairo University","drugs":["ketamine"],"nct":"NCT05957302","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2023-08-01","official":"ahmed hasanin, MD (Cairo University Kasr Alainy Faculty of Medicine)","src":"https://clinicaltrials.gov/study/NCT05957302","sites":["Ahmed Mohamed Hasanin — Cairo, Egypt"],"conds":["Ketamine","Fentanyl","Septic Shock"],"condg":["Other"],"enroll":86,"eid":"NCT05957302"},{"id":"study-NCT05227742","cat":"studies","name":"Exploratory Study of Low Dose Psilocybin","status":"WITHDRAWN","phase":"EARLY_Phase 1","sponsor":"University of Alabama at Birmingham","drugs":["psilocybin"],"nct":"NCT05227742","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-08-15","src":"https://clinicaltrials.gov/study/NCT05227742","sites":["University of Alabama at Birmingham — Birmingham, United States"],"conds":["Demoralization"],"condg":["Other"],"eid":"NCT05227742"},{"id":"study-NCT05523401","cat":"studies","name":"Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA","psilocybin"],"nct":"NCT05523401","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2023-08-16","official":"Matthias E Liechti, MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05523401","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":24,"eid":"NCT05523401"},{"id":"study-NCT06011746","cat":"studies","name":"Adding Ketamine to Levobupivacaine in Paravertebral Block in Thoracotomy","status":"COMPLETED","phase":"Phase 4","sponsor":"Tanta University","drugs":["ketamine"],"nct":"NCT06011746","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2023-08-30","src":"https://clinicaltrials.gov/study/NCT06011746","sites":["Tanta University — Tanta, Egypt"],"conds":["Ketamine","Levobupivacaine","Paravertebral Block","Acute Pain","Chronic Pain"],"condg":["Chronic pain & headache"],"enroll":60,"eid":"NCT06011746"},{"id":"study-NCT05997134","cat":"studies","name":"Three Regimens of Ketamine Infusion in Complex Regional Pain Syndrome","status":"UNKNOWN","phase":"Phase 4","sponsor":"Tanta University","drugs":["ketamine"],"nct":"NCT05997134","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2023-08-30","src":"https://clinicaltrials.gov/study/NCT05997134","sites":["Tanta University — Tanta, Egypt"],"conds":["Ketamine Infusion","Complex Regional Pain Syndromes"],"condg":["Chronic pain & headache"],"enroll":75,"eid":"NCT05997134"},{"id":"study-NCT05173831","cat":"studies","name":"Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT05173831","nsites":0,"start":"2023-09","official":"Chris Stauffer, MD (Associate Professor of Psychiatry at Oregon Health & Science University)","src":"https://clinicaltrials.gov/study/NCT05173831","conds":["PTSD"],"condg":["PTSD & trauma"],"eid":"NCT05173831"},{"id":"study-NCT05949554","cat":"studies","name":"Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","drugs":["ketamine"],"nct":"NCT05949554","nsites":0,"start":"2023-09","official":"Fabrice VALLEE, MD, PhD (Assistance Publique - Hôpitaux de Paris, Lariboisière Hospital, Department of Anesthesiology and Intensive Care); Joaquim MATEO, MD…","src":"https://clinicaltrials.gov/study/NCT05949554","conds":["Neuropathic Pain"],"condg":["Chronic pain & headache"],"eid":"NCT05949554"},{"id":"study-NCT03613792","cat":"studies","name":"Remifentanil Plus Ketamine for Dynamic Flexible Bronchoscopy","status":"WITHDRAWN","phase":"Phase 4","sponsor":"Beth Israel Deaconess Medical Center","drugs":["ketamine"],"nct":"NCT03613792","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-09","official":"Satya Krishna Ramachandran, MD (Beth Israel Deaconess Medical Center)","src":"https://clinicaltrials.gov/study/NCT03613792","sites":["Beth Israel Deaconess Medical Center (BIDMC) — Boston, United States"],"conds":["Bronchoscopy"],"condg":["Other"],"eid":"NCT03613792"},{"id":"study-NCT05661669","cat":"studies","name":"Ketamine for the Treatment for Alcohol Use Disorder in the ED","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Brigham and Women's Hospital","drugs":["ketamine"],"nct":"NCT05661669","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-09-01","src":"https://clinicaltrials.gov/study/NCT05661669","sites":["Brigham and Women's Faulkner Hospital — Boston, United States"],"conds":["Alcohol Use Disorder"],"condg":["Addiction & substance use"],"eid":"NCT05661669"},{"id":"study-NCT05958758","cat":"studies","name":"A Community of Practice Program With Psilocybin-assisted Therapy for End-of-Life Patients","status":"UNKNOWN","phase":"EARLY_Phase 1","sponsor":"The Roots to Thrive Society for Psychedelic Therapy","drugs":["psilocybin"],"nct":"NCT05958758","nsites":0,"start":"2023-09-01","src":"https://clinicaltrials.gov/study/NCT05958758","conds":["End of Life"],"condg":["End-of-life & palliative"],"enroll":64,"eid":"NCT05958758"},{"id":"study-NCT05416229","cat":"studies","name":"Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder","status":"COMPLETED","phase":"Phase 2","sponsor":"Anders Fink-Jensen, MD, DMSci","drugs":["psilocybin"],"nct":"NCT05416229","nsites":1,"countries":"Denmark","ccs":["DK"],"start":"2023-09-01","official":"Anders Fink-Jensen, Professor (Psychiatric Center Copenhagen, Frederiksberg Hospital)","src":"https://clinicaltrials.gov/study/NCT05416229","sites":["Psychiatric Center Copenhagen, Frederiksberg Hospital — Frederiksberg, Denmark"],"conds":["Alcohol Use Disorder"],"condg":["Addiction & substance use"],"enroll":60,"eid":"NCT05416229"},{"id":"study-NCT06184958","cat":"studies","name":"Potential Role of Intravenous Lidocaine Versus Intravenous Ketamine for Pain Management in Fibromyalgia Patients","status":"UNKNOWN","phase":"Phase 4","sponsor":"Ain Shams University","drugs":["ketamine"],"nct":"NCT06184958","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2023-09-02","src":"https://clinicaltrials.gov/study/NCT06184958","sites":["maha sadek El Derh — Cairo, Egypt"],"conds":["Anesthesia"],"condg":["Other"],"enroll":75,"eid":"NCT06184958"},{"id":"study-NCT05042466","cat":"studies","name":"Northwest Therapies Trauma Psilocybin Study Compassionate Use Study","status":"UNKNOWN","phase":"Phase 1","sponsor":"NWTraumatherapies","drugs":["psilocybin"],"nct":"NCT05042466","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-09-03","official":"Ross M Allison, Provider (NW Therapies Trauma Unit)","src":"https://clinicaltrials.gov/study/NCT05042466","sites":["Ross Allison NPI #1437519899 Administrator Of Study — Bozeman, United States"],"conds":["Trauma, Nervous System"],"condg":["PTSD & trauma"],"contact":{"n":"Ross M Allison, Plant Medicine On Boarding","p":"206-234-3087","e":"geriatric.bozemanhealth@gmail.com"},"enroll":30,"eid":"NCT05042466"},{"id":"study-NCT05709353","cat":"studies","name":"MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder","status":"UNKNOWN","phase":"Phase 2","sponsor":"University of Sydney","drugs":["MDMA"],"nct":"NCT05709353","nsites":2,"countries":"Australia","ccs":["AU"],"start":"2023-09-19","official":"Kirsten C Morley, PhD (University of Sydney)","src":"https://clinicaltrials.gov/study/NCT05709353","sites":["Drug Health Services, Royal Prince Alfred Hospital — Sydney, Australia","Turning Point — Richmond, Australia"],"conds":["PTSD","Alcohol Use Disorder","Alcohol Dependence","Post-traumatic Stress Disorder","Comorbidities and Coexisting Conditions"],"condg":["PTSD & trauma","Addiction & substance use"],"contact":{"n":"Kirsten C Morley, PhD","p":"61295153636","e":"Kirsten.morley@sydney.edu.au"},"enroll":120,"eid":"NCT05709353"},{"id":"study-NCT06631625","cat":"studies","name":"Effect of Addition of Dexmedetomidine or Ketamine to Intravenous Infusion of Lidocaine on Proinflammatory Cytokines in Pelvi-abdominal Cancer Surgeries.","status":"COMPLETED","phase":"Phase 1","sponsor":"Alexandria University","drugs":["ketamine"],"nct":"NCT06631625","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2023-09-24","src":"https://clinicaltrials.gov/study/NCT06631625","sites":["Faculty of medicine — Alexandria, Egypt"],"conds":["Pelvic Cancer","Abdominal Cancer","Surgery","Proinflammatory Cytokines"],"condg":["Cancer-related distress"],"enroll":45,"eid":"NCT06631625"},{"id":"study-NCT05907213","cat":"studies","name":"Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1)","status":"COMPLETED","phase":"Phase 1","sponsor":"Grace Lim, MD, MS","drugs":["ketamine"],"nct":"NCT05907213","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-09-25","official":"Grace Lim, MD, MSc (University of Pittsburgh)","src":"https://clinicaltrials.gov/study/NCT05907213","sites":["Magee Womens Hospital of UPMC — Pittsburgh, United States"],"conds":["Pain, Postoperative","Depression, Postpartum"],"condg":["Depression","Chronic pain & headache"],"enroll":12,"eid":"NCT05907213"},{"id":"study-NCT05128162","cat":"studies","name":"Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia","status":"COMPLETED","phase":"Phase 2","sponsor":"Kevin Boehnke","drugs":["psilocybin"],"nct":"NCT05128162","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-09-27","official":"Kevin F Boehnke, PhD (University of Michigan)","src":"https://clinicaltrials.gov/study/NCT05128162","sites":["Chronic Pain and Fatigue Research Center — Ann Arbor, United States"],"conds":["Fibromyalgia"],"condg":["Chronic pain & headache"],"enroll":17,"eid":"NCT05128162"},{"id":"study-NCT05961527","cat":"studies","name":"Group MDMA-therapy for Veterans With PTSD","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Portland VA Research Foundation, Inc","drugs":["MDMA"],"nct":"NCT05961527","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-10-01","src":"https://clinicaltrials.gov/study/NCT05961527","sites":["Portland-Vancouver VA — Vancouver, United States"],"conds":["PTSD"],"condg":["PTSD & trauma"],"enroll":23,"eid":"NCT05961527"},{"id":"study-NCT05894902","cat":"studies","name":"Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults","status":"UNKNOWN","phase":"Phase 1","sponsor":"Advanced Integrative Medical Science Institute","drugs":["ayahuasca"],"nct":"NCT05894902","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-10-01","official":"Leanna J Standish, ND PhD (AIMS Institute)","src":"https://clinicaltrials.gov/study/NCT05894902","sites":["AIMS Institute — Seattle, United States"],"conds":["Major Depression","Post Traumatic Stress Disorder"],"condg":["Depression","PTSD & trauma"],"contact":{"n":"Leanna J Standish, ND PhD","p":"2064201321","e":"Lstandish@aimsinstitute.net"},"enroll":12,"eid":"NCT05894902"},{"id":"study-NCT06138691","cat":"studies","name":"KET-RO Plus RO DBT for Treatment Resistant Depression","status":"COMPLETED","phase":"Phase 1","sponsor":"Washington University School of Medicine","drugs":["ketamine"],"nct":"NCT06138691","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-10-04","official":"Kirsten Gilbert, PhD (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT06138691","sites":["Washington University School of Medicine — St Louis, United States"],"conds":["Treatment Resistant Depression"],"condg":["Depression"],"enroll":16,"eid":"NCT06138691"},{"id":"study-NCT05979844","cat":"studies","name":"MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD","status":"COMPLETED","phase":"Phase 3","sponsor":"Dr. Leslie Morland","drugs":["MDMA"],"nct":"NCT05979844","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-10-06","official":"Leslie Morland (San Diego Veterans Healthcare System)","src":"https://clinicaltrials.gov/study/NCT05979844","sites":["VA San Diego Healthcare System, San Diego, CA — San Diego, United States"],"conds":["PTSD","Relational Problems"],"condg":["PTSD & trauma"],"enroll":16,"eid":"NCT05979844"},{"id":"study-NCT06094907","cat":"studies","name":"Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Universidade Federal do Rio Grande do Norte","drugs":["DMT"],"nct":"NCT06094907","nsites":1,"countries":"Brazil","ccs":["BR"],"start":"2023-10-09","official":"Draulio Araujo, Ph.D (Universidade Federal do Rio Grande do Norte); Marcelo Falchi, M.D. (Universidade Federal do Rio Grande do Norte)","src":"https://clinicaltrials.gov/study/NCT06094907","sites":["Hospital Universitário Onofre Lopes — Natal, Brazil"],"conds":["Depressive Disorder","Depression, Unipolar"],"condg":["Depression"],"enroll":14,"eid":"NCT06094907"},{"id":"study-NCT06070090","cat":"studies","name":"Tapping in Together: A Pilot Study on Group Acupuncture for Ketamine Experience Integration","status":"COMPLETED","phase":"N/A","sponsor":"Academy of Oriental Medicine Austin","drugs":["ketamine"],"nct":"NCT06070090","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-10-09","official":"William Morris, PhD, DAOM (Academy of Oriental Medicine Austin)","src":"https://clinicaltrials.gov/study/NCT06070090","sites":["Cardea Ketamine Space — New York, United States"],"conds":["Acupuncture"],"condg":["Other"],"enroll":15,"eid":"NCT06070090"},{"id":"study-NCT06073015","cat":"studies","name":"Effect of Esketamine on Reducing Postoperative Anxiety and Depression in Adolescent Patients","status":"UNKNOWN","phase":"EARLY_Phase 1","sponsor":"Henan Provincial People's Hospital","drugs":["esketamine"],"nct":"NCT06073015","nsites":0,"start":"2023-10-10","src":"https://clinicaltrials.gov/study/NCT06073015","conds":["Anxiety-depression"],"condg":["Depression","Anxiety"],"enroll":200,"eid":"NCT06073015"},{"id":"study-NCT05639322","cat":"studies","name":"Psychotherapy for Ketamine's Enhanced Durability in Chronic Neuropathic Pain: A Randomized Controlled Pilot Trial","status":"COMPLETED","phase":"Phase 4","sponsor":"Unity Health Toronto","drugs":["ketamine"],"nct":"NCT05639322","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2023-10-12","src":"https://clinicaltrials.gov/study/NCT05639322","sites":["St. Michael's Hospital — Toronto, Canada"],"conds":["Neuropathic Pain"],"condg":["Chronic pain & headache"],"enroll":30,"eid":"NCT05639322"},{"id":"study-NCT06001372","cat":"studies","name":"Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated With Non-operable GI Cancers","status":"TERMINATED","phase":"EARLY_Phase 1","sponsor":"University of Utah","drugs":["ketamine"],"nct":"NCT06001372","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-10-13","official":"Benjamin Lewis, MD (Huntsman Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT06001372","sites":["Huntsman Cancer Institute — Salt Lake City, United States"],"conds":["Gastrointestinal Cancer","Depression","Anxiety"],"condg":["Depression","Anxiety","Cancer-related distress"],"enroll":2,"eid":"NCT06001372"},{"id":"study-NCT06003218","cat":"studies","name":"Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation","status":"COMPLETED","phase":"N/A","sponsor":"Peking University First Hospital","drugs":["esketamine"],"nct":"NCT06003218","nsites":1,"countries":"China","ccs":["CN"],"start":"2023-10-16","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT06003218","sites":["Peking University First Hospital — Beijing, China"],"conds":["Liver Cancer","Radiofrequency Ablation","Esketamine","Dexmedetomidine"],"condg":["Cancer-related distress"],"enroll":88,"eid":"NCT06003218"},{"id":"study-NCT06164756","cat":"studies","name":"Long Term Follow Up KET-PD","status":"COMPLETED","sponsor":"Yale University","drugs":["ketamine"],"nct":"NCT06164756","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-10-18","official":"Sophie E. Holmes, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06164756","sites":["Yale New Haven Hospital — New Haven, United States"],"conds":["Parkinson's Disease","Depression"],"condg":["Depression","Neurology & cognition"],"enroll":49,"eid":"NCT06164756"},{"id":"study-NCT06081179","cat":"studies","name":"Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Zurich","drugs":["MDMA","psilocybin"],"nct":"NCT06081179","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2023-10-24","src":"https://clinicaltrials.gov/study/NCT06081179","sites":["Psychiatrische Universitätsklinik Zürich — Zurich, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":122,"eid":"NCT06081179"},{"id":"study-NCT05554627","cat":"studies","name":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","status":"WITHDRAWN","phase":"Phase 4","sponsor":"VA Office of Research and Development","drugs":["esketamine"],"nct":"NCT05554627","nsites":26,"countries":"United States","ccs":["US"],"start":"2023-10-27","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","sites":["Tuscaloosa VA Medical Center, Tuscaloosa, AL — Tuscaloosa, United States","Phoenix VA Health Care System, Phoenix, AZ — Phoenix, United States","Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR — Little Rock, United States","VA Long Beach Healthcare System, Long Beach, CA — Long Beach, United States","VA Palo Alto Health Care System, Palo Alto, CA — Palo Alto, United States","VA San Diego Healthcare System, San Diego, CA — San Diego, United States","Rocky Mountain Regional VA Medical Center, Aurora, CO — Aurora, United States","VA Connecticut Healthcare System West Haven Campus, West Haven, CT — West Haven, United States"],"conds":["Depressive Disorder, Major"],"condg":["Depression"],"eid":"NCT05554627"},{"id":"study-NCT06060210","cat":"studies","name":"Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion","status":"COMPLETED","phase":"Phase 4","sponsor":"Benha University","drugs":["ketamine"],"nct":"NCT06060210","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2023-10-29","official":"Fatma Ah Abdelfatah, MD (banha faculity of medicine)","src":"https://clinicaltrials.gov/study/NCT06060210","sites":["Banha faculity of medicine — Banhā, Egypt"],"conds":["Depression, Anxiety"],"condg":["Depression","Anxiety"],"enroll":110,"eid":"NCT06060210"},{"id":"study-NCT05344625","cat":"studies","name":"Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress","status":"WITHDRAWN","phase":"EARLY_Phase 1","sponsor":"Northwell Health","drugs":["ketamine"],"nct":"NCT05344625","nsites":0,"start":"2023-10-31","src":"https://clinicaltrials.gov/study/NCT05344625","conds":["Cancer-related Problem/Condition","Depressive Symptoms","Anxiety Disorders"],"condg":["Depression","Anxiety","Cancer-related distress"],"eid":"NCT05344625"},{"id":"study-NCT05718024","cat":"studies","name":"Night-time Dexmedetomidine-esketamine Infusion and Sleep Quality in ICU Patients","status":"COMPLETED","phase":"Phase 4","sponsor":"Peking University First Hospital","drugs":["esketamine"],"nct":"NCT05718024","nsites":1,"countries":"China","ccs":["CN"],"start":"2023-11-01","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT05718024","sites":["Peking University First Hospital — Beijing, China"],"conds":["Intensive Care Unit","Mechanical Ventilation","Dexmedetomidine","Esketamine","Sleep Quality"],"condg":["Other"],"enroll":174,"eid":"NCT05718024"},{"id":"study-NCT05399498","cat":"studies","name":"Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder","status":"COMPLETED","phase":"Phase 2","sponsor":"University of Chicago","drugs":["psilocybin"],"nct":"NCT05399498","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-11-01","official":"Jon E Grant, MD, JD, MPH (University of Chicago)","src":"https://clinicaltrials.gov/study/NCT05399498","sites":["University of Chicago — Chicago, United States"],"conds":["Borderline Personality Disorder","Major Depressive Disorder"],"condg":["Depression"],"enroll":9,"eid":"NCT05399498"},{"id":"study-NCT05592379","cat":"studies","name":"Consciousness, Psilocybin, and Well-Being","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Wisconsin, Madison","drugs":["psilocybin"],"nct":"NCT05592379","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-11-07","official":"Charles Raison, MD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT05592379","sites":["University of Wisconsin Hospital and Clinics — Madison, United States"],"conds":["Healthy","Psychedelic Experiences","Sleep"],"condg":["Healthy volunteers"],"enroll":6,"eid":"NCT05592379"},{"id":"study-NCT06117917","cat":"studies","name":"Esketamine Combined With Pregabalin on CPSP in Spinal Patients.","status":"UNKNOWN","phase":"Phase 2/Phase 3","sponsor":"Beijing Tiantan Hospital","drugs":["esketamine","ketamine"],"nct":"NCT06117917","nsites":1,"countries":"China","ccs":["CN"],"start":"2023-11-10","official":"Ruquan Han, M.D., Ph D (Beijing Tiantan Hospital)","src":"https://clinicaltrials.gov/study/NCT06117917","sites":["Beijing Tiantan Hospital — Beijing, China"],"conds":["Esketamine","Pregabaline","Chronic Post Operative Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Ruquan Han, M.D., Ph D","p":"8610-59976660","e":"ruquan.han@ccmu.edu.cn"},"enroll":150,"eid":"NCT06117917"},{"id":"study-NCT06199700","cat":"studies","name":"Esketamine for the Treatment of Rett Syndrome","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Children's Hospital of Fudan University","drugs":["esketamine"],"nct":"NCT06199700","nsites":1,"countries":"China","ccs":["CN"],"start":"2023-11-15","official":"Huiping Li (Children's Hospital of Fudan University)","src":"https://clinicaltrials.gov/study/NCT06199700","sites":["Xiamen Children's Hospital (Children's Hospital of Fudan University at Xiamen) — Xiamen, China"],"conds":["Rett Syndrome"],"condg":["Other"],"enroll":3,"eid":"NCT06199700"},{"id":"study-NCT05809271","cat":"studies","name":"Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT05809271","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2023-11-17","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital Basel, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05809271","sites":["University Hospital — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":25,"eid":"NCT05809271"},{"id":"study-NCT05242029","cat":"studies","name":"Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT05242029","nsites":0,"start":"2023-12","official":"Matthew W Johnson, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT05242029","conds":["Opioid Use Disorder"],"condg":["Addiction & substance use"],"eid":"NCT05242029"},{"id":"study-NCT06108830","cat":"studies","name":"Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients","status":"UNKNOWN","phase":"N/A","sponsor":"Tianjin Medical University General Hospital","drugs":["esketamine"],"nct":"NCT06108830","nsites":1,"countries":"China","ccs":["CN"],"start":"2023-12-01","official":"Guolin Wang (Tianjin Medical University General Hospital)","src":"https://clinicaltrials.gov/study/NCT06108830","sites":["Tianjin Medical University General Hospital — Tianjin, China"],"conds":["Sleep Disturbance"],"condg":["Other"],"contact":{"n":"Guolin Wang, MD","p":"+8615822855556","e":"wangguolinghad@hotmail.com"},"enroll":400,"eid":"NCT06108830"},{"id":"study-NCT06032624","cat":"studies","name":"Ketamine and Dexmedetomidine Comparative Study","status":"UNKNOWN","phase":"N/A","sponsor":"Sohag University","drugs":["ketamine"],"nct":"NCT06032624","nsites":0,"start":"2023-12-01","src":"https://clinicaltrials.gov/study/NCT06032624","conds":["Post Operative Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Mohammed Mahmoud, MD","p":"00201091328413","e":"mohamedmahmoud@med.sohag.edu.eg"},"enroll":50,"eid":"NCT06032624"},{"id":"study-NCT06806475","cat":"studies","name":"Sustained Ketamine Effectiveness for Suicidal Ideation","status":"COMPLETED","sponsor":"University Hospital, Montpellier","drugs":["ketamine"],"nct":"NCT06806475","nsites":1,"countries":"France","ccs":["FR"],"start":"2023-12-01","official":"Emilie OLIE, MD PhD (University Hospital, Montpellier)","src":"https://clinicaltrials.gov/study/NCT06806475","sites":["University Hospital, Montpellier — Montpellier, France"],"conds":["Depression - Major Depressive Disorder","Suicide"],"condg":["Depression"],"enroll":128,"eid":"NCT06806475"},{"id":"study-NCT06064162","cat":"studies","name":"Ketamine for MS Fatigue","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"Alta Bates Summit Medical Center","drugs":["ketamine"],"nct":"NCT06064162","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-12-05","official":"Deepak Soneji, MD (Sutter East Bay Medical Foundation)","src":"https://clinicaltrials.gov/study/NCT06064162","sites":["Alta Bates Summit Medical Center — Berkeley, United States"],"conds":["Multiple Sclerosis"],"condg":["Other"],"enroll":21,"eid":"NCT06064162"},{"id":"study-NCT06141876","cat":"studies","name":"Evaluation of Psilocybin-Assisted Psychotherapy in Treating Severe Depression in Patients With PTSD","status":"UNKNOWN","phase":"Phase 2","sponsor":"Apex Labs Ltd.","drugs":["psilocybin"],"nct":"NCT06141876","nsites":0,"start":"2023-12-15","src":"https://clinicaltrials.gov/study/NCT06141876","conds":["Post-traumatic Stress Disorder","Depression"],"condg":["Depression","PTSD & trauma"],"enroll":160,"eid":"NCT06141876"},{"id":"study-NCT06036511","cat":"studies","name":"Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD","status":"WITHDRAWN","phase":"Phase 1/Phase 2","sponsor":"University of New Mexico","drugs":["ketamine"],"nct":"NCT06036511","nsites":1,"countries":"United States","ccs":["US"],"start":"2023-12-31","official":"Snehal Bhatt, MD (UNM)","src":"https://clinicaltrials.gov/study/NCT06036511","sites":["University of New Mexico — Albuquerque, United States"],"conds":["PTSD"],"condg":["PTSD & trauma"],"eid":"NCT06036511"},{"id":"study-NCT06199011","cat":"studies","name":"Effect of Esketamine on Depressive Symptoms of Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy","status":"UNKNOWN","phase":"N/A","sponsor":"The Second Hospital of Anhui Medical University","drugs":["esketamine"],"nct":"NCT06199011","nsites":0,"start":"2024-01-01","src":"https://clinicaltrials.gov/study/NCT06199011","conds":["Depressive Symptoms"],"condg":["Depression"],"contact":{"n":"Chunxia Huang, PhD","p":"+8613500512159","e":"huangchunxia@ahmu.edu.cn"},"enroll":400,"eid":"NCT06199011"},{"id":"study-NCT06467513","cat":"studies","name":"To Investigate the Effect of Esketamine Hydrochloride on Pulmonary Complications","status":"UNKNOWN","phase":"Phase 4","sponsor":"Zhang XIao Mei","drugs":["esketamine"],"nct":"NCT06467513","nsites":1,"countries":"China","ccs":["CN"],"start":"2024-01-01","official":"Wei Chen (Staff member of Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University); Haiying Wang (Director of anesthesiology Department,…","src":"https://clinicaltrials.gov/study/NCT06467513","sites":["Affiliated Hospital of Zunyi Medical University — Zunyi, China"],"conds":["Heart Diseases","Heart Valve Diseases"],"condg":["Other"],"contact":{"n":"Xiaomei Zhang","p":"+0086 18786233321","e":"3233598996@qq.com"},"enroll":102,"eid":"NCT06467513"},{"id":"study-NCT05783492","cat":"studies","name":"INK Feasibility Study","status":"WITHDRAWN","phase":"Phase 3","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","drugs":["ketamine"],"nct":"NCT05783492","nsites":0,"start":"2024-01-01","src":"https://clinicaltrials.gov/study/NCT05783492","conds":["Procedural Sedation"],"condg":["Other"],"eid":"NCT05783492"},{"id":"study-NCT05675800","cat":"studies","name":"Psilocybin for Major Depressive Disorder","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Washington University School of Medicine","drugs":["psilocybin"],"nct":"NCT05675800","nsites":0,"start":"2024-01-01","official":"Ginger Nicol, MD (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT05675800","conds":["Major Depressive Disorder"],"condg":["Depression"],"eid":"NCT05675800"},{"id":"study-NCT06051227","cat":"studies","name":"Fentanyl OR Esketamine for Traumatic PAIN (FORE-PAIN) Trial","status":"TERMINATED","phase":"Phase 3","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","drugs":["esketamine"],"nct":"NCT06051227","nsites":1,"countries":"Netherlands","ccs":["NL"],"start":"2024-01-11","official":"Markus W Hollmann, Prof. dr. dr. (Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA))","src":"https://clinicaltrials.gov/study/NCT06051227","sites":["Ambulance Amsterdam — Amsterdam, Netherlands"],"conds":["Acute Pain Due to Trauma","Analgesia","Fentanyl","Esketamine","Emergency Medical Services"],"condg":["PTSD & trauma","Chronic pain & headache"],"enroll":235,"eid":"NCT06051227"},{"id":"study-NCT06366334","cat":"studies","name":"Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation","status":"UNKNOWN","phase":"N/A","sponsor":"Children's Hospital of Eastern Ontario","drugs":["ketamine"],"nct":"NCT06366334","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2024-01-15","official":"Tyrus Crawford, BA (CHEO)","src":"https://clinicaltrials.gov/study/NCT06366334","sites":["Children's Hospital Of Eastern Ontario — Ottawa, Canada"],"conds":["Suicidal Ideation","Suicidal Ideas"],"condg":["Other"],"contact":{"n":"Maala Bhatt, MD","p":"6137377600","e":"mbhatt@cheo.on.ca"},"enroll":20,"eid":"NCT06366334"},{"id":"study-NCT06252506","cat":"studies","name":"Molecular Imaging Study of Harmine/DMT: a Basic Research Approach","status":"COMPLETED","phase":"Phase 1","sponsor":"Insel Gruppe AG, University Hospital Bern","drugs":["DMT","ayahuasca"],"nct":"NCT06252506","nsites":2,"countries":"Switzerland","ccs":["CH"],"start":"2024-01-22","official":"Paul K Cumming, PhD (Insel Group AG)","src":"https://clinicaltrials.gov/study/NCT06252506","sites":["Department of Nuclear Medicine, Bern University Hospital — Bern, Switzerland","Psychiatric University Hospital Zurich — Zurich, Switzerland"],"conds":["Neuropharmacological Investigation of Ayahuasca…"],"condg":["Other"],"enroll":17,"eid":"NCT06252506"},{"id":"study-NCT05964647","cat":"studies","name":"Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD"],"nct":"NCT05964647","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2024-02-01","src":"https://clinicaltrials.gov/study/NCT05964647","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":20,"eid":"NCT05964647"},{"id":"study-NCT06235411","cat":"studies","name":"Psilocybin in Alcohol Use Disorder With Comorbid Depression","status":"COMPLETED","phase":"N/A","sponsor":"Centre Hospitalier Universitaire de Nīmes","drugs":["psilocybin"],"nct":"NCT06235411","nsites":1,"countries":"France","ccs":["FR"],"start":"2024-02-05","official":"Amandine Luquiens (CHU de Nimes)","src":"https://clinicaltrials.gov/study/NCT06235411","sites":["CHU — Nîmes, France"],"conds":["Alcohol-Related Disorders","Depressive Disorder","Addiction"],"condg":["Depression","Addiction & substance use"],"enroll":30,"eid":"NCT06235411"},{"id":"study-NCT05943665","cat":"studies","name":"MDMA for AUD/PTSD Comorbidity","status":"COMPLETED","phase":"Phase 2","sponsor":"Carolina L Haass-Koffler","drugs":["MDMA"],"nct":"NCT05943665","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-02-06","src":"https://clinicaltrials.gov/study/NCT05943665","sites":["Brown University — Providence, United States"],"conds":["Alcohol Use Disorder","Post Traumatic Stress Disorder"],"condg":["PTSD & trauma","Addiction & substance use"],"enroll":22,"eid":"NCT05943665"},{"id":"study-NCT05723276","cat":"studies","name":"Psilocybin in Functional Neurological Disorder","status":"COMPLETED","phase":"N/A","sponsor":"King's College London","drugs":["psilocybin"],"nct":"NCT05723276","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2024-02-14","src":"https://clinicaltrials.gov/study/NCT05723276","sites":["South London and Maudsley NHS Foundation Trust — London, United Kingdom"],"conds":["Functional Neurological Disorder"],"condg":["Other"],"enroll":20,"eid":"NCT05723276"},{"id":"study-NCT06160232","cat":"studies","name":"Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder","status":"UNKNOWN","phase":"Phase 2","sponsor":"Brugmann University Hospital","drugs":["psilocybin"],"nct":"NCT06160232","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2024-02-15","official":"Charles Kornreich, M.D. Ph.D. (Brugmann University Hospital, Free University of Brussels)","src":"https://clinicaltrials.gov/study/NCT06160232","sites":["Brugmann University Hospital — Brussels, Belgium"],"conds":["Severe Alcohol Use Disorder"],"condg":["Addiction & substance use"],"contact":{"n":"Laetitia Vanderijst, M.Sc.","p":"02 477 22 33","e":"laetitia.vanderijst@ulb.be"},"enroll":62,"eid":"NCT06160232"},{"id":"study-NCT05976698","cat":"studies","name":"LSD-Perceptual-Choice-Study","status":"COMPLETED","phase":"N/A","sponsor":"University Hospital, Basel, Switzerland","drugs":["LSD"],"nct":"NCT05976698","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2024-02-26","official":"Philipp Sterzer, Prof. Dr. (University Psychiatric Clinics Basel)","src":"https://clinicaltrials.gov/study/NCT05976698","sites":["University Psychiatric Clinics Basel — Basel, Switzerland"],"conds":["LSD Reaction"],"condg":["Other"],"enroll":30,"eid":"NCT05976698"},{"id":"study-NCT06531590","cat":"studies","name":"Anterior Shoulder Dislocation at Emergency Department","status":"UNKNOWN","sponsor":"Saglik Bilimleri Universitesi","drugs":["ketamine"],"nct":"NCT06531590","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2024-03-01","official":"gulsen akcay, ass. prof. (ass. prof. of organization)","src":"https://clinicaltrials.gov/study/NCT06531590","sites":["Etlik City Hospital — Ankara, Turkey"],"conds":["Shoulder Dislocation","Analgesia","Pain, Shoulder"],"condg":["Chronic pain & headache"],"contact":{"n":"gulsen akcay, ass. prof.","p":"+905052874949","e":"gulakcay@yahoo.com.tr"},"enroll":140,"eid":"NCT06531590"},{"id":"study-NCT06284668","cat":"studies","name":"Esketamine vs Remimazolam for Postoperative Sleep Disturbance and Anxiety","status":"COMPLETED","phase":"N/A","sponsor":"Tianjin Medical University General Hospital","drugs":["esketamine"],"nct":"NCT06284668","nsites":1,"countries":"China","ccs":["CN"],"start":"2024-03-04","official":"Guolin Wang (Tianjin Medical University General Hospital)","src":"https://clinicaltrials.gov/study/NCT06284668","sites":["Tianjin Medical University General Hospital — Tianjin, China"],"conds":["Sleep Disturbance"],"condg":["Other"],"enroll":315,"eid":"NCT06284668"},{"id":"study-NCT07415395","cat":"studies","name":"Acute Effects of Aerobic Exercise Intensity on Lower-Limb Muscle Strength and Power in Youth Gymnasts","status":"COMPLETED","phase":"N/A","sponsor":"Chaoran Han","drugs":["LSD"],"nct":"NCT07415395","nsites":1,"countries":"China","ccs":["CN"],"start":"2024-03-18","src":"https://clinicaltrials.gov/study/NCT07415395","sites":["Shanghai University of Sport — Shanghai, China"],"conds":["Acute Neuromuscular Responses to Aerobic Exercise in Elite…"],"condg":["Other"],"enroll":18,"eid":"NCT07415395"},{"id":"study-NCT06340958","cat":"studies","name":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","status":"COMPLETED","phase":"Phase 2","sponsor":"Clexio Biosciences Ltd.","drugs":["esketamine","ketamine"],"nct":"NCT06340958","nsites":23,"countries":"United States","ccs":["US"],"start":"2024-03-18","src":"https://clinicaltrials.gov/study/NCT06340958","sites":["Clinical Site 139 — La Jolla, United States","Clinical Site 131 — Lafayette, United States","Clinical Site 130 — Upland, United States","Clinical Site 102 — Hollywood, United States","Clinical Site 105 — Lauderhill, United States","Clinical Site 140 — Miami Springs, United States","Clinical Site 132 — Pensacola, United States","Clinical Site 118 — Atlanta, United States"],"conds":["Adjunctive Treatment of Major Depressive Disorder (MDD)"],"condg":["Depression"],"enroll":99,"eid":"NCT06340958"},{"id":"study-NCT06133309","cat":"studies","name":"Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State","status":"COMPLETED","phase":"N/A","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","drugs":["esketamine","ketamine"],"nct":"NCT06133309","nsites":1,"countries":"France","ccs":["FR"],"start":"2024-03-19","official":"Manuel DIAS ALVES, MD PhD (Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer)","src":"https://clinicaltrials.gov/study/NCT06133309","sites":["Centre Hospitalier Intercommunal Toulon La Seyne sur Mer — Toulon, France"],"conds":["Depressive Disorder"],"condg":["Depression"],"enroll":15,"eid":"NCT06133309"},{"id":"study-NCT06331182","cat":"studies","name":"Dexmedetomidine and Ketamine as an Adjuvant in External Oblique Intercostal Plane Block for Post Thoracotomy Pain","status":"COMPLETED","phase":"N/A","sponsor":"Tanta University","drugs":["ketamine"],"nct":"NCT06331182","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2024-03-26","official":"Mohammed S Elsharkawy, MD (Tanta University)","src":"https://clinicaltrials.gov/study/NCT06331182","sites":["Tanta University — Tanta, Egypt"],"conds":["Dexmedetomidine","Ketamine","External Oblique Intercostal Plane Block","Post Thoracotomy Pain"],"condg":["Chronic pain & headache"],"enroll":40,"eid":"NCT06331182"},{"id":"study-NCT06294639","cat":"studies","name":"ED50 of Esketamine for Laser Treatment in Children","status":"UNKNOWN","phase":"N/A","sponsor":"Air Force Military Medical University, China","drugs":["esketamine"],"nct":"NCT06294639","nsites":0,"start":"2024-03-27","src":"https://clinicaltrials.gov/study/NCT06294639","conds":["Anesthesia"],"condg":["Other"],"contact":{"n":"Zhi-Hong Lu","p":"+862984775343","e":"deerlu23@163.com"},"enroll":40,"eid":"NCT06294639"},{"id":"study-NCT06326606","cat":"studies","name":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"MycoMedica Life Sciences PBC","drugs":["psilocybin"],"nct":"NCT06326606","nsites":1,"countries":"Australia","ccs":["AU"],"start":"2024-03-27","official":"Sepehr Shakib (Principal Investigator at CMAX Clinical Research Pty Ltd)","src":"https://clinicaltrials.gov/study/NCT06326606","sites":["CMAX Clinical Research Pty Ltd — Adelaide, Australia"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":24,"eid":"NCT06326606"},{"id":"study-NCT06303037","cat":"studies","name":"Effect of Esketamine on 95% Induction Dose of Remimazolam","status":"COMPLETED","phase":"Phase 4","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","drugs":["esketamine"],"nct":"NCT06303037","nsites":1,"countries":"China","ccs":["CN"],"start":"2024-04-01","official":"Huacheng Liu (Second Affiliated Hospital of Wenzhou Medical University); Yuhang Cai (Second Affiliated Hospital of Wenzhou Medical University)","src":"https://clinicaltrials.gov/study/NCT06303037","sites":["The second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University — Wenzhou, China"],"conds":["Pediatric","Gastroscopy","ED95","Sedation"],"condg":["Other"],"enroll":80,"eid":"NCT06303037"},{"id":"study-NCT06354673","cat":"studies","name":"Stellate Ganglion Block Combined With Dexmedetomidine or Subanesthetic Ketamine Infusion for Treatment of Neurostorm.","status":"COMPLETED","phase":"N/A","sponsor":"Zagazig University","drugs":["ketamine"],"nct":"NCT06354673","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2024-04-04","official":"Eslam S. Almaghawry Mohamed, MD (Zagazig University)","src":"https://clinicaltrials.gov/study/NCT06354673","sites":["Zagazig university — Zagazig, Egypt"],"conds":["Paroxysmal Sympathetic Hyperactivity"],"condg":["Other"],"enroll":205,"eid":"NCT06354673"},{"id":"study-NCT06355180","cat":"studies","name":"Esketamine vs ECT for Acute Suicidality","status":"COMPLETED","phase":"N/A","sponsor":"Capital Medical University","drugs":["esketamine"],"nct":"NCT06355180","nsites":6,"countries":"China","ccs":["CN"],"start":"2024-04-16","official":"Gang Wang, MD (Beijing Anding Hospital, Capital Medical University)","src":"https://clinicaltrials.gov/study/NCT06355180","sites":["Wuhu Fourth People's Hospital — Wuhu, China","Beijing Anding Hospital — Beijing, China","Beijing Chaoyang District Third Hospital — Beijing, China","Beijing Daxing District Xinkang Hospital — Beijing, China","The Second People's Hospital of Dali Bai Autonomous Prefecture — Dali, China","Inner Mongolia Autonomous Region Mental Health Center — Hohhot, China"],"conds":["Mood Disorders","Suicidal Ideation","Depressive Episode"],"condg":["Depression"],"enroll":340,"eid":"NCT06355180"},{"id":"study-NCT06473896","cat":"studies","name":"Effect of Ketalar or Dexmedetomidine on Increased Sensitivity to Pain Following Treatment With Remifentanil","status":"UNKNOWN","phase":"N/A","sponsor":"Assaf-Harofeh Medical Center","drugs":["ketamine"],"nct":"NCT06473896","nsites":1,"countries":"Israel","ccs":["IL"],"start":"2024-04-18","official":"Sara Bar Yehuda, PhD (Shamir (Asaf Harofe) medical center)","src":"https://clinicaltrials.gov/study/NCT06473896","sites":["Shamir (Asaf Harofe) Medical Center — Be’er Ya‘aqov, Israel"],"conds":["Cholecystectomy"],"condg":["Other"],"contact":{"n":"Sara Bar Yehuda, PhD","p":"972528981004","e":"sarabar1@shamir.gov.il"},"enroll":90,"eid":"NCT06473896"},{"id":"study-NCT06344858","cat":"studies","name":"Characterization of the Temporal Profile of the Anti-nociceptive Effect of Ketamine Bolus Measured With ANI","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","drugs":["ketamine"],"nct":"NCT06344858","nsites":1,"countries":"Chile","ccs":["CL"],"start":"2024-04-30","official":"Luis I Cortinez, MD (Pontificia Universidad Catolica de Chile)","src":"https://clinicaltrials.gov/study/NCT06344858","sites":["Pontificia Universidad Catolica de Chile — Santiago, Chile"],"conds":["Analgesia","Ketamine","Pharmacokinetic"],"condg":["Other"],"enroll":20,"eid":"NCT06344858"},{"id":"study-NCT03752918","cat":"studies","name":"The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.","status":"WITHDRAWN","phase":"Phase 1","sponsor":"Yale University","drugs":["MDMA"],"nct":"NCT03752918","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-05","official":"Benjamin Kelmendi, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03752918","sites":["Enact Research Collaborative — New Haven, United States"],"conds":["Post Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"eid":"NCT03752918"},{"id":"study-NCT06388824","cat":"studies","name":"The Effect of Esketamine on Sleep Disturbance","status":"COMPLETED","phase":"N/A","sponsor":"Tianjin Medical University General Hospital","drugs":["esketamine"],"nct":"NCT06388824","nsites":1,"countries":"China","ccs":["CN"],"start":"2024-05-03","official":"Guolin Wang, MD, PhD (Tianjin Medical University General Hospital)","src":"https://clinicaltrials.gov/study/NCT06388824","sites":["Tianjin Medical University General Hospital — Tianjin, China"],"conds":["Sleep Disturbance"],"condg":["Other"],"enroll":204,"eid":"NCT06388824"},{"id":"study-NCT06430645","cat":"studies","name":"Effects of Esketamine on Recovery of Consciousness After Propofol Anesthesia","status":"UNKNOWN","phase":"N/A","sponsor":"Beijing Tiantan Hospital","drugs":["esketamine"],"nct":"NCT06430645","nsites":1,"countries":"China","ccs":["CN"],"start":"2024-05-05","official":"Ruquan Han, PhD (Beijing Tiantan Hospital)","src":"https://clinicaltrials.gov/study/NCT06430645","sites":["Beijing Tiantan Hospital, Capital Medical University — Beijing, China"],"conds":["Post-anesthesia Recovery"],"condg":["Other"],"contact":{"n":"Yang Li, Master","p":"+86 18810637134","e":"liyang0519@mail.ccmu.edu.cn"},"enroll":150,"eid":"NCT06430645"},{"id":"study-NCT06051721","cat":"studies","name":"A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)","status":"COMPLETED","phase":"Phase 2","sponsor":"Cybin IRL Limited","drugs":["DMT"],"nct":"NCT06051721","nsites":6,"countries":"United States","ccs":["US"],"start":"2024-05-10","official":"Amir Inamdar, MBBS, DNB, MFPM (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06051721","sites":["Research Centers of America — Hollywood, United States","Innovative Clinical Research, Inc. — Miami Lakes, United States","CenExel ACMR — Atlanta, United States","iResearch Atlanta — Decatur, United States","Uptown Research Institute — Chicago, United States","Cedar Clinical Research — Murray, United States"],"conds":["Generalized Anxiety Disorder"],"condg":["Anxiety"],"enroll":36,"eid":"NCT06051721"},{"id":"study-NCT06414941","cat":"studies","name":"The Effect of Dexmedetomidine and Esketamine Combined Infusion Quality of Sleep Undergoing Modified Radical Mastectomy","status":"UNKNOWN","phase":"N/A","sponsor":"Anqing Municipal Hospital","drugs":["esketamine"],"nct":"NCT06414941","nsites":1,"countries":"China","ccs":["CN"],"start":"2024-05-15","src":"https://clinicaltrials.gov/study/NCT06414941","sites":["Department of Anqing Hospital Anesthesiology — Anqing, China"],"conds":["Dexmedetomidine Plus Esketamine Affect Postoperative Sleep…"],"condg":["Other"],"contact":{"n":"Xu si qi, Doctor","p":"13865192106","e":"errtg555@163.com"},"enroll":105,"eid":"NCT06414941"},{"id":"study-NCT06077487","cat":"studies","name":"Ketamine-assisted Therapy for Advanced GI Cancer","status":"TERMINATED","phase":"Phase 4","sponsor":"Brian Anderson, MD","drugs":["ketamine"],"nct":"NCT06077487","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-05-17","official":"Brian T Anderson, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06077487","sites":["University of California, San Francisco — San Francisco, United States"],"conds":["Pancreatic Ductal Adenocarcinoma","Pain, Acute","Gastrointestinal Cancers","Demoralization"],"condg":["Cancer-related distress","Chronic pain & headache"],"enroll":1,"eid":"NCT06077487"},{"id":"study-NCT06389344","cat":"studies","name":"Effect of Esketamine on Conscious State in Patients With pDoC","status":"UNKNOWN","phase":"N/A","sponsor":"Beijing Tiantan Hospital","drugs":["esketamine"],"nct":"NCT06389344","nsites":1,"countries":"China","ccs":["CN"],"start":"2024-05-20","src":"https://clinicaltrials.gov/study/NCT06389344","sites":["Beijing Tiantan Hospital, Capital Medical University — Beijing, China"],"conds":["Esketamine","Consciousness Disorders"],"condg":["Other"],"contact":{"n":"Ruquan Han, M.D","p":"8610-59976660","e":"ruquan.han@ccmu.edu.cn"},"enroll":116,"eid":"NCT06389344"},{"id":"study-NCT06473285","cat":"studies","name":"Effects of Esketamine on Consciousness-related Brain Network Characteristics in Patients With Prolonged Disorders of Consciousness","status":"UNKNOWN","phase":"N/A","sponsor":"Beijing Tiantan Hospital","drugs":["esketamine"],"nct":"NCT06473285","nsites":1,"countries":"China","ccs":["CN"],"start":"2024-06-01","src":"https://clinicaltrials.gov/study/NCT06473285","sites":["Beijing Tiantan Hospital, Capital Medical University — Beijing, China"],"conds":["Prolonged Disorders of Consciousness"],"condg":["Other"],"enroll":80,"eid":"NCT06473285"},{"id":"study-NCT06588907","cat":"studies","name":"Pain Palliation in Forearm Fractures in the Emergency Department","status":"COMPLETED","phase":"N/A","sponsor":"Ankara Etlik City Hospital","drugs":["ketamine"],"nct":"NCT06588907","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2024-06-01","official":"Ahmet Burak Erdem (Ankara Etlik City Hospital)","src":"https://clinicaltrials.gov/study/NCT06588907","sites":["Ankara Etlik City Hospital — Ankara, Turkey"],"conds":["Forearm Fracture","Radius Fractures","Ulnar Fracture"],"condg":["Other"],"enroll":85,"eid":"NCT06588907"},{"id":"study-NCT06237569","cat":"studies","name":"Dose Low Dose Ketamine in Casesarian","status":"UNKNOWN","sponsor":"Inonu University","drugs":["ketamine"],"nct":"NCT06237569","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2024-06-01","official":"DUYGU DEMIROZ (Inonu University)","src":"https://clinicaltrials.gov/study/NCT06237569","sites":["Inonu universitesi — Malatya, Turkey"],"conds":["Postoperative Pain","Postpartum Depression"],"condg":["Depression","Chronic pain & headache"],"contact":{"n":"DUYGU DEMIROZ, dr","p":"+905319504421","e":"drduygudemiroz@hotmail.com"},"enroll":150,"eid":"NCT06237569"},{"id":"study-NCT06431386","cat":"studies","name":"Behavioural Activation Therapy and Esketamine for Resistant Depression","status":"TERMINATED","phase":"N/A","sponsor":"The Royal's Institute of Mental Health Research","drugs":["esketamine"],"nct":"NCT06431386","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2024-06-11","official":"Jeanne Talbot, MD PhD FRCP (The Royal's Institute of Mental Health Research)","src":"https://clinicaltrials.gov/study/NCT06431386","sites":["The Royal Ottawa Mental Health Centre — Ottawa, Canada"],"conds":["Depressive Disorder, Treatment-Resistant","Depressive Disorder, Major","Bipolar Disorder"],"condg":["Depression","Bipolar"],"enroll":6,"eid":"NCT06431386"},{"id":"study-NCT05695495","cat":"studies","name":"Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["DMT"],"nct":"NCT05695495","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2024-06-12","src":"https://clinicaltrials.gov/study/NCT05695495","sites":["Clinical Pharmacology & Toxicology, University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":36,"eid":"NCT05695495"},{"id":"study-NCT06432322","cat":"studies","name":"(GluEsk) Glutamate and Esketamine","status":"COMPLETED","phase":"N/A","sponsor":"University of Oxford","drugs":["esketamine"],"nct":"NCT06432322","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2024-06-14","official":"Riccardo De Giorgi, MD, DPhil, MRCPsych (University of Oxford, Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT06432322","sites":["Department of Psychiatry, University of Oxford, Warneford Hospital — Oxford, United Kingdom"],"conds":["Depression"],"condg":["Depression"],"enroll":16,"eid":"NCT06432322"},{"id":"study-NCT06111339","cat":"studies","name":"Ketamine for OUD and Suicidal Ideation in the ED","status":"TERMINATED","phase":"Phase 2","sponsor":"Brigham and Women's Hospital","drugs":["ketamine"],"nct":"NCT06111339","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-06-14","src":"https://clinicaltrials.gov/study/NCT06111339","sites":["Brigham and Women's Hospital — Boston, United States"],"conds":["Opioid Use Disorder","Suicidal Ideation"],"condg":["Addiction & substance use"],"enroll":4,"eid":"NCT06111339"},{"id":"study-NCT06230757","cat":"studies","name":"Psilocybin for Treatment-Resistant Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"University of Colorado, Denver","drugs":["psilocybin"],"nct":"NCT06230757","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-07-08","official":"Andrew M Novick, MD, PhD (University of Colorado, Denver)","src":"https://clinicaltrials.gov/study/NCT06230757","sites":["University of Colorado Anschutz Medical Campus — Aurora, United States"],"conds":["Major Depressive Disorder","Anhedonia","Treatment Resistant Depression"],"condg":["Depression"],"enroll":20,"eid":"NCT06230757"},{"id":"study-NCT06139016","cat":"studies","name":"Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment","status":"COMPLETED","phase":"N/A","sponsor":"Yale University","drugs":["esketamine","ketamine"],"nct":"NCT06139016","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-07-11","official":"Sina Nikayin, MD (Assistant Professor, Departement of Psychiatry, Yale University)","src":"https://clinicaltrials.gov/study/NCT06139016","sites":["Yale Psychiatry Hospital Interventional Psychiatry Services (IPS) unit — New Haven, United States"],"conds":["Depression"],"condg":["Depression"],"enroll":7,"eid":"NCT06139016"},{"id":"study-NCT05910775","cat":"studies","name":"Role Of Non-Specific Effects in The Treatment of Depression With Esketamine","status":"TERMINATED","phase":"N/A","sponsor":"Yale University","drugs":["esketamine","ketamine"],"nct":"NCT05910775","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-07-13","official":"Sina Nikayin, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT05910775","sites":["Yale Psychiatry Hospital Interventional Psychiatry Services (IPS) unit — New Haven, United States"],"conds":["Depressive Episode"],"condg":["Depression"],"enroll":1,"eid":"NCT05910775"},{"id":"study-NCT06498700","cat":"studies","name":"Intraoperative Subanesthetic Ketamine Versus Dexmedetomidine Infusion for Prevention of Post-traumatic Stress Disorder After Traumatic Brain Surgeries","status":"UNKNOWN","phase":"N/A","sponsor":"Zagazig University","drugs":["ketamine"],"nct":"NCT06498700","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2024-07-15","official":"marwa M Medhat (Zagazig University)","src":"https://clinicaltrials.gov/study/NCT06498700","sites":["Faculty of Medicine,Zagazig University — Zagazig, Egypt"],"conds":["Subanesthetic Ketamine Dexmedetomidin"],"condg":["Other"],"enroll":52,"eid":"NCT06498700"},{"id":"study-NCT07596095","cat":"studies","name":"Induction Agents in ECT: Effects on Seizure Duration, Quality, and Recovery","status":"COMPLETED","phase":"N/A","sponsor":"Dr. Lutfi Kirdar Kartal Training and Research Hospital","drugs":["ketamine"],"nct":"NCT07596095","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2024-07-17","official":"Gülten Arslan, MD (University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital)","src":"https://clinicaltrials.gov/study/NCT07596095","sites":["Kartal Dr. Lütfi Kırdar City Hospital — Istanbul, Turkey"],"conds":["Electroconvulsive Therapy","Anesthesia, General"],"condg":["Other"],"enroll":100,"eid":"NCT07596095"},{"id":"study-NCT06511947","cat":"studies","name":"Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects","status":"UNKNOWN","phase":"Phase 1","sponsor":"GH Research Ireland Limited","drugs":["DMT"],"nct":"NCT06511947","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2024-08-01","src":"https://clinicaltrials.gov/study/NCT06511947","sites":["GH Research Clinical Trial Site — London, United Kingdom"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"contact":{"n":"GH Research Limited Clinical Trial Enquiries","p":"+353 87 450 3237","e":"clinicaltrials@ghres.com"},"enroll":52,"eid":"NCT06511947"},{"id":"study-NCT06537375","cat":"studies","name":"Use of Ketamine in Severe Pain Syndromes","status":"COMPLETED","sponsor":"Erasme University Hospital","drugs":["ketamine"],"nct":"NCT06537375","nsites":1,"countries":"Belgium","ccs":["BE"],"start":"2024-08-01","src":"https://clinicaltrials.gov/study/NCT06537375","sites":["Hôpital Universitaire de Bruxelles - Hôpital erasme — Brussels, Belgium"],"conds":["Pain, Intractable","Pain, Chronic","Pain Syndrome","Pain Measurement"],"condg":["Chronic pain & headache"],"enroll":89,"eid":"NCT06537375"},{"id":"study-NCT06372197","cat":"studies","name":"Low-Income Group Psilocybin Assisted Therapy for Depression","status":"COMPLETED","phase":"N/A","sponsor":"Matthew Hicks","drugs":["psilocybin"],"nct":"NCT06372197","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-08-01","official":"Matthew R Hicks, ND, MS (National University of Natural Medicine)","src":"https://clinicaltrials.gov/study/NCT06372197","sites":["National University of Natural Medicine — Portland, United States"],"conds":["Depression"],"condg":["Depression"],"enroll":20,"eid":"NCT06372197"},{"id":"study-NCT06557239","cat":"studies","name":"Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy","status":"COMPLETED","sponsor":"Tatiana Aboulafia Brakha","drugs":["LSD"],"nct":"NCT06557239","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2024-08-05","src":"https://clinicaltrials.gov/study/NCT06557239","sites":["Geneva University Hospitals — Geneva, Switzerland"],"conds":["Depression, Anxiety"],"condg":["Depression","Anxiety"],"enroll":10,"eid":"NCT06557239"},{"id":"study-NCT06530706","cat":"studies","name":"Effect of Esketamine on Anxiety State in Patients Undergoing Abdominal Tumor Surgery","status":"COMPLETED","phase":"N/A","sponsor":"Zhejiang Cancer Hospital","drugs":["esketamine"],"nct":"NCT06530706","nsites":1,"countries":"China","ccs":["CN"],"start":"2024-08-05","src":"https://clinicaltrials.gov/study/NCT06530706","sites":["Zhejiang cancer hospital — Hangzhou, China"],"conds":["Anxiety State","Esketamine"],"condg":["Anxiety"],"enroll":185,"eid":"NCT06530706"},{"id":"study-NCT06543563","cat":"studies","name":"Esketamine in Microelectrode Recording-guided Subthalamic Deep-Brain Stimulation for Parkinson's Disease","status":"UNKNOWN","phase":"N/A","sponsor":"Beijing Tiantan Hospital","drugs":["esketamine"],"nct":"NCT06543563","nsites":1,"countries":"China","ccs":["CN"],"start":"2024-08-09","official":"Ruquan Han, MD,PhD (Study Principal Investigator)","src":"https://clinicaltrials.gov/study/NCT06543563","sites":["Beijing Tiantan Hospital, Capital Medical University — Beijing, China"],"conds":["PD - Parkinson's Disease","Deep Brain Stimulation","Esketamine"],"condg":["Neurology & cognition"],"contact":{"n":"Ruquan Han, MD,PhD","p":"8610-59976660","e":"ruquan.han@gmail.com"},"enroll":102,"eid":"NCT06543563"},{"id":"study-NCT06245564","cat":"studies","name":"Effect of Ketamine, Amitriptyline and Their Combination on Itch","status":"COMPLETED","phase":"N/A","sponsor":"Aalborg University","drugs":["ketamine"],"nct":"NCT06245564","nsites":1,"countries":"Denmark","ccs":["DK"],"start":"2024-08-20","src":"https://clinicaltrials.gov/study/NCT06245564","sites":["Center for Neuroplasticity and Pain Faculty of Medicine, Aalborg University — Gistrup, Denmark"],"conds":["Itch"],"condg":["Other"],"enroll":30,"eid":"NCT06245564"},{"id":"study-NCT06531837","cat":"studies","name":"Electroencephalographic Characteristics of Chronic Pain in Patients With Spinal Cord Injury","status":"UNKNOWN","phase":"N/A","sponsor":"Beijing Tiantan Hospital","drugs":["esketamine"],"nct":"NCT06531837","nsites":1,"countries":"China","ccs":["CN"],"start":"2024-08-25","official":"Ruquan Han, M.D., Ph D (Beijing Tiantan Hospital)","src":"https://clinicaltrials.gov/study/NCT06531837","sites":["Beijing Tiantan Hospital — Beijing, China"],"conds":["Chronic Pain"],"condg":["Chronic pain & headache"],"contact":{"n":"Ruquan Han, M.D., Ph D","p":"8610-59976660","e":"ruquan.han@ccmu.edu.cn"},"enroll":60,"eid":"NCT06531837"},{"id":"study-NCT06444243","cat":"studies","name":"Psilocybin-assisted Therapy for Alcohol Use Disorder","status":"UNKNOWN","phase":"Phase 2","sponsor":"University of Sydney","drugs":["psilocybin"],"nct":"NCT06444243","nsites":0,"start":"2024-09","official":"Paul Haber, PhD (University of Sydney); Kirsten C Morley, PhD (University of Sydney)","src":"https://clinicaltrials.gov/study/NCT06444243","conds":["Alcohol Use Disorder","Alcohol Dependence","Depression","Anxiety"],"condg":["Depression","Anxiety","Addiction & substance use"],"contact":{"n":"Kirsten C Morley, PhD","p":"95153636","e":"Kirsten.morley@sydney.edu.au"},"enroll":90,"eid":"NCT06444243"},{"id":"study-NCT07743333","cat":"studies","name":"Nebulized Lidocaine And Ketamine Before Fiberoptic Bronchoscopy","status":"COMPLETED","phase":"Phase 4","sponsor":"Alexandria University","drugs":["ketamine"],"nct":"NCT07743333","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2024-09-01","src":"https://clinicaltrials.gov/study/NCT07743333","sites":["Alexandria University Faculty of Medicine — Alexandria, Egypt"],"conds":["Fiberoptic Bronchoscopy (FOB)","Lung Cancer (Diagnosis)","Premedication"],"condg":["Cancer-related distress"],"enroll":134,"eid":"NCT07743333"},{"id":"study-NCT06299319","cat":"studies","name":"Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD","status":"COMPLETED","phase":"Phase 1","sponsor":"Centre for Addiction and Mental Health","drugs":["psilocybin"],"nct":"NCT06299319","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2024-09-01","official":"Gwyneth Zai, MD, MSc, PhD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT06299319","sites":["Centre for Addiction and Mental Health — Toronto, Canada"],"conds":["Obsessive-Compulsive Disorder"],"condg":["OCD"],"enroll":10,"eid":"NCT06299319"},{"id":"study-NCT06609538","cat":"studies","name":"The Impact of Preoperative Suggestion on Dreaming","status":"COMPLETED","phase":"N/A","sponsor":"Wonkwang University Hospital","drugs":["ketamine"],"nct":"NCT06609538","nsites":1,"countries":"South Korea","ccs":["KR"],"start":"2024-09-19","official":"Cheol Lee, M.D.,Ph.D (Wonkwang University Hospital)","src":"https://clinicaltrials.gov/study/NCT06609538","sites":["WonwangUH — Iksan, South Korea"],"conds":["Dream, Day","Ketamine Adverse Reaction","Propofol Adverse Reaction"],"condg":["Other"],"enroll":250,"eid":"NCT06609538"},{"id":"study-NCT06608030","cat":"studies","name":"Effect of Esketamine on Perioperative Negative Mood in Patients Undergoing Cardiac Valve Surgery","status":"COMPLETED","phase":"N/A","sponsor":"Chinese PLA General Hospital","drugs":["esketamine"],"nct":"NCT06608030","nsites":2,"countries":"China","ccs":["CN"],"start":"2024-09-23","src":"https://clinicaltrials.gov/study/NCT06608030","sites":["First Medical center of Chinese PLA General Hospital — Beijing, China","Beijing Tiantan Hospital — Beijing, China"],"conds":["Depression, Anxiety","Cardiac Surgery","S-ketamine"],"condg":["Depression","Anxiety"],"enroll":142,"eid":"NCT06608030"},{"id":"study-NCT06429657","cat":"studies","name":"Ketamine for Sedation in Severe Traumatic Brain Injury","status":"SUSPENDED","phase":"Phase 4","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","drugs":["ketamine"],"nct":"NCT06429657","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-09-23","official":"Bradley Dengler, MD (Uniformed Services University of the Health Sciences)","src":"https://clinicaltrials.gov/study/NCT06429657","sites":["Brooke Army Medical Center — Fort Sam Houston, United States"],"conds":["Severe Traumatic Brain Injury","Intracranial Hypertension","Intracranial Hemorrhage, Hypertensive"],"condg":["PTSD & trauma","Neurology & cognition"],"enroll":50,"eid":"NCT06429657"},{"id":"study-NCT06560658","cat":"studies","name":"Optimizing Microdosing and Meditation","status":"WITHDRAWN","phase":"N/A","sponsor":"National University of Natural Medicine","drugs":["psilocybin"],"nct":"NCT06560658","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-10-01","official":"Matthew Hicks, ND, MS (National University of Natural Medicine)","src":"https://clinicaltrials.gov/study/NCT06560658","sites":["National University of Natural Medicine — Portland, United States"],"conds":["Meditation","Microdosing"],"condg":["Other"],"eid":"NCT06560658"},{"id":"study-NCT06624878","cat":"studies","name":"Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer","status":"COMPLETED","phase":"N/A","sponsor":"Zhejiang Cancer Hospital","drugs":["esketamine"],"nct":"NCT06624878","nsites":1,"countries":"China","ccs":["CN"],"start":"2024-10-08","src":"https://clinicaltrials.gov/study/NCT06624878","sites":["Zhejiang cancer hospital — Hangzhou, China"],"conds":["Ovarian Cancer","Cytoreductive Surgery","Depressive Symptom"],"condg":["Depression","Cancer-related distress"],"enroll":568,"eid":"NCT06624878"},{"id":"study-NCT07074262","cat":"studies","name":"Comparison Between the Effect of Dexmedetomidine _midazolam and ketamine_midazolam Combination","status":"COMPLETED","phase":"N/A","sponsor":"Beni-Suef University","drugs":["ketamine"],"nct":"NCT07074262","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2024-10-10","official":"Mahmoud Attia Nassef, Professor (Anaesthesiology,Surgical intensive care and pain management,Faculty of Medicine,Beni-Suef University)","src":"https://clinicaltrials.gov/study/NCT07074262","sites":["Beni- Suef University Hospital — Banī Suwayf, Egypt"],"conds":["Postoperative Cognitive Dysfunction","Post Operative Delirium"],"condg":["Neurology & cognition"],"enroll":114,"eid":"NCT07074262"},{"id":"study-NCT07230392","cat":"studies","name":"Superficial Cervical Plexus Block Versus Ketamine in the Prevention of Chronic Pain After Thyroidectomy","status":"COMPLETED","phase":"Phase 4","sponsor":"University Tunis El Manar","drugs":["ketamine"],"nct":"NCT07230392","nsites":1,"countries":"Tunisia","ccs":["TN"],"start":"2024-10-14","official":"ibtissem BEN TALEB (University of Tunis El Manar, Anesthesia and critical care department, Taher Maamouri University Hospital,)","src":"https://clinicaltrials.gov/study/NCT07230392","sites":["Mohamed Taher Maamouri University Hospital — Nabeul, Tunisia"],"conds":["Chronic Pain","Thyroidectomy"],"condg":["Chronic pain & headache"],"enroll":69,"eid":"NCT07230392"},{"id":"study-NCT06816667","cat":"studies","name":"Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Biomind Labs Inc.","drugs":["DMT"],"nct":"NCT06816667","nsites":1,"countries":"Argentina","ccs":["AR"],"start":"2024-10-21","official":"Martin A. Bruno, PhD (Biomind Labs Inc.)","src":"https://clinicaltrials.gov/study/NCT06816667","sites":["Hospital Descentralizado Dr. Marcial V. Quiroga. — San Juan, Argentina"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":40,"eid":"NCT06816667"},{"id":"study-NCT06529939","cat":"studies","name":"The Effects of Psilocybin on Shared Experience in Film Processing","status":"UNKNOWN","phase":"N/A","sponsor":"Western University, Canada","drugs":["psilocybin"],"nct":"NCT06529939","nsites":0,"start":"2024-11","src":"https://clinicaltrials.gov/study/NCT06529939","conds":["Disorders of Consciousness","Psychedelic Experiences"],"condg":["Other"],"contact":{"n":"Adrian M. Owen","p":"519-661-2111","e":"uwocerc@uwo.ca"},"enroll":30,"eid":"NCT06529939"},{"id":"study-NCT06643637","cat":"studies","name":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"MycoMedica Life Sciences PBC","drugs":["psilocybin"],"nct":"NCT06643637","nsites":1,"countries":"Australia","ccs":["AU"],"start":"2024-11-08","src":"https://clinicaltrials.gov/study/NCT06643637","sites":["CMAX Clinical Research — Adelaide, Australia"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":16,"eid":"NCT06643637"},{"id":"study-NCT06620042","cat":"studies","name":"FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression","status":"COMPLETED","phase":"Phase 2","sponsor":"Brian Barnett","drugs":["ketamine"],"nct":"NCT06620042","nsites":2,"countries":"United States","ccs":["US"],"start":"2024-11-12","official":"Brian Barnett, MD (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT06620042","sites":["Cleveland Clinic Lutheran Hospital — Cleveland, United States","Cleveland Clinic Lutheran Hospital — Ohio City, United States"],"conds":["Bipolar Depression","Treatment Resistant Bipolar Depression"],"condg":["Depression","Bipolar"],"enroll":20,"eid":"NCT06620042"},{"id":"study-NCT06650800","cat":"studies","name":"Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression","status":"COMPLETED","phase":"N/A","sponsor":"Centre Hospitalier Universitaire de Nīmes","drugs":["psilocybin"],"nct":"NCT06650800","nsites":1,"countries":"France","ccs":["FR"],"start":"2024-11-19","official":"Ismaël Conejero (CHU Nimes)","src":"https://clinicaltrials.gov/study/NCT06650800","sites":["CHU de Nîmes, Hôpital Universitaire Carémeau — Nîmes, France"],"conds":["Depressive Disorder","Depressive Disorder, Treatment-Resistant","Hallucinogens","Reinforcement, Psychology"],"condg":["Depression"],"enroll":10,"eid":"NCT06650800"},{"id":"study-NCT06644170","cat":"studies","name":"A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer","status":"COMPLETED","phase":"Phase 1","sponsor":"University of Washington","drugs":["psilocybin"],"nct":"NCT06644170","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-11-19","official":"Anthony L. Back, MD (Fred Hutch/University of Washington Cancer Consortium)","src":"https://clinicaltrials.gov/study/NCT06644170","sites":["Fred Hutch/University of Washington Cancer Consortium — Seattle, United States"],"conds":["Hematopoietic and Lymphatic System Neoplasm","Metastatic Malignant Solid Neoplasm"],"condg":["Cancer-related distress"],"enroll":15,"eid":"NCT06644170"},{"id":"study-NCT04073433","cat":"studies","name":"Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2)","status":"WITHDRAWN","phase":"Phase 1","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT04073433","nsites":0,"start":"2024-12","official":"Marcela Ot'alora (Private Practice)","src":"https://clinicaltrials.gov/study/NCT04073433","conds":["Psychological Effects of Study Drug"],"condg":["Other"],"eid":"NCT04073433"},{"id":"study-NCT06741930","cat":"studies","name":"Pro-Epileptic Effects of IV Ketamine","status":"COMPLETED","phase":"Phase 4","sponsor":"Haseki Training and Research Hospital","drugs":["ketamine"],"nct":"NCT06741930","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2024-12-01","src":"https://clinicaltrials.gov/study/NCT06741930","sites":["Haseki Training and Research Hospital — Istanbul, Turkey"],"conds":["Epilepsy","Seizure"],"condg":["Neurology & cognition"],"enroll":300,"eid":"NCT06741930"},{"id":"study-NCT06746441","cat":"studies","name":"Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity…","status":"COMPLETED","phase":"Phase 2","sponsor":"Khyber Medical University Peshawar","drugs":["psilocybin"],"nct":"NCT06746441","nsites":1,"countries":"Pakistan","ccs":["PK"],"start":"2024-12-01","official":"Dr Mahvash Khan (Hayat Abad Medical Complex, Peshawar)","src":"https://clinicaltrials.gov/study/NCT06746441","sites":["Lady Reading Hospital, Pakistan — Peshawar, Pakistan"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":60,"eid":"NCT06746441"},{"id":"study-NCT06450210","cat":"studies","name":"Safety for Home Administration of Microdose Psilocybin Use","status":"COMPLETED","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT06450210","nsites":1,"countries":"United States","ccs":["US"],"start":"2024-12-06","official":"Sandeep M. Nayak, MD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06450210","sites":["5510 Nathan Shock Drive — Baltimore, United States"],"conds":["Psychedelic Experiences"],"condg":["Other"],"enroll":17,"eid":"NCT06450210"},{"id":"study-NCT06726382","cat":"studies","name":"KF2024#1-trial: Esketamine Interaction Study","status":"COMPLETED","phase":"Phase 1","sponsor":"Helsinki University Central Hospital","drugs":["esketamine"],"nct":"NCT06726382","nsites":1,"countries":"Finland","ccs":["FI"],"start":"2024-12-09","official":"Janne T Backman, MD, PhD (Helsinki University Central Hospital)","src":"https://clinicaltrials.gov/study/NCT06726382","sites":["Department of Clinical Pharmacology — Helsinki, Finland"],"conds":["Drug Interactions","Food-drug Interaction"],"condg":["Other"],"enroll":12,"eid":"NCT06726382"},{"id":"study-NCT06624137","cat":"studies","name":"Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics","status":"TERMINATED","sponsor":"Yale University","drugs":["LSD","ayahuasca","psilocybin"],"nct":"NCT06624137","nsites":2,"countries":"United States","ccs":["US"],"start":"2024-12-12","official":"Maximillian S Greenwald, BA (Yale University); Albert R Powers, MD, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06624137","sites":["Connecticut Mental Health Center — Hamden, United States","West Haven VA Medical Center — West Haven, United States"],"conds":["OCD","Major Depressive Disorder (MDD)","Alcohol Use Disorder (AUD)","Healthy Volunteer","Migraine","PTSD"],"condg":["Depression","PTSD & trauma","Addiction & substance use","Chronic pain & headache","OCD","Healthy volunteers"],"enroll":5,"eid":"NCT06624137"},{"id":"study-NCT06812221","cat":"studies","name":"Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"Biomind Labs Inc.","drugs":["DMT"],"nct":"NCT06812221","nsites":1,"countries":"Argentina","ccs":["AR"],"start":"2024-12-15","official":"Martin A. Bruno, PhD (Biomind Labs Inc.)","src":"https://clinicaltrials.gov/study/NCT06812221","sites":["Hospital Descentralizado Dr. Marcial V. Quiroga. — San Juan, Argentina"],"conds":["Mild Cognitive Impairment","Anxiety State","Depression Anxiety Disorder"],"condg":["Depression","Anxiety","Neurology & cognition"],"enroll":20,"eid":"NCT06812221"},{"id":"study-NCT06647056","cat":"studies","name":"Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures","status":"COMPLETED","phase":"N/A","sponsor":"Centre Hospitalier Universitaire de Nīmes","drugs":["psilocybin"],"nct":"NCT06647056","nsites":1,"countries":"France","ccs":["FR"],"start":"2024-12-19","official":"Ismaël CONEJERO (CHU Nimes)","src":"https://clinicaltrials.gov/study/NCT06647056","sites":["CHU de Nîmes, Hôpital Universitaire Carémeau — Nîmes, France"],"conds":["Psychogenic Nonepileptic Seizures","Psilocybin"],"condg":["Neurology & cognition"],"enroll":4,"eid":"NCT06647056"},{"id":"study-NCT06735079","cat":"studies","name":"A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD)","status":"WITHDRAWN","phase":"Phase 3","sponsor":"MGGM LLC","drugs":["ketamine"],"nct":"NCT06735079","nsites":2,"countries":"Italy; Switzerland","ccs":["CH","IT"],"start":"2024-12-27","src":"https://clinicaltrials.gov/study/NCT06735079","sites":["Mediolanum Cardio Research — Milan, Italy","Clinical Trial Unit - Ente Ospedaliero Cantonale (CTU-EOC) Area Formazione medica e Ricerca (AFRi) — Lugano, Switzerland"],"conds":["Major Depressive Disorder (MDD)"],"condg":["Depression"],"eid":"NCT06735079"},{"id":"study-NCT06762288","cat":"studies","name":"Transversus Abdominis Plan (TAP) Block for Transcatheter Aortic Valve Implantation (TAVI)","status":"COMPLETED","phase":"N/A","sponsor":"Istanbul University - Cerrahpasa","drugs":["ketamine"],"nct":"NCT06762288","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2024-12-28","official":"Kerem Erkalp, professor (Istanbul University - Cerrahpasa)","src":"https://clinicaltrials.gov/study/NCT06762288","sites":["Istanbul University-Cerrahpaşa — Istanbul, Turkey"],"conds":["Anesthesia","Analgesia","Block","Aortic Valve Stenosis"],"condg":["Other"],"enroll":50,"eid":"NCT06762288"},{"id":"study-NCT05562973","cat":"studies","name":"Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder","status":"WITHDRAWN","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT05562973","nsites":0,"start":"2025-01","official":"Matthew W Johnson, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT05562973","conds":["Post-Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"eid":"NCT05562973"},{"id":"study-NCT06471959","cat":"studies","name":"Psychedelic-assisted Group Program for First Responders","status":"UNKNOWN","phase":"Phase 1/Phase 2","sponsor":"Empower Research Inc","drugs":["psilocybin"],"nct":"NCT06471959","nsites":1,"countries":"Canada","ccs":["CA"],"start":"2025-01-01","official":"Reginald Peters, MD (University of British Columbia (Clinical Assistant Professor))","src":"https://clinicaltrials.gov/study/NCT06471959","sites":["Centre for Neurology Studies — Surrey, Canada"],"conds":["Psilocybin","Psychotherapy, Group"],"condg":["Other"],"contact":{"n":"Natasha Campbell, MSc","p":"1-778-874-7758","e":"natashacampbell@healthtechconnex.com"},"enroll":32,"eid":"NCT06471959"},{"id":"study-NCT06180759","cat":"studies","name":"Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["ketamine"],"nct":"NCT06180759","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2025-01-23","src":"https://clinicaltrials.gov/study/NCT06180759","sites":["Clinical Pharmacology & Toxicology, University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":17,"eid":"NCT06180759"},{"id":"study-NCT06538285","cat":"studies","name":"Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV","status":"COMPLETED","phase":"Phase 2","sponsor":"Nicky Mehtani, MD, MPH","drugs":["ketamine"],"nct":"NCT06538285","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-03-04","official":"Nicky Mehtani, MD MPH (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06538285","sites":["San Francisco Department of Public Health — San Francicso, United States"],"conds":["Methamphetamine Use Disorder"],"condg":["Addiction & substance use"],"enroll":17,"eid":"NCT06538285"},{"id":"study-NCT06879496","cat":"studies","name":"Comparison of Oral Dexmedetomidine, Ketamine Versus Midazolam for Premedication in Children Undergoing Injuinal Surgeries","status":"COMPLETED","phase":"N/A","sponsor":"Tanta University","drugs":["ketamine"],"nct":"NCT06879496","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2025-03-10","src":"https://clinicaltrials.gov/study/NCT06879496","sites":["Mohamed Zakarea Wfa — Tanta, Egypt"],"conds":["Pediatric","Anesthesia"],"condg":["Other"],"enroll":60,"eid":"NCT06879496"},{"id":"study-NCT06884514","cat":"studies","name":"Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA","psilocybin"],"nct":"NCT06884514","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2025-04-03","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital Basel, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT06884514","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":24,"eid":"NCT06884514"},{"id":"study-NCT06835699","cat":"studies","name":"Psilocybin Brain Stimulation and Imaging Pilot Study","status":"COMPLETED","phase":"Phase 1","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT06835699","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-04-18","official":"Ceyda Sayali, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06835699","sites":["Johns Hopkins School of Medicine — Baltimore, United States"],"conds":["Healthy Volunteers"],"condg":["Healthy volunteers"],"enroll":10,"eid":"NCT06835699"},{"id":"study-NCT05991232","cat":"studies","name":"Repeated Neurocognitive Measurements in Depressed Patients","status":"WITHDRAWN","phase":"Phase 1/Phase 2","sponsor":"Jay Fournier","drugs":["ketamine"],"nct":"NCT05991232","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-05-01","src":"https://clinicaltrials.gov/study/NCT05991232","sites":["The Ohio State University, Department of Psychiatry & Behavioral Health — Columbus, United States"],"conds":["Depression, Unipolar"],"condg":["Depression"],"eid":"NCT05991232"},{"id":"study-NCT06853041","cat":"studies","name":"ESKetamine Low-dose vs Ketamine Low-dose for Severe Acute Pain in Emergency Units, Comparison of PsychodyslEptic Effects","status":"COMPLETED","phase":"Phase 4","sponsor":"Centre Hospitalier Universitaire de Nice","drugs":["esketamine","ketamine"],"nct":"NCT06853041","nsites":1,"countries":"France","ccs":["FR"],"start":"2025-05-06","src":"https://clinicaltrials.gov/study/NCT06853041","sites":["CHU de NICE — Nice, France"],"conds":["Acute Pain"],"condg":["Chronic pain & headache"],"enroll":74,"eid":"NCT06853041"},{"id":"study-NCT06986109","cat":"studies","name":"Effect of Subanaesthetic Dose of Ketamine on Depth of Anaesthesia Consistency","status":"COMPLETED","phase":"N/A","sponsor":"Sir Ganga Ram Hospital","drugs":["ketamine"],"nct":"NCT06986109","nsites":1,"countries":"India","ccs":["IN"],"start":"2025-05-26","official":"Nitin Sethi, DNB (Sir Ganga Ram Hospital, New Delhi, INDIA); Amitabh Dutta, MD, PGDHR (Sir Ganga Ram Hospital, New Delhi, INDIA)","src":"https://clinicaltrials.gov/study/NCT06986109","sites":["Sir Ganga Ram Hospital — New Delhi, India"],"conds":["Anesthesia"],"condg":["Other"],"enroll":106,"eid":"NCT06986109"},{"id":"study-NCT07193901","cat":"studies","name":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","status":"COMPLETED","phase":"Phase 2","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","drugs":["ketamine"],"nct":"NCT07193901","nsites":15,"countries":"China","ccs":["CN"],"start":"2025-05-27","src":"https://clinicaltrials.gov/study/NCT07193901","sites":["The Sixth Hospital of Peking University — Beijin, China","BEIjing AnDing hospital capital medical university — Beijing, China","Beijing Huilongguan Hospital — Beijing, China","Brain Hospital of Hunan Province — Changsha, China","The Second Xiangya Hospital of Central South University — Changsha, China","The Fourth People's Hospital of Chengdu — Chengdu, China","Hangzhou Seventh People's Hospital — Hangzhou, China","Hefei Fourth People's Hospital(Anhui Mental Health Prevention and Treatment Center) — Hefei, China"],"conds":["Major Depressive Disorder (MDD"],"condg":["Depression"],"enroll":98,"eid":"NCT07193901"},{"id":"study-NCT07596810","cat":"studies","name":"Ketamine Added to Quadratus Lumborum Block for Pain Relief After Infant Pyeloplasty","status":"COMPLETED","phase":"Phase 4","sponsor":"Alexandria University","drugs":["ketamine"],"nct":"NCT07596810","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2025-06-01","src":"https://clinicaltrials.gov/study/NCT07596810","sites":["Alexandria University — Alexandria, Egypt"],"conds":["Ureteropelvic Junction Obstruction","Postoperative Pain"],"condg":["Chronic pain & headache"],"enroll":40,"eid":"NCT07596810"},{"id":"study-NCT06821087","cat":"studies","name":"Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19","status":"COMPLETED","phase":"Phase 2","sponsor":"University of Texas at Austin","drugs":["ketamine"],"nct":"NCT06821087","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-06-05","official":"W. Michael Brode, MD (University of Texas at Austin)","src":"https://clinicaltrials.gov/study/NCT06821087","sites":["UT Health Austin — Austin, United States"],"conds":["Long COVID"],"condg":["Other"],"enroll":20,"eid":"NCT06821087"},{"id":"study-NCT07017478","cat":"studies","name":"Mood Effects of Serotonin Agonists: Depression","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University of Chicago","drugs":["LSD"],"nct":"NCT07017478","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-06-09","official":"Hanna Molla (University of Chicago)","src":"https://clinicaltrials.gov/study/NCT07017478","sites":["University of Chicago — Chicago, United States"],"conds":["LSD","Major Depressive Disorder","Depression"],"condg":["Depression"],"enroll":41,"eid":"NCT07017478"},{"id":"study-NCT06795659","cat":"studies","name":"Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)","status":"COMPLETED","phase":"Phase 1/Phase 2","sponsor":"The University of Texas Health Science Center at San Antonio","drugs":["esketamine"],"nct":"NCT06795659","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-06-09","official":"Casey Straud, PsyD (The University of Texas Health Science Center at San Antonio)","src":"https://clinicaltrials.gov/study/NCT06795659","sites":["The University of Texas Health Science Center at San Antonio — San Antonio, United States"],"conds":["Post Traumatic Stress Disorder PTSD"],"condg":["PTSD & trauma"],"enroll":4,"eid":"NCT06795659"},{"id":"study-NCT07053345","cat":"studies","name":"A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression","status":"COMPLETED","phase":"Phase 4","sponsor":"Janssen Korea, Ltd., Korea","drugs":["esketamine"],"nct":"NCT07053345","nsites":6,"countries":"South Korea","ccs":["KR"],"start":"2025-06-09","official":"Janssen Korea, Ltd., Korea Clinical Trial (Janssen Korea, Ltd., Korea)","src":"https://clinicaltrials.gov/study/NCT07053345","sites":["Cha Ilsan Medical Center — Goyang Si Gyeonggi Do, South Korea","Wonkwang University Hospital — Iksan, South Korea","Kangbuk Samsung Hospital — Seoul, South Korea","Asan Medical Center — Seoul, South Korea","Samsung Medical Center — Seoul, South Korea","Kyung Hee University Hospital — Seoul, South Korea"],"conds":["Depressive Disorder, Treatment-Resistant"],"condg":["Depression"],"enroll":47,"eid":"NCT07053345"},{"id":"study-NCT06832683","cat":"studies","name":"Efficacy of Propofol-Ketamine and Sevoflurane in Children Undergoing Magnetic Resonance Imaging","status":"COMPLETED","phase":"N/A","sponsor":"Kocaeli City Hospital","drugs":["ketamine"],"nct":"NCT06832683","nsites":1,"countries":"Turkey (Türkiye)","ccs":["TR"],"start":"2025-06-19","official":"Bedirhan Günel, MD (Kocaeli City Hospital)","src":"https://clinicaltrials.gov/study/NCT06832683","sites":["Bedirhan Günel — Kocaeli, Turkey"],"conds":["Recovery Period","Hypoxemia","Patient Safety"],"condg":["Other"],"enroll":230,"eid":"NCT06832683"},{"id":"study-NCT07061886","cat":"studies","name":"Drug Effects on Mood and Behavior - Expectancy","status":"COMPLETED","phase":"EARLY_Phase 1","sponsor":"University of Chicago","drugs":["LSD"],"nct":"NCT07061886","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-06-26","official":"Hanna Molla (University of Chicago)","src":"https://clinicaltrials.gov/study/NCT07061886","sites":["University of Chicago — Chicago, United States"],"conds":["LSD"],"condg":["Other"],"enroll":42,"eid":"NCT07061886"},{"id":"study-NCT06868589","cat":"studies","name":"Reducing Pain With Methadone and Ketamine in Liver Transplant","status":"COMPLETED","phase":"Phase 4","sponsor":"Lahey Clinic","drugs":["ketamine"],"nct":"NCT06868589","nsites":2,"countries":"United States","ccs":["US"],"start":"2025-06-30","official":"Ryan Nazemian, MD, PhD (Lahey Clinic, Department of Anesthesiology, Perioperative and Pain Medicine)","src":"https://clinicaltrials.gov/study/NCT06868589","sites":["Lahey Clinicc — Burlington, United States","Lahey Clinic — Burlington, United States"],"conds":["Liver Transplantation"],"condg":["Other"],"enroll":50,"eid":"NCT06868589"},{"id":"study-NCT06353282","cat":"studies","name":"MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents","status":"WITHDRAWN","phase":"Phase 2","sponsor":"University of California, Los Angeles","drugs":["MDMA"],"nct":"NCT06353282","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-07-01","src":"https://clinicaltrials.gov/study/NCT06353282","sites":["UCLA Semel Institute for Neuroscience and Human Behavior — Los Angeles, United States"],"conds":["PTSD, Post Traumatic Stress Disorder","Adolescents","Psychotherapy"],"condg":["PTSD & trauma"],"eid":"NCT06353282"},{"id":"study-NCT07526454","cat":"studies","name":"Electroconvulsive Therapy Versus Intravenous Ketamine in Treatment-Resistant Major Depressive Disorder","status":"COMPLETED","phase":"N/A","sponsor":"Tanta University","drugs":["ketamine"],"nct":"NCT07526454","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2025-07-01","src":"https://clinicaltrials.gov/study/NCT07526454","sites":["Tanta University — Tanta, Egypt"],"conds":["Electroconvulsive Therapy","Intravenous Ketamine","Treatment-Resistant","Major Depressive Disorder"],"condg":["Depression"],"enroll":70,"eid":"NCT07526454"},{"id":"study-NCT07273851","cat":"studies","name":"Comparison of Propofol and Ketofol as Induction Agents for Electroconvulsive Therapy","status":"COMPLETED","phase":"N/A","sponsor":"Fauji Foundation Hospital","drugs":["ketamine"],"nct":"NCT07273851","nsites":1,"countries":"Pakistan","ccs":["PK"],"start":"2025-07-01","src":"https://clinicaltrials.gov/study/NCT07273851","sites":["Department of Anesthesia, Fauji Foundation Hospital, Rawalpindi, Pakistan — Rawalpindi, Pakistan"],"conds":["Major Depressive Disorder"],"condg":["Depression"],"enroll":80,"eid":"NCT07273851"},{"id":"study-NCT05803551","cat":"studies","name":"A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients","status":"TERMINATED","phase":"Phase 2","sponsor":"Mayo Clinic","drugs":["ketamine"],"nct":"NCT05803551","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-07-07","official":"Devang Sanghavi, MBBS, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT05803551","sites":["Mayo Clinic Florida — Jacksonville, United States"],"conds":["Depression"],"condg":["Depression"],"enroll":1,"eid":"NCT05803551"},{"id":"study-NCT07050368","cat":"studies","name":"A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers","status":"COMPLETED","phase":"Phase 1","sponsor":"MycoMedica Life Sciences PBC","drugs":["psilocybin"],"nct":"NCT07050368","nsites":1,"countries":"United Kingdom","ccs":["GB"],"start":"2025-07-28","src":"https://clinicaltrials.gov/study/NCT07050368","sites":["Hammersmith Medicines Research (HMR) — London, United Kingdom"],"conds":["Healthy Volunteer"],"condg":["Healthy volunteers"],"enroll":20,"eid":"NCT07050368"},{"id":"study-NCT06905652","cat":"studies","name":"Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants","status":"COMPLETED","phase":"Phase 1","sponsor":"University Hospital, Basel, Switzerland","drugs":["MDMA"],"nct":"NCT06905652","nsites":1,"countries":"Switzerland","ccs":["CH"],"start":"2025-07-29","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT06905652","sites":["University Hospital Basel — Basel, Switzerland"],"conds":["Healthy"],"condg":["Healthy volunteers"],"enroll":26,"eid":"NCT06905652"},{"id":"study-NCT07138781","cat":"studies","name":"Ketamine as an Adjuvant in External Oblique Intercostal Plane Block for Post Thoracotomy Pain","status":"COMPLETED","phase":"N/A","sponsor":"Tanta University","drugs":["ketamine"],"nct":"NCT07138781","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2025-08-23","src":"https://clinicaltrials.gov/study/NCT07138781","sites":["Tanta University — Tanta, Egypt"],"conds":["Ketamine","Adjuvant","External Oblique Intercostal Plane Block","Thoracotomy","Pain"],"condg":["Chronic pain & headache"],"enroll":50,"eid":"NCT07138781"},{"id":"study-NCT07838831","cat":"studies","name":"Ketamine Versus Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound Guided Bilateral Superficial Cervical Plexus Block in Thyroidectomy","status":"COMPLETED","phase":"N/A","sponsor":"Tanta University","drugs":["ketamine"],"nct":"NCT07838831","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2025-08-31","src":"https://clinicaltrials.gov/study/NCT07838831","sites":["Tanta University — Tanta, Egypt"],"conds":["Thyroidectomy","Bupivacaine","Dexmedetomidine"],"condg":["Other"],"enroll":60,"eid":"NCT07838831"},{"id":"study-NCT06810765","cat":"studies","name":"Trifecta Research Study","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Johns Hopkins University","drugs":["ibogaine"],"nct":"NCT06810765","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-09","official":"Sandeep Nayak, MD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06810765","sites":["Johns Hopkins Center for Psychedelic and Consciousness Research — Baltimore, United States"],"conds":["PTSD - Post Traumatic Stress Disorder","Cognitive Dysfunction","Brain Trauma","Brain Injuries"],"condg":["PTSD & trauma","Neurology & cognition"],"eid":"NCT06810765"},{"id":"study-NCT06919198","cat":"studies","name":"The Dreamy Jet Study","status":"WITHDRAWN","phase":"Phase 1","sponsor":"University of Wisconsin, Madison","drugs":["ketamine"],"nct":"NCT06919198","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-09","official":"Megan Peters, MD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT06919198","sites":["University of Wisconsin - Madison — Madison, United States"],"conds":["Sedation","Blood Drawing Procedure","Immunization","IV Placement"],"condg":["Other"],"eid":"NCT06919198"},{"id":"study-NCT06048263","cat":"studies","name":"The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series","status":"WITHDRAWN","phase":"Phase 2/Phase 3","sponsor":"Washington University School of Medicine","drugs":["ketamine"],"nct":"NCT06048263","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-10-15","official":"David Monks, MBCHB (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT06048263","sites":["Barnes-Jewish Hospital — St Louis, United States"],"conds":["Postpartum Depression"],"condg":["Depression"],"eid":"NCT06048263"},{"id":"study-NCT07194694","cat":"studies","name":"Dexmedetomidine vs Ketamine as Adjuvants to Bupivacaine in Transversus Abdominus Plane Block in Inguinal Hernioplasty","status":"COMPLETED","phase":"Phase 3","sponsor":"Ain Shams University","drugs":["ketamine"],"nct":"NCT07194694","nsites":1,"countries":"Egypt","ccs":["EG"],"start":"2025-10-22","src":"https://clinicaltrials.gov/study/NCT07194694","sites":["Ain Shams University Hospitals — Cairo, Egypt"],"conds":["Postoperative Pain Relief"],"condg":["Chronic pain & headache"],"enroll":60,"eid":"NCT07194694"},{"id":"study-NCT07103720","cat":"studies","name":"The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron","status":"COMPLETED","phase":"Phase 4","sponsor":"Mayo Clinic","drugs":["ketamine"],"nct":"NCT07103720","nsites":1,"countries":"United States","ccs":["US"],"start":"2025-11-05","official":"Alexei Gonzalez Estrada, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT07103720","sites":["Mayo Clinic Arizona — Scottsdale, United States"],"conds":["Allergy"],"condg":["Other"],"enroll":21,"eid":"NCT07103720"},{"id":"study-NCT04454684","cat":"studies","name":"A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Resilient Pharmaceuticals","drugs":["MDMA"],"nct":"NCT04454684","nsites":0,"start":"2026-02","official":"Adele Lafrance, PhD (Emotion Science)","src":"https://clinicaltrials.gov/study/NCT04454684","conds":["Anorexia Nervosa Restricting Type","Binge-Eating Disorder"],"condg":["Eating disorders"],"eid":"NCT04454684"},{"id":"study-NCT07182032","cat":"studies","name":"Ketamine in Central Sensitization","status":"WITHDRAWN","phase":"Phase 4","sponsor":"University Hospitals Cleveland Medical Center","drugs":["ketamine"],"nct":"NCT07182032","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-02-01","official":"Adi Cosic, DO (University Hospitals); Morgan Cheeks, MD (University Hosptials)","src":"https://clinicaltrials.gov/study/NCT07182032","sites":["University Hospitals Cleveland Medical Center — Cleveland, United States"],"conds":["Endometriosis","Chronic Pelvic Pain"],"condg":["Chronic pain & headache"],"eid":"NCT07182032"},{"id":"study-NCT07484906","cat":"studies","name":"Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies","status":"WITHDRAWN","phase":"Phase 2","sponsor":"University of New Mexico","drugs":["psilocybin"],"nct":"NCT07484906","nsites":0,"start":"2026-05-01","src":"https://clinicaltrials.gov/study/NCT07484906","conds":["Suicidal Ideation"],"condg":["Other"],"eid":"NCT07484906"},{"id":"study-NCT07211399","cat":"studies","name":"Transition From Acute to Chronic Opioid Use and Chronic Pain","status":"WITHDRAWN","phase":"EARLY_Phase 1","sponsor":"Jacques E. Chelly","drugs":["ketamine"],"nct":"NCT07211399","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-07-01","official":"Jacques Chelly, MD, PhD, MBA (University of Pittsburgh, UPMC)","src":"https://clinicaltrials.gov/study/NCT07211399","sites":["UPMC Shadyside Hospital — Pittsburgh, United States"],"conds":["Opioid Use Disorder"],"condg":["Addiction & substance use"],"eid":"NCT07211399"},{"id":"study-NCT06378528","cat":"studies","name":"Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)","status":"SUSPENDED","phase":"EARLY_Phase 1","sponsor":"University of Wisconsin, Madison","drugs":["ketamine"],"nct":"NCT06378528","nsites":1,"countries":"United States","ccs":["US"],"start":"2026-09","official":"Christopher Nicholas, PhD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT06378528","sites":["University of Wisconsin — Madison, United States"],"conds":["Posttraumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":5,"eid":"NCT06378528"},{"id":"study-NCT06419985","cat":"studies","name":"Ketamine HCl Prolonged Release Oral Tablets for CRPS","status":"SUSPENDED","phase":"Phase 2","sponsor":"University of Southern California","drugs":["ketamine"],"nct":"NCT06419985","nsites":1,"countries":"United States","ccs":["US"],"start":"2027-01","official":"Steven Richeimer, MD (Keck Medical Center of USC)","src":"https://clinicaltrials.gov/study/NCT06419985","sites":["Pain Center, Keck Medical Center of University of Southern California — Los Angeles, United States"],"conds":["Complex Regional Pain Syndromes"],"condg":["Chronic pain & headache"],"enroll":65,"eid":"NCT06419985"},{"id":"study-NCT04291521","cat":"studies","name":"Prospective Study of Induction Medications Used in the Trauma RSI","status":"WITHDRAWN","sponsor":"University of Southern California","drugs":["ketamine"],"nct":"NCT04291521","nsites":1,"countries":"United States","ccs":["US"],"start":"2027-01-01","official":"Catherine M Kuza, MD (Keck School of Medicine of the University of Southern California)","src":"https://clinicaltrials.gov/study/NCT04291521","sites":["Keck School of Medicine of the University of Southern California — Los Angeles, United States"],"conds":["Trauma","Rapid Sequence Intubation"],"condg":["PTSD & trauma"],"eid":"NCT04291521"},{"id":"study-NCT06005662","cat":"studies","name":"Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Johns Hopkins University","drugs":["psilocybin"],"nct":"NCT06005662","nsites":1,"countries":"United States","ccs":["US"],"start":"2027-04","official":"Sandeep Nayak, MD (Johns Hopkins School of Medicine)","src":"https://clinicaltrials.gov/study/NCT06005662","sites":["Johns Hopkins University — Baltimore, United States"],"conds":["Opioid Use Disorder"],"condg":["Addiction & substance use"],"eid":"NCT06005662"},{"id":"study-NCT06816433","cat":"studies","name":"Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002","status":"SUSPENDED","phase":"Phase 2","sponsor":"Global Coalition for Adaptive Research","drugs":["ketamine"],"nct":"NCT06816433","nsites":9,"countries":"United States","ccs":["US"],"start":"2028-05","src":"https://clinicaltrials.gov/study/NCT06816433","sites":["Homestead Associates in Research, Inc. — Miami, United States","Advanced Discovery Research — Atlanta, United States","Tripler Army Medical Center (TAMC) — Tripler AMC, United States","Cincinnati Veteran's Affairs Medical Center — Fort Thomas, United States","Walter Reed National Military Medical Center (WRNMC) — Bethesda, United States","Upstate Clinical Research Associates, LLC — Williamsville, United States","Wilford Hall Ambulatory Surgical Center (WHASC) — San Antonio, United States","Alexander T. Augusta Military Medical Center (ATAMMC): — Fort Belvoir, United States"],"conds":["Post Traumatic Stress Disorder"],"condg":["PTSD & trauma"],"enroll":200,"eid":"NCT06816433"},{"id":"study-NCT06102434","cat":"studies","name":"Safety Profile of Psilocybin for Cocaine Use Disorder","status":"SUSPENDED","phase":"EARLY_Phase 1","sponsor":"University of California, Los Angeles","drugs":["psilocybin"],"nct":"NCT06102434","nsites":1,"countries":"United States","ccs":["US"],"start":"2029-02-01","src":"https://clinicaltrials.gov/study/NCT06102434","sites":["University of California, Los Angeles — Los Angeles, United States"],"conds":["Cocaine Use Disorder"],"condg":["Addiction & substance use"],"enroll":10,"eid":"NCT06102434"},{"id":"study-NCT05945147","cat":"studies","name":"Ketamine and Midazolam Infusions for CRPS: Feasibility Study","status":"WITHDRAWN","phase":"Phase 2","sponsor":"Stanford University","drugs":["ketamine"],"nct":"NCT05945147","nsites":1,"countries":"United States","ccs":["US"],"start":"2099-01-01","official":"Theresa R Lii, MD, MS (Stanford University)","src":"https://clinicaltrials.gov/study/NCT05945147","sites":["Stanford University — Stanford, United States"],"conds":["Complex Regional Pain Syndromes"],"condg":["Chronic pain & headache"],"eid":"NCT05945147"}]}